,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,
Name,CAS #,SMILES,human VDss (L/kg),human CL (mL/min/kg),"fraction unbound 
in plasma (fu)",MRT (h),terminal  t1/2 (h),Reference,Comments ,Notes,Year of first disclosure,MW,HBA,HBD,TPSA_NO,RotBondCount,moka_ionState7.4,MoKa.LogP,MoKa.LogD7.4
α-hANP,85637-73-6,N1[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc2ccc(cc2)O)CCCNC(=N)N)Cc2ccccc2)CO)CC(=O)N)CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC(C)C)CCCNC(=N)N)CCCNC(=N)N)CO)CO)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC1=O)CC(C)C)CO)CCC(=O)N)[C@@H](C)CC)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)Cc1ccccc1,0.2,25.4,,0.13,0.22,"Nakao, K.; Sugawara, A.; Morii, N.; Sakamoto, M.; Yamada, T.; Itoh, H.; Shiono, S.; Saito, Y.; Nishimura, K.; Ban, T.; Kangawa, K.; Matsuo, H.; Imura, H.  The pharmacokinetics of α-​human atrial natriuretic polypeptide in healthy subjects. Eur. J. Clin. Pharmacol., 1986, 31, 101-103.","α-Human Atrial Natriuretic Peptide. MRT calculated from reported VDss and clearance. N=6, 100 ug of synthetic peptide, bolus.",,1982,3080.44,84,53,1403.4,75,cationic,-9,-9
(-)dOTC,160707-69-7,c1cn(c(=O)nc1N)[C@H]2CO[C@H](S2)CO,1.18,3,,6.5,19.2,"PATRICK F. SMITH, ALAN FORREST, CHARLES H. BALLOW, DAVID E. MARTIN,AND LOUISE PROULX. Absolute Bioavailability and Disposition of (-) and (+) 2'-Deoxy-3'-Oxa-4'-Thiocytidine (dOTC) following Single Intravenousand Oral Doses of Racemic dOTC in Humans. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,2000, 44,1609–1615.",Dosed as 100 mg of racemate. (-) form called apricitabine or (-) BCH10652. Data for (+) form reported as well. MRT from VDss and clearance. ,,1994,229.26,6,2,90.4,2,neutral,-1.9,-1.9
(+)dOTC,160707-68-6,c1cn(c(=O)nc1N)[C@@H]2CO[C@@H](S2)CO,0.84,3.9,,3.6,8.92,"PATRICK F. SMITH, ALAN FORREST, CHARLES H. BALLOW, DAVID E. MARTIN,AND LOUISE PROULX. Absolute Bioavailability and Disposition of (-) and (+) 2'-Deoxy-3'-Oxa-4'-Thiocytidine (dOTC) following Single Intravenousand Oral Doses of Racemic dOTC in Humans. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,
2000, 44,1609–1615.",Dosed as 100 mg of racemate. (-) form called apricitabine or (-) BCH10652. The (+) form is called (+)-BCH 10652; (+)-DOTC; BCH 10619. Data for (-) form reported as well. MRT from VDss and clearance. ,,1994,229.26,6,2,90.4,2,neutral,-1.9,-1.9
"1,3-DCQA",19870-46-3,O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c3ccc(O)c(O)c3)C(=O)O,0.79,8.7,,1.5,1.37,"Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325","1,3-dicaffeoylquinic acid. Data digitized from plot reported. All from average males/females. 6 vials EH product tested for content via HPLC. 1.26 mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.",,1964,516.45,12,7,211.3,9,anionic,2.1,-1.6
16-acetyl gitoxin,7242-07-1,C1([C@@H]2[C@@]3([C@@]([C@@H]4[C@@H]([C@@]5(CC[C@@H](O[C@@H]6O[C@@H](C)[C@@H]([C@@H](C6)O)O[C@@H]6O[C@@H](C)[C@@H]([C@@H](C6)O)O[C@@H]6O[C@@H](C)[C@@H]([C@@H](C6)O)O)C[C@@H]5CC4)C)CC3)(C[C@@H]2OC(=O)C)O)C)=CC(=O)OC1,0.78,0.18,0.07,72.3,51.6,"Hausten, K.-O. On the Pharmacokinetics of 16-Acetyl-gitoxin and Its Bioavailability from Pengitoxin-Containing Tablet Formulations. Int. J. Pharmacokin. Biopharm. 1986, 14, 357-364. ","16-O-acetylgitoxin. N=6, 65.3 kg average weight. 0.5 mg administered iv in 1 minute. MRT calculate from AUC and AUMC in turn calculated from C1, C2 and lamba 1 and 2. VDss then calculated from MRT and clearance reported. Fu reported by the author from own previous work. G. Hiiller, K.-O. Haustein, and D. Murawski. On the plasma-protein binding of 16-acetylgitoxin.
Int. J. Clin. Pharmacol. 19:200-202 (1981).",,1960,822.98,15,5,209.1,9,neutral,0.93,0.93
1-Aminocyclopropanecarboxylic Acid,22059-21-8,[H]N([H])C1(CC1)C(=O)O[H],0.73,1.5,,7.8,5.9,"Cherkofsky, S.C. (1995) 1-Aminocyclopropylcarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships.  J. Pharm. Sci.  84: 1231-1235.",,,1922,101.1,3,2,63.3,3,zwitterionic,-0.66,-2.4
"3,4-DCQA",14534-61-3,C1[C@@](C[C@H]([C@H]([C@@H]1OC(\C=C\c1cc(c(cc1)O)O)=O)OC(\C=C\c1cc(c(cc1)O)O)=O)O)(C(=O)O)O,0.63,34.58,,0.3,0.57,"Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325","3,4-dicaffeoylquinic acid. Data digitized from plot reported.  All from average males/females. 6 vials EH product tested for content via HPLC.  20.4  mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.",,1961,516.45,12,7,211.3,9,anionic,2.6,-1
"3,5-DCQA",2450-53-5,O[C@@H]1[C@@H](C[C@](O)(C[C@H]1OC(=O)\C=C\c2ccc(O)c(O)c2)C(=O)O)OC(=O)\C=C\c3ccc(O)c(O)c3,4.82,75.81,,1.05,3.17,"Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325","3,5-dicaffeoylquinic acid. Data digitized from plot reported.  All from average males/females. 6 vials EH product tested for content via HPLC. 16.44 mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.",,1963,516.45,12,7,211.3,9,anionic,2.6,-1.1
3-O-demethylfortimicin A,74842-47-0,N([C@@H]1[C@@H]([C@@H]([C@@H]([C@@H](O[C@@H]2[C@@H](CC[C@@H](O2)[C@@H](C)N)N)[C@@H]1O)N)O)O)(C)C(CN)=O,0.27,1.37,,3.3,2.9,"LAWRENCE T. SENNELLO, DAVID S. WILSON, JOANNE AFARIAN, LORRAINE S. HOLTAM, GREGORY NORMAN, DOUGLAS E. ROLLINS, AND KEITH G. TOLMAN. Single-Dose Pharmacokinetics of 3-0-Demethylfortimicin A in Humans after Intravenous and Intramuscular Administration. ANTIMICR. Agents CHEMOTHER.. 1986, 29, 400-404.",N=4 for each dose across 5 doses ( 1-16 mg/kg). VDss calculated from Vc and k12/k21 ratios. MRT from reported clearance and calculated VDss. 72.1 kg median weight reported.,,1980,391.46,11,7,203.5,5,cationic,-5.1,-8.2
5-Hydroxymethyl tolterodine,207679-81-0,CC(C)N(CC[C@H](C(C=CC=C1)=C1)C1C(=CC=C(C=1)CO)O)C(C)C,2.41,,0.5,,,PDR reference on fesoterodine. Accessed July 14 2014. http://www.pdr3d.com/detail.php?c=114031#section-12,"After oral administration, fesoterodine is well absorbed. Due to rapid and extensive hydrolysis by nonspecific esterases to its active metabolite 5-hydroxymethyl tolterodine, fesoterodine cannot be detected in plasma. Bioavailability of the active metabolite is 52%. VDss from dosing of actual metabolite.",,1994,341.49,3,2,43.7,8,cationic,4.1,0.67
852A,532959-63-0,[H]N([H])c1c2c(c3ccccc3n1)n(CCCCN([H])S(C)(=O)=O)c(CC)n2,3.1,7.7,,4.7,7.1,"Harrison LI, Astry C, Kumar S, et al. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol. 2007;47:962–969","Data digitized from plot in figure 2. All calculations almost identical to respective value reported. N = 6, 70 kg average weight assumed,  2 mg dose. 10'' bolus. VDss = 3.1 L/kg, Cl = 7.7 mL/min/kg, MRT = 4.7 h, t1/2 = 7.1 h. Compound also reported as 3M-001",,2003,361.46,7,2,102.9,8,cationic,2.3,1.8
Abacavir,136470-78-5,Nc1nc(NC2CC2)c3ncn([C@@H]4C[C@H](CO)C=C4)c3n1,0.84,13,0.5,1.1,1,"Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, and Stein DS. (1999) Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food.    Pharmacotherapy 19: 932-942.  Ziagen Product Label.",,,1991,286.33,7,3,101.9,4,neutral,0.99,0.99
Abanoquil,90402-40-7,COc1cc2CCN(Cc2cc1OC)c3cc(N)c4cc(OC)c(OC)cc4n3,6.3,14,,7.6,5.9,"Schafers RF, Elliott HL, Meredith PA, Miller SHK, and Reid JL (1991) Studies with abanoquil (UK-52,046) a novel quinoline α1-adrenoceptor antagonist:  II.  Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects.  Br. J. Clin. Pharmacol. 32: 605-610.",,,1984,395.45,7,1,79.1,5,cationic,3.5,1.2
Abexinostat,783355-60-2,CN(C)Cc1c2ccccc2oc1C(=O)NCCOc3ccc(cc3)C(=O)NO,2.6,16.33,,2.65,5.9,"S. D. Undevia, L. Janisch, R. L. Schilsky, D. Loury, S. Balasubramanian, C. Mani, M. Sirisawad, J. J. Buggy, R. A. Miller, M. J. Ratain. Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781. J. Clin. Oncol. 26, no. 90150 (May 2008) abstract 14514. http://ascopubs.org/doi/abs/10.1200/jco.2008.26.90150.14514. Accessed December 17 2016.","PCI 24781. CRA 024781. Data from 2h  intravenous infusions, daiyly for 3 days, every 3 weeks. 15 patients. 12M/3F. STD dose levels between 2 and 2.4 mg/kg.  Clearance 0.98 L.kg-1.h-1. MRT from clearance and VDss.",,2004,397.42,8,3,104.3,8,neutral,2,1.7
ABP-700,1446482-29-6,COC(=O)C1(CC1)OC(=O)c2cncn2[C@H](C)c3ccccc3,,50.08,,,0.24,"Michel M. R. F. Struys, M.D., Ph.D., F.R.C.A., Beatrijs I. Valk, B.Sc., Douglas J. Eleveld, Ph.D.,
Anthony R. Absalom, Peter Meyer,  Sascha Meier, Izaak den Daas,  Thomas Chou, Kai van Amsterdam, Jason A. Campagna,  Steven P. Sweeney, . A Phase 1, Single-center, Double-blind, Placebocontrolled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics–Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single Ascending Bolus Dose. Anesth. 2017  doi: 10.1097/ALN.00000000000016. Accessed May 12 2017.",Averaged across 9 doses from 0.1 to 1 mg/kg. N=50 overall. 70 kg average weight assumed. Fairly linear data. Data reported in SI but no VDss or MRT available despite being mentioned in the calculations.,,2012,314.34,6,0,70.4,7,neutral,2,2
Acamprosate,77337-76-9,OS(=O)(=O)CCCNC(=O)C,0.3,3.75,1,1.54,3.2,2003-Jul-23  PDF(2806k) Clinical Pharmacology and Biopharmaceutics Review 021431/S-000. FDA. Accessed through Pharmapendium. ,Structure and smiles refer to free acid. 666 mg iv through infusion. N=24. 70 kg assumed. Tables on page 12. negligible ppb (PDR).,,1984,181.21,5,2,83.5,4,anionic,-1.7,-5.2
Acarbose,56180-94-0,C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]3C=C(CO)[C@@H](O)[C@H](O)[C@H]3O,0.32,2.2,,2.4,2.7,"Putter J, Keup U, Krause HP, Muller L, and Weber H (1982) Pharmacokinetics of acarbose.  Int. Congr. Ser. 594: 38-48. ",mainly excreted renally after iv and mainly metabolized from gastrointestinal enzymes and bacteria after po dose (renal 1.7%),,1975,645.6,19,14,329,13,neutral,-9,-9
Acebutolol,37517-30-9,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(=O)C,1.7,10,0.74,2.8,3.5,"Kaye CM, Kumana CR, Leighton M, Hamer J, and Turner P (1976) Observations on the pharmacokinetics of acebutolol.  Clin. Pharmacol. Ther.  19: 416-420.  Meffin PJ, Winkle RA, Peters FA, and Harrison DC (1977) Acebutolol disposition after intravenous administration.  Clin. Pharmacol. Ther. 22: 557-567.  Roux A, Flouvat B, Chau NP, Letac B, and Lucsko M (1980) Pharmacokinetics of acebutalol after intravenous bolus administration.  Br. J. Clin. Pharmacol. 9: 215-217.","Vss calculated from digitized plots from Kaye, et al, and from reported microconstants from Roux, et al.",,1947,336.43,6,3,87.7,10,cationic,1.6,-0.23
Acecainide (N-acetylprocainamide),32795-44-1,CCN(CC)CCNC(=O)c1ccc(NC(=O)C)cc1,1.9,4,0.9,7.9,6.4,"Coyle JD, Boudoulas H, and Lima JJ (1991) Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.  Biopharm. Drug Dispos. 12: 599-612.   Connolly SJ and Kates RE (1982)  Clinical pharmacokinetics of N-acetylprocainamide.    Clin. Pharmacokinet. 7: 206-220.",,,1972,277.36,5,2,61.4,7,cationic,1.3,-0.26
Acenocoumarol,152-72-7,[H]OC1=C(C(=O)Oc2ccccc12)[C@H](CC(C)=O)c1ccc(cc1)[N+]([O-])=O,0.24,1.28,0.02,3.125,7.22,"Godbillon J, Richard J, Gerardin A, et al. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol 1981, 12, 621-629.","Data from 25 mg iv dose, N=2, 77.5 Kg average weight (N=4), VDss = average of R(+) and S(-) enantiomers. T½ and CL is the average of single enantiomers and racemate R,S(±) (see Table 1). MRT calculated from CL and VDss and fu from PB 98.0% (average of enantiomers and racemate). The average of all available values for every parameter are reported. There are many differences between two enantiomers alone and/or the racemate (see table 1 in reference)",,1953,353.33,7,1,106.7,6,anionic,2.5,0.12
Acetaminophen,103-90-2,CC(=O)Nc1ccc(O)cc1,1,5,0.52,3.3,2.5,"Rowlins MD, Henderson DB, Hijab AR (1977) Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 11: 283-286.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",VDss calculated from micro rate constants provided in Rowlins et al.,,1907,151.16,3,2,49.3,1,neutral,0.76,0.76
Acetazolamide,59-66-5,CC(=O)Nc1nnc(s1)S(=O)(=O)N,0.37,0.65,0.04,9.5,13,"Chapron DJ, Sweeney KR, Feig PU, and Kramer PA (1985) Influence of advanced age on the disposition of acetazolamide.  Br. J. Clin. Pharmacol. 19: 363-371.",VDss and t1/2 were calculated from C vs t data obtained by digitization of plots included in the reference.,,1950,222.25,7,2,115,2,neutral,-1.5,-1.6
"Acetylcysteine, N-",616-91-1,CC(=O)N[C@@H](CS)C(=O)O,0.55,3.1,0.17,3,5.5,"Prescott LF, Donovan JW, Jarvie DR, and Proudfoot AT. The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage.  Eur. J. Clin. Pharmacol. 1989, 37, 501-506.  Acetadote Product Label.",,,1921,163.19,4,2,66.4,3,anionic,-0.53,-3.8
"Acetylmethadol, L-",1477-40-3,CC[C@H](OC(=O)C)C(C[C@H](C)N(C)C)(c1ccccc1)c2ccccc2,8.3,5.4,0.2,26,18,"Walsh SL, Johnson RE, Cone EJ, and Bigelow GE (1998) Intravenous and oral l-.alpha.-acetylmethadol: pharmacodynamics and pharmacokinetics in humans.  J. Pharmacol. Exp. Ther.  285: 71-82.  Toro-Goyco E, Martin BR, and Harris LS (1980) Binding of 1-alpha-acetylmethadol and its metabolites to blood constituents.  Biochem. Pharmacol. 29: 1897-1902.",,,1966,353.5,3,0,29.5,9,cationic,4.5,3.2
Acetylsalicylic Acid,50-78-2,CC(=O)Oc1ccccc1C(=O)O,0.22,12,0.68,0.3,0.26,"Aarons L, Hopkins K, Rowland M, Brossel S, and Thiercelin JF (1989) Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt.   Pharm. Res. 6: 660-666.  Lee S, Johnson D, Klein J, and Eppler J (1995) Protein binding of acetylsalicylic acid and salicylic acid in porcine and human serum.  Vet. Human Toxicol. 37: 224-225",,,1907,180.16,4,1,63.6,3,anionic,1.6,-1.7
ACHT 4-10,4037-01-8,CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc3c[nH]c4c3cccc4)C(=O)NCC(=O)O)N,0.73,871,,0.01,0.06,"U. Bickel, J. Born, H.L. Fehm, M. Distler, and K. H. Voigt. The Behaviorally Active Peptide ACTH 4-10: Measurement in Plasma and Pharmacokinetics in Man.  Eur J Clin Pharmacol (1988) 35:371-377","4-10-Corticotropin, ACTH (4-10). MRT from clearance and VDss, 125 ug dose, very high clearance.",,1968,962.09,23,13,384.1,29,zwitterionic,-0.68,-4.5
Acivicin,42228-92-2,N[C@@H]([C@@H]1CC(=NO1)Cl)C(=O)O,0.5,0.69,,12,9.9,"McGovern JP, Pratt EA, Belt RJ, Taylor SA, Benjamin RS, Ardalan B, and Ohnuma T (1985) Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials.  Canc. Res.  45: 4460-4463.",VDss was calculated from C vs t data obtained by digitization of a plot for one subjected that was included in the reference.  Plasma concentrations were determined by bioassay.,,1973,178.57,5,2,84.9,2,zwitterionic,-0.38,-2.7
Aclidinium bromide,320345-99-1,c1ccc(cc1)OCCC[N+]23CCC(CC2)[C@H](C3)OC(=O)C(c4cccs4)(c5cccs5)O,4.3,48.5,,1.76,,PDR. Accessed August 07 2014. http://www.pdr3d.com/detail.php?c=82946#section-12,Assumed 70 kg as average weight. t1/2 iv not reported.  MRT from VDss and clearance. CAS number for bromide salt. Bromide ion omitted from smiles.,,2001,484.65,5,1,55.8,10,neutral,1.7,1.7
Actisomide,96914-39-5,CC(C)N(CC[C@@]1(C(N=C(C)N2CCCC[C@H]12)=O)c1ccccc1)C(C)C,0.58,6.79,0.7,1.58,1.89,"Cook CS et al. Pharmacokinetics of a novel antiarrhythmic drug, Actisomide. Pharm Res, 1993, 10(3), 427-433.","Data from 50 mg/person 5 min iv infusion, N=6, 62.8 Kg average weight. t½ taken as the β phase.  fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",,1985,369.54,4,0,35.9,6,cationic,4,2.6
Acyclovir,59277-89-3,NC1=Nc2c(ncn2COCCO)C(=O)N1,0.71,4.7,0.85,2.5,2.5,De Miranda P and Blum MR (1983) Pharmacokinetics of acyclovir after intravenous and oral administration.  J. Antimic. Chemother. 12(Suppl B): 29-37.,,,1976,225.2,8,3,114.8,4,neutral,-1.7,-1.8
Adefovir,106941-25-7,Nc1ncnc2c1ncn2CCOCP(=O)(O)O,0.42,3.7,0.96,1.9,1.6,"Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, and Jaffe HS. (1995) Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.  Antimic. Agents Chemother. 39: 2401-2405.   Hepsera Product Label.",,,1986,273.19,9,3,136.4,5,anionic,-1.6,-6.8
Adinazolam,37115-32-5,CN(C)Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4n12,0.98,6.2,0.31,2.6,2.1,"Fleishaker JC, Friedman H, and Pollock SR (1991)  Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.  Pharm. Res.  8: 162-167.",,,1972,351.83,5,0,46.3,3,neutral,1.3,1.3
AFN-1252,620175-39-5,Cc1c2ccccc2oc1CN(C)C(=O)/C=C/c3cc4c(nc3)NC(=O)CC4,0.43,0.9,,8.4,6.4,"Kaplan, Nachum; Garner, Colin; Hafkin, Barry. AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. European Journal of Pharmaceutical Sciences (2013), 50(3-4), 440-446.",Profile digitized from Fig. 4. Microdose of 100 ug of AFN-1252 tosylate (equivalent to ~68.6 ug of AFN-1252) 30min infusion. N=4 male with median BMI of 24 (70kg body weight assumed). ,,2003,375.42,6,1,75.7,4,neutral,2.1,2.1
AG-EE-388 ZW,135969-54-9,C(c1c(cc(cc1)CC(=O)N[C@@H](CC(C)C)c1c(cccc1)N1CCCCC1)OCC)(=O)O,0.28,2.04,,3,2.5,"Greischel, Andreas; Beschke, Klaus; Rapp, Hermann; Roth, Willy. Quantitation of the new hypoglycemic agent AG-EE 388 ZW in human plasma by automated highperformance
liquid chromatography with electrochemical detection. J. Chrom, Biomed App. 1991, 568, 246-252",1 mg dose but no N or average weight (assumed to be 70 kg) were reported. Electrochemical (specific) detection after administartion of 14-C labeled compound.,,1987,452.59,6,2,78.9,10,anionic,5.8,2.4
Ajmaline,4360-12-7,CC[C@@H]1[C@H](N2[C@H]3CC1C4[C@@H]2CC5([C@H]3N(c6c5cccc6)C)[C@@H]4O)O,4,9.8,0.24,6.8,7.3,"Roberto Padrini,  Donatella Piovan,  Antonio Javarnaro, Francesco Cucchini, Mariano Ferrari. Pharmacokinetics and Electrophysiological Effects of Intravenous Ajmaline. Clin. Pharmacokinet. 1993, 25, 408-414.//ppb: Köppel C, Wagemann A, Martens F. Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. Eur J Drug Metab Pharmacokinet. 1989, 14, 161-167.","Rauwolfine. N=10, average dose 67.4 mg, MRT from clearance and VDss. Average weight 67 kg.",,1931,326.43,4,2,46.9,1,cationic,1.8,1.5
Albuterol (salbutamol),18559-94-9,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1.9,7.8,0.92,4.1,2.4,"Boulton DW and Fawcett JP (1996) Enantioselective disposition of salbutamol in man following oral and intravenous administration.  Br. J. Clin. Pharmacol. 1996, 41, 35-40.  Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, and Ziccone SP (1986) Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate.  Br. J. Clin. Pharmacol.  22: 587-593.",Data for enantiomers were averaged.,,1962,239.31,4,4,72.7,4,cationic,0.63,-1.5
Alcuronium,23214-96-2,OC\C=C/1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C5=CN6[C@H]7C(=CN([C@H]35)c8ccccc48)[C@H]9C[C@H]%10[C@@]7(CC[N@@+]%10(CC=C)C/C/9=C/CO)c%11ccccc6%11,0.32,1.3,,4.1,3.6,"Walker J, Shanks CA, and Triggs EJ (1980)  Clinical pharmacokinetics of alcuronium chloride in man.  Eur. J. Clin. Pharmacol. 17: 449-457. ",,,1960,666.89,6,2,46.9,6,neutral,-4.8,-4.8
Alectinib,1256580-46-7,CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C,6.35,7.69,0.003,13.77,11.7,"Peter N. Morcos, Li Yu, Katrijn Bogman, Mika Sato, Hisakazu Katsuki, Kosuke Kawashima, David J Moore, Matt Whayman, Keith Nieforth, Katja Heinig, Elena Guerini, Dieter Muri, Meret Martin-Facklam and Alex Phipps. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiot. Early online 2016, DOI: 10.1080/00498254.2016.1179821//ppb: FDA review https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000PharmR.pdf. Accessed May 1 2017.","Microtracer dose of 14C-labelled compound administered 3.75 hours after a 600 mg po dose. N= 6, 74.8 kg average reported. MRT from clearance and VDss.//ppb at 0.1, 1 and 10 ug/mL.",,2010,482.62,6,1,72.4,4,cationic,5.2,4.9
Alendronate,66376-36-1,C(P(O)(O)=O)(P(O)(O)=O)(CCCN)O,0.33,2.6,0.22,2.1,3.1,"Trimethylsilyldiazomethane derivatization coupled with solid-phase extraction for the determination of alendronate in human plasma by LC-MS/MS Meixia Chen, Ke Liu, Dafang Zhong, Xiaoyan Chen. Anal Bioanal Chem (2012) 402:791–798. ppb: reported by PDR :Protein binding in human plasma is approximately 78%. Accessed December 30 2014. http://www.pdr3d.com/detail.php?c=13132#section-3","Data digitized from plot reported. 10 mg dose, 4 hrs infusion, N=10, 70 kg average weight assumed, reported AUCinf. 935 ng.h/mL",,1978,249.1,8,6,161.3,5,anionic,-3,-8.1
Alfacalcidol,41294-56-8,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,,0.82,,,48.6,"L. Brandi, M. Egfjord, K. Olgaard. Pharmacokinetics of 1,25(OH)2D3 and 1a(OH)D3 in normal and uraemic men. Nephrol. Dial. Transpl. 2002, 17, 829-842.","1alpha-Hydroxy-vitamin D3. 1-Hydroxycholecalciferol. No volume of distribution reported. Clearance calculated from AUC0-72 hrs, N=6, 59.2 kg average weight, 4 ug dose iv.",,1954,400.64,2,2,40.5,6,neutral,7.3,7.3
Alfentanil,71195-58-9,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)c3ccccc3)C1=O,0.45,3.9,0.086,1.9,1.6,"Bower S and Hull CJ (1982) Comparative pharmacokinetics of fentanyl and alfentanil.  Br. J. Anaesth. 54: 871-877.  McDonnell CG, Malkan D, Van Pelt FD, and Shorten GD (2003) Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin.    Eur. J. Anaesth. 20: 662-667.  Meuldermans WEG, Hurkmans RMA, and Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.    Arch. Int. Pharmacodyn. Ther.  257: 4-19.  Lemmens HJ, Burm AG, Bovill JG, Hennis PJ, and Gladines MP (1992)  Pharmacodynamics of alfentanil. The role of plasma protein binding.    Anesthesiol.  76: 65-70.",,,1980,416.52,9,0,81.1,9,neutral,2.8,2.7
Alfuzosin,81403-80-7,COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C3CCCO3,1.5,5.9,0.14,4.2,4.8,"Guinebault P, Colafranceschi C, Bianchetti G, Thenot JP, Maillard D, Thiercelin JF, Larribaud J, and Morselli PL (1984) Absolute bioavailability of alfuzosin, a new α1-​post synaptic receptor antagonist, after oral and intravenous administration.  Biopharm. Pharmacokinet. 2nd European Congress 2: 578-583. ppb: The PDR states: Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL). Median value taken. Accessed January 7 2015. http://www.pdr3d.com/detail.php?c=76486#section-13.",VDss calculated from C vs t data obtained by digitization of the plots included in the reference.,,1982,389.45,9,2,111.8,8,cationic,2.3,1.8
Alinidine,33178-86-8,N(c1c(cccc1Cl)Cl)(C=1NCCN1)CC=C,2.72,12,0.4,3.77,3.14,"Arndts, D.; Warnkross, H.; Rominger, K. L.; Justus, H. Proof of the Linearity of the Pharmacokinetics of Alidine in Man. Eur. J. Clin. Pharmacol. (1981), 21, 201-207.//ppb: R. E. Heckner. Systematic study of protein binding of biologically active substances. Pharmatherapeutica, 1973, 2, 177-186.","ST 567. 10 mg dose, specific RIA, N=5, average weight 74.7. MRT from VDss and clearance.//ppb: equilibrium dialysis, 0.4 ug/mL starting concentration in blood.",,1971,270.16,3,1,27.6,4,cationic,3,1.7
Alizapride,59338-93-1,COc1cc2nn[nH]c2cc1C(=O)NCC3CCCN3CC=C,1.6,6.6,,4,2.8,"Houin G, Barre J, and Tillement JP. Absolute intramuscular, oral, and rectal bioavailability of alizapride.  J. Pharm. Sci.  (1984) 73: 1450-1453.",VDss calculated from C vs t data obtained by digitization of the plots included in the reference.,,1975,315.37,7,2,83.1,6,cationic,1.9,0.91
Allopurinol,315-30-0,O=C1NC=Nc2[nH]ncc12,0.58,11,0.97,0.88,0.8,"Breithaupt H and Tittel M (1982) Kinetics of allopurinol after sinlge intravenous and oral doses.  Eur. J. Clin. Pharmacol. 22: 77-84.  Elion GB, Kovensky A, Hitchings GH, Metz E, and Rundles RW (1966) Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.    Biochem. Pharmacol. 15: 863-889.",,,1913,136.11,5,2,70.1,0,neutral,-1.3,-1.4
Almitrine,27469-53-0,C(N1CCN(c2nc(nc(n2)NCC=C)NCC=C)CC1)(c1ccc(F)cc1)c1ccc(F)cc1,35.37,0.97,0.01,607,1344,"Bernhard R. Winkelmann, Thomas H. Kullmer, Dieter G. Kneissi, Dietmar Trenk, Hartmut Kronenberger. Low-dose Almitrine Bismesylate in the Treatment of Hypoxemia due to Chronic Obstructive Pulmonary Disease. Chest, 1994; 105, 1383-1391.////ppb: Bromet N; Singlas E. Clinical pharmacokinetics of almitrine dimesylate. Presse medicale, 1984, 13, 2071-2077.","N=7, average weight 64 kg. 60 mg dose. VD reported taken as VDss after calculation from clearance and t 1/2 yielded a much higher value. MRT from clearance and VDss.",,1970,477.55,7,2,69.2,10,neutral,6,6
Almokalant,123955-10-2,C(c1ccc(cc1)OC[C@@H](C[N@@](CCC[S@@](=O)CCC)CC)O)#N,1.8,11.3,,2.65,2.4,"Electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias Wiesfeld A C; Crijns H J; Tobe T J; Almgren O; Bergstrand R H; Aberg J; Haaksma J; Lie K I. The American journal of cardiology (1992), 70(11), 990-996.",Intravenous infusion (10') of 4.5 mg. N=10. Data reported in table III. MRT from VDss/clearance,,1989,352.49,5,1,73.6,13,cationic,2,1.4
Almorexant,871224-64-5,CNC(=O)C(N1CCC2=C(C=C(OC)C(OC)=C2)[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,9.75,10.2,,15.9,34.3,"Absolute Oral Bioavailability of Almorexant, a Dual Orexin Receptor Antagonist, in Healthy Human Subjects. Matthias Hoch  Petra Hoever, Jochen Zisowsky, Anthony Priestley,
David Fleet, Jasper Dingemanse. Pharmacology 2012;89:53–57.","N=20, 20 mg dose, 70 kg assumed. 30' infusion. MRT from VDss and clearance.",,2005,512.56,5,1,50.8,8,neutral,5.5,5.5
Almotriptan,154323-57-6,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,2.2,8.9,0.6,4.2,3.4,"Gras J, Llenas J, Jansat JM, Jáuregui J, Cabarrocas X, Palacios JM (2002) Almotriptan, a New Anti-Migraine Agent: A Review CNS Drug Rev. 8: 217-234.  Jansat, JM, Costa J, Salva P, Fernandez FJ, and Martinez-Tobed A (2002) Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.  J. Clin. Pharmacol. 42: 1303-1310.","VDss calculated from MRT and CL reported in Jansat, et al. ",,1994,335.46,5,1,56.4,6,cationic,1.8,0.63
Alosetron,122852-42-0,Cc1[nH]cnc1CN2CCc3c(C2=O)c4ccccc4n3C,1.1,8.7,0.18,2.1,1.6,"Kock KM, Palmer JL, Noordin N, Tomlinson JJ, and Baidoo C (2002) Sex and age differences in the pharmacokinetics of alosetron.  Br. J. Clin. Pharmacol. 53: 238-242.  Lotronex Product Label",,,1989,294.35,5,1,53.9,2,neutral,1.4,1.4
Alpiropride,81982-32-3,C1C[N@@]([C@@H](C1)CNC(c1c(cc(c(c1)S(NC)(=O)=O)N)OC)=O)CC=C,2.3,5.47,,7,4.8," F. BRESSOLLE, J. BRES and M. SNOUSSI. High-performance liquid chromatographic determination of a new benzamide in biological fluids for use in a human pharmacokinetic study. Journal of Chromatography, Biomedical Applications  1985 343, 443-448","Reported as Riv 2093. N=12, 50 mg dose. 67 kg weight calculated from VDss (L/kg), clearance (L/h) and MRT.",,1982,382.48,8,3,113.8,8,cationic,0.97,-0.1
Alprazolam,28981-97-7,Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4n12,0.8,0.74,0.29,18,12,"Smith RB, Kroboth PD, Vanderligt JT, Phillips JP, and Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.  Psychopharmacology 84: 452-456.  Greenblatt DJ and Wright CE (1993) Clinical pharmacokinetics of alprazolam. Therapeutic implications.    Clin. pharmacokinet. 24: 453-471.  ",VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.,,1970,308.76,4,0,43.1,1,neutral,2,1.9
Alprenolol,13655-52-2,CC(C)NCC(O)COc1ccccc1CC=C,3.2,15,0.18,3.6,2.5,"Bodin NO, Borg KO, Johansson R, Obianwu H, Svensson R. The absorption, distribution, and excretion of alprenolol in man, dog, and rat.  Acta Pharmacol. Toxicol. 1974, 35, 261-269.   Imamura H, Komori T, Ismail A, Suenaga A, and Otagiri M (2002)  Stereoselective protein binding of alprenolol in the renal diseased state.  Chirality 14: 599-603.",VDss and CL calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1966,249.35,3,2,41.5,8,cationic,2.4,0.64
Alprostadil,745-65-3,CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O,2.4,45.4,,0.9,1.9,"W. Cawello , H. Schweel , R. Miiller, R. Bonn, H.W. Seyberth. Metabolism and pharmacokinetics of prostaglandin E1 administered
by intravenous infusion in human subjects. Eur J Clin Pharmacol (1994) 46:275-277","PGE1. Plot available for digitization. Calculation perforrmed via Phoenix after digitization. Dose 60 ug 2h of infusion, N=12",,1956,354.48,5,3,94.8,13,anionic,3.5,0.93
Alvimopan,156053-89-3,C[C@H]1CN(CC[C@@]1(C)c2cccc(c2)O)C[C@H](Cc3ccccc3)C(=O)NCC(=O)O,0.43,5.84,0.2,1.24,5.3,Biopharmaceutics review: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021775_ENTEREG_CAPSULES_BIOPHARMR.pdf. Accessed on April 11 2017.,"iv dose, 12 mg, 70 kg assumed as average weight. 6% F; 35% renal clearance. MRT from VDss/clearance.",,1994,424.53,6,3,89.9,8,zwitterionic,3.1,0.28
Amantadine,768-94-5,NC12CC3CC(CC(C3)C1)C2,6.6,4.8,0.33,23,16,Aoki FY and Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride.  Clin. Pharmacokinet. 14: 35-51.,,,1957,151.25,1,1,26,0,cationic,2.5,-0.43
Amdinocillin,32887-01-7,CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(=O)O,0.37,6.3,0.9,1,1.1,"Patel IH, Bornemann LD, Brocks VM, Fang LS, Tolkoff-Rubin NE, and Rubin RH (1985) Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency.  Antimicrob. Agents Chemother. 28: 46-50.//ppb: Tan, James S.; Salstrom, Sara Jane; File, Thomas M., Jr. Levels of amdinocillin in human plasma and interstitial fluid following intravenous administration. The American Journal of Medicine 1983, 75, 65-67.",Mecillinam. VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.,,1971,325.43,6,1,73.2,3,zwitterionic,2.4,0.068
Amezinium,41658-78-0,c1c(cc([n+](n1)c1ccccc1)OC)N,4,5.1,,13,14.1,"Kaumeier S, Kehrhahn OH, Morgenthaler H, Neugebauer G. Absolute bioavailability of amezinium. A cross-over study after i.v. and p.o. application.Arzneimittelforschung. 1981;31(9a):1653-7.","BRN 4141517. 72 kg reported data. N=8, 10 mg, MRT from VDss and clearance. (all average)",,1973,202.23,4,1,52,2,neutral,-0.75,-0.75
Amifloxacin,86393-37-5,c12c(c(c(C(O)=O)cn1NC)=O)cc(F)c(c2)N1CCN(C)CC1,,4.56,,,4.66,"Schentag J J et al. Pharmacokinetics of Amifloxacin After Oral and Intravenous Administration. Review of infectious diseases. 1989  11, suppl 5","Average of 4 (doses 200, 400, 600 every 12h and 400 every 8h, N=5  male for each one). Values reported as steady state. Average CL renal = 2.38 mL/min/kg (52% of total)",,1983,334.35,7,2,77.8,3,cationic,2.4,0.2
Amifostine,20537-88-6,C(SP(O)(O)=O)CNCCCN,0.09,30.65,,0.05,0.15," LESLIE M. SHAW, PH.D., ANDREW T. TURRISI, M.D., DONNA J. GLOVER, M.D., HEATHER S. BONNER, B.S., A. LORRAINE NORFLEET, B.S., CLARE WEILER, R.N.
AND MORTON M. KLIGERMAN, M.D. HUMAN PHARMACOKINETICS OF WR-2721. Int. J. Radiation Oncology Bio. Phys.. 1986, 12, 1501-1504.","WR-2721, NSC 296961. 12 patients with different types of tumor. 70.8 kg average weight. 150 mg/m2, 10 seconds injection.",,1969,214.22,5,4,95.6,7,cationic,-1.4,-3.8
Amikacin,37517-28-5,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O,0.16,1.1,0.88,2.4,2.4,"Lanao JM, Dominguez-Gil A, Tabernero JM, and De Castro S (1979)  Pharmacokinetics of amikacin (BB-K8) in patients with normal or impaired renal function.  Int. J. Clin. Pharmacol. Biopharm. 17: 171-175.  Clarke JT, Libke RD, Regamey C, and Kirby WMM (1974) Comparative pharmacokinetics of amikacin and kanamycin.  Clin. Pharmacol. Ther.  15: 610-616.  Brunnemann SR and Segal JR (1991) Amikacin serum protein binding in spinal cord injury.  Life Sci. 49: PL1-PL5.",CL calculated from reported compartmental model parameters. Protein binding data averaged from two papers.,,1974,585.6,18,13,331.9,10,cationic,-9,-9
"Aminocamptothecin, 9-",91421-43-1,CC[C@@]1(O)C(=O)OCC2=C1C=C3N(Cc4cc5c(N)cccc5nc34)C2=O,2.2,6.5,0.003,5.6,7,"Herben VM, van Gijn R, Schellens JH, Schot M, Lieverst J, Hillebrand MJ, Schoemaker NE, Porro MG, Beijnen JH, and ten Bokkel Huinink WW (1999)  Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.  J. Clin. Oncol.17: 1906-1914.  Masubuchi N, May RD, and Atsumi R (2004)  A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.  Clin. Cancer Res. 10: 6722-6731.",,,1984,363.37,7,2,105.8,1,neutral,1.1,1.1
"Aminohexanoic acid, 6-",60-32-2,NCCCCCC(=O)O,0.39,2.5,0.92,2.6,4.9,"Frederiksen  MC, Bowsher DJ, Ruo TI, Henthorn TK, Ts'ao CH, Green D, and Atkinson AJ (1984) Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects.  Clin. Pharmacol. Ther. 35: 387-393.  McNicol GP, Fletcher AP, Alkjaersig N, and Sherry S (1962) The absorption, distribution, and excretion of e-aminocaproic acid following oral or intravenous administration to man.  J. Lab Clin. Med. 59: 15-24.",Aminocaproic acid ,,1909,131.17,3,2,63.3,5,zwitterionic,0.16,-2.1
Aminolevulinic acid,106-60-5,NCC(CCC(O)=O)=O,0.12,1.88,0.88,1.06,0.83,1999-Nov-19  PDF(1255k) Pharmacology Review 020965/S-000. NDA 20-965 page 21.,"Levulan kerastick. N=6, 1.34 mg/kg. MRT from VDss and Cl.",,1948,131.13,4,2,80.4,4,zwitterionic,-2,-2.8
"Aminosalicylic acid, 5-",89-57-6,Nc1ccc(O)c(c1)C(=O)O,0.33,9.3,0.39,0.59,0.61,"Bondesen S, Hegnhoj J, Larsen F, Hansen H, Hansen CP, and Rasmussen SN (1991) Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation.  Digest. Dis. Sci.  12: 1735-1740.  Way EL, Smith PK, Howie DL, Weiss R, and Swanson R (1948) The absorption, distribution, excretion, and fate of para-aminosalicylic acid.  J. Pharmacol. Exp. Ther. 93: 368-382.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",Mesalamine. Mesalazine. VDss and t1/2 calculated from data obtained by digitization of C vs t plots provided in the references.,,1907,153.14,4,3,83.6,1,anionic,0.67,-2.6
Amiodarone ,1951-25-3,CCCCc1oc2ccccc2c1C(=O)c3cc(I)c(OCCN(CC)CC)c(I)c3,60,1.9,0.0002,620,820,"Ujhelyi MR, Klamerus KJ, Vadiei K, O'Rangers E, Izard M, Neefe DL, Zimmerman JJ, and Chow MSS (1996) Disposition of intravenous amiodarone in subjects with normal and impaired renal function.  J. Clin. Pharmacol. 36: 122-130.  Veronese ME, McLean S, and Hendriks R (1988) Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.  Br. J. Clin. Pharmacol 26: 721-731.",,,1962,645.31,4,0,43,11,cationic,7.5,6.2
Amiprilose,56824-20-5,O1[C@H]2[C@@H]([C@H]([C@H]1[C@H](O)CO)OCCCN(C)C)OC(C)(C)O2,1.04,3.48,0.97,5,4.07,"Garrett E R; Van Peer A; Altmayer P; Schuermann W; Lucker P. Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-Dglucofuranose
hydrochloride in normal human volunteers. J. Pharmacokin. Biopharm. 1982, 10, 247-264","3-O-(3-(Dimethylamino)propyl)-1,2-O-(1-methylethylidene)-alpha-D-glucofuranose. 96% excreted in urine. All subjects taken. VDss calculated from MRT and clearance. MRT in turn calculated via C1, C2 and lambda 1 and lambda 2. All values taken from overall means.",,1975,305.37,7,2,80.6,7,cationic,-0.32,-2.4
Amitriptyline,50-48-6,CN(C)CCC=C1c2ccccc2CCc3ccccc13,8.7,6.1,0.07,24,17,Jorgensen A and Hansen V (1976) Pharmacokinetics of amitriptyline infused intravenously in man.  Eur. J. Clin. Pharmacol.  10: 337-341.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.    Naunyn-Sch Arch. Pharmacol. 327: 260-265.,,,1960,277.4,1,0,3.2,3,cationic,4.6,3.3
Amlodipine,88150-42-9,CCOC(=O)C1=C(COCCN)NC(=C(C1c2ccccc2Cl)C(=O)OC)C,17,7,0.005,40,34,"Faulkner JK, McGibney D, Chasseaud LF, Perry JL, and Taylor IW (1986) The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br. J. Clin. Pharmacol. 22: 21-25.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",VDss calculated from C vs t data obtained by digitization of the plot in Faulkner et al.,,1983,408.88,7,2,99.9,10,cationic,2,0.44
Amodiaquine,86-42-0,CCN(CC)Cc1cc(ccc1O)Nc2ccnc3c2ccc(c3)Cl,17.4,217,,1.34,2.1,"White, N. J.; Looareesuwan, Sornchai; Edwards, G.; Phillips, R. E.; Karbwang, Juntra; Nicholl, Deborah D.; Bunch, C.; Warrell, D. A.. Pharmacokinetics of intravenous amodiaquine. British Journal of Clinical Pharmacology (1987), 23(2), 127-135",N=6 10 mg/kg as 4 hours infusion. 50 kg average weight. Clearance reported as 13 L.kg-1.h-1 in healthy volunteer (data taken) while an average of 5 L.kg-1.h-1 was reported for 10 malaria patients. Same dose and infusion time. MRT from VDss and clearancePlots available. EXTREMELY HIGH CLEARANCE.,,1948,355.86,4,2,48.4,6,cationic,5.4,2
Amonafide,69408-81-7,c12c3C(N(CCN(C)C)C(c1cccc2cc(c3)N)=O)=O,7.33,19.32,,6.34,4.78,"Clinical Pharmacokinetics of Amonafide (NSC 308847) in 62 Patients. W. Kreis, M.D., Ph.D.,l K. Chan, Ph.D., D. R. Budman, M.D.,S. L. Allen, M.D., D. Fusco, B.S.N., A. Mittelman, M.D., J. Freeman, M.S., K. Hock, B.A., S. Akerman, B.S., A. Calabro, M.S., C. Puccio, M. Spigelman, M.D.Cancer Investigation, 1996, 14(4), 320-327.","Data reported in Table 1. Weight-averaged across all patients. Linear PK. VDss from CL and MRT reported, t1/2 from compartmental analysis.",,1978,283.33,5,1,66.6,3,neutral,1.5,1.3
Amoxicillin,26787-78-0,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,0.25,3.3,0.85,1.3,1.1,"Arancibia A, Guttmann J, Gonzalez G, and Gonzalez C (1980) Absorption and disposition kinetics of amoxicillin in normal human subjects.  Antimicrob. Agents Chemother. 17: 199-202.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",,,1970,365.4,8,4,133,4,zwitterionic,0.42,-1.3
AMP579,213453-89-5,CC[C@H](Cc1c(ccs1)Cl)Nc2c3ccn(c3ncn2)[C@@H]4C[C@@H]([C@H]([C@H]4O)O)C(=O)NCC,0.84,12,0.03,1.18,1.33,"Peter N. Zannikos, PharmD, PhD, Bradford K. Jensen, PhD, Bruno X. Boutouyrie, MD,
Lisa Tripp, BS, Luo Yongyi, MS, Tracy McGowan, MD, Scott A. Waldman, MD, PhD,
and Howard E. Greenberg, MD, MS. Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End-Stage Renal Insufficiency. Journal of Clinical Pharmacology, 2000;40:745-751","Data taken from Table II. N=6, healthy volunteers, 50 ug/kg as a 6-hour infusion. MRT from clearance and VDss. Seemingly no significant difference with renally impaired patients.",,1998,478.01,8,4,112.3,8,neutral,2.6,2.6
Amphetamine (-d),51-64-9,c1(ccccc1)C[C@H](C)N,6.1,9.7,0.8,10,7.3,"Angagard E, Gunne LM, Jonsson LE and Niklasson F (1970) Pharmacokinetics and clinical studies on amphetamine dependent subjects.  Eur. J. Clin. Pharmacol. 3: 3-11.  Busto U, Bendayan R, and Sellers EM (1989) Clinical pharmacokinetics of non-opiate abused drugs.  Clin. Pharmacokinet. 16: 1-26.  De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S. Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet. 2004, 43, 157-185.",PK reported as monoexponential decline so reported VD was used as VDss.  CL calculated from VD and t1/2.,,1946,135.21,1,1,26,2,cationic,1.8,-0.64
Amphotericin B,1397-89-3,[H]N([H])[C@@H]1[C@@H]([C@@H](O[C@@H]2C[C@H]3[C@H](C(=O)O[H])[C@H](C[C@@](C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@@H](C)[C@H](C)[C@@H]([C@@H](C)C=CC=CC=CC=CC=CC=CC=C2)O[H])O[H])O[H])O[H])O[H])O[H])(O[H])O3)O[H])O[C@H](C)[C@H]1O[H])O[H],0.62,0.17,0.03,61,40,"Kan, V. L.; Bennett, J. E.; Amantea, M. A.; Smolskis, M. C.; McManus, E.; Grasela, D. M.; Sherman, J. W. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers. J. Infect. Dis. 1991, 164, 418-421.","Bellmann, R. Curr. Clin. Pharmacol., 2007, 2, 37-58. VDss 0.62 L/kg. PK parameters variability due to formulation and disease state, reported in a plethora of references, cited by the same author. Actual data data taken from Kan et al. J. Infect. Dis. 1991, 164, 418-421. N=16 healthy volunteers.",,1945,924.08,18,12,319.6,15,zwitterionic,3.1,0.41
Ampicillin,69-53-4,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,0.22,2.8,0.85,1.3,1.4,"Blum RA, Kohli RK, Harrison NJ, and Schentag JJ (1989) Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.    Antimic. Agents Chemother. 33: 1470-1476.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",,,1953,349.4,7,3,112.7,4,zwitterionic,0.85,-0.85
Amrinone,60719-84-8,NC1=CC(=CNC1=O)c2ccncc2,1.3,8.9,0.89,2.4,2,"Hamilton RA, Kowalsky SF, Wright EM, Cernak P, Benziger DP, Stroshane RM, and Edelson J (1986)  Effect of the acetylator phenotype on amrinone pharmacokinetics.  Clin. Pharmacol. Ther. 40: 615-619.  Koprda V, Trnovec T, and Landmann H (1986) The binding of amrinone to plasma proteins.  Pharmazie 41: 300-301.",CL value from rapid acetylators only.,,1977,187.2,4,2,68,1,neutral,-0.67,-0.73
Amsacrine,51264-14-3,COc1cc(NS(=O)(=O)C)ccc1Nc2c3ccccc3nc4ccccc24,1.6,4.3,0.029,6.2,4.7,"Jurlina JL, Varcoe AR, and Paxton JW (1985) Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia.  Canc. Chemother. Pharmacol.  14: 21-25.  Paxton JW, Kim SN, and Whitfield LR (1990) Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.  Cancer Res.  50: 2692-2697.","VDss reported in Paxton, et al, and cites Jurlina, et al.,  references which has only Vdbeta at 1.7 L/kg.  Used value from Paxton report.",,1973,393.46,6,2,80.3,5,cationic,4,0.85
Amsalog,80841-47-0,CNC(=O)c1cccc2c(Nc3ccc(NS(=O)(=O)C)cc3OC)c4cccc(C)c4nc12,0.3,2.6,0.0011,1.9,2.4,"Paxton JW, Hardy JR, Evans PC, Harvey VJ, and Baguley BC (1988) The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in a phase 1 trial.  Canc. Chemother. Pharmacol. 22: 235-240.  Fyfe D, Prce C, Langley RE, Pagonis C, Houghton J, Osborne L, Woll PJ, Gardner C, Baguley BC, and Carmichael J (2001) A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.  Canc. Chemoher. Pharmacol. 47: 333-337.  Paxton JW, Kim SN, and Whitfield LR (1990) Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.  Cancer Res.  50: 2692-2697.",,,1981,464.54,8,3,109.4,6,cationic,3.5,0.63
Amygdalin,29883-15-6,O1[C@@H](O[C@@H](c2ccccc2)C#N)[C@@H]([C@@H](O)[C@@H]([C@H]1CO[C@@H]1O[C@@H]([C@@H](O)[C@@H]([C@H]1O)O)CO)O)O,0.21,1.88,,1.83,1.23,"Xiaobing Li  Fuguo Shi, Pan Gua, Lingye Liua, Hua Heb,, Li Dinga. A sensitive LC–MS/MS method for simultaneous determination of amygdalin and paeoniflorin in human plasma and its application.  Journal of Pharmaceutical and Biomedical Analysis 92 (2014) 160–164","N=2, 70 kg assumed. 4 hours infusion. Digitized from plot. Huoxue-Tongluo lyophilized powders for injection (6 g, containing 25.3 mg of amygdalin and 35.8 mg of paeoniflorin) were supplied by Jiangsu Kanion Pharmaceutical Co., Ltd. (Lianyun-gang, China). ",,1885,457.43,12,7,202.3,8,neutral,-3.8,-3.8
Anhydrovinblastine,38390-45-3,CCC1=C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](OC(=O)C)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC)C1,12,12,,17,18,"Ramnath N, Schwartz GN, Smith P, Bong D, Kanter P, Berdzik J, and Creaven PJ (2003) Phase I and pharmacokinetic study of anhydrovinblastine every three weeks in patients with refractory solid tumors.  Canc. Chemother. Pharmacol. 51: 227-230.",VDss was calculated from C vs t data obtained by digitization of the plots provided in the reference.  Median values for CL and t1/2 were reported.,,1971,792.96,12,2,133.9,10,cationic,4.8,4.5
Anidulafungin,166663-25-8,CCCCCOc1ccc(cc1)c2ccc(cc2)c3ccc(cc3)C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)C(NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)c7ccc(O)cc7)[C@@H](C)O,0.57,0.21,0.16,45,40,"Dowell JA, Schranz J, Baruch A, and Foster G (2005) Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.  J. Clin. Pharmacol. 45: 1373-1382.  Eraxis Product Label.",,,1993,1140.24,24,14,377.4,14,neutral,1.6,1.6
Antazoline,91-75-8,c1ccc(cc1)CN(CC2=NCCN2)c3ccccc3,3.9,19.67,,3.45,2.29,"Joanna Giebułtowicza,, Roman Piotrowski, Jakub Baran, Piotr Kułakowski,Piotr Wroczyński.  Application of a novel liquid chromatography/tandem massspectrometry method for the determination of antazoline in humanplasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokineticand hemodynamic effects of PHenazolinum (ANTazoline mesylate)]human pharmacokinetic study. J. of Pharm. Biomed. Anal.  2016, 123, 113–119.","N=9, intravenous dose, 100 mg. Data reported as median. ",,1944,265.35,3,1,27.6,5,cationic,2.8,0.28
Antipyrine,60-80-0,CN1N(C(=O)C=C1C)c2ccccc2,0.77,0.64,0.93,20,12,"Andreasen PB and Vesell ES (1974) Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.  Clin. Pharmacol. Ther. 16: 1059-1065.  Danhof M, vanZuilen A, Boeijinga JK, and Breimer DD (1982) Studies of the different metabolic pathways of antipyrine in man.  Eur. J. Clin. Pharmacol.  21: 433-441.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003)  Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",Danhof reference not included for VDss (would require digitization); Andreason reference used a one-compartment model so VDc = VDss.,,1890,188.23,3,0,23.5,1,neutral,0.19,0.19
Antofloxacin,119354-43-7,O=C(C(C(=C(C(=C1F)N(CCN2C)CC2)OC2)N(C3)[C@H]2C)=C1N)C=3C(O)=O,2.42,2.2,0.82,18.3,20.1,"Pharmacokinetics of antofloxacin hydrochloride, a novel fluoroquinolone, after single-dose intravenous administration in healthy Chinese male volunteers.  Wang et al. Xenobiot. 2010, 40, 344-349","Data digitized and calculation performed via WinNonLin 5.2. N=12. 300 mg mg dose, average weight 61 kg. Linear PK reported (200, 300, 400 mg doses). Ppb reported by same authors.",,1988,376.38,8,2,99.3,2,zwitterionic,1.5,-0.73
Apalcillin,63469-19-2,[H]N(C([C@@H](c1ccccc1)N([H])C(c1cnc2cccnc2c1O[H])=O)=O)[C@@H]1C2N(C1=O)[C@@H](C(=O)O[H])C(C)(C)S2,0.16,1.9,0.1,1.4,1.2,"Busch von U., Heinzel g., Seyfarth H., Mielenz H. Arzneim.-Forsch. 1982, 32, 1131-1135.  Investigation of the pharmacokinetics of apalcillin in man.",Data digitized is reported only for 1 subject (subject 3) AUC reported for individual subject in close agreement with reported clearance and AUC as well as for t1/2. N=7 and 70 kg average weight assumed. Subject # 3 in the middle of range and considered representative of cohort. Protein binding reported as approximately 90%.,,1977,521.55,11,4,161.8,8,anionic,1.8,-1.6
Apixaban,503612-47-3,N1(CCc2c(C1=O)n(nc2C(=O)N)c1ccc(cc1)OC)c1ccc(cc1)N1CCCCC1=O,0.3,0.8,0.13,,12,"FDA aproval data. Accessed through PharmaPendium on June 23 2014.https://www.pharmapendium.com/fda.do?document=a9a1a313612e0fc9f6473123da9f3f58&drugName=Apixaban&reference=32
clearance  3.43 L/h and t1/2 12 h. 70 kg assumed. VDss 21 L.",Assumed 70 kg as average weight. ,,2003,459.5,9,1,110.8,5,neutral,2.5,2.5
Apomorphine,58-00-4,c12c3c4c(ccc(c4O)O)C[C@H]1[N@@](CCc2ccc3)C,1.6,40,0.05,0.67,0.68,"van der Geest R, van Laar T, Kruger PP, Gubbens-Stibbe JM, Boddé HE, Roos RA, Danhof M.Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin. Neuropharmacol. 1998, 21, 159-168.  Smith RV, Velagapudi RB, McLean AM, and Wilcox RE (1985) Interactions of apomorphine with serum and tissue proteins.  J. Med. Chem. 28:  613-620.",Apokyn. N=10 (5M and 5F) 30 ug/kg in 15 minutes. MRT from VDss and clearance. Monocompartmental fit.,,1891,267.32,3,2,43.7,0,cationic,3,2.1
Apremilast,608141-41-9,CCOc1cc(ccc1OC)[C@@H](CS(=O)(=O)C)N2C(=O)c3cccc(c3C2=O)CC(=O)C,,2.38,0.32,,6.03,PDR. Accessed October 13 2014. http://www.pdr3d.com/detail.php?c=132827#section-13,OTEZLA. VD reported (likely to be Vz) at 87 L. Clearance reported as 10 L/hr and 70 kg average weight assumed. Ppb reported as 68%. T1/2 calculated from Vz and clearance.,,2002,459.51,8,0,107.1,9,neutral,1.2,1.2
Aprepitant,170729-80-3,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1c3ccc(F)cc3)c4cc(cc(c4)C(F)(F)F)C(F)(F)F,0.94,1,0.05,16,13,"Majumdar AK, Howard L, Goldberg, MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K,  Knops A, De Lepeleire I, Michiels N, and Petty KJ (2006) Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.  J. Clin. Pharmacol. 46: 291-300.  Emend Product Label.",,,1995,534.43,7,2,75.2,6,neutral,4.1,4.1
AR-709,663214-64-0,CN(C)C(=O)c1c(c2cc(ccc2[nH]1)Cl)Cc3cc4c(cc(c(c4o3)OC)OC)Cc5cnc(nc5N)N,5.06,7.49,,11.27,44.55,"G. Lappin, M. J. Boyce,  T. Matzow, S. Lociuro,
M. Seymour, S. J. Warrington. A microdose study of 14C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung. Eur. J. Clin. Pharmacol. 2013, 69, 1673-1682","AR-A014418. 100 ug dose, N=4, 70 kg assumed. Data digitized from plot (unchanged compound profile) reported and PK parameters calculated via PKSolver. Time point (but not concentration) corrected using text time point.",,2005,534.99,10,3,145.8,7,neutral,3.5,3.3
Arbekacin,51025-85-5,O1[C@H](O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@H]2O[C@@H](CC[C@H]2N)CN)N)NC([C@H](CCN)O)=O)[C@H](O)[C@H]([C@@H]([C@H]1CO)O)N,0.21,1.28,,2.73,2.46,"HIROMI KUMON, AKIHIRO MIZUNO, YOSHITSUGU NASU, MASAYA TSUGAWA,
MIKIO KISHI and HIROYUKI OHMORI. PHARMACOKINETICS OF ARBEKACIN IN HEALTHY VOLUNTEERS AND PATIENTS WITH RENAL INSUFFICIENCY","HBK. N=3, healthy adults (CCr 100 mL/min). MRT from clearance and VDss, 70 kg average weight assumed.",renal clearance 1.12 mL.min-1.kg-1 (87%),1973,552.62,16,11,297.3,10,cationic,-7.5,-9
Argatroban,74863-84-6,C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCNC(=N)N)NS(=O)(=O)c2cccc3CC(C)CNc23,0.17,5,0.46,0.57,0.4,"Hauptmann, J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol  2002, 57,  751-758. ppb: The PDR states: Argatroban is 54% bound to human serum proteins, with binding to albumin and α1 – acid glycoprotein being 20% and 34%, respectively. Accessed January 7 2015. http://www.pdr3d.com/detail.php?c=135305#section-12.",,,1980,508.63,11,6,177.7,10,zwitterionic,1.5,-0.84
Aripiprazole,129722-12-9,Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl,4.9,0.83,0.01,98,75,Abilify Product Label.,CL value in FDA documents on-line.,,1990,448.39,5,1,44.8,7,cationic,5.2,4.7
Artesunate,88495-63-0,C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,15,1070,0.25,0.32,0.22,"Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul, W, Ruangveerayuth R, and WhiteNJ (2006) The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.    Eur. J. Clin. Pharmacol.  62: 1003-1009.  Li Q, Xie LH, Haeberle A, Zhang J, and Weina P (2006) The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans.  Am. J. Trop. Med. Hyg. 75: 817-826.",,,1982,384.42,8,1,100.5,5,neutral,3,2.9
Articaine,23964-58-1,s1c(C(OC)=O)c(NC([C@@H](C)NCCC)=O)c(c1)C,7.7,126.7,0.46,1.04,0.98,"Vree, Torn B.; Simon, Marc A. M.; Gielen, Mathieu J. M.; Booij, Leo H. D. J. Regional metabolism of articaine in 10 patients undergoing intravenous regional anesthesia during day case surgery. British Journal of Clinical Pharmacology, 1997, 44, 29-34.//ppb:  Oertel, Reinhard; Richter, K. Plasma protein binding of the local anesthetic drug articaine and its metabolite articainic acid. Pharmazie, 1998, 53, 646-647.","Average weight reported as 70.5 kg. 200 mg dose, N=10. // ppb: In the range of 0.5-​5 μg​/mL articaine had a linear protein binding. Data at pH 7.5. Much higher binding (71%) at pH 8.5.",,1969,284.37,5,2,67.4,7,cationic,1.9,1.2
Asarone,2883-98-9,c1(c(cc(OC)c(c1)OC)OC)\C=C\C,1,8.8,,1.9,3.7,"Yang, Zhenghong; Wu, Chuang. Absolute bioavailability of synthetic asarone in healthy volunteers. Zhongguo Yiyuan Yaoxue Zazhi (1997), 17(4), 165-167","Data digitized from plot reported. 
Reported data:
16 mg iv
 N=12 
Avg BW = 58.8 kg 
AUC0~inf = 396±250 ng*h/mL (AUC calculated within range, 513 ng*h/mL) ",,1930,208.25,3,0,27.7,4,neutral,2.7,2.7
Ascorbic acid,50-81-7,[C@H]1(C(=C(C(=O)O1)O)O)[C@H](CO)O,0.35,1.05,0.26,5.5,11.4,"Zetler, G. Seidel, G., Siegers, G-P, Iven. H. Pharmacokinetics of ascorbic acid in man. Eur. J. Clin. Pharmacol. 1976, 10, 273-282.// (L. John Hoffer, Line Robitaille, Robert Zakarian, David Melnychuk, Petr Kavan, Jason Agulnik,Victor Cohen, David Small Wilson H. Miller, Jr. High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial. PLOS ONE  DOI:10.1371/journal.pone.0120228 April 7, 2015)","N=3, dosed as 500 mg of sodium ascorbate (435 mg of ascorbic acid). 79 kg average weight. Not clear whether lactone or acid was followed as the analysis was performed colorimetrically. Structure entered as lactone//Also, the work of Hoffer et al. PLoS was utilized for calculations after digitization. 0.6 g/kg over 90 minutes, N=12, 76 kg average weight. Only Cmax and C5.5 hr were reported (= Clast) and were digitized very accurately. VDss = 0.21 L/kg and clearance 1.07 mL/min/kg, MRT 3.24 hr and t1/2 2.36 hr. NEW DATA ENTERED MAY 23 2016 and  NOT AVERAGED ACROSS THE TWO REPORTS.",,1923,176.12,6,4,107.2,2,anionic,-3,-5.5
Asenapine,65576-45-6,c12c(cccc1)Oc1ccc(cc1[C@@H]1[C@@H]2CN(C1)C)Cl,23,12.4,0.05,30.9,,PDR. Accessed February 18 2013. http://www.pdr3d.com/detail.php?c=82606#section-14,SAPHRIS. Asenapine is a high clearance drug with a clearance after intravenous administration of 52 L/h. VDss 20-25 L/kg. 95% bound. 70 kg assumed.no t1/2 reported. MRT from VDss and clearance. ,,1985,285.77,2,0,12.5,0,cationic,4.7,3.1
Aspoxicillin,63358-49-6,N12[C@@H]([C@@H](NC([C@@H](c3ccc(O)cc3)NC([C@@H](CC(NC)=O)N)=O)=O)C2=O)SC(C)(C)[C@@H]1C(O)=O,0.27,2.82,,1.61,1.45,"F. KEES, K. G. NABER, H. GROBECKER. In-vitro-Aktivitat von Aspoxicillin und Pharmakokinetik bei Probanden. Zeitschrift fuer Antimikrobielle und Antineoplastische Chemotherapie, 1987, 5, 53-60.","4 g dose, N=10, median weight 72 kg. MRT from clearance and VDss.",,1977,493.53,12,6,191.2,8,anionic,-1.7,-3.8
Astragaloside IV,84687-43-4,CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O,0.12,0.74,0.14,2.78,2.65,"Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers. Xu, Meijuan; Yin, Jungang; Xie, Liyan; Zhang, Jun; Zou, Chong; Zou, Jiandong; Liu, Fang; Ju, Wenzheng; Li, Ping Phytomed. 2013, 20, 1105-1111.// ppb: Xu, Duo; Liu, Mei; Yang, Bo; Yin, Qiong-yu; Lu, Yu. Determination of protein-​binding rate of adenosine and astragaloside IV in Anchuanshu pills in human plasma by LC-​MS​/MS. Zhongnan Yaoxue, 2016, 14, 282-285."," N=6, 400 mL variable rate infusion (1 to 4 mL.min-1) infusion, of a 9 mg/100 mL solution, 36 mg total dose, 59.9 kg average weight. AUC 0-inf_obs reported 13. 59 μg/ml*h; AUC 0-inf_obs calculated 13. 49 μg/ml*h; < 1 % difference.",,1982,784.97,14,9,228.2,6,neutral,-0.048,-0.048
Astromicin,55779-06-1,O1[C@@H]([C@@H](CC[C@H]1[C@@H](N)C)N)O[C@@H]1[C@H]([C@@H]([C@H](OC)[C@H](N(C)C(CN)=O)[C@H]1O)O)N,0.23,1.37,,2.8,2,"Nakashima, Mitsuyoshi; Takiguchi, Yoshiharu; Inoue, Akinobu; Kobayashi, Satoshi. Phase I study on intravenous drip infusion of astromicin. apanese Journal of Antibiotics. 1986, 39, 1453-1472.","KW-1070. 200 mg dose, N=6, Average weight 70.8 kg. 1 hr intravenous drip. VDss calculated from Vc and k12/k21 ratio. MRT = VDss/clearance.",,1975,405.49,11,6,192.5,6,cationic,-4.6,-7.7
Asunaprevir,630420-16-5,COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)c5cc(Cl)ccc15,2.77,11.78,0.012,3.92,20,"http://www.bmscanada.ca/static/products/en/pm_pdf/SUNVEPRA_E_PM.PDF. Accessed July 29 2016.//ppb: McPhee, Fiona; Sheaffer, Amy K.; Friborg, Jacques; Hernandez, Dennis; Falk, Paul; Zhai, Guangzhi; Levine, Steven; Chaniewski, Susan; Yu, Fei; Barry, Diana; et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrobial Agents and Chemotherapy (2012), 56(10), 5387-5396. ",70 kg average weight assumed. 100 ug iv tracer dose after 100 mg capsule p.o. MRT calculated from VDss and clearance. t1/2 median of range reported.,,2003,748.29,14,3,182.3,12,anionic,5.5,2.4
Atenolol,29122-68-7,CC(C)NCC(O)COc1ccc(CC(=O)N)cc1,0.95,2.5,0.94,6.3,6.1,"Mason WD, Winer N, Kochak G, Cohen I, and Bell R (1979) Kinetics and absolute bioavailability of atenolol.  Clin. Pharmacol. Ther.  25: 408-415.  Henry JA and Mitchell SN (1981)  Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.    Br. J. Clin. Pharmacol. 11: 119P-120P. ",VDss calculated from reported micro constants. ,,1970,266.34,5,3,84.6,8,cationic,0.35,-1.4
Atipamizole,104054-27-5,[nH]1cncc1C1(Cc2c(C1)cccc2)CC,2.7,19.6,,2.3,1.7,"SAKARI KARHUVAARA, ANTERO KALLIO, MIKA SCHEININ, MARKKU ANTTILA, JARMO S. SALONEN & HARRY SCHEININ. Pharmacological effects and pharmacokinetics of atipamezole, a novel 0L2-adrenoceptor antagonista randomized, double-blind cross-over study in healthy male volunteers. Br. J. clin. Pharmac. (1990), 30, 97-106","Data digitized from plot at 100 mg dose (linear PK). N=6, 73 kg average weight. N= 6, 73 kg average weight. Reported AUC = 1.19 mg.h.L-1; Clearance = 1.14 L.h-1.kg-1. ",,1986,212.29,2,1,28.7,2,neutral,2.6,2.4
Atomoxetine,83015-26-3,CNCC[C@@H](Oc1ccccc1C)c2ccccc2,0.85,9.3,0.02,1.5,5.2,Strattera Product Label,CYP2D6 EM data MRT is calculated as VD/CL; CL was calculated as CLpo/F (F=63%),,1982,255.35,2,1,21.3,6,cationic,3.6,1.5
Atovaquone,95233-18-4,OC1=C([C@@H]2CC[C@H](CC2)c3ccc(Cl)cc3)C(=O)c4ccccc4C1=O,0.6,0.15,0.001,67,63,Mepron Product Label,,,1984,366.84,3,1,54.4,2,anionic,5.5,3.4
Atracurium,64228-79-1,COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]4(C)CCc5cc(OC)c(OC)cc5C4Cc6ccc(OC)c(OC)c6)cc1OC,0.1,5.7,0.52,0.29,0.31,"Cameron M, Donati F, and Varin F (1995) In vitro plasma protein binding of neuromuscular blocking agents in different subpopulations of patients.    Anesth. Analg. 81: 1019-1025.   deBros FM, Lai A, Scott R, deBros J, Batson AG, Goudsouzian N, Ali HH, Cosimi AB, and Savarese JJ (1986) Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients.    Anesth. Analg. 65: 743-746.  Ward S, Neill EAM, Weatherly BC, and Corall IM (1983) Pharmacokinetics of atricurium besylate in healthy patients after a single i.v. bolus dose.  Br. J. Anaesth. 55: 113-118.","VDss calculated from estimated C vs t data from Cameron, et al, and from reprted microconstants from Ward, et al.",,1980,929.15,14,0,126.4,26,neutral,1.7,1.7
Atropine,51-55-8,CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)C(CO)c3ccccc3,3.3,7.6,0.61,7.2,4.1,"Adams RG, Verma P, Jackson AJ, and Miller RL (1982) Plasma pharmacokinetics of intravenously administered atropine in normal human subjects.  J. Clin. Pharmacol. 22: 477-481.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",,,1878,289.37,4,1,49.8,5,cationic,2.2,0.6
Avarofloxacin,878592-87-1,COc1c2c(cc(c1N3CCC/C(=C(/CN)\F)/C3)F)c(=O)c(cn2C4CC4)C(=O)O,1.13,0.78,0.34,24.21,19.64,"J. Michael Davenport, Paul Covington, Mark Gotfried, Matthew Medlock, Prapoch Watanalumlerd, Gail McIntyre, Lisa Turner, and June Almenoff. Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2//ppb: G Eichenbaum, MK Pugsley, DJ Gallacher, R Towart, G McIntyre, U Shukla, JM Davenport, HR Lu, J Rohrbacher, and V Hillsamer. Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2. Br. J. Clin. Pharmacol. 2012, 166, 1694-1707.","JNJ-Q2. Acorafloxacin. Data digitized from plot reported. 75 mg dose chosen as ""bracketed by the range 15-150 mg. Generally linear PK. 70 kg average weight assumed. 90-minute infusion. AUC 0-inf reported as 25 ug.h.mL. Calculated 22.9 ug.h.mL. 9% difference. ppb midpoint of range: 62% at 2 ug/mL and 70% at 20 ug/mL.",,2006,419.42,7,2,97.8,5,zwitterionic,2.8,0.44
Avibactam,1192500-31-4,N12C(=O)N([C@H](CC[C@H]1C(=O)N)C2)OS(=O)(=O)O,0.24,2.76,0.93,1.4,1.7,"Riccobene, Todd A.; Su, Sheng Fang; Rank, Douglas. Single- and multiple-​dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrobial Agents and Chemotherapy 2013, 57(3), 1496 –1504.//ppb: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM425458.pdf",600 mg dose. 1-hr Iv infusion. 70 kg weight assumed as average. Reported as 93% renally excreted. ,,2011,265.24,9,2,130.2,3,neutral,-2.1,-5.6
Avitriptan,151140-96-4,CNS(=O)(=O)Cc1ccc2c(c1)c(c[nH]2)CCCN3CCN(CC3)c4c(cncn4)OC,0.87,6.44,,2.25,5.26,"Marathe, P. H.; Greene, D. S.; Barbhaiya, R. H. Disposition of [14C]avitriptan in rats and humans. Drug Metab. and Disp. 1997, 25, 881-888","N=12, 10 mg infusion in 30'. MRT from VDss and clearance.",,1993,458.58,9,2,103.4,9,cationic,2.1,1.4
Avosentan,290815-26-8,O=S(=O)(c1ncc(cc1)C)Nc1nc(c2ccncc2)nc(c1Oc1ccccc1OC)OC,0.27,0.52,,8.8,7.2,"Dieterle W, Hengelage T. Absolute bioavailability and pharmacokinetics of avosentan in man. Int. J. Clin. Pharmacol. Ther. 2009, 47, 587-594.","Data calculated after digitization of plot. 10 mg dose, 70-kg weight assumed. 20' infusion N=25. AUC reported 4696 ng.h.mL-1 vs. a calculated value of 4581 ng.h.mL-1.",,2000,479.51,10,1,125.4,8,anionic,3.5,0.026
Axitinib,319460-85-0,CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4,,5,0.004,,4.3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf. Accessed on September 26 2015.,t1/2 reported as a range 2.5-6.1 h. Mid-point taken. VD reported as 68 L but not specified as VDbeta or VDss. 70 kg assumed. 1 mg iv dose.,,2011,386.47,5,2,70.7,5,neutral,4,4
Azacytidine,320-67-2,NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,0.47,35,,0.22,0.36,"Marcucci G, Silverman L, Eller M, Lintz L, and Beach CL (2005) Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.  J. Clin. Pharmacol. 45:  597-602. ",VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.,,1964,244.2,9,4,141,2,neutral,-3,-3
Azapropazone,13539-59-8,CCCC1C(=O)N2N(C1=O)c3cc(C)ccc3N=C2N(C)C,0.12,0.14,0.004,14,17,"Gikalov I, Kaufmann R, and Schuster O (1982) Humanpharmakokinetik verschiedener i.v. dosen von azapropazon (HPLC-bestimmung).    Arzn. Forsch. 32: 423-426.",VDss was calculated from C vs t data provided in the reference.,,1966,300.36,6,0,56.2,3,anionic,1.3,0.098
AZD4877,1176760-49-8,Cc1ccc(cc1)C(=O)N(CCCN)C(c2nc3c(c(ns3)C)c(=O)n2Cc4ccccc4)C(C)C,6.74,5.83,,19,16.3,"A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors  Infante J R; Kurzrock R; Spratlin J; Burris H A; Eckhardt S G; Li J; Wu K; Skolnik J M; Hylander-Gans L; Osmukhina A; Huszar D; Herbst R S. Cancer chemotherapy and pharmacology 2012, 69 (1)165-72","Weighted average of data reported in table 4. Part A and B across all doses with data reported (range 5-45 mg). T/12 across 20 patients, MRT, Cl and VDss across 17 patients. Average data : clearance 24.5 L/h, VDss = 471.8 L, MRT 19.05 h and t1/2 16.3 hours. Average of 70 kg used for body weight.",,2004,503.66,7,1,94.1,9,cationic,3.6,1.1
Azelastine,58581-89-8,CN1CCCC(CC1)N2N=C(Cc3ccc(Cl)cc3)c4ccccc4C2=O,15,9,0.17,27,22,"Weliky I, Howard JR, and Wichmann JK (1990) Absolute bioavailability and pharmacokinetics of azelastine.  Pharm. Res. 7: S-247.  Estelle F, Simons R, and Simons KJ (1999) Clinical pharmacology of new histamine H1 receptor antagonists.  Clin. Pharmacokinet. 36: 329-352.",,,1980,381.9,4,0,35.9,3,cationic,3.8,2.4
Azimilide,149908-53-2,CN1CCN(CCCCN2C(=O)CN(\N=C\c3oc(cc3)c4ccc(Cl)cc4)C2=O)CC1,13,2.4,0.06,100,79,"Corey AE, Agnew JR, Valentine SN, Nesbitt JD, Wagner DL, Powell JH, and Thompson GA (1999) Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation.  J. Clin. Pharmacol. 39: 1272-1276.",,,1993,457.95,8,0,72.9,8,cationic,3.5,2.2
Azithromycin,83905-01-5,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,33,10,0.88,57,69,"Luke DR, Foulds G, Cohen SF, and Levy B (1996) Safety, toleration, and pharmacokinetics of intravenous azithromycin.  Antimic. Agents Chemother.  40: 2577-2581.  Foulds G, Shepard RM, and Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues.  J. Antimic. Chemother. 25(Suppl. A):  73-82.",Protein binding is concentration dependent; cited value measured at concentrations observed after IV dosing.,,1953,748.98,14,5,180.1,7,cationic,2.2,-0.18
Azlocillin,37091-66-0,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c4ccccc4)C(=O)N2[C@H]1C(=O)O,0.26,2.5,0.65,1.7,1.2,"Haen E, Remien J, Richter E, Frank U, and Adam D (1985) Uber die bedeutung der applikationsgeschwindigkeit fur die pharmakokinetischen parameter von azlocillin und mexlocillin.    Arz. Forsch. 35: 864-868.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",Pharmacokinetic parameters were calculated from C vs t data provided in the reference.,,1972,461.49,11,4,148.1,5,anionic,0.84,-2.5
Aztreonam,78110-38-0,C[C@H]1[C@H](NC(=O)\C(=N/OC(C)(C)C(=O)O)\c2csc(N)n2)C(=O)N1S(=O)(=O)O,0.18,1.5,0.4,2.1,1.5,"Burgess DS, Summers KK, and HardinTC (1999) Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.  Clin. Ther. 21: 1882-1889.  Swabb EA, Sugerman A, Frantz M, Platt TB, and Stern M (1983) Renal handling of the monobactam azthreonam in healthy subjects.  Clin. Pharmacol. Ther. 33: 609-614.",,,1981,435.43,13,4,201.6,7,anionic,-0.95,-6.2
Baclofen,1134-47-0,c1cc(ccc1C(CC(=O)O)CN)C,0.65,1.7,0.69,6.36,5.24,"Suresh K. Agarwal, Robert L. Kriel, James C. Cloyd, Lisa D. Coles, Lisa A. Scherkenbach, Michael H. Tobin and Linda E. Krach. Pilot Study Assessing Pharmacokinetics and Tolerability of Oral and Intravenous Baclofen in Healthy Adult Volunteers. J Child Neurol published online 14 July 2014. DOI: 10.1177/0883073814535504. ppb (UF method): Wuis EW, Dirks MJ, Termond EF, Vree TB, Van der Kleijn E. 1989. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol 37:181–184.","N=12, digitized from plot reported. 5 mg dose. 70 kg average weight assumed. ",,1962,193.24,3,2,63.3,4,zwitterionic,1.1,-1.2
Bambuterol,81732-65-2,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C,1.6,18,,1.4,2.6,"Nyberg L, Rosenborg J, Weibull E, Jonsson S, Kennedy BM, and Nilsson M (1998) Pharmacokinetics of bambuterol in healthy subjects.   Br. J. Clin. Pharmacol. 45: 471-478.",,,1982,367.44,8,2,91.3,7,cationic,1.3,-0.27
Basimglurant,802906-73-6,Cc1c(nc(n1c2ccc(cc2)F)C)C#Cc3ccnc(c3)Cl,9.7,2.8,0.01,57.4,78.9,"Elena Guerini, Simone Schadt, Gerard Greig, Ruth Haas, Christophe Husser, Manfred Zell, Christoph Funk, Thomas Hartung, Andreas Gloge, and Navita L. Mallalieu.  A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans. Xenobiotica, (2017), 47, 144-153.//ppb: Lothar Lindemann, Richard H. Porter, Sebastian H. Scharf, Basil Kuennecke, Andreas Bruns, Markus von Kienlin, Anthony C. Harrison, Axel Paehler, Christoph Funk, Andreas Gloge, Manfred Schneider, Neil J. Parrott, Liudmila Polonchuk, Urs Niederhauser, Stephen R. Morairty, Thomas S. Kilduff, Eric Vieira, Sabine Kolczewski, Juergen Wichmann, Thomas Hartung, Michael Honer, Edilio Borroni, Jean-Luc Moreau, Eric Prinssen, Will Spooren, Joseph G. Wettstein, and Georg Jaeschke. Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression. J. Pharmacol. Exp. Ther. 2015,  353, 213-233","100 ug dose as radiotracer of 13C6-basimglurant, via 30' infusion. N=6, 70 kg average weight assumed. MRT from VDss and clearance.",,2004,325.77,3,0,30.7,3,neutral,4,4
Batanopride,102670-46-2,c1(c(cc(Cl)c(c1)N)C(NCCN(CC)CC)=O)O[C@@H](C(C)=O)C,1.5,9.32,0.46,2.68,2.7,"J. V. St. Peter, M. E. Brady, E. E Foote, K.A. Dandekar, L. Smaldone, J. L. Pykkonen, W. E Keane, and C. E. Halstenson. The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment. Eur J Clin Pharmacol (1993) 45:59-53 ","N=13 (8M/5F) 78 kg average weight reported, 3.6 mg/kg 15 minutes i.v. infusion. Normal subjects only. MRT from clearance and VDss.",,1986,355.86,6,2,84.7,9,cationic,1.7,0.15
Batifiban,710312-77-9,[C@@H]12N(C(=O)[C@H](Cc3c4c([nH]c3)cccc4)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CCSSC[C@H](NC1=O)C(=O)N)CCCNC(=N)N)CC(=O)O)CCC2,0.42,2.88,,2.45,2.12,"Chen, Hui; Qiao, Jian; Li, Qian; Deng, Jungang; Tan, Zhirong; Guo, Tao; Li, Weiyong. Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple dose administration to healthy Chinese subjects. Journal of Huazhong University of Science and Technology, Medical Sciences 2009, 29, 12-18.","N=12, 220 ug/kg dose iv bolus (highly linear AUC across 3 doses) 58.3 kg average weight, calculation performed via PK solver. AUC reported 1374 ug.h.L-1, calculated 1271 ug.h.L-1, 8% difference.",,2003,817.94,20,11,323.9,10,zwitterionic,-3.7,-6
Bazedoxifene,198481-32-2,c1cc2n(c(c3ccc(cc3)O)c(c2cc1O)C)Cc1ccc(OCCN2CCCCCC2)cc1,15.4,6.7,0.02,37.5,30,EMA approval package. https://www.pharmapendium.com/emea.do?document=4c0872d79ea3bbd57566034c1b98c34e&drugName=Bazedoxifene+acetate&reference=17. Accessed 06-13-2014.,Study conducted solely in post-menopausal women. MRT from clearance and VDss. Median fu taken from two values reported.,,1999,470.6,5,2,57.9,7,cationic,6.6,5.5
BB 83698,325795-25-3,CC(C)(C)[C@H](NC(=O)[C@H](CC1CCCC1)CN(O)C=O)C(=O)N2CCN(Cc3ccc4OCOc4c3)CC2,1.1,3.1,0.2,5.9,9.4,"Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, and Johnson KW. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimic. Agents Chemother. (2004)  48: 4835-4842.",,,2001,530.66,10,2,111.6,9,neutral,2.1,2.1
Becatecarin,119673-08-4,n1([C@H]2[C@@H]([C@@H](O)[C@@H]([C@H](O2)CO)OC)O)c2c3c(c4C(=O)N(C(c4c2c2c1c(Cl)ccc2)=O)CCN(CC)CC)c1cccc(c1[nH]3)Cl,8.9,3.13,,45.4,48.9,"Anthony W. Tolcher, S. Gail Eckhardt, John Kuhn, Lisa Hammond, Geoffrey Weiss, Jinee Rizzo, Cheryl Aylesworth, Manuel Hidalgo, Amita Patnaik, Garry Schwartz, Sally Felton, Elizabeth Campbell, and Eric K. Rowinsky. Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties. Journal of Clinical Oncology, 2001, 19, 2937-2947.","NSC655649. BMS 181176. N= 43 total, doses from 20 a 744 mg/m2. Data reported here as weighted average across all doses in Table 5.",,1988,669.55,11,4,140.5,8,cationic,3,2.5
Beclabuvir,958002-33-0,CN1C[C@H]2CC[C@@H](C1)N2C(=O)[C@]34C[C@H]3c5cc(ccc5-c6c(c7ccc(cc7n6C4)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8)OC,0.5,1.33,0.01,6.38,5.38,"Hao Jianga, Craig Titsch, Jianing Zenga, Barry Jones, Philip Joyce, Yash Gandhi,Wesley Turley, Richard Burrell, Anne F. Aubry, Mark E. Arnold. Overcoming interference with the detection of a stable isotopically labeled microtracer in the evaluation of beclabuvir absolute bioavailability using a concomitant microtracer approach. J. Pharm. Biomed. Anal. 2017, 143, 9–16.//ppb : Nicholas A. Meanwell. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J. Med. Chem. 2016, 59, 7311−7351.",BMS-791325.  70 kg average weight assumed. MRT from clearance and VDss. Micro-dose (100  g) of the stable isotopically labeled tracer via intravenous (IV) infusion started after oral dosing of beclabuvir (150 mg) and at about Tmax. ,,2007,659.84,10,1,104.2,6,zwitterionic,3.1,0.74
Beclomethasone dipropionate,5534-09-8,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C,0.29,36,0.13,0.1,0.5,"Daley-Yates PT, Price AC, Sisson JR, Pereira A, and Dallow N (2001)  Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.    Br. J.. Clin. Pharmacol.  51: 400-409.  Beconase AQ Product Label",,,1964,521.04,7,1,107,8,neutral,4,4
Belinostat,414864-00-9,c1c(cccc1\C=C\C(NO)=O)S(=O)(=O)Nc1ccccc1,0.8,23.6,0.06,0.6,1.6,"U Lassen, LR Molife, M Sorensen, S-A Engelholm, L Vidal, R Sinha, RT Penson, P Buhl-Jensen, E Crowley, J Tjornelund, P Knoblauch,  JS de Bono. Phase I trial of belinostat with carboplatin and/or paclitaxel. British Journal of Cancer (2010) 103, 12 – 17. ppb: The PDR states: In vitro plasma studies have shown that between 92.9% and 95.8% of belinostat is bound to protein in an equilibrium dialysis assay, and was independent of belinostat plasma concentrations from 500 to 25,000 ng/mL. 94% taken as median. Accessed January 7 2015. http://www.pdr3d.com/detail.php?c=126664#section-12",Belinostrat administrated in combination with carboplatin and/or paclitaxel. MRT calculated form VDss and CL. VDss and CL corrected with 1.73 m2/70 kg body surface/body weight factor. (see table II in ref. cited). N=30 (23 patients. For 7of them day 1 and day 3 PK profiles are available) ,,2002,318.35,6,3,95.5,5,neutral,1.5,1.4
Bendamustine,16506-27-7,c12n(C)c(CCCC(=O)O)nc1cc(N(CCCl)CCCl)cc2,0.22,4.49,0.05,0.81,0.41,"Ogura et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Science, 2010, 101, 2054-2058. ppb: The PDR states: In vitro, the binding of bendamustine to human serum plasma proteins ranged from 94-96% and was concentration independent from 1-50 μg/mL. Accessed January 2 2015. http://www.pdr3d.com/detail.php?c=135686#section-13","Plasma data with time point adjusted to match the reported times. N=6, 70 kg average weight assumed, 120 mg/m2 dose (= 2.96 mg/kg, using 1.73 m2/70 kg conversion), 1-hr infusion.",,1973,358.26,5,1,58.4,9,zwitterionic,3,0.65
Benperidol,2062-84-2,Fc1ccc(cc1)C(=O)CCCN2CCC(CC2)N3C(=O)Nc4ccccc34,3.8,8.3,,7.5,5.8,"Seiler W, Wetzel H, Hillert A, Schoellnhammer G, Langer M, Barlage U, and Hiemke C (1994) Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application.  Psychopharmacology 116: 457-463.",,,1961,381.44,5,1,52.6,6,cationic,3.7,2.9
Benzydamine,642-72-8,c1(OCCCN(C)C)c2c(n(n1)Cc1ccccc1)cccc2,1.53,2.28,0.8,11.4,8.1,"G. A. BALDOCK, R. R. BRODIE, L. F. CHASSEAUD, T. TAYLOR AND L. M. WALMSLEY. PHARMACOKINETICS OF BENZYDAMINE AFTER INTRAVENOUS, ORAL, AND TOPICAL DOSES TO HUMAN SUBJECTS. BIOPHARMACEUTICS & DRUG DISPOSITION, 1991, 12, 481-492.//ppb: Chasseaud LF, Catanese B. Pharmacokinetics of benzydamine. Int J Tissue React. 1985, 7, 195-204.","Benzidamine. N=6 (male subject) 70 kg average weight reported, 5 mg dose",,1964,309.41,4,0,30.3,7,cationic,4.2,0.76
Bepridil,64706-54-3,N(c1ccccc1)(C[C@@H](N1CCCC1)COCC(C)C)Cc1ccccc1,10.1,8.7,0.001,19.3,14.9,"Pharmacokinetics of intravenous bepridil in patients with coronary disease By Lesko, Lawrence J.; Benotti, Joseph R.; Alpert, Joseph S.; Brady, Priscilla M.; McCue, Jane E.; Weiner, Bonnie H.; Ockene, Ira S. From Journal of Pharmaceutical Sciences (1986), 75(10), 952-4. ppb: NIGEL J. WATERS, RACHEL JONES, GARETH WILLIAMS, BINDI SOHAL (2008). Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein Binding, 97, 4586-4595.",MRT= VDss/CL. N=10. All patients with normal baseline hemodynamic and renal functions. Plots available.,,1977,366.54,3,0,15.7,10,cationic,5.4,4.9
Berubicin,677017-23-1,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO)O)N)OCc6ccccc6,48,18.5,,43.2,34.6,"R. Kazerooni, C. Conrad, C. Baud, M. Johansen, N. Thapar, C. Meyer, W. Priebe, and T. Madden. Phase I clinical pharmacokinetics of RTA 744: A blood brain barrier penetrating anthracycline active against high-grade glioma. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 25, No 18S (June 20 Supplement), 2007: 2045 
",Also known as RTA 744.  CAS number refers to free base. N=20. Dose range: 1.2 to 9.6 mg/m2. 1.73 m2/70 kg,,2004,633.64,12,5,195.1,8,cationic,2.5,-0.07
Betamethasone,378-44-9,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1.3,2.8,0.36,7.9,5.6,"Petersen MC, Nation RL, McBride WG, Ashley JJ, and Moore RG (1983) Pharmacokinetics of betamethasone in healthy adults after intravenous administration.  Eur. J. Clin. Pharmacol. 25: 643-650. ",VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.,,1960,392.46,5,3,94.8,2,neutral,1.7,1.7
Betamipron,3440-28-6,OC(=O)CCNC(=O)c1ccccc1,0.28,9.2,0.17,0.51,0.59,"Saito A (1991) Pharmacokinetics of panipenem/betamipron.  Chemotherapy (Tokyo)  39(Suppl. 3): 227-235.  Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, and Kawahara Y (1992) Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data.    Antimic. Agents Chemother. 36: 1810-1816.",VDss calculated from C vs t data provided in the reference.,,1920,193.2,4,2,66.4,4,anionic,0.56,-2.5
Betaxolol,63659-18-7,CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,4.8,3.4,0.4,24,17,"Ludden TM, Boyle DA, Gieseker D, Kennedy GT, Crawford MH, Ludden LK, and Clementi WA (1988) Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects.  J. Pharm. Sci. 77: 779-783.  Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.    Br. J. Clin. Pharmacol. 11: 119P-120P. ",,,1977,307.43,4,2,50.7,11,cationic,2.6,0.81
Bevantolol,59170-23-9,COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC,0.67,5.5,0.015,2,1.9,"McNeil JJ, Drummer OH, Anderson AIE, and Louis WJ (1986) Pharmacokinetics and concentration-effect relationships of bevantolol (CI-775) in normal volunteers.  J. Cardiovasc. Pharmacol. 8: 1201-1207.  Ichikawa M, Haruki S, Esumi Y, Takaichi M, Seki H, and Shiina M (1992) Metabolic fate of bevantolol hydrochloride.  Absorption, distribution and excretion in rats and dogs after single oral administration.  Yakuri to Chiryo 20: 1695-1708. ",VDss calculated from reported microconstants.,,1976,345.43,5,2,59.9,10,cationic,2.9,1.9
BI2536,755038-02-9,c12c(N(C(=O)[C@H](N1C1CCCC1)CC)C)cnc(n2)Nc1c(cc(C(=O)NC2CCN(CC2)C)cc1)OC,31.2,17.1,,31.3,40.1,"Peter M. Ellis, Quincy S. Chu, Natasha Leighl, Scott A. Laurie, Holger Fritsch, Birgit Gaschler-Markefski, Steve Gyorffy, Gerd Munzert.A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small- Cell Lung Cancer. Clinical Lung Cancer, Vol. 14, No. 1, 19-27, 2013","Weighted average of 26 patients across six doses (Table 5) from 100 to 325 mg, administered as 1 hour infusion. 70 kg average weight assumed. ",,2004,521.65,10,2,102.9,7,cationic,4.3,2.8
Biapenem,120410-24-4,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(=C(N2C1=O)C(=O)[O-])SC3C[n+]4cncn4C3,0.2,2.5,0.92,1.3,1.1,"Shiba K, Maezawa H, Yoshida M, Sakai O, and Saito A (1994) Basic and clinical studies of biapenem.  Chemotherapy 42(Suppl. 4): 322-329.  Yamashita N, Kawashima K, Nomura K, Takeuchi H, Hikida M, and Naruke T (1994) Pharmacokinetics of biapenem in laboratory animals.    Chemotherapy 42(Suppl. 4): 243-250.",,,1986,350.39,8,1,102.4,4,anionic,-3.1,-5.4
Bidisomide,103810-45-3,[H]N([H])C([C@](CCN1CCCCC1)(CCN(C(C)C)C(C)=O)c1ccccc1[Cl])=O,2.6,5.43,,7.9,12," Cook, Chyung S.; Ames, Gregory B.; Smith, Margaret E.; Kowalski, Kenneth G.; Karim, Aziz. Absorption and disposition of a new antiarrhythmic agent bidisomide in man. Pharmaceutical Research, 1993, 10 (11), 1675-1682. ","Data from 1 mg/kg 20 min iv infusion, N=6, 70 kg average weight. t½ taken as the γ phase",,1986,407.98,5,1,66.6,9,cationic,2.9,1.8
Bilastine,202189-78-4,C(C(C)(c1ccc(cc1)CCN1CCC(CC1)c1nc2c(n1CCOCC)cccc2)C)(=O)O,0.61,2.87,0.13,3.56,5.16,"B. Sádaba, A. Gómez-Guiu, J. R. Azanza, I. Ortega, R. Valiente. Oral Availability of Bilastine. Clin Drug Investig 2013, 33, 375–381.//ppb: Erminia Ridolo,Marcello Montagni, Laura Bonzano, Cristoforo Incorvaia, and Giorgio Walter Canonica. Bilastine: new insight into antihistamine treatment. Clin. Mol. Allergy.2015, 13, 1-6.","N=12 healthy volunteers, 65.9 kg average, 10 mg dose. BA 61%. Data digitized and PK parameters calculated via PKSolver. AUCinf normalized reported 82.23 ng.h.mL-1.mg-1. Calculated, 87.94 ng.h.mL-1.mg-1. 7% difference. % renal clearance from ratio of clearances 72.8%",,1998,463.61,6,1,67.6,10,zwitterionic,4.2,1.3
Bilobalide,33570-04-6,CC(C)(C)C1(O)CC2OC(=O)CC23C(=O)OC4OC(=O)C(O)C134,2.5,10,,4,3.2,"Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A (1995) Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biolba (EGb 761).  Therapie  50: 137-144.",,,1971,326.3,8,2,119.4,0,neutral,-3.4,-3.4
Bimatoprost,155206-00-1,C(\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(=O)NCC)=C\[C@H](CCc1ccccc1)O,0.67,25,0.12,,0.45,PDR. Accessed February 18 2013. http://www.pdr3d.com/detail.php?c=85286#section-10,"Clearance in blood but no B/P reported. MRT not yet calculable. Following an intravenous dose of radiolabeled bimatoprost (3.12 mcg/kg) to six healthy subjects, the maximum blood concentration of unchanged drug was 12.2 ng/mL and decreased rapidly with an elimination half-life of approximately 45 minutes. The total blood clearance of bimatoprost was 1.5 L/hr/kg. Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces. No true mass balance reported to show whether bimatoprost was intact or not.",,1994,415.57,5,4,89.8,12,neutral,3.3,3.3
Binodenoson,144348-08-3,c1nc2c(nc(nc2n1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N/N=C/C4CCCCC4)N,0.4,35.8,,0.19,0.21,"Richard J. Barrett, PhD, Michael J. Lamson, PhD, James Johnson, PhD, William B. Smith, MD, FACC.  Pharmacokinetics and safety of binodenoson after
intravenous dose escalation in healthy volunteers. Journal of Nuclear Cardiology, 2005, Volume 12, Number 2;166-171","Data digitized from plot (3 ug/kg) reported. N=6, 75.6 kg average (overall) weight. 10 minutes infusion. AUCinf calculated within 2% of AUCinf reported.",,1992,391.42,11,5,163.9,5,cationic,-0.18,-0.18
Biolimus A9,851536-75-9,O=C1N2[C@H](C(=O)O[C@H]([C@@H](C[C@H]3C[C@@H](OC)[C@@H](CC3)OCCOCC)C)CC(=O)[C@H](C)/C=C(\C)/[C@@H](O)[C@@H](OC)C(=O)[C@@H](C[C@@H](/C=C/C=C/C=C(/[C@H](C[C@H]3O[C@](C1=O)(O)[C@H](C)CC3)OC)\C)C)C)CCCC2,44.5,12.2,,60.9,93.9,"Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor biolimus A9 in healthy individuals . Steudel, Wolfgang; Dingmann, Colleen; Zhang, Yan-Ling; Bendrick-Peart, Jamie; Clavijo, Claudia; Shulze, John; Betts, Ronald; Christians, Uwe  Journal of Clinical Pharmacology (2011), 51(1), 29-39.","Umirolimus. Non linear PK. Highest tolerated dose used (0.075 mg/kg, N=5). VDss calculated from Clearance (0.73 L/h/kg) and MRT (60.9 h) Umirolimus",,2005,986.28,15,2,193.7,11,neutral,6.7,6.7
Biperiden,514-65-8,OC(CCN1CCCCC1)(C2CC3CC2C=C3)c4ccccc4,12,12,0.097,17,24,"Grimaldi R, Perucca E, Ruberto G, Gelmi C, Trimarchi F, Hollmann M, and Crema A (1986) Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects.  Eur. J. Clin. Pharmacol.  29: 735-737.  Nakashima E, Yokogawa K, Ichimura F, Kurata K, Kido H, Yamaguchi N, and Yamana T (1987) A physiologically based pharmacokinetic model for biperiden in animals and its extrapolation to humans.  Chem. Pharm. Bull. 35: 718-725.",,,1955,311.46,2,1,23.5,5,cationic,4.4,2.5
Biricodar,159997-94-1,N1([C@@H](CCCC1)C(=O)OC(CCCc1cnccc1)CCCc1cnccc1)C(=O)C(c1cc(c(c(c1)OC)OC)OC)=O,1.34,8.5,,2.62,1.1,"Ronald A. Peck, Jan Hewett, Matthew W. Harding, Yow-Ming Wang, Pravin R. Chaturvedi, Anish Bhatnagar,
Harvey Ziessman, Frank Atkins, and Michael J. Hawkins. Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin. Journal of Clinical Oncology,  2001, Vol 19, 3130-3141","VX-710 COMBINED DATA FROM TABLE 6. MRT from VDss and Clearance
There were no differences in VX-710 pharmacokinetic parameter values between the VX-710 single-agent infusion cycle and the combination therapy cycle (VX-710–doxorubicin), as shown in Fig 3, where selected pharmacokinetic parameters of VX-710 from all patients were plotted by cohorts. VX-710 has linear pharmacokinetics as indicated by the lack of dose dependence in CLs and Vss. In lieu of the observed linear pharmacokinetics, Table 6 summarizes the pharmacokinetic parameters of VX-710 for the combined data from all dose groups and both treatment phases, except for Css, which was proportional to dose and hence summarized by dose cohorts.",,1994,603.71,10,0,117.1,16,neutral,5.4,5.4
Bisaramil,89194-77-4,CCN1C[C@H]2CN(C)C[C@@H](C1)C2OC(=O)c3ccc(Cl)cc3,9,17,,8.8,8.6,"Gemesi L, Kapas M, Matos L (1993)  Pharmacokinetic study of bisaramil in man.  Acta Pharm. Hungarica  63: 327-333. ",VDss calculated from reported C vs t data table.,,1982,322.83,4,0,32.8,4,cationic,3.3,1.8
Bisoprolol,66722-44-9,CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,2.4,3.7,0.66,11,10,"Horikiri Y, Suzuki T, and Mizobe M (1998) Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans.  J. Pharm. Sci. 87: 289-294.  Leopold G, Pabst J, Ungethuem W, and Buehring KU (1986) Basic pharmacokinetics of bisoprolol, a new highly beta1-selective adrenoceptor antagonist.  J. Clin. Pharmacol. 26: 616-621.  ",VDss calculated from C vs t data obtained by digitization of the plot provided by Leopold et al.,,1978,325.44,5,2,59.9,12,cationic,2.2,0.46
Bivalirudin,128270-60-0,C([C@H]1N(CCC1)C([C@@H](Cc1ccccc1)N)=O)(=O)N[C@H](C(N1[C@H](C(=O)NCC(=O)NCC(NCC(=O)NCC(=O)N[C@H](C(NCC(=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@H](C(N[C@H](C(N[C@@H](Cc2ccc(O)cc2)C(N[C@@H](CC(C)C)C(=O)O)=O)=O)CCC(O)=O)=O)CCC(O)=O)[C@H](CC)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)Cc2ccccc2)=O)CC(O)=O)=O)CC(=O)N)=O)CCC1)=O)CCCNC(N)=N,0.27,8.1,1,0.43,0.42,"Guixiang Pana, Xiaoming Wang, Yuhong Huang, Xiumei Gao, Yuefei Wang. Development and validation of a LC–MS/MS method for determination of bivalirudin in human plasma: Application to a clinical pharmacokinetic study J.Pharm. Biomed. Anal.. 2010, 52 105–109.//CHA IDong, WANG Rui, BA INan, CA IYun LIANG B ei- bei. Pharmacokinetics of bivalirudin injections in Chinese healthy volunteers. Chin. J. Clin Pharmacol. 2011, 27, 280-282.// ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/090816s000lbl.pdf. Accessed July 14 2014.",Weighted average of data from both papers. N=9 (pana et al) and N=36 (Chai et al.) Doses from 0.5 to 1.05 mg/kg infusion//ppb from fda label. Bivalirudin does not bind to plasma proteins (other than thrombin) or to red blood cells.,,1990,2180.29,57,28,901.6,67,anionic,-6.6,-9
Bizelesin,129655-21-6,c12c(N(C(c3cc4cc(NC(Nc5cc6c([nH]c(c6)C(N6c7c(c8c([nH]cc8C)c(c7)O)[C@@H](C6)CCl)=O)cc5)=O)ccc4[nH]3)=O)C[C@H]2CCl)cc(O)c2c1c(c[nH]2)C,0.05,0.5,,1.7,1.6,"Pitot, Henry C.; Reid, Joel M.; Sloan, Jeff A.; Ames, Matthew M.; Adjei, Alex A.; Rubin, Joseph; Bagniewski, Pamela G.; Atherton, Pamela; Rayson, Daniel; Goldberg, Richard M; Erlichman, Charles. A phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin. Cancer Res. 2002, 8, 712-717.",Weighted average over 17 patients with doses ranging from 0.1 ug/m2 to 1 ug/m2.  1.73m2/70 kg conversion factor used.,,1990,815.7,13,8,185.4,6,neutral,5.9,5.9
Bleomycin,11056-06-7,O([C@H]([C@H](NC(c1nc([C@@H](NC[C@@H](C(N)=O)N)CC(N)=O)nc(c1C)N)=O)C(N[C@@H]([C@H]([C@@H](C(N[C@H](C(NCCc1nc(c2nc(C(NCCC[S+](C)C)=O)cs2)cs1)=O)[C@@H](C)O)=O)C)O)C)=O)c1c[nH]cn1)[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H]([C@@H](O)[C@@H](O2)CO)OC(N)=O)O)[C@@H]([C@@H](O)[C@@H](O1)CO)O,0.43,1.26,,5.77,3.9,FDA label Accessed October 1 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf,Data reported in L/m2. 1.73 m2/70 kg. MRT from VDss and clearance.,,1966,1415.55,38,20,627.1,36,cationic,-9,-9
BLP1654,28889-87-4,N12[C@@H](C(S[C@@H]2[C@@H](C1=O)NC(=O)[C@@H](c1ccccc1)NC(=O)NC(=N)N)(C)C)C(=O)O,0.24,1.6,0.8,2.5,2.09,"JOHN T. CLARKE, ROBERT D. LIBKE, EDWARD D. RALPH, RUEDI P. LUTHY, and WILLIAM M. M. KIRBY. Human Pharmacokinetics of BL-P1654 Compared with Ampicillin. Antimicr. Agents Chemother., 974, 6, 729-733. ",Data average of 2 cohhorts of 4 subjects. 5 and 30' infusion of 1 g of BLP1654. data reported as L/1.73m2 and mL/min/1.73 m2. 1.73m2/70 kg conversion factor used.,,1970,434.47,11,6,177.7,6,zwitterionic,0.061,-2.3
BMS-214662,195987-41-8,O=S(=O)(N1Cc2cc(ccc2N(Cc3cnc[nH]3)C[C@H]1Cc4ccccc4)C#N)c5cccs5,0.84,9.6,0.01,1.4,1.6,"Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, and Clark JW (2004) Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1 hour intravenous infusion in patients with advanced solid tumors.  Clin. Canc. Res.  10: 2222-2230.//ppb: Helen J. Mackay, Ronald Hoekstra, Ferry A. L. M. Eskens, Walker J. Loos, Donna Crawford, Maurizio Voi, Anne Van Vreckem, T. R. Jeffrey Evans, Jaap Verweij. A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2004, 10, 2636-2644.",,,1997,489.61,7,1,93.1,7,neutral,3.6,3.5
Bortezomib,179324-69-7,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,10,19,0.17,8.8,18,"Papandreou CN, Daliani D, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, and Logothetis CJ (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.  J. Clin. Oncol. 22: 2108-2121.  Velcade Product Label.",,,1996,384.24,8,4,124.4,9,neutral,0.8,0.8
Bosentan,147536-97-8,COc1ccccc1Oc2c(NS(=O)(=O)c3ccc(cc3)C(C)(C)C)nc(nc2OCCO)c4ncccn4,0.29,2.1,0.037,2.3,4.1,"Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J, Van Marle S, Viischer HW, and Jonkman JHG (1999)  Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.  J. Clin. Pharmacol. 39:  703-714.  Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Van Marle SP, Peeters PAM, Jonkman JHG, and Jones CR (1996) Pharmacokinetics pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.  Clin. Pharmacol. Ther. 60: 124-137.",,,1992,551.61,11,2,145.6,10,anionic,3.9,0.76
Brexpiprazole,913611-97-9,c1cc(c2ccsc2c1)N3CCN(CC3)CCCCOc4ccc5ccc(=O)[nH]c5c4,1.46,0.34,0.002,70.95,54.37,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205422Orig1Orig2s000ClinPharmR.pdf. Accessed April 10 2017.,"data digitized from Figure 1 (left panel, iv). 0.25 mg dose, 1 hr infusion, N=16, healthy subjects. 70 kg average weight assumed. Very large extrapolation from AUC0-t to inf reported due likely to overestimation of t 1/2. Cltot reported as 19.8 mL.h-1.kg-1 (and calculated via AUC0-t) vs. calculated as 20.61 mL.h-1.kg-1. ",,2006,433.57,5,1,48.6,7,cationic,5,2.6
Brivaracetam,357336-20-0,CCC[C@H]1CN([C@@H](CC)C(=O)N)C(=O)C1,0.56,0.75,0.825,12.47,8.98,"Armel Stockis, Jan Hartstra, Muriel Mollet, and Salah Hadi. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. Epilepsia, doi: 10.1111/epi.13433// ppb: reported by Sargentini-Maier ML, Espie P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 2008, 36:36–45.","N=25, 100 mg dose as iv bolus, 70 kg average weight assumed. Data digitized from plot reported. Reported AUCinf 31.95 ug.h.mL-1, calculated AUCinf 31.77 ug.h.mL-1.",,2001,212.29,4,1,63.4,5,neutral,0.82,0.82
Bromazepam,1812-30-2,Brc1ccc2NC(=O)CN=C(c3ccccn3)c2c1,0.85,0.51,0.48,28,21,"Raaflaub VJ and Speiser-Courvoisier J (1974) Zur pharmakokinetik von bromazepam beim menschen.  Arz. Forsch. 24: 1841-1844.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.    Molec. Pharmacol. 12: 612-619.",Parameters calculated from C vs t data provided in the reference.,,1962,316.15,4,1,54.3,1,neutral,2,2
Bromfenac,91714-94-2,Nc1c(CC(=O)O)cccc1C(=O)c2ccc(Br)cc2,0.11,1.3,0.0011,1.5,2.6,"Gumbhir-Shah K, Cevallos WH, DeCleene SA, Halstenson CE, and Korth-Bradley JM (1997) Absolute bioavailability of bromfenac in humans.  Ann. Pharmacother. 31: 395-399.",,,1984,334.16,4,2,80.4,4,anionic,3.3,0.33
Bromopride,4093-35-0,CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,3.1,13,0.6,4,2.9,"Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, and Taylor T (1986) Pharmacokinetics and bioavailability of the anti-emetic agent bromopride.  Biopharm. Drug Dispos.  7: 215-222.",VDss was calculated using C vs t data provided in the reference.,,1964,344.25,5,2,67.6,7,cationic,2,0.44
Bromotetrandrine,62067-29-2,O(C)c1c2c3c(c(c1OC)Br)CCN([C@H]3Cc1cc(c(cc1)OC)Oc1ccc(C[C@H]3c4cc(O2)c(OC)cc4CCN3C)cc1)C,51,9.6,0.22,88.2,59.4," Zheng L; Qing Y-P; Xu N; Yu Q; Wang Y; Wang F-P; Li Z-Y. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-​dose intravenous administration in healthy Chinese volunteers. Journal of clinical pharmacy and therapeutics (2010), 35(1), 113-119.//ppb: Xiao SH, Wei GL, Lu R, Liu CX, Wang FP. Pharmacokinetics of bromotetrandrin (W198) in rats and beagle dogs. Yao Xue Xue Bao. 2004, 39, 301-304. ","Data digitized from plot reported. N=10, 30 mg/m2 dose only. AUC reported 1311.3 ug.h/L. Calculated AUC 1279.4 ng.h/mL. From ppb reference (abstract): The plasma protein binding ratio of W198 with human serum protein was 78.0%.",,1977,701.65,8,0,61.9,4,cationic,8.3,7.2
Brostallicin,203258-60-0,c1c(cn(c1C(=O)NCC/N=C(/N)N)C)NC(=O)c1n(cc(c1)NC(=O)c1cc(cn1C)NC(=O)c1cc(cn1C)NC(=O)C(=C)Br)C,0.36,5.15,,1.2,8.3,"A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid TumorsA. Craig Lockhart,1 Martin Howard, Kenneth R. Hande, Bruce J. Roth,Jordan D. Berlin, Franzanne Vreeland, Angela Campbell, Erminia Fontana,Francesca Fiorentini, Camilla Fowst, Victoria A. Paty, Odessa Lankford, and Mace L. Rothenberg Clin. Cancer. Res. 2004, v. 10, 468-475.","Reported AUC(0-inf) = 385.6 ng.h/mL, N= 6, 4.8 mg/m2, 1.73 m2/70 kg conversion factor. 10' infusion.",,1998,723.58,17,7,229.6,12,neutral,1.9,1.9
Brotizolam,57801-81-7,Cc1nnc2CN=C(c3ccccc3Cl)c4cc(Br)sc4n12,0.75,2,0.092,6,4.8,"Jochemsen R, Wesselman JGJ, Hermans J, Van Boxtel CJ, and Breimer DD (1983) Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration.  Br. J. Clin. Pharmacol. 16(Suppl. 2): 285-290.  Jochemsen R, Joeres RP, Wesselman JG, Richter E, and Breimer DD (1983) Pharmacokinetics of oral brotizolam in patients with liver cirrhosis.  Br. J. Clin. Pharmacol.  16(Suppl 2): 315S-322S.",VDss was calculated using data obtained by digitization of the C vs t plot provided in the reference.,,1975,393.69,4,0,43.1,1,neutral,2.8,2.7
Budesonide,51333-22-3,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,3.9,20,0.13,3.2,2.8,"Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, and Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.  Eur. J. Resp. Dis. 63: 86-95.  Entocort EC Product Label.",VDss was calculated using data obtained by digitization of the C vs t plot provided in the reference.,,1973,430.53,6,2,93.1,4,neutral,3,3
Buflomedil,55837-25-7,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,1.3,5.6,0.4,3.9,3.3,"Gundert-Remy U, Weber E, Lam G, Chiou WL, Mann W, and Aynilian GH (1981) The clinical pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration.  Eur. J.Clin. Pharmacol. 20: 459-63.  Rey E, D'Athis P, Richard MO, Fillastre JP, and Olive G (1984) Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.  Int. J. Clin. Pharmacol. Ther. Toxicol. 12: 648-652.",,,1978,307.38,5,0,48,8,cationic,2.5,0.52
Bufuralol,54340-62-4,CCc1cccc2cc(oc12)C(O)CNC(C)(C)C,1.7,8.9,0.19,3.2,2.3,"Dayer P, Balant L, Kupfer A, Striberni R, and Leemann T (1985) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.  Eur. J. Clin. Pharmacol. 28: 317-320.  Foti RS and Fisher MB (2004) Impact of incubation conditions on bufuralol human clearance predictions: Enzyme lability and nonspecific binding.  Drug Metab. Dispos. 32: 295-304.",CYP2D6 extensive metabolizers only.  VDss calculated from C vs t data obtained by digitization of the plots included in the reference.,,1975,261.36,3,2,45.7,4,cationic,3.3,1.7
Bumecaine,30103-44-7,CCCCN1CCCC1C(=O)Nc2c(cc(cc2C)C)C,1.73,19.19,,1.51,1.58,"Piotrovskii, V. K.; Blagodatskikh, S. V.; Ryabokon, O. S.; Metelitsa, V. I.; Smirnov, V. K.; Gorshkov, V. A.; Mazur, N. A.; Pryanishnikova, N. T.  Clinical pharmacokinetics of pyromecaine. I. Single intravenous administration Khimiko-Farmatsevticheskii Zhurnal (1983), 17(12), 1427-32","Pyromecaine. N=10 all male patients, 100 mg iv dose. MRT from reported clearance and VDss.",,1970,288.43,3,1,32.3,5,cationic,4,3.3
Bumetanide,28395-03-1,CCCCNc1cc(cc(c1Oc2ccccc2)S(=O)(=O)N)C(=O)O,0.16,2.5,0.031,1.1,1.2,"Pentikainen PJ, Pasternack A, Lampainen E, Neuvonen PJ, and Penttila A (1985) Bumetanide kinetics in renal failure.  Clin. Pharmacol. Ther. 37:  582-528.  Lau HSH, Hyneck ML, Berardi RR, Swartz RD, and Smith DE (1986) Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure.  Clin. Pharmacol. Ther. 39: 635-645.  Cook JA, Smith DE, Cornish LA, Tankanow RM, Nicklas JM, and Hyneck ML (1988) Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure.  Clin. Pharmacol. Ther. 44: 487-500.",Data combined from three references.,,1970,364.42,7,3,118.7,8,anionic,3.4,0.56
Bunazosin,80755-51-7,CCCC(=O)N1CCCN(CC1)c2nc(N)c3cc(OC)c(OC)cc3n2,0.72,4.8,0.06,2.5,2,"Morishita N, Tomono Y, Hasegawa J, and Heuer HJ (1993)  Single dose crossover study to evaluate the absolute bioavailability of a sustained-release formulation of bunazosin (E1015) in healthy male volunteers.  Drug Invest.  6:  5-9.  Yamato C, Takahashi T, Tadano K, Kinoshita K, and Fujita T (1985)  The metabolic fate of bunazosin hydrochloride (2). Studies on the transfer to fetus and milk, plasma protein binding, tissue accumulation and effect on drug-metabolizing enzymes. Oyo Yakuri  30: 257-265.",,,1980,373.45,8,1,93.8,5,neutral,2.7,2.6
Bupivacaine,38396-39-3,CCCCN1CCCCC1C(=O)Nc2c(C)cccc2C,0.84,4.3,0.056,3.3,3.1,"Burm AGL, Van der Meer AD, Van Kleef JW, Zeijlmans PWM, and Groen K (1994) Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate.  Br. J. Clin. Pharmacol. 38: 125-129.",Values for enantiomers were averaged.,,1957,288.43,3,1,32.3,5,cationic,4,3.4
Buprenorphine,52485-79-7,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56,4.9,19,0.04,4.9,3.2,"Kuhlman JJ, Lalani S, Magluilo, J, Levine B, Darwin WD, Johnson RE, and Cone EJ (1996) Human pharmacokinetics of intravenous, sublingual and buccal buprenorphine.  J. Anal. Toxicol. 20: 369-378.   Elkader A and Sproule B (2005)  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.  Clin. pharmacokinet. 44: 661-680.",,,1968,467.64,5,2,62.2,4,cationic,4.4,3.1
Busulphan,55-98-1,CS(=O)(=O)OCCCCOS(=O)(=O)C,0.55,2.4,1,3.8,3.4,"Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringden O, Eber S, Seger R, and Ljungman P (2002) A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.  Bone Marrow Transplantation  30: 833-841.  Ehrsson H and Hassan M (1984) Binding of busulfan to plasma proteins and blood cells.  J. Pharm. Pharmacol.   36: 694-696.",,,1950,246.3,6,0,86.7,7,neutral,-0.72,-0.72
Buthionine sulfoximine,5072-26-4,C([S@@](CCCC)(=N)=O)C[C@@H](C(O)=O)N,0.26,2.28,,1.9,1.68,"Phase I Trial of Buthionine Sulfoximine in Combination With Melphalan in Patients With Cancer. Peter J. O'Dwyer, Thomas C. Hamilton, Frank P. LaCreta, James M. Gallo, Deborah Kilpatrick, Theresa Halbherr, James Brennan, Michael A. Bookman, John Hoffman, Robert C. Young, Robert L. Comis, and Robert F. Ozols. J. Clin. Oncol. 1996,14:249-256.","BRN 2367136,  NSC 326231, NSC 381100. Data weight-averaged from table 5 across both R/S isomers. MRT calculated from VDss and clearance. 70 kg assumed, N=23 total, 5-17 g/m2 dose.
",,1960,222.31,5,3,104.2,7,zwitterionic,-0.19,-2.5
Butorphanol,42408-82-2,Oc1ccc2C[C@H]3N(CC4CCC4)CC[C@@]5(CCCC[C@@]35O)c2c1,12,41,0.17,5.3,4.8,"Vachharajani NN, Shyu WC, Garnett WR, Morgenthien EA and Barbhaiya RH (1996) The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.  Clin. Pharmacol. Ther. 60: 283-294.   Gaver RC, Vasiljev M, Wong H, Monkovic I, Swigor JE, Van Harken DR, and Smyth RD (1980) Disposition of parenteral butorphanol in man.  Drug Metab. Dispos. 8: 230-235.",,,1973,327.46,3,2,43.7,2,cationic,3.2,2.1
Butylbiguanide,692-13-7,CCCCNC(=N)NC(=N)N,1.84,6.58,0.9,4.66,4.62,"Lintz, W.; Berger, W.; Aenishaenslin, W.; Kutova, V.; Baerlocher, Ch.; Kapp, J. P.; Beckmann, R. Butylbiguanide concentration in plasma, liver, and intestine after intravenous and oral administration to man. Eur. J. Clin. Pharmacol. (1974), 7(6), 433-48.","N=4, diabetic patients, 77 kg average weight reported, 50 mg dose i.v. VDss from V1 and k12, k21. MRT from VDss and clearance. Renal clearance 73%. Total radioactivity but noted that there is no metabolism by the authors so that the equivalence radiioactivity=compound is valid. ",,1959,157.22,5,5,97.8,6,cationic,-0.61,-4.1
Cabazitaxel,183133-96-2,C1(C2=C([C@H](C[C@]1([C@H]([C@H]1[C@](C(=O)[C@@H]2OC)([C@H](C[C@@H]2[C@]1(CO2)OC(=O)C)OC)C)OC(=O)c1ccccc1)O)OC(=O)[C@@H]([C@H](c1ccccc1)NC(=O)OC(C)(C)C)O)C)(C)C,48,11,0.24,72.7,74.5,"Mita, Alain C.; Denis, Louis J.; Rowinsky, Eric K.; DeBono, Johann S.; Goetz, Andrew D.; Ochoa, Leonel; Forouzesh, Bahram; Beeram, Muralidhar; Patnaik, Amita; Molpus, Kathleen; Semiond, Dorothee; Besenval, Michele; Tolcher, Anthony W. Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clin.Cancer Res. 2009, 15,723-730. ppb: Men, Lei; Lin, Hong-li; Shao, Yan-jie; Zhao, Yun-li; Zhao, Xing; Tang, Xing; Yu, Zhi-guo. Determination of human plasma protein binding rate of cabazitaxel by UPLC-​MS​/MS. Zhongguo Xinyao Yu Linchuang Zazhi, 2014, 33, 379-383. Data from abstract and using mid-concentration range. 2-fold lower at high concentration range (fu 0.12) but similar at low concentration. Taken from abstract in English.","XRP6258 or RPR116258A or Jevtana. 23 patients overall. Doses from 10 to 25 mg/m2 as 1 hour infusion. Weighted average and 1.73m2/70kg factor used. Reported (weighted) average of clearance and VDss 26.77 L/h/m2 and 1942.8 L/m2, respectively. MRT=VDss/Cl.",,1996,835.93,15,3,202.4,14,neutral,4,4
Caderofloxacin,153808-85-6,n1(cc(c(c2cc(c(c(c12)OC(F)F)N1C[C@@H](NCC1)C)F)=O)C(=O)O)C1CC1,1.1,2.7,,7.1,5.9,"Pharmacokinetics of caderofloxacin hydrochloride after intravenous infusion in healthy volunteers. WANG Yuan-yuan，ZHANG Jing，ZHANG Deng-shan，ZOU Ying，LIU Guang-yu. Chinese Journal of New Drugs 2011, 20( 23) 2377-2380.","Caderofloxacin, CS-940. Data digitized from plot of mean data after an infusion (1 hr) of 0.4 g of compound to 10 male and female healthy volunteers. Data reported in Table 1 are average of separate PK calculations in Table 2.  Reported AUCinf as 45.1 ug.mL.h-1.  ",,1990,411.38,7,2,83.8,5,zwitterionic,2.5,-0.28
Caffeine,58-08-2,CN1C(=O)N(C)c2ncn(C)c2C1=O,0.63,1.4,0.64,7.5,4.9,Blanchard J and Sawers SJA (1983) Comparative pharmacokinetics of caffeine in young and elderly men.  J. Pharmacokinet. Biopharm. 11: 109-126.,VDss was calculated from C vs t data obtained by digitization of the plot included in the reference.  ,,1968,194.19,6,0,58.4,0,neutral,0.078,0.078
Calcitonin,21215-62-3,CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc4cnc[nH]4)NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](Cc6ccccc6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc7ccc(cc7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N,0.23,10,,0.38,0.82,"Antonin, K. H.; Saano, V.; Bieck, P.; Hastewell, J.; Fox, R.; Lowe, P.; Mackay, M. Colonic absorption of human calcitonin in man. Clin. Sci. 1992, 83, 627-631","Cibacalcin. Data digitized from plot reported. N=8, 0.5 mg dose in 90 min infusion. 70.5 kg average weight (males) and 63 kg average weight (females)  reported. Overall average (N=4/gender) as 67 kg. AUCinf calculated 744.8 ng.min/mL, reported AUC 694.8 ng.min/mL",,1968,3419.86,85,45,1359.6,105,cationic,-9,-9
Calcitriol,32222-06-3,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,0.25,0.31,,13.29,11,"L. Brandi, M. Egfjord, K. Olgaard. Pharmacokinetics of 1,25(OH)2D3 and 1a(OH)D3 in normal and uraemic men. Nephrol. Dial. Transpl. 2002, 17, 829-842.","1,25-(OH)2D3. Ro 21-5535.1-alpha,25-Dihydroxycholecalciferol. Data digitization performed from plot (figure 3) reported. AUC0-72 reported as 3378.6 pg.h.mL-1. AUC0-72 reported as 3522.52 pg.h.mL-1. 4% difference.",,1971,416.64,3,3,60.7,5,neutral,6,6
Canagliflozin,842133-18-0,Cc1ccc(cc1Cc2ccc(s2)c3ccc(cc3)F)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,1.19,2.74,0.01,7.25,10.3,PDR. https://www.pdr3d.com/detail.php?c=183524#section-12. Accessed August 5 2016.,70 kg average weight assumed. No dose reported. MRT from Clearance and VDss. T1/2 from ORAL dose of 100 mg.,,2005,444.52,5,4,90.1,5,neutral,3.3,3.3
Candesartan,139481-59-7,CCOc1nc2cccc(c2n1Cc3ccc(cc3)c4ccccc4c5[nH]nnn5)C(=O)O,0.13,0.37,0.002,5.9,9.7,"Reference through PP. 1997-Apr-30  PDF(1259k)
Clinical Pharmacology and Biopharmaceutics Review 020838/S-000 Part 01 NDA 20838.",4 mg 14C of candesartan iv. MRT from VDss and Cl,,1991,440.45,9,2,118.8,7,anionic,4.9,-0.31
Candoxatrilat,123122-54-3,[H]N(C1CCC(CC1)C(=O)O[H])C(C1(CCCC1)CC[C@@H](COCOC)C(=O)O[H])=O,0.25,2.3,0.872,1.81,16,"McDowell, Garry; Nicholls, D. Paul. The therapeutic potential of candoxatril, a neutral endopeptidase inhibitor, in humans. Cardiovascular Drug Reviews, 2000, 18, 259-270. ","Data from 150 mg iv dose. MRT calculated from CL and VDss.  fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",,1989,399.48,8,3,122.2,13,anionic,1.6,-3.6
Cangrelor,163706-06-7,CSCCNc1nc(SCCC(F)(F)F)nc2n([C@@H]3O[C@@H]([C@H]([C@H]3O)O)CO[P@@](O[P@@](O)(=O)C(Cl)(P(O)(O)=O)Cl)(O)=O)cnc12,0.035,9.06,0.02,0.07,0.14," Akers Wendell S; Oh Jennifer J; Oestreich Julie H; Ferraris Suellen; Wethington Mary; Steinhubl Steven R. Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist. Journal of clinical pharmacology (2010), 50(1), 27-35.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204958orig1s000clinpharmr.pdf. Accessed July 12 2017.","Digitized and then averaged from two groups. N=10 and N=9. 81 kg average with total dose 10 677 ug, and 79 kg average with total dose 20704 ug, respectively.",,1994,776.36,17,7,255.9,15,anionic,-1.4,-8.6
Cannabidiol,13956-29-1,CCCCCc1cc(O)c([C@@H]2C=C(C)CC[C@H]2C(=C)C)c(O)c1,6.69,13.55,,8.23,23.82,"Ohlsson, Agneta; Lindgren, Jan Erik; Andersson, Susanne; Agurell, Stig; Gillespie, Hampton; Hollister, Leo E. Biomed. Single-dose kinetics of deuterium-labeled cannabidiol in man after smoking and intravenous administration. Envir. Mass Spectr. (1986), 13(2), 77-83.","DEUTERATED COMPOUND. Calculations performed from tabular data reported. N=5, with some time points with N=4 or 3. Average weight 78.6 kg. AUC0-72 = 16670 ng.h.mL-1. Calculated AUC 18240 ng.h.mL-1. 9% difference.",,1940,314.46,2,2,40.5,6,neutral,7.4,7.4
Cannabinol,521-35-7,c12c3c(OC(c1ccc(c2)C)(C)C)cc(CCCCC)cc3O,16.98,17.85,,15.86,25.51,"Eva Johansson, Agneta Ohlsson, Jan-Erik Lindgren, Stig Agurell, Hampton Gillespie, Leo E. Hollister. Single-dose Kinetics of Deuterium-labelled Cannabinol in Man After Intravenous Administration and Smoking. BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, 1987, 14, 495-499","DEUTERATED COMPOUND. Calculation performed from data reported in Table. AUC inf reported within 3% of calculated. N=6, 20 mg dose, 72.2 kg average weight.",,1896,310.43,2,1,29.5,4,neutral,6.7,6.7
Captopril,62571-86-2,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,0.75,12,0.73,1,2,"Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DM (1982)  Captopril kinetics. Clin. Pharmacol. Ther. 31: 452-458.  Creasy WA, Morrison RA, Singhvi SM, and Willard DA (1988) Pharmacokinetics of intravenous captopril in healthy men.  Eur. J. Clin. Pharmacol. 35: 367-370.",Combined data from Creasy and Duchin papers.  Note that protein binding also has S-S bond component.,,1977,217.29,4,1,57.6,3,anionic,0.97,-2.2
Carbazeran,70724-25-3,c1(c(OC)cc2c(c1)c(nnc2)N1CCC(CC1)OC(NCC)=O)OC,0.67,37.6,0.08,0.25,0.25,"Kaye B, Offerman JL, Reid JL, Elliott HL, Hillis WS. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiot. 1984, 14, 935-945,// ppb: Zientek M, Jiang Y, Youdim, K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.  Drug Metab. Dispos. 38: 1322-1327.",VDss calculated from mean C vs t data in the paper,,1978,360.41,8,1,85.8,6,neutral,2.3,2.3
Carbenicillin,4697-36-3,CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O,0.17,1.9,0.52,1.5,1.1,"Libke RD, Clarke JT, Ralph ED, Luthy RP, and Kirby WMM (1975) Ticarcillin vs carbenicillin: clinical pharmacokinetics.  Clin. Pharmacol. Ther.  17: 441-446.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",,,1964,378.4,8,3,124,5,anionic,1.2,-5.4
Carboplatin,41575-94-4,N[Pt+2]1(N)[O-]C(=O)C2(CCC2)C(=O)[O-]1,0.26,1.5,1,3,2,"Elferink F, van der Vijgh WJ, Klein I, Vermorken JB, Gall HE, and Pinedo HM (1987) Pharmacokinetics of carboplatin after i.v. administration.    Cancer Treatment Rep.  71: 1231-1237.  Gaver RC, George AM, and Deeb G (1987) In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.  Cancer Chemother. Pharmacol. 20: 271-276.",Used 1.6 m2 = 60 kg since the study was done in all females.,,1982,369.24,6,2,108.8,0,n/a,n/a,n/a
Carebastine,90729-42-3,C1C(CCN(C1)CCCC(c1ccc(C(C(=O)O)(C)C)cc1)=O)OC(c1ccccc1)c1ccccc1,0.41,0.4,0.05,16.7,9.8,"J.M. JANSAT, C.F. LASTRA, E.L. MARINO Comparative study of different weighting methods in non-linear regression analysis: implications in the parametrization of carebastine after intravenous administration in healthy volunteers. Int. J. Clin. Pharmacol. Ther., Vol. 1998, 36, 340-344.//ppb: A del Cuvillo, J Mullol, J Bartra, I Dávila, I Jáuregui, J Montoro, J Sastre, AL Valero. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006, 16, Suppl. 1:3-12.","Data taken from Table 1. 77 kg median weight, 10 mg total dose. N=8. VDss from MRT and clearance.",,1985,499.64,5,1,66.8,11,zwitterionic,5.9,3
Carfilzomib,868540-17-4,C1O[C@]1(C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)CN1CCOCC1)CCc1ccccc1)=O)CC(C)C)=O)Cc1ccccc1)=O)CC(C)C)=O)C,0.13,39.5,0.02,0.05,1.1,"Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction
of Carfilzomib. Zhengping Wang, Jinfu Yang, Christopher Kirk, Ying Fang, Melissa Alsina, Ashraf Badros, Kyriakos Papadopoulos, Alvin Wong, Tina Woo, Darrin Bomba, Jin Li, and Jeffrey R. Infante. Drug Metab Dispos 2013, 41:230–237.","Data digitized from Wang et al. DMD 2013, 41, 230-237. N=3, cycle 1 day 1.  20 mg/m2 with 1.73 m2/kg was used as the conversion factor. Digitization somewhat difficult. AUC reported as 238 hr*ng/mL. Clearance reported as 146 L/h (= 34.8 mL/min/kg) vs. calculated as 39.5 mL/min/kg. Values are slightly above 10% variation between the two sets.",,2005,719.91,12,4,158.5,20,neutral,5,4.9
Carmustine (BCNU),154-93-8,ClCCNC(=O)N(CCCl)N=O,1.2,78,0.23,0.26,0.37,"Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, and Frei E (1986) Pharmacokinetics and immediate effects of high-dose carmustine in man.  Canc. Treatm. Rep. 70: 877-880. ",Used VD as VDss because PK was first order.,,1946,214.05,5,1,61.8,5,neutral,1.4,1.4
Carnitine_L,406-76-8,C([N+](C)(C)C)[C@@H](CC(=O)[O-])O,0.4,1.6,1,4.2,5,"Sahajwalla CG, Helton ED, Purich ED, Hoppel CL, Cabana BE. Comparison of L-Carnitine Pharmacokinetics With and Without Baseline Correction Following Administration of Single 20-mglkg Intravenous Dose. J Pharm Sci. 1995 May;84(5):634-9. ppb: the PDR states: Levocarnitine was not bound to plasma protein or albumin when tested at any concentration or with any species including the human. Accessed January 2 2015. http://www.pdr3d.com/detail.php?c=138037#section-5","All data from table 3, calculated as average dose 1,485 mg (MW161, 9,223,602 nmol), 74 kg average weight.N=15. VDss taken as 29 L (free corrected, not conjugated L-carnitine). MRT from VDss and clearance. AUC taken as 1318 nmol.hr/mL.",70-85% excreted unchanged. Same paper as for ref. for data.,1902,161.2,4,1,60.4,4,anionic,-4.6,-4
Carocainide,66203-00-7,C1CCN(C1)CCOc1c(OC)c2occc2c(c1NC(NC)=O)OC,0.8,3.2,,4.2,5,"Rovei V, Strolin Benedetti M, Daniel C, Moulin A, Donath A. Pharmacokinetics and metabolism of the antiarrhythmic carocainide in man. Xenobiot. 1985, 15, 953-964.","Data digitized from plot reported. Within range reported but not in close agreement with mean AUC. 100 mg, N=6, median weight 65 kg. ppb saturable as reported in the work cited.",,1978,363.41,8,2,85.5,7,cationic,1.4,0.3
Carprofen,53716-49-7,CC(c1ccc2c3cc(ccc3[nH]c2c1)Cl)C(=O)O,0.22,0.51,0.001,7.2,9.9,"Crevoisier C. Pharmacokinetc properties of carprofen in humans.  Eur J Rheumatol Inflamm. 1982, 5: 492-502",RO 20-5720. Rimadyl. MRT from VDss and clearance.,,1974,273.71,3,2,53.1,2,anionic,4,0.95
Carteolol,51781-06-7,c12c(cccc1OC[C@@H](CNC(C)(C)C)O)NC(=O)CC2,,10.1,,,4.7,"T. Ishizaki, A. Ohnishi, T. Sasaki, K. Kushida, Y. Horai , K. Chiba , and T. Suganuma. Pharmacokinetics and Absolute Bioavailability of Carteolol,a New beta-Adrenergic Receptor Blocking Agent. Eur J Clin Pharmacol (1983) 25:95-101","Data digitized from plot reported. 0.21 mg/kg free base dose, N=8, 62 kg average weight. Free base taken as plasma concentration corrected by authors to reflect that. N=1 only. Clearance value from paper kept.",65% excreted in urine unchanged,1974,292.37,5,3,70.6,5,cationic,1.3,-0.6
Carumonam,87638-04-8,NC(=O)OC[C@@H]1[C@H](NC(=O)\C(=N/OCC(=O)O)\c2csc(N)n2)C(=O)N1S(=O)(=O)O,0.18,1.5,0.72,2,1.6,"Weidekamm E, Kronenberger D, Portmann R, Stoeckel K, Egger HJ, and Dubach UC (1985) Single dose pharmacokinetics and absolute bioavailability of the new monocyclic .beta.-lactam carumonam (Ro 17-2301, AMA-1080).  Recent Adv. Chemother., Proc. 14th Int. Congr. Chemother. (Antimicrobial Sect. 2),  1335-1336.   Kita Y, Fugono T, and Imada A (1987) Pharmacokinetics of carumonam in experimental animals.  Chemotherapy 35(Suppl. 2): 187-197.","Ro 172301, AMA-1080. ",,1983,466.4,16,5,253.9,10,anionic,-2.8,-8
Carvedilol,72956-09-3,COc1ccccc1OCCNCC(O)COc2cccc3[nH]c4ccccc4c23,1.3,7.8,0.02,2.8,2.4,"Neugebauer G, Akpan W, Mollendorff E, Neubert P, and Reiff K (1987) Pharmacokinetics and disposition of carvedilol in humans.  J. Cardiovasc. Pharmacol. 10(Suppl 11): S85-S88.   Coreg Product Label.",,,1979,406.47,6,3,75.7,10,cationic,3.6,2.9
Carzelesin,119813-10-4,c1(N(CC)CC)cc2oc(C(Nc3ccc4c(c3)cc([nH]4)C(N3C[C@H](c4c5c([nH]cc5C)c(OC(=O)Nc5ccccc5)cc34)CCl)=O)=O)cc2cc1,0.09,2.9,,0.51,0.48,"Data as average of two different single patient profiles (N=2):   (1) Van Tellingen, Olaf; Nooijen, Willem J.; Schaaf, Larry J.; Van Der Valk, Martin; Van Asperen, Judith; Henrar, Roland E. C.; Beijnen, Jos H. Comparative pharmacology of the novel cyclopropylpyrroloindole-​prodrug carzelesin in mice, rats, and humans. Cancer Research (1998), 58(11), 2410-2416.     (2) van Tellingen O, Punt CJ, Awada A, Wagener DJ, Piccart MJ, Groot Y, Schaaf LJ, Henrar RE, Nooijen WJ, Beijnen JH. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemother Pharmacol. 1998;41(5):377–384."," (1) data digitized from Fig. 4.  Dose 300 ug/m2 (0.0075 mg/kg), infusion T=10 min, N=1*. (2) data digitized from Fig. 5 (dose 210 ug/m2 (0.00525 mg/kg), infusion T=10 min, N=1**.
* reported data: see Table 4 (data seems to be for 3 patients (N=3) presented in Table 1 in van Tellingen O. et al, Cancer Chemother Pharmacol, 1998, 41, 377-384). The actual digitized values (AUC, CL, ...) seem to agree with the values reported for the last patient in Table 1.
** 48th patient in Table 1, reported data: see Table 1 where the AUC, CL, half times, ... for all patients are reported (CL = 0.29 L/h/kg)",,1988,729.22,11,4,136,10,neutral,7.7,7.7
Casopitant,414910-27-3,c1(cc(cc(c1)[C@H](N(C(=O)N1CC[C@@H](C[C@@H]1c1c(cc(cc1)F)C)N1CCN(CC1)C(=O)C)C)C)C(F)(F)F)C(F)(F)F,2.77,3.07,1,15.04,15.6,"Mario Pellegatti, Ellenia Bordini, Patrizia Fizzotti, Andy Roberts, and Brendan M. Johnson. Disposition and Metabolism of Radiolabeled Casopitant in Humans. Drug Metab. Disp. 2009, 37, 1635-1645.// ppb: Bauman, John W.; Antal, Joyce M.; Adams, Laurel M.; Johnson, Brendan M.; Murray, Sharon C.; Peng, Bin; Kirby, Lyndon C.; Lebowitz, Peter F.; Marbury, Thomas C.; Swan, Suzanne; Gutierrez, Maria. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-​1 receptor antagonist. Invest. New Drugs, 2012, 30, 662–671.",70 kg average weight assumed. N=6. 15 minutes infusion of a 90 mg dose. MRT from VDss and clearance.,,2002,616.61,6,0,47.1,4,neutral,5.4,5.4
Caspofungin,162808-62-0,CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(O)C(NCCN)NC(=O)C2C(O)CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(O)CN3C(=O)C(NC1=O)C(C)O)C(O)C(O)c4ccc(O)cc4)C(O)CCN,0.13,0.14,0.035,15,27,"Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC (2004) Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.  Antimic. Agents Chemother.  48: 815-823.",VDss was calculated from rate micro-contants provided in the reference.,,1994,1093.31,25,16,412,23,cationic,-1.4,-6.3
CB 10-277,7203-91-0,CN(C)N=Nc1ccc(cc1)C(=O)O,0.25,1.3,,3,2.5,"Foster BJ, Newell DR, Carmichael J, Harris AL, Gumbrell LA, Jones M, Goodard PM, and Calvert AH (1993) Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.  Br. J. Canc. 67: 362-368.",Parameters were calculated using C vs t data obtained by digitzation of the plot provided in the reference.,,1965,193.2,5,1,65.3,3,anionic,2.5,-0.32
CDK-712,626252-75-3,C([C@H]1c2c(cc(c(c2)O)O)CCN1)c1c2c(ccc1)cccc2,1.09,156,,0.12,1.58,"Sang-In Park,JaeWoo Kim, Kyung-Sang Yu, In-Jin Jang, SeungHwan Lee. Changes in Cardiac Function After a Single Intravenous Administration of CKD-712 in Healthy Male Volunteers. Clin Drug Investig 2017 37, 393–403.","Data digitized from plot reported in SI. 160 ug/kg dose, N=6, 1 h infusion. Generally linear except a deviation at 320 ug/kg dose. Starting dose 20 ug/kg. AUC0-inf reported as 16.40 ug.h.L-1. AUC0-inf calculated as 17.09 ug.h.L-1. 4% difference.",,2003,305.37,3,3,52.5,2,cationic,3.7,2.6
Cefadroxil,50370-12-2,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C2=O)C(=O)O,0.23,2.5,0.39,1.5,1.1,"Marino EL, Dominguez-Gil A, and Muriel C (1982) Influence of dosage form and administration route on the pharmacokinetic parameters of cefadroxil.  Int. J. Clin. Pharmacol. Ther. Toxicol. 20: 73-77.   Aratani H, Kono S, Tateishi H, Negita S, and Yamanaka Y (1980) Pharmacological studies on cefadroxil.  II.  Pharmacokinetics.  Chemotherapy 28(Suppl. 2): 75-82. ",,,1973,363.39,8,4,133,4,zwitterionic,-0.7,-2.1
Cefamandole,34444-01-4,Cn1nnnc1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@H](O)c4ccccc4)C3=O)C(=O)O,0.16,3.6,0.25,0.75,0.75,"Brogard JM, Kopferschmitt J, Spach MO, Grudet O, and Lavillaureix J (1979) Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.  J. Clin. Pharmacol. 19: 366-377.  Leroy A, Fillastre JP, Oksenhendler G, and Humbert G (1977) Pharmacokinetics of cefamandole in normal subjects and in uraemic patients.  Drugs Exptl. Clin. Res. 3: 51-59.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.","VDss and CL calculated from two-compartment terms listed in Brogard, et al. and from a digitized plot in Leroy, et al..",,1973,462.5,11,3,150.5,7,anionic,-0.37,-3.4
Cefatrizine,51627-14-6,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)CSc3c[nH]nn3)c4ccc(O)cc4,0.22,3.3,0.4,1.1,1.2,"Pfeffer M, Gaver RC, and Ximenez J (1983) Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine. Antimicr. Agents Chemother. 24: 915-920. Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",Analysis done by bioassay.,,1974,462.5,11,5,174.5,7,anionic,-0.69,-4.7
Cefazedone,56187-47-4,c1(nnc(s1)C)SCC=1CS[C@H]2N(C1C(O)=O)C([C@H]2NC(Cn1cc(c(c(c1)Cl)=O)Cl)=O)=O,0.13,0.95,,2.3,1.91,"Pharmacokinetic study of cefazedone sodium given by intravenous drip infusion in healthy volunteers. Ren, Ping; Zheng, Heng; Liu, Xinxia; Yuan, Shiying; Wang, Jing; Qian, Zhenyu; Wu, Dan; Gu, Shifen; Chen, Hui 
Zhongguo Yaoxue Zazhi (Beijing, China) (2012), 47(4), 291-295 (Chin, Pharm. J.)","Refosporene. 0.5, 1 and 2 g infusion. N=10/dose. Healthy volunteers. Reported 20.8 kg/m2 weight index. Seemingly a very low value and 70 kg weight assumed. VDss from clearance and MRT reported.",,1975,548.44,10,2,134.5,7,anionic,0.66,-2.3
Cefazolin,25953-19-9,Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn4cnnn4)C3=O)C(=O)O)s1,0.12,0.89,0.18,2.2,1.7,"Chanson P, Joly V, Contrepois A, Garaud JJ, Bauchet J, Mohler J, Nguyen PC, and Carbon C (1987) Alteration of gentamicin and cefazolin kinetics with control of the hypothyroid state in humans.  Antimic. Agents Chemother. 31: 645-637.  Decroix MO, Zini R, Chaumeil JC, and Tillement JP (1988) Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs.  Biochem. Pharmacol. 37: 2807-2814.  Bergan T (1977) Comparatve pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.  Chemother. 23: 389-404.","VDss assumed to be equal to reported VD in Chanson, et al., because 1st order kinetic model.",,1969,454.51,12,2,156.1,7,anionic,-1.2,-4.2
Cefbuperazone,76610-84-9,CCN1CCN(C(=O)N[C@H]([C@H](C)O)C(=O)N[C@@]2(OC)[C@H]3SCC(=C(N3C2=O)C(=O)O)CSc4nnnn4C)C(=O)C1=O,0.19,1.1,,2.9,1.9,"Liu, Dongbo; Geng, Taohua; Wang, Yiya; Ding, Li. Pharmacokinetic profile of cefbuperazone in healthy Chinese volunteers after single and multiple drip intravenous infusion by HPLC-​MS​/MS. Journal of Pharmaceutical and Biomedical Analysis, 2016, 129, 28-33. N=36 across three doses, VDss from MRT and clearance. Highly linear PK. 70 kg weight assumed.",60% recovered unchanged after 12 hours in urine.,,1980,627.65,18,4,229.5,10,anionic,-2.4,-5.4
Cefcanel,41952-52-7,Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@H](O)c4ccccc4)C3=O)C(=O)O)s1,0.13,2.6,,0.83,1,"Edwall B, Arvidsson A, Lake-Bakaar D, Lanbeck-Vallen K, and Yisak W (1993) Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects.  Drug Metab. Dispos.  21: 171-177. ",,,1973,478.57,9,3,132.7,7,anionic,0.83,-2.2
Cefclidin,105239-91-6,[H]N([H])C(C12CC[N+](CC1)(CC2)CC1CSC2[C@@H](C(N2C=1C(=O)O[H])=O)N([H])C(C(c1nc(N([H])[H])sn1)=NOC)=O)=O,0.27,1.7,,2.6,2.2,"Akiyama K. et al. Pharmacokinetics on cefclidin in patients with liver insufficiency. Chemother. (Tokyo) 1997, 40, 678-682.","VDss calculated from reported V1 and k12,k21 constants in patients with liver insufficiency.  However, plots and statements regarding healthy volunteers confirmed the essentially equal profiles in healthy subjects. N=16, 57.5 average weight.",,1986,551.62,14,4,203.2,10,anionic,-5.6,-4.6
Cefepime,88040-23-7,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)[O-])C[N+]3(C)CCCC3)\c4csc(N)n4,0.28,2.2,0.78,2.1,1.9,"Kalman D, Barriere SL, Johnson BL (1992) Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.  Antimicrob. Agents Chemother. 36: 453-457.  Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, and Martin RR (1992) Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Agents Chemother. 36: 552-557",,,1983,480.56,11,2,150,7,anionic,-3.6,-2.7
Cefetamet,65052-63-3,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)C)\c3csc(N)n3,0.28,1.9,0.78,2.5,2.1,"Koup JR, Dubach UC, Brandt R, Wyss R, and Stoeckel K (1988) Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.  Antimic. Agents Chemother. 32: 573-579.",Ro 15-8074. ,,1977,397.43,10,3,147.2,5,anionic,0.36,-2.6
Cefixime,79350-37-1,Nc1nc(cs1)\C(=N\OCC(=O)O)\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C=C,0.24,1,0.31,3.9,3.2,"Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ, Weiss AI, Yacobi A, and Silber BM (1988) Absolute bioavailability of cefixime in man.  J. Clin. Pharmacol. 28: 700-706. ",,,1981,453.45,12,4,184.5,8,anionic,-0.38,-6.7
Cefmenoxime,65085-01-0,N12[C@@H]([C@@H](NC(\C(c3csc(n3)N)=N/OC)=O)C2=O)SCC(=C1C(O)=O)CSc1n(nnn1)C,0.2,3.65,0.31,0.77,0.89,"Granneman, G. Rrichard; Sennello, Lawrence T.; Steinberg, Frank J.; Sonders, Robert C. Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects.Antimicrobial Agents and Chemotherapy (1982), 21(1), 141-5. ppb: MASAHIRO KONDO, YUMIKO NOJI and KANJI TSUCHIYA. Binding of cefmenoxime (SCE-1365) to human serum proteins. Chemother. (Tokyo) 1981, 29 (S-1) 200-205.","Average of 30 subjects in 6 cohorts, 3 intravenous infusion and 3 intravenous bolus injections. 500, 1000, 2000 mg doses in each dosing regimen.",,1977,511.56,14,3,190.8,8,anionic,-0.15,-3.2
Cefmetazole,56796-20-4,CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(=C(N2C1=O)C(=O)O)CSc3nnnn3C,0.13,1.5,0.15,1.5,1.5,"Ko H, Cathcart SK, Griffith DL, Peters GR, and Adams WJ (1989) Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.   Antimicr. Agents Chemother. 33: 356-361.  Tan JS, Salstrom SJ, Signs SA, Hoffman HE, and File TM (1989) Pharmacokinetics of intravenous cefmetazole with emphasis on comparison between predicted theoretical levels in tissue and actual skin window fluid levels.  Antimicr. Agents Chemother. 33:  924-927.",,,1975,471.53,12,2,163.3,10,anionic,-1.4,-4.3
Cefodizime,69739-16-8,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)CSc3nc(C)c(CC(=O)O)s3)\c4csc(N)n4,0.054,0.61,0.18,1.5,4.2,"Bryskier A, Procyk T, Tremblay D, Lenfant B, and Fourtillan JB (1990) The pharmacokinetics of cefodizime following intravenous and intramuscular administration of a single dose of 1.0 g.  J. Antimic. Chemother. 26(Suppl C): 59-63.  Scaglione F, Demartini G, Arcidiacono MM, Dugnani S, and Fraschini F (1997) Serum protein binding and extravascular diffusion of cefodizime and ceftriaxone. An in vivo study.  Clin. Drug Inv. 14: 211-216.",VDss calculated from C vs t data provided in the reference.,,1978,584.67,13,4,197.4,10,anionic,1.3,-4.9
Cefonicid,61270-58-4,N12[C@@H]([C@@H](NC([C@@H](c3ccccc3)O)=O)C2=O)SCC(=C1C(O)=O)CSc1n(nnn1)CS(O)(=O)=O,0.14,0.38,0.02,5.8,5.1,"Cross-over study of the pharmacokinetics of cefonicid administered intravenously or intramuscularly to healthy adult humans. J.B. FOURTILLAN , A. LEROY, M.A. LEFEBVRE , G. HUMBERT, J.P. FILLASTRE, G. REUMONT and N. RAMIS. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1985, 10, 225-230. //ppb:Dudley, Michael N.; Shyu, Wen Chyi; Nightingale, Charles H.; Quintiliani, Richard. Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans Antimicr. Ag Chemother. 1986, 30, 565-569. Ex vivo data and concentration dependent. 2% free at 100 ug/mL. 18% free immediately after administration iv.","Reported data in Table II:
AUC = 621 ug*h/mL t1/2 = 5.24 h CLt = 25.8 ml/min/l.73m2. Calculated AUC  =  633.2  µg-h/mL. Average weight 68 kg.",,1976,542.57,14,4,204.9,9,anionic,-1.5,-6.7
Cefoperazone,62893-19-0,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)CSc4nnnn4C)c5ccc(O)cc5)C(=O)C1=O,0.17,1.3,0.07,2.2,1.8,"Kalman D, Barriere SL, Johnson BL (1992) Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.  Antimicrob. Agents Chemother. 36: 453-457.",,,1976,645.67,17,4,220.3,9,anionic,-1.2,-4.3
Ceforanide,60925-61-3,NCc1ccccc1CC(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)CSc4nnnn4CC(=O)O,0.17,0.66,0.19,4.3,3,"Pfeffer M, Gaver RC, and Van Harken DR (1980) Human pharmacokinetics of a new broad-spectrum parenteral cephalosporin antibiotic, ceforanide.  J. Pharm. Sci. 69: 398-403.",,,1976,519.55,13,4,193.6,10,anionic,-1.3,-4.7
Cefoselis,122841-10-5,CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C([O-])=O)C[n+]1ccc(N)n1CCO)c1csc(n1)N,0.3,1.77,,2.78,2.9,"Qiu et al. Cefoselis, Chin J Clin Pharmacol. 2009, 25, 207-210.","FK-037. N=5 each dosing regimen (1g cefoselis solfate in winnonlin analysis) 60 kg average weight. 1 hr infusion. (A Vss = 0.21 L/kg after 0.5 hr infusion 1g dose is reported by Wise et al. Antimicr Ag Chemother 1994, 38, 2369-2372. Compound named FK-037)",solfate,1989,522.56,14,4,205.1,9,anionic,-1.9,-4.2
Cefotaxime,63527-52-6,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)COC(=O)C)\c3csc(N)n3,0.19,2.7,0.6,1.2,1.2,"Wise R, Baker S, and Livingston R (1980) Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.  Antimic. Agents Chemother.  18: 369-371.  Esmieu F, Guilbert J, Rosenkilde HC, Ho I, LeGo A (1980) Pharmacokinetics of cefotaxime in normal human volunteers.  J. Antimic. Chemother.  6(suppl A): 83-92.","VDss calculated from C vs t data provided in the reference. fu reported as 0.3 by Hamada T, Ueta E, Kodama H, Osaki T. The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-binding activities. J Oral Pathol Med. 2002, 31, 109-116.",,1957,455.47,12,3,173.5,8,anionic,-0.053,-3.1
Cefotetan,69712-56-7,CO[C@]1(NC(=O)C2SC(=C(C(=O)N)C(=O)O)S2)[C@H]3SCC(=C(N3C1=O)C(=O)O)CSc4nnnn4C,0.13,0.42,0.15,5.2,4.5,"Zimmerman J, Cohen A, and Thyrum P (1989)  Absolute bioavailability and noncompartmental analysis of intravenous and intramuscular Cefotan (cefotetan) in normal volunteers.  J. Clin. Pharmacol. 29: 151-157.  Carver PL, Nightingale CH, and Quintiliani R (1989) Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers.    J. Antimic. Chemother. 23:  99-106.",,,1977,575.62,15,4,219.9,9,anionic,-1.8,-7.1
Cefotiam,61622-34-2,CN(C)CCn1nnnc1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc4csc(N)n4)C3=O)C(=O)O,0.26,5.8,0.5,0.76,0.84,"ANNE-MARIE BRISSON, ANDRE BRYSKIER, LAURETTE MILLERIOUX, AND JEAN-BERNARD FOURTILLAN. Pharmacokinetics of Cefotiam Administered Intravenously and Intramuscularly to Healthy Adults. Antimicrob. Agents Chemother. 1984, 26, 513-518 //ppb:  V. Querol-Ferrer, R. Zini, J.-P. Tillement. The blood binding of cefotiam and cyclohexanol, metabolites of the prodrug cefotiam hexetil, in-vitro. J. Pharm. Pharmacol. 1991, 43, 863-866","CGP 14221E. N=8, 5F/3M, 1000 mg iv dose, 59 kg average weight reported. Data reported in tabular fom and PK calculated via PKSolver. Reported AUC inf 47.8 ug.h.mL-1; calculated 48.7 47.8 ug.h.mL-1. Approximately 50% excreted renally.",,1976,525.63,13,3,172.5,10,zwitterionic,-1.2,-4.3
Cefoxitin,35607-66-0,CO[C@]1(NC(=O)Cc2cccs2)[C@H]3SCC(=C(N3C1=O)C(=O)O)COC(=O)N,0.17,3.6,0.73,0.79,0.81,"Ko H, Cathcart SK, Griffith DL, Peters GR, and Adams WJ (1989) Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.   Antimicr. Agents Chemother. 33: 356-361.   ",,,1971,427.45,10,3,148.3,8,anionic,-0.81,-3.8
Cefozopran,113359-04-9,[H]N([H])c1nc(C(C(N([H])[C@H]2C(N3C(=C(CN4C=CN5C4=CC=C[N-]5)CS[C@H]23)C(=O)O[H])=O)=O)=NOC)ns1,0.24,2.1,0.74,2,1.7,"Shiba, K; Hori, S; Yoshida, M; Shimada, J; Saito, A; Sakai, O.  Fundamental and clinical investigation of cefozopran. Chemotherapy (Tokyo) (1993), 41(Suppl. 4), 187-194. fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191","Calculated via WinNonLin from reported plasma data. Fu 0.92 from Hamada T, Ueta E, Kodama H, Osaki T. The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-binding activities. J Oral Pathol Med. 2002, 31, 109-116.",,1986,516.53,14,3,180.7,9,anionic,-1.3,-4.8
Cefpimizole,84880-03-5,[H]N(C([C@@H](c1ccccc1)N([H])C(c1c(C(=O)O[H])ncn1[H])=O)=O)[C@@H]1C2N(C(=C(C[n+]3ccc(CCS(=O)(=O)O[H])cc3)CS2)C(=O)O[H])C1=O,0.21,1.7,,2.1,1.8,"Lakings DB, Friis JM,Browm RJ, Allen HR (1984) Pharmacokinetics of cefpimizole in hormal humans after single- and multiple-dose intravenous infusion. Antimicr. Agents Chemother. 26, 802-806.","1000 mg dose, data digitized from reported plot N=6, 70-kg average weight 2 0' infusion.",,1982,671.68,16,6,240,15,anionic,-3.5,-9
Cefpiramide,70797-11-4,O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccc(O)cc3)NC(=O)C\4=C\N\C(=C/C/4=O)C)CSc5nnnn5C)C(=O)O,0.15,0.48,0.03,5.2,5.4,Conte JE (1987) Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function. Antimicr. Agents Chemother. 31(10) 1585-1588.,"N=10, weight assumes as 70 kg, 2 gram dose as 30 minutes iv infusion.  Clp reported as 2 L/h/1.73 m2 and converted using the factor 1.73 m2/70 kg. ppb taken as mid-point as variable across concentrations taken ex-vivo from fu 0.05 at 205 ug/mL (1 hour) to 0.01at 41.1 ug/mL at 8 hours.",,1979,612.64,15,5,208.7,9,anionic,-0.78,-3.9
Cefpirome,84957-29-9,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)[O-])C[n+]3cccc4CCCc34)\c5csc(N)n5,0.24,1.9,0.9,2.1,1.7,"Nakayama I, Akieda Y, Yamaji E, Nitta Y, Ohishi M, Katagiri K, Imamura N, and Takase K (1992) Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers,  J. Clin. Pharmacol. 32: 256-266.  Tabata S, Shimura T, Maeda T, Hayashi S, Kobayashi I, and Saito A (1991) Protein binding of cefpirome sulfate in man and animals and its displacing effect on bilirubin bound to human serum albumin.    Chemotherapy  39(Suppl. 1):  109-114.",,,1982,514.58,11,2,153.9,7,anionic,0.7,-1.6
Cefprozil,92665-29-7,C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C2=O)C(=O)O,0.21,2.9,0.59,1.2,1.2,"Shyu WC, Shah VR, Campbell DA, Wilber RB, Pittman KA, and Barbhaiya RH (1992) Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans. J. Clin. Pharm. 32: 798-803.  Shyu WC, Shukla UA, Shah VR, Papp EA, and Barbhaiya RH (1991)  Simultaneous high-performance liquid chromatographic analysis of cefprozil diastereomers in a pharmacokinetic study.  Pharm. Res.  8: 992-996.",Racemate data,,1984,389.43,8,4,133,5,zwitterionic,-0.39,-1.8
Cefroxadin,51762-05-1,COC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O,0.17,4.78,0.1,0.59,0.74,"André Gerardin, Jean B. Lecaillon,  Jean P. Schoeiler, 
Guy Humbert,  and Jacqueline Guibert. Pharmacokinetics of Cefroxadin (CGP 9000) in Man. J. Phrmacokin. Biopharm. 1982, 10, 15-26.","CGP900. Cefroxadine. N=4, 50 mg iv. 70 kg average weight. VDss from V1 and k12, k21, k13 and k31. The k13 and k31 values were ony reported for two subjects and they were used for the VDss calculation. Some variability observed for the rate constants but V1 fairly consistent. Text reports the same VDss obtained by those calculations. MRT from the latter and clearance. 95% reported as excreted renally. fu < 0.1 but no accurate value reported.",,1974,365.4,8,3,122,5,zwitterionic,-0.95,-3.5
Cefsulodin,62587-73-9,NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c4ccccc4)S(=O)(=O)O)C3=O)C(=O)[O-])cc1,0.29,1.96,,2.47,1.64,"G. Richard Granneman, Lawrence T. Sennello,  Robert C. Sanders, Beverly Wynne, and Elizabeth W. Thomas. Cefsulodin kinetics in healthy subjects after intramuscular
and intravenous injection. Clin. Pharmacol. 1982, 31, 95-103.","CGP 7174/E. Structure and CAS number corresponding to free acid. N=13 across 3 doses (500 mg N=5; 1000 mg, N= 4; 2000 mg, N= 4). VDss from V1 and k12 and k21. MRT from VDss and clearance.",,1978,532.55,12,3,190.9,8,anionic,-3.7,-6.1
Ceftaroline fosamil,229016-73-3,C1(=O)[C@H]([C@@H]2N1C(=C(CS2)Sc1scc(n1)c1cc[n+](cc1)C)C(=O)[O-])NC(=O)/C(=N\OCC)c1nc(sn1)NP(=O)(O)O,0.53,83.6,0.8,0.11,0.09,"Ref. through PP. 2010-Oct-15  PDF(2616k)
Clinical Pharmacology and Biopharmaceutics Review 200327/S-000 Part 01 ","N=18, averaged across 3 doses at 50, 100 and 250 mg (N=6 each).",All metabolic (prodrug),1999,684.68,16,4,223.2,11,anionic,-4.6,-7.1
Ceftazidime,72558-82-8,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)[O-])C[n+]3ccccc3)\c4csc(N)n4)C(=O)O,0.31,2.4,0.79,2.2,1.8,"Kalman D, Barriere SL, Johnson BL (1992) Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.  Antimicrob. Agents Chemother. 36: 453-457.  Wise R, Armstrong GC, Brown RM, and Andrews JM (1981) The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers.  J. Antimic. Chemother. 8(SupplB): 277-282.  Lam YWF, Duroux MH, Gambertoglio JG, Barriere SL, and Guglielmo BJ (1988) Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers.  Antimic. Agents Chemother. 32: 298-302.",VDss calculated for Wise et al from C vs t data provided in the reference.  Plasma analysis done by bioassay.,,1979,546.58,13,3,191.2,9,anionic,-1.7,-4.1
Ceftezole,26973-24-0,s1cnnc1SCC1=C(N2C(=O)[C@H]([C@H]2SC1)NC(Cn1nnnc1)=O)C(=O)O,,5.37,,,0.64,"Ohkawa, Mitsuo; Kuroda, Kyoichi. Pharmacokinetics of ceftezole in patients with normal and impaired renal function. Chemotherapy (Basel, Switzerland) (1980), 26(4), 242-7.","VDss not reported and clerance in ml.min-1.m-2. 1.73 m2/70 kg conversion factor used. N=4, with median weight 53 kg. Normal subjects only. 81% excreted renally. 2 g infusion drip in 2 hr. Very scant plot.",,1969,440.48,12,2,156.1,7,anionic,-1.8,-4.8
Ceftizoxime,68401-81-0,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(=O)O)\c3csc(N)n3,0.2,2.1,0.72,1.6,1.5,"Yamasaku F and Suzuki Y (1983) Pharmacokinetics of cefotaxime, ceftizoxime and cefmenoxime in healthy volunteers after i.v. constant infusion.  Chemotherapy 31: 842-850.  Peterson LR, Gerding DN, Van Etta, LL, Eckfeldt JH, and Larson TA (1982) Pharmacokinetics, protein binding, and extravascular distribution of ceftizoxime in normal subjects.  Antimic. Agents Chemother. 22: 878-881.",VDss calculated from C vs t data provided in the reference.,,1978,383.4,10,3,147.2,5,anionic,-0.22,-3.2
Ceftobiprole,209467-52-7,Nc1nc(ns1)\C(=N\O)\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)\C=C\4/CCN([C@@H]5CCNC5)C4=O,0.27,1.5,0.62,3,3.3,"Schmitt-Hoffmann A, Roos B, Schleimer M, Sauer J, Man A, Nashed N, Brown T, Perez A, Weidekamm E, and Kovacs P (2004) Single dose pharmacokinetics and study of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.  Anitmic. Agents Chemother.  48: 2570-2575.    Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MGP, Then RL (2001) In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci.  Anitmic. Agents Chemother.  45: 825-836.",Administered as a prodrg BAL-5788.,,1998,534.57,14,5,203.4,6,zwitterionic,-1.5,-4
Ceftolozane,689293-68-3,NCCNC(=O)NC4=CN(CC=3CS[C@H]2N(C(=O)[C@H]2NC(=O)C(=N\OC(C)(C)C(=O)O)/c1nc(N)sn1)C=3C(=O)O)N(C)C4=N,0.17,1.16,0.81,2.39,2.58,"Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses Miller, Benjamin; Hershberger, Ellie; Benziger, David; Trinh, My My; Friedland, Ian  Antimicrobial Agents and Chemotherapy (2012), 56(6), 3086-3091.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf. Accessed July 12 2017.","CXA-101. FR 264205. N=6 for three doses, 500, 1000, 2000 mg. Renal clearance reported as essentially complete. 71.4 kg average weight. MRT calculated from Cl and VDss.",,2004,666.69,20,8,294.9,12,zwitterionic,-4.7,-9
Ceftriaxone,73384-59-5,Cn1c(nc(=O)c(n1)O)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/c4csc(n4)N)SC2)C(=O)O,0.12,0.22,0.1,9.6,7.6,"Data from PDR. Accessed February 19, 2013. http://www.pdr3d.com/detail.php?c=33025#section-4. ","Ro-139904. ROCEPHIN®. Concentration-dependent ppb. 95% at < 25 ug/mLto 85 % at 300 ug/mL.Mid-point taken. 0.5 mg dose in healthy human. 30’ infusion, linear PK at higher doses. Calculation perforrmed via Phoenix with data reported (0.5 mg dose).","Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour. Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 µg/mL to a value of 85% bound at 300 µg/mL. Ceftriaxone crosses the blood placenta barrier.",1980,554.58,15,4,215.2,8,anionic,-3.2,-8.4
Cefuroxime,55268-75-2,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)COC(=O)N)\c3occc3,0.15,2.2,,1.1,1.1,"Gower PE and Dash CH (1977) The pharmacokinetics of cefuroxime after intravenous injection.  Eur. J. Clin. Pharmacol. 12: 221-227.  Benson JM, Boudinot FD, Pennell AT, Cunningham FE, and DiPiro JT (1993) In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera.  Antimic. Agents Chemother. 37: 1343-1347.",VDss calculated from reported micro rate constants.  Concentration dependent protein binding.,,1975,424.39,12,3,174.1,8,anionic,-0.19,-3.2
Cefuzonam,82219-78-1,s1c(cnn1)SCC1=C(N2[C@H](SC1)[C@@H](NC(\C(c1csc(n1)N)=N/OC)=O)C2=O)C(=O)O,0.2,4.1,0.12,0.82,1.14,"M. TOMISAWA, I. NAKAYAMA, and A. SAITO.  Antimicrobial Activity and Pharmacokinetics of L-105, a New Cephem Antibiotic Agent. RECENT ADV. CHEMOTHER.1985, Antimicr. Sect. 2, 891-892.//ppb: Hamada T, Ueta E, Kodama H, Osaki T. The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-binding activities. J Oral Pathol Med. 2002, 31, 109-116","L-105. Cosmosin. 1 gm dose, N=21 70 kg average weight assumed. MRT from VDss and clearance. Structure refers to neutral compound.",~ 50% urinary excretion.,1982,513.59,12,3,173,8,anionic,0.51,-2.5
CEP-18770,847499-27-8,C(N[C@H](C(N[C@@H](CC(C)C)[B](O)O)=O)[C@@H](C)O)(=O)C(=NC(=C1)C(=C2)C=CC=C2)C=C1,0.87,0.29,,50.6,42.1,"Sala F et al. Development and validation of a high-performance liquid chromatography–tandemmass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study. J. Mass. Spectrom. 2010, 45, 1299–1305",Data digitized from figure 4,"Delanzomib. Data received by Dr. M. Zucchetti, Mario Negri Research Institute, Milan, Italy.  See also Gallerani, Zucchetti et al. Eur. J.  Cancer 2013, 49, 290-296.",2005,413.28,8,5,131.8,9,neutral,1.9,1.9
Cephacetrile,10206-21-0,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC#N)SC1)C(=O)O,0.49,3.69,,2.21,2.02,"A. Dominguez-Gil , M. C. Castifieiras, J. M. Tabernero, J. L. Rodriguez Colmmes and S. de Castro. .Pharmacokinetics of Cephacetrile in Patients with Normal or Impaired Renal Function. Eur. J. Clin. Pharmacol. 1978, 13, 445-448.",Cefacetrile. N=8 subject with normal renal function. 54.4 average weight. 15 mg/kg iv. MRT from VDss and clearance. The latter value calculated via dose divided (A/alpha + B/beta) as AUC . AUC calculated as 67.66 ug.h.mL-1. Comment in text hints a low protein binding but no data available.,,1966,339.32,9,2,136.8,7,anionic,-1.5,-4.5
Cephalexin,15686-71-2,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c3ccccc3)C2=O)C(=O)O,0.21,3.9,0.85,0.89,0.57,Kirby WMM and De Maine JB (1971) Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.  Postgrad. Med. J. Suppl. 47(Cephalosporin Antibiotics):  41-46.,Pharamacokinetic parameters calculated from C vs t data obtained by digitization of plots included in the reference.,,1967,347.39,7,3,112.7,4,zwitterionic,-0.27,-1.6
Cephaloridine,50-59-9,[O-]C(=O)C1=C(C[n+]2ccccc2)CS[C@@H]3[C@H](NC(=O)Cc4cccs4)C(=O)N13,0.46,3.3,0.8,2.3,1.5,"Brogard JM, Brandt C, Dorner M, and Dammron A (1976)  Adjustment of cephaloridine (Keflodin).  Dosage according to its pharmacokinetics.    Chemotherapy 22: 1-11.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated from digitized C vs t plot provided in the report.,,1915,415.49,7,1,93.4,6,anionic,-1.5,-0.53
Cephalothin,153-61-7,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc3cccs3)C2=O)C(=O)O,0.07,1.8,0.22,0.65,0.95,"Bergan T (1977) Comparatve pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.  Chemother. 23: 389-404.  Kuroyama M, Kumano K, Motohashi S, Kimura T, Murase S, and Tomonaga F (1992) Protein binding of 14 cephems in healthy subjects and patients with chronic renal failure.  Chemotherapy 40: 898-908.",,,1962,396.44,8,2,113,7,anionic,0.069,-2.9
Cephapirin,21593-23-7,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc3ccncc3)C2=O)C(=O)O,0.13,2.7,0.55,0.8,1.2,"Bergan T (1977) Comparatve pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.  Chemother. 23: 389-404.",,,1946,423.46,9,2,125.9,8,anionic,-0.63,-3.6
Cephradine,38821-53-3,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(=O)O,0.21,3.3,0.95,1.1,0.85,"Rattie ES, Bernardo PD, and Ravin LJ (1976) Pharmacokinetic interpretation of cephradine levels in serum after intravenous and extravascular administration in humans.  Antimic. Agents Chemother.  10: 283-287.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss estimated from C vs t data obtained by digitzation of plots provided in the reference.,,1973,349.4,7,3,112.7,4,zwitterionic,0.48,-2
Cerivastatin,145599-86-6,COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)c1c2ccc(F)cc2)C(C)C,0.33,2.9,0.01,1.8,1.8,"Muck W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, and Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int. J. Clin. Pharmacol. Ther. 35: 255-260.  Baycol Product Label.",,,1994,459.55,6,3,99.9,11,anionic,4.3,1.1
Cetrorelix,120287-85-6,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc3ccc(Cl)cc3)NC(=O)[C@@H](Cc4ccc5ccccc5c4)NC(=O)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(=O)N,0.39,1.2,0.14,5.4,12,"Pechstein B, Nagaraja NV, Hermann R, Romeis P, Locher M, and Derendorf H (2000) Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers.  J. Clin. Pharmacol. 40: 266-274.  Cetrotide Product Label.",VDss calculated from reported micro rate constants.,,1988,1431.04,31,17,495.7,39,cationic,1,-2.4
CG200745,936221-33-9,CN(C)CCCNC(=O)\C(=C\CCCCC(=O)NO)\COc1cccc2ccccc12,0.45,1.82,,4.1,2.1,"Kyu-pyo Kim, Seong Joon Park, Jeong-Eun Kim, Yong Sang Hong, Jae-Lyun Lee, Kyun-Seop Bae, Hyunju Cha, Sool-Ki Kwon,  Seonggu Ro, JoongMyung Cho, Tae Won Kim. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies. Investigational New Drugs (2015), 33(5), 1048-1057",Data digitized from plot reported at 24 mg/m2. 1.73 m2/70 kg conversion factor used. N=10. Deemed linear across a wide range of doses by authors and no accumulation (d1/d15). Clearance calculated as 7.65 L/hr; reported as 6.92  (+/- 1.31) L/hr at the same dose.,,2007,427.54,7,3,90.9,13,cationic,2.4,0.86
CGP15720A,73998-69-3,c1cc(ccc1C(=O)O)NC(=O)NCCN2CCN=C2c3ccncc3,0.35,1.67,,3.52,4.9,"L. Pendyala, S. Madajewicz, P.J. Creaven. Human pharmacokinetics of 1-[2-[2-(4 pyridyl)-2-imidazolinyl-(1)]-ethyl]-3-(4-carboxyphenyi) urea (CGP 15720A). Invest. New Drugs 1985, 3: 375-381.","N=17, multiple dose levels from 0.5-3 mg/m2/day, 70 kg assumed and average seemingly from multiple levels. MRT from VDss and clearance.",renal clearance ~ 60% of total,1979,353.38,8,3,106.9,6,zwitterionic,1.5,-0.84
CGP31608,107740-67-0,C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)CN)C(=O)O)O,0.23,7.67,,0.5,0.5,"R. Wise, J. M. Webberky, J. M. Andrews and J. P. Asbby. The pharmacokinetics and tissue penetration of intravenously administered CGP 31608. Journal of Antimicrobial Chemotherapy (1988) 21, 85-91",Data digitzed from plot reported. 1 g administered to N=6 volunteers in 1 hr infusion. 82.2 kg average weight. Calculated AUCinf essentially identical to reported value.,,1985,244.27,6,3,103.9,3,zwitterionic,-2.4,-4.7
CGP36742,123690-78-8,O=[P@@](O)(CCCC)CCCN,,1.56,,,2.1,"Christoph H. Gleiter,  Gisbert Forger, Huns-jorg Mobius. Pharmacokinetics of CGP 36,742, an orally active GABAB antagonist, in human. J Clln PharmacoI 1996, 36, 428-438.","N=12, 600 mg dose in 15' infusion. 0.28 L/kg VD, likely to be VDz.",Identical total and renal clearance.,1989,179.2,3,2,63.3,6,zwitterionic,0.68,-1.6
Chenodeoxycholic acid,474-25-9,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,0.19,5.7,,0.57,1.42,"van Berge-Henegouwen GP, Hofmann AF. Pharmacology of chenodeoxycholic acid. II. Absorption and metabolism. Gastroenterol. 1977, 73, 300-309.","Chenic acid. Data digitized from plot and converted from % dose/mL into mas/volume units. Radiocativity measured but it was determined that there was no circulating metabolites from GC and total radioactivity determination (same AUC) after po dosing. Data digitized and PK parameters calculated via PKsolver. No usable reported data available. 1 mg total dose assumed to convert concentration data. N=6, 70 kg average weight assumed.",,1924,392.57,4,3,77.8,4,anionic,4.4,2
Chlorambucil,305-03-3,OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,0.26,2.8,0.01,1.5,1.1,"Newell DR, Calvert AH, Harrap KR, and McElwain TJ (1983) Studies on the pharmacokinetics of chlorambucil and prednimustine in man.  Br. J. Clin. Pharmacol. 15: 253-258.   Leukeran Product Label.",VDss calculated from C vs t data obtained by digitization of plots provided in the reference for two subjects administered a 10 mg dose.,,1953,304.21,3,1,40.5,9,anionic,3.8,1.2
Chloramphenicol,56-75-7,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)N(=O)=O,0.94,2.4,0.34,6.5,4.6,"Narang APS, Datta DV, Nath N, and Mathur VS (1981) Pharmacokinetic study of chloramphenicol in patients with liver disease.  Eur. J. Clin. Pharmacol. 20: 479-483.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.","One compartment pharmacokinetics, so VDc = VDss.",,1970,323.13,7,3,115.4,6,neutral,0.54,0.54
Chlorazepate,23887-31-2,OC(=O)C1N=C(c2ccccc2)c3cc(Cl)ccc3NC1=O,0.2,1.1,,3,2.4,"Bertler A, Lindgren S, Magnusson JO, and Malmgren H (1983) Pharmacokinetics of chlorazepate after intravenous and intramuscular administration.  Psychopharmacol.  80: 236-239.",VDss calculated from digitized C vs t plot provided in the report.,,1970,314.72,5,2,78.8,2,anionic,2.4,-0.91
Chlordiazepoxide,58-25-3,CNC1=Nc2ccc(Cl)cc2C(=N(=O)C1)c3ccccc3,0.25,0.37,0.056,11,8.3,"Desmond PV, Patwardhan RV, Schenker S, and Hoyumpa AM (1980) Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man.  Eur. J. Clin. Pharmacol. 18: 275-278.  Boxenbaum HG, Geitner KA, Dixon WR, Spiegel HE, Symington J, Christian R, Moore JD, Weissman L, and Kaplan SA (1977) Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HCl in healthy subjects: single-dose studies by the intravenous, intramuscular, and oral routes.  J. Pharmacokinet. Biopharm. 5: 3-23.  Desmond PV, Roberts, RK, Wood AJJ, Dunn GD, Wilkinson GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.    Br. J. Clin. Pharmacol.  9: 171-175.  ",,,1955,299.75,4,1,53.1,2,neutral,1.4,1.4
Chlormethiazole,533-45-9,Cc1ncsc1CCCl,6.6,33,0.36,3.3,4.5,"Neuvonen PJ, Pentikainen PJ, Jostell KG, and Syvalahti E (1981) Effect of ethanol on the pharmacokinetics of chlormethiazole in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 19: 552-560.  Jostell KG, Agurell S, Allgen LG, Kuylenstierna B, Lindgren JE, Aberg G, and Osterlot G (1978) Pharmacokinetics of clomethiazole in healthy adults.  Acta Pharmacol. Toxicol. 43: 180-189.  Moore RG, Triggs EJ, Shanks CA, and Thomas J (1975) Pharmacokinetics of chlormethiazole in humans.  Eur. J. Clin. Pharmacol.  8: 353-357.  Pentikainen PJ, Neuvonen PJ, Jostell KG (1980) Pharmacokinetics of clormethiazole in healthy volunteers and patients with cirrhosis of the liver.  Eur. J. Clin. Pharmacol. 17: 275-284. "," VDss calculated from reported micro rate constants in the references by Moore, et al., and Jostell, et al.",,1935,161.65,1,0,12.9,2,neutral,1.9,1.9
"Chlorophenylpiperazine, m-",51639-49-7,Clc1cccc(c1)N2CCNCC2,2.5,6.1,,7,4.7,"Feuchtl A, Bagli M, Stephan R, Frahnert C, Kolsch H, Kuhn KU, and Rao ML (2004) Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implications for the pharmacodynamic profile. Pharmacopsychiatry 37: 180-188.",,,1974,196.68,2,1,15.3,1,cationic,2.3,0.61
Chloroquine,54-05-7,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,140,4.1,0.43,740,570,"White NJ (1985) Clinical pharmacokinetics of antimalaria drugs.  Clin. Pharmacokinet.  10: 187-215.  Aderounmu AF, Salako LA, Lindstroem B, Walker O, and Ekman L (1986) Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans.  Br. J. Clin. Pharmacol. 22: 559-564.",,,1974,319.87,3,1,28.2,8,cationic,5.3,2
Chlorpheniramine,132-22-9,CN(C)CCC(c1ccc(Cl)cc1)c2ccccn2,3.3,2.5,0.7,22,22,"Huang SM, Athanikar NK, Sridhar K, Huang YC, and Chiou WL (1982) Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults.  Eur. J. Clin. Pharmacol. 22: 359-365.  Hiep BT, Gimenez F, Khanh V, Hung NK, Thuillier A, Farinotti R, and Fernandez C (1999) Binding of chlorpheniramine enantiomers to human plasma proteins.  Chirality 11: 501-504.",,,1949,274.79,2,0,16.1,5,cationic,3.3,1.4
Chlorpromazine,50-53-3,CN(C)CCCN1c2ccccc2Sc3ccc(Cl)cc13,10,16,0.056,10,11,"Yeung PKF, Hubbard JW, Korchinski ED, and Midha KK (1993)  Pharmacokinetics of chlorpromazine and key metabolites.  Eur. J. Clin.Pharmacol. 45: 563-569.  Koytchev R, Alken RG, Kirkov V, Neshev G, Vagaday M, and Kunter U (1994) Absolute bioverfugbarkeit von chlorpromazin, promazin, und promethazin.  Arz. Forsch. 44: 121-125.  Curry SH (1970) Plasma protein binding of chlorpromazine.  J. Pharm. Pharmacol. 22: 193-197.",VDss was calculated from C vs t data obtained by digitization of the plot included in the reference.  Protein binding value cited is at a concentration observed in the pharmacokinetic study.,,1972,318.86,2,0,6.5,4,cationic,5.2,3.6
Chlorpropamide,94-20-2,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,0.19,0.045,0.03,70,46,Huupponen R and Lammintausta R (1981) Chlorpropamide bioavailability and pharmacokinetics.  Int. J. Clin. Pharmacol. Ther. Toxicol. 19: 331-333.,VDss was calculated from C vs t data obtained by digitization of the plot included in the reference.  ,,1955,276.74,5,2,75.3,4,anionic,2.1,-0.29
Chlorprothixene,113-59-7,CN(C)CC\C=C/1\c2ccccc2Sc3ccc(Cl)cc13,13.7,11.5,,20.7,25.8,"Bagli, Metin; Rao, Marie Luise; Hoeflich, Gereon; Kasper, Siegfried; Langer, Michael; Barlage, Uwe; Beneke, Manfred; Sueverkruep, Richard; Moeller, Hans-Juerger
Pharmacokinetics of Chlorprothixene after Single Intravenous and Oral Administration of Three Galenic Preparations. Arzneimittel-Forschung 1996, 46(3), 247-250.
","N=8, 75.6 kg average weight, 100 mg dose as a 60 minutes infusion.",,1958,315.86,1,0,3.2,3,cationic,5.5,4.2
Chlortetracycline,57-62-5,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O,0.9,2,0.52,7.4,7,"Kunin CM, Darnbush AC, and Finland M. Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest. 1959, 38, 1950-1963.",Parameters were calculated from C vs t data obtained by digitization of the plot included in the reference.  ,,1945,478.88,10,6,181.6,2,anionic,-0.2,-3.1
Chlorthalidone,77-36-1,NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc23,3.9,1.5,0.24,43,36,"Fleuren HLJ, Thien TA, Verwey-van Wissen CPW, and von Rossum JM (1979) Absolute bioavailability of chlorthalidone in man: a cross over study after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 15: 35-50.  Dieterle W, Wagner J, and Faigle JW (1976)  Binding of chlorthalidone (Hygroton) to blood components in man.  Eur. J. Clin. Pharmacol. 10: 37-42.",,,1959,338.77,6,3,109.5,2,neutral,0.85,0.84
Cibenzoline,53267-01-9,C1CN=C(N1)C2CC2(c3ccccc3)c4ccccc4,4.1,8.6,0.5,7.8,7.3,"Cifenline. Aronoff G, Brier M, Mayer ML, Barbalas M, Aogaichi K, Sloan R, Brazzell R, and Massarella J (1991) Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. J. Clin. Pharmacol. 31: 38-44.  Reidenberg MM, Lorenzo BJ, Drayer DE, Kluger J, Nestor T, Regnier JC, Kowal BA, and Bekersky I (1988) A nonradioactive iothalamate method for measuring glomerular filtration rate and its use to study the renal handling of cibenzoline.  Ther. Drug Monit. 10: 434-437.",,,1974,262.35,2,1,24.4,3,cationic,2.8,-0.64
Cicaprost,94079-80-8,CCC#CC[C@H](C)[C@H](O)C#C[C@H]1[C@H](O)C[C@@H]2C\C(=C/COCC(=O)O)\C[C@H]12,0.08,3.8,,0.35,1.1,"Hildebrand M, Staks T, Schutt A, and Matthes H (1989) Pharmacokinetics of 3H-cicaprost in healthy volunteers.  Prostaglandins  37: 259-273.",VDss was calculated from MRT from a paper cited in the reference. ,,1984,374.47,5,3,87,10,anionic,2.6,-0.63
Ciclesonide,126544-47-6,C1(C=C[C@@]2([C@H]3[C@H](C[C@@]4([C@@]5([C@@H](C[C@@H]4[C@@H]3CCC2=C1)O[C@H](C1CCCCC1)O5)C(COC(C(C)C)=O)=O)C)O)C)=O,2.9,33.3,0.01,1.45,1.04,"Nave R. Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide. Clin Pharmacokinet. 2009, 48(4), 243–252.","Data from review article Clin. Pharmacokinet. 2009, 48, 243-252, confirmed by Dr. R. Nave, e-mail 7/27/2009. VDss 2.9 L/kg and 2.0 L/h/kg.  No full publication available for this presentation/abstract. MRT from VDss and clearance.// Nave R, Bethke TD, van Marle SP, Zech K (2004) Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokin. 43(7) 479-486.//N=6, 0.64 mg dose, 72.6 kg average weight, MW = 540.69, 10' infusion.  Lower VDss (~ 10-fold) and Cl (~ 22 mL/min/kg).","E-mail message, July 27 2009. For ciclesonide our focus is always the active metabolite. Nevertheless we have generated a few data for the parent compound ciclesonide following iv administration (reference 29 of the review manuscript). The data of this study were presented in 2002 on a congress and in the abstract the following is stated: ""The mean volume of distribution was 2.9 l/kg and the total clearance was 2.0 l/h/kg for the parent compound following intravenous administration"". Sorry, there is no full publication available for this study. 
The reference 28 is on the ADME of 14C-ciclesonide and there may be limintations in terms of PK of the parent compound (for example number of subjects and sensitivity of the bioanalytical assay). ",1992,540.69,7,1,99.1,6,neutral,4.8,4.8
Ciclotropium,764602-65-5,CC([N@+]1([C@@H]2C[C@@H](C[C@@H]1CC2)OC(=O)[C@@H](C3CCCC3)c4ccccc4)C)C,1.25,8.41,,2.48,3.3,"Liebmann B, Mayer S, Mutschler E, Spahn-Langguth H. Studies on the metabolic clearance of ciclotropium to alpha-phenylciclopentylacetic acid using a new enantiospecific metabolite assay. Arzneim.-Forsch. 1992, 42, 1354-1358.","2 volunteers, 70 kg average weight assumed, compound administered at a dose of 10 mg as 15' infusion. Volunteer 1 yielded an AUC0-inf with 1% from reported (rep, 268 ng.h.mL-1), volunteer 2 yielded an AUC0-inf within 12% of reported (rep. 342 ng.h.mL-1). Data digitized separately and PK parameters averaged after calculations. 82% recovered unchanged in urine.",,1982,370.55,3,0,26.3,6,neutral,1.6,1.6
Cidofovir,113852-37-2,NC1=NC(=O)N(C[C@@H](CO)OCP(=O)(O)O)C=C1,0.49,2.5,1,3.3,2.6,"Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJM, and Jaffe HS (1995) Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.  Antimic. AgentsChemother. 39: 1247-1252.",,,1987,279.19,9,4,145.7,6,anionic,-3.2,-8.4
Cilastatin,82009-34-5,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(=O)O)\C(=O)O,0.15,2.3,0.6,1.1,0.86,"Saito A. Pharmacokinetics of panipenem/betamipron.  Chemotherapy 1991, 39(Suppl. 3): 227-235.   Primaxin IV Product Label.  ",VDss calculated from C vs t data provided in the reference.,,1983,358.45,7,4,129.7,11,anionic,-0.068,-4.6
Cilazaprilat,90139-06-3,c1ccc(cc1)CC[C@H](N[C@@H]1C(N2[C@@H](CCC[N@@]2CCC1)C(O)=O)=O)C(O)=O,3.7,2.1,,29.5,50.6,"P. E. O. WILLIAMS, A. N. BROWN, S. RAJAGURU, R. J. FRANCIS, G. E. WALTERS, J. McEWEN & C. DURNIN. The pharmacokinetics and bioavailability of cilazapril in normal man. Br. J. Clin. Pharmacol. 1989, 27, 181S-188S","N=12, 74 kg average weight, 2.5 mg dose.
Reported AUC (0-24) = 192 ng.hr/mL
Clearance (24hr) = 12.3 L/h (= 2.8 mL/min/kg)
ppb variable from 24% at high concentration and 95% at low concentration (not reported)",91% excreted unchanged as per Williams et al.,1984,389.45,8,3,110.2,7,anionic,0.35,-5.4
Cilengitide,188968-51-6,N1(C)C([C@H](NC([C@@H](NC(CNC([C@H](CCCNC(N)=N)NC([C@@H]1C(C)C)=O)=O)=O)CC(=O)O)=O)Cc1ccccc1)=O,0.26,1.18,,3.67,3.6,"Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel
inhibitor of the integrins avb3 and avb5 in patients with advanced solid tumours F.A.L.M. Eskens, H. Dumezb, R. Hoekstra, A. Perschl, C. Brindley, S. Bottcher,W. Wynendaele, J. Drevs, J. Verweij, A.T. van Oosterom European Journal of Cancer 39 (2003) 917–926",(EMD121974) Weighted averages of 40 total patients across doses from 30 to 1600 mg/m2. MRT calculated from averaged VDss and clearance. ,,1997,588.66,15,8,235.9,10,zwitterionic,-1.4,-3.7
Cilomilast,153259-65-5,COc1ccc(cc1OC2CCCC2)[C@@]3(CC[C@H](CC3)C(=O)O)C#N,0.23,0.5,0.006,8.5,7.9,"Zussman BD, Davie CC, Kelly J, Murdoch RD, Clark DJ, Schofield JP, Walls C, Birrell C, Webber D, Quinlan J, Ritchie SY, and Carr A (2001)  Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast.  Pharmacother. 21: 653-660.  Down G, Siederer S, Lim S, and Daley-Yates P (2006) Clinical pharmacology of cilomilast.  Clin. Pharmacokinet. 45: 217-233.",,,1993,343.42,5,1,79.6,6,anionic,3.6,0.89
Cimetidine,51481-61-9,CN\C(=N/CCSCc1nc[nH]c1C)\NC#N,1.2,8.1,0.78,2.5,2.2,"Arancibia A, Schindler I, Paccot E, Ruiz I, Gonzalez G, Mella F, and Thambo S (1985) Pharmacicinetique de la cimetidine apres administration d'une dose unique par voie intraveineuse rapide et d'une autre par voie orale.  Therapie  40: 87-92.  Bauer LA, Wareing-Tran C, Edwards WAD, Raisys V, Ferreri L, Jack R, Dellinger EP, and Simonowitz D  (1985) Cimetidine clearance in the obese.  Clin. Pharmacol. Ther. 37: 425-430.  Gugler R, Muller-Liebenau B, and Somogyi A (1982) Altered disposition and availability of cimetdine in liver cirrhotic patients.  Br. J. Clin. Pharmacol. 14: 421-429.  Schentag JJ, Cerra FB, Calleri GM, Leising ME, French MA, and Bernhard H (1981) Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients.  Clin. Pharmacol. Ther. 29: 737-743.",,,1963,252.34,6,3,88.9,8,neutral,-0.23,-0.29
Cimetropium,150521-16-7,C[N+]1([C@@H]2C[C@H](C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)c4ccccc4)CC5CC5,1.12,25,,0.74,0.83,"B. P. IMBIMBO, S. DANIOTTI, A. VIDI, D. FOSCHI, F . SAPORITI,  L. FERRANTE. Discontinuous Oral Absorption of Cimetropium Bromide, a New Antispasmodic Drug. J. Pharm. Sci. 1986, 75, 680-684. ","N=8, 10 mg dose. Clearance reported in table III. MRT calculated from AUC and AUMC in turn calculated from A, B, α and β. VDss obtained from MRT and clearance. T1/2 reported.",46% excreted unchanged in urine.,1973,358.45,5,1,59.1,7,neutral,-2.8,-2.8
Cinacalcet ,226256-56-0,c1cccc2cccc(c12)[C@H](NCCCc1cc(C(F)(F)F)ccc1)C,17.6,18.3,0.05,16,19.9,Ref. through PP. 2004-Feb-12  PDF(1502k) Pharmacology Review 021688/S-000 Part 01 ,Cinacalcet is approximately 93% to 97% bound to plasma protein(s).,reported as extensively metabolize and then excreted in urine but no defined amounts. See ref. for PK data.,2001,357.41,1,1,12,6,cationic,6.6,5.1
Cinaciguat,329773-35-5,[H]OC(CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(=O)O[H])=O,0.24,9,,0.44,0.25,"Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G: Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol 2008, 48:1400-1410","Weighted average of 5 doses from 50 ug/h to 250 ug/h infusion (4 hour). N=28 total, average weight 81.8 kg. Also known as BAY 58-2667. 
t1/2 used reported as dominant, i.e. determined in the 1-hr period after end of infusion.",,2001,565.7,6,2,87.1,19,anionic,7.4,2.5
Ciprofloxacin,85721-33-1,OC(=O)C1=CN(C2CC2)c3cc(N4CCNCC4)c(F)cc3C1=O,2.1,8.3,0.7,4.2,3.8,"Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet 41:  741-750.  Jaehde U, Soergel F, Reiter A, Sigl G, Naber KG, and Schunack W (1995)  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.    Clin. Pharmacol. Ther. 58: 532-541.  Lettieri JT, Rogge MC, Kaiser L, Echols RM, and Heller AH (1992) Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.  Antimic. Agents Chemother. 36: 993-996.  Ljungborg B and Nilsson-Ehle I (1988) Pharmacokinetics of intravenous ciprofloxacin at three different doses.  J. Antimic. Chemother. 22: 715-720.",,,1983,331.34,6,2,72.9,3,zwitterionic,1.8,-0.63
Ciramadol,51356-59-3,c1cc(cc(c1)O)[C@@H]([C@@H]1[C@@H](CCCC1)O)N(C)C,,2.2,,,3.85,"M. T. ROSSEEL, M. G. BOGAERT,  and W. OOSTERLINCK. Preliminary pharmakokinetics of intravenous ciramadol in humans. Int. J. Pharmacol. Ther. Toxicol. 1984, 22, 304-306.","N=8, 70 kg average weight assumed, 30 mg dose. Data difficult to digitize from plot resulting in exceesive extrapolation to Co. Clearance and t1/2 taken from reported values. Vdarea 0.8 L/kg.",,1977,249.35,3,2,43.7,3,cationic,2.7,2.1
Cisapride,81098-60-4,c1(c(cc(N)c(c1)Cl)OC)C(N[C@@H]1[C@@H](C[N@@](CCCOc2ccc(F)cc2)CC1)OC)=O,1.2,1.5,0.02,12.9,11.7,"Ref. through PP. 1992-Mar-17  PDF(7171k) Medical/Clinical Review 020210/S-000. ppb: PDR states: PROPULSID® binds to an extent of 97.5-98% to plasma proteins, mainly to albumin. Accessed December 301 2014. http://www.pdr3d.com/detail.php?c=10088#section-5",Calculation perforrmed via Phoenix after digitization. 4 mg dose. N=6 ,Ref. through PP. 1992-Mar-17  PDF(7171k) Medical/Clinical Review 020210/S-000 ,1983,465.95,7,2,86,9,cationic,3.5,3
Cisatracurium,96946-41-7,COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]4(C)CCc5cc(OC)c(OC)cc5[C@H]4Cc6ccc(OC)c(OC)c6)cc1OC,0.14,5.4,0.62,0.43,0.42,"Bergeron LB, Bevan DR, Berrill A,Kahwaji R, and Varin F (2001) Concentration–Effect Relationship of Cisatracurium at Three Different Dose Levels in the Anesthetized Patient.  Anesthesiology 95: 314-323.  Roy JJ and Varin F (2004) Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",,,1995,929.15,14,0,126.4,26,neutral,1.7,1.7
Citalopram,59729-33-8,CN(C)CCCC1(OCc2cc(ccc12)C#N)c3ccc(F)cc3,12,4.3,0.2,47,33,"Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jorgensen T, and Sidhu J (1998) Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.  Eur. J. Clin. Pharmacol. 54: 237-242.  Celexa Product Label.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1977,324.39,3,0,36.3,6,cationic,4.1,2
Cladribine,4291-63-8,Nc1nc(Cl)nc2c1ncn2[C@H]3C[C@H](O)[C@@H](CO)O3,7.7,14,0.79,9.2,16,"Saven A, Cheung WK, Smith L, Moyer M, Johannsen T, Rose E, Gollard R, Kosty M, Miller WE, and Piro LD (1996) Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy.  J. Clin. Oncol. 14: 978-983.    Albertioni F, Herngren L, Juliusson G, and Liliemark J (1994) Protein binding of 2-chloro 2'-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia.    Eur. J. Clin. Pharmacol. 46: 563-564.",,,1963,285.69,8,3,119.3,2,neutral,-0.56,-0.56
Clarithromycin,81103-11-9,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,1.5,7.3,0.23,3.4,2.8,"Chu SY, Deaton R, and Cavanaugh J (1992) Absolute bioavailability of clarithromycin after oral administration in humans.  Antimic. Agents Chemother. 36: 1147-1150.  Kuroyama M, Motohashi S, Kumano K, and Yago K (1996)  Protein binding of clarithromycin in patients with chronic renal failure.  Jap. J. Antibiotics 49: 256-263.  Davey PG (1991) The pharmacokinetics of clarithromycin and its 14-OH metabolite.  J. Hosp. Infec. 19(Suppl A): 29-37.",VDss calculated from C vs t sata obtained by digitization of the plot provided in the reference,,1981,747.95,14,4,182.9,8,cationic,2.3,1
Clavulanic Acid,58001-44-8,OC\C=C\1/O[C@@H]2CC(=O)N2[C@H]1C(=O)O,0.22,3.1,0.91,1,0.9,"Davies BE, Boon R, Horton R, Reubi FC, and Descoeudres CE (1988) Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin. Br. J. Clin. Pharmacol. 26: 385-390.  de la Pena A and Derendorf H (1999) Pharmacokinetic properties of beta-lactamase inhibitors.  Int. J. Clin. Pharmacol. Ther. 37: 63-75.",,,1975,199.16,6,2,87.1,2,anionic,-1.2,-4.6
Clazosentan,180384-56-9,[H]N(c1c(c(nc(c2ccnc(c2)c2nnnn2[H])n1)OCCO[H])Oc1ccccc1OC)S(c1ccc(C)cn1)(=O)=O,0.23,10.5,0.02,0.4,2.6,"van Giersbergen, Paul L. M.; Gunawardena, Kulasiri A.; Dingemanse, Jasper. Influence of ethnic origin and sex on the pharmacokinetics of clazosentan. J. Clin. Pharmacol. 2007, 47, 1374-1380.//ppb: P.L.M. van Giersbergen, A. Treiber and J. Dingemanse. In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans.  Int. J. Clin. Pharmacol. Ther., 2009,  47, 169-177","12 Caucasian and 12 Japanese subjects. 3 sequential 4-h infusion at 1, 5 and 15 mg/h.  Average weight 61 kg. Compartmental analysis with V1,V2,V3 and Vss reported. MRT calculated from Cl and Vss. t1/2 taken as the g phase.",,1996,577.57,15,3,200.1,12,anionic,2.9,-2.3
Clentiazem,96125-53-0,c1([C@H]2[C@H](C(N(CCN(C)C)c3c(cc(cc3)Cl)S2)=O)OC(C)=O)ccc(OC)cc1,9.7,13.7,0.1,12.3,10.6,"Ajit K. Shah, Vi jay 0. Bhargava,  Scott J. Weir,  and Dennis H. Giesing. Pharmacokinetics of Clentiazem After Intravenous and Oral Administration in Healthy Subjects. J ClIn Pharmacol 1993;33:354-359. ppb Fukushima, Takeshi; Nakamura, Susumu; Ito, Yutaka; Takaiti, Osasi. Studies on the protein binding of clentiazem. Yakubutsu Dotai 1992, 7, 845-852. From abstract in English. reported as ~90% bound and steady across a wide concentration range.",Data reported in Table 2. 20 mg dose. N=24. Weight reported as 77.6 kg on average.,,1984,448.96,6,0,59.1,7,cationic,3.9,3.5
Clevidipine,167221-71-8,CCCC(=O)OCOC(=O)C1=C(C)NC(=C(C1c2cccc(Cl)c2Cl)C(=O)OC)C,0.58,142,0.0038,0.07,0.3,"Ericsson H, Fakt C, Hoglund L, Jolin-Mellgard A, Nordlander M, Sunzel M, and Regardh CG (1999) Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion.  Eur. J. Clin. Pharmacol. 55: 61-67.  Ericsson H, Tholander B, and  Regardh CG (1999)  In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases, in different animal species and man.  Eur. J. Pharm. Sci. 8: 29-37.",Data for the enantiomers were averaged.,,1995,456.32,7,1,90.9,10,neutral,4.4,4.4
Clinafloxacin,105956-97-6,NC1CCN(C1)c2c(F)cc3C(=O)C(=CN(C4CC4)c3c2Cl)C(=O)O,1.9,4.7,0.96,6.7,5.4,"Randinitis EJ, Brodfuehrer JI, Eiseman I, and Vassos AB (2001) Pharmacokinetics of clinafloxacin after single and multiple doses.  Antimic. Agents Chemother. 45: 2529-2535.  Wise R, Ashby JP, and Andrews JM.  In vitro activity of PD 127,391, an enhanced-spectrum quinoline.    Antimic. Agents Chemother.  1988, 32: 1251-1256.",,,1986,365.79,6,2,86.9,3,zwitterionic,2.6,0.29
Clindamycin,18323-44-9,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,0.79,4.5,0.06,2.9,2.1,"Gatti G, Flaherty J, Bubp J, White J, Borin M, and Gambertoglio J (1993) Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS.  Antimic. Agents Chemother. 37: 1137-1143.  Gordon RC, Regamey C, and Kirby WMM (1973)  Serum protein binding of erythromycin, lincomycin, and clindamycin. J. Pharm. Sci. 62: 1074-1077.",,,1958,424.98,7,4,102.3,7,cationic,1.3,0.96
Clodronate,10596-23-3,C(P(O)(O)=O)(P(O)(O)=O)(Cl)Cl,0.88,1.6,0.64,9.2,43.2,"Pharmacokinetics of clodronate in renal failure. H. Saha, P. Castren-Kortekangas, S. Ojanen, A. Juhakoski, J. Tuominen, O. Tokola, A. Pasternack. Journal of Bone and Mineral Research
 1994, 9, 1953–1958.//ppb: Pentikäinen PJ1, Elomaa I, Nurmi AK, Kärkkäinen S. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol. 1989, 27, 222-228.",Weighted average of 3 control groups. 30 mg for each group. Weighted average of control weights in Table 1 taken as 73.5 kg.,,1966,244.89,6,4,115.1,2,anionic,-1.2,-7.5
Clofarabine,123318-82-1,n1c(N)c2c(nc1Cl)n([C@H]1[C@H]([C@@H]([C@H](O1)CO)O)F)cn2,1.75,7.7,0.53,3.8,4,"Clofarabine administration weekly to adult patients with advanced solid tumors in a phase I dose-finding studyJournal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 7109. C. C. Cunningham, J. Nemunaitis, N. Senzer, S. Vukelja, D. Richards, V. Vukovic, S. Weitman","See also data reported by Bonate et al. Nat. Rev. Drug Disc. 2006, 5, 855-863. ppb 0.43",,1989,303.68,8,3,119.3,2,neutral,-0.77,-0.77
Clomipramine,303-49-1,CN(C)CCCN1c2ccccc2CCc3ccc(Cl)cc13,13,8.2,0.029,26,26,"Ollagnier M, Pellet J, Gay JP, Lang F, Ouvry MC, and Blanchon Y (1984) Pharmacocinetique d'une dose unique de clomipramine, en intraveneuse, chez le voluntaire sain.  Therapie  39: 237-245.  Nyberg G and Maartensson E (1984)  Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.",Pharmacokinetic parameters were calculated from C vs t provided in the reference. ,,1961,314.85,2,0,6.5,4,cationic,5.1,3.4
Clonazepam,1622-61-3,Clc1ccccc1C2=NCC(=O)Nc3ccc(cc23)N(=O)=O,2.9,0.88,0.15,55,38,"Crevoisier C, Delisle MC, Joseph I, and Foletti G (2003) Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers.  Eur. Neurol. 49: 173-177.  Lucek RW and Coutinho CB.  (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12:  612-19.",VDss calculated using C vs t data obtained by digitization of the plot included in the reference.,,1963,315.71,6,1,87.3,2,neutral,2.7,2.7
Clonidine,4205-90-7,Clc1cccc(Cl)c1NC2=NCCN2,3.3,4,0.56,14,7.6,"Vanholder R, Van Landschoot N, De Smet R, Schoots A, and Ringoir S (1988) Drug protein binding in chronic renal failure: evaluation of nine drugs.  Kidney Int. 33: 996-1004.  Frisk-Holmberg M, Paalzow L, and Edlund PO (1981) Clonidine kinetics in man-evidence for dose dependency and changed pharmacokinetics during chronic therapy.  Br. J. Clin. Pharmacol. 12: 653-658.",Used 1.27 mg/kg dose level data from Frisk-Holmberg et al.  VDss calculated from reported exponential fit parameters.,,1971,230.09,3,2,36.4,2,cationic,2,0.84
Clopidogrel,113665-84-2,COC(=O)[C@H](c1ccccc1Cl)N2CCc3c(ccs3)C2,2.01,23.65,0.02,1.42,5.06,"Daniel J Cushing, Paul F Souney, Warren D Cooper Gerald L Mosher,Michael P Adams, Stephen Machatha, Bing Zhang and Peter R Kowey. Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Clin. Exp. Pharmacol. Physiol. 2012 39, 3–8.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf. Accessed May 8 2017.","Data digitized from plot reported. N=24, 300 mg dose, highly linear pharmacokinetics (AUC) from 0.1 to 300 mg. Average weight 75.6 kg.",,1988,321.82,3,0,29.5,4,neutral,3.3,3.3
Clozapine,5786-21-0,CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24,1.6,2.5,0.055,11,10,"Cheng YF, Lundberg T, Bondesson U, Lindstrom L, and Gabrielsson J (1988) Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur. J. Clin. Pharmacol. 34: 445-449.   Schaber G, Stevens I, Gaertner HJ, Dietz K, and Breyer-Pfaff U (1998) Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.  Br. J. Clin. Pharmacol. 46: 453-459. ",,,1963,326.82,4,1,30.9,1,cationic,4.5,4.1
Cobimetinib,934660-93-2,c1cc(c(cc1I)F)Nc2c(ccc(c2F)F)C(=O)N3CC(C3)([C@@H]4CCCCN4)O,15.4,2.8,0.05,96.6,68.8,"Luna Musib, Edna Choo, Yuzhong Deng, Steve Eppler, Isabelle Rooney, Iris T. Chan, and Mark J. Dresser. Absolute Bioavailability and Effect of Formulation Change, Food, or
Elevated pH with Rabeprazole on Cobimetinib Absorption in Healthy Subjects. Mol. Pharmaceutics 2013, 10, 4046−4054.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf. Accessed May 09, 2017.","70 kg average weight assumed. N=13, 2 mg infusion in 30 minutes.",,2007,531.31,5,3,64.6,4,cationic,3.7,3
Cocaethylene,529-38-4,CCOC(=O)[C@H]1[C@H](C[C@@H]2CC[C@H]1N2C)OC(=O)c3ccccc3,1.6,13,0.64,2,1.5,"Perez-Reyes M, Jeffcoat AR, Myers M, Sihler K, and Cook CE (1994) Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine.  Psychopharmacol. 116: 428-432.  Bailey DN (1997) Effect of drugs and cocaine metabolites on cocaine and cocaethylene binding to uman serum in vitro.  Ther. Drug Monit. 19: 427-430.",Parameters were calculated from C vs t data obtained by digitization of plots in the reference.,,1979,317.38,5,0,55.8,6,cationic,3.3,2.4
Cocaine,50-36-2,COC(=O)[C@H]1[C@H](C[C@@H]2CC[C@H]1N2C)OC(=O)c3ccccc3,2,32,0.12,1,0.76,"Chow MJ, Ambre JJ, Ruo TI, Atkinson AJ, Bowsher DJ, and Fischman MW (1985) Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin. Pharmacol. Ther. 38: 318-324.  Javaid JI, Musa MN, Fischman M, Schuster CR, and Davis JM (1983) Kinetics of cocaine in humans after intravenous and intranasal administration.  Biopharm. Drug Dispos. 4: 9-18.  Edwards DJ and Bowles SK (1988) Protein binding of cocaine in human serum.  Pharm. Res.  5: 440-442.  Parker, Robert B.; Williams, Cheri L.; Laizure, S. Casey; Lima, John J.  Factors affecting serum protein binding of cocaine in humans.    Journal of Pharmacology and Experimental Therapeutics  (1995),  275(2),  605-10.","Paper by Javaid, et al. reported one compartment kinetics so VDss = C0/Dose. ",,1976,303.35,5,0,55.8,5,cationic,2.8,1.9
Codeine,76-57-3,COc1ccc2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5Oc1c2[C@]45CCN3C,3.5,15,0.7,3.9,4,"Guay DRP, Awni WM, Findlay JWA, Halstenson CE, Abraham PA, Opsahl JA, Jones EC, and Matzke GR (1988) Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease.  Clin. Pharmacol. Ther. 43: 63-71.  Mohammed SS, Christopher MM, Mehta P, Kedar A, Gross S, and Derendorf H (1993) Increased erythrocyte and protein binding of codeine in patients with sickle cell disease.  J. Pharm. Sci. 82: 1112-1117.",,,1970,299.36,4,1,41.9,1,cationic,1.3,0.29
Colchicine,64-86-8,COC1=CC=C2C(=CC1=O)[C@H](CCc3cc(OC)c(OC)c(OC)c23)NC(=O)C,6.1,2.1,0.61,49,58,"Ferron GM, Rochdi M, Jusko WJ, and Scherrmann JM (1996) Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol. 36: 874-883.  Sabouraud A, Chappey O, Dupin T, and Scherrmann JM (1994)  Binding of colchicine and thiocolchicoside to human serum proteins and blood cells.  Int. J. Clin. Pharmacol. Ther. 32: 429-432.",,,1971,399.44,7,1,83.1,5,neutral,1.1,1.1
Combretastatin A4 Phosphate,222030-63-9,c1(cc(c(c(c1)OC)OC)OC)/C=C\c1ccc(c(c1)OP(=O)(O)O)OC,0.11,5.86,0.23,0.3,0.47,"Afshin Dowlati, Kelly Robertson, Matthew Cooney, William P. Petros, Michael Stratford, John Jesberger, Niusha Rafie, Beth Overmoyer, Vinit Makkar, Bruce Stambler, Anne Taylor, John Waas, Jonathan S. Lewin, Keith R. McCrae and Scot C. Remick. A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer. Cancer Res. 2002 62, 3408-3416","70 kg average weight assumed. Data reported across doses and N=25. High variability. MRT from VDss and clearance. ppb:  Plasma protein binding characteristics of anti-​tumor drug Combretastatin A4 phosphate in several species. Huaxi Yaoxue Zazhi, 2009, 24, 45-47. From abstract in English. Some variability with concentration but data seemingly tight (0.13-0.29 fu range). Mid-concentration data taken.",,1989,396.33,8,2,103.7,8,anionic,2.9,-0.95
Conivaptan,210101-16-9,Cc1nc2CCN(C(=O)c3ccc(NC(=O)c4ccccc4c5ccccc5)cc3)c6ccccc6c2[nH]1,0.76,3,0.01,4.2,6.7,Vaprisol Product Label,VDss was calculated using C vs t data obtained by digitization of the plot provided in the product label.,,1998,498.57,6,2,78.1,4,cationic,5.5,5
Copanlisib,1032568-63-0,COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5,10.34,6.42,,26.8,25.2,"Toshihiko Doi · Nozomu Fuse · Takayuki Yoshino · Takashi Kojima ·
Hideaki Bando · Hideaki Miyamoto · Masato Kaneko · Motonobu Osada ·
Atsushi Ohtsu. A Phase I study of intravenous PI3K inhibitor copanlisib
in Japanese patients with advanced or refractory solid tumors. Cancer Chemother Pharmacol (2017) 79:89–98","BAY 80-6946. N=7, 1 hr infusion at 0.8 mg/kg dose. Data digitized from plot reported and PK parameters calculated via PKSolver. AUCinf reported 2350 ug.h.L-1; calculated 2073 ng.h.mL-1. 13% difference",,2008,480.52,12,2,139.8,8,cationic,0.69,-1.1
Cositecan,203923-89-1,CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5ccccc5c4CC[Si](C)(C)C)O,3.26,4.2,,13.33,13.2,"Stuart A. Grossman, Kathryn A. Carson, Surasak Phuphanich, Tracy Batchelor, David Peereboom, L. Burt Nabors, Glenn Lesser, Fredrick Hausheer, and Jeffrey G. Supko, for the New Approaches to Brain Tumor Therapy CNS Consortium. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro-Oncology 10, 608–616, 2008",Karenitecin. VDss reported as average at 136 L/m2 and clearance as average at 10.2 L/h/m2. N=12. 1.73 m2/70 kg used. MRT from VDss and clearance. ,,1998,448.59,6,1,81.4,4,neutral,4.5,4.5
Cotinine,486-56-6,CN1[C@@H](CCC1=O)c2cccnc2,1.1,0.89,,21,17,"Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, and Adlkofer F (1988) Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers.  Klin. Wochenschr. 66(Supp 11): 5-11.  Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, and Enzell CR (1990) The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers.  Eur. J. Clin. Pharmacol. 38: 281-287. ",VDss calculated from C vs t data obtained by digitization of the plots provided in the references.,,1956,176.22,3,0,33.2,1,neutral,-0.33,-0.33
Coumarin,91-64-5,c12c(ccc(o1)=O)cccc2,1.1,23.6,0.17,0.78,0.8,"Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man. Ritschel, W. A.; Brady, M. E.; Tan, H. S. I.; Hoffmann, K. A.; Yiu, I. M.; Grummich, K. W. European Journal of Clinical Pharmacology (1977), 12(6), 457-461. ppb: Loren M. Berry, Chao Li, and Zhiyang Zhao. Species Differences in Distribution and Prediction of Human Vss from Preclinical Data Drug Metab. Disp. 2011, 39, 2103-2106.",Vc = Dose/Co reported. VDss = Vc*(1+ k12/k21). MRT = VDss/Cl. 68 kg average weight. N=4 16.78 mg dose.,,1884,146.14,2,0,30.5,0,neutral,1.6,1.6
CP-4055,188181-42-2,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=CC(=NC2=O)N,0.14,4.53,,0.51,0.36,"Dueland, Svein; Aamdal, Steinar; Lind, Michael J.; Thomas, Hilary; Liland Sandvold, Marit; Gaullier, Jean-Michel;Rasch, Wenche. Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A phase I study.  Acta Oncol. 2009, 48, 137-145.",ELACYT. Elacytarabine. N=24 across doses from 30 mg/m2 to 240 mg/m2 except 60 mg/m2 which was seemingly showing a much higher clearance and VDss than other infusions with a very high error. Only 30' data infusion taken. The 2 hr infusion at 240 mg/m2 for 2 hrs did not show a significant difference form the 30' infusion at the same dose. 1.73 m2/70kg factor used. MRT from VDss and clearance.,,1997,507.66,9,3,134.7,19,neutral,5,5
CP-65207,96865-21-3,C1(N2C(=C(S[C@@H]3C[S@@](CC3)=O)S[C@H]2[C@H]1[C@H](O)C)C([O-])=O)=O,0.21,5.1,0.9,0.7,0.9,"Pharmacokinetics of the Penem CP-65,207 and Its Separate Stereoisomers in Humans G. FOULDS,l A. K. KNIRSCH, J. D. LAZAR, T. G. TENSFELDT, AND N. GERBER. Antimicr. Agents Chemother. 1991, 35, 665-671.//ppb: Thomas Gootz, Dennis Girard, William Schelkley, Thomas Tensfeldt, George Foulds, Michael Kellogg, John Stam, Benedict Campbell1f, John Jasys, Paul Kelbaugh, Robert Volkmann and Ernest Hamanaka. PHARMACOKINETIC STUDIES IN ANIMALS OF A NEW PARENTERAL PENEM CP-65,207 AND ITS ORAL PRODRUG ESTER. J. Antibiot. 1990, 43, 422-432"," Na salt. Na omitted from smiles. Average of single enantiomers dosed as racemate and analyzed separately, N=12 each, 1 g 10 min' infusion. Similar values found. Mean weight 74.8 kg.",,1985,348.44,6,1,97.7,4,anionic,-1.8,-4.7
CPW 86-363,84080-55-7,Cn1c(nnn1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N/OCC(=O)O)/c4cc[nH]n4)SC2)C(=O)O,0.22,1.83,,1.8,1.33,"U. GANZINGER, F. SCHATZ, H. HABERL, A. HASLBERGER, H. SCHIEL, G. HiTZENBERGER. Comparative pharmacokinetic analysis of latamoxef and CPW 86-363, a novel carboxy-pyrazol-cephalosporine and formation of N-methyl-thiotetrazole. Int. J. Clin. Pharmacol., Ther. and Toxicol., 1987,  25, 152-156.","N=8, 1 g dose iv bolus, 70 kg median weight reported. T1/2 as 0.693/β ",,1982,523.5,16,4,217.9,10,anionic,-1.2,-7.5
Crizotinib,877399-52-5,C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4,22.15,9.75,0.09,37.9,38.9,"Huiping Xu, P, Melissa O’Gorman, Tanya Boutros, Nicoletta Brega,  Constantino Kantaridis,  Weiwei Tan, Akintunde Bello. Evaluation of Crizotinib Absolute Bioavailability, the Bioequivalence of
Three Oral Formulations, and the Effect of Food on Crizotinib Pharmacokinetics in Healthy Subjects. J. Clin. Pharmacol., 2104, 55, 104–113.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202570s009lbl.pdf. Accessed, July 12 2017.","N=14, 50 mg iv dose, 80 kg average weight reported. MRT from VDss and clearance.",,2006,450.34,6,2,78,5,cationic,4.3,2.3
CUDC-101,1012054-59-9,COc1cc2c(cc1OCCCCCCC(=O)NO)c(ncn2)Nc3cccc(c3)C#C,0.56,11.99,,0.78,5.01,"Toshio Shimizu, Patricia M. LoRusso, Kyri P. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon S. Smith, Drew W. Rasco, Theresa A. Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert Laliberte, Maurizio Voi, Anthony W. Tolcher. Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2014, 20, 5032–5040.","1hr infusion. Weighted average of 24 patients acrosss five doses (75-300 mg/m2), average weight assumed to be 70 kg. All data from table 5. MRT from VDss and clearance.",,2008,434.49,8,3,105.6,12,neutral,4.3,4.3
Cyanamide,420-04-2,C(N)#N,0.78,17,,0.8,0.43,"R. OBACH, J. TORRENT, H. COLOM, J. PRUGONOSA, C. PERAIRE AND
J. DOMENECH. PHARMACOKINETICS AND ORAL BIOAVAILABILITY OF CARBIMIDE IN MAN. BIOPHARMACEUTICS & DRUG DISPOSITION, VOL. 12, 425434 (1991)","CARBIMIDE. Clearance a bit variable but within good agreement. N=16 in 4 groups receiving 0.1, 0.3, 0.6, 1.0 mg/kg. Data taken as average of all groups. MRT from VDss and clearance.",,1886,42.04,2,1,49.8,0,cationic,-0.82,-0.82
Cyclizine,82-92-8,CN1CCN(CC1)C(c2ccccc2)c3ccccc3,16.5,14.5,,15.46,13.53,"R.B. Walker , I. Kanfer.  Pharmacokinetics of cyclizine following intravenous administration to human volunteers.  Eur. J. Pharm. Sci. 1996, 4, 301-306.","Nautazine. Marezine. N=6, 83 kg as median weight. 25 mg bolus dose.",,1949,266.38,2,0,6.5,3,cationic,3.2,2.4
Cyclopentenyl cytosine,90597-22-1,c1cn(c(=O)nc1N)[C@@H]2C=C([C@H]([C@H]2O)O)CO,,3.61,,,,"Pedro M. Politi , Fuming Xie , William Dahut, Harry Ford, Jr. , James A. Kelley , Anne Bastian, Ann Setser , Carmen J. Allegra , Alice P. Chert, J. Michael Hamilton , Susan F. Arbuck, Peter Linz , Harry Brammer , Jean L. Grem. Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother Pharmacol (1995) 36:513 523.",Infusion plot with N=1 available. Clearance reported as 146 mL/min/m2. 1.73 m2/70 kg conversion factor used.,,1983,239.23,7,4,121.6,2,neutral,-2.9,-2.9
Cyclophosphamide,50-18-0,ClCCN(CCCl)P1(=O)NCCCO1,0.73,1.1,0.87,11,8,"Juma FD, Rogers HJ, and Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br. J. Clin. Pharmacol. 8: 209-217.  Juma FD, Rogers HJ, and Trounce JR (1979) The kinetics of salivary elimination of cyclophosphamide in man.  Br. J. Clin. Pharmacol. 8: 455-458.",VDss calculated from microconstants reported in the reference.,,1946,261.09,4,1,41.6,5,neutral,0.79,0.55
Cyclosporine,59865-13-3,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,3.3,7.5,0.068,7.3,7.3,"Legg B, Gupta SK, Rowland M, Johnson RWG, and Solomon LR (1988) Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration.  Eur. J. Clin. Pharmacol. 34: 451-460.  Min DI, Lee M, Ku YM, and Flanigan M (2000) Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers.  Clin. Pharmacol. Ther. 68: 478-486.   ",Reported whole blood parameters converted to plasma parameters using a blood/plasma ratio of 1.3.,,1974,1202.61,23,5,278.8,15,neutral,6.6,6.6
CYT997,917111-44-5,O(C)C(C=C(C1)C(N=C(N[C@@H](CCC)C2C=CC=NC=2)C2C)=NC=2)=C(NC(NCC)=O)C=1,3.41,22.2,,2.5,2.9," Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. Lickliter, J. D.; Francesconi, A. B.; Smith, G.; Burge, M.; Coulthard, A.; Rose, S.; Griffin, M.; Milne, R.; McCarron, J.; Yeadon, T.; et al. British Journal of Cancer (2010), 103(5), 597-606","Lexibulin. Data digitized from plot reported, 269 mg/m2 dose and converted using 1.73 m2/70 kg factor. N=4. 24 hour infusion. Good agreement (9%) with reported AUC-last.",,2005,434.53,8,3,101.1,9,neutral,4.3,4.3
Cytarabine,147-94-4,[H]N([H])C1C=CN(C(N=1)=O)[C@H]1[C@H]([C@@H]([C@@H](CO[H])O1)O[H])O[H],0.67,41.67,0.87,0.28,0.17,"Breithaupt H et al.,  Clinical results and pharmacokinetics of high-​dose cytosine arabinoside (HD ARA-​C). Cancer, 1982, 50, 1248-1257. ppb: Van Prooijen, H. C.; Vierwinden, G.; Wessels, J.; Haanen, C. Cytosine arabinoside binding to human plasma proteins. Arch. Int. Pharmacodyn. Ther. 1977, 229, 199-205.",MK 8242. Tarabine. AC-1075. Data from 1-12 g doses with 2-3.5 hours iv infusion N=5 (see table 2 and 4) (Ara-C),,1966,243.22,8,4,128.6,6,neutral,-3,-3
Dabigatran,211914-51-1,[H]N=C(c1ccc(cc1)N([H])Cc1nc2cc(ccc2n1C)C(N(CCC(=O)O[H])c1ccccn1)=O)N([H])[H],0.85,1.93,0.65,7.4,7.3,"Blech S, Ebner T, Ludwig-Schwellinger E, et al. The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. Drug Metabol Disp 2008, 36, 386-399.","N=5, 5 mg dose iv bolus, average weight 80.2 kg.  See notes from e-mail reply from Dr. Blech.  Free means ""unconjugated"" not ""unbound"".  Cl 155 mL/min, and VDss 68.6 L.",,1998,471.51,10,4,150.2,11,zwitterionic,0.25,-1.1
Dabrafenib,1195765-45-7,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,0.65,2.86,0.003,3.8,2.6,"Denton CL, Minthorn E, Carson SW, Young GC, Richards-Peterson LE, Botbyl J, Han C, Morrison RA, Blackman SC, Ouellet D. Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients With BRAF V600 Mutation‐Positive Solid Tumors. J. Clin. Pharmacol. 2013, 53, 955-961.//ppb reported in PDR as 99.7%. https://www.pdr3d.com/detail.php?c=167028#section-13. Accessed August 4 2016.","N= 4. 70 kg average weight used. 50 ug iv of 14C-dabrafenib concomitant with 150 mg po. MRT from VDss and clearance. Animal data availble in 4 species (mouse, rat, dog and monkey).",,2009,519.56,7,2,110.9,5,neutral,5.3,5.2
Dacarbazine,4342-03-4,CN(C)N=Nc1nc[nH]c1C(=O)N,1.2,2.6,1,7.8,6.2,"Loo TL, Housholder GE, Gerulath AH, Saunders PH, and Farquhar D (1976) Mechanism of action and pharmacology studies with DITC (NSC-45388) Canc. Treatment Rep. 60: 149-152.  DITC-DOME Product Label",Parameters calculated from C vs t data obtained by digitization of a plot provided in the reference.,,1953,182.18,7,2,99.7,3,neutral,-0.12,-0.12
Dacinostat,404951-53-7,c1ccc2c(c1)c(c[nH]2)CCN(CCO)Cc3ccc(cc3)/C=C/C(=O)NO,2.17,7.6,0.23,4.78,12.43,"Johann S. de Bono, Rebecca Kristeleit, Anthony Tolcher,  Peter Fong, Simon Pacey, Vasilios Karavasilis,Monica Mita, Heather Shaw, Paul Workman, Stan Kaye, Eric K. Rowinsky, WynneAherne, Peter Atadja, Jeffrey W. Scott, and Amita Patnaik. Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor w itha Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2008, 14, 6663-6673",NVP-LAQ824 Digitized from plot at 72 and 6 mg/m2 and then weight-averaged (n=13 at 72 mg/m2 and 3 at 6 mg/kg). Good agreement with AUCinf reported. 1.73m2/70 kg conversion factor used.,,2003,379.45,6,4,88.6,9,cationic,1.8,1.5
Daclatasvir,1009119-64-5,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2ncc([nH]2)c3ccc(cc3)c4ccc(cc4)c5cnc([nH]5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C,0.67,1,0.01,11.19,13.5,DAKLINZA. PDR prescribing information. http://pdr3d.com/detail.php?c=159566#section-12. Accessed October 16 2015.,"70 kg assumed. iv tracer plus 60 mg dose. PDR: With multiple dosing, protein binding of daclatasvir in HCV-infected subjects was approximately 99% and independent of dose at the dose range studied (1-100 mg). In subjects who received daclatasvir 60 mg tablet orally followed by 100 μg [13C,15N]-daclatasvir intravenous dose, estimated volume of distribution at steady state was 47 L. Following multiple-dose administration of daclatasvir in HCV-infected subjects, with doses ranging from 1 mg to 100 mg once daily, the terminal elimination half-life of daclatasvir ranged from approximately 12 to 15 hours. In subjects who received daclatasvir 60 mg tablet orally followed by 100 μg [13C,15N]-daclatasvir intravenous dose, the total clearance was 4.2 L/h.",,2008,738.88,14,4,174.6,13,neutral,5.3,5.2
Dalbavancin,171500-79-1,CN[C@H]1C(=O)N[C@@H]2Cc3ccc(Oc4cc5cc(Oc6ccc(cc6Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]5NC(=O)[C@@H](NC2=O)c8cc(Oc9cc1ccc9O)cc(O)c8Cl)c%10ccc(O)c(c%10)c%11c(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%12O)cc(O)cc%11[C@H](NC7=O)C(=O)NCCCN(C)C)c4O[C@@H]%13O[C@@H]([C@@H](O)[C@H](O)[C@H]%13NC(=O)CCCCCCCCC(C)C)C(=O)O)cc3,0.14,0.01,0.02,230,170,"Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, Mroszczak EJ, Campbell KCM, and Kelly E (2004) Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.  Antimic. Agents Chemother. 48: 940-945.   Jabés D, Candiani G, Romanó G, Brunati C, Riva S, and Cavaleri M (2004) Efficacy of Dalbavancin against Methicillin-Resistant Staphylococcus aureus in the Rat Granuloma Pouch Infection Model.  Antimicrob. Agents Chemother. 48: 1118-1123.",,,1995,1816.69,38,21,572.5,22,zwitterionic,4.3,0.73
Dalfampridine,504-24-5,c1(ccncc1)N,2.6,9.3,1,4.7,3.6,"Donald R. A. Uges, Pharm.D., Yung Jai Sohn, M.D.,* Ben Greijdanus,Arnold H. J. Scat, Ph.D., Sandor Agoston, M.D., Ph.D. 4-Aminopyridine kinetics. Clin. Pharmacol. Ther. 1982, 31, 587-593.","4-aminopyridine. N=9 (7M and 2F). 71.6 kg average weight, 20 mg dose.","Donald R. A. Uges, Pharm.D., Yung Jai Sohn, M.D.,* Ben Greijdanus,Arnold H. J. Scat, Ph.D., Sandor Agoston, M.D., Ph.D. 4-Aminopyridine kinetics. Clin. Pharmacol. Ther. 1982, 31, 587-593. Approximately 90% excreted unchanged in urine.",1915,94.11,2,1,38.9,0,cationic,-0.12,-1.4
Dalfopristin,112362-50-2,CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C/C(=C/[C@@H](O)CC(=O)Cc3occ(n3)C2=O)/C,0.39,16,0.82,0.41,0.74,"Chevalier P, Rey J, Pasquier O, Rouzier-Panis R, Harding N, and Montay G (2001) Multiple-dose pharmacokinetics and safety of two regimens of quinupristine/dalfopristin (Synercid) in healthy volunteers.  J. Clin. Pharmacol. 41: 404-414.  Bergeron M and Montay G (1997) The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.  J. Antimic. Chemother. 39(Supp. 1): 129-138.  Bearden DT (2004)  Clinical pharmacokinetics of quinupristin/dalfopristin.  Clin. Pharmacokinet. 43: 239-252.",,,1986,690.85,13,2,176.7,7,neutral,0.6,0.6
Danazol,17230-88-5,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=Cc5c(cno5)C[C@]34C,5.18,15.71,,5.49,2.31,"Sunesen VH, Vedelsdal R, Kristensen HG, Christrup L, Müllertz A. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci. 2005 24, 297-303.","N=8, 50 mg iv dosed as 30' infusion. 86 kg average weight reported. Data digitized and PK parameters calculated via Phoenix v. 6.4.0.768. AUCinf very close to AUCt. AUC(not specified) reported as 531 ng.h.mL-1; calculated AUCinf as 616.7 ng.h.mL-1. 16% error.",,1963,337.46,3,1,46.6,1,neutral,3.7,3.7
Danoprevir,850876-88-9,CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4Cc5cccc(F)c5C4)C(=O)NS(=O)(=O)C6CC6,0.22,11.53,0.02,0.32,1.81,"Barbara J. Brennan, Agne`s Poirier, Sebastian Moreira, Peter N. Morcos, Petra Goelzer,  Rene´e Portmann, Jiney Asthappan, Christoph Funk, Patrick F. Smith.Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir. Clin. Pharmacokin. 2015, 54, 237-249.//ppb: Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Nájera I, Smith P, Shulman NS, Tran JQ.Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol. 2011, 55, 972-979.","RO5190591. R 7227. N=12, 70 kg average weight assumed, 6 mg dose as 1 h infusion. Data digitized and PK parameters calculated via PKSolver. Reported AUC(0-inf) 122 ng.h.m-1; calculated 123. 9 ng.h.m-1. 1% difference.",Very low BA (1.15%) from iv and 100 mg po dose. ,2005,731.83,14,3,180.5,7,anionic,4.4,1.4
Dantrolene,7261-97-4,O=C1CN(\N=C\c2oc(cc2)c3ccc(cc3)N(=O)=O)C(=O)N1,0.37,0.43,,14,10,"Podranski T, Boullion T, Schumacher PM, Taguchi A, Sessler DI, and Kurz A (2005) Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work? Anesth. Analg.  101: 1695-1699. ",,,1967,314.25,9,1,121,4,anionic,1.4,1
Danusertib,827318-97-8,N(C(=O)C(=CC=C1N(CCN2C)CC2)C=C1)C(C(=C1C2)CN2C([C@H](OC)C(=CC=C2)C=C2)=O)=NN1,2.5,6.1,,6.8,25,"Weighted data digitized from Fig. 1B (N=12, dose 500 mg/m2 (12.5 mg/kg) 24h i.v. infusion) and Fig. 1C (N=6, dose 750 mg/m2 (18.75 mg/kg) 24h i.v. infusion) in Cohen, Roger B.; Jones, Suzanne F.; Aggarwal, Charu; von Mehren, Margaret; Cheng, Jonathan; Spigel, David R.; Greco, F. Anthony; Mariani, Mariangela; Rocchetti, Maurizio; Ceruti, Roberta; Comis, Silvia; Laffranchi, Bernard; Moll, Jurgen; Burris, Howard A.  A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors.   Clinical Cancer Research  (2009),  15(21),  6694-6701.","The Fig. 4 is not plotted in van Tellingen O. et al, Cancer Chemother Pharmacol, 1998, 41, 377-384 where another patient profile with a different dose is shown in the Fig. 5",,2005,474.55,9,2,93.8,6,cationic,1.6,0.62
Dapagliflozin,461432-26-8,[C@H]1([C@H]([C@@H]([C@H](C(O1)c1ccc(c(c1)Cc1ccc(cc1)OCC)Cl)O)O)O)CO,1.7,3,0.09,9.5,12.2,"Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin Boulton, David W.; Kasichayanula, Sreeneeranj; Keung, Chi Fung; Arnold, Mark E.; Christopher, Lisa J.; Xu, Xiaohui; LaCreta, Frank  British Journal of Clinical Pharmacology (2013), 75(3), 763-768. ",80 ug labelled iv dose given at Tmax of a po pharmacological dose (5mg). N=7 and 70 kg average weight assumed.MRT from Cl and Vss. ,"In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans. S M. Obermeier, M. Yao, A. Khanna, B. Koplowitz, M. Zhu, W. Li, B. Komoroski, S. Kasichayanula, L. Discenza, W. Washburn, W. Meng, B. A. Ellsworth, J. M. Whaley, and
W. G. Humphreys. Drug Metab. Disp.  38:405–414, 2010.  Likely to be glucuronidated but no quantitative data available. fu taken from this ref.",2002,408.87,6,4,99.4,6,neutral,2.3,2.3
Dapsone,80-08-0,Nc1ccc(cc1)S(=O)(=O)c2ccc(N)cc2,0.83,0.48,0.25,29,22,Pieters FAMJ and Zuidema J (1987) The absolute bioavailability of dapsone in dogs and humans.  Int. J. Clin. Pharmacol. Ther. Toxicol. 25: 396-400.  Biggs JT and Levy L (1971)  Binding of dapsone and monacetyldapsone by human plasma proteins.  Proc. Soc. Exp. Biol. Med. 137: 692-695.,VDss calculated from C vs t data obtained by digitization of plot provided in the reference.,,1908,248.3,4,2,86.2,2,neutral,0.97,0.97
Daptomycin,103060-53-3,CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)c4ccccc4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)C(CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(=O)O,0.088,0.16,0.083,9.2,8.1,"Dvorchik BH, Brazier D, DeBruin MF, and Arbeit RD (2003)  Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimic. Agents Chemother. 47: 1318-1323.  Woodworth JR, Nyhart EH, Brier GL, Wolny JD, and Black HR (1992) Single dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers.  Antimic. Agents Chemother. 36: 318-325.  Benvenuto M, Benzinger DP, Yankelev S, and Vigliani G (2006) Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.  Antimic. Agents Chemother. 50: 3245-3249.","VDss calculated from C vs t data obtained by digitization of plot provided in the Benvenuto, et al. references.",,1986,1620.67,43,22,702,35,anionic,-6.4,-9
Darapladib,356057-34-6,c1(ccc(cc1)CSc1nc(=O)c2c(n1CC(=O)N(CCN(CC)CC)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F)CCC2)F,11.9,4.11,,48.1,40.9,"Mehul Dave, Mike Nash, Graeme C. Young, Harma Ellens, Mindy H. Magee, Andrew D. Roberts, Maxine A. Taylor, Robert W. Greenhill, and Gary W. Boyle. Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans. Drug Metab Dispos 2014, 42:415–430.",SB-480848. 70 kg average weight assumed. 8 mg dose over 3 hours infusion. N=8. MRT from VDss and clearance.,,2001,666.77,6,0,58.4,13,cationic,6.5,5.1
Darifenacin,133099-04-4,NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c4ccccc4)c5ccccc5,2.6,12,0.02,3.6,3.6,Skerjanec A (2006) The clinical pharmacokinetics of darifenacin.  Clin. Pharmacokinet. 45: 325-350.  Enablex Product Label.,Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1990,426.55,4,1,55.6,7,cationic,3.8,2.5
Darunavir,206361-99-1,CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)c4ccc(cc4)N,,7.81,0.05,,15,PDR. Accessed February 20 2013. http://www.pdr3d.com/detail.php?c=80691#section-13,No VDss reported. Clearance 32.8 L/h (iv). 70 kg assumed.,"PDR. Accessed February 20 2013. http://www.pdr3d.com/detail.php?c=80691#section-13. After intravenous administration, the clearance of darunavir, administered alone and co-administered with 100 mg twice daily ritonavir, was 32.8 L/h and 5.9 L/h, respectively. Assigned to be metabolic on the basis of this observation. ",1995,547.66,10,3,140.4,12,neutral,2.8,2.8
Dasabuvir,1132935-63-7,CC(C)(C)c1cc(cc(c1OC)c2ccc3cc(ccc3c2)NS(=O)(=O)C)n4ccc(=O)[nH]c4=O,2.13,,0.005,,5.7,PDR http://www.pdr3d.com/detail.php?c=186040#section-12. Accessed August 9 2016. Table 6.,No iv AUC or clearance. Protein binding reported > 99.5. Median t1/2 taken and 70 kg average weight assumed.,,2009,493.57,8,2,110.3,5,neutral,4.3,0.75
Daunorubicin,20830-81-3,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)C)O)N)O,32.05,47.57,0.06,11.23,14.24,"Aquilur Rahman, Anita Goodman, Wayne Foo, Jimmie Harvey, Frederick P. Smith, and Philip S. Schein.  Clinical Pharmacology of Daunorubidn in Phase I Patients With Solid Tumors: Development of an Analytical Methodology for Daunorubicin and Its Metabolites. Sem. Oncol.,  1984, 11, 36-44.//ppb: Gillian Whitaker, Amy Lillquist, Stephanie A. Pasas, Robert O'Connor, Fiona Regan,Craig E. Lunte, Malcolm R. Smyth. CE-LIF method for the separation of anthracyclines: Application to protein binding analysis in plasma using ultrafiltration. J. Sep. Sci. 2008, 31, 1828 – 1833.",30 to 60 mg/m2 to patients with with normal hepatic and renal function. 1.73 m2/70kg conversion factor used. N not reported. MRT from clearance and VDss.,,1953,527.52,11,5,185.8,4,cationic,1,-1.6
Deacetyl metipranolol,57193-14-3,c1(c(c(c(cc1C)OC[C@@H](CNC(C)C)O)C)C)O,3.6,16.2,,3.7,3.1,"U. Abshagen, G. Betzien, B. Kaufmann, G. Endele. Pharmacokinetics of Metipranolol in normal man. Eur. J. Clin. Pharmacol, 1982, 21, 293-301.","Data digitized from 20 mg PK profile in figure 3 in . N=10, 20 mg dose, 0.8 h infusion, 78 kg.
Reported AUC 283 hr*ug/L
t1/2 = 2.91 h
Clearance = 20.3 mL/sec (= 15.6 mL/min/kg)",very low renal clearance (12%),1974,267.36,4,3,61.7,6,cationic,2.6,0.77
Decitabine,2353-33-5,NC1=NC(=O)N(C=N1)[C@H]2C[C@H](O)[C@@H](CO)O2,4.6,130,1,0.59,0.58,"van Groeningen CJ, Leyva A, O'Brien AMP, Gall HE, and Pinedo HM (1986) Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.  Cancer Res. 46: 4831-4836.  Dacogen Product Label.",NSC 127716,,1964,228.21,8,3,120.7,2,neutral,-2,-2
Deferasirox,201530-41-8,[H]OC(c1ccc(cc1)n1c(c2ccccc2O[H])nc(c2ccccc2O[H])n1)=O,0.2,0.84,0.004,4.07,4.05,"Sechaud R et al. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J. Clin. Pharmacol. 2008, 48, 919-925. ppb: H. Markus Weiss, Marcel Fresneau, Gian P. Camenisch, Olivier Kretz, and Gerhard Gross, IN VITRO BLOOD DISTRIBUTION AND PLASMA PROTEIN BINDING OF THE IRON CHELATOR DEFERASIROX (ICL670) AND ITS IRON COMPLEX FE-[ICL670]2 FOR RAT, MARMOSET, RABBIT, MOUSE, DOG, AND HUMAN. Drug Metab Disp, 2006, 34, 971-975."," N=17, 70-kg average weight assumed, 130 mg dose as 90 minutes infusion.",,1997,373.36,7,3,108.5,7,anionic,4.5,1.3
Deferolimus,572924-54-0,C1CCN2[C@@H](C1)C(=O)O[C@@H](CC(=O)[C@@H](C=C([C@H]([C@H](C(=O)[C@@H](C[C@@H](C=CC=CC=C([C@H](C[C@@H]1CC[C@H]([C@](C(=O)C2=O)(O1)O)C)OC)C)C)C)OC)O)C)C)[C@H](C)C[C@@H]1CC[C@H]([C@@H](C1)OC)OP(=O)(C)C,3.2,1.1,,48.5,46.3,"Hartford CM et al. A Phase I trial to determine the safety, tolerability, and maximum tolerated dose of deferolimus in patients with advanced malignancies. Clin. Cancer Res. 2009, 15, 1428-1434. ","Ridaforolimus, MK 8669, AP23573.  82 kg median weight, weight-averaged across 41 patients and 6 doses. Average VDss 261 L, average clearance 5.34 L/h. NOT a sirolimus prodrug.",,2003,990.21,15,2,201.5,8,neutral,6.4,6.4
Degarelix,214766-78-6,c1(cc2ccccc2cc1)C[C@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](CO)C(N[C@H](C(N[C@@H](C(N[C@H](C(N[C@H](C(N1[C@@H](C(N[C@@H](C(N)=O)C)=O)CCC1)=O)CCCCNC(C)C)=O)CC(C)C)=O)Cc1ccc(cc1)NC(N)=O)=O)Cc1ccc(cc1)NC([C@H]1CC(NC(N1)=O)=O)=O)=O)=O)Cc1cnccc1)=O)Cc1ccc(cc1)Cl)=O)NC(C)=O,0.74,0.68,0.1,18.1,18.6,"Australian Public Assessment Report for Degarelix. Therapeutic Goods Administration , Department of Health and Ageing, Australian Goverment
Health Safety Regulation (May 2010) (AusPAR Firmagon Degarelix Ferring Pharmaceuticals Pty Ltd PM-2008-2254-4 Date of Finalisation 16 February 2010)","Doses: IV degarelix infusions of 3.7 (n=6), 9.87 (n=6), 24.7 (n=9), and 49.4 (n=9) µg/kg
All data are taken as the median of the min and max values of the reported short range. VDss (L/kg) = 0.74 (range 0.65-0.82)
CL (mL/min/kg) = 0.68 (range 0.58 - 0.78)
MRT (h) = 18.1 (calculated from averaged VDss and CL)
t1/2 = 18.6 (range 13.6 - 23.7)
plasma fraction unbound (ex vivo) = 0.1 PPB: Plasma protein binding was determined in plasma samples collected at 1, 12, 
and 24 hours after the end of a 30 µg/kg IV infusion to 6 healthy males [CS05]. Mean protein binding was 90.7%, 90.5%, and 88.6% at 1, 12, and 24 hours post-infusion, respectively. In an in vitro study [1475/094], mean human plasma protein binding of degarelix was 90.5% over the concentration range 20 to 160 ng/mL. Binding to serum albumin (76.3%) and a1-acid glycoprotein (78.2%) was high in comparison with binding to high density lipoproteins (mean 57.9%) and gamma globulin (40.0%). 
There were no data on plasma-blood partitioning.",,1998,1632.26,34,17,512.9,41,cationic,2.9,0.72
Dehydroandrographolide succinate,786593-06-4,O=C(O)CCC(=O)O[C@@H]3CC[C@@]2(C)[C@H](/C=C/C1=CCOC1=O)C(=C)CC[C@@H]2[C@]3(C)COC(=O)CCC(=O)O,0.13,2,,1,1.9,"Shuijun Li , DingYang, MengqiZhang, JuzhenZhou, RuiLi , ChuanLua, YunLiua YanmeiLiua
Yiping Wang, ChenYua. Determination of dehydroandrographolide succinate in humanplasma by liquid
chromatography tandem mass spectrometry(LC–MS/MS): Method development
validation and clinical pharmacokinetic study. Journal of Chromatography B, 878 (2010) 2274–2279.",Data digitized from mean plasma vs. time concentratrion profile in Fig. 5 (N=9). 1h-indfused dose of 160 mg corrected as free acid. 70 kg body weight assumed. MRT calculated from VDss and CL. T1/2 reported of 1.8h,,2004,532.58,10,2,153.5,13,anionic,2,-3.7
Delafloxacin,189279-58-1,c1c2c(c(c(c1F)N3CC(C3)O)Cl)n(cc(c2=O)C(=O)O)c4c(cc(c(n4)N)F)F,0.35,2.33,0.16,2.5,2.1,"Randall Hoover; Thomas Hunt; Michael Benedict; Susan K. Paulson; Laura Lawrence; Sue Cammarata and Eugene Sun. Safety, Tolerability,and Pharmacokinetic Properties of
Intravenous Delafloxacin After Single and Multiple Dosesin Healthy Volunteers. Clin. Ther. 2016, 38, 53-65. // ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf.","Data digitized from plot reported at 750 mg dose, 1-hr iv infusion,  N=8, 73.8 kg as average weight reported across entire cohort. T1/2 taken as very long in report but concentration at < 2% of Cmax after 12 hours. Extrapolation using 3-12 hr interval (5 points). AUCinf reported 74.4 ug.hr.mL-1 and calculated as 72.2 ug.hr.mL-1 (3% deviation). Clearance not linear across entire range and a mid point (750 mg) was chosen from range of 300 to 1200 mg.  35% excreted unchanged renally.",,1997,440.76,8,3,121.7,3,anionic,2.5,-0.0083
Delorazepam (Chlordesmethyldiazepam),2894-67-9,Clc1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,2.2,0.17,0.051,220,200,"Bareggi SR, Pirola R, Potvin P, and Devis G (1995) Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam.  Eur. J. Clin. Pharmacol. 48: 265-268.  Sennesael J, Verbeelen D, Vanhaelst L, Pirola R, and Bareggi SR (1991) Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis.  Eur. J. Clin. Pharmacol. 41:65-68.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.   Molec. Pharmacol.  12: 612-619.",Parameters were determined from C vs t data obtained by digitization of the C vs t plots for normal subjects provided in the references and averaged (N=2).,,1962,305.16,3,1,41.5,1,neutral,3.6,3.6
Demethylchlortetracycline,127-33-3,CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N,1.3,1.1,0.59,17,12,"Kunin, CM, Darnbush AC, and Finland M. Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest. 1959, 38, 1950-63.",Calculated from digitized plots ,,1957,464.85,10,6,181.6,2,anionic,-0.19,-2.9
Denaverine,3579-62-2,CCC(CC)COC(C(=O)OCCN(C)C)(c1ccccc1)c2ccccc2,7.1,5.7,,21,34,"Staab A, Schug BS, Larsimont V, Elze M, Thummler D, Mutschler E, and Blume H (2003) Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral, and rectal single doses.  Eur. J. Pharm. Sci. 18: 121-128.",,,1963,383.52,4,0,38.8,12,cationic,5.3,4.3
Deoxycytidine-5F-2',10356-76-0,c1c(c(nc(=O)n1[C@H]2C[C@@H]([C@H](O2)CO)O)N)F,0.91,5.09,,2.98,0.78,"Edward M. Newman · Robert J. Morgan · Shivaani Kummar · Jan H. Beumer · M. Suzette Blanchard ·
Christopher Ruel · Anthony B. El‑Khoueiry · Mary I. Carroll · Jessie M. Hou · Chun Li · Heinz J. Lenz ·
Julie L. Eiseman · James H. Doroshow. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5‑fluoro‑2′‑deoxycytidine, administered with tetrahydrouridine. Cancer Chemother. Pharmacol. 2015, ","Data weight-averaged across 3 doses (67, 100 and 133 mg/m2, N= 7, 16, and 6, respectively) 3 hr iv infusion, administered with 350 mg/m2 of tetrahydrouridine. 1.73 m2/70 kg conversion factor assumed. MRT from VDss and clearance.",,1959,245.21,7,3,110.6,2,neutral,-2,-2
Deramciclane,120444-71-5,C[C@@]12CC[C@@H](C1(C)C)C[C@@]2(c3ccccc3)OCCN(C)C,7.7,4.88,0.05,26.6,26.6,"Risto Huupponen, Outi Paija, Markku Salonen, Harry Bjorklund, Juha Rouru,  Markku Anttila. Pharmacokinetics of Deramciclane, a Novel Anxiolytic Agent, after Intravenous and Oral Administration. Drugs R&D 2003; 4 (6): 339-345. //ppb: J . VISY, I. FITOS, G. MADY, M . SIMONYI AND I. KLEBOVICH. Plasma Protein Binding of Deramciclane in Different Species. Pharm. Sci. 1996, 2, 315-318.","N=12, 30 mg dose. All data from table I. Same t1/2 and MRT reported. //ppb: value dependent on concentration fu 1.8% at 0.9 uM and 7.5% at 200 uM. Median value taken.",,1992,301.47,2,0,12.5,5,cationic,4,2.6
"Desacetylpaclitaxel, 4-; 4-methyl carbonate",172481-83-3,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7)C(=C([C@@H](OC(=O)C)C3=O)C5(C)C)C,6.9,8.6,,13,31,"du Bois A, Jung B, Loehr A, Schaller-Kranz T, Cohen M, Frickhofen N (2006) A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours.  Br. J. Cancer. 94: 79-84.", BMS-188797,,1995,869.91,16,4,230.5,15,neutral,2.3,2.3
Desferrioxamine,70-51-9,C(CCC(NCCCCCN(C(C)=O)O)=O)(N(CCCCCNC(CCC(N(CCCCCN)O)=O)=O)O)=O,1.35,8.33,,2.7,3.05,"P. LEE, N. MOHAMMED, L. MARSHALL, A. D. ABEYSINGHE, A. C. HIDER, J. B. PORTER, AND S. SINGH. INTRAVENOUS INFUSION PHARMACOKINETICS OF DESFERRIOXAMINE IN
THALASSAEMIC PATIENTS. Drug Metab. Disp. 1993, 21, 640-644.","Deferoxamine. EC 200-738-5. N=11, clearance as dose over AUC appears to be correct. Dose 50 mg/kg/24hr over 48 hours. MRT appears a bit smaller than when calculated from reported AUMC, AUC and clearance. AUC0-inf 354 umol.h.L-1; AUMC0-inf  9170 umol.h2.L-1. All data taken as is from paper. MW 560.69",,1960,560.68,14,6,205.8,23,cationic,-2.6,-5.8
Desipramine,50-47-5,CNCCCN1c2ccccc2CCc3ccccc13,15,11,0.16,23,22,"Ciraulo DA, Barnhill JG, and Jaffe JH (1988) Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.  Clin. Pharmacol. Ther.  43: 509-518.  Brosen K and Gram LF (1988) First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.  Clin. Pharmacol. Ther.  43: 400-406.  Nyberg G and Maartensson E (1984)  Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.",VDss calculated from C vs t data obtained by digitization of plots provided in the references.  Data from CYP2D6 poor metabolizers not included.,,1959,266.38,2,1,15.3,4,cationic,3.8,1.4
Desmethyldiazepam,1088-11-5,Clc1ccc2NC(=O)CN=C(c3ccccc3)c2c1,0.45,0.12,0.03,63,46,"Klotz U, Antonin KH, Brugel H, and Bieck PR (1977) Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease.  Clin. Pharmacol. Ther. 21: 430-436.  Lucek RW and Coutinho CB. (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12: 612-619.",,,1961,270.71,3,1,41.5,1,neutral,3,3
Desmopressin,16679-58-6,NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(=O)N)NC1=O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)N,0.3,1.4,,3.6,3,"Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard, JP, and Djurhuus JC (2004) Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur. J. Clin. Pharmacol.  60: 397-402.",DDAVP. ,,1950,1069.22,26,14,435.4,20,cationic,-4.9,-8.4
Desvenlafaxine,93413-62-8,c1cc(ccc1O)[C@@H](CN(C)C)C1(CCCCC1)O,3.5,4.9,0.7,11.8,8.4,"Nichols, Alice I.; Behrle, Jessica A.; Richards, Lyette S.; Parker, Vernon D.; Posener, Joel A.; Fruncillo, Richard; Paul, Jeffrey The absolute bioavailability of desvenlafaxine in healthy subjects. Journal of Bioequivalence & Bioavailability (2012), 4(2), 18-23.   ","Data digitized from Fig.1 in reference.
Nichols, Alice I.; et al. Dose 50 mg 1h infusion, AUC = 2442 ng*h/mL, t1/2 = 9.8 h, CL = 0.268 L/h/kg, Vz = 3.66 L/kg The plasma protein binding of desvenlafaxine is low (30%) and is independent of drug concentration. PDR.  Accessed February 20 2013. http://www.pdr3d.com/detail.php?c=84482#section-15.  ",,1984,263.38,3,2,43.7,4,cationic,2.9,0.95
Dexamethasone,50-02-2,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,0.94,3.3,0.32,4.7,3.7,"Rose JQ, Yurchak AM, Meikle AW, and Jusko WJ (1981) Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.  J. Pharmacokinet. Biopharm. 9: 1-14.  Tsuei SE, Moore RG, Ashley JJ, and McBride WG (1979) Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults.  J. Pharmacokinet. Biopharm. 7: 249-264.",,,1955,392.46,5,3,94.8,2,neutral,1.7,1.7
Dexanabinol,112924-45-5,CCCCCCC(C)(C)c1cc(c2c(c1)OC([C@@H]3[C@@H]2CC(=CC3)CO)(C)C)O,5.06,21.38,,3.94,7.33,"Brewster, M. E.; Pop, E.; Foltz, R. L.; Reuschel, S.; Griffith, W.; Amselem, S.; Biegon, A. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211 ), a neuroprotectant agent, in normal volunteers. International Journal of Clinical Pharmacology and Therapeutics, 1997, 35, 361-365.","HU-211. Data digitized for the 100 mg dose. Highly linear PK between 50, 100 and 200 mg. N=9 and 77.21 kg average weight derived from clearance data in mL/min and in mL/min/kg. AUCinf 60,579 ng.min/mL against reported AUC of 54,315 ng.min/mL. (11% difference).",,1987,386.57,3,2,49.7,7,neutral,7.6,7.5
Dexfenfluramine,3239-44-9,CCN[C@@H](C)Cc1cccc(c1)C(F)(F)F,11,11,0.66,18,14,"Cheymol G, Weissenburger J., Poirier JM, Gellee C. (1995) The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.  Br. J. Clin. Pharmacol. 39: 684-687.  De la Torre R, Farre M, Navarro M, Pacifici R,  Zuccaro P, and Pichini S (2004) Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet. 43: 157-185.",(S)-Fenfluramine.  It was also reported as fenfluramine (data referring to d-fenfluramine = (S)-fenfluramine) from: FDA Approval package. 1996-Apr-29  PDF(6817k) Approval Package 020344 Part 04. Data very similar to those extracted by reference cited.,,1958,231.26,1,1,12,4,cationic,3.5,1.7
Dexloxiglumide,119817-90-2,CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,0.18,3.7,0.024,0.79,1.2,"Webber C, Roth A, Persiani S, Peard AJ, Makovec F, Kapil RP, John BA, Holding JD, D'Amato M, Cybulski, ZR, Chasseaud LF, and Rovati LC (2003) Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects.  Xenobiotica  33: 625-641.",Protein binding data for 1 ug/mL concentration is included.,,1988,461.38,7,2,95.9,14,anionic,4.2,1
Dexmedetomidine,145108-58-3,C[C@H](c1c[nH]cn1)c2cccc(C)c2C,1.6,11,0.06,2.5,2.2,"Anttila A, Penttila J, Helminen A, Vuorilehto L, and  Scheinin H (2003)  Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br. J. Clin. Pharmacol. 56: 691-693.  Precedex Product Label.",,,1994,200.28,2,1,28.7,2,neutral,2.8,2.7
Dexmethylphenidate,40431-64-9,c1ccc([C@H]([C@H]2CCCCN2)C(OC)=O)cc1,2.65,6.67,0.87,6.62,8,PDR. Accessed February 20 2013. http://www.pdr3d.com/detail.php?c=64365#section-3. ,MRT from VDss and clearance. 70 kg assumed. ,"PDR. Accessed February 20 2013. http://www.pdr3d.com/detail.php?c=64365#section-3. The main urinary metabolite was ritalinic acid, accountable for approximately 80% of the dose.",1972,233.31,3,1,38.3,4,cationic,2.1,0.84
Dexniguldipine,120054-86-6,COC(=O)C1=C(C)NC(=C([C@@H]1c2cccc(c2)N(=O)=O)C(=O)OCCCN3CCC(CC3)(c4ccccc4)c5ccccc5)C,8.4,9.3,,15,22,"Goedhals L, Bezwoda WR, Abratt RP, Rathgeb F, Goebel KJ, and Wurst W (1995) Bioavailability and pharmacokinetic characteristics of dexniguldipine-HCl, a new anticancer drug.  Int. J. Clin. Pharmacol. Ther. 33: 664-669.      ",VDss calculated from C vs t data obtained by digitization of plots provided in the reference.,,1987,609.71,9,1,113.7,12,cationic,6.8,5.9
Dexrazoxane,24584-09-6,C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,0.55,3.1,1,3,2.5,"Rosing H, Ten Bokkel Huinink WW, Van Gijn R, Rombouts RFM, Bult A, and Beijnen JH (1999) Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).  Eur. J. Drug Metab. Pharmacokinet. 24: 69-77.  Zinecard Product Label.",ICRF 187. Zinecard.,,1969,268.27,8,2,98.8,3,neutral,-0.45,-0.5
Dextromoramide,357-56-2,C[C@H](CN1CCOCC1)C(C(=O)N2CCCC2)(c3ccccc3)c4ccccc4,0.47,2.19,,3.88,3.18,"Lancon J.P.; Pechinot A.; D'athis P.; Pechinot M.; Pointaire P.; Obadia J.F.; Caillard B. Dextromoramide pharmacokinetics in surgical patients. Ann. Fr. Anesth. Reanim. 1989, 8, 488-492.","N=9, and 5 mg iv dose. All data reported in table. 59 kg average weight",,1957,392.53,4,0,32.8,6,neutral,3.4,3.4
Dezocine,53648-55-8,c12[C@@]3([C@H]([C@@H](CCCCC3)Cc1ccc(c2)O)N)C,5.6,27.5,0.08,4.6,3.9,"Wilson JM, Cohen RI, Kezer EA, Schange SJ, Smith ER. Single- and multiple-dose pharmacokinetics of dezocine in patients with acute or chronic pain.J Clin Pharmacol. 1995 Apr;35(4):398-403.",Doses from 5-20. averaged by authors.,,1976,245.36,2,2,46.3,0,cationic,3,1.1
DHA Paclitaxel,199796-52-6,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@H]([C@@H](NC(=O)c1ccccc1)c2ccccc2)C(=O)O[C@H]3C[C@@]4(O)[C@@H](OC(=O)c5ccccc5)[C@@H]6[C@@]7(CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(=O)C)C(=C3C)C4(C)C)OC(=O)C,0.068,0.025,0.0038,45,60,"Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, and Baker SD (2003) Disposition of docosahaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.  Clin. Cancer Res. 9: 151-159.",Pharmacokinetic paremeters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1997,1164.38,16,3,227.4,30,neutral,9,9
Diatrizoic Acid (Amidotrizoate),117-96-4,CC(=O)Nc1c(I)c(NC(=O)C)c(I)c(C(=O)O)c1I,0.26,1.7,1,2.6,1.8,"Feldman S, Hayman LA, and Hulse M (1984) Pharmacokinetics of low- and high-dose intravenous diatrizoate contrast media administration.    Invest. Radiol. 19: 54-57.  Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.",,,1953,613.91,6,3,95.5,3,anionic,0.98,-2.3
Diazepam,439-14-5,CN1C(=O)CN=C(c2ccccc2)c3cc(Cl)ccc13,1,0.38,0.023,44,42,"Klotz U, Avant GR, Hoyumpa A, Schenker S, and Wilkinson (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man.  J. Clin. Invest. 55: 347-359.  Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, and Lundborg P (1990) Effect of omeprazole and cimetidine on plasma diazepam levels.  Eur. J. Clin. Pharmacol. 39: 51-54.  Herman RJ and Wilkinson GR (1996) Disposition of diazepam in young and elderky subjects after acute and chronic dosing.  Br. J. Clin. Pharmacol. 42: 147-155.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.    Molec. Pharmacol. 12:  612-619.  Desmond PV, Roberts RK, Wood AJJ, Dunn GD, Wilkinson GR, and Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175.",,,1961,284.74,3,0,32.7,1,neutral,2.8,2.8
Diazoxide,364-98-7,CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,0.21,0.06,0.06,58,48,"Oglivie RI, Nadeau JH, and Sitar DS (1982) Diazoxide concentration-response relation in hypertension. Hypertension 4: 167-173.   Kirsten R, Nelson K, Kirsten D, and Heintz B (!988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",,,1961,230.67,4,1,58.5,0,neutral,1.2,1.2
Dibekacin,34493-98-6,NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1,0.13,0.8,,2.7,2.4,"Arancibia A, Chavez J, Ibarra R, Ruiz I, Icarte A, Thambo S, and Chavez H (1987) Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.  Int. J. Clin. Pharmacol, Ther. Toxicol. 25: 38-43.  Goto M, Sugiyama M, and Ishizaki T (1980) Pharmacokinetic studies with dibekacin, a new aminoglycoside, after intravenous and intramuscular administration to human volunteers.  Antimic. Agents Chemother. 18: 372-376.",Plasma concentrations measured with a bioassay.,,1971,451.52,13,9,247.9,6,cationic,-6,-8
Dichloroacetic Acid,79-43-6,OC(=O)C(Cl)Cl,0.19,5.3,,0.6,0.65,"Jia M, Coats B, Chadha M, Frentzen B, Perez-Rodriguez J, Chadik PA, Yost RA, Henderson GN, and Stacpoole PW (2006) Human Kinetics of Orally and Intravenously Administered Low-Dose 1,2-13C-Dichloroacetate.  J. Clin. Pharmacol.  46: 1449-1459.",,,1885,128.94,2,1,37.3,1,anionic,0.9,-2.5
Diclofenac,15307-86-5,OC(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl,0.22,3.5,0.005,1,1.4,"Willis JV, Kendall MJ, Flinn RM, Thornhill DP, and Welling PG (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration.  Eur. J. Clin. Pharmacol. 16: 405-410.  Leucuta SE, Rus V, Bolosiu H, Mocan A, Polinicencu C, and Bojita M (1996) Farmacocinetica diclofenacului sodic administrat in doza unica pe cale intravenosa si orala sub forma de solutie injectabilia experimentala.  Farmacia 43: 43-50.  Chan KKH, Vyas KH, and Brandt KD (1987) In vitro protein binding of diclofenac sodium in plasma and synovial fluid.    J. Pharm. Sci. 76: 105-108.",VDss calculated using micro rate constants and exponential fit parameters reported in the references.  ,,1968,296.15,3,2,49.3,4,anionic,4,1.1
Dicloxacillin,3116-76-5,Cc1onc(c1C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O)c4c(Cl)cccc4Cl,0.11,2,0.033,0.92,0.88,"Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 9, 42-48.  Roder BL, Frimodt-Moller, Espersen F, and Rasumussen SN (1995) Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bacteriocidal titers in healthy subjects after oral administration.  Infection 23: 107-112.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  ",,1964,470.33,8,2,113,4,anionic,3.3,0.023
Didanosine,69655-05-6,OC[C@@H]1CC[C@@H](O1)n2cnc3C(=O)NC=Nc23,0.77,11,0.95,1.2,1.4,"Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR, Pittman KA, and Barbhaiya RH (1991) Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.  Clin. Pharmacol. Ther. 49: 523-535.  Videx Product Label.","2',3'-Dideoxyinosine, NSC612049",,1979,236.23,7,2,88.7,2,neutral,-0.93,-0.95
Didemnin B,77327-05-0,N1(C([C@H]2N(C([C@@H](NC([C@H](C([C@@H](OC(C[C@@H]([C@H](NC([C@H]([C@H](OC([C@@H]1Cc1ccc(cc1)OC)=O)C)NC([C@H](N(C([C@H]1N(C(=O)[C@@H](O)C)CCC1)=O)C)CC(C)C)=O)=O)[C@H](CC)C)O)=O)C(C)C)=O)C)=O)CC(C)C)=O)CCC2)=O)C,1.42,12.22,,1.94,4.8,"Benvenuto J A; Newman R A; Bignami G S; Raybould T J; Raber M N; Esparza L; Walters R S. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. Investigational new drugs 1992, 10, 113-117.",NSC-325319. 10 patients and 13 courses. 1.73 m2/70 kg conversion factor. 5.6 to 76 mg/m2 doses. Average across all courses. ,,1981,1112.35,22,5,287.9,15,neutral,3.5,3.5
Dienogest,65928-58-7,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,0.6,1.29,0.1,8.52,11,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022252_Orig-1_ClinPharmR.pdf Accessed May 19 2017,Dinagest. Visanne. ZK 37659. Average weight assumed to be 70 kg. 85 mcg 3H-dienogest. MRT from VDss and clearance.,,1977,311.42,3,1,61.1,2,neutral,2.1,2.1
Diflomotecan,220997-97-7,[H]O[C@]1(CC)CC(=O)OCC2=C1C=C1c3c(CN1C2=O)cc1cc(c(cc1n3)F)F,1.42,8.42,0.125682021,3.87,3.1,"Scott L; Soepenberg O; Verweij J; de Jonge M J A; Th Planting A S; McGovern D; Principe P; Obach R; Twelves C. A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-​min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Annals of Oncology, 2007, 18(3), 569-575.    fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",Data corrected for body surface area from weight averaged 0.05-0.15 mg/m2 iv infusion (20 min) doses (N=3 to N=11) (see Table 5). Conversion of 1.73 m2 to 70 Kg.,,1999,398.36,6,1,79.7,2,neutral,-0.7,-0.7
Diflunisal,22494-42-4,OC(=O)c1cc(ccc1O)c2ccc(F)cc2F,0.097,0.1,0.0016,14,10,Nuernberg B and Brune K (1989) Buffering the stomach content enhances the absorption of diflunisal in man.  Biopharm. Drug Dispos. 10: 377-387.   Lin JH (1989) Species differences in protein binding of diflunisal.  Drug Metab. Dispos. 17: 221-223.,Parameters calculated from a digitized C vs t plot provided in the report.  Note: N=1,,1968,250.2,3,2,57.5,2,anionic,3.7,0.31
Digitoxin,71-63-6,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C,0.44,0.043,0.066,170,180,"Ochs HR, Grube E, Greenblatt DJ, Arendt R, and Bodem G (1981) Pharmacokinetics and pharmacodynamics of intravenous digoxin and digitoxin.  Klin. Wochenschr. 59: 889-897.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",VDss calculated using C vs t data obtained from digitization of a plot reported in the reference.,,1907,764.94,13,5,182.8,7,neutral,1.2,1.2
Digoxin,20830-75-5,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C,4.1,1.7,0.7,40,38,"Cusack B, Kelly J, O'Malley K, Noel J, Lavan J, and Horgan J (1979) Digoxin in the elderly: pharmacokinetic consequences of old age.  Clin. Pharmacol. Ther. 25: 772-776.  Ohnhaus EE, Spring P, and Dettli L (1972) Protein binding of digoxin in human serum.    Eur. J. Clin. Pharmacol.  5: 34-36.",VDss calculated using C vs t data obtained from digitization of a plot reported in the reference.,,1930,780.94,14,6,203.1,7,neutral,0.21,0.21
Dihydrocodeine,125-28-0,CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](CC[C@H]3[C@H]1C5)O)OC,1.07,4.21,,4.08,3.42,"F. J. Rowell, R. A. Seymour, and M. D. Rawlins. Pharmacokinetics of Intravenous and Oral Dihydrocodeine and its Acid Metabolites. Eur J Clin Pharmacol 1983, 25, 419-424.","Values calculated from A,B, alpha and beta constants reported for N=7 volunteers, 30 mg dose, average weight 70 kg. VDss calculated via V1 and k12,k21 as wellas MRT and clearance obtained via macroconstants. ",,1912,301.38,4,1,41.9,1,cationic,2,0.29
Dihydroergosine,7288-61-1,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C)NC(=O)[C@@H]4C[C@@H]5c6cccc7c6c(c[nH]7)C[C@H]5N(C4)C)O,4.02,12.85,,5.01,8.84,"Cvelbar, Polona; Culig, J.; Kopitar, Z.; Lenardic, A.; Urbancic-Smerkolj, Janja; Zorz, M. Bioavailability of dihydroergosine in healthy volunteers. Proc. - 3rd Eur. Congr. Biopharm. Pharmacokinet., 1987, Volume 3, 147-53","N=8, 0.75 mg dose, 75 kg median weight. Clearance recalculated from dose and AUC. Erroneously reported as 0.96 mL/min when it should have been 0.96 L/min.",Nice example of enterohepatic recirculation.,1943,549.66,10,3,118.2,4,cationic,3.7,3.2
Dihydroergotamine,511-12-6,N12[C@@]([C@H]3N(CCC3)C([C@@H]1Cc1ccccc1)=O)(O[C@](NC([C@@H]1C[C@@H]3c4c5c(c[nH]c5ccc4)C[C@H]3[N@@](C1)C)=O)(C)C2=O)O,0.33,15.07,0.07,0.36,0.55,"J. KANTO, H. ALLONEN, K. KOSKI, M. KOULU, R. LAMMINTAUSTA, R. MANTYLA, T. KLEIMOLA, and T. SIlRTOLA. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neuroiogical patients after a single intravenous injection. ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20148s7s8lbl.pdf. Accessed May 10 2017.","N=5, 70 kg average weight reported, 1 mg dose. MRT from clearance and VDss. Data were also digitized and, although the digitization was difficult, the VDss is very close to reported with a clearance somewhat inferior but within 20%. The data reported were deemed more reliable than those in Little et al and Wyss et al.","Data from Wysss et all seems inconsistent with labeling of plot and results after digitization. P. A. Wyss, J. Rosenthaler, E. Niiesch, and W. H. Aellig. Pharmacokinetic investigation of oral and IV dihydroergotamine in healthy subjects. Eur. J. Clin. Pharmacol. 1991 41, 597-602. Intially digitized and then discarded. Similarly, data digitized from Little et al. seemed to agree with Kanto et al but differed (~25% in clearance) even when the AUC was corrected to being only 10% different fom the data reported by Little and co-authors. Br. J. Clin. Pharmacol. 1982, 13 785-790.",1942,583.68,10,3,118.2,4,cationic,3.8,3.3
Dihydroquinidine,1435-55-8,CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c3ccnc4ccc(OC)cc34,2.8,4.2,0.22,11,5.7,"Ueda CT, Williamson BJ, and Dzindzio BS (1976) Disposition kinetics of dihydroquinidine following quinidine administration.  Res. Comm. Chem. Path. Pharmacol. 14: 215-225.  Leroyer R, Varoquaux O, Guillebastres R, Jarreau C, Normand JP, Jaillon P, Advenier C, and Pays M (1986) Study on protein binding of 3-(R)- and 3-(S)-hydroxy derivatives of quinidine and dihydroquinidine.  Therapie  41: 159-162.",,,1913,326.43,4,1,45.6,4,cationic,3.2,1.7
Dilevalol,75659-07-3,C[C@H](CCc1ccccc1)NC[C@H](O)c2ccc(O)c(c2)C(=O)N,4.8,29,,2.8,3.3,"Neubeck M, Becker C, Henke D, Roesch W, Spahn-Langguth H, and Mutschler E. (1993) Pharmacokinetics of dilevalol and its conjugates in man: assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies.  Arz. Forsch. 43: 953-957.",,,1980,328.41,5,4,95.6,8,cationic,1.8,0.97
Diltiazem,42399-41-7,COc1ccc(cc1)[C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(=O)C,4.1,13,0.18,5.3,5.6,"Hoglund P and Nilsson LG (1988) Physiological disposition of intravenously administered 14C-labeled diltiazem in healthy volunteers.  Ther. Drug Monit. 10: 401-409.  Kolle EU, Ochs HR, and Vollmer KO (1983) Pharmacokinetic model of diltiazem.  Arz. Forsch. 33: 972-977.  Kirsten R, Nelson K, Kirsten D, and Heintz B (!988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.",Different values reported for terminal phase half-life in the Hoglund and Nillson vs the Kolle et al reports.,,1973,414.52,6,0,59.1,7,cationic,3.1,2.7
Dimetindene,5636-83-9,C=1(c2c(cccc2)CC1CCN(C)C)[C@@H](c1ccccn1)C,2.16,4.83,,5.98,4.6,"Arnera, V.; Wermeille, M.; Wellman, M.; Llull, J. B.; Althaus, M. A.; Balant, L. P. Pharmacokinetics of dimetindene after intravenous and oral administration to healthy volunteers. Arzneimittel-Forschung, 1990, 40, 1346-1348.","Data digitized from plot. AUCinf calculated within 2% of reported AUCinf. N=8, 4 mg dose, 75 kg median weight taken from reported range.",,1960,292.42,2,0,16.1,5,cationic,4,2.5
Dinaciclib,779353-01-4,c1(cc(nc2n1ncc2CC)N1[C@@H](CCCC1)CCO)NCc1cn(=O)ccc1,0.32,4.65,,1.1,2.1,"John J Nemunaitis, Karen A Small, Paul Kirschmeier, Da Zhang, Yali Zhu, Ying-Ming Jou, Paul Statkevich, Siu-Long Yao and Rajat Bannerji. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. Journal of Translational Medicine 2013, 11:259 (page1-14)","Data digitized from plot reported and compared to AUC in supplementary information. Day 1, 12 mg/m2, N=11. AUC(inf) 92% of reported. 70 kg weight assumed.",,2004,396.49,8,2,88.7,7,neutral,0.88,0.88
Diphenhydramine,58-73-1,CN(C)CCOC(c1ccccc1)c2ccccc2,6.5,9.8,0.19,11,9.3,"Meredith CG, Christian CD, Johnson RF, Madhavan SV, and Schenker S (1984) Diphenhydramine disposition in chronic liver disease.  Clin. Pharmacol. Ther. 35: 474-479.  Spector R, Choudhury AK, Chiang CK, Goldberg MJ, and Ghoneim MM (1980) Diphenhydramine in Orientals and Caucasians.  Clin. Pharmacol. Ther. 28: 229-234.",,,1945,255.35,2,0,12.5,6,cationic,3.5,2.3
Diprafenone,81447-80-5,CCC(C)(C)NCC(O)COc1ccccc1C(=O)CCc2ccccc2,1.2,11,0.017,1.9,1.5,"Trenk D, Wagner F, Sachs W, and Jaehnchen E (1989) Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man.    Eur. J. Clin. Pharmacol. 37: 313-316.",,,1983,369.5,4,2,58.6,11,cationic,4,2
Diprophylline,479-18-5,CN1C(=O)N(C)c2ncn(CC(O)CO)c2C1=O,0.42,4.8,,1.5,1.7,Zuidema J and Merkus FWHM (1981) Pharmacokinetics and pharmacodynamics of diprophylline.  Pharm. Weekbl. 3: 1320-221.,Diphyllin. Propyphillin. VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.,,1902,254.24,8,2,98.9,3,neutral,-1.2,-1.2
Dipyridamole,58-32-2,c12c(c(N3CCCCC3)nc(n2)N(CCO)CCO)nc(N(CCO)CCO)nc1N1CCCCC1,0.82,2,0.009,6.8,13,"Bjornsson TD, Mahony C. Clinical pharmacokinetics of dipyridamole. Thromb Res Suppl. 1983, 4, 93-104.","Data from digitization of PK profile reported in Fig 2 in reference. Dose 20 mg 4min infusion, N=6, BW = 60 kg. Reported data in table 1 : CL (mL/min/kg) = 2.3  t1/2(h) = 11.6, Vz(L/kg) = 2.35. Vz from digitization = 2.3 L/kg",,1939,504.63,12,4,145.4,12,cationic,2,1.4
Disopyramide,3737-09-5,CC(C)N(CCC(C(=O)N)(c1ccccc1)c2ccccn2)C(C)C,0.52,0.9,0.16,9.6,7,"Lima JJ, Haughey DB, and Leier CV (1984) Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.  J. Pharmacokinet. Biopharm. 12: 289-313.",,,1962,339.47,4,1,59.2,8,cationic,2.2,-0.11
Distigmine,17299-00-2,c1(OC(N(CCCCCCN(C(Oc2c[n+](ccc2)C)=O)C)C)=O)c[n+](ccc1)C,1,0.2,,82.4,59.8,"Vree TB, Waitzinger J, Hammermaier A, Radhofer-Welte S.Absolute bioavailability, pharmacokinetics, renal and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine-bromide in healthy volunteers. International journal of clinical pharmacology and therapeutics, 1999,37, 393-403.","UBRETID. CAS number and SMILES entered dication only (no Br-). N=6, 86.2 kg average weight. 3' infusion. Bromide salt CAS # = 15876-67-2",85% excreted unchanged after renally (14.8 mL/min vs. totl of 17.1 mL/min) from ref. cited.,1957,416.51,8,0,66.8,11,neutral,-5.7,-5.7
Disufenton sodium,168021-79-2,[Na+].[Na+].c1(cc(c(cc1)\C=[N+](\C(C)(C)C)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-],0.18,1.35,0.6,2.2,3.6,"Cheng Y.-F et al. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: A phase I, randomized, double blind (within dose panel) , placebo-controlled study in healthy chinese volunteers. (2008) Clin. Ther. 30, 2342-2353.",NXY059. CXY 059 and cerovive. N=27 chinese subjects and 28 caucasian subjects. Weight 60.8 and 72. 6 kg respectively. Chinese subjects averaged across doses and data for noncompartmental analysis reported. Overall average reported. Also as CXY 059 and cerovive.,,1995,381.33,8,0,140.5,3,neutral,-3.5,-8.5
Dixyrazine,2470-73-7,CC(CN1CCN(CC1)CCOCCO)CN2c3ccccc3Sc4c2cccc4,4.06,16.27,,4.16,3.11,"Liedholm H, Lidén A, Kroon L, Melander A, Wåhlin-Boll E. Pharmacokinetics of dixyrazine: low bioavailability improved by food intake. Drug-Nutr. Interact. 1985, 3, 87-92","N =8, median weight 64 kg, 10 mg dose equivalent to 23386 nmol or 365.4 nmol/kg (MW 427.61). Data digitized from plot. First point digitized separately due to Y-axis ""break"". AUC0-12 reported as 2.5-fold of actual to normalize to po dose. After correction calculated AUC0-12 within 6% of reported value. ",,1958,427.6,5,1,39.2,9,cationic,3.8,3
Dobesilic acid,88-46-0,O=S(=O)(O)c1c(O)ccc(O)c1,0.12,0.87,,2.41,2.01,"G. Franke, T. Schneider, W. Siegmund, A. Scherber. Bioavailability studies of calcium dobesilate- a case of flip-flop kinetics. Pharmazie, 1985, 40, 562-563. ","N=10, iv bolus, 500 mg dose, 68.7 kg average weight. AUCinf digitized 139.7 mg.h.L-1, reported 139 mg.hr.L-1 (AUC0-t digitized 137.4 mg.hr.L-1). ",Administered as calcium salt. Structure and CAS# refers to neutral compound.,1923,190.17,5,3,94.8,1,neutral,-1.1,-4
Dobutamine,34368-04-2,c1(cc(CCN[C@@H](CCc2ccc(cc2)O)C)ccc1O)O,,115,,,,"R A Berg, J F Padbury, R L Donnerstein, S E Klewer, J J Hutter, Jr. Dobutamine pharmacokinetics and pharmacodynamics in normal children and adolescents.  J.Pharmacol. Exp. Ther. 1993 265 (3) 1232-1238.",No other data reported.,,1974,301.38,4,4,72.7,7,cationic,3.4,1.7
Docetaxel,114977-28-5,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6)C(=C([C@@H](O)C3=O)C5(C)C)C,2.1,14,0.04,2.5,11,"Rosing H, Lustig V, van Warmerdam LJC, Huizing MT, ten Bokkel Huinink WW, Schellens JHM, Rodenhuis S, Bult A, and Beijnen JH (2000) Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.    Cancer Chemother. Pharmacol. 45: 213-218.  Minami H, Kawada K, Sasaki Y, Igarashi T, Saeki T, Tahara M, Itoh K, and Fujii H (2006) Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients.  Cancer Sci.  97: 235-241.",,,1988,807.88,15,5,224.4,12,neutral,3,3
Dofetilide,115256-11-6,CN(CCOc1ccc(NS(=O)(=O)C)cc1)CCc2ccc(NS(=O)(=O)C)cc2,3.3,5.2,0.36,11,8.1,"Gemmill JD, Howie CA, Meredith PA, Kelman AW, Rasmussen HS, Hillis WS, and Elliott HL (1991) A dose ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers.  Br. J. Clin. Pharmacol. 32: 429-432.  Smith DA, Rasmussen HS, Stopher DA, and Walker DK (1992) Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man.  Xenobiotica 22: 709-719.",,,1987,441.56,8,2,104.8,11,cationic,1.9,1.2
Dolasetron,115956-12-2,O=C(O[C@@H]1C[C@@H]2CC3C[C@H](C1)N2CC3=O)c4c[nH]c5ccccc45,2,180,0.49,0.19,0.13,"Dimmit DC, Choo YS, Martin LA, Arumugham T, Hahne WF, and Weir SJ (1999) Intravenous pharmacokinetcs and absolute oral bioavailability of dolasetron in healthyl volunteers: part 1.  Biopharm. Drug Disp. 20, 29-39. ppb: Stuart W. Paine, Karelle Menochet, Rebecca Denton, Dermot F. McGinnity, and Robert J. Riley. Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption, Drug Metab. Disp. 2011, 39:1008–1013",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1988,324.37,5,1,62.4,3,cationic,3.3,2.4
Domperidone,57808-66-9,Clc1ccc2N(C3CCN(CCCN4C(=O)Nc5ccccc45)CC3)C(=O)Nc2c1,3.4,9.5,0.082,6,7.5,"Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, and Reyntjens H (1981) On the pharmacokinetics of domperidone in animals and man.  IV.  The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.  Eur. J. Drug Metab. Pharmacokinet.  6: 61-70. ","VD calculated from micro rate constants reported in the paper by Heykants, et al.",,1977,425.91,7,2,67.9,5,cationic,3.6,3.1
Dopamine,51-61-6,c1(cc(c(O)cc1)O)CCN,0.74,65.9,0.87,0.19,0.42,"Data digitized from Fig. 1 P.-0. JARNBEG, L. BENGTSSOJN, E KSTRANaD, B. HAMBERCER Dopamine Infusion in Man. Plasma Catecholamine Levels and Pharmacokinetics. Acta anaesth. scand. 1981, 25, 328-331.//ppb: Gunhild Franksson and Erik Änggård The Plasma Protein Binding of Amphetamine,  Catecholamines and  Related Compounds. Acta Pharmacol. Toxicol.1970, 28,  209-214.","N=8 for 2 and 5 ug/kg/min, 30' infusion. Data digitized from Fig.1",,1910,153.18,3,3,66.5,2,cationic,0.56,-2
Doripenem,148016-81-3,[H]N1C[C@@H](C[C@H]1CN([H])S(N([H])[H])(=O)=O)SC1=C(C(=O)O[H])N2C([C@@H]1C)[C@@H](C2=O)[C@H](C)O[H],0.23,3.26,0.92,1.2,1.2,"Cirillo I. et al. Pharmacokinetics, safety and tolerability of doripenem after 0.5-, 1- and 4-hour infusions in healthy volunteers. J. Clin. Pharmacol. 2009, 49, 798-806.","N=96, average weight 72.1 kg. Data reported as weighted average of 5 dosing regimens (infusions) from 500 to 1000 mg and 0.5 to 4 hours. Average VDss 16.96 L and clearance 14.12 L/h. renal clearance 10.3 L/h = 2.38 ml/min/kg or 73% of total clearance.",,1993,420.5,10,5,162.1,10,zwitterionic,-1.5,-3.9
Doxacurium,133814-18-3,COc1cc(CC2c3c(CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]4(C)CCc5cc(OC)c(OC)c(OC)c5C4Cc6cc(OC)c(OC)c(OC)c6)cc(OC)c(OC)c3OC)cc(OC)c1OC,0.22,2.7,0.53,1.4,1.7,"Cook DR, Freeman JA, Lai AA, Robertson KA, Kang Y, Stiller RL, Aggarwal S, Abou-Donia MM, and Welch RM (1991) Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. Anesth. Analg. 72: 145-150.   Roy JJ and Varin F (2004) Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",,,1990,1035.22,18,0,163.4,29,neutral,0.57,0.57
Doxapram,309-29-5,CCN1CC(CCN2CCOCC2)C(C1=O)(c3ccccc3)c4ccccc4,1.2,5.3,,3.7,4.1,Robson RH and Prescott LF (1978) A pharmacokinetic study of doxapram in patients and volunteers.  Br. J. Clin. Pharmacol. 7: 81-87.  ,VDss calculated from digitized from plot reported,,1963,378.51,4,0,32.8,6,neutral,3.2,3.1
Doxazosin,74191-85-8,COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4COc5ccccc5O4,1.3,1.6,0.017,14,10,"Meredith PA, Elliott HL, Kelman AW, and Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoreceptor agonists in normotensive volunteers.  J. Cardiovasc. Pharmacol. 7: 532-537.  Vincent J, Meredith PA, Elliott HL, and Reid JL (1986) The pharmacokinetics of doxazosin in elderly normotensives.  Br. J. Clin. Pharmacol. 21: 521-524.  Kaye B, Cussans NJ Faulkner JK, Stopher DA, and Reid JL (1986) The metabolism and kinetics of doxazosin in man, mouse, rat and dog.    Br. J. Clin. Pharmacol. 21(Suppl. 1): 19S-25S.",,,1979,451.48,10,1,112.3,4,neutral,2.6,2.6
Doxepin,1668-19-5,CN(C)CC\C=C\1/c2ccccc2COc3ccccc13,12,14,0.2,15,15,"Yan JH, Hubbard JW, McKay G, Korchinski ED, Midha KK (2002) Absolute bioavailability and stereoselective pharmacokinetics of doxepin.    Xenobiotica 32: 615-623.  Virtanen R, Iisalo E, and Irjala K (1982) Protein binding of doxepin and desmethyldoxepin.  Acta Pharmacol. Toxicol.  51: 159-164.",Z- and E isomer data were averaged.,,1962,279.38,2,0,12.5,3,cationic,4.2,2.8
Doxifluridine,3094-09-5,C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=C(F)C(=O)NC2=O,0.28,11,0.61,0.46,0.35,"Schaaf LJ, Dobbs BR, Edwards IR, and Perrier DG (1988) The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.  Eur. J. Clin. Pharmacol. 34: 439-443.  Meynial D, Lopez A, Malet-Martino MC, Hoffmann JS, and Martino R (1988) Application of fluorine-19 nuclear magnetic resonance to the determination of plasma-protien binding of 5'-deoxy-5-fluorouridine, a new antineoplastic fluoropyrimidine.  J. Pharm. Biomed. Anal. 6: 47-59.",Concentration dependent; fu data cited is for the lowest concentration.,,1958,246.19,7,3,99.1,1,neutral,-1.3,-1.5
Doxofylline,69975-86-6,c12c(n(c(=O)n(c2=O)C)C)ncn1CC1OCCO1,1.03,6.83,,2.5,1.66,"Bologna E; Lagana A; Terracino D; Bolignari P; Biffignandi P. Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis. The Journal of international medical research. 1990, 18, 282-288.","Data digitized from plot. 100 mg dose. 66 average weight reported. Systemic clearance in text reported as 6.90 mL.min-1.kg-1 and in very good agreement with calculations. However, clearance reported in table 1 and labeled total clearance (in mL/min) was 683.6. Divided by 66 kg weight yields 10.35 mL.min-1.kg-1. Also, sd for clearance much lower than actual from the values reported. sd reported 197.8 mL.min-1, calculated from data reported 484.5 mL.min-1. ",,1978,266.25,8,0,80.3,2,neutral,-0.36,-0.36
Doxorubicin,23214-92-8,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,22,15,0.28,24,32,"Carmaggi CM, Comparsi R, Strocchi E, Testoni F, Angelli B, and Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics.  Canc. Chemother. Pharmacol. 21: 221-228.  Piscitelli SC, Rodvold KA, Rushing DA, and Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.  Clin. Pharmacol. Ther. 53: 555-561.  Eksborg S, Ehrsson H, and Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to adriamycin.    Cancer Chemother. Pharmacol. 10: 7-10.","Adriamycin, Adriblastin.",,1971,543.52,12,6,206.1,5,cationic,0.46,-2.2
Doxycycline,564-25-0,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=C(C(=O)N)C(=O)[C@@]3(O)C(=C2C(=O)c4c(O)cccc14)O)O,0.69,0.46,0.12,25,14,"Nguyen VX, Nix DE, Gillikin S, and Schentag JJ (1989)  Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.  Antimic. Agents Chemother. 33: 434-436.  Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, and Tillement JP (1983) The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.  Br. J. Clin. Pharmacol. 16: 245-252.  Raghuram TC and Krishnaswamy K (1982) Pharmacokinetics and plasma steady-state levels of doxycycline in undernutrition.  Br. J. Clin. Pharmacol. 14: 785-789.",,,1958,444.43,10,6,181.6,2,anionic,-0.64,-3.3
DP-b99,222315-88-0,CCCCCCCCOCCOC(=O)CN(CC(=O)O)c1ccccc1OCCOc2ccccc2N(CC(=O)O)CC(=O)OCCOCCCCCCCC,1.1,14,,1.3,3.5,"Rosenberg G, Angel I, and Kozak A (2005) Clinical pharmacology of DP-b99 in healthy volunteers: First administration to humans.  Br. J. Clin. Pharmacol. 60: 7-16. ",,,1999,788.96,14,2,170.6,37,anionic,8.9,4.4
DQ-2556,102253-70-3,c1cc(cc[n+]1CC1=C(N2C([C@H]([C@H]2SC1)NC(=O)\C(=N\OC)c1nc(sc1)N)=O)C(=O)[O-])c1cnco1,0.22,1.76,,2.64,1.78,"M. Nakashima, T. Uematsu, M. Kanamaru,  A. Mizuno, K. Matsubayashi, 0. Okazaki,  S. Hashimoto,  H. Hakusui,  and Y. Osada. Phase I Study of DQ-2556, a New Parenteral 3-Quaternary Ammonium Cephalosporin Antibiotic. J Clin Pharmacol. 1993, 33,57-62","Data from Table I (5 minutes infusion) N=5/dose across 3 doses (500, 1000 and 2000 mg). 67.5 average weight reported. MRT from VDss and clearance.",Renal clearance 82%,1985,541.56,13,2,180.3,8,anionic,-1.6,-0.63
Dronedarone,141626-36-0,CS(=O)(=O)Nc1cc2c(c(oc2cc1)CCCC)C(=O)c1ccc(cc1)OCCCN(CCCC)CCCC,20,33.33,0.02,10,16,PDR. Accessed February 20 2013. http://www.pdr3d.com/detail.php?c=77881#section-14,MRT from VDss and Cl. 70 kg assumed. Ppb > 98%,,1992,556.76,7,1,89.1,18,zwitterionic,7.3,4.7
Droperidol,548-73-2,n1(c2c(cccc2)[nH]c1=O)C=1CC[N@@](CCCC(c2ccc(F)cc2)=O)CC1,1.41,8.92,,2.73,1.9,"Gupta, Suneel K.; Southam, Mary; Hwang, Stephen. Pharmacokinetics of droperidol in healthy volunteers following intravenous infusion and rectal administration from an osmotic drug delivery module. Pharm. Res. 1992, 9, 694-696.","76 kg average weight. 125 ug/hr, N=8. VDss from clearance and MRT reported.",,1963,379.43,5,1,58.1,6,cationic,3,0.54
Drotaverine,14009-24-6,CCOc1ccc(\C=C\2/NCCc3cc(OCC)c(OCC)cc23)cc1OCC,1.9,3.5,0.12,9,9.3,"Bolaji OO, Onyeji CO, Ogundani AO, Olugbade TA, and Ogunbona FA (1996) Pharmacokinetics and bioavailability of drotaverine in humans.  Eur. J. Drug Metab. Pharmacokinet. 21: 217-221.  Vargay Z, Deutsch T, Szatmari I, Szuts T, Varkonyi P, Kerpel-Fronius S, and Eckhardt S (1984) The fate of drtoaverine-acephyllinate in rat and man II.  Human pharmacokinetics of drotaverine-14C-acephyllinate.  Eur. J. Drug Metab. Pharmacokinet. 9: 17-29.",VDss calculated from C vs t data obtained by digitization of the data provided in the reference.,,1962,397.51,5,1,48.9,9,neutral,4.6,4.6
Duloxetine,116539-59-4,"s1cccc1[C@@H](Oc1cccc2c1cccc2)CCNC
",,8.57,0.04,,12,"Found through Pharmapendium. FDA. PDF(395k)
ANNEX I",VDss not reported. 70 kg assumed. ,,1988,297.41,2,1,21.3,6,cationic,4,2.5
DX-52-1,96251-59-1,c12[C@@H]([N@@]3[C@@H]([C@@H]4C[C@@H]([C@@H]([N@@]4C)[C@@H]3Cc1cccc2OC)C(=O)O)C#N)CO,0.23,3.06,,1.23,1.52,"Bunnell, Craig A.; Supko, Jeffrey G.; Eder, Joseph Paul, Jr.; Clark, Jeffrey W.; Lynch, Thomas J.; Kufe, Donald W.; Shulman, Lawrence N. Phase I clinical trial of 7-​cyanoquinocarcinol (DX-​52-​1) in adult patients with refractory solid malignancies. Cancer Chemotherapy and Pharmacology. 2001, 48, 347-355.","NSC607097. 1.73 m2/70 kg conversion factor used. VDss reported as 9.53 L/m2 and clearance 7.43 L/m2/h, in Table 4. N=12.",,1984,357.4,7,2,97,4,anionic,-0.018,-3.2
DX9065a,150612-55-8,CC(=N)N1CC[C@@H](C1)Oc2ccc(cc2)[C@H](Cc3ccc4ccc(cc4c3)C(=N)N)C(=O)O,1.55,1.86,,14.4,24.02,"Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Nobuyuki Murayama, MS, Makoto Tanaka, PhD, Satoshi Kunitada, PhD, Hirohisa Yamada, MS, Takashi Inoue, MS, Yasuko Terada, BS, Masami Fujita, MD, Yasuo Ikeda, MD. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66, 258-264.","Data for 24 patients (N=6/group) across 5, 10, 20 nd 30 mg doses. Median weight 61.7 kg reported. Structure and CAS number referring to  free base.",,1993,444.53,7,4,123.5,8,cationic,3.8,-1.3
E7107,630100-90-2,N1(CCN(CC1)C1CCCCCC1)C(=O)O[C@H]1C=C[C@@H]([C@H](OC(=O)C[C@@H](CC[C@@]1(C)O)O)C(=C\C=C\[C@](C[C@H]1O[C@@H]1[C@@H]([C@H](CC)O)C)(C)O)\C)C,10.1,47.9,,3.5,9.2,"Ferry A.L.M. Eskens, Francisco J. Ramos, Herman Burger, James P. O'Brien, Adelaida Piera, Maja J.A. de Jonge, Yoshiharu Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, Jose Baselga, and Josep Tabernero. Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors. Clin Cancer Res 2013;19:6296-6304.",70 kg assumed. Weighted average of multiple doses on day (table 3). MRT fromVDss and clearance. Data generally comparable between day 1 and 15.,,2003,718.96,11,4,152.5,11,cationic,5,4
E7974,610787-07-0,CC(C)[C@@H](\C=C(/C)\C(=O)O)N(C)C(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C(C)(C)C,1.26,0.97,,21.5,17.5,"A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors Rocha-Lima, Caio M.; Bayraktar, Soley; MacIntyre, Jessica; Raez, Luis; Flores, Aurea M.; Ferrell, Annapoorna; Rubin, Eric H.; Poplin, Elizabeth A.; Tan, Antoinette R.; Lucarelli, Antonio; Zojwalla, Naseem. Cancer (Hoboken, NJ, United States) 2012 , 118 (17), 4262-4270, ","Analog of Hemiasterlin. N=27, weight-averaged values across doses (0.18-0.58 mg/2). 70 kg average weight used. Averages from table 3:  VDss 88 L, Cl 4.09 L/h, t1/2 17.5 h  MRT from VDss and Cl.",,2003,437.62,7,2,89.9,8,anionic,4,1.4
Ecallantide,460738-38-9,N[C@@H](CCC(=O)O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H]1C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N4[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H]5C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC(=O)O)=O)CCCNC(N)=N)=O)[C@@H](O)C)=O)CSSC1)=O)CCSC)=O)CCCCN)=O)CCCCN)=O)CSSC5)=O)CCC(=O)O)=O)CCC(=O)O)=O)CC(C)C)=O)CO)=O)CCC(=O)O)=O)Cc1ccccc1)=O)CCCNC(N)=N)=O)CC(=O)N)=O)CCC(=O)N)=O)CC(=O)N)=O)=O)CCC(=O)O)=O)CSSC3)=O)=O)=O)Cc1ccc(cc1)O)=O)[C@@H](C)CC)=O)Cc1ccccc1)=O)CCC(=O)O)=O)CCC(=O)O)=O)=O)CCC(=O)N)=O)CCCNC(N)=N)=O)[C@@H](O)C)=O)Cc1ccccc1)=O)[C@@H](C)CC)=O)CC(=O)N)=O)Cc1ccccc1)=O)Cc1ccccc1)=O)Cc1c[nH]c3c1cccc3)=O)CCCNC(N)=N)=O)CCC4)=O)Cc1[nH]cnc1)=O)C)=O)C)=O)CCCNC(N)=N)=O)=O)CCC2)=O)=O)CC(=O)O)=O)CC(=O)O)=O)C)=O)CCCCN)=O)Cc1ccccc1)=O)C)=O)=O)Cc1ccccc1)=O)CO)=O)Cc1[nH]cnc1)=O)CCSC)=O)C)=O,0.18,1.6,,1.9,1.8,"PP. FDA Approval Package. 2009-May-31  PDF(4025k)
Clinical Pharmacology and Biopharmaceutics Review 125277/S-000 Part 01",N=24 across single dose and infusion times. 70 kg assumed. MRT from VDss and Cl.,,2004,7061.89,179,101,2895.9,246,anionic,-9,-9
Edaravone,89-25-8,N1(c2ccccc2)N=C(C)CC1=O,0.23,1.42,0.89,2.65,2.36,"Data from 20 mg dose iv profile shown in Fig. 2 of Hao Li,Kun Xu, Yongqing Wang, Hongwen Zhang, Tianping Li, Ling Meng, Xiaojian Gong, Haibo Zhang, Ning Ou and Jinman Ruan  
Phase I Clinical Study of Edaravone in Healthy Chinese Volunteers. Drugs RD 2012; 12 (2): 65-70.//ppb:Dao-quan Tang, Yin-jie Li, Zheng Li, Ting-ting Bian, Kai Chen, Xiao-xiao Zheng, Yan-yan Yu, Shui-shi Jiang. Study on the interaction of plasma protein binding rate between edaravone and taurine in human plasma based on HPLC analysis coupled with ultrafiltration technique.","Data digitized. Only dose 20mg 0.5h iv infusion, N=10 (5 male/ 5 female, mean body weight = 59.7kg from Table 1) has been used (Dose linearity)
Reported data (Table 2:
AUC0-t:  3.64 mg*h/L
AUC0-inf: 3.79 mg*h/mL
CL:  0.1 L/min (1.68 mL/min/kg)
t1/2:  2.34 h",,1891,174.2,3,0,32.7,1,neutral,2.2,2.2
Edotecarin,174402-32-5,OCC(CO)NN1C(=O)c2c(C1=O)c3c4ccc(O)cc4n([C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)c3c6[nH]c7cc(O)ccc7c26,1.45,25.3,,0.95,4.01,"Hurwitz, Herbert I.; Cohen, Roger B.; McGovren, J. Patrick; Hirawat, Samit; Petros, William P.; Natsumeda, Yutaka; Yoshinari, Tomoko. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2007, 59, 139-147.","PF-804950. J-107088. N=9, 15 mg/m2 iv infusion over 2 h. 1.73 m2/70 kg assumed. 
Reported AUC(0-last) 200 ± 49.3 ng.h.mL-1; calculated 240 ng.h.mL-1. 20% difference, data accepted.",,1995,608.55,15,10,241.2,6,anionic,-2.3,-2.8
Edoxaban,480449-70-5,c1(nc2c(s1)CN(CC2)C)C(=O)N[C@H]1[C@@H](NC(=O)C(=O)Nc2ncc(Cl)cc2)CC[C@H](C(=O)N(C)C)C1,1.53,5.19,0.5,4.91,6.7,"Nobuko Matsushima, Frank Lee, Toshiyuki Sato, Daniel Weiss, and Jeanne Mendell. Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clinical Pharmacology in Drug Development, 2013,  2, 358–366//ppb: Ogata, Koichiro; Mendell-Harary, Jeanne; Tachibana, Masaya; Masumoto, Hiroshi; Oguma, Toshihiro; Kojima, Masazumi; Kunitada, Satoshi Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers    J.  Clin. Pharmacol. 2010, 50: 743-753","N=35, 30 mg via 30' inf. 70 kg average weight assumed. MRT from Clearance and VDss.",,2003,548.06,11,3,136.6,6,neutral,1.5,1.3
Edrophonium,312-48-1,CC[N+](C)(C)c1cccc(O)c1,1.1,9.6,,1.9,1.8,"Morris RB, Cronnelly R, Miller RD, Stanski DR, and Fahey MR (1981) Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man.  Anesthesiol. 54: 399-402.",,,1950,166.24,2,1,20.2,2,neutral,-3.1,-3.2
Eletriptan,143322-58-1,CN1CCC[C@@H]1Cc2c[nH]c3ccc(CCS(=O)(=O)c4ccccc4)cc23,1.6,5.3,0.15,5,4.2,"Milton AK, Scott NR, Allen MJ, Abel S, Jenkins VC, James GC, Rance DJ, and Eve MD (2002) Pharmacokinetics, pharmacodynamics, and safety of the 5-HT1B/1D agonist eletriptan following intravenous and oral administration.  J. Clin. Pharmacol. 42: 528-539.  Relpax Product Label.",VDss was calculated from C vs t data obtained by digitization of the plot (0.102 mg/kg dose only) included in the reference.,,1992,382.52,4,1,53.2,6,cationic,3.7,2.2
Eliglustat,491833-29-5,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](c2ccc3c(c2)OCCO3)O,,20.95,0.21,,7.7,"CerdelgaTM, prescribing information. http://www.cerdelga.com/pdf/cerdelga_prescribing_information.pdf. Accessed December 8 2015.","88 L/h clearance reported in healthy human after 42 mg dose. T1/2 for EMs was 6.5 and for PMs it was 8.9. Median (7.7 h taken). 70 kg assumed. ppb 76 to 83%. a value of 0.21 was taken for fu (79% bound).The prescribing information states: 
After intravenous (IV) administration, the volume of distribution of eliglustat was 835 L in CYP2D6 EMs, suggesting wide distribution to tissues (CERDELGA is only for oral use). VD likely to be VDz.",,2003,404.54,6,2,71,11,cationic,3.2,2.4
Elinafide,162706-37-8,C(CCNCCN1C(=O)c2c(ccc3ccccc23)C1=O)NCCN1C(=O)c2c(ccc3ccccc23)C1=O,12,5.7,,35.2,52.6,"Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies Miguel A. Villalona-Calero, Joseph P. Eder, Deborah L. Toppmeyer, Lee F. Allen, Robert Fram, Raja Velagapudi, Michael Myers, Anthony Amato, Kathleen Kagen-Hallet, Betty Razvillas, Donald W. Kufe, Daniel D. Von Hoff, and Eric K. Rowinsky. Journal of Clinical Oncology, 2001 19, 857-869.",LU79553. N=14 across doses ranging from 2 to 24 mg/m2/day.,,1995,520.58,8,2,98.8,10,cationic,3.7,2.9
Elisidepsin,681272-30-0,CC[C@H](C)CCC(=O)N[C@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]2[C@H](OC(=O)[C@@H](NC(=O)/C(=C/C)/NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)[C@@H](C)CC)C(C)C)Cc3ccccc3)C(C)C)C,5.55,3.85,,24.02,74.1,"Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C, Gil M, Coronado C, Soto-Matos A, Cullell-Young M, Iglesias Dios JL, Evans TR. A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2012, 70, 673-681","PM02734 (with CAS 915713-02-9 as TFA salt). Highly variable t1/2 from 1h to 135 h as dose increased to a 10 mg flat dose. FROM THE REFERENCE: No drug accumulation between cycles was found. Mean plasma CL was 14.2 l/h, mean Vss was 563 l, and mean t1/2 was 108 h. Inter-patient variability for CL, Vss, and t1/2 after the first infusion was 38, 84, and 55 %, respectively. Intra- patient variability was lower (21, 72, and 36 %) but could only be assessed in 6 patients with available data for both infusions.",,2004,1477.87,30,14,442.1,33,cationic,5.8,3.4
Eltanolone,128-20-1,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2,22,0.01,1.5,4.7,"Dale O, Hynne H, Parivar K, Johansson E, and Widman M. Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. Acta Anaesthesiol. Scand. 1999, 43, 415-420.",Pregnanolone. ,,1937,318.49,2,1,37.3,1,neutral,4,4
Eltoprazine,98224-03-4,O1c2cccc(c2OCC1)N1CCNCC1,3.6,8,,10.5,8.2,"van Harten J, Mathlener IS, Raghoebar M. Pharmacokinetics of eltoprazine in healthy subjects. Drug Metabol Drug Interact. 1990;8(1-2):149-58.",N=20-22 (depending on data) across two doses of 3 and 8 mg. 1h infusion,,1985,220.27,4,1,33.7,1,cationic,0.93,-0.46
Enalaprilat,76420-72-9,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2CCC[C@H]2C(=O)O,0.38,1.6,0.62,4,39,"Hockings N, Ajayi AA, and Reid JL (1986) Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.  Br. J. Clin. Pharmacol. 21: 341-348.  Mujais  SK, Quintanilla A, Zahid M, Koch K, Shaw W, and Gibson T (1992) Renal handling of enalaprilat.    Am. J. Kidney Dis. 19: 121-125.",,,1980,348.39,7,3,106.9,8,anionic,0.73,-3.4
Enalkiren,113082-98-7,C(CC(C)(N)C)(N[C@H](C(N[C@@H](Cc1c[nH]cn1)C(N[C@H]([C@H]([C@@H](O)CC(C)C)O)CC1CCCCC1)=O)=O)Cc1ccc(cc1)OC)=O,0.11,0.45,0.07,3.1,1.72,"Gupta, SK; Granneman, GR; Boger, RS; Hollenberg, NK; Luther, RR. Simultaneous modeling of the pharmacokinetics and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor) I: single dose study. Drug Metab. Disp. 1992, 20, 821-825.ppb: Brian D. Dayton, Herman H. Stein, Jerome Cohen, William R. Baker, Steven A. Boyd, Stephen L. Condon, B. Gregory Donner, Anthony K. L. Fung, Jay R. Luly, Saul H. Rosenberg, Keith W. Woods, and Hollis D. Kleinert. Effects of Angiotensinase Inhibitors on Plasma Protein Binding and IC50 Determinations of Renin Inhibitors. CLIN. CHEM. 1992, 38, 2239-2243.","Abbott-64662. N=16, 70 kg average weight reported. 90 minutes infusion. Average dose 15.32 mg. VDss from 7 subjects. Data taken from Table 1.",,1979,656.86,12,7,191.7,18,cationic,2.5,0.16
Encainide,66778-36-7,COc1ccc(cc1)C(=O)Nc2ccccc2CCC3CCCCN3C,2.2,13,0.26,2.8,2.6,"Wensing G, Monig H, Ohnhaus EE, and Hoensch HP (1991) Pharmacokinetics of encainide in patients with cirrhosis.  Cardiovasc. Drugs Ther. 5: 733-740.   C Funck-Brentano, J Turgeon, RL Woosley, and DM Roden (1989) Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics.  Influence of genetic polymorphism.    Journal of Pharmacology and Experimental Therapeutics  249:  134-42.  Jaillon P (1990) Pharmacokinetics and metabolism of encainide.  Cardiovasc. Drugs Ther.  4(Suppl 3): 561-565.","EM data only from Funck-Bretano, et al. and Wensing et al. reports.",,1972,352.47,4,1,41.6,6,cationic,4.7,3
Endralazine,39715-02-1,N\N=C\1/NN=C2CCN(CC2=C1)C(=O)c3ccccc3,2.2,13,,2.7,5.6,"Reece PA, Cozamanis I, and Zacest R (1983) Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability.  Eur. J. Clin. Pharmacol. 25: 553-556.",,,1972,269.3,6,2,83.1,1,cationic,1.9,1.9
Enfuvirtide,159519-65-0,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3c[nH]c4c3cccc4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc5c[nH]c6c5cccc6)C(=O)N[C@@H](Cc7ccccc7)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc8cnc[nH]8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc9ccc(cc9)O)NC(=O)C,0.07,0.36,0.08,3.2,4,"PP data. 2003-Mar-27  PDF(1771k)
Clinical Pharmacology and Biopharmaceutics Review 021481/S-000 Part 01 ", 70 kg assumed. MRT from VDss and Cl. T 1/2 reported < 4 h.,,1994,4491.88,115,63,1902.9,151,anionic,-9,-9
Eniporide,176644-21-6,Cc1cc(c(cc1C(=O)NC(=N)N)S(=O)(=O)C)n2cccc2,1.1,8.2,,2.3,2.2,"Kovar A, Peters T, Beier N, and Derendorf H (2001) Pharmacokinetic/pharmacodynamic evaluation of the NHE inhibitor Eniporide.  J. Clin. Pharmacol. 41: 139-148.",,,1996,320.37,7,3,118,4,neutral,0.4,0.24
Enoxacin,74011-58-8,CCN1C=C(C(=O)O)C(=O)c2cc(F)c(nc12)N3CCNCC3,2,5.4,0.8,6.2,5.1,"Nix DE, Lebsack ME, Chapelsky M, Sedman AJ, Busch J, and Norman A (1993)  Effect of oral antacids on disposition of intravenous enoxacin.    Antimic. Agents Chemother. 37: 775-777.   Wise R, Lister D, McNulty CAM, Griggs D, and Andrews JM (1986) The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.  Infection  14: S196-S202.  Bergogne-Berezin E (2002)  Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750.",,,1980,320.32,7,2,85.8,3,zwitterionic,1.4,-1.1
Enoximone,77671-31-9,c1(C(c2ccc(SC)cc2)=O)c([nH]c([nH]1)=O)C,1.48,19.1,0.3,1.33,1.94,"SHlGEMlCHl MORITA, YONElCHl SAWAI, JOEL F . HEEG,  YUlCHl KOIKE. Pharmacokinetics of Enoximone after Various Intravenous Administrations to Healthy Volunteers. J. Pharm. Sci. 1995, 84, 152-157. Data averaged with Alken RG, Belz GG, Haegele KD, Meinicke T, and Schechter PJ (1984) Kinetics of fenoximone, a new cardiotonic, in healthy subjects. Clin. Pharmacol. Ther. 36: 209-216.  Hook RH, Boxenbaum H, Thompson GA, and Okerholm RA (1988) Human serum and plasma protein binding of enoximone and its sulfoxide metabolite.  J. Pharm. Sci. 77: 1012-1017. VDss 1.8 L/kg, clearance 29 mL/min/kg, MRT 1 h and t1/2 1 h.","doses from 0.25 mg/kg to 2 mg/kg N=6 for each dose. Data as average across doses. Fenoximone, same compound. Data weight-averaged. Enoximone kept",,1980,248.3,4,2,65.7,3,neutral,1.3,1.3
Enprofylline,41078-02-8,CCCN1C(=O)NC(=O)c2nc[nH]c12,0.63,4,0.55,2.6,1.8,"Lunell E, Borga O, and Alarsson R (1984) Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.  Eur. J. Clin. Pharmacol. 26: 87-93.  Kraan J, Borgstrom L, Koeter GH, Laseur M, Jonkman JHG, and deNoord OE (1988) Creation of four consecutive intantaneous steady-state plasma concentration plateaus of theophylline and enprofylline by repeated infusions with expoonentially decreasing delivery rates. Eur. J. Clin. Pharmacol. 35: 657-661.  Borga O, Larsson R, and Lunell E (1986) Effects of probenecid on enprofylline kinetics in man.  Eur. J. Clin. Pharmacol. 30: 221-223.  Tegner K, Borga O, and Svensson I (1983) Protein binding of enprofylline.  Eur. J. Clin. Pharmacol. 25: 703-708.",,,1973,194.19,6,2,78.1,2,anionic,-0.075,-1.4
Entacapone,130929-57-6,CCN(CC)C(=O)\C(=C\c1cc(O)c(O)c(c1)N(=O)=O)\C#N,0.27,12,0.02,0.38,2.4,"Heikkinen H, Saraheimo M, Antila S, Ottoila P, and Pentikainen PJ (2001) Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique.   Eur. J. Clin. Pharmacol. 56: 821-826.   Najib J (2001)  Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of parkinson's disease. Clin. Ther. 23: 802-832.",,,1988,305.29,8,2,130.4,6,anionic,1.6,-0.08
Epiroprim,73090-70-7,c1ccn(c2c(cc(Cc3c(nc(nc3)N)N)cc2OCC)OCC)c1,2.5,3.5,0.12,,9.4,"OLIVIER LUTTRINGER, FRANK-PETER THEIL, PATRICK POULIN, ANNE H. SCHMITT-HOFFMANN, THEODOR WALTER GUENTERT, THIERRY LAVE´ Physiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in Humans. J. Pharm. Sci. 2003, 92, 1990-2007","MRT from VDss and clearance. N=4, 100 mg dose.",,1980,353.42,7,2,101.2,7,neutral,3,2.9
Epirubicin,56420-45-2,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,45,20,0.25,38,36,"Carmaggi CM, Comparsi R, Strocchi E, Testoni F, Angelli B, and Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics.  Canc. Chemother. Pharmacol. 21: 221-228.  Carmaggi CM, Strocchi E, Martoni A, Angelelli B, Comparsi R, anmd Pannuti F (1985) Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.  Drugs Exptl. Clin. Res. 11: 285-294.  Eksborg S, Ehrsson H, and Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to adriamycin.  Canc. Chemother. Pharmacol. 10: 7-10. ppb reported as concentration dependent and lower than 0.25 (as fu) by Wei-zheng. Zhang, Walter Cosolo, John Zalcberg, In vitro Binding of MX2 (KRN8602) and Epirubicin to Human Plasma Protein. Pharmacol. 1997, 55, 279-284.",,,1975,543.52,12,6,206.1,5,cationic,0.46,-2.2
Epothilone folate,958646-17-8,Cc1nc(cs1)/C=C(\C)/[C@@H]2C[C@H]3[C@H](N3CCOC(=O)OCCSSC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)c4ccc(cc4)NCc5c[nH]c-6nc(nc(=O)c6n5)N)CCC[C@@H]([C@@H]([C@H](C(=O)C([C@H](CC(=O)O2)O)(C)C)C)O)C,0.09,2.46,,0.6,0.5,"P. P. Peethambaram, L. C. Hartmann, D. J. Jonker , M. de Jonge, E. R. Plummer, L. Martin,  J. Konner, J. Marshall, G. D. Goss, V. Teslenko, P. L. Clemens, L. J. Cohen, C. M. Ahlers, L. Alland. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agentin humans with advanced solid tumors.Invest New Drugs (2015) 33:321–331","BMS-743593. Data digitized from plot reported for Day 4. N=6, 17 mg dose, iv bolus.  No accumulation on Day 4 vs. day 1. Roughly linear from 10 mg to 33 mg dose. AUCinf 16% larger than reported (1648 vs. 1422 ng.hr.mL-1). Reported %CV 32%. 70 kg assumed.",,2007,1569.74,38,17,601.4,39,anionic,-1.9,-9
Epristeride,119169-78-7,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C=C(CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)O,0.54,0.33,0.03,27,27,"Benincosa LJ, Audet PR, Lundberg D, Zariffa N, and Jorkasky DK (1996) Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects.  Biopharm, Drug Dispos. 17: 249-258.  Li JT, Zheng Z, and Jin J (2000) Pharmacokinetics of epristeride in healthy male volunteers.  Zhongguo Linchuang Yaolixue Zazhi 16: 424-428.",,,1988,399.57,4,2,66.4,2,anionic,4.8,2.2
Eprosartan,133040-01-4,CCCCc1ncc(\C=C(/Cc2cccs2)\C(=O)O)n1Cc3ccc(cc3)C(=O)O,0.17,1.9,0.017,1.5,2.1,"Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, Zariffa N, Boyle D, Jorkasky D (1998)  Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food.  Biopharm. Drug Dispos. 19: 351-356.  Kovacs SJ, Tenero DM, Martin DE, Ilson BE, and Jorkasky DK (1999) Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.  Pharmacotherapy 19: 612-619. ",,,1990,424.51,6,2,92.4,10,anionic,4.4,-1.1
Eptaloprost,90693-76-8,[H]OC(CCCOCC=C1C[C@H]2C[C@H]([C@@H](C#C[C@H]([C@@H](C)CC#CCC)O[H])[C@H]2C1)O[H])=O,2.4,66.2,,0.59,0.41,"Hildebrand M, Inter-species Extrapolation of Pharmacokinetic Data of Three Procyclin-Mimetics, Prostaglandins, 1994, 48, 297-312."," t1/2=0.693/kel. 
Data reported and used for allometric scaling were taken from other publications by the same author.",,1984,402.52,5,3,87,15,anionic,3,0.22
Eptifibatide,188627-80-7,NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)C(Cc3c[nH]c4ccccc34)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O)C(=O)N,0.17,1.2,0.75,2.4,4.2,"Gretler D, Guerciolini R, and Williams PJ (2004) Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin. Ther. 26: 390-398.  Integrilin Product Label.",,,1993,831.96,20,11,323.9,11,zwitterionic,-3.2,-5.5
Eravacycline,1207283-85-9,CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(c(c4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)O)NC(=O)CN5CCCC5)F,2.3,3.71,0.18,10.3,,"Kevin P. Connors, Seth T. Housman, J. Samuel Pope, John Russomanno, Edward Salerno, Eric Shore, Susan Redican, David P. Nicolau. Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women. Antimicrobial Agents and Chemotherapy, 2014, 58 (4), 2113–2118.","N=20, 80 kg average weight reported. Footnote from table 1: Eravacycline was administered at 1.0 mg/kg every 12 h for seven doses. MRT from VDss and clearance. T1/2 not reported.",,2010,558.56,12,6,193.7,5,cationic,0.3,-3.9
Ergotamine,113-15-5,CN1C[C@@H](C=C2[C@H]1Cc3c[nH]c4cccc2c34)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](Cc8ccccc8)N6C5=O,3.6,15,0.02,4,2.1,"Ibraheem JJ, Paalzow L, and Tfelt-Hansen P (1985) Linear pharmacokinetics of intravenous ergotamine tartrate.  Eur. J. Clin. Pharmacol. 29: 61-66.",VDss calculated from compartmental parameters provided in the reference.,,1920,581.66,10,3,118.2,4,neutral,3.6,3.5
Eribulin,253128-41-5,NC[C@@H](O)C[C@H]5O[C@H]4C[C@H]9O[C@@H](CC[C@@H]1O[C@H](CC1=C)CC[C@@]32O[C@@H]6[C@@H]8O[C@H](C2)[C@H](O3)[C@@H]8O[C@H]7CC[C@H](CC(=O)O[C@@H]4[C@H]5OC)O[C@H]67)C[C@@H](C)C9=C,1.46,0.75,0.43,32.5,37.8,"A Phase I Study of EribulinMesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced SolidMalignancies
Sanjay Goel, Alain C.Mita, MonicaMita, Eric K. Rowinsky, Quincy S. Chu, NancyWong, Christopher Desjardins, FangF ang, Mendel Jansen, Dale E. Shuster,SridharMani,and Chris H.Takimoto. Clin Cancer Res 2009;15:4207-. ppb: The PDr reports: The human plasma protein binding of eribulin  at concentrations of 100 ng/mL to 1,000 ng/mL ranges from 49% to 65%. 57% taken as median. Accessed December 31 2014. http://www.pdr3d.com/detail.php?c=128591#section-12","E 7389. 0.25-1.4 mg/m2, 1.73m2/70kg conversion factor. Total number of patients 31. Weighted average",,1999,731.87,13,2,155.6,4,cationic,2.1,0.36
Eritoran,185955-34-4,CCCCCCCCCCCC(=O)CC(=O)N[C@H]1[C@@H](OP(=O)(O)O)O[C@H](CO[C@@H]2O[C@H](COC)[C@@H](OP(=O)(O)O)[C@H](OCC[C@@H](CCCCCCC)OC)[C@H]2NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](O)[C@@H]1OCCCCCCCCCC,0.048,0.013,,62,51,"Wong YN, Rossignol D, Rose JR, Kao R, Carter A, and Lynn M (2003) Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.  J. Clin. Pharmacol. 43: 735-742.  Rossignol DP, Wasan KM, Choo E Yau E, Wong N, Rose J, Moran J, and Lynn M (2004) Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.    Antimic. Agents Chemother. 48: 3233-3240.",Protein binding driven by lipoproteins--not reported directly,,1996,1313.66,21,7,293.6,59,anionic,9,1.7
Erlotinib,183321-74-6,n1cnc(c2cc(c(cc12)OCCOC)OCCOC)Nc1cc(ccc1)C#C,0.77,1.69,0.07,7.55,6.5,"A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin M. Ranson · H. Shaw · J. Wolf · M. Hamilton ·S. McCarthy · E. Dean · A. Reid · I. Judson. Cancer Chemother Pharmacol (2010) 66:53–58. ppb; The PDR states: Following absorption, erlotinib is approximately 93% protein bound to albumin and alpha-1 acid glycoprotein (AAG). Accessed december 31 2014. http://www.pdr3d.com/detail.php?c=3144#section-3","Data weighted across 25, 50 and 75 mg infusion doses. Median data reported and used.",,1996,393.44,7,1,74.7,11,neutral,3.8,3.8
Ertapenem,153832-46-3,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(=C(N2C1=O)C(=O)O)S[C@@H]3CN[C@@H](C3)C(=O)Nc4cccc(c4)C(=O)O,0.12,0.45,0.1,4.4,3.8,"Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, Mistry G, Hesney M, Xi L, Li SX, Haesen R, Blum RA, Lins RL, Greenberg H, Waldman S, Deutsch P, and Rogers JD (2002) Pharmacokinetics of ertapenem in healthy young volunteers.  Antimic. Agents Chemother. 46: 3506-3511.",Protein binding non-linear over the concentration range studied in vivo; median value used.,,1993,475.51,10,5,156.3,7,anionic,0.43,-4.8
Erythromycin,114-07-8,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,0.95,5.6,0.1,2.8,2,"Welling, PG; Craig, WA. Pharmacokinetics of Intravenous Erythromycin. Journal of phermaceutical Sciences 1978, 67(8), 1057-1059.",,,1951,733.93,14,5,193.9,7,cationic,1.8,0.47
Escin Ia,123748-68-5,C(O)[C@@]12[C@H](C3=CC[C@H]4[C@@]([C@@]3(C[C@H]2O)C)(C)CC[C@@H]2[C@]4(C)CC[C@@H]([C@@]2(CO)C)O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O)[C@@H](O)[C@@H]([C@H](O2)C(=O)O)O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)CC([C@H]([C@@H]1OC(=O)C)OC(=O)/C(=C/C)/C)(C)C,0.28,1.65,,2.85,2.4,"A liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of escin Ia and escin Ib in human plasma: application to a pharmacokinetic study after intravenous administration. Lidong Liu, Xiujun Wu,Dan Wu, Yingwu Wang, Pengfei Li, Yantong Sun, Yan Yang, Jingkai Gua and Yimin Cui. Biomed. Chromatogr. 2010; 24: 1309–1315",Data digitized from plots reported. 3 mg dose. N=10 70 kg average weight assumed. ,,1989,1131.26,24,13,388,16,anionic,-1.2,-4.5
Escin Ib,26339-90-2,C(O)[C@@]12[C@H](C3=CC[C@H]4[C@@]([C@@]3(C[C@H]2O)C)(C)CC[C@@H]2[C@]4(C)CC[C@@H]([C@@]2(CO)C)O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O)[C@@H](O)[C@@H]([C@H](O2)C(=O)O)O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)CC([C@H]([C@@H]1OC(=O)C)OC(=O)/C(=C\C)/C)(C)C,0.23,2.55,,1.5,1.8,"A liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of escin Ia and escin Ib in human plasma: application to a pharmacokinetic study after intravenous administration. Lidong Liu, Xiujun Wu,Dan Wu, Yingwu Wang, Pengfei Li, Yantong Sun, Yan Yang, Jingkai Gua and Yimin Cui. Biomed. Chromatogr. 2010; 24: 1309–1315",Data digitized from plots reported. 2 mg dose reported. Clearance not corresponding to calculated while AUC within 10%.  N=10 70 kg average weight assumed. ,,1989,1131.26,24,13,388,16,anionic,-1.2,-4.5
Esmolol,81147-92-4,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,1.2,290,0.59,0.07,0.15,"Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, and Lai CM (1983) Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin. Pharmacol. Ther. 34: 427-434.  Okamura M, Kumagai M, Murasaki Y, Ohkura T, Miyamoto Y, Kawai Y, Tamura T, Takariki Y, and Tomisawa H (2001) Stereoselective pharmacokinetics of esmolol enantiomers.  Yakubutsu Dotai 16: 427-435.",,,1981,295.37,5,2,67.8,10,cationic,2,0.18
Esomeprazole,119141-88-7,c12c([nH]c(n1)[S@@](Cc1c(c(c(C)cn1)OC)C)=O)ccc(c2)OC,0.2,3.85,0.03,0.9,0.83,"PP. FDA approval package. 2004-Jun-18  PDF(2708k)
Clinical Pharmacology and Biopharmaceutics Review 021689/S-000 ",MRT from VDss and Cl. 70 kg assumed. ,"Following single-dose oral administration of omeprazole, the majority of the dose (about 77%) is eliminated in urine as at least six metabolites. FIRST PASS.",1988,345.42,6,1,77.1,5,neutral,2.2,2.2
Estradiol,50-28-2,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,1.2,30,0.016,0.7,1.7,"Kuhnz W, Gansau C, and Mahler M (1993) Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17beta estradiol.  Arz. Forsch. 43: 966-973.  Bruning PF and Bonfrer JMG (1986) Free fatty acid concentrations correlated with the available fraction of estradiol in human plasma.  Cancer Res. 46: 2606-2609.",,,1946,272.38,2,2,40.5,0,neutral,3.7,3.7
Estramustine phosphate,4891-15-0,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(=O)(O)O,0.12,0.94,0.5,2.1,2.4,"Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, and Hartley-Asp B (2002) Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.  J. Clin. Oncol.  20: 1115-1127.  Gunnarsson PO, Andersson SB, Johansson SA, Nilsson T, and Plym-Forshell G (1984) Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.  Eur. J. Clin. Pharmacol. 26: 113-119.//ppb: Charles D. Smith, Jack T. Zilfou, Xinqun Zhang, Gary R. Hudes, and Kenneth D. Tew. Modulation of P-Glycoprotein Activity by Estramustine Is Limited by Binding to Plasma Proteins. Cancer, 1995,75, 2597-2604.","Compartmental model parameters from Gunnarsson, et al. were used in the calculation of VDss.",,1964,520.38,7,2,96.3,8,anionic,5,1
Ethacrynic Acid,58-54-8,CCC(=C)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,0.26,8.7,,0.5,0.5,"Lacreta FP, Brennan JM, Nash SL, Comis RL, Tew KD, and O'Dwyer P (1994) Pharmacokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer.  J. Pharmacol. Exp. Ther. 270:  1186-1191.",Edecrin,,1962,303.14,4,1,63.6,6,anionic,2.8,-0.46
Ethambutol,74-55-5,CC[C@@H](CO)NCCN[C@@H](CC)CO,1.7,10,0.18,2.7,3.1,"Lee CS Brater DC, Gambertoglio JG, and Benet LZ (1980) Disposition kinetics of ethambutol in man.  J. Pharmacokinet. Biopharm. 8: 335-346.   Holdiness MR (1984) Clinical pharmacokinetics of the antituberculosis drugs.  Clin. Pharmacokinet. 9: 511-544.",,,1961,204.31,4,4,64.5,9,cationic,-0.38,-2.5
Ethimizol,64-99-3,c1(c(ncn1CC)C(NC)=O)C(NC)=O,0.73,12.1,0.92,1,0.83,"Trnovec T; Soltes L; Durisova M; Kallay Z; Koprda V; Piotrovskii L B  Pharmacokinetics of ethimizol in man. Die Pharmazie (1985), 40(6), 410-1","N=5, dose 1 mg infusion, average weight reported 69.2 kg. ppb linear across two orders of magnitude concentration ~ 10-7 to 10-9 M)",,1961,210.23,6,2,76,3,neutral,-0.55,-0.55
Ethinylestradiol,57-63-6,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C,4.3,7,0.014,11,9.7,"Kuhnz W, Humpel M, Biere H, and Gross D (1996) Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women.  Eur. J. Clin. Pharmacol. 50: 231-235.  Kuhnz W, Pfeffer M, and Al-Yacoub G (1990) Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.  J. Ster. Biochem.  35: 313-318.  Pacifici GM, Viani A, Rizzo G, and Carrai M (1989) Plasma protein binding of ethinylestradiol: effect of disease and interaction with drugs.    Int. J. Clin. Pharmacol. Ther. Toxicol.  27: 362-365.",,,1937,296.4,2,2,40.5,1,neutral,3.5,3.5
Ethinylestradiol-17-Sulfate,75803-36-0,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(OS(=O)(=O)O)C#C,0.61,1.3,,7.8,9.3,"Goldzieber JW, Mileikowsky G, Newburger J, Dorantes A, and Stavchansky SA (1988) Human pharmacokinetics of ethinyl estradiol 3-sulfate and 17-sulfate.  Steroids 51: 63-79.",VDss calculated from reported micro-constants.,,1980,376.47,5,2,83.8,3,anionic,1.9,1.8
Ethinylestradiol-3-Sulfate,24560-70-1,C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(=O)(=O)O)ccc34)[C@@H]1CC[C@@]2(O)C#C,2.3,4.7,0.011,8.2,8.4,"Goldzieber JW, Mileikowsky G, Newburger J, Dorantes A, and Stavchansky SA (1988) Human pharmacokinetics of ethinyl estradiol 3-sulfate and 17-sulfate.  Steroids 51: 63-79.  Reed MJ and Fotherby K (1980) Interaction of ethinyloestradiol sulphate with plasma proteins.  J. Steroid Biochem. 13: 495-497.",VDss calculated from reported micro-constants.,,1969,376.47,5,2,83.8,3,neutral,1.6,-1.9
Etilefrine,709-55-7,CCNCC(O)c1cccc(O)c1,2.1,14,0.77,2.5,2.2,"Hengstmann JH, Weyand U, and Dengler HJ (1975) The physiological disposition of etilefrine in man.  Eur. J. Clin. Pharmacol.  9: 179-187.",VDss calculated from reported micro-constants.,,1950,181.23,3,3,52.5,4,cationic,0.57,-0.9
Etomidate,33125-97-2,CCOC(=O)c1cncn1[C@H](C)c2ccccc2,2.7,13,0.23,2.9,3.5,"Van hamme MJ, Ghoneim MM, and Ambre JJ (1978) Pharmacokinetics of etomidate, a new intravenous anesthetic.  Anesthesiology 49: 274-277.   de Ruiter G, Popescu DT, deBoer AG, Smeekens JB, Breimer DD (1981) Pharmacokinetics of etomidate in surgical patients. Arch. Int. Pharmacodynam. Ther. 249: 180-188.  Meuldermans WEG and Heykants JJP (1976) The plasma protein binding and distribution of etomidate in dog, rat and human blood.  Arch. Int. Pharmacodynam. Ther. 221: 150-162.","Microconstant values from Van Hamme, et al., were used to estimate VDss.  Data were combined with deRuyter et al. ",,1884,244.29,4,0,44.1,5,neutral,2.8,2.8
Etonogestrel,54048-10-1,[C@@]12([C@H]([C@H]3[C@H](C(=C)C2)[C@@H]2C(=CC(=O)CC2)CC3)CC[C@]1(C#C)O)CC,2.87,2,0.02,23.6,25,"PP. FDA approval package. 2006-Jun-16  PDF(2755k)
Clinical Pharmacology and Biopharmaceutics Review 021529/S-000",Vdss reported with large s.d.  201 +/- 149 L. MRT from VDss and Cl. 70 kg assumed.150 ug low bolud dose,,1974,324.46,2,1,37.3,2,neutral,4,4
Etoposide,33419-42-0,COc1cc(cc(OC)c1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)c6cc7OCOc7cc26,0.18,0.5,0.12,6,5.7,"Pfluger KH, Schmidt L, Merkel M, Jungelas H, and Havemann K (1987) Drug monitoring of etoposide (VP16-213).  Canc. Chemother. Pharmacol. 20: 59-66.  Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, Bukowski R, Gandara D, Goss G, et al. (1995) Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.  J. Clin. Oncol. 13: 2835-2841.  Lee, KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.   Pharm. Res. 20: 1015-1021.",,,1946,588.56,13,3,160.8,5,neutral,-0.43,-0.43
Etoricoxib,202409-33-4,Cc1ccc(cn1)c2ncc(Cl)cc2c3ccc(cc3)S(=O)(=O)C,1.5,0.79,0.081,32,26,"Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, and Agrawal NGB (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.    Drug Metab. Dispos. 31: 224-232.  Agrawal NGB, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, Larson PJ, Cote J, Dilzer SC,  Lasseter KC, Alam I, Petty KJ, and Gottesdiener KM (2003) Pharmacokinetics of etoricoxib in patients with hepatic impairment.  J. Clin. Pharmacol. 43: 1136-1148.",,,1998,358.84,4,0,59.9,3,neutral,3.5,3.5
Evacetrapib,1186486-62-3,Cc1cc(C)c2N(C[C@@H]3CC[C@H](CC3)C(=O)O)CCC[C@H](N(Cc4cc(cc(c4)C(F)(F)F)C(F)(F)F)c5nnn(C)n5)c2c1,1.82,0.84,0.001,36.15,51.94,"Ellen A. Cannady, Aktham Aburub,Chris Ward, Chris Hinds Boris Czeskis, Kenneth Ruterbories, Jeffrey G. Suico, Jane Royalty Demetrio Ortega, Brian W. Pack, Syed L. Begum, William F. Annes, Qun Lin, and David S. Small. Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [13C8]-evacetrapib as a tracer. J. Label Compd. Radiopharm 2016, 59 238–244.//ppb: Friedrich S, Kastelein JJP, James D, Waterhouse T, Nissen SE, Nicholls SJ, Krueger KA. The pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins. CPT: Pharmacometrics Syst Pharmacol 2014; 3: e94","LY 2484595. N=8, 7M/1F, 74.6 kg average weight, 175 ug of 13-C8 tracer as a 4 hr infusion. Data digitized from plot reported and PK parameters calculated via PKSolver. Reported normalized AUC(0-inf): 248 ng.h.mL-1.mg-1; calculated normalized AUC(0-inf): 266.02 ng.h.mL-1.mg-1. 7% difference.",,2010,638.65,8,1,87.4,7,zwitterionic,7.5,5.2
Exatecan (acid),276680-63-8,O1C([C@@](c2cc3n(c(c2C1)=O)Cc1c2c4c(cc(c(c4CC[C@@H]2N)C)F)nc31)(CC)O)=O,0.44,0.96,,7.6,6.7,"Royce ME, Rowinsky EK, Hoff PM, Coyle J, DeJager R, Pazdur R, and Saltz LB (2004) A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patiets with metastatic adenocarcinoma of the colon or rectum.  Invest. New Drugs 22: 53-61.",PK data are for ring-opened acid form,,2000,435.45,7,2,107.4,1,neutral,2,1.7
Ezogabine,150812-12-7,C(Nc1c(cc(NCc2ccc(F)cc2)cc1)N)(=O)OCC,2.5,8.3,0.2,5,9,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf. accessed March 13 2012.http://www.pdr3d.com/detail.php?c=126688#section-15 ppb: the PDR states: Data from in vitro studies indicate that ezogabine and NAMR are approximately 80% and 45% bound to plasma protein, respectively. (NAMR is a metabolite). Accessed December 31 2014. http://www.pdr3d.com/detail.php?c=126688#section-15",,,1993,303.33,5,3,76.4,6,neutral,3.1,3.1
F992,162277-99-8,O=C([C@H](CSCCCC(N[C@@H](C1=O)CC2=CC=CC=C2)=O)NC([C@@H](NC([C@@](C)(NC([C@@H](N1)CC3=CC=CS3)=O)CC)=O)CC(N)=O)=O)N(C[C@H](O)C4)[C@@H]4C(N[C@@H](C(NCC(N)=O)=O)CCCNC(N)=N)=O,0.31,0.87,,5.63,4.28,"T. Callréus, J. Lundahl, A. Broeders, P. Höglund.  Pharmacokinetics and antidiuretic effect of a new vasopressin analogue (F992) in overhydrated male volunteers. Eur J Clin Pharmacol (1999) 55: 293-298.",Average of data reported in Table 1. 4 and 8 ug dose (N=8 in each case). Average weight 76.3,,1995,1028.21,24,13,392.3,18,cationic,-2.9,-6
Falipamil,77862-92-1,C1(c2cc(c(OC)cc2CN1CCC[N@@](CCc1cc(c(cc1)OC)OC)C)OC)=O,2.4,15.71,0.12,2.62,2.04,"Roth, W.; Koss, F. W.; Hallinan, D.; Lambe, R.; Darragh, A.. Pharmacokinetics of falipamil after intravenous administration to humans. J. Pharm. Sci. 1990, 79, 415-419.",N=6 but complete data in table available for N=5. 100 mg dose. Data for parent. 67 kg as median weight taken from range. ,,1981,428.52,7,0,60.5,11,cationic,3,2.3
Famotidine,76824-35-6,NC(=N)Nc1nc(CSCCC(=N)NS(=O)(=O)N)cs1,1.2,6.6,0.84,3,2.8,"Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, Antonello J, Vlasses P, Ryan JR, and Williams RL (1987) Single-dose pharmacokinetics and bioavailability of famotidine in man.  Results of multicenter collaborative studies.  Biopharm. Drug Dispos. 8: 549-560.",VDss calculated from C vs t data obtained by digitization of the plots provided in the reference.,,1980,337.45,9,6,170.8,9,neutral,-1.3,-1.4
Faropenem,106560-14-9,C(=O)(O)C1=C(S[C@H]2N1C(=O)[C@@H]2[C@@H](C)O)[C@H]1CCCO1,0.18,2.23,,1.34,1.4,"Pharmacokinetics of faropenem after multiple intravenous infusion administration in Chinese healthy volunteersSU K e- jian, SUN L,i YANG Juan, LIU Jin Chinese Journal of Clinical Pharmacology, 2011, 27, 110-113","VDss from MRT and clearance. 600 mg dose in 1-hr infusion, N=11.",,1986,285.32,6,2,87.1,3,anionic,-1,-4.4
Fasudil,103745-39-7,O=S(=O)(N1CCCNCC1)c2cccc3cnccc23,1.22,77.5,,0.26,0.44,"HAN Min, CHEN Huaying, LIN Yang , ZHOU Zijie, WANG Lifeng, BAI Mei, LI Jing, WANG K. The Investigation on Pharmacokinetics of FasudilAfter a Single Dose Intravenous infusion. Chin Pharm. J. 2011, 46, 293-296.","Fasudil mesylate, N=12, 59 kg average weight, 35 mg dose = 26.31 mg free base. Data digitized from Figure 2. Fairly large error on the plot. Digitization deemed accurate although results differ from error range reported. Data accepted after discussion.",,1986,291.37,5,1,62.3,2,cationic,1.2,0.49
Felodipine,72509-76-3,CCOC(=O)C1=C(C)NC(=C(C1c2cccc(Cl)c2Cl)C(=O)OC)C,4.4,11,0.0036,6.7,10,"Edgar B, Regardh CG, Johnsson G, Johansson L, Lundborg P, Lofberg I, and Ronn O (1985) Felodipine kinetics in healthy men.  Clin. Pharmacol. Ther. 38: 205-211.","VDss calculated from compartmental parameters provided in the reference by Edgar, et al., 1985.",,1980,384.25,5,1,64.6,6,neutral,4.2,4.2
Fenoldopam,67227-56-9,c12[C@@H](c3ccc(O)cc3)CNCCc1c(c(O)c(c2)O)Cl,0.5,41.5,0.12,0.2,1,"PP. Fenoldopam Mesylate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 019922 1997-Sep-25  PDF(1763k)",N=12 healthy volunteers. 1 ug/kg/min dose. MRT from VDss and clearance.,"PP. Fenoldopam Mesylate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 019922 1997-Sep-25  PDF(1763k)",1980,305.76,4,4,72.7,1,cationic,2.7,1.9
Fenoprofen,29679-58-1,C([C@@H](c1cc(Oc2ccccc2)ccc1)C)(=O)O,0.1,0.6,0.02,2.8,2.24," Physiological disposition of fenoprofen in man.  II.  Plasma and Urine Pharmacokinetics after Oral and Intravenous Administration. Rubin, Alan; Rodda, Bruce E.; Warrick, Patricia; Ridolfo, Anthony; Gruber, Charles M.  Journal of Pharmaceutical Sciences (1971), 60(12), 1797-801. ppb: Physiological disposition of fenoprofen in man.  III.  Metabolism and protein binding of fenoprofen. Rubin, Alan; Warrick, Patricia; Wolen, Robert L.; Chernish, Stanley M.; Ridolfo, Anthony S.; Gruber, Charles M., Jr. J. Pharmacol. Exp. Ther.  1972, 183, 449-457. ","N=4, data calculated as average of V1+V2; microconstant also available. Median weight 67.5 kg.  MRT = VDss/CL. One-compartment model data used.",,1970,242.27,3,1,46.5,4,anionic,3.2,0.48
Fenoterol,13392-18-2,CC(Cc1ccc(O)cc1)NCC(O)c2cc(O)cc(O)c2,1.2,29,0.53,0.69,0.87,"Warnke K, Hildebrandt R, Gunther K, Langen U, and Gundert-Remy U (1992) The pharmacokinetics of the beta2-adrenoreceptor agonist fenoterol in healthy women.  Eur. J. Clin. Pharmacol.  43: 663-665.  Heel RC, Brigden RN, Speight TM, and Avery GS (1978) Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma.  Drugs 15: 3-32.","Study subjects all women, so a body weight of 55 kg was assumed.",,1970,303.35,5,5,92.9,6,cationic,1.5,0.7
Fenspiride,5053-06-5,O=C1NCC2(CCN(CCc3ccccc3)CC2)O1,3,2.6,,19,14,"Montes B, Catalan M, Roces A, Jeanniot JP, and Honorato JM (1993) Single-dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial.  Eur. J. Clin. Pharmacol. 45: 169-172.  ",VDss calculated from C vs t data included in the reference.,,1965,260.33,4,1,41.6,3,cationic,2,0.16
Fentanyl,437-38-7,CCC(=O)N(C1CCN(CCc2ccccc2)CC1)c3ccccc3,0.89,4.7,0.16,3.2,3,"Fung DL and Eisele JH (1980) Fentanyl pharmacokinetics in awake volunteers.  J. Clin. Pharmacol.  20: 652-658.  Schleimer R, Benjamani E, Eisele J, and Henderson G (1977) Pharmacokinetics of fentanyl as determined by radioimmunoassay.  Clin. Pharmacol. Ther.  23: 188-194.  Meuldermans WEG, Hurkmans RMA, and Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.    Arch. Int. Pharmacodyn. Ther. 257: 4-19.",,,1963,336.47,3,0,23.5,6,cationic,4.1,2.8
Fimasartan,247257-48-3,CCCCc1nc(c(c(=O)n1Cc2ccc(cc2)c3ccccc3c4[nH]nnn4)CC(=S)N(C)C)C,0.6,9.6,,1.1,5.5,"Jong-Lyul Ghim, Soo Heui Paik,  M. Hasanuzzaman, Yong Ha Chi, Hyang-Ki Choi,  Dong-Hyun Kim,  Jae-Gook Shin.  Absolute Bioavailability and Pharmacokinetics of the Angiotensin II Receptor Antagonist Fimasartan in Healthy Subjects. J. Clin. Pharmacol. 2016, 56, 576-580.","N=16, 30 mg dose, 1 h infusion. No average weight reported but data available on weight basis. ",,1999,501.65,8,1,92.6,10,cationic,4.1,0.71
Finafloxacin,209342-40-5,c1c2c(c(c(c1F)N3C[C@H]4[C@H](C3)OCCN4)C#N)n(cc(c2=O)C(=O)O)C5CC5,1.42,5.75,0.75,4.11,13.42,"Max Taubert, Joseph Chiesa, Mark Lückermann, Carsten Fischer, Axel Dalhoff,Uwe Fuhr. Pharmacokinetics of intravenous finafloxacin in healthy volunteers. Antimicr. Agents Chemother. 2017. Posted on line August 7 2017. doi:10.1128/AAC.01122-17.","MRT from VDss and clearance. N=29 (total), 1 hr infusion across doses from 200 to 1000 mg. average weight 75.9 kg. All data weight-averaged by number of subjects with very high concordance across doses (linear PK).",,1998,398.39,8,2,107.6,4,anionic,1.1,-1.9
Finasteride,98319-26-7,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,1.1,2.4,0.095,7.6,6,"Steiner JF (1996) Clinical pharmacokinetics and pharmacodynamics of finasteride.  Clin. Pharmacokinet. 30: 16-27.  Carlin JR, Hoglund P, Eriksson LO, Christofalo P, Gregoire SL, Taylor AM, and Andersson KE (1992) Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans.  Drug Metab. Dispos. 20: 148-155",,,1985,372.54,4,2,58.2,1,neutral,3.2,3.2
Fingolimod,162359-55-9,c1(ccc(cc1)CCCCCCCC)CCC(CO)(N)CO,17.3,1.53,0.002,189,144,"PP. Fingolimod Hydrochloride - FDA Approval Package
Pharmacology Review 022527/S-000 Part 04","MRT from VDss and Cl. N=11, (5M/6F) 1 mg dose iv injection, reported average weight 69.1 kg. Reported source, study A0108. ppb reported as 99.7 to 99.9% across species. 99.8% taken","PDR. Accessed February 21 2013. http://www.pdr3d.com/detail.php?c=64159#section-13.  After oral administration, about 81% of the dose is slowly excreted in the urine as inactive metabolites. Fingolimod and fingolimod-phosphate are not excreted intact in urine but are the major components in the feces with amounts of each representing less than 2.5% of the dose. ",1994,307.47,3,3,66.5,12,cationic,3.7,2.6
Flavopiridol,146426-40-6,CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccccc4Cl,1.5,6.1,0.06,4,5.2,"Zhai S Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo AJ, Melillo G, Fuse E, and Figg WD (2003) Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.  Anti-Cancer Drugs. 14: 125-135.  Rudek MA, Bauer KS, Lush RM, Stinson SF,  Senderowicz AM, Headlee DJ, Arbuck SG,  Cox MC, Murgo AJ, Sausville EA, and Figg WD (2003) Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.  Ann. Pharmacother. 37: 1369-1374. ",,,1961,401.84,6,3,90.2,2,zwitterionic,3.6,2.4
Flecainide,54143-55-4,FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2,6.1,4.9,0.52,21,12,"Wang T, Siddoway LA, Thompson KA, Conard GJ, Bergstrand RH, Kvam D, Roden DM, and Woosley RL (1988) The development and testing of intravenous dosing regimens: application to flecainide for teh suppression of ventricular arrhythmias.  Clin. Pharmacol. Ther. 43: 499-508.  Tjandra-Maga TB, Verbesselt R, Van Hecken A, Mullie A, and DeSchepper PJ (1986) Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man.  Br. J. Clin. Pharmacol. 22: 309-316.  Munafo A, Buchlin T, Tuto D, and Biollaz J (1992) The effect of low dose quinidine on the disposition of flecainide in healthy volunteers.  Eur. J. Clin. Pharmacol. 43: 441-443.  Johnston A, Muhiddin KA, and Hamer J (1982) Serum protein binding of flecainide.  Br. J. Clin. Pharmacol. 13: 606P.","VDss from the reference by Wang, et al, was calculated using the compartmental parameters reported in the reference.",,1979,414.34,5,2,59.6,7,cationic,3.1,1.6
Fleroxacin,79660-72-3,CN1CCN(CC1)c2c(F)cc3C(=O)C(=CN(CCF)c3c2F)C(=O)O,1.6,2.4,0.73,11,8.6,"Weidekamm E, Portmann R, Suter K, Partos C, Dell D, and Lucker PW (1987) Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.  Antimic. Agents Chemother. 31: 1909-1914.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750.",,,1981,369.34,6,1,64.1,4,zwitterionic,2,-0.27
Flomoxef,99665-00-6,n1(nnnc1SCC1=C(N2[C@H](OC1)[C@@](C2=O)(OC)NC(=O)CSC(F)F)C(O)=O)CCO,0.19,4.1,0.64,0.77,0.6,"Saito, Haruo; Kimura, Tadashi; Takeda, Taizo; Kishimoto, Seiji; Oguma, Takayoshi; Shimamura, Kenji. Pharmacokinetics of flomoxef in mucosal tissue of the middle ear and mastoid following intravenous administration in humans. Chemotherapy (Basel, Switzerland), 1990, 36, 193-199.//ppb:Hamada, Toshihiro; Ueta, Eisaku; Kodama, Hiroyuki; Osaki, Tokio. The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-​binding activities. J. Oral Pathol. Med. 2002, 31, 109-116. ","VDss from Vc and k12/k21. Clearance from dose/AUC. MRT from Clearance and VDss. 1 g dose, N=6, 70 kg weight assumed.",,1984,496.47,13,3,169,11,anionic,-0.98,-4
Flucloxacillin,5250-39-5,Cc1onc(c1C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O)c4c(F)cccc4Cl,0.19,2.4,0.043,1.3,1.4,"Adam D, Koeppe P, and Heilmann (1983) Pharmacokinetics of amoxicillin and flucloxacillin following the simultaneous intravenous administration of 4 g and 1 g respectively.  Infection  11: 150-154.  Bergan T, Engeset A, Olszewski W, Oestby N, and Solberg R (1986) Extravascular penetration of highly protein-bound flucloxacillin.  Antimic. Agents Chemother. 30: 729-732.  Roder BL, Frimodt-Moller, Espersen F, and Rasumussen SN (1995) Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bacteriocidal titers in healthy subjects after oral administration.  Infection 23: 107-112.",,,1968,453.87,8,2,113,4,anionic,2.8,-0.5
Fluconazole,86386-73-4,c1c(cc(c(C(Cn2ncnc2)(O)Cn2cncn2)c1)F)F,0.75,0.31,0.89,40,30,"Foulds G, Wajszczuk C, Weidler DJ, Garg DJ, and Gibson P (1988) Steady state parenteral kinetics of fluconazole in man.  Ann. N.Y. Acad. Sci. 544: 427-30.  Humphrey MJ, Jevons S, and Tarbit MH (1985) Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Animic. Agents Chemother. 28: 648-653.",,"From PDR. Accessed march 6 2013.http://www.pdr3d.com/detail.php?c=9255#section-4.  In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug. About 11% of the dose is excreted in the urine as metabolites.",1930,306.27,7,1,81.7,5,neutral,0.19,0.19
Flucytosine,2022-85-7,NC1=C(F)C=NC(=O)N1,0.68,2,1,5.7,4.2,"Cutler RE, Blair AD, and Kelly MR (1978) Flucytosine kinetics in subjects with normal and impaired renal function.  Clin. Pharmacol. Ther. 24; 333-342.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",,,1957,129.09,4,2,67.5,0,neutral,-2.3,-2.3
Fludarabine,21679-14-1,Nc1nc(F)nc2c1ncn2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O,2.2,3.2,0.76,12,11,"Kuo GM, Boumpas DT, Illei GG, Yarboro C, Pucino F, and Burstein AH (2001) Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. Pharmacother. 21: 528-533.  Knebel W, David JC, Sanders WD, Fessler B, Yarboro C, Pucino F, and Boumpas DT (1998) The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis.  Pharmacotherapy 18: 1124-1229.   Fludara Product Label","9-beta-D-Arabinofuranosyl-2-fluoroadenine, NSC 118218. Data from Kuo, et al were digitized prior to calculation of VDss.  Micro rate constants from Knebel were used to calculated VDss.",,1969,285.23,9,4,139.5,2,neutral,-1.8,-1.8
Flumazenil,78755-81-4,CCOC(=O)c1ncn2c1CN(C)C(=O)c3cc(F)ccc23,0.8,16,0.58,1,0.78,"Janssen U, Walker S, Maier K, von Gaisberg U, and Klotz U (1989) Flumazenil disposition and elimination in cirrhosis.  Clin. Pharmacol. Ther.  46: 317-323. Pomier-Layrargues G, Giguere JF, Lavoie J, Willems B, and Butterworth RF (1989) Pharmacokinetics of benzodiazepine antagonist RO 15-1788 in cirrhotic patients with moderate or severe liver dysfunction.  Hepatology  10: 969-972.  Klotz U, Ziegler G, and Reimann IW (1984)  Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.  Eur. J. Clin. Pharmacol. 27: 115-117. ",,,1981,303.29,6,0,64.4,3,neutral,1,1
Flunisolide,3385-03-3,O1[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@@]5(C)[C@H]4[C@H](C[C@@]3([C@]2(C(CO)=O)OC1(C)C)C)O,1.08,9.5,0.24,1.89,1.68,"Flunisolide metabolism and dynamics of a metabolite.Chaplin MD, Rooks W II, Swenson EW, Cooper WC, Nerenberg C and Chu NI. Clin Pharmacol Ther 1980, 27:402-413.//ppb: Loren M. Berry, Chao Li, and Zhiyang Zhao. Species Differences in Distribution and Prediction of Human Vss from Preclinical Data Drug Metab. Disp. 2011, 39, 2103-2106.","N=9, 1 mg dose. Calculated from reported plot (figure 3) in blood corrected for B/P =0.89. Data in blood and 0.89 B/P reported. Table involving 12 subjects (median weight 81.8 kg) but plot referring to 9 of them. The calculations below were performed after a correction to yield plasma concentration and some adjustment of time points digitized to approach reported AUC (C0 inserted manually). Reported blood AUC for N=12 17.64 hr*ng/mL corresponding to 19.82 hr*ng/mL. 8% difference from computed values.  ",,1963,434.5,6,2,93.1,2,neutral,2.5,2.5
Flunitrazepam,1622-62-4,CN1C(=O)CN=C(c2ccccc2F)c3cc(ccc13)N(=O)=O,1.9,1.4,0.17,23,25,"Kangas L, Kanto J, and Pakkanen A (1982) A pharmacokinetic and pharmacodynamic study of flunitrazepam.  Int. J. Clin. Pharmacol. Ther. Toxicol.  20: 585-588.  Lucek RW and Coutinho CB (!976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12:  612-619.",VDss calculated from C vs t data obtained by digitization of the plot included in the reference.,,1963,313.28,6,0,78.5,2,neutral,2.1,2.1
Fluocortolone,152-97-6,[C@H]12[C@H]3[C@@]([C@H]([C@@H](C3)C)C(=O)CO)(C[C@@H]([C@@H]1[C@@]1(C(=CC(=O)C=C1)[C@H](C2)F)C)O)C,0.68,7,0.04,1.6,1.3,"Täuber U, Haack D, Nieuweboer B, Kloss G, Vecsei P, Wendt H. The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol. 1984, 22, 48-55.//ppb: Fellier, H.; Gleispach, H.; Esterbauer, H. Binding of cortisol, fluocortolone, and difluocortolone to human plasma proteins.  J. Clin. Chem. Clin. Biochem. 1977, 15, 545-548","VDss calculated from noncompartmental analysis of the mean of the individual C vs t data provided in the reference.N=5, mean BW = 64 kg, dose was 5 mg",,1962,376.46,4,2,74.6,2,neutral,2.3,2.3
Fluorescein,2321-07-5,Oc1ccc2c(Oc3cc(O)ccc3C24OC(=O)c5ccccc45)c1,0.14,1.3,0.11,1.8,1.6,"Larsen M, Loft S, Hommel E, and Lund-Andersen H (1988) Fluorescein and fluorescein glucuronide in plasma after intravenous injection of fluorescein.  Acta Opthamol. 66: 427-432.  ",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1931,332.31,5,2,76,0,neutral,3.9,3.9
"fluorodideoxycytidine, 2- (2FddC)",119555-47-4,c1cn(c(=O)nc1N)[C@H]2[C@H](C[C@H](O2)CO)F,0.7,6.1,1,1.9,1.8,"Williams, P. E. O.; Muirhead, G. J.; Sereni, D.; Rousseau, F. S.; Edelman, K.; Hooker, M. Pharmacokinetics of 2-​fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus. British Journal of Clinical Pharmacology (1993), 35(3), 255-260","N=28, abg BW= 67kg. Dose = 0.03, 0.1 and 0.3 mg/kg. Average PK of digitized profiles of the highest three doses shown in Figure 1. Average of data reported in Table 2: CL = 5.7 mL/min/kg (23.1 L/h), term. t1/2 1.9h",,1988,229.21,6,2,90.4,2,neutral,-1.2,-1.2
"Fluorouracil, 5-",51-21-8,FC1=CNC(=O)NC1=O,0.23,26,0.64,0.15,0.12,"Port RE, Daniel B, Ding RW, and Herrmann R (1991) Relative importance of dose, body surface area, sex, and age for 5-flurouracil clearance.  Oncology 48: 277-281.  Schaaf LJ, Dobbs BR, Edwards IR, and Perrier DG (1987) Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.  Eur. J. Clin. Pharmacol. 32: 411-418.  Esposito M, Rosso R, and Santi L (1974) Plasma protein binding of antineoplastic drugs in rats and humans.  IRCS Library Compendium 2: 1180.",5-FU shows dose dependent kinetics; low dose data cited.,,1946,130.08,4,2,58.2,0,neutral,-0.93,-1.1
Flupentixol,2709-56-0,c1ccc2c(c1)/C(=C/CCN3CCN(CC3)CCO)/c4cc(ccc4S2)C(F)(F)F,,4.14,,,34.2,"Joergensen, A.; Andersen, J.; Bjoerndal, N.; Dencker, S. J.; Lundin, L.; Malm, U. Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with
flupentixol and cis(Z)-flupentixol decanoate. Psychopharmacol.1982, 77, 58-65.","N-7009. Flupenthixol. Siplaril. Administered iv at 2 mg dose, to N=9 schizophrenic patients, as a mixture 1:1 of diastereomers. Not clear whether the analysis referred to Z-flupentixol (CAS # 53772-82-0). CAS number and structure refers to compound with unspecified double bond geometry. Average weight calculated as exactly 70 kg.No VDss reported.",,1963,434.52,3,1,26.7,5,cationic,4.8,3.9
Fluphenazine,69-23-8,[H]OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,2.9,9.7,0.04,5,12.3,"Koytchev R. et al. Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. Eur. J. Clin. Pharmacol. 1996, 51, 183-187.  fu from Waters et al, 2008.","N=14, 2.5 mg i.v. bolus, 72 kg average weight. VDss calculated from Cl and MRT.",,1958,437.52,4,1,29.9,7,cationic,4.5,3.7
Flupirtine,56995-20-1,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N,1.1,1.6,0.15,11,8.5,Hlavica VP and Niebch G (1985) Untersuchungen zur pharmakokinetik und biotransformation des analgetikums flupirtin beim menschen.  Arz. Forsch. 35: 67-74. ,VDss calculated from C vs t data obtained by digitization of the plots in the reference.,,1979,304.32,6,3,89.3,6,cationic,3.1,2.7
Fluticasone furoate,397864-44-7,C[C@@H]1C[C@H]2C3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)c5ccco5)C)O)F)C)F,4.95,13.4,,,10.6,"Ann Allen, BA; Geoff Down, MB BS FFPM; Amy Newland, MSc; Karen Reynard, BSc; Vicki Rousell, BSc; Emma Salmon, MSc; and Rebecca Scott, PhD Absolute Bioavailability of Intranasal Fluticasone Furoate in Healthy Subjects. Clin. Ther, 2007, 29, 1415-1420","73 kg average weight, N= 16, 250 ug iv.",,2002,538.58,6,1,94.1,6,neutral,3.7,3.7
Fluticasone propionate,80474-14-2,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF,3.6,17,0.1,3.9,6,"Brutsche MH, Brutsche IC, Munavvar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A., and Woodcock A (2000) Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.  Lancet  356: 556-561.  Mackie AE, Ventresca GP, Fuller RW, and Bye A (1996) Pharmacokinetics of intravenous fluticasone propionate in healthy subjects.  Br. J. Clin. Pharmacol. 41: 539-542.",,,1981,500.57,5,1,80.7,6,neutral,3.3,3.3
Fluvastatin,93957-54-1,CC(C)n1c(\C=C\[C@H](O)C[C@H](O)CC(=O)O)c(c2ccc(F)cc2)c3ccccc13,0.42,16,0.0079,0.44,0.7,"Tse F L; Jaffe J M; Troendle A  Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.    Journal of clinical pharmacology  (1992),  32(7),  630-8.  Tse FLS, Nickerson DF, and Yardley WS (1993) Binding of fluvastatin to blood cells and plasma proteins.  J. Pharm. Sci. 82: 942-947.",,,1984,411.47,5,3,82.7,8,anionic,2.9,-0.11
Fluvoxamine,54739-18-3,c1(\C(CCCCOC)=N\OCCN)ccc(C(F)(F)F)cc1,23.5,31.95,0.2,12.26,12.5,"J. van Harten, F. Kok, A. Lönnebo  and A. Grahnén. Pharmacokinetics of fluvoxamine after intravenous and oral administration. Eur. Neuropsychopharmacology, 1994, 4, 331.","Average of two doses, N=17 per dose, 70 kg/average weight assumed. 10 and 30 mg doses as iv infusion in 60 minutes. Clearance from dose/AUC, then averaged. MRT from VDss and clearance. ","Ppb from PDR label. Absolute BA from paper 53% (po dose 50 mg, crossover with iv doses)",1977,318.33,4,1,56.8,9,cationic,3.1,1.2
Folic acid,59-30-3,c1cc(ccc1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCc2cnc3c(n2)c(=O)nc([nH]3)N,9.7,52,0.5,3.1,2.6,"Menke A; Weimann H J; Achtert G; Schuster O; Menke G. Absolute bioavailability of folic acid after oral administration of a folic acid tablet formulation in healthy volunteers. Arzneimittel-Forschung (1994), 44(9), 1063-1067// ppb: Elsborg L. Binding of Folic Acid to Human Plasma Proteins. Acta Haematol 1972,48, 207–212.","N=17. Dose = 5 mg  6min infusion. BW = 87.5 kg
PK iv profile reported in table 1. Concentration corrected from predose level of 18.2 ng/mL. MRT Calculated from VDss and CL.
AUC0-12h (ng*h/mL) = 1546 (reported 1550). AUC0-inf (ng*h/mL) = 1601",,1946,441.4,13,6,213.3,9,anionic,-1.3,-8.6
Folinic acid,58-05-9,NC1=NC(=O)C2=C(NCC(CNc3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N2C=O)N1,0.25,5.8,0.087,0.8,1.3,"Greiner PO, Zittoun J, Marquet J, and Cheron JM (1989) Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. Br. J. Clin. Pharmacol. 28: 289-295.  Christophidis N, Louis WJ, Lucas I, Moon W, and Vajda FJ (1981) Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy.  Cancer Chemother Pharmacol. 6: 59-64.  ",Data from (-) enantiomer used.,,1948,473.44,14,7,215.6,9,anionic,-2.1,-7.6
Fomepizole,7554-65-6,c1(cn[nH]c1)C,0.35,0.73,,7.94,4.42,"KENNETH E. MCMARTIN , C. SIMON SEBASTIAN, DAVID DIES , DAG JACOBSEN. Kinetics and metabolism of fomepizole in healthy humans. Clin. Toxicol. 2012, 50, 375–383","N=5, average weight assumed to be 70 kg. 7 mg/kg = 85.3 umol/kg (MW 82.1). Data digitized from plot reported and analyzed via PKSolver. AUC reported 1880 umol.h.L-1; calculated 1953.3 umol.h.L-1.",,1930,82.1,2,1,28.7,0,neutral,0.72,0.72
Fondaparinux,104993-28-4,"S(=O)(=O)(O)OC[C@@H]1[C@H]([C@@H]([C@@H](NS(=O)(=O)O)[C@H](O1)OC)O)O[C@H]1[C@H](OS(=O)(=O)O)[C@H]([C@@H]([C@H](C(=O)O)O1)O[C@@H]1[C@H](NS(=O)(=O)O)[C@H]([C@@H]([C@H](O1)COS(=O)(=O)O)O[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)O)O)O)NS(=O)(=O)O)C(=O)O)OS(=O)(=O)O)O
",,0.07,0.21,,19.3,"François Donat, Jean Pierre Duret, Alix Santoni, Roger Cariou, José Necciari, Harry
Magnani and Rik de Greef. The Pharmacokinetics of Fondaparinux
Sodium in Healthy Volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 1-9. ppb: Paolucci F , Claviés MC , Donat F , Necciari. Fondaparinux Sodium Mechanism of Action Identification of Specific Binding to Purified and Human Plasma-Derived Proteins J . Clin Pharmacokinet 2002; 41 Suppl. 2: 11-18","two sd at 4 mg averaged in elderly subjects. Fairly close values across other doses. N= 66. Only Vz reported. 7.9 and 10.8 L for the same two groups.t1/2 18.4 and 20.3 h, respectively. Ppb: 79% reported as unspecific binding in plasma. Table II in reference cited.",Almost completely excreted renally unchanged.,1986,1508.26,52,19,805.5,30,anionic,-9,-9
Forodesine,209799-67-7,[nH]1cnc2c([nH]cc2[C@@H]2N[C@@H]([C@H]([C@H]2O)O)CO)c1=O,,1.56,,,11.6,"A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)
Varsha Gandhi, John M. Kilpatrick, William Plunkett, Mary Ayres, Leigh Harman, Min Du, Shanta Bantia, Jan Davisson, William G. Wierda, Stefan Faderl, Hagop Kantarjian, and Deborah Thomas. BLOOD, 2005   VOLUME 106, (13)4253-4260.",Only Vz reported. Infusion across 5 patients. One patient received 4 doses. N = 8 total. ,,1998,266.25,8,6,134.3,2,cationic,-3.9,-4.3
Fosaprepitant,172673-20-0,n1([nH]c(nc1=O)C[N@@]1[C@H]([C@H](OCC1)O[C@H](C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1ccc(cc1)F)P(=O)(O)O,0.07,18.6,0.02,0.06,2.2,"Kenneth C. Lasseter, Jay Gambale, Bo Jin, Art Bergman, Marvin Constanzer, James Dru, Tae H. Han, Anup Majumdar,Judith K. Evans and M. Gail Murphy. Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects. J Clin Pharmacol 2007 47: 834-840.",average of two doses iv. Very tight data. MRT from VDss and Cl.,"PP.     Fosaprepitant Dimeglumine - EMA Approval Package
Assessment Report EMEA/42754/2008 ",1995,614.41,10,3,129.9,7,anionic,2.4,-3.5
Foscarnet,4428-95-9,OC(=O)P(=O)(O)O,0.5,2.1,0.85,4,4.7,"Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, and Jacobson MA (1995) Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.    Clin. Pharmacol. Ther. 57: 403-412.  Sjovall J, Bergdahl S, Movin G, Ogenstad S, and Saarimaki M (1989) Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.  Antimic. Agents Chemother. 33: 1023-1031.",Long terminal phase t1/2 of 88 h reported in Sjovall with a 3-compartment model.,,1924,126.01,5,3,94.8,1,anionic,-1.2,-7.6
Fosfluconazole,194798-83-9,OP(=O)(O)OC(Cn1cncn1)(Cn2cncn2)c3ccc(F)cc3F,0.15,1.3,0.042,2,2.1,"Sobue S, Tan K,  Layton G, Leclerc V, and Weil A (2004) The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.  Br. J. Clin. Pharmacol. 57: 773-784.",,,1997,386.25,10,2,128.2,7,anionic,-0.79,-5.1
Fosfomycin,23155-02-4,C[C@@H]1O[C@@H]1P(=O)(O)O,0.32,2,1,2.7,1.9,"Goto M, Sugiyama M, Nakajima S, and Yamashina H (1981) Fosfomycin kinetics after intravenous and oral administration to human volunteers.    Antimic. Agents Chemother. 20: 393-397.  Potel G, Meignier M, Baron D, Reynaud A, Touze MD, and Cortieu AL (1989) Pharmacokinetics of fosfomycin in normal and burn patients.  Effect of probenecid.  Drugs Exptl. Clin. Res. 15: 177-184.  Kestle DG and Kirby WMM (1970) Clinical pharmacology and in vitro activity of phosphonomycin.  Antimic. Agents Chemother. 332-337 (Chem Abstr. 75:62036).",,,1969,138.06,4,2,70.1,1,anionic,-0.62,-5.7
Fosinoprilat,95399-71-6,OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(=O)(O)CCCCc2ccccc2)C3CCCCC3,0.13,0.32,0.006,6.8,9.4,"Kostis JB, Garland WT, Delaney C, Norton J, and Liao WC. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.  Clin. Pharmacol. Ther. 1995, 58, 660-665",,,1985,435.49,6,2,94.9,9,anionic,4.2,-1
Fosphenytoin,93390-81-9,C1(c2ccccc2)(c2ccccc2)C(=O)N(C(=O)N1)COP(=O)(O)O,0.06,3.5,0.05,0.17,0.16,"Aweeka, Francesca T.; Gottwald, Mildred D.; Gambertoglio, John G.; Wright, Teresa L.; Boyer, Thomas D.; Pollock, Alan S.; Eldon, Michael A.; Kugler, Alan R.; Alldredge, Brian K. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia (1999), 40(6), 777-782.  ",Dosed and monitored as phosphenytoin. Healthy subjects only. 0.37 g in 30' infusion.,"Aweeka, Francesca T.; Gottwald, Mildred D.; Gambertoglio, John G.; Wright, Teresa L.; Boyer, Thomas D.; Pollock, Alan S.; Eldon, Michael A.; Kugler, Alan R.; Alldredge, Brian K. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia (1999), 40(6), 777-782.  ",1984,362.27,8,3,116.2,5,anionic,1.7,-3.3
Fostriecin,87810-56-8,C[C@@](O)(\C=C\[C@H]1CC=CC(=O)O1)[C@@H](C[C@@H](O)\C=C/C=C\C=C\CO)OP(=O)(O)O,0.086,1.2,,1.2,1.5,"de Jong RS, Mulder NH, Uges DRA, Sleijfer DT, Hoppener FJP, Groen HJM, Willemse PHB, van der Graaf WTA, and de Vries EGE (1999) Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.  Br. J. Cancer 79: 882-887.",,,1983,430.39,9,5,153.7,11,anionic,-0.81,-4.4
Fotemustin,92118-27-9,P(=O)(OCC)(OCC)C(NC(=O)N(CCCl)N=O)C,0.62,18.5,,0.55,0.38,"R.M. J. Ings, A. J. Gray, A.R. Taylor, B.H. Gordon, M. Breen, M. Hiley, R. Brownsill, N. Marchant, R. Richards, D. Wallace, T. Hughes, R. Thomas, J. Williams, C. Lucas and D.B. Campbell Disposition, Pharmacokinetics, and Metabolism of 14C-Fotemustine in Cancer Patients. Eur. J. Cancer, 1990, 26,  838-842.","N=2. Double digitization and average of PK data. Patient 1 and 2 52.4 and 73.9 kg weight, F and M, respectively. 133.9 and 176.1 mg dose, respectively. 1 hr infusion and excellent agreement with reported clearance and Vz. Patient 1 1365 mL/min calculated and 1426 mL/min reported; patient 2 787 mL/min calculated and 764 mL/min reported.",,1984,315.69,8,1,97.3,9,neutral,1.5,1.5
Frovatriptan,158747-02-5,CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(=O)N,3.6,2.5,0.85,22,24,"Buchan P, Keywood C, Wade A, and Ward C (2002) Clinical pharmacokinetics of frovatriptan.  Headache  42(Suppl 2): s54-s62.",,,1994,243.3,4,3,70.9,2,cationic,1.3,-0.86
Fulvestrant,129453-61-8,[H]Oc1ccc2c(C[C@H](CCCCCCCCCS(CCCC(C(F)(F)F)(F)F)=O)C3[C@@H]2CC[C@@]2(C)[C@H]3CC[C@@H]2O[H])c1,4.15,11.8,0.01,5.86,16,"Robertson JFR, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. British Journal of Cancer, 2004, 90(Suppl 1), S7-S10. ppb: The PDR states: Fulvestrant is highly (99%) bound to plasma proteins; VLDL, LDL and HDL lipoprotein fractions appear to be the major binding components. Accessed January 11 2015. http://www.pdr3d.com/detail.php?c=82597#section-12.",  Data from 1-h iv infusion doses. MRT calculated from CL and VDss,,1989,606.77,3,2,57.5,16,neutral,9,9
Furosemide,54-31-9,NS(=O)(=O)c1cc(C(=O)O)c(NCc2occc2)cc1Cl,0.12,1.6,0.012,1.3,2.5,"Smith DE, Lin ET, and Benet LZ (1980) Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.  Drug Metab. Dispos. 8: 337-342.  Hammerlund MM, Paalzow LK, and Odlind B (1984) Pharmacokinetics of furosemide in man after intravenous and oral administration.  Application of moment analysis. Eur. J. Clin. Pharmacol. 26: 197-207",,,1948,330.74,7,3,122.9,5,anionic,1.8,-1.4
Fusidate sodium,751-94-0,C(=O)([O-])C(=C1\[C@@H](OC(=O)C)C[C@@]2([C@@]3(CC[C@H]4[C@@H]([C@@H](CC[C@@]4(C)[C@@H]3[C@H](O)C[C@@H]12)O)C)C)C)\CC\C=C(\C)C,0.23,0.35,0.02,10.6,9.8,"A. M. Taburet, J. Gufbert, M. D. Kitris, H. Sorensen, J. F. Acar and E. Singes. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. Journal of Antimicrobial Chemotherapy (1990) 25, Suppl. B, 23-31.//ppb: Markus A. Zeitlinger, Hartmut Derendorf, Johan W. Mouton, Otto Cars, William A. Craig, David Andes, and Ursula Theuretzbacher. Protein Binding: Do We Ever Learn? ANTIMICROB AGENTS CHEMOTHER., 2011, 55, 3067–3074.","N=8, 61.6 kg average weight, dose 500 mg 2 hr infusion. VDss calculated from MRT and clearance from first dose.",,1962,515.7,6,2,106.9,6,anionic,5.7,3.3
Fuzlocillin,66327-51-3,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](c3ccc(cc3)O)NC(=O)N4CCN(C4=O)/N=C/c5ccco5)C(=O)O)C,0.2,3.61,,0.92,1.3,"Wise, R.; Cadge, B.; Gillett, A. P.; Bhamjee, A.; Livingston, R.; Welling, P. G.; Thornhill, D. P. Pharmacokinetics of Bay k 4999, a new broad-spectrum penicillin. Antimicrobial Agents and Chemotherapy (1979), 15(5), 670-3.","Bay k 4999. N=6 healthy male volunteer, 76 kg average weight, 2 g dose. VDss reported as 20.1% of body weight. MRT from VDss and clearance.",,1978,570.57,14,4,185.4,7,anionic,1.4,-2
Gabapentin,60142-96-3,NCC1(CC(=O)O)CCCCC1,0.71,1.7,0.97,7,5.3,"Vollmer KO, Anhut H, Thomann P, Wagner F, and Jahnchen D (1989) Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin.  Adv. Epileptol. 17: 209-211.  Neurontin Product Label.",,,1976,171.24,3,2,63.3,3,zwitterionic,0.55,-1.7
Gadobenate ,113662-23-0,[N]1(CC(=O)[O-])([Gd+3]2[N@@](CC1)(CC[N@@]2([C@@H](C([O-])=O)COCc1ccccc1)CC(=O)[O-])CC([O-])=O)CC(=O)[O-],0.21,1.6,1,2.2,1.81,"Gadobenate Dimeglumine - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021357/S-000. Accessed through Pharmapendium. Ppb: PDR states: In vitro studies showed no appreciable binding of gadobenate ion to human serum proteins. http://www.pdr3d.com/detail.php?c=109299#section-14. Accessed December 27 2014.","N=4, 0.3 mmol/kgh dose. MRT from VDss and cleranace. Structure and CAS referring to gadobenic acid dianion.","Gadobenate Dimeglumine - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021357/S-000. Accessed through Pharmapendium",1988,665.71,14,0,209.9,14,n/a,n/a,n/a
Gadobutrol,770691-21-9,[Gd+3]1234567OC([C@@H](CO)[N]81CC[N]4(CC[N]3(CC[N]2(CC8)CC(=O)[O-]6)CC(=O)[O-]5)CC(=O)[O-]7)CO,0.22,2,1,1.8,1.3,"Gadobutrol - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 201277/S-000 Part 03. Accessed through Pharmapendium. Ppb: PDR states: Gadobutrol does not display any particular protein binding.  http://www.pdr3d.com/detail.php?c=123580#section-14. Accessed december 27 2014.","N=24, doses from 0.05 to 0.4 mmol/kg averaged across all groups. VDss from MRT and clearance.","Gadobutrol - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 201277/S-000 Part 03. Accessed through Pharmapendium",1991,603.7,13,2,134.8,2,n/a,n/a,n/a
Gadodiamide,131410-48-5,CNC1=O[Gd+3]234567N(CCN2(C1)CC(=O)[O-]3)(CCN4(CC(=O5)NC)CC(=O)[O-]6)CC(=O)[O-]7,0.2,1.79,,1.85,1.46,"van Wagoner, M., O'Toole, M., Worah, D., Leese, P. T., Quay, S. C. A Phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest. Radiol., 1991, 11, 980-986.","DV7572. Omniscan. Renal clearance 98% of total. Data digitized and PK parameters calculated via PKSolver. Average of 0.1 mmol/kg and 0.3 mmol/kg doses, expressed as Gd (atomic weight 157.25). N=5/dose. AUC reported within 6 and 11% of calculated at 0.1 mmol/kg and 0.3 mmol/kg, respectively.",,1990,576.68,13,5,131.8,0,n/a,n/a,n/a
Gadofosveset,742680-48-4,C(C([N+]([Gd+++]([N+]1(C2)C3)([N+](C2)(C2)C4)([O-]5)([O-]6)([O-]C3=O)([O-]C4=O)[O-]C2=O)(CC6=O)CC5=O)C1)C(=CC=C1OCC)C=C1,0.15,0.1,0.16,22.7,16.3,PDR Accessed on March 15 2013. http://www.pdr3d.com/detail.php?c=7685#section-13,0.03 mmol/kg dose.  VDss from MRT and clearance.,PDR Accessed on March 15 2013. http://www.pdr3d.com/detail.php?c=7685#section-13,2014,679.73,14,0,151.1,4,n/a,n/a,n/a
Gadopentetate,80529-93-7,O=C1C[N]23CC[N]45CC(=O)[O-][Gd+3]2424([O-]1)([O-]C(=O)C5)[O-]C(=O)C[N]2(CC3)CC(=O)[O-]4,0.27,1.94,1,2.3,1.6,PDR Accessed March 15 2013 http://www.pdr3d.com/detail.php?c=63841#section-4, VDss from MRT and clearance.,PDR Accessed March 15 2013. http://www.pdr3d.com/detail.php?c=63841#section-4,1982,545.56,13,0,141.9,0,n/a,n/a,n/a
Gadoteridol,120066-54-8,[N]123CC[N]45CC[N]67CC[N]8(CC1)CC(=O)[O-][Gd+3]3578([OH]C(C2)C)([O-]C(=O)C4)[O-]C(=O)C6,0.2,1.5,,2.2,1.6,PDR accessed August 08 2013 http://www.pdr3d.com/detail.php?c=49389#section-4. ppb: PDR states It is unknown if protein binding of ProHance occurs in vivo. But no information on in vitro data is reported. http://www.pdr3d.com/detail.php?c=50092#section-4. Accessed december 27 2014., VDss from MRT and clearance.,http://www.pdr3d.com/detail.php?c=49389#section-4,1988,558.68,11,1,97.9,0,n/a,n/a,n/a
Gadoversetamide,131069-91-5,COCCNC1=O[Gd+3]234567O=C(CN2(CCN3(CCN4(CC(=O)[O-]5)C1)CC(=O)[O-]6)CC(=O)[O-]7)NCCOC,0.16,1.2,1,2.2,1.7,OptiMARK Product Label.,,,1990,664.79,15,5,150.2,6,n/a,n/a,n/a
Gadoxetate,770677-60-6,C(C([N+]([Gd+++]([N+]1(C2)C3)([N+](C2)(C2)C4)([O-]5)([O-]6)([O-]C3=O)([O-]C4=O)[O-]C2=O)(CC6=O)CC5=O)C1)C(=CC=C1OCC)C=C1,0.21,3.57,0.9,1,0.95,PDR accessed March 15 2013 http://www.pdr3d.com/detail.php?c=89667#section-13, VDss from MRT and clearance. Ppb < 10%. CAS number of disodium salt = 135326-22-6,,2009,679.73,14,0,151.1,4,n/a,n/a,n/a
GAL-021,1380341-99-0,CCCNc1nc(NCCC)nc(n1)N(C)OC,2.17,11.9,,3.04,5.61,"J. F. McLeod, J. M. Leempoels, S. X. Peng, S. L. Dax, L. J. Myers and F. J. Golder. GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. Br. J. Anaesth. 2014, 113, 875-883.",Data reported as average of 24 subject (bottom line in Table 4) across cohorts 1-3 and period 1-9. Very tight data across all doses cohorts. MRT from VDss and clearance.,,2012,254.33,7,2,75.2,8,neutral,2.3,2.3
Galanthamine,357-70-0,COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24,2.3,5.6,0.83,6.8,5.3,"Westra P, van Thiel MJS, Vermeer GA, Soeterbroek AM, Scaf AH, and Claessens HA (1986) Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients.  Br. J. Anaesth. 58: 1303-1307.  Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M, and Kewitz H (1991) Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.  Clin. Pharmacol. Ther. 50: 420-428.  Zhao Q, Iyer GR, Verhaeghe T, and Truyen L (2002) Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J. Clin. Pharmacol. 42: 428-436",,,1951,287.35,4,1,41.9,1,cationic,1.8,1.1
Gallamine triethiodide,65-29-2,CC[N+](CC)(CC)CCOc1cccc(c1OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC,0.27,1.51,,2.98,2.52,"M.I. Ramzan, E. J. Triggs, C. A. Clarks. Pharmacokinetics studies in man with gallamine triethiodide. Eur.  J. Clin. Pharmacol. 1980, 17, 145-152.",CAS number corresponding to gallamine triethiodide used.  Iodide atoms removed to keep only SMILES for trication neuromuscular blocker.  N=14 with data entered as average of single 4 and 6 mg iv bolus dose. MRT from VDss and clearance.,,1947,510.82,6,0,27.7,21,neutral,-7.7,-7.7
Gallopamil,16662-47-8,c1([C@@](CCC[N@@](CCc2cc(c(OC)cc2)OC)C)(C(C)C)C#N)cc(c(OC)c(c1)OC)OC,1.75,14.3,0.07,2.04,1.8,"Eichelbaum M. Pharmakokinetik und Metabolismus von. Gallopamil. Zeitschrift ftir Kardiologie 78 (Suppl. 5): 20-24, 1989.  ppB; Stieren, B.; Buehler, V.; Hege, H. G.; Hollmann, M.; Neuss, H.; Schlepper, M.; Weymann, J. Edited by Kaltenbach, Martin; Hopf, Ruediger  Gallopamil:  Pharmakol. Klin. Wirkungsprofil Kalziumantagonisten (1983), 90-96. From abstract in English.",Data digitized from plot in figure 4. 70 kg average weight assumed. 2 mg dose iv bolus. N=12. Reported AUC 29.6 ng.hr/mL. Reported clearance 1.2 L/min.,,1963,484.63,7,0,73.2,15,cationic,4.3,2.8
Gambogic acid,2752-65-0,C1(=O)[C@@]2(C\C=C(\C)C(=O)O)[C@@]34Oc5c(c6c(c(c5C(C3=C[C@@H]1C[C@@H]4C(O2)(C)C)=O)O)C=C[C@](O6)(CC\C=C(\C)C)C)C\C=C(\C)C,0.99,1.24,,13.3,14.6,"Data digitized from plot reported in Determination of gambogic acid in human plasma by liquid
chromatography-atmospheric pressure chemical ionization–mass spectrometr y  Li Ding , Di Huang,  Jinwan Wang b Shuting Li. Journal of Chromatography B, 846 (2007) 112–118","AUC0-inf reported 12660 ug.hr.L, N=6, 35 mg/m2. AUC0-inf calculated within 10% of reported. 1.73m2/70kg conversion factor.",,1955,628.75,8,2,119.4,8,anionic,7.9,4.9
Ganciclovir,82410-32-0,NC1=Nc2c(ncn2COC(CO)CO)C(=O)N1,1,4.6,0.99,3.7,3.7,"Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, and Smith RB (1995) Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/d dosing regimens in human immunodeficiency virus and cytomegalovirus seropositive patients.  Clin. Ther.  17: 425-432.   Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, and Jacobson MA (1995) Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.  Clin. Pharmacol. Ther. 57: 403-412.  Cytovene-IV Product Label",,,1982,255.23,9,4,135,5,neutral,-2.6,-2.6
Ganglioside GM1,37758-47-7,O([C@@H]1[C@@H]([C@H]([C@H](O[C@@H]2[C@H](O[C@@H](OC[C@@H]([C@@H](\C=C\CCCCCCCCCCCCC)O)NC(CCCCCCCCCCCCCCCCC)=O)[C@@H]([C@H]2O)O)CO)O[C@@H]1CO)O)OC[C@@H]([C@@H]([C@H]1[C@@H]([C@H](C[C@](O1)(C(O)=O)O)O)NC(C)=O)O)O)[C@H]1[C@@H]([C@H]([C@@H](O)[C@H](O1)CO)O[C@@H]1O[C@@H]([C@H](O)[C@@H]([C@H]1O)O)CO)NC(C)=O,0.07,0.02,,55,77.4,"Rost, K. Ludwig; Brockmoeller, Juergen; Weber, Willi; Roots, Ivar. Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to
healthy volunteers. Clin. Pharmacol. Ther. 1991, 50, 141-149.","Ganglioside A2. Ganglioside G4. Ganglioside GM1A. N=3 subjects, 21 d dosing at 100 mg/day iv. 68.8 kg average weight. No data reported but indication that the compound is very highly bound to plasma proteins.",,1969,1546.82,34,20,540.6,52,anionic,-0.53,-4
Ganirelix,124904-93-4,"N([C@@H](C(=O)N[C@H](C(N[C@H](C(N[C@@H](C(N[C@@H](C(=O)N[C@@H](C(N[C@H](C(N[C@H](C(=O)N1[C@H](C(N[C@@H](C(N)=O)C)=O)CCC1)CCCC\N=C(\NCC)NCC)=O)CC(C)C)=O)CCCC\N=C(/NCC)NCC)Cc1ccc(cc1)O)=O)CO)=O)Cc1cccnc1)=O)Cc1ccc(cc1)Cl)Cc1ccc2c(c1)cccc2)C(=O)C
",0.21,0.63,0.18,5.61,9.09,"Oberyé JJ, Mannaerts BM, Kleijn HJ, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril. 1999 Dec;72(6):1001-1005.","19 female volunteers, 63.1 kg average weight, 0.25 mg dose. Data digitized from plot reported. AUC (0-inf) reported as 105 ng.h.mL-1; calculated value 104.6 ng.h.mL-1. Difference < 1%.",,1989,1570.32,31,16,451.5,48,cationic,5.7,3.4
Garenoxacin,194804-75-6,[H]N1Cc2cc(ccc2[C@H]1C)c1ccc2C(C(=CN(C3CC3)c2c1OC(F)F)C(=O)O[H])=O,1,1.23,0.25,13.7,,"Hayakawa, Hiroyoshi; Fukushima, Yoko; Kato, Hiroshi; Fukumoto, Hiroyuki; Kadota, Takumi; Yamamoto, Hiroyuki; Kuroiwa, Hiroyuki; Nishigaki, Junko; Tsuji, Akira. (2003) Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metab. Disp. 31 (11) 1409-1418.","Also known as ganefloxacin and T 3811. Human data reported from a presentation bY Gajjar, D. et al at 2001 ICAAC.  Average weight taken as 70 kg. MRT from VDss and Cl. Data to be confirmed.",,1997,426.41,6,2,78.9,6,zwitterionic,3.4,1.1
Gatifloxacin,112811-59-3,COc1c(N2CCNC(C)C2)c(F)cc3C(=O)C(=CN(C4CC4)c13)C(=O)O,1.7,2.8,0.8,11,10,"Gajjar DA, LaCreta FP, Uderman HD, Kollia GD, Duncan G, Birkhofer MJ, and Grasela DM (2000) A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.  Pharmacotherapy  20: 49S-58S.  Perry C, Balfour J, and Lamb H (1999) Gatifloxacin.  Drugs 58: 683-698.",,,1987,375.39,7,2,82.1,4,zwitterionic,2.1,-0.65
Gavestinel,153436-22-7,[H]N(C(C=Cc1c2c(cc(cc2n([H])c1C(=O)O[H])[Cl])[Cl])=O)c1ccccc1,0.12,0.089,0.002,22.47,,"Iavarone L et al. First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol, 1999, 39, 560-566. ","Data from 100 mg iv dose, 70 Kg weight. MRT calculated from CL and VDss. GV150526. 
fu reported as fu% but unlikely to be %.  Likely to be fu.",,1993,375.21,5,3,82.2,5,anionic,4.6,1.8
Gefitinib,184475-35-2,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,23,12,0.089,32,34,"Swaisland, HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, and Duvauchelle T (2005) Single-dose clinical pharmacokinetics studies of gefitinib.  Clin. Pharmacokinet. 44: 1165-1177.  McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CMF, Clarkson-Jones JA, Herron W, and Swaisland HC (2004) Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.  Xenobiotica 34: 917-934",,,1986,446.9,7,1,68.7,8,cationic,4.3,3.9
Gemcitabine,95058-81-4,NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F,1.5,32,1,0.81,1,"Paitnik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, terada K, Gentner L, Rybak ME, Richards H, Zhang S, and Rowinsky EK (2003) A phase I pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.  Clin. Canc. Res. 9: 4761-4771.  Gemzar Product Label.",Parameters calculated from data obtained by digitization of the plot provided in the reference.,,1984,263.2,7,3,108.4,2,neutral,-1.9,-1.9
Gemifloxacin ,175463-14-6,CO/N=C/1\CN(CC1CN)c2c(cc3c(=O)c(cn(c3n2)C4CC4)C(=O)O)F,3.52,7.2,0.3,8.1,8.3,"PP. Gemifloxacin Mesylate - FDA Approval Package
Microbiology Review 021158/S-000 Part 07. Table 8.","N=23, 250 mg dose, 70 kg assumed. MRT from VDss and Cl.  ppb from label.",,1995,389.38,9,2,123,5,zwitterionic,1.7,-0.26
Genaconazole,120924-80-3,C[C@@H]([C@@](O)(Cn1cncn1)c2ccc(F)cc2F)S(=O)(=O)C,0.62,0.19,,54,49,"Mojavrian P, Radwanski E, Affirme MB, Cayen MN, and Lin CC (1994) Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.  Antimic. Agents Chemother.  38: 2758-2762.",VDss calculated from digitized plots.,,1989,331.34,6,1,85.1,5,neutral,-0.18,-0.18
Gentamicin,1403-66-3,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@@H](CC[C@H]3N)[C@@H](C)N)[C@@H]2O)OC[C@]1(C)O,0.33,1,1,5.5,4.7,"Bertino JS, Booker LA, Franck P, and Rybicki B (1991) Gentamicin pharmacokinetics in patients with malignancies.  Antimic. Agents Chemother.  35: 1501-1503.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.",,,1963,463.57,12,8,213.7,6,cationic,-4.1,-7.1
Gestodene,60282-87-3,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C,0.46,0.8,0.023,9.6,10,"Tauber U, Tack JW, and Matthes H (1989) Single dose phakmacokinetics of gestodene in women after intravenous and oral administration.  Contraception 40: 461-476.    Kuhnz W, Pfeffer M,and Al-Yacoub G (1990) Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.  J. Steroid Biochem. 35: 313-318.  Gui LQ and Humpel M (1990) Serum protein binding characteristics of cyproterene acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man.  J. Steroid Biochem. 35: 319-326.","VDss deteremined from Cvs t data obtained by digitization of plots in Tauber, 1989.  Protein binding very different in two reports: 0.006 in Kuhnz et al vs 0.04 in Gui and Humpel; value entered is the average.",,1977,310.43,2,1,37.3,2,neutral,4.1,4.1
GHRP-6,87616-84-0,c1(c[nH]c2c1cccc2)C[C@@H](C(N[C@@H](C(N[C@H](C(=O)N)CCCCN)=O)Cc1ccccc1)=O)NC([C@@H](NC([C@H](NC([C@H](Cc1[nH]cnc1)N)=O)Cc1c[nH]c2c1cccc2)=O)C)=O,0.42,3.1,,2.45,2.46,"Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers Cabrales, Ania; Gil, Jeovanis; Fernandez, Eduardo; Valenzuela, Carmen; Hernandez, Francisco; Garcia, Idrian; Hernandez, Ariadna; Besada, Vladimir; Reyes, Osvaldo; Padron, Gabriel; Berlanga, Jorge; Guillen, Gerardo; Gonzalez, Luis Javier European Journal of Pharmaceutical Sciences 48 (2013) 40–46","Data reported in Table 3. 100, 200, 400 ug/kg iv N=3 per dose. Average of all data.His-( -Trp)-Ala-Trp-( -Phe)-Lys-NH2, MW = 872.44 Da. Reported clearance 0.19, 0.17 and 0.20 L/h/kg, respectively.",,1983,873.01,18,11,300.9,23,cationic,0.42,-2.4
Ginkgolide A,15291-75-5,C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)C36[C@@H](OC(=O)[C@@H]6O)OC4(C(=O)O5)[C@@]12O,0.62,2.3,,4.6,3.8,"Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A. Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biloba (EGb 761).  Therapie 1995, 50, 137-144.",,,1967,408.4,9,2,128.6,0,neutral,-3.3,-3.4
Ginkgolide B,15291-77-7,C[C@@H]1C(=O)O[C@H]2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)C36[C@@H](OC(=O)[C@@H]6O)OC4(C(=O)O5)[C@@]12O,0.91,2.3,0.8,6.6,5.2,"Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A (1995) Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biloba (EGb 761).  Therapie  50: 137-144. ppb: Protein binding ratio of Ginkgolide B in plasma Chen, Wei-dong; Liang, Yan; Xie, Lin; Wang, Lei; Wu, Yong; Wang, Dian-lei. Anhui Yiyao, 2012, 16, 154-157. From abstract in English.",,,1967,424.4,10,3,148.8,0,neutral,-4.3,-4.5
Ginsenoside RD,52705-93-8,C[C@@]12[C@@H]([C@]3(C)[C@@H](CC2)C(C)(C)[C@H](CC3)O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O)[C@@H](O)[C@@H]([C@H](O2)CO)O)C[C@H]([C@H]2[C@@]1(C)CC[C@@H]2[C@@](O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O)(CCC=C(C)C)C)O,0.11,0.09,,20.2,18.5,"Pharmacokinetics and Safety of Ginsenoside Rd Following a Single or Multiple Intravenous Dose in Healthy Chinese Volunteers. Xing Zeng, PhD, Yuanhui Deng, BS, Yi Feng, MS, Yiming Liu, PhD, Liu Yang, MS, Yu Huang, MS, Jing Sun, BS, Weixiong Liang, MD, and Yongyuan Guan, MD. J. Clin. Pharmacol. 2010, 50, 285-292.","VDss calculated from reported clearance and MRT. 10, 40 and 75 mg doses, N=10 each cohort. Average values taken.",,1974,947.15,18,12,298.1,13,neutral,-0.39,-0.39
Gisadenafil,334826-98-1,C(C)c1c2c(nn1CCOC)c(=O)nc([nH]2)c1c(OCC)ncc(c1)S(=O)(=O)N1CCN(CC1)CC,2.4,14.3,,2.8,4,"Kenny J. Watson, John Davis, and Hannah M. Jones. Application of Physiologically Based Pharmacokinetic Modeling to Understanding the Clinical Pharmacokinetics of UK-369,003. Drug Metabolism and Disposition 2011, 39, 1203–1213.","UK-369,003. MRT from VDss and Cl. 70 kg assumed for clearance. 1 mg/kg dose",,2001,519.62,12,1,135.5,10,cationic,0.96,0.26
Glibornuride,26944-48-9,Cc1ccc(cc1)S(=O)(=O)NC(=O)N[C@H]2[C@H]3CC[C@@]([C@H]2O)(C3(C)C)C,0.27,0.34,,13,9.2,"K. STOECKEL, V. TRUEB, U. C. DUBACH, R. C. HEINTZ, V. ASCALONE, I. FORGO, U. HENNES. Lack of effect of tenoxicam on glibornuride kinetics and response. Br. J. clin. Pharmac. (1985), 19, 249-254","20 mg dose, N=8, 69.4 kg average weight.MRT from clearance and VDss",,1968,366.48,6,3,95.5,3,anionic,2.4,0.62
Gliclazide,21187-98-4,C1[C@@H]2[C@@H](CN1NC(NS(c1ccc(C)cc1)(=O)=O)=O)CCC2,0.43,0.41,0.03,17.5,16.4,"Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers  Delrat, P.; Paraire, M.; Jochemsen, R. Biopharmaceutics & Drug Disposition (2002), 23(4), 151-157. ppb: (from abstract in English) Xu, Shanshan; Xue, Yuehua; Tian, Ziyou; Chen, Saizhen; Wang, Zhichao; Wang, Renye. Effect of irbesartan on the plasma protein binding rate of gliclazide in vitro Zhongguo Linchuang Yaoxue Zazhi. 2013, 22, 151-155","N=2, 73 kg reported average weight. MRT = VDss/CL.",,1968,323.41,6,2,78.5,3,anionic,1.7,0.2
Glimepiride,93479-97-1,CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@@H]3CC[C@@H](C)CC3)C1=O,0.19,0.5,0.005,6.3,10,"Badian M, Korn A, Lehr KH, Malerczyk V, and Waldhaust W (1994) Absolute bioavailability of glimepiride (Amaryl) after oral administration.  Drug Metab. Drug Inter. 11: 331-339.  Amaryl Product Label.",Parameters calculated from C vs t data digitized from a plot provided in the reference.  Data reported in the table in the reference did not correspond to data obtained from the plot.,,1988,490.62,9,3,124.7,7,anionic,4.2,2.1
Glipizide,29094-61-9,Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,0.16,0.56,0.02,4.8,3.3,"Pentikainen PJ, Neuvonen PJ, and Penttila A (1983) Pharmacokinetics and pharmacodynamics of glipizide in health volunteers.  Int. J. Clin. Pharmacol. Ther. Toxicol. 21: 98-107.  Fuccella LM, Tamassia V, and Valzelli G (1973) Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide.  J. Clin. Pharmacol. New Drugs 13: 68-75.",,,1970,445.54,9,3,130.1,7,anionic,2.1,0.0081
Gludopa,52370-58-8,c1(cc(C[C@H](NC(=O)CC[C@@H](C(O)=O)N)C(O)=O)ccc1O)O,0.21,4.6,,0.74,0.5,"Y. A. BOATENG, H. E. BARBER, T. M. MacDONALD, J. C. PETRIE & M. R. LEE. Disposition of y-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. Br. J. clin. Pharmac. (1991), 31, 419-422","Average of 100 and 250 u/kg doses, N=5 per cohort.",,1974,326.3,9,6,170.2,8,anionic,-1.1,-5.9
Glufosfamide,132682-98-5,P(O[C@H]1[C@@H]([C@H]([C@H](O)[C@H](O1)CO)O)O)(=O)(NCCCl)NCCCl,0.24,1.6,0.71,2.49,2.37," Data (N=13, doses 3200-6000 mg/m2 6h i.v. infusion) reported in Table 5 in Shimizu, Toshio; Okamoto, Isamu; Tamura, Kenji; Satoh, Taroh; Miyazaki, Masaki; Akashi, Yusaku; Ozaki, Tomohiro; Fukuoka, Masahiro; Nakagawa, Kazuhiko.  Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors.    Cancer Chemotherapy and Pharmacology  (2010),  65(2),  243-250.  MRT calculated from CL and VDss.      fu as average of all human serum and human plasma measures reported in Table 4 in Stueben, Joerg; Port, Ruediger; Bertram, Barbara; Bollow, Ursula; Hull, William E.; Schaper, Marianne; Pohl, Joerg; Wiessler, Manfred.  Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent .beta.-D-glucosylisophosporamide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.    Cancer Chemotherapy and Pharmacology  (1996),  38(4),  355-365.","Data as weighted average of three doses across 13 patients (3,200/4,500/6000 mg/m2, N-3/7/3). Conversion factor used 1.73m2/70 kg. 6-hour infusion. Also reported as D 19575 ",,1990,383.16,9,6,140.5,9,neutral,-2.3,-2.3
Glyburide,10238-21-8,COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,0.08,0.82,0.021,1.6,2.2,"Jonsson A, Chan JCN, Rydberg T, Vaaler S, Hallengren B, Cockram CS, Critchley JAJH, and Melander A (2000) Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes.    Eur. J. Clin. Pharmacol. 55: 721-727. Spraul M, Streeck A, Nieradzik M, and Berger M (1989) Uniform elimination pattern for glibenclamide in healthy caucasian males.  Arz. Forsch. 39: 1449-1450. George S, McBurney A, and Cole A (1990) Possible protein binding displacement interaction between glibenclamide and metolazone.  Eur. J. Clin. Pharmacol. 38: 93-95.",glibenclamide,,1966,494,8,3,113.6,8,anionic,4.1,2
Glyceryl 1-nitrate,624-43-1,C([C@@H](CO)O)O[N+](=O)[O-],0.76,3.63,,4.12,2.5,"H. LAUFEN, M. LEITOLD. Glyceryl-1-nitrate pharmacokinetics in healthy volunteers. Br. J. Clin. Pharmac. (1987), 23, 287-293.","N=10, 20 mg kg dose administered via 1hr infusion, 77.9 kg average weight.",,1949,137.09,6,2,92.8,4,neutral,-0.51,-0.51
Glycopyrrolate bromide,596-51-0,C(C1CCCC1)(c1ccccc1)(C(=O)OC1C[N+](CC1)(C)C)O.[Br-],0.37,16.8,,0.37,0.65,"Penttilä J et al. Pharmacokinetic-pharmacodynamic model for the anticholinergic effect of glycopyrrolate. Eur J Clin Pharmacol, 2001, 57, 153-158","Data from Table 1. micro dose (5 µg/kg), N=8, 3 compartments. MRT calculated from VDss and CL. T1/2 compartment 3. Body weights 60-80kg. ",CL renal ~68% ,1960,398.33,4,1,46.5,5,neutral,-0.23,-0.23
Glycyrrhizin,1405-86-3,C1([C@H]2[C@@]([C@@]3(C([C@H]4[C@@](CC[C@@](C4)(C(O)=O)C)(C)CC3)=C1)C)(CC[C@@H]1[C@@]2(CC[C@@H](C1(C)C)O[C@@H]1[C@H](O[C@@H]2O[C@@H]([C@@H](O)[C@@H]([C@H]2O)O)C(O)=O)[C@H]([C@H](O)[C@H](O1)C(O)=O)O)C)C)=O,0.06,0.13,,7.83,8.83,"Tekla G.J. van Rossum, MD, Arnold G. Vulto, PhD, Wim C. J. Hop, MSc, PhD, Solko W. Schalm, MD, PhD Pharmacokinetics of Intravenous Glycyrrhizin After Single and Multiple Doses in Patients with Chronic Hepatitis C Infection. CLlNICALTHERAPEUTICS, 1999,21, 2080-2090","Weighted average over 4 doses (80, 160, 200, 240) from table II (Day1). N=33 overall. ",,1880,822.93,16,8,267,7,anionic,1.5,-7.5
GPX-150,236095-29-7,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=N)OC)O)(C(=O)CO)O)N)O,15.45,15,,17.16,13.8,"Sarah A. Holstein,  James C. Bigelow, Richard D. Olson, Robert E. Vestal, Gerald M. Walsh , Raymond J. Hohl.  Phase I and pharmacokinetic study of the novel anthracycline
derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. Invest New Drugs (2015) 33:594–602","N=7, 256 mg/m2 dose, iv infusion, multiple cycles. 1.73m2/70 kg conversion factor used. MRT from VDss and clearance. ",imino derivative of doxorubicin,1999,542.53,12,7,212.8,5,cationic,0.036,-2.9
Granisetron,109889-09-0,CN1[C@@H]2CCC[C@H]1C[C@H](C2)NC(=O)c3nn(C)c4ccccc34,3.7,9.1,0.35,6.7,5.2,"Allen A, Asgill CC, Pierce DM, Upward J, and Zussman BD (1994) Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects.  Eur. J. Clin. Pharmacol.  46: 159-162.  Kytril Product Label.","VDss calculated from CL and MRT provided in Allen, et al., 1994.",,1988,312.41,5,1,50.2,2,cationic,2.8,1.2
Grepafloxacin,119914-60-2,c1(c(c2c(c(F)c(cc2n(c1)C1CC1)N1C[C@@H](C)NCC1)C)=O)C(=O)O,,5.9,0.82,,9.2,"PP. Grepafloxacin Hydrochloride - FDA Approval Package Review 020695
ppb: Clinical Pharmacology and Biopharmaceutics . Determination of protein binding of gyrase inhibitors by means of continuous ultrafiltration G Zlotosa, M Oehlmannb, P Nickelb, U Holzgrabe. Journal of Pharmaceutical and Biomedical Analysis, 1998, 18,  847–858","N=5/dose, 100 and 200 mg iv dose. No VDss reported. ",,1988,359.39,6,2,74.6,3,zwitterionic,2.8,-0.015
GSK1322322,1152107-25-9,N1(C(COCC1)CN(C1)C(=C(C(=NC2C)NNC(C(CC3CCCC3)CN(C=O)O)=O)F)N=2)C1,0.75,5.6,,2.2,4.2,"Donna Mamaril-Fishman, John Zhu, Min Lin, Clive Felgate, Lori Jones, Patrick Stump,Esaie Pierre, Chester Bowen, Odin Naderer, Etienne Dumont, Parul Patel, Peter D. Gorycki, Bo Wen, Liangfu Chen, and Yanli Deng. Investigation of Metabolism and Disposition of GSK1322322, a PDF Inhibitor, in Healthy Humans Using Entero-Test® For Biliary Sampling. Drug Metab Dispos  2014 42:1314-1325","Lanopepden. 70 kg weight assumed. 1000 mg iv dose over 1 hr infusion. MRT from VDss and clearance. Data from table 2. See also, Naderer, O. J. et al. J. Clin. Pharmacol. 2013, 53, 1168-1175.",,2009,479.55,11,3,123.2,8,cationic,-0.21,-1.2
GSK2140944,1075236-89-3,c1cc(=O)n2c3c1ncc(=O)n3[C@@H](C2)CN4CCC(CC4)NCc5cc6c(cn5)OCCC6,2.7,9.23,,4.86,12.6,"Negash, Kitaw; Andonian, Clara; Felgate, Clive; Chen, Cathy; Goljer, Igor; Squillaci, Bianca; Nguyen, Dung; Pirhalla, Jill; Lev, Mally; Schubert, Ernest; Tiffany, Courtney; Hossain, Mohammad; Ho, May. The metabolism and disposition of GSK2140944 in healthy human subjects. Xenobiotica, 2016, 46, 683-702","Gepotidacin. 1000 mg, 2 hr infusion, data in mL/min/kg and L/kg reported by authors on a 70 kg basis. MRT calculated as VDss/clearance.",59% excreted unchanged in urine from iv dose.,2008,448.52,9,1,94.3,5,cationic,-0.75,-2.5
GSK2239633,1240516-71-5,COc1cccc2c1c(NS(=O)(=O)c3ccc(Cl)s3)nn2Cc4cccc(CNC(=O)C(C)(C)O)c4,1.65,5.1,,5.43,13.5,"Cahn, Anthony; Hodgson, Simon; Wilson, Robert; Robertson, Jonathan; Watson, Joanna; Beerahee, Misba; Hughes, Steve C.; Young, Graeme; Graves, Rebecca; Hall, David; van Marle, Sjoerd; Solari, Roberto. Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-​chemokine receptor 4 antagonist, in healthy male subjects: results from an open-​label and from a randomised study. BMC Pharmacology and Toxicology 2013 14:14.","microdose, 100 ug. N=6, average weight 71.9 kg. Also reported as GSK2239633A. Gem-dimethyl derivative = compound 7r in reference 28 cited by PK reference.",,2010,549.06,9,3,122.6,8,anionic,3.2,1.2
GSK2251052,1093643-37-8,B1(c2c(cccc2OCCCO)[C@H](O1)CN)O,2.37,4.1,,9.6,11.6,"Gary D Bowers, David Tenero, Parul Patel, Phuong Huynh, James Sigafoos, Kathryn O’Mara, Graeme C Young, Etienne Dumont, Elizabeth Cunningham, Milena Kurtinecz, Patrick Stump, JJ Conde, John P Chism, Melinda J Reese, Yun Lan Yueh and John F Tomayko. Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibiotic.  Drug Metabolism & Disposition (2013), 41(5), 1070-1081","Epetraborole. MRT from VDss and clearance. 1500 mg dose, 83.1 kg as average weight, N=6, 1 hour infusion.","GSK2251052 is metabolically eliminated.
98% radioactivity recovery (~90% urine, ~8 feces), with only 29% of dose as unchanged.
",2008,237.06,5,3,84.9,5,cationic,-0.61,-3.7
GSK269984A,892664-17-4,c1cc(nc(c1)C(=O)O)Cc2cc(ccc2OCc3ccc(cc3F)Cl)Cl,0.77,2,,6.4,8.15,"Thor Ostenfeld, Claire Beaumont, Jonathan Bullman, Maria Beaumont, Phillip Jeffrey. Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A. Br J Clin Pharmacol 2012, 74:6, 1033–1044.","GSK269984A free acid or GSK269984B. 100 ug. Microdose. N=5, average weight 81.6 kg. MRT from VDss and clearance. Structure and CAS number refer to free acid. ",,2006,406.23,4,1,59.4,6,anionic,6,3.2
GSK461364,929095-18-1,NC(C1=C(C=C(N(C2=C3)C=NC2=CC=C3CN4CCN(C)CC4)S1)O[C@H](C)C5=CC=CC=C5C(F)(F)F)=O,12,20,,10,10.3,"D. Olmos et al. Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies. Clin Cancer Res 2011;17:3420-3430",Weighted average on the basis of PK data set. 25-300 mg total dose range. Once and twice weekly (the latter on day 1). N=37 patients for 72 PK sets. 4hr infusion.70 kg dose assumed. MRT from VDss and clearance.,,2007,543.6,7,1,76.6,7,cationic,4.1,3
Guanfacine,29110-47-2,NC(=N)NC(=O)Cc1c(Cl)cccc1Cl,5.6,4.5,0.28,22,15,"Carchman SH, Crowe JT, and Wright GJ (1987) The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers.  J. Clin. Pharmacol. 27: 762-767.",CL and VDss were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1969,246.09,4,3,79,3,cationic,1.3,0.17
Guanylcisteine,40454-21-5,N([C@H](C(O)=O)CS)C(N)=N,0.25,2.88,,1.39,1.34,"R. Cadórniga, E. Barcia, I. T. Molina, A. Galiano, J.A. Gutiérrez. Estudio farmacocinetico de la guanil-cisteina. Rev farmacol Clin Exp 1987, 4, 325-331.","N=10, 69.4 kg average weight, 600 mg dose. VDss from Vc and k12/k21. Clearance from dose and AUC.",,1961,163.2,5,4,99.2,4,zwitterionic,-1.1,-3.4
Haloperidol,52-86-8,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3,17,7.8,0.08,36,35,"Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, and Hollister LE (1983) Haloperidol kinetics after oral and intravenous administration.  Clin. Pharmacol. Ther. 33: 477-484.  Chang WH, Lam YWF, Jann MW, and Chen H (1992) Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.  Psychopharmacology 106: 517-522.  Cheng YF, Paalzow LK, Bondesson U, Ekblom B, Eriksson K, Eriksson SO, Lindberg A, and Lindstrom L (1987) Pharmacokinetics of haloperidol in psychotic patients.  Psychopharmacology 91: 410-414.  Forsman A and Ohman R (1977) Studies on serum protein binding of haloperidol.  Curr. Ther. Res. 21: 245-255.",,,1958,375.86,3,1,40.5,6,cationic,4.3,3.3
Heptaminol,372-66-7,CC(CCCC(C)(C)O)N,2.14,10.72,,3.24,2.5,"Von F. Kees, P. Pominiak und H. Grobecker. Untersuchungen zur Bioverfiigbarkeit von Heptaminol bei Probanden. Arzneim.-Forsch./Drug Res. 1987, 37, 1182-1185","N=10, 65 kg median weight reported. 250 and 300 mg dose, with essentially identical PK parameters. Data for the 250 mg dose taken. MRT from VDss and clearance",,1948,145.24,2,2,46.3,3,cationic,1.4,-1.6
Heroin,561-27-3,"CC(=O)Oc1ccc2c3c1O[C@@H]4[C@]35CC[N@@]([C@H](C2)[C@@H]5C=C[C@@H]4OC(=O)C)C
",1.31,212.3,,0.1,0.062,"Elisabeth J. Rook, Jan M. van Ree, Wim van den Brink, Michel J. X. Hillebrand, Alwin D. R. Huitema, Vincent M. Hendriks, Jos H. Beijnen. Pharmacokinetics and Pharmacodynamics of High Doses of Pharmaceutically Prepared Heroin, by Intravenous or by Inhalation Route in Opioid-Dependent Patients. Basic & Clinical Pharmacology & Toxicology 2006, 98, 86–96.","N=11, 73 kg average weight reported. No actual dose reported. 930 L/h average clearance at ""steady-state"" after iv doses to ""chasers"" and VD as 96 L but without specification of type of volume. VD taken as Vbeta = VDss as seemingly showing  1 compartment behavior. T1/2 of terminal phase: 3.7 minutes. MRT = t1/2/0.693.",,1906,369.41,6,0,65.1,4,cationic,1.9,1.1
Hexobarbital,56-29-1,CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O,1.1,3.4,0.53,5.4,4.9,"Breimer DD, Honhoff C, Zilly W, Richter E, and van Rossum JM (1975) Pharmacokinetics of hexabarbital in man after intravenous infusion.  J. Pharmacokinet. Biopharm. 3: 1-11.  Zilly W, Breimer DD, and Richter E (1975) Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.  Eur. J. Clin. Pharmacol. 9: 219-227.  Zilly W, Breimer DD, and Richter E (1978) Hexobarbital disposition in compensated and decompensated cirrhosis of the liver.  Clin. Pharmacol. Ther. 23: 525-534.",,,1927,236.27,5,1,66.5,1,neutral,1.8,1.8
Homoharringtonine,26833-87-4,[C@@]123[C@@H]([C@@H](C(=C1)OC)OC(=O)[C@](CC(=O)OC)(O)CCCC(O)(C)C)c1c(cc4c(c1)OCO4)CCN2CCC3,1.8,2.96,,10.2,9.8,"Clinical pharmacology of homoharringtonine Savaraj N; Lu K; Dimery I; Feun L G; Burgess M; Keating M; Loo T L 
Cancer treatment reports (1986), 70(12), 1403-7.  ","Omacetaxine mepesuccinate Reported averages in table 1 for HHT. Dosed by 6-hour infusion at 3-4 mg/m2, N=8. MRT from Cl and VDss.",,1970,545.62,10,2,124,10,cationic,0.95,0.17
Hydralazine,86-54-4,N\N=C\1/NN=Cc2ccccc12,1.5,85,0.12,0.29,1,"Ludden TM, Shepherd AMM, McNay JL, and Lin MS (1983) Effect of intravenous dose on hydralazine kinetics after administration.  Clin. Pharmacol. Ther.  34: 148-152.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ","From Ludden, et al., used 1.02 umol/kg dose group.  Blood values corrected to plasma using B/P=1.68.  ",,1949,160.18,4,2,62.8,0,cationic,2.4,-1.1
Hydrocortisone,50-23-7,C[C@]12CCC(=O)C=C1CC[C@H]3[C@@H]4CC[C@](O)(C(=O)CO)[C@@]4(C)C[C@H](O)[C@H]23,0.38,5.7,0.2,1.9,1.6,"Derendorf H, Moellmann H, Barth J, Mollman C, Tunn S, and Krieg M (1991) Pharmacokinetics and oral bioavailability of hydrocortisone.    J. Clin. Pharmacol. 31: 473-476.   Toothaker RD and Welling PG (1982) Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression.  J. Pharmacokinet. Biopharm. 10: 147-156.  Mager DE and Jusko WJ (2002) Quantitative structure pharmacokinetic/pharmacodynamic relationships of corticosteroids in man.  J. Pharm. Sci. 91: 2441-2451.",,,1946,362.46,5,3,94.8,2,neutral,1.5,1.5
Hydroflumethiazide,135-09-1,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F,2.2,9.7,,3.8,5.2,Broers O and Jacobsen S (1979) Distribution and elimination of hydroflumethiazide in man.  Eur. J. Clin. Pharmacol. 16: 125-131.,VDss calculated from reported micro constants.  CL calculated from Vdbeta and t1/2,,1959,331.29,7,3,118.4,1,neutral,0.047,0.032
Hydromorphone,466-99-9,CN1CC[C@@]23[C@H]4CCC(=O)[C@@H]2Oc5c(O)ccc(C[C@@H]14)c35,4.3,28,0.86,2.6,2.3,Dilaudid-HP Product Label,,,1945,285.34,4,1,49.8,0,cationic,1.5,0.47
"Hydroxycamptothecin, 10-",19685-09-7,CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5ccc(cc5c4)O)O,0.22,2.23,,1.63,1.67,"LI Su, ZHANG Li, GUANG Zhong-zhen, ZHAN Jing, LI Yu-yan , JIANG Wen-qi. Absolute bioavailability of hydroxycamptothecin tablets in cancer patients. Chin. J. Clin. Pharmacol. 2005, 22, 46-49.(written in Chinese) ","N=8, 12 mg.m-2 dose, conversion factor 1.73m2/70kg, 30 minutes infusion. Data digitized and PK parameters calculated via PKSolver. AUC reported as 2171 ug.h.L-1 (not specified); AUS (inf) calculated as 2211 ng.h.mL-1. 2% difference.",,1969,364.35,7,2,101.6,1,neutral,1.4,1.4
Hydroxychloroquine,118-42-3,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,700,11,0.57,1300,850,"Tett SE, Cutler DJ, Day RO, and Brown KF (1988) A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br, J. Clin. Pharmacol. 26: 303-313.  Brocks DR, Skeith KJ, Johnston C, Emamibafrani J, Davis P, Russell AS, and Jamali F (1994) Hematologic disposition of hydroxychloroquine enantiomers. J. Clin. Pharmacol. 34: 1088-1097. ",,,1891,335.87,4,2,48.4,9,cationic,4.1,1.5
"Hydroxycotinine, 3'-",34834-67-8,CN1[C@@H](C[C@@H](O)C1=O)c2cccnc2,0.85,1.8,,7.9,5.9,"Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, and Adlkofer F (1988) Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers.  Klin. Wochenschr. 66(Supp 11): 5-11.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1960,192.21,4,1,53.4,1,anionic,-1.5,-2
"Hydroxydihydroquinidine, 3(S)-",85405-59-0,CC[C@@]1(O)CN2CC[C@H]1C[C@@H]2[C@@H](O)c3ccnc4ccc(OC)cc34,6.8,12,0.47,9.4,6.7,"Jaillon P, Poirier JM, Lecocq B, Jarreau C, Pays M, Richard MO, and Cheymol G (1986) Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.  Eur. J. Drug Metab. Pharmacokinet. 11: 233-238.  Leroyer R, Varoquaux O, Guillebastres R, Jarreau C, Normand JP, Jaillon P, Advenier C, and Pays M (1986) Study on protein binding of 3-(R)- and 3-(S)-hydroxy derivatives of quinidine and dihydroquinidine.  Therapie 41: 159-162.",,,1982,342.43,5,2,65.8,4,cationic,2.2,1.4
"Hydroxyimipramine, 2-",303-70-8,CN(C)CCCN1c2ccccc2CCc3cc(O)ccc13,6.6,9.2,0.36,12,10,"Ciraulo DA, Barnhill JG, Jaffe JH, Ciraulo AM, and Tarmey MF (1990) Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls.  J. Studies Alcohol 51: 366-372.",VDss calclated from C vs t data obtained by digitization of the plot included in the reference.,,1959,296.41,3,1,26.7,4,cationic,3.9,2.2
Hydroxymidazolam,59468-90-5,c1cc2n3c(cnc3CO)CN=C(c3ccccc3F)c2cc1Cl,0.77,9.71,0.1,1.3,1.1,"Mandema, Jaap W.; Tuk, Bert; Van Steveninck, Alfred L.; Breimer, Douwe, D.; Cohen, Adam F.; Danhof, Meindert.   Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite  -hydroxymidazolam in healthy volunteers.    Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)  (1992),  51(6),  715-28.","1-hydroxymidazolam, a-hydroxymidazolam. 70 kg assumed using data reported in table 1 (average obtained from dose in mg and mg/kg was 69.2). MRT from VDss and clearance. N=8 at doses around 0.1 mg/kg.",,1976,341.77,4,1,50.4,2,neutral,1.9,1.9
"hydroxypropyl cyclodextrin,β-",128446-35-5,O1[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@@H]([C@@H](O[C@H]4O[C@@H]([C@H]([C@H](O)[C@H]4O)O[C@H]4O[C@@H]([C@H]([C@H](O)[C@H]4O)O[C@H]4O[C@@H]([C@@H](O[C@H]5O[C@@H]([C@@H](O[C@H]6O[C@@H]([C@@H]1[C@H](O)[C@H]6O)CO)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)CO)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO.[*]CCO,0.21,1.8,,1.9,1.6,"Szathmary, S.C.; Seiler, K.U.; Luhmann, I.; Huss, H.J. Pharmacokinetic behavior and absolute bioavailability of hydroxypropyl-beta-cyclodextrin after increasing doses in volunteers. Cyclodextrins : 5th International symposium : Papers, 1990, 535-540.",N=8/leg. Assumes 70 kg BW. Averaged data from 6 dose levels (0.5 to 3 gm) ,,1987,1180.04,36,22,574.3,8,n/a,n/a,n/a
Hydroxysafflor yellow A,78281-02-4,C1(C(=C([C@@](C(=C1C(\C=C\c1ccc(cc1)O)=O)O)(O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)=O,0.2,1,0.22,3.6,2.9," Pharmacokinetic properties of hydroxysafflor yellow A in healthy Chinese female volunteers. Yang, Zhifu; Yang, Jing; Jia, Yanyan; Tian, Yun; Wen, Aidong  Journal of Ethnopharmacology (2009), 124, (3), 635-638. ppb: Wang, Jianming; Zou, Tian; Zhang, Yuanyuan; Fan, Ning. Study on plasma protein-​binding rate of hydroxysafflor yellow A in safflor yellow powder injection. Zhongchengyao (2011), 33(6), 947-949. Data from abstract in English.","HSYA, Safflomin A. Data digitized from figure 1. 1 hr infusion, all female chinese subjects, average weight 57.1 kg. 35, 70 and 140 mg doses. N=12 per dose group.",,1981,612.53,16,12,295.4,7,neutral,-0.48,-0.51
"Hydroxystaurosporine, 7-",112953-11-4,CN[C@@H]1C[C@H]2OC(C)([C@@H]1OC)n3c4ccccc4c5c6[C@@H](O)NC(=O)c6c7c8ccccc8n2c7c35,0.15,0.0037,0.0022,680,790,"Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, and Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.  Canc. Res. 58: 3248-3253.  Dees EC, Baker SD, O'Reilly S, Rudek MA, Davidson SB, Aylesworth C, Elza-Brown K, Carducci MA, and Donehower RC (2005) A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.  Clin. Canc. Res.  11: 664-671.",UCN-01. Used data from 95 mg/m2 group.,,1987,482.53,8,3,89.7,2,cationic,2.5,-0.29
Hydroxyurea,127-07-1,NC(=O)NO,0.52,1.5,1,4.8,3.4,"Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.  Blood 91:1533-1541",,,1908,76.05,4,3,75.3,0,neutral,-1.5,-1.5
Hypericin,548-04-9,Cc1cc(O)c2C(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6C(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c56,0.25,0.13,,32,42,"Kerb R, Brockmuller J, Staffeldt B, Ploch M, and Roots I (1996) Single dose and steady-state pharmacokinetics of hypericin and pseudohypericin.  Antimic. Agents Chemother.  40: 2087-2093.",Data from two subjects with very high variability.,,1912,504.44,8,6,155.5,0,anionic,5.2,1.8
Ibandronic Acid (Ibandronate),114084-78-5,CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,0.55,1.8,0.15,5.1,14,"Barrett J, Worth E, Bauss F, and Epstein S (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update.  J. Clin. Pharmacol. 44: 951-965",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1981,319.23,8,5,138.5,9,anionic,-0.58,-5.9
Ibrutinib,936563-96-1,C=CC(=O)N1CCCC(C1)[n@]2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N,9.75,16.4,0.03,9.9,5,FDA site label information: accessed March 16 2015.http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205552s002lbl.pdf.,70 kg assumed. Data reported in L (VDss) or L/h (clearance). MRT form VDss and clearance. Clearance 62 (fasted) to 76 (fed) L/h. Midpoint taken. T1/2 4 to 6 hours. 5 taken as midpoint.,,2007,440.5,8,1,99.2,5,neutral,4,4
Ibuprofen,15687-27-1,CC(C)Cc1ccc(cc1)C(C)C(=O)O,0.15,0.82,0.006,3,1.6,"Martin W, Koselowske G, Toberich H, Kerkmann T, Mangold B, and Augustin J (1990) Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man.  Biopharm. Drug Dispos. 11: 265-278.  Lee KJ,  Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",,,1961,206.28,2,1,37.3,4,anionic,3.2,0.34
Ibutilide,122647-31-8,CCCCCCCN(CC)CCCC(O)c1ccc(NS(=O)(=O)C)cc1,12,26,0.6,7.7,7,"Jungbluth GL, Della-Coletta ASA, and VanderLugt JT (1991) Evaluation of the pharmacokinetics and pharmacodynamics of ibutilide fumarate and its enantiomers in healthy male volunteers.  Pharm. Res. 8: S-249.  Howard PA (1999) Ibutilide: an antiarrythmic agent for the treatment of atrial fibrillation or flutter.  Ann Pharmacother. 33: 38-47.",,,1985,384.58,5,2,69.6,14,cationic,4.4,2.4
Idarubicin,58957-92-9,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5ccccc5C(=O)c4c(O)c23)C(=O)C,38,24,0.076,26,16,"Robert J (1993) Clinical pharmacokinetics of idarubicin.  Clin. Pharmacokinet. 24: 275-288.  Kessel M, Gieseler F, and Woodcock BG (1999) Influence of serum protein on the uptake and retention of idarubicin by sensitive and multidrug resistant human leukemic cells.  Eur. J. Clin. Pharmacol. 55: 369-373.",Compendium of intravenous data with median values.,,1976,497.49,10,5,176.6,3,cationic,1.3,-1.5
Idazoxan,79944-58-4,C1CN=C(N1)C2COc3ccccc3O2,3.3,10,,5.5,4.2,"Muir NC, Lloyd-Jones JG, Nichols JD, and Clifford JM (1986) The pharmacokinetics after intravenous and oral administration in man of the alpha2-adrenoreceptor antagonist idazoxan (RX781094).  Eur. J. Clin. Pharmacol.  29: 743-745.",VDss calculated from digitized plots.,,1981,204.23,4,1,42.8,1,cationic,0.27,-2.5
Idrapril,127420-24-0,C1CC[C@@H]([C@@H](C1)C(=O)N(C)CC(=O)NO)C(O)=O,1,6.3,1,2.8,2.6,"Zanchi, A.; Nussberger, J.; Criscuoli, M.; Capone, P.; Brunner, H. R. Angiotensin-​converting enzyme inhibition by hydroxamic zinc-​binding idrapril in humans. Journal of Cardiovascular Pharmacology (1994), 24(2), 317-322//ppb: Criscuoli, Marco; Lippi, Annalisa; Mengozzi, Grazia; Sardelli, Giuliana; Subissi, Alessandro; Giachetti, Antonio. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans. Drug Metab. Disp. 1993, 21, 835-840.","N=8 , average BW = 74kg. 1, 5 and 25mg iv doses in sequence with 1 week of was-out interval. Repoorted PK of 1mg dose.  PK from 1mg profile in Fig. 5. Reported data in Table 3: CL = 446 mL/min (6.0 mL/min/kg) and term. T1/2 = 3h","The 5mg iv profile should be dose-proportional to 1mg based on the dose and AUC, but the reported CL in Table 3 is higher for 5mg. Not dose-proportionality for 25mg iv dose.",1989,258.27,7,3,106.9,4,anionic,-1,-3.5
Idrocilamide,6961-46-2,c1(\C=C\C(NCCO)=O)ccccc1,0.11,0.99,,1.93,1.35,"H. Maier-Lenz, L. Ringelski, A. Windhorfer zur.Pharmakokinetik nnd Bioverfiigba1·keit des Myotonolytikums N-(Hydroxy-2-athyl)-cinnarnid. Arzneim.-Forsch. 1980, 30, 1813-1816.","LCB-29. Brolitene. N=10, 60 mg iv dose, 68 kg average weight
Reported AUC = 11.31 +/- 4.9 ug.hr/mL AUC computed as  14.8 ug.h/mL from plot digitization but within sd and thus accepted.
lambda z = 0.7 hr-1
VD reported = 7.4 L",,1948,191.23,3,2,49.3,4,neutral,0.86,0.86
IDX899,1097733-15-7,c12c(ccc(c1)Cl)[nH]c(c2P(=O)(c1cc(cc(c1)/C=C/C#N)C)OC)C(=O)N,0.56,1.71,,5.5,4.4,"Microdose Pharmacokinetics of IDX899 and IDX989, Candidate HIV-1 Non-NucleosideReverse Transcriptase Inhibitors, Following Oral and Intravenous Administration in Healthy Male Subjects. Xiao-Jian Zhou,  R. Colin Garner,  DSc, Sheila Nicholson,  C. James Kissling,and Douglas Mayers. J Clin Pharmacol  2009, 49 (12) 1408-1416. ","GSK2248761. No structure available in SciFinder as of January 14 2012. Available in cited paper. Data digitized from figure 2. 3% difference in AUCinf with reported value. Microdose of 100 ug but PK confirmed for oral legs at pharmacologically relevant doses of 200 and 1200 mg. Iv infusion of 30' N=8, 76.6 kg average weight. ",Also reported as GSK 2248761 in SciFinder,2009,413.79,6,2,109,6,neutral,2.9,2.9
IDX989,1254181-18-4,c12c(ccc(c1F)Cl)[nH]c(c2P(=O)(c1cc(cc(c1)/C=C/C#N)C)OC)C(=O)N,0.97,1.83,,8.9,7.4,"Microdose Pharmacokinetics of IDX899 and IDX989, Candidate HIV-1 Non-NucleosideReverse Transcriptase Inhibitors, Following Oral and Intravenous Administration in Healthy Male Subjects. Xiao-Jian Zhou,  R. Colin Garner,  DSc, Sheila Nicholson,  C. James Kissling,and Douglas Mayers. J Clin Pharmacol  2009, 49 (12) 1408-1416. ","No structure available in SciFinder as of January 14 2012. Available in cited paper. Data digitized from figure 2. 6% difference in AUCinf with reported value (11.2 ug.h/mL reported, 11.9 ug.h/mL calculated). Microdose of 100 ug but PK NOT confirmed for oral legs at pharmacologically relevant doses of 200 and 1200 mg as in the case of IDX899. Iv infusion of 30' N=8, 76.6 kg average weight. ",,2009,431.78,6,2,109,6,neutral,2.9,2.9
Ifenprodil,23210-56-2,CC(C(c1ccc(cc1)O)O)N2CCC(CC2)Cc3ccccc3,18.99,64.57,,4.9,4.32,"Jing Yang,ChengtaoLu,WeiSong,JiankangLi,YiDing,YanrongZhu,JinyiCao, Likun Ding, YanyanJia, AidongWenn. Determination of ifenprodil by LC–MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. Acta Pharm. Sin.B, 2013, 3, 180-184.","Data digitized from plot reported. N=10, 62 kg median weight assumed, 15 mg dose,  0.5 hr infusion. Highly linear data. Other doses administered: 5 and 10 mg. AUCinf reported as 63.1 ng.h.mL-1. Calculated AUCinf value 62.44 ng.h.mL-1. 1% difference.",,1968,325.44,3,2,43.7,5,cationic,3.6,1.8
Ifetroban,143443-90-7,CCCCCNC(=O)c1coc(n1)[C@H]2[C@@H](Cc3ccccc3CCC(=O)O)[C@@H]4CC[C@H]2O4,4.4,6.4,,11,22,"Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, and Barbhaiya RH (2000) Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.  Drug Metab. Dispos. 28: 973-980.",,,1992,440.53,7,2,102,11,anionic,4,1.2
Ifosfamide,3778-73-2,ClCCNP1(=O)OCCCN1CCCl,0.62,1.1,1,9.4,6.6,"Corlett SA, Parker D, and Chrystyn H (1995) Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.  Br. J. Clin. Pharmacol. 39: 452-455.  ",,,1953,261.09,4,1,41.6,5,neutral,0.88,0.88
Ilaprazole,172152-36-2,Cc1c(ccnc1CS(=O)c2[nH]c3ccc(cc3n2)n4cccc4)OC,0.19,0.73,,4.32,3.59,"Hongyun Wang, Ning Ou, Liwei Lang, Ruihua Shi, Pei Hu and Ji Jiang. Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses. Xenobiotica, ahead of press, 2016. Downloaded March 27, 2016.","Data digitized from plot reported. N=15, 62.6 kg average weight reported, 20 mg dose, 45' infusion. AUCinf reported 7057 ng.hr.mL-1; calculated 7334 ng.hr.mL-1. Highly linear also at doses of 5 and 10 mg, but only highest digitized as showing the most interpretable plot.",,1995,366.44,6,1,72.8,5,anionic,2.7,1.9
Iloprost,78919-13-8,CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(=C/CCCC(=O)O)\C[C@H]12,0.37,16,0.4,0.39,0.57,Krause W and Krais T (1986) Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloproset in man.  Eur. J. Clin. Pharmacol. 30: 61-68.  Hildebrand M (1997) Pharmacokinetics and tolerablity of oral iloprost in thromboangitis obliterans patients.  Eur. J. Clin. Pharmacol. 53: 51-56.  Ventavis Product Label.,VDss calculated from digitized plots.  VDss and CL data are the average of the two reports; t1/2 data are only from Hildebrandt. ,,1981,360.49,4,3,77.8,9,anionic,3.5,0.96
Imatinib,152459-95-5,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,3.9,3.3,0.05,20,22,"Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Sieberling M, Pokorny R, Capdeville R, and Lloyd P (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.  J. Clin. Pharmacol. 44: 158-162. Gleevec Product Label.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1993,493.6,8,2,86.3,7,cationic,4.4,3.3
Imidafenacin,170105-16-5,[H]N([H])C(C(CCn1ccnc1C)(c1ccccc1)c1ccccc1)=O,1.51,6.1,0.12,4.1,3.2,"Ohno T, Nakade S, Nakayama K, et al. Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br J Clin Pharmacol 2008, 65, 197-202.//ppb: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/URITOS_Tablets01mg.pdf. Accessed June 30 2017.","N=14, 0.1 mg/kg, 15' inf. healthy volunteers, 80.6 average weight, 122 L VDss, Cltot 29.5 L/h.",,1995,319.4,4,1,60.9,6,neutral,1.8,1.7
Imipenem,64221-86-9,C[C@@H](O)[C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCNC=N,0.24,3,0.86,1.3,0.95,Saito A (1991) Pharmacokinetics of panipenem/betamipron.  Chemotherapy 39(Suppl. 3): 227-235.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.,VDss calculated from C vs t data provided in the reference.,,1977,299.35,7,4,113.7,7,zwitterionic,-0.81,-3.1
Imipramine,50-49-7,CN(C)CCCN1c2ccccc2CCc3ccccc13,12,13,0.075,15,16,Brosen K and Gram LF (1988) First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.  Clin. Pharmacol. Ther.  43: 400-406.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.   Danon A and Chen Z (1979) Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia.  Clin. Pharmacol. Ther. 25: 316-321.,VDss was calculated using C vs t data obtained from plots provided in the reference.,,1959,280.41,2,0,6.5,4,cationic,4.3,2.7
Imipramine N-oxide,6829-98-7,CN(=O)(C)CCCN1c2ccccc2CCc3ccccc13,1.9,12,,2.6,1.8,Nagy A and Hansen T (1978) The kinetics of imipramine N-oxide in man.  Acta Pharmacol. Toxicol. 42: 58-67.,VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.,,1962,296.41,3,0,20.3,4,neutral,0.84,0.84
Incadronate (acid),124351-85-5,C1CCCC(CC1)NC(P(=O)(O)O)P(=O)(O)O,0.24,2.16,0.9,1.85,1.82,"T. Usui, Y. Oiso, A. TOMITA , E. OGATA, T. UCHIDA, K. IKEDA , T. WATANABE I, S. HIGUCHI. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia. Int. J. Clin. Pharmacol. Ther. 1997, 35, 239-244.
","Average of 4 subjects per dose across 4 doses. 0.2, 0.4, 0.8 and 1.6 mg. 70 kg median weight taken from range. Renal clearance ~ 63% across latter three dose. MRT from VDss and clearance.",,1989,287.19,7,5,127.1,4,anionic,-0.55,-5.8
Indacaterol,312753-06-3,[C@@H](O)(c1ccc(c2c1ccc(=O)[nH]2)O)CNC1Cc2c(C1)cc(c(c2)CC)CC,19.4,4.48,0.05,72.4,92.5,"Pharmapendium. Indacaterol Maleate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 022383/S-000 Part 02. Data from Table 1 on page 4 of 47.",200 ug iv dose. 70 kg assumed. MRT from VDss and Cl. Plasma protein binding from PDR. Accessed February 22 2013.,,2000,392.49,5,4,85.3,6,cationic,2.6,0.27
Indinavir,150378-17-9,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc3ccccc3)C(=O)N[C@@H]4[C@H](O)Cc5ccccc45,0.82,18,0.36,0.76,1,"Yeh KC, Stone JA, Carides AD, Rolan P, Woolf E, and Ju WD (1999) Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis.  J. Pharm. Sci. 88: 568-573.  Boffito M, Hoggard PG, Reynolds HE, Bonora S, Meaden ER, Sinicco A, Di Perri G, and Back DJ (2002) The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.  Br. J. Clin. Pharmacol. 54: 262-268.",VDss and t1/2 were calculated from data obtained by digitization of C vs t plots (group C) provided in the report.  Established from PDR that most of radiocativity found in feces was not parent. Thus the compound was absorbed and metabolized before being excreted in feces and urine.,,1957,613.79,9,4,118,11,neutral,3,2.9
Indisulam,165668-41-7,c1(ccc(cc1)S(=O)(=O)N)S(=O)(=O)Nc1cccc2c(c[nH]c12)Cl,0.68,0.72,0.001,16.9,20.3,"E. Raymond, W.W. ten Bokkel Huinink, J. Taı¨eb, J.H. Beijnen, S. Faivre, J. Wanders, M. Ravic, P. Fumoleau, J.P. Armand, and J.H.M. Schellens. Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer. J. Clin. Onc., 2002, Vol 20, 3508-3521. ppb: SATURABLE BINDING TAKEN at 3.5 uM total concentration. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes Zandvliet, Anthe S.; Copalu, William; Schellens, Jan H. M.; Beijnen, Jos H.; Huitema, Alwin D. R. Drug Metabolism and Disposition 2006, 34, 1041-1046, 2006 ",E7070. Weighted average of 6 patients across 100 and 200 mg/m2 (linear). Generally non-linear pharmacokinetics and high percentage of extrapolated AUC. 70-kg average weight assumed.,,1995,385.85,7,3,122.1,4,neutral,1.3,1
Indocyanine Green,3599-32-4,CC1(C)\C(=C\C=C\C=C\C=C/C2=[N+](CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)\N(CCCCS(=O)(=O)O)c5ccc6ccccc6c15,0.035,6.8,0.05,0.086,0.065,"Vanakoski J, Idanpaan-Heikkila JJ, and Seppala T (1996) Exposure to high environmental temperature in the sauna does not change plasma indocyanine green (ICG) clearance in healthy subjects.  Pharmacol. Toxicol. 78: 94-98.   IC-Green Product Label.",,Reported CAS number of Na salt. Structure without Na. CAS number of component: 28782-33-4,1958,752.98,8,1,117.8,14,anionic,5.4,3.1
Indomethacin,53-86-1,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c3ccc(Cl)cc3,0.096,1.3,0.01,1.2,1.4,"Yeh KC, Berger ET, Breault GO, and Lei BE (1982) Effect of sustained release on the pharmacokinetic profile of indomethacin in man.  Biopharm. Drug Dispos. 3: 219-230.  Indocin Product Label.",CL and half-life were calculated from C vs t data included in the reference.  VDss was calculated using micro rate constants provided.,,1955,357.79,5,1,68.5,5,anionic,3.4,0.59
Indoprofen,31842-01-0,N1(c2ccc(cc2)C(C(=O)O)C)C(=O)c2c(C1)cccc2,0.12,0.65,0.01,2.7,2.11,"Tamassia, V.; Corvi, G.; Moro, E.; Tosolini, G. P.; Fuccella, L. M.  Pharmacokinetics and bioavailability of indoprofen in man. Eur. J. Clin. Pharmacol. (1976), 10(3-4), 257-62",K4277. Data digitized from plot reported at 100 mg dose. N=4. Average weight 68.1 kg. AUC calculated 32.67 ug.h.mL-1; AUC reported 32.43 ug.h.mL-1.,,1972,281.31,4,1,57.6,3,anionic,2.4,-0.59
Indoramin,26844-12-2,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c4ccccc4,4.9,20,0.15,4.1,4.3,"Norbury HM, Franklin RA, Marrott PK, and Warrington SJ (1983) Pharmacokinetics of intravenous indoramin in middle aged male and female volunteers.  Eur. J. Clin. Pharmacol.  25: 243-246.",Cited fu value at lowest concentration which was relevant to the plasma concentrations.  VDss calclated from digitized plot.,,1969,347.45,4,2,48.1,5,cationic,3.8,3.3
INO-1001,3544-24-9,C(=O)(N)c1cc(N)ccc1,1.9,7.9,,4,5,"A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma. Agop Y. Bedikian, Nicholas E. Papadopoulos, Kevin B. Kim, Wen-Jen Hwu, Jade Homsi, Michelle R. Glass, Suzanne Cain, Patrick Rudewicz, Laurent Vernillet, and Patrick Hwu. Cancer Investigation, 2009, 27,756–763.","NSC36962. Weighted average of 100, 200 and 400 mg doses, 1-hr infusion,",,1917,136.15,3,2,69.1,1,neutral,-0.11,-0.11
Inogatran,155415-08-0,C1[C@@H](C(=O)NCCCNC(N)=N)N(CCC1)C(=O)[C@H](NCC(=O)O)CC1CCCCC1,0.26,6.1,0.76,0.71,1,"Ann-Catrine Teger-Nilsson, Ulf Eriksson, DaVid Gustafsson, Ruth Bylund, Gunnar Fager, Peter Held. Phase I Studies on Inogatran, a New Selective Thrombin Inhibitor. JCC Feb 1995 abstract 931-115 p. 117A, :  doi:10.1016/0735-1097(95)91943-R Accessed May 8 2013. ppb: Ulf G. Eriksson, Lars Renberg, Ulf Bredberg, Ann-Catrine Teger-Nilsson and Carl Gunnar Regardh. Animal Pharmacokinetics of Inogatran, a Low Molecular-Weight Thrombin Inhibitor with Potential Use as an Antithrombotic Drug. Biopharm. Drug Dispos. 1998, 19: 55–64.",total dose 25 umol iv bolus (N=16). Vdss reported as 0.26 mL/kg. MRT calculated from VDss and CL. ppb data ranging from 20 to 28% bound across species. Median taken.,,1993,438.56,10,6,160.6,12,cationic,-0.46,-3.4
Intoplicine,125974-72-3,CN(C)CCCNc1ncc(C)c2[nH]c3ccc4cc(O)ccc4c3c12,11,18,,11,19,"Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M, and Catimel G (1996) Phase I and pharmacology study of  intoplicine  (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer  patients.  Anti-Cancer Drugs 7: 166-174",,,1990,348.44,5,3,64.2,5,cationic,3.8,-1.2
Iodixanol,92339-11-2,c1(N(CC(CN(c2c(c(c(I)c(c2I)C(NC[C@@H](CO)O)=O)C(NC[C@@H](CO)O)=O)I)C(C)=O)O)C(C)=O)c(c(c(I)c(c1I)C(NC[C@@H](CO)O)=O)C(NC[C@@H](CO)O)=O)I,0.2,1.44,1,2.3,2.1,"Human pharmacokinetics of iodixanol Svaland, M. G.; Haider, T.; Langseth-Manrique, K.; Andrew, E.; Hals, P. A.  Investigative Radiology (1992), 27(2), 130-3. ppb: Jacobsen P B; Blindheim L; Skotland T. Bioanalytical methods for iodixanol and their application to studies on metabolism and protein binding. Acta radiologica. Supplementum. 1995, 399, 61-66.","Digitized from 0.3 g I/kg dose (=0.61 g I/kg), dose linearity observed, N=10 78 kg average weight. Reported Cl (total) at that dose 115 mL/min = 1.47 mL/min/kg. (94% renally excreted unchanged)",,1984,1550.18,21,13,339.1,22,neutral,-3.9,-3.9
Iododoxorubicin,83997-75-5,[H]N([H])[C@H]1C[C@H](O[C@H]2C[C@@](Cc3c2c(c2C(c4c(cccc4OC)C(c2c3O[H])=O)=O)O[H])(C(CO[H])=O)O[H])O[C@@H](C)[C@H]1I,53.6,140,,6.4,10.3,"Robert J; Armand J P; Huet S; Klink-Alakl M; Recondo G; Hurteloup P. Pharmacokinetics and metabolism of 4'-​iodo-​4'-​deoxy-​doxorubicin in humans. J. Clin. Oncol. 1992,10(7), 1183-1190.","N=16, across several dose. Average of VDss 2,171 +/- 1,551 L/m2. Clearance 340+/- 133 L/hr/m2. Conversion factor 1.73 m2/70 kg. ",,1982,653.42,11,5,185.8,10,cationic,1.9,-0.74
Iohexol,66108-95-0,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,0.16,2,1,1.3,1.5,"Back SE, Krutzen E, and Nilsson-Ehle P. Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest. 1988, 48, 247-253.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1955,821.14,12,8,199.9,12,neutral,-2.8,-2.8
Iomeprol,78649-41-9,[H]N(C[C@@H](CO[H])O[H])C(c1c(c(C(N([H])C[C@@H](CO[H])O[H])=O)c(c(c1I)N(C)C(CO[H])=O)I)I)=O,0.23,1.4,1,2.7,2.3,"Lorusso et al. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal imperiment or end-stage renal disease requiring hemodyalisis. Invest. Radiol. 2001, 36, 309-316. ppb: Rosati G. Clinical pharmacology of iomeprol. European journal of  1994, 18 Suppl 1 S51-60",Only data in healthy volunteers taken. N=6. 50 ml of 400 mg I/mL solution of iomeprol.,,1981,777.09,11,7,179.7,15,neutral,-2.1,-2.1
Iopamidol,60166-93-0,C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,0.28,1.9,1,2.5,2.1,"McKinstry DN, Rommel AJ, and Sugerman AA (1984) Pharmacokinetics, metabolism, and excretion of iopamidol in healthy subjects.  Invest. Radiol. 19: s171-s174.",,,1976,777.09,11,8,188.4,10,neutral,-2.3,-2.3
Iopentol,89797-00-2,c1(c(c(c(I)c(c1I)C(NC[C@@H](CO)O)=O)C(NC[C@@H](CO)O)=O)I)N(C[C@@H](COC)O)C(C)=O,0.2,1.27,1,2.64,2.04,"Waaler A; Jorgensen N P; Koksvik B; Skinnemoen K; Andrew E. Pharmacokinetics of iopentol in healthy volunteers. Acta radiol. Suppl. 1987, 370, 113-117.//ppb: Thomas Lehnert, Erich Keller, Klaus Gondolf, Tanja Schäffner, Hermann Pavenstädt and Peter Schollmeyer. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant, 1998, 13,358–362.","Dose expressed in gI/kg. 2.19 correction factor for MW of iopentol (reported as such in plot). Dose digitized 1.2 gI/kg corresponding to 2.36 gI/kg of iopentol. Digitization yielded clearance within 20% of reported. No AUC available. Linear kinetics within range of doses. N =8, 74 kg average weight, infusion time 5.5 min",Completely excreted renally. Unchanged,1984,835.16,12,7,188.9,13,neutral,-2.2,-2.2
Iopromide,73334-07-3,COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I,0.22,1.4,0.99,2.6,2.6,"Krause W, Schuhmann-Giampieri G, Staks T, and Kaufmann J (1994) Dose proportionality of iopromide pharmacokinetics and tolerability after IV injection in healthy volunteers.  Eur. J. Clin. Pharmacol.  46: 339-343.  Ultravist Product Label",,,1980,791.11,11,6,168.7,11,neutral,-2.2,-2.2
Iothalamic acid (Iothalamate),2276-90-6,CNC(=O)c1c(I)c(NC(=O)C)c(I)c(C(=O)O)c1I,0.17,2.4,0.98,1.2,1.3,"Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.  Bollerup AC, Hesse B, and Steiness E (1975) Renal handling of iodamide and diatrizoate.  Evidence of active tubular secretion of iodamide.  Eur. J. Clin. Pharmacol. 9: 63-67.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1964,613.91,6,3,95.5,3,anionic,1.4,-2
Iotrolan,79770-24-4,c1(c(c(c(I)c(c1I)C(N[C@@H]([C@@H](CO)O)CO)=O)C(N[C@@H]([C@@H](CO)O)CO)=O)I)N(C(CC(N(c1c(c(c(I)c(c1I)C(N[C@@H]([C@@H](CO)O)CO)=O)C(N[C@@H]([C@@H](CO)O)CO)=O)I)C)=O)=O)C,0.23,1.49,1,2.56,2.03,"P. Scholz, H.-J. Weinmann, W. Mutzel, and T. Staks. Pharmacokinetics of lotrolan After Intravenous Injection into Healthy Volunteers. ortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband. 1989, 128, 211-214.//ppb: Mutzel W; Press W R; Weinmann H J. Physicochemical properties and general pharmacology of the nonionic dimer iotrolan. Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband. 1989, 128, 28-32.","Data obtained after calculation from raw data reported in table 1. 650 mgI/kg used as dose (linear PK). N=3, 73 kg average weight. Clearance standardized to 1.73m2 in paper and clearance calculated in mL.min-1.kg-1 was multiplied by 70 kg (1.73 m2/70kg factor) to yield 104.46 mL.min-1 or 1.16  the reported 90 mL.min-1 clearance.",Nearly complete renal clearance,1981,1626.23,24,16,399.8,24,neutral,-5.8,-5.8
Ipratropium,60205-81-4,[H]OC[C@@H](C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C(C)C)c1ccccc1,5.1,31.4,0.95,2.7,1.64,"Ensing K., de Zeeuw R.A., Nossent  G.D., Koeter G.H, Cornelissen, P.J.G. et al. ( 1989)  Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Eur. J. Clin. Pharmacol. 36, 189-194.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191","N=10, 74 kg average weight VDss calculated as sum of Vc, Valpha and Vbeta reported. 2 mg/dose administered in 20'. ",,1962,332.46,4,1,46.5,7,neutral,-0.72,-0.72
Irbesartan,138402-11-6,CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)c4ccccc4c5nnn[nH]5,0.94,2.3,0.1,6.8,14,"Vachharajani NN, Shyu WC, Chando TJ, Everett DW, Greene DS, Barbhaiya RH (1998) Oral bioavailabiity and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers.  J. Clin. Pharmacol. 38: 702-707.  Avalide Product Label.",,,1991,428.53,7,1,87.1,7,anionic,4.6,1.1
Irinotecan,97682-44-5,CCc1c2CN3C(=O)C4=C(C=C3c2nc5ccc(OC(=O)N6CCC(CC6)N7CCCCC7)cc15)[C@@](O)(CC)C(=O)OC4,3.5,7,0.51,8.3,9,"Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, and Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.  Clin. Pharmacol. Ther. 72: 265-275.  Camptosar Product Label.","No t1/2 reported from Xie, et al.",,1985,586.68,10,1,112.5,5,cationic,4.3,2.4
Irofulven,158440-71-2,CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1,3.1,140,,0.4,0.3,"Paci A, Rezai K, Deroussent A, De Valeriola D, Re M, Weill S, Cvitkovic E, Kahatt C, Shah A, Waters S, Weems G, Vassal G, and Lokiec F (2006) Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.  Drug Met. Disp. 34: 1918-1926.",,,1994,246.3,3,2,57.5,1,neutral,1.4,1.4
Isavuconazole,241479-67-4,[H]O[C@](Cn1cncn1)(c1cc(ccc1F)F)[C@@H](C)c1nc(cs1)c1ccc(C#N)cc1,5.37,0.85,0.01,105.5,86.9,"Schmitt-Hoffmann A. et al. Single-​ascending-​dose pharmacokinetics and safety of the novel broad-​spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrobial Agents and Chemotherapy, 2006, 50(1), 279-285. //ppb: Robert W. Townsend,corresponding author1 Shahzad Akhtar,1 Harry Alcorn, Jolene K. Berg, Donna L. Kowalski, Salim Mujais, and Amit V. Desai. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017, 73, 669–678.","PK profiles refer to BAL4815 after iv infusion of prodrug BAL8557. BAL4815 = Isavuconazole
Data from 50,100,200 mg equivalents of BAL4815 iv infusion (1 h) dose of prodrug BAL8557, N=18, 77.1(SD 10.4) average weight (57-100Kg). t½ taken as the β phase",,1999,437.47,6,1,87.6,8,neutral,4,4
Isepamicin,58152-03-7,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CN)OC[C@]1(C)O,0.32,1.3,0.95,4.1,24,"Nomeir AA, Radwanski E, Cutler D, Affrime M, Christopher D, Korduba C, Batra V, Lin C, and Cayen MN (1997) Single-dose pharmacokinetics of isepamicin in young and geriatric volunteers.  J. Clin. Pharmacol. 37: 1021-1030.  Tod M, Padoin C, and Petitjean O (2000)  Clinical pharmacokinetics and pharmacodynamics of isepamicin.  Clin. Pharmacokinet. 38: 205-223.  ",,,1975,569.6,17,12,297.7,9,cationic,-8.7,-9
Isoglycirrhizinate (acid),691410-17-0,[H]OC([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]1[C@H]([C@@H]([C@@H](C(=O)O[H])O[C@@H]1O[C@@H]1CC[C@@]2(C)C3C(C=C4[C@H]5C[C@@](C)(CC[C@@]5(C)CC[C@]4(C)[C@@]3(C)CC[C@@H]2C1(C)C)C(=O)O[H])=O)O[H])O[H])O[H])O[H])O[H])=O,0.09,0.05,,30.9,23.1,"Sun L. et al. Phase I safety and pharmacokinetic study of magnesium isoglycyrrhizinate after single and multiple intravenous doses in Chinese healthy volunteers. J. Clin.Pharmacol. 2007, 47, 767-773."," CAS number reported is the one of the Mg salt. 1405-86-3 for the acid. N=9, 63 kg average weight, 30' inf.; 100 mg dose. Dosed as magnesium salt. Data (VDss) verified by plot (100 mg dose) digitization and PK analysis via Phoenix.",The acid (as well as glycyrrhizine) was reported in 1880.The 2003 ref. was found for the Mg salt.,1880,822.93,16,8,267,15,anionic,1.5,-7.5
Isomazole,86315-52-8,[H]n1c2ccncc2nc1c1ccc(cc1OC)S(C)=O,1.67,20.7,0.48,1.3,1.2,"Woodworth, James R.; Delong, A. F.; Fasola, A. F.; Oldham, S. Isomazole disposition in man as a function of dose and route of administration. Biopharm. Drug Disp. 1991, 12, 673-686."," fu = 0.48. N=9, 70 kg average weight assumed. 16.1 mg dose and 30' infusion. 
Data digitized from plots reported by Woodworth et al. Data normalized to middle dose as reported as average in the plot from multiple doses. Calculated data within 8% of reported. VDb = 1.82 L.kg-1 and AUCinf = 201 ng.hr.mL-1.",,1983,287.34,5,1,67.9,3,neutral,1,1
Isoniazide,54-85-3,NNC(=O)c1ccncc1,0.82,7.4,1,1.8,1,"Advenier C, St.Aubin A, Gobert C, Houin G, Albengres E, and Tillement JP (1980) Pharmacokinetics of isoniazid in the elderly.  Br. J. Clin. Pharmacol. 10: 167-169.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.","VDss calculated from reported micro rate constants.  CL and t1/2 are for fast acetylators.  CL and t1/2 for slow acetylatore were 3.7 mL/min/kg and 3.1h, respectively.",,1952,137.14,4,2,68,1,neutral,-1,-1
Isoproterenol,7683-59-2,CC(C)NCC(O)c1ccc(O)c(O)c1,1.5,56,0.71,0.43,0.41,"Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, and Gordin A (1995) The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.  Clin. Pharmacol. Ther. 58: 221-227.  Sager G, Bratlid H, and Little C (1987) Binding of catecholamines to alpha-1 acid glycoprotein, albumin and lipoproteins in human serum.  Biochem. Pharmacol. 36:  3607-3612.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1947,211.26,4,4,72.7,4,cationic,0.79,-0.8
Isosorbide Dinitrate,87-33-2,O=N(=O)O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)ON(=O)=O,1.9,31,0.72,1,1.7,"Platzer R, Reutemann G, and Galeazzi RL (1982) Pharmacokinetics of intravenous isosorbide dinitrate.  J. Pharmacokinet. Biopharm. 10: 575-586.  Santoni Y, Iliadis A, Cano JP, Luccioni R, and Frances Y (1986) Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.  J. Pharmacokinet. Biopharm. 14: 1-17.  Straehl P and Galeazzi RL (1985) Isosorbide dinitrate bioavailability, kinetics, and metabolism. Clin Pharmacol Ther. 38:140-149",,,1939,236.14,10,0,128.6,4,neutral,0.82,0.82
Isosorbide-2-Mononitrate,16106-20-0,O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)ON(=O)=O,0.86,6.2,,2.3,1.9,"Straehl P, Galeazzi RL, and Soliva M (1984) Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.  Clin. Pharmacol. Ther.  36: 485-491.//",,,1967,191.14,7,1,93.7,2,neutral,-0.38,-0.38
Isosorbide-5-Mononitrate,16051-77-7,O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)ON(=O)=O,0.7,2,1,5.8,4.1,"Major RM, Taylor T, Chasseaud LF, Darragh A, and Lambe RF (1984) Isosorbide 5-mononitrate kinetics.  Clin. Pharmacol. Ther. 35: 653-659.  Straehl P, Galeazzi RL, and Soliva M (1984) Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.  Clin. Pharmacol. Ther.  36: 485-491.",,,1967,191.14,7,1,93.7,2,neutral,-0.38,-0.38
Isoxicam,34552-84-6,CN1C(=C(O)c2ccccc2S1(=O)=O)C(=O)Nc3cc(C)on3,0.19,0.07,0.035,44,33,"Kolle EU and Vollmer KO (1986) Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.  Br. J. Clin. Pharmacol. 22(Suppl 2): 135S-141S.  Jolliet P, Simon N, Bree F, Urien S, Pagliara A, Carrupt PA, Testa B, and Tillement JP (1997) Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.  Pharm. Res. 14: 650-656.",VDss calculated from C vs t data obtained by digitization of plots in the reference.,,1946,335.34,8,2,113,2,anionic,2.4,-0.77
Isradipine,75695-93-1,COC(=O)C1=C(C)NC(=C(C1c2cccc3nonc23)C(=O)OC(C)C)C,1.5,26,0.04,1,3.3,"Christensen HR, Antonsen K, Simonsen K, Lindekar A, Bonde J, Angelo HR, and Kampmann JP (2000) Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?  Pharmacol. Toxicol. 86: 178-182.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1980,371.39,8,1,103.8,6,neutral,3,3
Itraconazole,84625-61-6,CCC(C)N1N=CN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(OCC5COC(Cn6cncn6)(O5)c7ccc(Cl)cc7Cl)cc4,7.4,5.1,0.002,24,25,"Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, and Cauwenbergh G (1989) The clinical pharmacokinetics of itraconazole: an overview.  Mycoses  32(Suppl 1): 67-87.  ",VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1983,705.63,12,0,100.8,11,neutral,5.8,5.8
Ivabradine,155974-00-8,N1(C(Cc2c(CC1)cc(c(c2)OC)OC)=O)CCC[N@@](C)C[C@@H]1c2cc(c(cc2C1)OC)OC,1.66,10.27,0.28,2.69,,"Ragueneau, Isabelle; Laveille, Christian; Jochemsen, Roeline; Resplandy, Guillemette; Funck-Brentano, Christian; Jaillon, Patrice. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998, 64, 192-203//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206143Orig1s000PharmR.pdf. Accessed May 28 2017.","S-16257. N=18, 10 mg iv bolus, 70 kg average weight assumed. No t1/2 reported and MRT from VDss and clearance.",,1993,468.59,7,0,60.5,10,cationic,3,1.8
IVL745,229627-58-1,COc1ccc(CN(CCC(=O)O)C(=O)CNC(=O)Cc2ccc(NC(=O)Nc3ccccc3C)c(OC)c2)cc1OC,0.25,11,,0.38,1.6,"Rohatagi S, Shah B, Zhang J, Zeng Z, Kirkesseli S, and Jensen BK (2004) Estimating mass balance for inhaled drugs in humans: An example with a VLA-4 antagonist, IVL745.  J. Clin. Pharmacol. 44: 348-358.",,,1999,592.64,12,4,155.5,14,anionic,2.7,-0.014
Ixabepilone,219989-84-1,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)\C(=C\c3csc(C)n3)\C,11,10,0.2,18,17,"Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, and Fojo T (2003)  Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on daily schedule for five days.  J. Clin. Oncol. 21: 1866-1873.//ppb: Francis Y. F. Lee , Robert Borzilleri, 
Craig R. Fairchild, Amrita Kamath, Richard Smykla, Robert Kramer, Gregory Vite. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008,  63, 157–166.",,,1999,506.7,7,3,112,2,neutral,3.9,3.9
Ixazomib,1072833-77-2,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,3.61,0.5,0.01,119,97,"Assouline S E; Chang J; Cheson B D; Rifkin R; Hamburg S; Reyes R; Hui A-M; Yu J; Gupta N; Di Bacco A; Shou Y; Martin P.  Phase 1 dose-​escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed​/refractory lymphoma. Blood Cancer Journal (2014) 4, e251; doi:10.1038/bcj.2014.71//ppb: Gupta, Neeraj; Hanley, Michael J.; Harvey, R. Donald; Badros, Ashraf; Lipe, Brea; Kukreti, Vishal; Berdeja, Jesus; Yang, Huyuan; Hui, Ai-Min; Qian, Mark; Zhang, Xiaoquan; Venkatakrishnan, Karthik; Chari, Ajai. A pharmacokinetics and safety phase 1​/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-​stage renal disease requiring haemodialysis. Brit. J.  Haem., 2016, 174, 748-759.","MLN 2238. Data digitized from curve in Figure 1a. N=5, 3.11 mg/m2 dose. Only AUC 0-168h reported (1680 ng.hr/mL and calculated value was 1886 ng.hr/mL, corresponding to a ratio calculated/reported of 1.12). Cearance calculated with AUCinf (2547 ng.hr/mL or 25% extrapolation) and t1/2 essentially identical to reported value for Day 14 dosing. 2-fold accumulation observed.",,2008,361.03,6,4,98.7,7,neutral,2.2,2.2
Kahalide F,149204-42-2,"N1(C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)CCCC(C)C)C(C)C)=O)[C@H](O)C)=O)C(C)C)=O)C(C)C)=O)[C@@H](C(N[C@H](C(N[C@@H](C(N[C@@H]2C(N[C@@H](C(N[C@H](C(N[C@@H](Cc3ccccc3)C(N\C(C(N[C@H](C(O[C@@H]2C)=O)C(C)C)=O)=C/C)=O)=O)C(C)C)=O)[C@H](CC)C)=O)=O)[C@H](CC)C)=O)CCCN)=O)CCC1
",0.11,3.9,,0.48,0.57,"Jeany M. Rademaker-Lakhai, Simon Horenblas,Willem Meinhardt, Ellen Stokvis,Theo M. de Reijke, Jose´ M. Jimeno,Luis Lopez-Lazaro, Jose´ A. Lopez Martin, Jos H. Beijnen, Jan H.M. Schellens.Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer. Clin Cancer Res. 2005, Vol. 11, 1854–1862.",Average weight taken as 70 kg. Weighted average of multiple doses. From 320 to 930 ug/m2/d. N=28 overall. MRT from VDss and clearance. Somewhat lower clearance and VDss at higher doses (> 560 ug/m2/d) but all averaged.,,1993,1477.87,30,14,442.1,33,cationic,5.8,3.4
Kanamycin,59-01-8,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,0.26,1.4,0.99,3.1,2.1,"Kirby WMW, Clarke JT, Libke RD, and Regamey C (1976) Clinical pharmacology of amikacin and kanamycin.  J. Infect. Dis. 134: S312-S315.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.    Clarke JT, Libke RD, Regamey C, and Kirby WMM (1974) Comparative pharmacokinetics of amikacin and kanamycin.  Clin. Pharmacol. Ther. 15: 610-616.","VDss, CL not reported in Clarke paper but could be digitized.",,1957,484.5,15,11,282.6,6,cationic,-7.9,-9
Ketamine,6740-88-1,CNC1(CCCCC1=O)c2ccccc2Cl,2.9,19,0.47,2.5,2.8,"Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD, and Brune K (1993) Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method.  Br. J. Anaesth. 70: 666-671.  Pedraz JL, Lanao JM, Calvo MB, Muriel C, Hernandez-Arbeiza J, and Dominguez-Gil A (1987) Pharmacokinetic and clinical evaluation of ketamine administered by i.v. and epidural routes.  Int. J. Clin. Pharmacol. Ther. Toxicol. 25: 77-80.  Clements JA and Nimmo WS (1981) Pharmacokinetics and analgesic effect of ketamine in man.  Br. J. Anaesth. 53: 27-30.  Dayton PG, Stiller RL, Cook DR, and Perel JM (1983) The binding of ketamine to plasma proteins:  emphasis on human plasma.  Eur. J. Clin. Pharmacol. 24: 825-831.  Hijazi Y and Boulieu R (2002) Protein binding of ketamine and its active metabolites in human serum.  Eur. J. Clin. Pharmacol. 58: 37-40.",Racemate; data were combined.,,1963,237.73,2,1,29.1,2,cationic,2.6,2.2
Ketanserin,74050-98-9,Fc1ccc(cc1)C(=O)C2CCN(CCN3C(=O)Nc4ccccc4C3=O)CC2,3.9,6.7,0.055,9.7,12,"Heykants J, Van Peer A, Woestenborghs R, Gould S, and Mills J (1986) Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration.  Eur. J. Clin. Pharmacol. 31: 343-350.  Persson B, Pettersson A, and Hedner T (1987) Pharmacokinetics of ketanserin in patients wuith essential hypertension.  Eur. J. Clin. Pharmacol. 32: 259-265.  Trenk D, Mosler A, Kirch W, Meinertz T, and Jahnchen E (1983) Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.  J. Cardiovasc. Pharmacol. 5: 1034-1039.  Barendregt JN, Van Peer A, Van Der Hoeven JG, Van Oene JC, and Tjandra YI (1990) Ketanserin pharmacokinetics in patients with renal failure. Br. J. Clin. Pharmacol. 29: 715-723.  Reimann IW, Okonkwo PO, and Klotz U (1983) Pharmacokinetics of ketanserin in man. Eur. J. Clin. Pharmacol. 25: 73-76.  ",,,1980,395.43,6,1,69.7,5,cationic,3.5,2.8
Ketobemidone,469-79-4,CCC(=O)C1(CCN(C)CC1)c2cccc(O)c2,0.48,9.2,,0.87,2.3,"Bondesson U, Arner S, Anderson P, Boreus LO, and Hartvig P (1980) Clinical pharmacokinetics and oral bioavailability of ketobemidone.  Eur. J. Clin. Pharmacol.  17: 45-50.",Calculated from reported rate micro-constants.,,1946,247.33,3,1,40.5,3,cationic,1.5,0.0027
Ketoprofen,22071-15-4,CC(C(=O)O)c1cccc(c1)C(=O)c2ccccc2,0.13,1.6,0.008,1.4,2.1,"Debruyne D, de Ligny BH, Ryckelynck JP, Albessard F, and Moulin M (1987) Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion.  Clin. Pharmacokinet. 12: 214-221.  Lee KJ,  Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",,,1968,254.28,3,1,54.4,4,anionic,2.9,-0.072
Ketorolac,74103-06-3,OC(=O)C1CCn2c1ccc2C(=O)c3ccccc3,0.11,0.35,0.0068,5.2,5.1,"Jung D, Mroszczak E, and Bynum L (1988) Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration.  Eur. J. Clin. Pharmacol. 35: 423-425.  Reed MD, Myers CM, and Blumer JL (2001) Influence of midazolam on the protein binding of ketorolac.  Curr. Ther. Res.  62: 558-565.  Mroszczak EJ, Lee FM, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, and Cho DK (1987) Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans.  Drug Metab. Dispos. 15: 618-626",,,1978,255.27,4,1,59.3,3,anionic,2.5,-0.76
KNI-272,147318-81-8,c12c(cccc1cncc2)OCC(N[C@H](C(N[C@H]([C@@H](C(N1[C@@H](CSC1)C(NC(C)(C)C)=O)=O)O)Cc1ccccc1)=O)CSC)=O,0.11,10.5,,0.17,0.44,"BRIGITTA U. MUELLER, BARRY D. ANDERSON, MAUREEN Q. FARLEY, ROBERT MURPHY, JUDY ZUCKERMAN, PAUL JAROSINSKI, KAREN GODWIN, CINDY L. MCCULLY, HIROAKI MITSUYA, PHILIP A. PIZZO, FRANK M. BALIS. Pharmacokinetics of the Protease Inhibitor KNI-272 in Plasma and Cerebrospinal Fluid in Nonhuman Primates after Intravenous Dosing and in Human Immunodeficiency Virus-Infected Children after Intravenous and Oral Dosing. Antimicr. Agents Chemother. 1998, 42, 1815-1818.","Kynostatin 272. Dosed to children at 200 mg/m2 to children. Median age 9.7 years, N=5 from data in table 2. MRT from VDss and clearance.",,1992,667.84,11,4,150,13,neutral,2,1.9
KRN-5500,151276-95-8,CCCCCCCCC\C=C\C=C\C(=O)NCC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](Nc2[nH]cnc3ncnc23)O[C@H]1[C@@H](O)CO,0.17,2.7,,1.1,1.3,"Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, and Clark JW (2003) Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.  Clin. Canc. Res. 9: 5178-5186.",,,1993,589.68,14,8,214.8,17,neutral,1.3,1.2
KRN8602,105026-50-4,c1c(c2c(cc1)C(=O)c1c(c(O)c3c(c1O)[C@@H](O)[C@@](O)(CC)C[C@@H]3O[C@@H]1C[C@@H]([C@@H]([C@@H](O1)C)O)N1CCOCC1)C2=O)O,20.9,42.8,0.09,8,10.7,"Kerrie Clarke, Russell L. Basser, Darryl Maher, Denis J. Morgan, Jonathan Cebon, Richard M. Fox, John S. Hill, Carole Alt, Jane Bartlett, Howard Geldard, Andrew H. Kaye, and Michael D. Green. Phase I and Pharmacokinetic Study of KRN8602 Alone and With Filgrastim in Patients With Advanced Cancer. J Clin Oncol. 1998, 16:2181-2187.",Weighted average of 27 patients receiving KRN 8062 only. 10-50 mg/m2 dose range. 70-kg weight assumed. AUC units not reported. CAS of HCl salt.,,1986,585.6,12,6,186.4,4,neutral,1.4,1.2
KW-2170,207862-44-0,NCCCNc1ccc2c(CNCCO)nn3c4c(O)ccc(O)c4C(=O)c1c23,12,18,,11,32,"Saeki T, Eguchi K, Takashima S, Sugiura T, Hida T, Horikoshi N, Aiba K, Kuwabara T, and Ogawa M (2004) Phase I and pharmacokinetic study of KW-2170, a novel pyrazoloacridone compound, in patients with malignant tumors.  Cancer Chemother. Pharmacol.  54: 459-468.",,,1998,397.43,9,6,145.7,8,cationic,-0.21,-3.6
KW-2478,819812-04-9,CCc1c(cc(c(c1CC(=O)N(CCOC)CCOC)C(=O)c2ccc(c(c2)OC)OCCN3CCOCC3)O)O,1.32,6.87,,3.21,5.94,"K Yong, J Cavet, P Johnson, G Morgan, C Williams, D Nakashima, S Akinaga, H Oakervee
and J Cavenagh. Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. Br. J. Cancer, 2016, 114, 7-13."," Data digitized across 4 doses (14, 99, 132, 176 mg/m2) and simultaneously fit via Phoenix. Then data weight-averaged by number of subjects. As an example, reported AUCinf 992 and 11501 ng.hr.mL-1 at 14 and 176 mg/m2. Calculated 970 and 11351  ng.hr.mL-1 at the same doses. Doses (N)in mg/m2:  14 (3), 99 (3), 132 (6), 176 (6). 1.73m2/70 conersion factor used. May have resulted in slightly different clearance but was kept as such for consistency.",,2005,574.66,11,2,127.2,16,neutral,1.9,1.6
L-5-hydroxytryptophan,4350-09-8,c1cc2c(cc1O)c(c[nH]2)C[C@@H](C(=O)O)N,0.8,1.72,,7.75,6.14,"Magnussen, I.; Nielsen-Kudsk, F. Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. Acta Pharmacologica et Toxicologica (1979), 44(4), 308-14.","Oxyfan. Oxitriptan. CAS number and structure referring to L form. DL form reported with CAS # 56-69-9. N=5, 0.2 mg/kg, 67 kg average weight. VDss calculated from Vc and k12,k21. MRT from VDss and clearance. Clearance reported as 105.5 mL.min-1.kg-1 but ACTUAL value (dose of 0.98 umol/kg over AUC) shows a value of 1.72. reported value likely to be in mL.h-1.kg-1.",,1954,220.22,5,4,99.3,3,zwitterionic,0.033,-1.6
L-648051,91541-18-3,S(c1ccc(C(=O)CCC(=O)O)cc1)(=O)(=O)CCCOc1c(c(O)c(cc1)C(=O)C)CCC,,17.44,,,0.04,"Biollaz, J.; Stahl, E.; Hsieh, J. Y.; Distlerath, L.; Jaeger, A.; Leuenberger, P.; Schelling, J. L.. Tolerability and pharmacokinetics of L 648051. A leukotriene D4-receptor antagonist, in healthy volunteers. Eur. J.  Clin. Pharmacol. (1988), 33(6), 603-607.","N=3, 68.8 kg, 5 minutes infusion. Average across doses (35-72 mg total). VD refers to Vdbeta and only individual plots (difficult to digitized) were reported.",,1984,476.54,8,2,135,13,anionic,2.7,0.13
L-692429,145455-23-8,[H]N(C(CC(C)(C)N([H])[H])=O)[C@@H]1CCc2ccccc2N(Cc2ccc(cc2)c2ccccc2c2nnnn2[H])C1=O,0.2,3.05,0.06,1.1,3.8,"Gertz B J; Barrett J S; Eisenhandler R; Krupa D A; Wittreich J M; Seibold J R; Schneider S H Growth hormone response in man to L-​692,​429, a novel nonpeptide mimic of growth hormone-​releasing peptide-​6. J. Clin. Endocrin. Metab. 1993, 77, 1393-1397. ppb:  K H Leung, D A Cohn, R R Miller, G A Doss, R A Stearns, R E Simpson, W P Feeney and S H Chiu Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species. Drug Metabolism and Disposition1996, 24, 753-760.",MK 0751. Data from 1.0 mg/kg dose (others administered) N=6. 70 kg average weight assumed.,,1992,509.6,9,3,129.9,8,zwitterionic,4.1,1.8
"L-778,123",183499-57-2,c1cc(cc(c1)Cl)N2CCN(CC2=O)Cc3cncn3Cc4ccc(cc4)C#N,0.8,3.2,,4.2,2.6,"Carolyn D. Britten, Eric K. Rowinsky, Steven Soignet, Amita Patnaik, Siu-Long Yao, Paul Deutsch, Yih Lee, Robert B. Lobell, Kathryn E. Mazina, Heather McCreery, Sandy Pezzuli and David Spriggs. A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies. Clinical Cancer Research, 2001, 7, 3894-3903","Data digitized from plot reported for one representative subject, 168 hr infusion at 560 mg/m2/day. Average AUC reported 1310 uM.hr +/- 563, clearance reported as 130.8  +/- 41.6 ml/min/m2. Values estimated from loading dose assuming 4-5*t1/2 for steady state (10-13 hrs) and VDss estimated from loading dose (calculated as 303 mg/m2) /Css (reported). Clearance and t1/2 reported, MRT from VDss and clearance.",,1996,405.88,6,0,65.2,6,neutral,2.6,2.6
Labetalol,36894-69-6,CC(CCc1ccccc1)NCC(O)c2ccc(O)c(c2)C(=O)N,4.8,23,0.5,3.5,4.4,"Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers. Br. J. Clin. Pharmacol. 43: 563-570.  Martin LE, Hopkins R, and Bland R (1976) Metabolism of labetalol by animals and man.  Br. J. Clin. Pharmacol. (Supp): 695-710",,,1972,328.41,5,4,95.6,8,cationic,1.8,0.97
Lacosamide,175481-36-4,"C(=O)([C@@H](COC)NC(=O)C)NCc1ccccc1
",0.58,0.57,0.85,17.2,12.3,"Bioequivalence of Intravenous and Oral Formulations of the Antiepileptic Drug Lacosamide. Willi Cawello, Rainer Bonn, Hilmar Boekens. Pharmacology 2012;90:40-46 . ppb: < 15% as reported by PDR. http://www.pdr3d.com/detail.php?c=130625#section-14. Accessed December 30 2014.","Data after 200 mg 15 min infusion (N=16, mean BW = 77.3 kg) digitized from Fig 1 reported in Willi Cawello, Rainer Bonn, Hilmar Boekens. Bioequivalence of Intravenous and Oral Formulations of the Antiepileptic Drug Lacosamide Pharmacology 2012, 90, 40–46. Reported data: AUC(0–t), h*µg/ml 72.33 (±17.4), AUC(0–inf), h*µg/ml 75.40 (±17.0), T1/2, h 12.6, Calculated data, AUCINF_obs h*ug/mL 76.41",,1996,250.29,5,2,67.4,6,neutral,-0.2,-0.2
Ladirubicin,171047-47-5,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5ccccc5C4=O)O)(C(=O)C)O)N6CC6)OS(=O)(=O)C,2.95,23.54,0.006,2.09,7.33," de Jonge, M. J. A.; Verweij, J.; van der Gaast, A.; Valota, O.; Mora, O.; Planting, A. S. Th.; Mantel, M. A.; Van Den Bosch, S.; Lechuga, M. J.; Fiorentini, F.; Hess, D; Sessa, C. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur. J. Cancer 2002, 38, 2407-2415.",PNU 159548. FCE28729. Weighted average of doses between 1 and 16 mg.m-2 with data only from 10' infusion. Data from 1 hr infusion not reported for VDss (only clearance) and not used. Total N=49 across dose. MRT from VDss and clearance.,,1995,601.62,12,3,176.7,6,neutral,1.5,1.4
Lamifiban,144412-49-7,NC(=N)c1ccc(cc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N3CCC(CC3)OCC(=O)O,0.29,1.9,0.94,2.5,2.1,"Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, and Chou RC (1996) Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggergeation inhibitor.  J. Pharm. Pharmacol.  48: 573-577.",,,1992,468.5,10,5,166,9,zwitterionic,0.93,-0.3
Lamivudine,134678-17-4,NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2,1.3,4.8,0.94,4.4,9.1,"Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, and Hussey EK (1995) Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35: 1174-1180.  Takubo T, Hirayama S, Moriya T, Minamide Y, Kato T, Nakamura R, and Kinami J (1997) Studies on the metabolic fate of lamivudine (II): tissue distribution, transfer into fetus and milk, plasma protein binding and distribution to erythrocytes of lamivudine in rats.  Yakubutsu Dotai 12: 92-101.",,,1991,229.26,6,2,88.1,2,neutral,-1,-1
Lanicemine,153322-05-5,c1ccc(cc1)C(Cc2ccccn2)N,1.62,1.8,,15.06,10.4,"Khanh H. Bui,  Diansong Zhou, Felix Agbo, and Jian Guo. Effect of Multiple Intravenous Doses of Lanicemine (AZD6765) on the Pharmacokinetics of Midazolam in Healthy Subjects. J. Clin. Pharmacol. 2015, 55(9) 1024–1030.","AZD6765. N=46, 75.1kg  average weight1 hr infusion of 150 mg of lanicemine. MRT from clearance and MRT. See also, Guo J, Zhou D, Grimm SW, Bui KH. Pharmacokinetics,metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects. Xenobiotica. 2015;45(3):244– 255.",,1993,198.26,2,1,38.9,3,cationic,1.6,0.31
Laniquidar,197509-46-9,COC(c1cnc2C(=C3CCN(CC3)CCc3ccc(cc3)OCc3ccc4ccccc4n3)c3ccccc3CCn12)=O,6.03,14.14,0.001,7.1,10.6,"De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780. ",70 kg average weight assumed.  MRT calculated from CL and VDss. 50 mg iv dose,,1997,584.71,7,0,69.5,8,cationic,7.4,6.8
Lanreotide,108736-35-2,c1(c2c(cccc2)[nH]c1)C[C@@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC([C@@H](CSSC[C@@H](NC([C@@H](NC([C@@H](NC1=O)CCCCN)=O)C(C)C)=O)C(N[C@@H]([C@@H](C)O)C(=O)N)=O)NC(=O)[C@@H](N)Cc1ccc2c(c1)cccc2)=O,0.2,5.7,,0.57,1.03,"Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency. Tomlinson B, Thomas NG, Lan IW, Barbanoj M, Antonijoan RM, Drazna E, Ramis J, Obach R, Peraire C. Clin. Pharmacokinet. 2006, 45, 1003-1011.",N=23 healthy volunteers; 7 ug/kg in 20' infusion. Microdose?,,1987,1096.32,21,13,355.1,17,cationic,1.3,-2.3
Lansoprazole,103577-45-3,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c2nc3ccccc3[nH]2,0.28,4.4,0.021,1.1,1,"Gerloff J, Mignot A, Barth H, and Heintze K (1996) Pharmacokinetics and absolute bioavailability of lansoprazole.  Eur. J. Clin. Pharmacol. 50: 293-297.  Freston JW, Pilmer BL, Chiu YL, Wang Q, Stolle JC, Griffin JS, and Lee CQ (2004) Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.  Alimentary Pharmacol. Ther. 19: 1111-1122.  Karol MD, Machinist JM, and Cavanaugh JM (1995) Pharmacokinetics of lansoprazole in hemodialysis patients.  J. Clin. Pharmacol.  35: 815-820.",,,1986,369.36,5,1,67.9,5,neutral,2.5,2.4
Laromustine,173424-77-6,CS(=O)(=O)[N@@](N(S(=O)(=O)C)C(=O)NC)CCCl,0.88,23.1,,0.63,0.49,"A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory LeukemiaFrancis Giles, Deborah Thomas,Guillermo Garcia-Manero, Stefan Faderl,Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli,Sima Jeha,Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill,Caroline Clairmont, Mario Sznol, and Hagop Kantarjian Cli. Cancer Res. 2004 Vol. 10, 2908–2917.","VNP40101M or cloretazine. Dose range from 220 to 708 ,g/m2. Weighted average across number of courses for each dose. MRT calculated from VDss and clearance reported. Variable infusion time (15-70 minutes)",,1996,307.78,8,1,103.9,5,neutral,-1.4,-1.4
Laropiprant,571170-77-9,CS(=O)(=O)c1cc(cc2c1n(c3c2CC[C@@H]3CC(=O)O)Cc4ccc(cc4)Cl)F,1,1.21,,13.7,11.8,"Christopher R. Gibson, Ping Lu, Cheri Maciolek, Christen Wudarski, Zoe
Barter, Karen Rowland-Yeo, Mark Stroh, Eseng Lai & Deborah A. Nicoll-
Griffith. Using human recombinant UDPglucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiot., 2013, 43, 1027-1036.","MK-0524. N=12, 40 mg dose in 1 hr infusion. Average weight assumed to be 70 kg.  MRT from reported clearance and VDss.",,2003,435.9,5,1,76.4,5,anionic,3.5,1.2
Larotaxel,156294-36-9,O=C1[C@@]23[C@@H]([C@@]4(OC(=O)C)[C@@H](C[C@@H]2C3)OC4)[C@H](OC(=O)c2ccccc2)[C@]2(C(C(=C(C)[C@H](C2)OC(=O)[C@@H]([C@@H](NC(=O)OC(C)(C)C)c2ccccc2)O)C1OC(=O)C)(C)C)O,17,10.8,,26.1,33.9,"Nobuyuki Yamamoto · Narikazu Boku ·Hironobu Minami. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol (2009) 65:129–136. RPR109881A has also been reported (dihydrate of larotaxel, CAS # 192573-38-9) by Sessa C, Cuvier C, Caldiera S, Bauer J, Van Den Bosch S, Monnerat C, Semiond D, Perard D, Lebecq A, Besenval M, and Marty M (2002) Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.  Ann. Oncol. 13: 1140-1150. VDss 12 L/kg, clearance 14 mL/min/kg, MRT 14 h and t1/2 20 h. Larotaxel kept.","Weighted average of 3 cohorts with a total of 18 patients. Doses 60, 75 and 90 mg/m2. Table 4.",,1994,831.9,15,3,210.3,14,neutral,3.3,3.3
Latanoprost,130209-82-4,C([C@@H]1[C@H]([C@H](O)C[C@@H]1O)CC[C@H](CCc1ccccc1)O)\C=C\CCCC(OC(C)C)=O,,6.7,0.1,,0.28,"Pharmapendium. 1996-Jan-16  PDF(965k)
Clinical Pharmacology and Biopharmaceutics Review 020597",Vz reported as 0.16 L/kg.,"PDR. Accessed July 31 2014.http://www.pdr3d.com/detail.php?c=118286#section-3.  Metabolism: Latanoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation is primarily metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites via fatty acid β-oxidation.. Excretion: The elimination of the acid of latanoprost from human plasma is rapid (t1/2=17 min) after both intravenous and topical administration. Systemic clearance is approximately 7 mL/min/kg. Following hepatic β-oxidation, the metabolites are mainly eliminated via the kidneys. Approximately 88% and 98% of the administered dose is recovered in the urine after topical and intravenous dosing, respectively.",1990,432.59,5,3,87,14,neutral,5.2,5.2
Lefamulin,1061337-51-6,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O,1.32,3.96,0.17,5.53,6.4,"M. Zeitlinger, R. Schwameis, A. Burian, B. Burian, P. Matzneller, M. Muller, W. W. Wicha, D. B. Strickmann and W. Prince. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother 2016; 71: 1022–1026.","Data digitized from plot reported. N=12 healthy males, 150 mg as 1-h infusion, 77.6 kg, average weight. AUC0-12 reported as 5772 ng.h.mL-1. calculated 6667 ng.h.mL-1. 15% difference.",,2008,507.73,6,3,109.8,6,cationic,3.4,0.75
Lenapenem,149951-16-6,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)[C@@H](CCNC)O)C(=O)O)[C@@H](C)O,0.22,2.02,,2.04,1.48,"Mitsuyoshi Nakashlma, Toshihiko Uematsu, Kazuhiro Kosuge, Susumu Nakagawa, Shunsuke Hata and Minoni Sanada. Pharmacokinetics and safety of BO-2727, a new injectable 1-P-methyI carbapenem antibiotic, and its effect on the faecal microflora in healthy male volunteers. Journal of Antimicrobial Chemotherapy (1994) 33, 987-998.","N=18, averaged across 3 doses at 250, 500 and 1000 mg (N=6 each). 66 kg average weight reported. 73% urinary recovery.","reported as BO-2727 (HCl salt, CAS #  149882-71-3)",1993,399.5,8,5,122.1,8,zwitterionic,-1.2,-3.6
Lesinurad,878672-00-5,c1ccc2c(c1)c(ccc2n3c(nnc3Br)SCC(=O)O)C4CC4,0.29,1.43,0.02,3.33,5,"http://irwdpi.com/zurampic/zurampic.pdf#page=1 Prescribing information. Accessed February 27, 2017.","RDEA594, Zurampic. Absolute BA approximately 100%. 70 kg average weioght assumed. MRT from clearance and VDss. Ppb reported as > 98%.",,2006,404.28,5,1,68,5,anionic,2.4,-0.86
Letrozole,112809-51-5,N#Cc1ccc(cc1)C(c2ccc(cc2)C#N)n3cncn3,1.9,0.57,0.41,59,45,"Sioufi A, Gauducheau N, Pineau V, Marfil F, Jaouen A, Cardot JM, Godbillon J, Czendlik C, Howald H, Pfister C, and Vreeland F (1997) Absolute bioavailability of letrozole in healthy postmenopausal women.  Biopharm Drug Dispos. 18: 779-89.   Colussi DM, Parisot CY, and Lefevre GY (1998) Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor.  J. Clin. Pharmacol. 38: 727",,,1987,285.3,5,0,78.3,5,neutral,2.1,2.1
Leuprolide,53714-56-0,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)[C@H](Cc5c[nH]cn5)NC(=O)[C@@H]6CCC(=O)N6,0.38,2,0.54,3.1,2.9,"Sennello LT, Finley RA, Chu SY, Jagst C, Max D, Rollins DE, and Tolman KGJ (1986) Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration.  J. Pharm. Sci. 75: 158-160.  Eligard Product Label",,,1974,1209.4,28,16,429,33,cationic,-0.092,-4.1
Levetiracetam,102767-28-2,N1([C@H](C(=O)N)CC)C(=O)CCC1,0.6,0.9,0.9,11.15,8.23,"Steven Ramael, Agnès Daoust, Christian Otoul, Nathalie Toublanc, Mona Troenaru, Zhihong (Sarah) Lu, Armel Stockis. Levetiracetam Intravenous Infusion: A Randomized, Placebo-controlled Safety and Pharmacokinetic Study. Epilepsia, 2006, 47, 1128-1135. ppb: Stuart W. Paine, Karelle Menochet, Rebecca Denton, Dermot F. McGinnity, and Robert J. Riley. Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption, Drug Metab. Disp. 2011, 39:1008–1013","Keppra. UCB L-059. Data digitize from plot reported. 3000 mg 15 minutes iv infusion. N=6 healthy volunteers, average weight 74.6 kg. Other doses available and linearity observed. AUC(0-inf) reported as 754 ug.h.mL-1. AUC(0-inf) calculated 751 ug.h.mL-1. < 1 % difference.",From PDR. Accessed February 22 2013.http://www.pdr3d.com/detail.php?c=52829#section-4  Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.,1985,170.21,4,1,63.4,3,neutral,-0.48,-0.48
Levobupivacaine,27262-47-1,C(Nc1c(cccc1C)C)([C@H]1[N@@](CCCC)CCCC1)=O,0.49,8.7,0.03,0.94,0.79,"Bardsley, Hazel; Gristwood, Robert; Baker, Helen; Watson, Norma; Nimmo, Walter. A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers Full Text British Journal of Clinical Pharmacology (1998), 46(3), 245-249. ppb: Bernadette Th. Veering, M.D., Ph.D., Anton G. L. Burm, M.Sc., Ph.D.,Hilde-Marieken Feyen, M.D.,Wim Olieman,
John H. M. Souverijn, M.Sc., Ph.D.,  Jack W. van Kleef, M.D., Ph.D. Pharmacokinetics of Bupivacaine during Postoperative Epidural Infusion Enantioselectivity and Role of Protein Binding. Anesth. 2002, 92, 1062-1069. Slightly time dependent during infusion and enantioselctive binding for (+) isomer but very similar. ","Data digitized from Figure 4 in:reference. N=14, 20-150 mg range of doses due to 2-15 min of range of 10 mg/min infusion
An average of 56.1 mg dose and a 5.61 min of infusion time have been assumed",,1968,288.43,3,1,32.3,5,cationic,4,3.4
Levocabastine,79516-68-0,[H]OC([C@@]1(CCN(C[C@H]1C)C1CCC(CC1)(C#N)c1ccc(cc1)F)c1ccccc1)=O,1.17,0.43,0.453,45.3,33,"De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780.  ",70 kg average weight assumed.  MRT calculated from CL and VDss. 0.2 mg iv dose,,1962,420.52,4,1,64.3,6,zwitterionic,4.3,2
Levodopa,59-92-7,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,1.7,23,0.76,1.2,1.3,"Robertson DRC, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, and George CF (1989) The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.  Br. J. Clin. Pharmacol. 28: 61-69.  Rizzo V, Memmi M, Moratti R, Melzi d'Eril G, and Perucca E (1996) Concentrations of L-dopa in plasma and plasma ultrafiltrates.  J. Pharm. Biomed. Anal. 14: 1043-1046",,,1932,197.19,5,4,103.8,3,zwitterionic,-0.25,-1.9
Levofloxacin,100986-85-4,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(=O)O,1.2,1.9,0.75,11,8.8,"Furlanut M, Brollo L, Lugatti E, Di Qual E, Dolcet F, Talmassons G, and Pea F (2003) Pharmacokinetic aspects of levofloxacin 500mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections.  J. Antimic. Chemother. 51: 101-106.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones. Clin. Pharmacokinet. 41: 741-750.",,,1991,361.37,7,1,73.3,2,zwitterionic,1.9,-0.4
Levoleucovorin,68538-85-2,C(=O)([C@@H](NC(=O)c1ccc(cc1)NC[C@@H]1N(c2c(=O)nc([nH]c2NC1)N)C=O)CCC(=O)O)O,0.27,4.1,,1.1,1.1,"Eberhard Schleyer á Karl Lenhard Rudolph, Jan Braess á Michael Unterhalt á Gerhard Ehninger Wolfgang Hiddemann á Wolfgang Kern, Impact of the simultaneous administration of the (+)- and (-)-forms
of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. Cancer Chemother Pharmacol (2000) 45: 165-171","Structure and CAS number referring to free acid. Also reported as dl-CF. N=4, 100 mg/m2, 70 kg weight assumed, 10' infusion, MRT from VDss and clearance.",,1948,473.44,14,7,219.8,9,anionic,-2,-7.7
Levomepromazine,60-99-1,COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1,12,9.9,,21,30,"Bagli M, Hoflich G, Rao, ML, Langer M, Baumann P, Kolbinger M, Barlage U, Kasper S, and Moller HJ (1995) Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects.  Int. J. Clin. Pharmacol. Ther. 33: 646-652.",,,1956,328.47,3,0,15.7,5,cationic,4.9,3.3
Levonorgestrel,797-63-7,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,1.5,1.8,0.025,14,9.4,"Stead RJ, Grimmer SFM, Rogers SM, Back DJ, Orme MLE, Hodson ME, and Batten JC (1987) Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.  Thorax 42: 59-64.  Aviane Product Label.",,,1963,312.45,2,1,37.3,2,neutral,3.5,3.5
Levoprotiline,76496-68-9,c1ccc2c(C3(CCC2c2ccccc32)C[C@H](CNC)O)c1,18.8,14.6,,21.4,18.8," Pharmacokinetics of the antidepressant levoprotiline after intravenous and peroral administration in healthy volunteers 
By Kaiser G; Ackermann R; Dieterle W; Reimann I W; Bieck P R 
From Biopharmaceutics & drug disposition (1992), 13(2), 83-93. Language: English, Database: MEDLINE 
","N=12, 15 mg dose in 10' infusion. Average weight 60.6 kg.  T1/2 checked and actually numerically identical to VDss. MRT = VDss/CL. Data in blood.",,1980,293.4,2,2,32.3,4,cationic,3,0.98
Levorphanol,77-07-6,c12[C@@]34[C@H]([C@@H](Cc1ccc(c2)O)[N@](C)CC3)CCCC4,11.5,15.7,0.6,12.2,13.5,PDR prescribing information. Accessed July 31 2014. http://www.pdr3d.com/detail.php?c=1589#section-3. ,"PDR. AccessedJuly 31 2014. http://www.pdr3d.com/detail.php?c=1589#section-3. The pharmacokinetics of levorphanol have been studied in a limited number of cancer patients following intravenous (IV), intramuscular (IM) and oral (PO) administration. Following IV administration, plasma concentrations of levorphanol decline in a triexponential manner with a terminal half-life of approximately 11 to 16 hours and a clearance of 0.78 to 1.1 L/kg/hr. Based on terminal half-life, steady-state plasma concentrations should be achieved by the third day of dosing. Levorphanol is rapidly distributed (<1 hr) and redistributed (1 to 2 hours) following IV administration and has a steady-state volume of distribution of 10 to 13 L/kg. In vitro studies of protein binding indicate that levorphanol is only 40% bound to plasma proteins.",,1948,257.37,2,1,23.5,0,cationic,3,0.98
Levosimendan,141505-33-1,C[C@@H]1CC(=O)NN=C1c2ccc(NN=C(C#N)C#N)cc2,0.24,3.8,0.02,1.1,1.1,"Sundberg S, Antila S, Scheinin H, Hayha M, Virtanen M, and Lehtonen L (1998) Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.  Int. J. Clin. Pharmacol. Ther. 36: 629-635.  Lilleberg J, Antila S, Karlsson M, Mieminen MS, and Pentkainen PJ (1994) Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.  Clin. Pharmacol. Ther. 56: 554-563.  Wikberg T, Korkolainen T, and Karlsson M (1996) Enantiomeric bioanalysis of simendan and levosimendan by chiral high-performance liquid chromatigraphy.  Chirality 8: 511-517.",,,1992,280.28,7,2,113.4,5,anionic,2.2,0.87
Libenzapril,109214-55-3,C([C@@H](N[C@H]1CCc2c(cccc2)N(CC(O)=O)C1=O)CCCCN)(O)=O,1.98,1.23,,29.3,,"Gregory M. Kochak, PhD, R. Leslie Choi, PhD, Jacqueline K. deSilva, MD, and P. Reydel-Bax, BS. Pharmacodynamic Dependent Disposition of the Angiotensin Converting Enzyme Inhibitor, Libenzapril.J. ClIn Pharmacol 1990;30:138-143","Doses of 1.7 and 4 mg. N=12 73.1 kg average weight. Non linear behavior for MRT and VDss at 12 mg dose, but clearance stable. Data at 1.7 and 4 mg weight-averaged (N=4 and 8, respectively). T1/2 not reported.",,1985,363.41,8,4,133,9,anionic,0.21,-2.4
Licarbazepine,29331-92-8,c12CC(c3c(N(c2cccc1)C(=O)N)cccc3)O,0.72,0.88,0.7,13.6,9.8,"Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine. G. Flesch, C. Czendlik, D. Renard, and P. Lloyd. Drug Metab. Disp. 2011, 39:1103–1110.//ppb: Fortuna, Ana; Alves, Gilberto; Falcao, Amilcar; Soares-da-Silva, Patricio. Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharm.  Drug Disp., 2010, 31, 362-366.","MHD or GP 47779 or BIA 2-005. Sum of data on racemate. CAS number of racemate. N=12. Small differences between enantiomers. Administered iv as racemate at 250 mg, via 30' minutes infusion. 70-kg average weight assumed. Renal clearance available. MRT = VDss/Cl.",,1970,254.28,4,2,66.6,0,neutral,1.9,1.9
Lidocaine,137-58-6,CCN(CC)CC(=O)Nc1c(C)cccc1C,1.8,16,0.33,1.9,1.6,"Bauer LA, Brown T, Gilbaldi M, Hudson L, Nelson S, Raisys V, and Shea JP (1982) Influence of long-term infusions on lidocaine kinetics.  Clin. Pharmacol. Ther. 31: 433-437.  Bennett PN, Aarons LJ, Bending MR, Steiner JA, and Rowland M (1982) Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependecy studies in man.  J. Pharmacokinet. Biopharm. 10: 265-281.  Grossman SH, Davis D, Kitchell BB, Shand DG, and Routledge PA (1982) Diazepam and lidocaine plasma protein binding in renal disease.  Clin. Pharmacol. Ther. 31: 350-357.  Barry M, Keeling PW, Weir D, and Feely J (1990) Severity of cirrhosis and the relationship of alpha 1-acid glycoprotein concentration to plasma protein binding of lidocaine.  Clin. Pharmacol. Ther.  47: 366-370.",Lignocaine. Maricaine.,,1946,234.34,3,1,32.3,5,cationic,2.7,2
Linagliptin,668270-12-0,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,16,1.9,,140,129,"PDR. Accessed March 6 2013. http://www.pdr3d.com/detail.php?c=79838#section-13.  Linagliptin - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 201280/S-000 Part 03. Accessed through Pharmapendium.","VDss taken from PDR. 70 kg assumed. Clearance averaged across 4 doses (non-linear due to ppb) from FDA review. MRT from VDss and clearance. The mean apparent volume of distribution at steady state following a single intravenous dose of linagliptin 5 mg to healthy subjects is approximately 1110 L, indicating that linagliptin extensively distributes to the tissues. Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/L to 75%-89% at ≥30 nmol/L, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin. At high concentrations, where DPP-4 is fully saturated, 70% to 80% of linagliptin remains bound to plasma proteins and 20% to 30% is unbound in plasma. Plasma binding is not altered in patients with renal or hepatic impairment.",,2004,472.54,10,1,113.5,5,cationic,3.1,1.5
Lincomycin,154-21-2,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,1,2.1,,7.5,5.6,Gwilt PR and Smith RB (1986) Protein binding and pharmacokinetics of lincomycin following intravenous administration of high doses.  J. Clin. Pharmacol.  26: 87-90.,Averaged values over three doses.  Saturable protein binding reported.,,1962,406.54,8,5,122.5,7,cationic,0.001,-0.75
Linezolid,165800-03-3,CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCOCC3)c(F)c2,0.58,1.8,0.69,5.4,4.5,"Stalker DJ, Jungbluth GL, Hopkins NK, and Batts DH (2003) Pharmacokinetics and tolerance of single- and multiple-dose oral and intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.  J. Antimic. Chemother. 51: 1239-1246.  Zyvox Product Label.",,,1995,337.35,7,1,71.1,4,neutral,1.1,1.1
"Lipoic acid, R(+)-α",1200-22-2,C1CSS[C@@H]1CCCCC(=O)O,0.1,11.5,,0.14,0.21,"Hermann, R.; Niebch, G.; Borbe, H. O.; Fieger-Bueschges, H.; Ruus, P.; Nowak, H.; Riethmueller-Winzen, H.; Peukert, M.; Blume, H. Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers. European Journal of Pharmaceutical Sciences (1996), 4(3), 167-174.",200 mg (racemic) iv 4min infusion. N=12. Digitized from figure 3. AUC differing by 4% from reported.,,1951,206.33,2,1,37.3,5,anionic,2.4,0.038
"Lipoic acid, S(-)-α",1077-27-6,C1CSS[C@H]1CCCCC(=O)O,0.11,13.4,,0.13,0.21,"Hermann, R.; Niebch, G.; Borbe, H. O.; Fieger-Bueschges, H.; Ruus, P.; Nowak, H.; Riethmueller-Winzen, H.; Peukert, M.; Blume, H. Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers. European Journal of Pharmaceutical Sciences (1996), 4(3), 167-174.",200 mg (racemic) iv 4min infusion. N=12. Digitized from figure 3.  AUC differing by 12% from reported.,,1956,206.33,2,1,37.3,5,anionic,2.4,0.038
Liraglutide,204656-20-2,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc2c[nH]c3c2cccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc4ccc(cc4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](Cc6cnc[nH]6)N)C(=O)O,,0.01,0.01,,8.1,"Liraglutide - FDA Approval Package
Pharmacology Review 022341/S-000 Part 01. Accessed through Pharmapendium.",VDss not reported. Vz 0.07 L/kg.,,1998,3751.2,94,54,1513.8,132,anionic,-5.7,-5.7
Lisdexamfetamine,608137-32-2,"C[C@@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)N
",0.6,17,,0.6,1.2,"Jasisnki DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. Journal of Psychopharmacology, 2009,  23, 410–418","N=9, 69.5 kg average weight. No data reported for LDX. Lisine prodrug (amide) of dexamfetamine. CAS: 51-64-9 (+)-(S)-amphetamine",,2005,263.38,4,3,81.1,8,cationic,0.95,-2.1
Lisinopril,76547-98-3,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2CCC[C@H]2C(=O)O,0.89,1.2,1,12,42,"Beermann B, Till AE, Gomez HJ, Hichens M, Bolognese JA, and Junggren IL (1989) Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers.  Biopharm. Drug Dispos. 10: 397-409.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482. ",VDss calculated using C vs t data obtained by digitization of the plots provided in the reference.  Dose levels averaged.,,1980,405.49,8,4,133,12,anionic,0.66,-3
Lisuride,18016-80-3,c12c3C=4[C@H]([N@@](C[C@H](C4)NC(N(CC)CC)=O)C)Cc1c[nH]c2ccc3,1.73,13.3,,2.17,1.8,"Krause W; Mager T; Kuhne G; Duka T; Voet B. The pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular, and subcutaneous injection. European journal of clinical pharmacology, 1991, 40, 399-403.","Data digitized from plot reported, N=12, 78 kg median weight, 25 ug dose. AUCinf calculated as 401 pg.hr.mL-1 with reported AUC (not specified) as 363 pg.hr.mL-1",,1962,338.45,5,2,51.4,3,neutral,2.9,2.8
Lomefloxacin,98079-51-7,N1[C@@H](C)CN(CC1)c1c(F)cc2c(c(cn(c2c1F)CC)C(O)=O)=O,2.04,3.98,,7.89,8.1,"Determination of lomefloxacin in human plasma by HPLC and its pharmacokinetics of intravenous infusion  Liu, Xiaodong; Xie, Lin; Zhong, Bing; Xu, Bingchuan; Xu, Qun; Liu, Guoqing  Chin. Pharmacol. Bull. (1996), 12(1), 26-29","N=8, 65 kg median weight, 200 mg iv dose. 1 h infusion. Individual plasma data data, Vss calculated as MRT*Cl.",,1985,351.35,6,2,74.6,3,zwitterionic,2.4,-0.34
Lomeguatrib,192441-08-0,c1c(csc1COc2c3c(nc[nH]3)nc(n2)N)Br,,21.55,,,2.92,"Ranson, Malcolm; Middleton, Mark R.; Bridgewater, John; Lee, Siow Ming; Dawson, Martin; Jowle, Debra; Halbert, Gavin; Waller, Sue; McGrath, Helen; Gumbrell, Lindsey, R. Stanley McElhinney,Dorothy Donnelly, T. Brian H. McMurry, and Geoffrey P.Margison. Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2006, 12, 1577-1584.","N=3, 70 kg average weight assumed. N=30 across 10, 20 and 40 mg/m2 doses. All data from DAY 1. Only Vc was reported and averaged to 1.11 L/kg across 30 patients and three doses.","O(6)-(4-Bromothenyl)guanine. 
6-((4-Bromo-2-thienyl)methoxyl)purin-2-amine
",1997,326.17,6,2,89.7,3,neutral,2.2,2.2
Lomitapide,182431-12-5,c1cccc2c1C(c1c2cccc1)(CCCCN1CCC(CC1)NC(c1c(cccc1)c1ccc(cc1)C(F)(F)F)=O)C(NCC(F)(F)F)=O,16.3,8.7,0.002,31.2,39.7,PDR prescribing information. Accessed July 31 2014 http://www.pdr3d.com/detail.php?c=115562#section-13//http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000ClinpharmR.pdf.,The mean lomitapide volume of distribution at steady state is 985-1292 liters. Lomitapide is 99.8% plasma-protein bound. Absolute BA reported. Data assumed to be from iv dose. Assumed 70 kg. No clearance value reported in pdr but available in fda report cited.,"From  In a mass-balance study, a mean of 59.5% and 33.4% of the dose was excreted in the urine and feces, respectively. In another mass-balance study, a mean of 52.9% and 35.1% of the dose was excreted in theurine and feces, respectively. Lomitapide was not detectable in urine samples. M1 is the major urinary metabolite. Lomitapide is the major component in the feces. The mean lomitapide terminal half-life is 39.7 hours.",1996,693.72,5,2,61.4,10,cationic,8.7,7.5
Lorazepam,846-49-1,OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O,1.3,1,0.09,22,17,"Wermeling DPH, Miller JL, Archer SM, Manaligod JM, and Rudy AC (2001) Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J. Clin. Pharmacol. 41: 1225-1231.  Desmond PV, Roberts RK, Wood AJJ, Dunn GD, Wilkinson, GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175.  ",,,1963,321.16,4,2,61.7,1,neutral,2.9,2.9
Lorcainide,59729-31-6,CC(C)N1CCC(CC1)N(C(=O)Cc2ccccc2)c3ccc(Cl)cc3,6.6,16,0.15,6.9,6.5,"Klotz U, Mueller-Seydlitz P, and Heimburg P (1979) Disposition and antiarrythmic effect of lorcainide.  Int. J. Clin. Pharmacol. Biopharm. 17: 152-158.  Klotz U, Mueller-Seydlitz P, and Heimburg P (1978) Pharmacokinetics of lorcainide in man:  a new antiarrhythmic agent.  Clin. Pharmacokinet. 3: 407-418.",,,1977,370.92,3,0,23.5,5,cationic,4.9,3
Lormetazepam,848-75-9,CN1C(=O)C(O)N=C(c2ccccc2Cl)c3cc(Cl)ccc13,1.6,4,0.12,6.7,4.9,"Humpel M, Illi V, Milius W, Wendt H, and Kurowski M (1979) The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. Eur. J. Drug Metab. Pharmacokinet. 4: 237-243.",Pharmacokinetic parameters were calculated from C vs t obtained by digitization of the plot included in the reference.,,1963,335.18,4,1,52.9,1,neutral,2.8,2.8
Losartan,114798-26-4,CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)c3ccccc3c4nnn[nH]4,0.37,8.2,0.01,0.75,1.8,"Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, and Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 58: 641-649.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",,,1988,422.91,7,2,92.5,8,anionic,4.2,0.7
Losmapimod,585543-15-3,CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C,1.67,3.77,,7.38,6.95," Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Losmapimod following a Single Intravenous or Oral Dose in Healthy Volunteers. Barbour April M; Sarov-Blat Lea; Cai Gengqian; Fossler Michael J; Sprecher Dennis L; Graggaber Johann; McGeoch Adam T; Maison Jo; Cheriyan Joseph. Br. J. Clin. Pharmacol. 2013, 76, 99-106.",Data extracted from table and weight-averaged across 1 (N=4) and 3 (N=12) mg/kg dose. MRT from VDss and Cl.,,2003,383.46,5,2,71.1,5,neutral,4.2,4.2
Lovastatin (acid),75225-51-3,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H]12,0.87,7.2,0.043,1.3,1.4,"Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S (1989) The physiological disposition of lovastatin.  Drug Metab Dispos. 17: 166-173.",Pharmacokinetic paramaters were calculated using C vs t data obtained by digitization of the plot provided in the reference.,,1980,422.55,6,3,104.1,11,anionic,4.2,1.4
Loxiglumide,107097-80-3,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,0.24,1,,4,5.2,"Setnikar I, Chiste R, Makovec F, Rovati LC, and Warrington SJ (1988) Pharmacokinetics of loxiglumide after single intravenous or oral doses in man.  Arz. Forsch. 38: 716-720.",VDss was calculated from rate micro-contants provided in the reference.,,1987,461.38,7,2,95.9,14,anionic,4.2,1
Lubeluzole,144665-07-6,[H]O[C@@H](CN1CCC(CC1)N(C)c1nc2ccccc2s1)COc1ccc(c(c1)F)F,2.6,1.7,0.003,26,21.6,"Herron, Jerry; Lee, Peter; Pesco-Koplowitz, Luana; Gajjar, Diptee; Soo, Yuh Wen; Woestenborghs, Robert. Determination of the dose proportionality of single intravenous doses (5, 10, and 15 mg) of lubeluzole in healthy volunteers. Clin. Ther. 1998, 20(4), 682-690. Three-way cross-over study in 11,10 and 12 healthy subjects at 5, 10 and 15 mg dose respectively as 1-hr inf. Male and female subjects, 70 kg reported average weight. Weight-averaged VDss 220 L; 3.1 L/kg, Cl= 1.8 mL/min/kg; MRT = 28.7 h; t1/2 = 23.5h//Van de Velde, V.; Crabbe, R.; Van Peer, A.; Woestenborghs, R.; Van Osselaer, N.; Hantson, L.; Heykants, J. Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects. Int. J. Clin. Pharmacol. Ther. 1998, 36, 490-493. N=8, total of 31 administrations across 6 doses 2.5 to 25 mg, each separated by 13 days. 30' inf. 79 kg average weight. Weight averaged data: VDss= 2.15 L/kg, Cl= 1.54 mL/min/kg; MRT = 23.3 h; t1/2 = 19.8h. fu from De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780.  ",AVERAGED ACROSS TWO REPORTS (N almost identical); Weight averaged within each report. ,,1992,433.51,5,1,48.8,8,cationic,4.9,4.4
Lurbinectedin,497871-47-3,Cc1cc2c(c(c1OC)O)[C@@H]3[C@@H]4[C@H]5c6c(c7c(c(c6OC(=O)C)C)OCO7)[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)c9c(c1cc(ccc1[nH]9)OC)CCN8,7.3,2.76,,44.03,50.68,"Luis Paz-Ares,  Martin Forster,  Valentina Boni, Sergio Szyldergemajn, Jesús Corral, Samantha Turnbull,  Antonio Cubillo,  Carlos Fernandez Teruel, Iker López Calderero, Mariano Siguero, Patrick Bohan, Emiliano Calvo. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. Invest New Drugs 2017, 35, 198–206.",PM01183. 70 kg average weight assumed. Weight average of data with N=40 across four dose/combination with gemcitabine. Very close data. 1 hr infusion. MRT from clearance and VDss.,,2003,784.87,14,4,164.3,4,cationic,2.4,1.8
Lurtotecan,149882-10-0,CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5cc6c(cc5c4CN7CCN(CC7)C)OCCO6)O,4.77,25.07,,3.5,3.54,"CJH Gerrits, GJ Creemers, JHM Schellens, P Wissel, AS Th Planting, R Kunka, K Selinger,
M de Boer-Dennert, Y Marijnen, M Harteveld, J Verweij. Phase I and pharmacological study of the new topoisomerase I inhibitor G1147211, using a daily x 5 intravenous administration. British Journal of Cancer (1996) 73, 744-750.","GG211 or GI147211. NX211. Quantitation of lactone form. Weight averaged value across several doses, from Table IV (Day 1). N=17 overall. 1.73m2/70 kg factor used.",,1993,518.56,10,1,106.4,3,cationic,1,-0.084
LY2090314,603288-22-8,C1(C2C3C(N(C(C=3C(N=C(N3C=CC4)C=4)=C3)=O)[H])=O)[C@@H](N(C=2)C2)[C@@H](C=C(C=1)F)CN(C2)C(=O)N(CCCC1)C1,1.2,10.3,0.02,1.9,2.7,"Pharmacokinetics, metabolism, and excretion of the GSK-3 inhibitor LY2090314 in rats, dogs, and humans: A case study in rapid clearance by extensive metabolism with low circulating metabolite exposures. Maciej J. Zamek-Gliszczynski, Trent L. Abraham, Jeffrey J. Alberts, Palaniappan Kulanthaivel, Kimberley A. Jackson, Kay H. Chow, Denis J. McCann, Haitao Hu, Shelby Anderson, Nathan A. Furr, Robert J. Barbuch, and Kenneth C. Cassidy. Drug Metabolism & Disposition (2013), 41(4), 714-726",N=12 across dose range from 10 to 120 mg. 70 kg assumed as average weight. N=2 per dose group.,,2003,514.55,9,1,90.3,2,neutral,3.5,3.5
LY2140023,635318-55-7,S1(=O)(=O)C[C@@]([C@H]2[C@@H]1[C@@H]2C(=O)O)(NC(=O)[C@H](CCSC)N)C(=O)O,0.44,9.73,,0.75,0.84,"WILLIAM F. ANNES, AMANDA LONG, JENNIFER W. WITCHER, MOSUN A. AYAN-OSHODI, MARY PAT KNADLER, WEI ZHANG, MALCOLM. MITCHELL, KAREN CORNELISSEN, STEPHEN D. HALL.(2015) Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023).  J. Pharm. Sci. 104:207–214.",Pomaglumetad methionil. Average weight 80.5 kg. N=18. MRT from clearance and VDss. Data referring to dosing AND analysis of prodrug.,100 ug (microdose),2003,366.41,9,4,163.9,7,anionic,-3,-7.6
LY404039,635318-11-5,S1(=O)(=O)[C@@H]2[C@H]([C@](C1)(N)C(=O)O)[C@H]2C(=O)O,0.21,2.4,,1.44,1.23,"WILLIAM F. ANNES, AMANDA LONG, JENNIFER W. WITCHER, MOSUN A. AYAN-OSHODI, MARY PAT KNADLER, WEI ZHANG, MALCOLM. MITCHELL, KAREN CORNELISSEN, STEPHEN D. HALL. (2015) Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023). J. Pharm. Sci. 104:207–214.",Pomaglumetad. Average weight 80.5 kg. N=17. MRT from clearance and VDss.  Active compound dosed as such iv.,100 ug (microdose),2003,235.21,7,3,134.8,2,anionic,-3,-8.1
Mannitol,69-65-8,O[C@@H]([C@@H]([C@@H](CO)O)O)[C@@H](CO)O,0.24,1.2,,3.5,4.7,"EMA assessment report of Mannitol (EMEA/H/C/001252):
study DPM-PK-101","Data digitized from Table 3 in the report. N=18 male, 70 kg body weight assumed. 500 mg dose.

Reported data (Table 2):
AUC0-inf = 100236 ng*h/mL
CL = 5099 mL/h (1.21 mL/min/kg)
CLr = 4439 mL/h (mainly renally excreted)
t1/2 = 4.5 h
Vd = 34.3 L (0.49 L/kg)",,1946,182.17,6,6,121.4,5,neutral,-3.6,-3.6
Maprotiline,10262-69-8,CNCCCC12CCC(c3ccccc13)c4ccccc24,45,14,0.11,54,51,"Maguire KP, Norman TR, Burrows GD, and Scoggins BA (1980) An evaluation of maprotiline intravenous kinetics and comparison of two oral doses.  Eur. J. Clin. Pharmacol.18: 249-254.  Lynn K, Braithwaite R, Dawling S, and Rosser R (1981) Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis.  Eur. J. Clin. Pharmacol. 19: 73-77.","VDss calculated from reported compartmental paramaters included in the reference by Maguire, et al.",,1966,277.4,1,1,12,4,cationic,4.1,1.7
Maraviroc,376348-65-1,[H]N(C(C1CCC(CC1)(F)F)=O)[C@H](CCN1[C@H]2CC[C@@H]1CC(C2)n1c(C)nnc1C(C)C)c1ccccc1,2.3,9.4,0.25,4.2,12.8,"Abel S. et al. (2008) Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy males subjects. Br. J. Clin. Pharmacol. 65:Suppl.1 60-67//ppb from Walker et al. DMD 2005, 33, 587-595","N=8 in study 2 cohort 1 and N=8 in cohort 2. Overall average weight 80 kg, average of two cohhorts at 30 mg i.v.",,2001,513.67,6,1,63,8,cationic,4.5,3.1
Maxipost,187523-35-9,COc1ccc(Cl)cc1[C@]2(F)C(=O)Nc3cc(ccc23)C(F)(F)F,10,15,0.0038,11,37,"Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, and Klunk LJ (2005) Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled maxipost (BMS-204352) in humans.  Drug Metab. Dispos. 33: 83-93.  Krishna R, Yao M, Kaczor D, Vachharajani N, and Srinivas NR. (2001) In vitro protein binding studies with BMS-204352: lack of protein binding displacement interaction in human serum.  Biopharm. Drug Dispos. 22: 41-44.",Flindokalner. BMS-204352,,1997,359.7,3,1,38.3,2,anionic,4.1,2.5
Mazapertine,134208-17-6,CC(C)Oc1ccccc1N1CCN(CC1)Cc1cccc(c1)C(N1CCCCC1)=O,1.54,6.17,0.011,4.2,4.6,"DDe Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780.  ",MRT calculated from CL and VDss. 2.8 mg iv dose,,1993,421.58,5,0,36,6,neutral,4.2,4
MDAM,176857-41-3,C=C(C[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)CCC2=CN=C3C(=N2)C(=NC(=N3)N)N)C(=O)O,0.7,3.08,,3.78,8.2,"Mary Johansen, Thomas Zukowski, Paulo M. Hoff, Robert A. Newman, Dan Ni, Toni Hutto James Abbruzzeese, Elmer Berghorn Frederick Hausheer, Timothy Madden. Final results of a phase I and pharmacokinetic study of γ-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors. Cancer Chemother Pharmacol (2004) 53: 370–376","γ-METHYLENE-10-DEAZAAMINOPTERIN. N=16, across several dose, weight-averaged 80-300 mg/m2. 1.73m2/70 kg factor used. SD up to 100% of reported values. MRT from VDSs and clearance.",,1996,451.44,12,5,207.3,9,anionic,0.16,-6
ME-344,1374524-68-1,Cc1c(ccc2c1OC[C@H]([C@H]2c3ccc(cc3)O)c4ccc(cc4)O)O,1.2,8.42,,2.38,5.3,"Jennifer R. Diamond, Barbara Goff, Martin D. Forster, Johanna C. Bendell,  Carolyn D. Britten, Michael S. Gordon,  Hani Gabra,  David M. Waterhouse,  Mark Poole, D. Ross Camidge,  Erika Hamilton,  Kathleen M. Moore.  Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest. New Drugs. DOI: 10.1007/s10637-017-0444-1.","N=13, 87.2 kg average weight from back calculation of VDss in L and L/kg. MRT from clearance and VDss. ",,2012,348.39,4,3,69.9,2,neutral,4.2,4.2
Mebendazole,31431-39-7,COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c3ccccc3,1.2,15,0.086,1.3,1.1,"Dawson M, Braithwaite PA, Roberts MS, Watson TR (1985) The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.  Br. J. Clin. Pharmacol. 19: 79-86.",,,1946,295.29,6,2,84.1,4,neutral,3,-0.42
Medifoxamine,32359-34-5,C(Oc1ccccc1)(Oc1ccccc1)CN(C)C,2.8,13.7,,3.4,4.4,"S. SALEH, A. JOHNSTON and P. TURNER. Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans. Br. J. Clin. Pharmacol. (1990), 30, 621-624","Data digitized from figure 1. Reported data: 
N=12 (6M, 6F)
Avg BW = 66.3 kg
100 mg, 15 min infusion
Mean AUC = 1799 ug*h/L
CL = 1001 mL/min (15.2 mL/min/kg)
t1/2 = 3 h (Likely not well selected terminal points!)
Elimination pathway = metabolic (unchanged % dose = 0.3 iv) , but biliary excretion not investigated ",See notes from ref. in adjacent cell.,1971,257.33,3,0,21.7,6,neutral,3.1,2.8
Medroxalol,56290-94-9,CC(CCc1ccc2OCOc2c1)NCC(O)c3ccc(O)c(c3)C(=O)N,7.9,16,,8.2,11,"Haegele KD, Jaillion P, Cheymol G, Alken RG, Schechter PJ, and Koch-Weser J (1983) Kinetics of medroxalol, a beta and alpha-adrenoceptor antagonist.  Clin. Pharmacol. Ther.34: 785-791.  Keeley FJ, Weiner DL, and Okerholm RA (1983) Bioavailability of medroxalol in man.  Biopharm. Drug Dispos.  4: 305-309.",Calculations were done using data from digitization of the C vs t plot in the reported reference by Keeley et al. and from C vs t data listed in Haegele et al..,,1975,372.41,7,4,114,8,cationic,1.7,0.84
Melagatran,159776-70-2,NC(=N)c1ccc(CNC(=O)[C@@H]2CCN2C(=O)[C@H](NCC(=O)O)C3CCCCC3)cc1,0.23,1.9,0.93,2,1.6,"Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislen K, Fager G, and Gustafsson D (2003) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.  Drug Metab. Dispos. 31: 294-305.",,,1996,429.51,9,5,148.6,9,cationic,-0.76,-2.6
Melatonin,73-31-4,c12c([nH]cc1CCNC(C)=O)ccc(c2)OC,1.1,16.5,0.39,1.1,1.1,"Rob L. DeMuro, Anne N. Nafziger, David E. Blask, Anne M. Menhinick and Joseph S. Bertino, Jr.  The Absolute Bioavailability of Oral Melatonin. J Clin Pharmacol 2000;40:781-784.//ppb:Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. Endocrinol. 1972, 91, 1213-1218.","Data digitized from Figure 1 
Reported data (Table 1):N=12 (6M, 6F), Avg body weight = 77.9 kg, 2 mg iv 3 min infusion, AUC = 1631.61 ng*min/mL, t1/2 59.5 min (1 h)// ppb: no significant differences between human and rat ppb. Concentration independent but temperature dependent: fu at 4 °C = 0.22",,1958,232.28,4,2,54.1,4,neutral,1.4,1.4
Meloxicam,71125-38-7,CN1C(=C(O)c2ccccc2S1(=O)=O)C(=O)Nc3ncc(C)s3,0.15,0.12,0.003,21,18,"Narjes H, Turck D, Busch U, Heinzel G, and Nehmiz G (1996) Pharmacokinetics and tolerability of meloxicam after i.m. administration.  Br. J. Clin. Pharmacol. 41: 135-139.  Busch U, Heinzel G, and Narjes H (1995) The effect of cholestyramine on the pharmaciokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man.  Eur. J. Clin. Pharmacol. 48: 269-272.   Turck D, Busch U, Heinzel G, and Narjes H (1997) Clinical pharmacokinetics of meloxicam.  Arz. Forsch. 47: 253-258. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, and Kummer M (1995) Meloxicam. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab. Dispos. 23: 1206-1213.  Tuerck D, Schwarz A, Hoeffler D, Narjes HH, Nehmiz G, and Heinzel G (1996) Pharmacokinetics of meloxicam in patients with end-stage renal failure on hemodialysis. A comparison with healthy volunteers.  Eur. J. Clin. Pharmacol.  51: 309-313.",,,1979,351.4,7,2,99.6,2,anionic,2.6,-0.7
Melperone,3575-80-2,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,14,46,,5,3.9,"Borgstrom L, Larsson H, and Molander L (1982) Pharmacokinetics of parenteral and oral melperone in man.  Eur. J. Clin. Pharmacol.  23: 173-176.",Data from 20 mg dose.  All pharmacokinetic parameters calculated from digitized C vs t plot in the reported reference.,,1964,263.35,2,0,20.3,5,cationic,3.7,1.7
Melphalan,148-82-3,N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(=O)O,0.48,7,0.14,1.1,1,"Woodhouse KW, Hamilton P, Lennard A, and Rawlins MD (1983) The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dosing regimen.  Eur. J. Clin. Pharmacol. 24: 283-285.  Hersh MR, Ludden TM, Kuhn JG, and Knight WA (1983) Pharmacokinetics of high dose melphalan.  Invest. New Drugs. 1: 331-334.  Gera S, Musch E, Osterheld HKO, and Loos U (1989) Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.  Canc. Chemother. Pharmacol. 23: 76-80.  Grieg NH, Sweeney DJ, and Rapoport SI (1987) Melphalan concentration dependent protein binding in healthy humans and rats.  Eur. J. Clin. Pharmacol. 32: 179-185.",,,1946,305.2,4,2,66.6,8,zwitterionic,2,0.36
MEN-10755 ,211100-13-9,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3C[C@@](O)(Cc4c(O)c5C(=O)c6ccccc6C(=O)c5c(O)c34)C(=O)CO)O[C@H]2C,2.4,2.5,,17,21,"Bos AME, deVries EGE, Dombernovsky P, Aamdal S, Uges DRA, Schrijvers D, Wanders J, Roelvink MWJ, Hanauske AR, Bortini S, Capriati A, Crea AEG, and Vermorken JB (2001) Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase 1 studies in adults with advanced solid tumors.  Canc. Chemother. Pharmacol. 48: 361-369.",Sabarubicin. CAS # and structure referring to free base. CAS # for HCl salt = 169317-77-5. The code MEN-10755 is reported only with the salt by SciFinder.,,1998,643.64,14,7,235.5,6,cationic,0.54,-2.2
Menogaril,71628-96-1,c12c3c([C@@]4(O[C@@H](O3)[C@@H](O)[C@@H]([C@@H]4O)N(C)C)C)cc(c1C(c1c(c3[C@@H](C[C@@](Cc3cc1C2=O)(C)O)OC)O)=O)O,9.14,11.61,,13.13,13.22,"Merrill J. Egorin, David A. Van Echo, Margaret Y. Whitacre, Alan Forrest, Lawrence M. Sigman, Kathrin L. Engisch, and Joseph Aisner (1986). Human Pharmacokinetics, Excretion, and Metabolism of the Anthracycline Antibiotic Menogaril (7-OMEN, NSC 269148) and Their Correlation with Clinical Toxicities. CANCER RESEARCH 46, 1513-1520",NSC 269148. Menogarol. 7-OMEN. Average clearance and VDss as reported by authors. 1.73 m2/70 factor used. Overall 24 stuides at different doses (infusion). MRT from clearance and VDss.,"From paper cited: In humans, as in rabbits (8), neither urinary or biliary excretion of 7-OMEN and its fluorescent metabolites represented a major route of drug clearance.",1978,541.55,11,5,166.2,2,zwitterionic,1.4,-1.2
Meperidine,57-42-1,CCOC(=O)C1(CCN(C)CC1)c2ccccc2,2.3,4.9,0.42,6.4,7.9,"Chan K, Tse J, Jennings F, and Orme ML (1987) Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction.  J. Clin. Pharmacol. 27: 516-22.  Verbeek RK, Cardinal JA, and Wallace SM (1984) Effect of age and sex on the plasma binding of acidic and basic drugs.  Eur. J. Clin. Pharmacol. 27: 91-97.",Meperidol. Meperidine. VDss calculated from C vs t data provided in the reference.,,1940,247.33,3,0,29.5,4,cationic,3,1.8
Mepindolol,23694-81-7,Cc1cc2c([nH]1)cccc2OCC(CNC(C)C)O,2.17,5.83,0.51,6.21,4.61,"Gugler, R.; Kreis, L.; Dengler, H. J.. Pharmacokinetics of a new b-adrenoceptor blocking agent, LF 17-895, in man Arzneimittel-Forschung (1975), 25(7), 1067-72.",LF 17895 described as sulfate (CAS # 56396-94-2). C15-H22-N2-O2.1/2H2-O4-S.  PK parameters calculated via PKSOlver using tabulated data (no digitization) reported and assuming the dose of 4 mg was intended to be mepindolol not  sulfate. AUC0-inf reported numerically identical to calculated but in ug.h.mL-1 as opposed to ng.h.mL-1. Most likely a typo since the data were taken as average from table. Clearance would be too far had the dose been administered as 3.37 mg (0.84 correction factor).  ppb from chromatographic method.,,1969,262.35,4,3,57.3,6,cationic,2.1,0.37
Mepivacaine,96-88-8,CN1CCCCC1C(=O)Nc2c(C)cccc2C,0.95,6.8,0.3,2.5,2,"Burm AGL, Cohen IMC, van Kleef JW, Vletter AA, Olieman W, and Groen K (1997) Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers.  Anesth. Analg. 84: 85-89.  Allgayer H, Zahringer J, Bach P, and Bircher J (1984) Lack of effect of haemodialysis on mebendazole kinetics: studies in a patient with echinococcosis and renal failure.  Eur. J. Clin. Pharmacol. 27: 243-245.",Average of two enantiomers.,,1951,246.35,3,1,32.3,2,cationic,2.5,2
Meprobamate,57-53-4,CCCC(C)(COC(=O)N)COC(=O)N,0.7,0.6,1,19,14,"Held H and Oldershausen HF (1969) Zur pharmakokinetik von meprobamat bei chronischen hepatopathien und arzneimittelsucht. Klin. Wschr. 47: 78-80.  Douglas JF, Bradshaw WH, Ludwig BJ, and Powers D (1964) Interaction of plasma protein with related 1,3-propanediol dicarbamates.  Biochem. Pharmacol. 13: 537-539.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1951,218.25,6,2,104.6,8,neutral,0.91,0.91
Meptazinol,54340-58-8,CCC1(CCCCN(C)C1)c2cccc(O)c2,3.3,28,0.73,2,1.7,"Norbury HM, Franklin RA, and Graham DF (1983) Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers.  Eur. J. Clin. Pharmacol. 25: 77-80.  Gepts E, Sonck WA, Camu F, and Vercruysse A (1987) Pharmacokinetics of intravenously administered meptazinol during general anesthesia in man.  Eur. J. Anaesth. 4: 35-43.  Franklin RA (1988) The clinical pharmacokinetics and metabolism of the analgesic meptazinol.  Xenobiotica 18: 105-112.","VDss was calculated from C vs t data provided in the reference by Norbury, et al.",,1976,233.35,2,1,23.5,2,cationic,3.1,1.5
"Mercaptopurine, 6-",50-44-2,S=C1NC=Nc2[nH]cnc12,1,15,0.85,1.1,1,"Coffey JJ, White CA, Lesk AB, Rogers WI, and Seppick AA (1972) Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients.  Cancer Res. 32: 1283-1289.  Esposito M, Rosso R, and Santi L (1974)  Plasma protein binding of antineoplastic drugs in rats and humans.    IRCS Library Compendium  2: 1180.",Purinethiol.U 4748. Pharmacokinetic parameters were calculated using the mean C vs t values from three study subjects receiving intravenous 500 mg/m2. ,,1953,152.18,4,2,53.1,0,neutral,-1.8,-2
Meropenem,96036-03-2,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(=C(N2C1=O)C(=O)O)S[C@@H]3CN[C@@H](C3)C(=O)N(C)C,0.3,3.9,0.87,1.3,1,"Burman LA, Nilsson-Ehle I, Hutchinson M, Haworth SJ, and Norrby SR (1991) Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.  J. Antimic. Chemother. 27: 219-224.  Leroy A, Fillastre JP, Etienne I, Borsa-Lebas F, and Humbert G (1992) Pharmacokinetics of meropenem in subjects with renal insufficiency.  Eur. J. Clin. Pharmacol. 42: 535-538.  Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, and Humbert G (1992) Pharmacokinetics of meropenem (ICI 194660) and its metabolite (ICI 213689) in healthy subjects and in patients with renal impairment.  Antimic. Agents Chemother. 36: 2794-2798.  Sumita Y, Nouda H, Tada E, Kohzuki T, Kato M, Okuda T, and Fukasawa M (1992) Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals.  Chemotherapy 40(Suppl. 1): 123-131.",,,1957,383.46,8,3,110.2,5,zwitterionic,-1,-3.5
Mesna,19767-45-4,C(S(=O)(=O)O)CS,0.65,20.5,,0.52,0.36,"C. A. JAMES, T. G. K. MANT and  H. J. ROGERS. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects  Br. J. clin. Pharmac. (1987), 23, 561-568","N=6, 800 mg dose, first order behavior. VD reported as VDz but taken as VDss. CAS number of the sodium salt and smiles of the free acid.",,1954,142.2,3,1,54.4,2,anionic,-0.71,-4.2
Metadoxine,74536-44-0,Cc1c(c(c(cn1)CO)CO)O.C1CC(=O)N[C@@H]1C(=O),0.66,7.9,,1.38,0.98,"LU Yuan，KANG Zisheng，LIU Yan，LI Tianyun and XIAO Yonghong. Pharmacokinetics of metadoxine for inj ection after repeated doses
in healthy volunteers. Chin. Med. J. 2007, 120, 166-168.","data digitized from plot (day 1). N=10, 900 mg dose, 3 hours iv infusion, 69 kg average weight. Digitized AUCinf in close agreement (5%) with reported AUC inf. Structure and CAS number both refer to ion-pair deemed to be the active component studied.",,1979,282.29,7,4,119.8,3,neutral,-0.56,-0.57
Metaproterenol,586-06-1,CC(C)NCC(c1cc(cc(c1)O)O)O,6.03,14.07,0.9,7.14,6.41,"Dengler HJ, Hengstmann JH. Metabolism and pharmacokinetics of orciprenaline in various animal species and man. Arch. Int. Pharmacodyn. 1976, 223, 71-87.//ppb: Heckner, R.M. Systematic study of protein binding of biologically active substances. Pharmather. 1979, 2, 177-186.",ORCIPRENALINE. N=5 after infusion (20-30') of 0.8 mg of the drug. 70 kg assumed as average weight. T1/2 calculated from 0.693/beta. MRT from VDss/clearance.,,1961,211.26,4,4,72.7,4,cationic,0.56,-0.66
Metazosin,95549-92-1,[H]N([H])c1c2cc(c(cc2nc(n1)N1CCN(CC1)C([C@H](C)OC)=O)OC)OC,0.44,0.53,,13.7,,"Lapka R. et al. (1989) Interspecies pharmacokinetics scaling of metazosin, a novel alpha-adrenergic antagonist. Biopharm. Drug Disp. ,10, 581-589.","Average of 6 volunteers receiving a 10 mg dose as a 3-min infusion, plus 6 volunteers receiving a 6 mg dose in a 30-min infusion. 73 kg average weight. Data essentially identical among cohorts. Compound also referred as kenosin or VUFB15111. t 1/2 not reported but plot available.",,1984,375.42,9,1,103,6,neutral,1.1,0.99
Metergoline,17692-51-2,c12c3[C@@H]4[C@H]([N@@](C[C@@H](C4)CNC(OCc4ccccc4)=O)C)Cc1cn(c2ccc3)C,0.57,9.6,,1,0.93,"Martini, A.; Moro, E.; Marrari, P.; Pacciarini, M. A.; Sega, R.; Dell'osso, L.; Bertelli, A., Jr.; Tamassia, V. Pharmacokinetics and bioavailability of metergoline in healthy volunteers after single i.v. and oral administration.  International Journal of Clinical Pharmacology Research (1983), 3(1), 27-34.","FI 6337. Liserdol. N=7, average weight 72 kg, 4 mg dose. Data digitized from figure 1.  AUC(0-inf) reported : 95 ±6 ng*h/mL; AUC(0-inf) calculated: 97 ng*h/mL",,1964,403.52,5,1,46.5,5,cationic,3.9,3.4
Metformin,657-24-9,CN(C)C(=N)NC(=N)N,0.64,7.4,1,1.4,1.7,"Pentikainen PJ, Neuvonen PJ, and Penttila A (1979) Pharmacokinetics of metformin after intravenous and oral administration to man.  Eur. J. Clin. Pharmacol. 16: 195-202.",VDss calculated from reported rate micro-constants.,,1961,129.16,5,4,89,3,cationic,-2,-5.5
Methadone,76-99-3,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c2ccccc2,4.4,1.7,0.21,43,31,"Nilsson MI, Gronbladh L, Widerlov E, and Anggard E (1983) Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures.  Eur. J. Clin. Pharmacol. 25: 497-501.  Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, and Sjoegren P (1996) Stereoselective pharmacokinetics of methadone in chronic pain patients.  Ther. Drug Monit. 18: 221-227.  Berkowitz BA (1976) The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.  Clin. Pharmacokinet. 1: 219-230. ",,,1946,309.45,2,0,20.3,7,cationic,3.7,2.5
Methamphetamine,537-46-2,CN[C@@H](C)Cc1ccccc1,4.3,4.4,0.85,16,12,"Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, and Jones RT (2003) The bioavailability of intranasal and smoked methamphetamine.  Clin. Pharmacol. Ther. 74: 475-486.  Cook CE, Jeffcoat AR, Hill JM, Pugh DE,  Patetta PK, Sadler BM, White WR, and Perez-Reyes M (1993) Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride.  Drug Metab. Dispos. 21: 717-723.  Mendelson J, Jones RT, Upton R, and Jacob P (1995) Methamphetamine and ethanol interactions in humans.  Clin. Pharmacol. Ther. 57: 559-568.  De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S (2004) Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet. 43: 157-185.",Values for individual stereoisomers were averaged.,,1919,149.23,1,1,12,3,cationic,2.1,-0.2
Methicillin,61-32-5,COc1cccc(OC)c1C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O,0.32,6.6,0.43,0.8,0.64,"Yaffe SJ, Gerbacht LM, Mosovich LL, Mattar ME, Danish M, and Jusko WJ (1977) Pharmacokinetics of methicillin in patients with cystic fibrosis.  J. Infect. Dis. 135: 828-831.  Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 9, 42-48.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.  Baur G, Kurz H, Trunk H (1977) Alteration of  protein binding during storage of human plasma preparations.  Anaesthesist 26: 148-150.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  ",,1959,380.42,8,2,105.2,5,anionic,1.7,-1.6
Methimazole,60-56-0,CN1C=CNC1=S,0.86,3.7,,3.8,2.4,Hengstmann JH and Hohn H (1985) Pharmacokinetics of methimazole in humans.  Klin. Wochenschr. 63: 1212-1217.,,,1896,114.17,2,1,15.3,0,neutral,-0.12,-0.12
Methohexital,151-83-7,CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O,1.1,12,0.27,1.5,1.6,"Breimer DD (1976) Pharmacokinetics of methohexitone following intravenous infusion in humans.  Br. J. Anaesth. 48: 643-649.  Brand L, Mark LC, Snell MM, Vrindten P, and Dayton PG (1963) Physiologic disposition of methohexital in man.  Anesthesiol. 24: 331-335.",,,1955,262.3,5,1,66.5,5,neutral,1.8,1.7
Methotrexate,59-05-2,CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0.43,2.1,0.37,3.4,3.9,"Bore P, Bruno R, Lena N, Favre R, and Cano JP (1987) Methotrexate and 7-hydroxymethotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate.  Eur. J. Canc. Clin. Oncol. 23: 1385-1390.  Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, and Furst DE (1989) Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.  J. Pharm. Sci. 78: 165-171.  Esposito M, Rosso R, and Santi L (1974) Plasma protein binding of antineoplastic drugs in rats and humans.  IRCS Library Compendium 2: 1180.",,,1948,454.44,13,5,210.5,9,anionic,-0.25,-6.4
"Methoxypsoralen,8-",298-81-7,COc1c2c(ccc(=O)o2)cc3c1occ3,0.61,12,0.09,0.88,,"Billard, Valerie; Gambus, Pedrol L.; Barr, Juliana; Minto, Charles F.; Corash, Laurence; Tessman, John W.; Stickney, Janice L.; Shafer, Steven L. The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans Br. J. Clin. Pharmacol. 1995, 40, 347-360.","8-MOP. Oxsoralen. 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one. N=18, 79.8 kg average weight. Data averaged across all subjets and 3 doses, 5, 10 and 15 mg by authors.no t 1/2 reported. Ppb taken from reference cited in this work.",,1911,216.19,4,0,53.2,1,neutral,2.1,2.1
Methyldopa,555-30-6,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,0.69,3.5,0.85,3.3,5.9,"Skerjanec A, Campbell NRC, Robertson S, and Tam YK (1995) Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects.  J. Clin. Pharmacol. 35: 275-280.  Stenbaek O, Myhre E, Rugstag HE, Arnold E, and Hansen T (1977) Pharmacokinetics of methyldopa in healthy man.  Eur. J. Clin. Pharmacol. 12: 117-123.  Myhre E, Rugstad HE, and Hansen T (1982) Clinical pharmacokinetics of methyldopa.  Clin. Pharmacokinet. 7: 221-233.",,,1952,211.21,5,4,103.8,3,zwitterionic,0.66,-2.1
Methylergometrine,113-42-8,c12c3C=4[C@H]([N@@](C[C@@H](C4)C(N[C@@H](CC)CO)=O)C)Cc1c[nH]c2ccc3,0.96,7.18,,2.25,1.85,"A.N.J.A. de Groot, T.B. Vree, Y.A. Hekster, M. van den Biggelaar-Martea, P.W.I. van Dongen,  I. van Roosmalen. Variation in Bioavailability of
Oral Methylergometrine in Healthy Male Volunteers. Drug Invest., 1994, 8, 345-351.","N=6, 74.7 kg average weight, 0.152 mg dose (free base).",,1946,339.43,5,3,68.4,4,neutral,1.7,1.6
Methylnaltrexone,73232-52-7,C[N+]1(CC2CC2)CC[C@]34[C@H]5Oc6c(O)ccc(C[C@@H]1[C@]3(O)CCC5=O)c46,2.6,22,0.87,2,2.5,"Yuan CS, Doshan H, Charney MR, O'Connor M, Karrison T, Maleckar SA, Israel RJ, and Moss J (2005) Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.  J. Clin. Pharmacol.  45: 538-546. ppb: Reported by PDR as The fraction of methylnaltrexone bromide bound to human plasma proteins is 11.0% to 15.3%, as determined by equilibrium dialysis. Aceessed December 2014. http://www.pdr3d.com/detail.php?c=7437#section-13",CAS # for methyl naltrexone bromide. CAS for parent 83387-25-1. SMILES entered for parent without bromide anion.,,1979,356.44,5,2,66.8,2,neutral,-2.7,-1.4
"Methylnortestosterone, 7α-, 19-",3764-87-2,C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@H]13,0.8,20,,0.67,0.65,"Kumar N, Suvisaari J, Tsong YY, Aguillaume C, Bardin CW, Lahteenmaki P, and Sundaram K (1997) Pharmacokinetics of 7a-methyl-19-nortestosterone in men and cynomolgus monkeys.  J. Androl. 18: 352-358.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1962,288.42,2,1,37.3,0,neutral,3.5,3.5
Methylphenidate,113-45-1,COC(=O)C(C1CCCCN1)c2ccccc2,2.2,9.42,0.85,4.5,4.8,"Srinivas NR, Hubbard JW, Korchinski ED, and Midha KK (1993) Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.  Pharm. Res. 10: 14-21.  De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S (2004) Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet. 43: 157-185.",Data for individual stereoisomers were averaged.,,1947,233.31,3,1,38.3,4,cationic,2.1,0.84
Methylprednisolone,83-43-2,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)C=CC(=O)C=C14,1.2,6.1,0.23,3.5,2.3,"Booker BM, Magee MH, Blum RA, Lates CD, and Jusko WJ (2002)  Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers.  Clin. Pharmacol. Ther. 72: 370-382.",,,1957,374.47,5,3,94.8,2,neutral,2,2
"Methylthiomethylpaclitaxel, 7-",160237-25-2,CSCO[C@H]1C[C@H]2OC[C@@]2(OC(=O)C)[C@H]3[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7)C(=C([C@@H](OC(=O)C)C(=O)[C@]13C)C5(C)C)C,11,6.4,,29,32,"Sun W, Stevenson JP, Gallagher ML, Vaughn D, Hahn SM, Haller DG, Cohen M, Kopit J, Gallant G, and O'Dwyer PJ (2003) Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.  Clin. Canc. Res. 9: 5221-5227.",,,1994,914.02,15,3,210.3,17,neutral,4.1,4.1
Metoclopramide,364-62-5,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,3.2,5.7,0.6,9.4,7.2,"Magueur E, Hagege H, Attali P, Singlas E, Etienne JP, and Taburet AM (1991) Pharmacokinetics of metoclopramide in patients with liver cirrhosis.  Br. J. Clin. Pharmacol. 31: 185-187.  Webb D, Buss DC, Fifield R, Bateman DN, and Routledge PA  The plasma protein binding of metoclopramide in health and renal disease. Br. J. Clin. Pharmacol. 21: 334-336.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1964,299.8,5,2,67.6,7,cationic,1.9,0.37
Metocurine,5152-30-7,COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc5ccc(C[C@H]6c7cc(Oc1c2)c(OC)cc7CC[N+]6(C)C)cc5,0.4,1.2,0.65,5.6,5.1,"Brotherton WP and Matteo RS (1981) Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure.  Anesthesiology 55: 273-276.  Avram MJ, Shanks CA, Henthorn TK, Ronai AK, Kinzer J, and Wilkinson CJ (1987) Metocurine kinetics in patients undergoing operations requiring cardiopulmonary bypass.  Clin. Pharmacl. Ther. 42: 576-581.",VDss calculated from micro rate constants provided in the reference.,,1950,652.82,8,0,55.4,4,neutral,2.3,2.3
Metolazone,17560-51-9,CC1Nc2cc(Cl)c(cc2C(=O)N1c3ccccc3C)S(=O)(=O)N,1.6,1.4,0.05,19,20,"Tilstone WJ, Dargie H, Dargie EN, Morgan HC, and Kennedy AC (1974) Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure.  Clin. Pharmacol. Ther. 16: 322-329.","C vs t data was for total radioactivity, justified in the reference that radioactivity in plasma was due to just unchanged drug.",,1967,365.83,6,2,92.5,2,neutral,3.5,3.5
Metopimazine,14008-44-7,CS(=O)(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN4CCC(CC4)C(=O)N,,12.14,,,4,"GAILLOT J , LE ROUX Y, COURNOT A. , DUCHIER J. , FRYDMAN A. PHARMACOKINETICS OF HETOPIMAZINE AFTER SINGLE AND REPEATED ORAL
ADMINISTRATION IN YOUNG HEALTHY SUBJECTS.","Vogalene. 10 mg iv dose. N=12, 70 kg average weight assumed. VD (beta) reported as 300 L.",,1960,445.6,6,1,83.7,6,cationic,2.5,0.91
Metoprolol,51384-51-1,COCCc1ccc(OCC(O)CNC(C)C)cc1,3.1,13,0.88,4,3.6,"Jordo L, Attman PO, Aurell M, Johansson L, Johnsson G, and Regardh CG (1980) Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.  Clin. Pharmacokinet. 5: 169-180.  Schaaf LJ, Campbell SC, Mayersohn MB, Vagedes T, and Perrier DG (1987) Influence of smoking and gender on the disposition kinetics of metoprolol.  Eur. J. Clin. Pharmacol. 33: 355-361.  Richard J, Cardot JM, and Godbillon J (1994) Inter-and intra-subject variability of metoprolol kinetics after intravenous administration.  Eur. J. Drug metab. Pharmacokinet. 19: 157-162.  Johnsson G and Regardh CG (1976) Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.  Clin. Pharmacokinet. 1: 233-263.",VDss calculated using micro rate constants reported in the reference by Richard et al.  ,,1951,267.36,4,2,50.7,9,cationic,1.9,0.064
Metrizoate,1949-45-7,CN(C(=O)C)c1c(I)c(NC(=O)C)c(I)c(C(=O)O)c1I,0.17,2.7,1,1,1.3,"Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference. CAS number and structure refer to the free acid.,,1962,627.94,6,2,86.7,3,anionic,1.4,-1.9
Metronidazole,443-48-1,Cc1ncc(N(=O)=O)n1CCO,0.4,0.85,0.96,7.8,7.1,"Sanvordekar DR, Chien YW, Lin TK, Lambert HJ (1975) Binding of metronidaole and its derivatives to plasma proteins: an assessment of drug binding phenomenon.  J. Pharm Sci. 64: 1797-1803.   Bergan T and Thorsteinsson SB (1986) Pharmacokinetics of metronidazole and its metabolites in reduced renal function.  Chemotherapy 32: 305-318.",Plasma concentraions determined using a bioassay.,,1946,171.15,6,1,83.9,3,neutral,-0.44,-0.44
Mexiletine,31828-71-4,CC(N)COc1c(C)cccc1C,5.9,8.3,0.36,12,9.9,"Pentikainen PJ, Hietakorpi S, Halinen MO, and Lampinen LM (1986) Cirrhosis of the liver markedly impairs the elimination of mexiletine.  Eur. J. Clin. Pharmacol. 30: 83-88.  McErlane KM, Igwemezie L., Kerr CR (1987) Stereoselective serum protein binding of mexiletine enantiomers in man.  Res. Comm. Chem. Path. Pharmacol. 56: 141-144.",Average of two enantiomers.,,1971,179.26,2,1,35.3,3,cationic,2.2,0.55
Mezlocillin,51481-65-3,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(=O)(=O)C)c4ccccc4)C(=O)N2[C@H]1C(=O)O,0.09,2.1,0.7,0.71,1.2,"Modr Z, Dvoracek K, Janku I, and Krebs V (1982) Beitrag zur pharmakokinetik und dosierung von mezlocillin bei intravenoser infusion. Infection 10(Supp 3): s190-s195.   Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated using micro rate constants reported in the reference.  ,,1974,539.58,13,3,173.5,6,anionic,1,-2.3
Mianserin,24219-97-4,N12[C@@H](c3c(cccc3)Cc3c1cccc3)C[N@@](C)CC2,13.75,21.9,0.05,10.5,9.6," Shami, Munzir; Elliott, Henry L.; Kelman, Andrew W.; Whiting, Brian  The pharmacokinetics of mianserin. British Journal of Clinical Pharmacology (1983), 15(Suppl. 2), 313-22. ppb: Kristensen C B; Gram L F; Kragh-Sorensen P Mianserin protein binding in serum and plasma from healthy subjects and patients with depression and rheumatoid arthritis Psychopharmacology (1985), 87(2), 204-2066.",Average of 8 volunteers. 0.15 mg/kg dose via iv infusion in 15 minutes.  Average weight assumed to be 70 kg. MRT as VDss/CL. Three-compartment analysis.,,1973,264.36,2,0,6.5,0,cationic,3.1,2.3
Mibefradil,116644-53-2,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc4cc(F)ccc4[C@@H]1C(C)C,3.1,4,0.005,13,13,"Welker HA (1998) Single- and multiple-dse mibefradil pharmacokinetics in normal and hypertensive subjects.  J. Pharm. Pharmacol. 50: 983-987.  Welker HA, Wiltshire H, and Bullingham R (1998) Clinical pharmacokinetics of mibefradil. Clin. Pharmacokinet. 35: 405-423.",,,1988,495.63,6,1,67.4,12,cationic,5.9,3.8
Mibenratide,1239011-83-6,C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCC(=O)O)CC(=O)O)C)CCC(=O)N)C(C)C)Cc3ccccc3)CC(=O)O)CO)NC(=O)[C@@H](NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)Cc5ccc(cc5)O)CC(=O)N)CC(=O)O)CCCCN)CCCNC(=N)N)CCCNC(=N)N,0.38,68.11,,0.09,0.25,"Ivo P. Nnane, Alexei H. Plotnikov, Gary Peters, Maureen Johnson, Clare Kojak, Apinya Vutikullird, Jay Ariyawansa, Ronald De Vries, Brian E. Davies. Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-b1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants. Clin Pharmacokinet. 2016, 55, 225–236. ","JNJ-54452840. UNII-P1T1143877. COR-1. http://adisinsight.springer.com/drugs/800031439. Linking JNJ-54452840 to COR-1 and mibenratide. Weighted average of 92 subjects across 3 doses (20, 80, 240 mg). 44 Japanese and 48 Caucasian.  72.5 kg average weight. MRT from VDss and clearance.",,2010,2097.25,57,32,940.7,34,anionic,-9,-9
Micafungin,235114-32-6,CCCCCOc1ccc(cc1)c2onc(c2)c3ccc(cc3)C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)C(NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)c7ccc(O)c(OS(=O)(=O)O)c7)[C@H](O)CC(=O)N,0.21,0.17,0.0023,21,16,"Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, and Bekersky I (2005) Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.  J. Clin. Pharmacol. 45: 1018-1024.  Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, and Bekersky I (2005) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol.  45: 1145-1152.",,,1996,1270.27,32,16,510.4,18,neutral,-3.9,-7.4
Miconazole,22916-47-8,c1cc(c(cc1Cl)Cl)COC(Cn2ccnc2)c3ccc(cc3Cl)Cl,7.14,9.48,0.08,12.55,19.75,"P. J. Lewi , J. Boelaert, R. Daneels, R. De Meyere, H. Van Landuyt, J. J. P. Heykants. Pharmacokinetic profile of intravenous miconazole in man. Comparison of Normal Subjects and Patients with Renal Insufficiency. Eur. J. Clin. Pharmacol. 1976, 10, 49-54.//ppb: Stevens DA, Levine HB, Deresinski SC: Miconazole in coccidioidomycosis II. Therapeutic and pharmacologic studies in man. Am J Med 1976, 60, 191-202.","Monistat. MJR1762. R 18134. PK parameters calculated from tabular data reported for 4 normal subjects. AUCinf within 16% if AUC reported as 0-inf. 11% if AUC0-t was reported. 522 mg dose, iv bolus. 70 kg average weight assumed.",,1948,416.13,3,0,27,6,neutral,5.8,5.8
Micronomicin,52093-21-7,C1C[C@@H](N)[C@H](O[C@@H]1CNC)O[C@@H]1[C@@H]([C@H]([C@@H](C[C@@H]1N)N)O[C@@H]1[C@@H]([C@H]([C@](CO1)(O)C)NC)O)O,0.15,1.1,,2.4,2.1,"KEIZO MATSUMOTO, HARUMI SHISHIDO and ATSUSHI TAKAHASHI. PHARMACOKINETIC AND CLINICAL EVALUATIONS OF
MICRONOMICIN BY INTRAVENOUS DRIP INFUSION. 1985, 38, 135-143.","Data digitized from plot reported for 60 mg dose. N= 5, 60.1 kg average weight (all malee) 1 hour intravenous drip. AUCinf within 3% of reported.",,1973,463.57,12,8,199.7,7,cationic,-4.2,-6.9
Midazolam,59467-70-8,Cc1ncc2CN=C(c3ccccc3F)c4cc(Cl)ccc4n12,1.1,5.3,0.017,3.5,3.1,"Heizmann P, Eckert M, and Ziegler WH (1983) Pharmacokinetics and bioavailability of midazolam in man.  Br. J. Clin. Pharmacol. 16: 43s-49s.  Pentikainen PJ, Valisalmi L, Himberg JJ, and Crevoisier C (1989) Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.  J. Clin. Pharmacol. 29: 272-277.  ",,,1956,325.77,3,0,30.2,1,neutral,3.1,3.1
Midodrine,42794-76-3,c1(c(ccc(c1)OC)OC)[C@@H](CNC(CN)=O)O,0.67,27.9,0.7,0.4,0.6,"PP. Midodrine Hydrochloride - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 019815", Data calculated from mean concentration reported in table 1 of ref.70 kg assumed.,"PP. Midodrine Hydrochloride - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 019815. Glycine rapidly cleaved to yield desglymidodrine.",1973,254.28,6,3,93.8,6,cationic,-1.3,-2.2
Mifamurtide,83461-56-7,OC[C@@H](O)[C@@H](O)[C@H](O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](C)C(=O)NCCOP(O)(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(N)=O)[C@H](C=O)NC(C)=O,5.8,48.7,,1.98,2.05,"Karthik Venkatakrishnan,William G. Kramer, Timothy W. Synold, Daniel B. Goodman ,Evin Sides III, Cristina Oliva. A pharmacokinetic, pharmacodynamic,
and electrocardiographic study of liposomal mifamurtide
(L-MTP-PE) in healthy adult volunteers.  J Clin Pharmacol (2012) 68:1347–1355.",MTP-PE. Open form (sugar) reported by Scifinder and ChemIDPlus. Data reported in L and L/m2 (or corresponding units for clearance). 70 kg assumed. 4 mg dose in 30 minutes infusion. N=21. Liposomal preparation. MEPACT (approved in Europe),,1982,1237.5,25,10,383.9,58,anionic,4.9,1.4
Mifepristone,84371-65-3,C1=2[C@H]([C@H]3[C@]([C@@](C#CC)(O)CC3)(C)C[C@@H]1c1ccc(N(C)C)cc1)CCC=1C2CCC(C1)=O,0.45,0.5,0.02,15.7,16.6,Mifepristone - http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20687_Mifepristone_clinphrmr_P2.pdf. Ppb from label in FDA package. Accessed September 22 2015.,"70 kg assumed. 20 mg dose, N=10.",,1982,429.59,3,1,40.5,3,neutral,4.8,4.8
Miglitol,72432-03-2,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,0.28,1.7,1,2.7,2.3,"Ahr AH, Boberg M, Brendel E, Krouse HP, and Steinke W (1997) Pharmacokinetics of miglitol.  Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.  Arz. Forsch. 47: 734-745.",Pharmacokinetic parameters were calculated from plasma total radioactivity measurements after administration of radiolabelled miglitol.  Analysis of samples showed that miglitol parent drug was the only drug-related entity.,,1979,207.22,6,5,104.4,3,neutral,-3.1,-3.3
Mildronate,76144-81-5,C(CCN[N+](C)(C)C)([O-])=O,0.7,2.8,,4.3,6.2,"Ye Penga,, Jing Yangb, ZhiRui Wang, Jingwen Wang, Yu Liub, Zhuojing Luoa, AiDong Wen. Determination of mildronate by LC–MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. Journal of Chromatography B, 878 (2010) 551–556","meldonium. VDss from reported MRT and clearance. Average of 3 doses,  250, 500 and 1000 mg, N= 10 each. 70 kg average weight assumed.",,1980,146.19,4,1,52.2,4,zwitterionic,-6.6,-8.9
Milnacipran,92623-85-3,C1[C@@H]([C@@]1(C(=O)N(CC)CC)c1ccccc1)CN,4.51,8.17,0.87,8.17,6.48,"Pharmacokinetics of milnacipran in liver impairment C. Puozzo, H. ALBIN, G. VINCON, D. DEPREZ, I.M. RAYMOND, M. AMOURETII. European Journal of Drug Metabolism and Pharmacokinetics 1998, Volume 23, 273-279.  Puozzo C.; Rostin, N. Montastruc JL, Hoin G. Absolute bioavailability study of midalcipran (F2207) in volunteers.Proc. - Eur. Congr. Biopharm. Pharmacokinet., 3rd, Aiache JM, Hirtz J. Clermont-Ferrand, 1987, 59-63. ppb: PDR. Accessed December 28 2014. http://www.pdr3d.com/detail.php?c=82396#section-14. ADMINISTERED AS HYDROCHLORIDE RACEMATE.","Weighed AVERAGE of BOTH references Data digitized from figure 1 from 1998 paper. N=6 control patients, unchanged milnacipram, 50 mg/dose, 1 hr infusion, reported AUC = 1522 ng.h/mL. Reported clearance 34.3 L/h. Average weight 73.3 kg. Data obtained prior to average: VDss 3.72 L/kg, clearance 6.7 mL/min/kg, MRT 7.9 hr  t1/2 6.65 hr. 1987 paper: F-2207. N=70, 50 mg dose in 1 h infusion, N=12, 70 kg median weight reported (59-80 kg). Other refs available for studies in renal or hepatic impairment by the same first author. Data obtained prior to average: VDss 4.9 L/kg, clearance 8.9 mL/min/kg, MRT 8.9 hr  t1/2 6.4 hr. ","1987 paper: reported Cltotal as 37.6 L/h/1.73m2, MRT 8.9 h. VDss from MRT and clearance. Clr as 22.3 L/h/1.73m2.",1985,246.35,3,1,46.3,5,cationic,0.9,-1.8
Milrinone,78415-72-2,CC1=C(C=C(C#N)C(=O)N1)c2ccncc2,0.25,6.2,0.035,0.67,0.8,"Stroshane RM, Koss RF, Biddlecome CE, Luczkowec C, and Edelson J (1984) Oral and intravenous pharmacokinetics of milrinone in human volunteers.  J. Pharm. Sci. 73: 1438-1441.  Woolfrey SG, Hegbrant J, Thysell H, Fox PA, Lendrem DW, Lockwood GF, Lasher K, Rogers J, and Greenslade D (1995) Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure.  J. Pharm. Pharmacol. 47: 651-655.",,,1981,211.22,4,1,65.8,2,anionic,-0.055,-0.57
Minocycline,10118-90-8,CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)N(C)C,1.6,1.2,0.005,22,17,"Simon VC, Malerczyk V, Preuss I, Schmidt K, and Grahman H (1976) In vitro aktivitat und pharmakokinetik von minocyclin.  Arz. Forsch. 26: 556-560. ppb: Hashimoto, T. FUNDAMENTAL STUDIES ON PHARMACOKINETICS OF ANTIBIOTICS. PART 1. BINDING OF ANTIBIOTICS TO PLASMA PROTEINS. Chemotherapy (Tokyo). 1973, 21, 38-44","Calculated from C vs t data given in Table 4 for the 200 mg dose in Simon, et al.",,1946,457.48,10,5,164.6,3,zwitterionic,0.36,-1.9
Minoxidil,38304-91-5,c1(N2CCCCC2)cc(n(=O)c(n1)N)N,0.9,11.5,1,1.3,1.5,Minoxidil - FDA Approval Package Administrative documents 019501 Part 01. Accessed through Pharmapendium.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018154s026lbl.pdf. Accessed July 10 2017.,"N=8, 76.3 kg average weight. Average of two doses.",,1967,209.25,6,2,91.1,1,neutral,0.9,0.9
Mipomersen,1000120-98-8,Cc1cn(c(=O)[nH]c1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)([O-])S[C@H]3C[C@@H](O[C@@H]3COP(=O)([O-])S[C@H]4C[C@@H](O[C@@H]4COP(=O)([O-])S[C@H]5C[C@@H](O[C@@H]5COP(=O)([O-])S[C@H]6C[C@@H](O[C@@H]6COP(=O)([O-])S[C@H]7C[C@@H](O[C@@H]7COP(=O)([O-])S[C@H]8C[C@@H](O[C@@H]8COP(=O)([O-])S[C@H]9C[C@@H](O[C@@H]9COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cc(c(nc1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cc(c(=O)[nH]c1=O)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cc(c(nc1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cc(c(nc1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)n1cnc2c1nc([nH]c2=O)N)CO)n1cnc2c1ncnc2N)n1cnc2c1nc([nH]c2=O)N)n1cc(c(=O)[nH]c1=O)C)n1cc(c(nc1=O)N)C)n1cc(c(=O)[nH]c1=O)C)n1cnc2c1nc([nH]c2=O)N)n1cc(c(nc1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)n1cc(c(=O)[nH]c1=O)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)n1cc(c(nc1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)n1cc(c(nc1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)n1cnc2c1ncnc2N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)n1cc(c(nc1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)n1cc(c(nc1=O)N)C)OCCOC)O,0.1,0.67,0.05,2.4,17.6,"Rosie Z. Yu, Tae-Won Kim, An Hong, Tanya A. Watanabe, Hans J. Gaus, and Richard S. Geary. Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100. Drug Metab. Disp. 2007, 35:460–468."," ISIS 301012 Parent Acid
, Data digitized from plot reported. ~3 mg/kg dose reported as approximated value for 200 mg dose, in 2-hr iv infusion. No weight reported and dose actually taken as 200 mg/70 kg = 2.86 mg/kg for consistency, assuming a 70 kg average weight. Reported AUC 68.2 ug.hr.mL-1 (not specified whether inf or 0-t). Calculated AUCinf and AUCall 71.2 and 71 ug.hr.mL-1, respectively. Clearance rported 40.9 mL.hr-1.kg-1, calculated 40.1 mL.hr-1.kg-1. T1/2 calculated with the last two points only.",,2008,7158,189,26,2667.6,156,n/a,n/a,n/a
Mirabegron,223673-61-8,O=C(Cc1csc(N)n1)Nc3ccc(CCNC[C@H](O)c2ccccc2)cc3,23.8,13.6,0.29,29.3,50,"Mirabegron, prescribing information. PDR. Accessed July 31 2014. http://www.pdr3d.com/detail.php?c=91002#section-12","Assumed 70 kg as average weight.MRT from VDss and clearance.  See also:  Eltink, Charlotte et al. Int. J.  Clin. Pharmacol. Ther., 2012, 50, 838-849.",,1999,396.51,6,4,100.3,9,cationic,1.8,0.34
Mirtazapine,85650-52-8,CN1CCN2C(C1)c3ccccc3Cc4cccnc24,4.2,8,0.15,8.8,15,"Voortman G and Paanakker JE (1995) Bioavailability of mirtazepine from Remeron tablets after single and multiple oral dosing.  Human Psychopharmacol. 10: s83-s96.  ppb: Timmer CJ, Sitsen JM, and Delbressine LP (2000) Clinical pharmacokinetics of mirtazapine.  Clin. Pharmacokinet. 38: 461-74.",,,1976,265.35,3,0,19.4,0,cationic,2.3,1.1
Mitonafide,54824-17-8,c12c3cccc1cc(cc2C(=O)N(C3=O)CCN(C)C)[N+](=O)[O-],11.3,34.6,,5.6,28.7,"Pharmacokinetics characterization of mitonafide in man. Brode E, Poveda Velasco A, Díaz-Rubio E, Rosell Costa R, Benavides Fissure A. Meth. Find. Exp. Clin. Pharmacol. 1992, 14(2), 131-140",Individual subject plasma levels and PK data reported. Data corrected for individual surface area and weight and then averaged. Very long t1/2 (gamma),,1975,313.31,7,0,83.8,4,neutral,2.3,2.1
Mitoxantrone,65271-80-9,OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12,12,7.9,0.25,25,53,"Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, and Bugat R (1993) Plasma and cellular pharmacokinetics of mitoxantrone in high dose chemotherapeutic regimen for refractory lymphomas.  Canc. Res. 53: 4850-4854.  Scott LJ and Figgitt DP (2004) Mitoxantrone: a review of its use in multiple sclerosis.  CNS Drugs 18: 379-396.",,,1952,444.48,10,8,163.2,12,cationic,-0.37,-3.2
Mivacurium (cis/cis),106791-40-6,COc1cc2CC[N+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]3(C)CCc4cc(OC)c(OC)cc4C3Cc5cc(OC)c(OC)c(OC)c5)C(Cc6cc(OC)c(OC)c(OC)c6)c2cc1OC,0.27,5.2,0.7,0.87,0.83,"Head-Rapson AG, Devlin JC, Parker CJ, Hunter JM (1994) Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth.  73: 613-618.  Roy JJ and Varin F (2004) Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",,,1986,1029.26,16,0,144.9,30,neutral,2.3,2.3
Mizolastine,108612-45-9,n1(Cc2ccc(cc2)F)c(N2CCC(CC2)N(C)c2nccc([nH]2)=O)nc2c1cccc2,0.38,1.03,,6,9.6,"Florence Mesnil, Catherine Dubruc, France Mentre, Sylvie Huet, Alain Mallet, and Jean-Paul Thenot. Pharmacokinetic Analysis of Mizolastine in Healthy Young Volunteers After Single Oral and Intravenous Doses: Noncompartmental Approach and Compartmental Modeling  J. Pharmacokin. and Biopharm. Vol. 25. No. 2, 1997, 125-147.","Assumed 70 kg. N=18. 10 mg in 30' infusion. 5 mg iv 30 min infusionN=1, PK profile of the single subject 15. Data digitized from Figure 2 in ref cited
70kg BW assumed

Reported mean data for all 18 subjects (Table I):
N=18
AUC = 1059 ng*h/mL
CL = 4.9 L/h (1.17 mL/min/kg)
t1/2 = 12.9 h",,1987,432.49,7,1,70.1,5,neutral,3.5,3.5
Moclobemide,71320-77-9,Clc1ccc(cc1)C(=O)NCCN2CCOCC2,1.1,10,0.77,1.8,1.5,"Schoerlin MP, Mayersohn M, Korn A, and Eggers H (1987) Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.  Clin. Pharmacl. Ther. 42: 395-404.  Raaflaub J, Haefelfinger P, and Trautman KH (1984) Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.  Arz. Forsch. 34: 80-82.  Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, and Pfefen JP (1991) Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.  Clin. Pharmacol. Ther. 49: 32-38.  Schoerlin MP, Horber FF, Frey FJ, and Mayersohn M (1990) Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function.  J. Clin. Pharmacol. 30: 272-284.  Schoerlin MP and Guentert TW (1989) Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human.  Psychiatrische Praxis  16(Suppl 1): 11-17.",,,1957,268.74,4,1,41.6,4,neutral,1.4,1.3
Moexipril ,103775-10-6,C(c1ccccc1)C[C@H](N[C@H](C(N1Cc2c(C[C@H]1C(O)=O)cc(OC)c(c2)OC)=O)C)C(OCC)=O,,6.3,0.12,,1.3,Moexipril Hydrochloride - FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020312 Part 01. Package accessed through Pharmapendium. March 7 2013.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-312_Moexipril_Univasc.pdf. Accessed June 27 2017.,"VD reported in PDR as about 183 liters, but not specified as VDss or VDz. Likely to be latter. 70 kg assumed as average weight. Accessed March 7 2013.//ppb: data from young subjects. Bining in elderly subjects ~ 48%.",excreted in feces and urine (mostly urine) as moexiprilat (diacid). See label of FDA review package.,1958,498.57,9,2,114.4,12,anionic,3,-0.37
Molsidomine,25717-80-0,[n+]1(N2CCOCC2)cc([NH-]C(OCC)=O)on1,1.4,11,1,2.1,1.6,"J. Ostrowski, and K. Resag, Pharmacokinetics of molsidomine in humans. American Heart Journal.1985, 109, 641-643",70 kg assumed. 2 mg dose iv. N not reported.,95% radioactivity recovered with only 2% unchanged compound in urine.,1969,243.24,8,1,84.6,4,neutral,-2.3,-2.3
Mometasone Furoate,83919-23-7,C(c1ccco1)(=O)O[C@]1([C@@]2([C@H]([C@@H]3[C@]([C@@]4(C(=CC(=O)C=C4)CC3)C)(Cl)[C@H](C2)O)C[C@H]1C)C)C(CCl)=O,2.2,12.7,0.01,2.9,4.4,Mometasone Furoate - FDA Approval PackageClinical Pharmacology and Biopharmaceutics Review 021067/S-000. Accessed through Pharmapendium on March7 2013. VDss reported on label in the same package.,70 kg assumed. 400 ug dose.,,1982,521.43,6,1,94.1,5,neutral,4.5,4.5
Montelukast,158966-92-8,CC(C)(O)c1ccccc1CC[C@@H](SCC2(CC(=O)O)CC2)c3cccc(\C=C\c4ccc5ccc(Cl)cc5n4)c3,0.15,0.68,0.002,3.8,5,"Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, Freeman A, Seiberling M, Merz M, and Cheng H (1997) Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.  Biopharm. Drug Dispos. 18: 769-777.  Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, and Somers G (1996) Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.  Pharm. Res. 13: 445-448.",,,1995,586.18,4,2,70.4,11,anionic,8.3,4.8
Morinidazole,92478-27-8,OC(CN1CCOCC1)Cn2c(cnc2C)[N+]([O-])=O,0.75,1.6,,7.9,6.2,"Gao, Ruina; Li, Liang; Xie, Cen; Diao, Xingxing; Zhong, Dafang; Chen, Xiaoyan. Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-​glucuronides catalyzed by UDP glucuronosyltransferase 1A9. Drug Metabolism & Disposition (2012), 40(3), 556-567:","Data from FIG. 6 in 
Reported data (Table 1):
AUC0-t(ng*h/mL) 74,866
AUC0–inf(ng*h/mL) 75,964
t1/2 6.15 h
dose 500 mg 0.7 h infusion, N=12, 70 kg body weight assumed ",,1994,270.29,8,1,93.7,5,neutral,-0.81,-0.88
Morphine,57-27-2,CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@@H]2C=C[C@@H]4O)c35,2.3,26,0.65,1.5,2,"Owen JA, Sitar DS, Berger L, Briwnell L, Duke PC, and Mitenko PA (1983) Age related morphine kinetics.  Clin. Pharmacil. Ther. 34: 364-368.  Berkowitz BA (1976) The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.  Clin. Pharmacokinet. 1: 219-230.  Lotsch J, Weiss M, Kobal G, and Geisslinger G (1998) Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration.  Clin. Pharmacol. Ther. 63: 629-639.  Aitkenhead AR, Vater M, Achola K, Cooper MS, and Smith G (1984) Pharmacokinetics of single-dse I.V. morphine in normal volunteers and patients with end-stage renal disease.  Br. J. Anaesth. 56: 813-819.",,,1928,285.34,4,2,52.9,0,cationic,1.1,0.093
Morphine-6-Glucuronide,20290-10-2,CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@@H]2C=C[C@@H]4O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(=O)O)c35,0.12,2.2,0.67,0.91,1.4,"Lotsch J, Weiss M, Kobal G, and Geisslinger G (1998) Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration.  Clin. Pharmacol. Ther. 63: 629-639.//ppb: Mashayekhi, S. O.; Ghandforoush-Sattari, M.; Buss, D. C.; Routledge, P. A.; Hain, R. D. W. Impact of anti-​cancer drugs and other determinants on serum protein binding of morphine 6-​glucuronide. Daru, Journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2010, 18, 107-113.",,,1968,461.46,10,5,149.1,3,zwitterionic,-0.47,-2.4
Moxalactam,64952-97-2,CO[C@]1(NC(=O)[C@H](C(=O)O)c2ccc(O)cc2)[C@H]3OCC(=C(N3C1=O)C(=O)O)CSc4nnnn4C,0.17,0.72,0.39,3.9,2.9,"Wise R, Baker S, and Livingston R (1980) Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.  Antimic. Agents Chemother. 18: 369-371.  Standiford HC, Drusano GL, Bustamante CI, Rivera G, Forrest A, Tatem B, Leslie J, and Moody M (1986) Imipenem coadministered with cilastatin compared with moxalactam:  integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.  Antimic. Agents Chemother. 29: 412-417.",Latamoxef.,,1977,520.47,15,4,206.3,9,anionic,-0.95,-4.2
Moxifloxacin,151096-09-2,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(=O)O,1.4,2.4,0.6,9.7,8.2,Avelox IV Product Label. PDR accessed July 31 2014. http://www.pdr3d.com/detail.php?c=49480#section-15,VDss calculated using C vs t data obtained by digitization of the plot provided in the label.,,1993,401.43,7,2,82.1,4,zwitterionic,2.4,-0.36
Moxonidine,75438-57-2,COc1nc(C)nc(Cl)c1NC2=NCCN2,1.8,11,0.93,2.7,2.2,"Theodor R, Weimann HJ, Weber W, and Michaelis K (1991) Absolute bioavailability of moxonidine.  Eur. J. Drug Met. and Pharmacokin. 16: 153-159.  Schaefer HG, Toublanc N, and Weimann HJ (1998) The pharmacokinetics of moxonidine.  Rev. Contemp. Pharmacother.  9: 481-490.",,,1980,241.68,6,2,71.4,3,cationic,0.55,0.13
Mycophenolic acid,24280-93-1,c12c(c(c(C\C=C(\CCC(O)=O)C)c(c1C)OC)O)C(=O)OC2,0.77,2.33,0.02,6.5,9.7,"Mycophenolic Acid - FDA Approval Package Pharmacology and Biopharmaceutics Review 050791/S-000. ppb: Christopher J. Kochansky, Daniel R. McMasters,Ping Lu, Kenneth A. Koeplinger,Haley H. Kerr, Magang Shou,and Kenneth R. Korzekwa Impact of pH on Plasma Protein Binding in Equilibrium Dialysis. Mol. Pharm. 2008, 5, 438-448. Vaue at 10% CO2 (pH 7.4).",70 kg assumed. 360 mg dose. MRT from VDss and clearance.,> 60% found in urine as glucuronide. Not clear if from oral or iv dose.  See label in FDA approval package.,1913,320.34,6,2,93.1,6,anionic,3.2,0.58
Nadolol,42200-33-9,CC(C)(C)NCC(O)COc1cccc2CC(O)C(O)Cc12,1.9,2.9,0.14,11,9.2,"Morrison RA, Singhvi SM, Creasey WA, and Willard DA (1988) Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects.  Eur. J. Clin. Pharmacol. 33: 625-628.  Patel L, Johnston A, and Turner P (1984) Nadolol binding to human serum proteins.  J. Pharm. Pharmacol. 36: 414-415.",,,1973,309.4,5,4,81.9,5,cationic,1.1,-0.79
Nafamostat,81525-10-2,c1cc(ccc1C(=O)Oc2ccc3cc(ccc3c2)C(=N)N)NC(=N)N,5.71,81.96,,1.15,1.84,"Cao, Yan-guang; Zhang, Ming; Yu, Dan; Shao, Jing-ping; Chen, Yuan-cheng; Liu, Xiao-quan. A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study. Anal. Bioanal Chem. 2008, 391, 1063-1071",N=10. 5M/5F 70 kg average weight assumed 40 mg dose iv 120 minutes drip.,5M/5F,1981,347.37,7,5,138.1,6,cationic,1.9,-3.2
Nafarelin,76932-56-4,c1(c2c(cccc2)[nH]c1)C[C@@H](NC([C@@H](Cc1c[nH]cn1)NC([C@@H]1CCC(N1)=O)=O)=O)C(N[C@@H](C(N[C@@H](Cc1ccc(O)cc1)C(N[C@@H](Cc1cc2c(cccc2)cc1)C(N[C@@H](C(N[C@@H](C(N1[C@@H](CCC1)C(NCC(N)=O)=O)=O)CCCNC(N)=N)=O)CC(C)C)=O)=O)=O)CO)=O,0.14,0.72,0.19,3.33,3.5,"Chaplin  ML (1992). Bioavailability of nafarelin in healthy volunteers. Am J Obstet Gynecol, 166, 762-765. ppb: Reported as 78-84% bound (81% taken as median) by  Chan R L; Chaplin M D . Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist. Biochemical and biophysical research communications (1985), 127(2), 673-9. ","70 kg assumed as average weight but likely to be lower. AUCinf from data digitized digitized calculated as 8.26 ng.hr.mL-1 vs. reported as 7.9 ng.hr.mL-1.  Yet clearance reported as 0.93 mL.min-1.kg-1 vs. calculated as 43.22 mL.hr-1.kg-1, or 0.72 mL.min-1.kg-1. Likely to be due to a different dose in mg/kg basis, and thus due to weight. Total dose 25 ug. N=15 (average plot).",25 ug (microdose),1980,1322.47,30,17,472.1,34,cationic,-0.4,-4.4
Nafcillin,147-52-4,CCOc1ccc2ccccc2c1C(=O)N[C@H]3[C@H]4SC(C)(C)[C@@H](N4C3=O)C(=O)O,0.22,3.3,0.13,1.1,0.7,"Waller ES, Sharanevych MA, and Yakatan GJ (1982) The effect of probenecid on nafcillin disposition.  J. Clin. Pharmacol.  22: 482-489.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated using micro rate constants reported in the reference.  Note: Plasma concentrations determined by bioassay; assumes no active metabolites.,,1962,414.47,7,2,95.9,5,anionic,3.5,0.18
Naftopidil,57149-07-2,c1ccc2ccccc2c1OC[C@@H](CN1CCN(CC1)c1c(cccc1)OC)O,,11,0.008,,3.3,"M.J.G. Farthing, E.M. Alstead, S.M.L. Abrams, G. Haug, A. Johnston, R. Hermann, G. Niebch, P. Ruus, K.H. Moltz and P. Turner. Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. Postgrad Med J (I 994) 70, 363 366.  ppb: Tadakiyo SUZUKI. Hiroto MIYANAGA. Fumio SAKAMOTO Jun-ichi KATAYAMA, Yasuhisa AUACHI. Drug lnteraction in Human Plasma Protein Blnding of Naftopidil (KT-611). Iyakuhin Kenkyu 1999 30(9):435",Attempted digitization with very extended terminal phase. AUC not reported and computed clearance significantly lower than reported Clearance (AUCinf) 8.9 mL/min/kg.,,1975,392.49,5,1,45.2,7,cationic,3.9,2.5
Nalbuphine,20594-83-6,O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC6CCC6)c45,4.6,22,0.5,3.5,3.7,"Aitkenhead AR, Lin ES, and Achola KJ (1988) The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers.  Br. J. Clin. Pharmacol. 25: 264-268.   Jaillion P, Gardin ME, Lecocq B, Richard MO, Meignan S, Blondel Y, Grippat JC, Bergnieres J, and Vergnoux O (1989) Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients.  Clin. Pharmacol. Ther. 46: 226-233",,,1967,357.44,5,3,73.2,2,cationic,2,1.2
Nalmefene,55096-26-9,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]56[C@@H](Oc1c25)C(=C)CC[C@@]36O,8.2,15,0.65,9.1,8.8,"Frye RF, Matzke GR, Jallad NS, Wilhelm JA, Bikhazi GB (1996) The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.  Br. J. Clin. Pharmacol. 42: 301-306.  Dixon R, Ghowes J, Gentile J, Hsu HB, Hsaio J, Garg D, Weidler D, Meyer M, and Tuttle R (1986) Nalmefene: inravenous safety and kinetics of a new opioid antagonist.  Clin. Pharmacol. Ther. 39: 49-53.  Frye RF, Matzke GR, Schade R, Dixon R, and Rabinovitz M (1997) Effects of liver disease on the disposition of the opioid antagonist nalmefene.  Clin. Pharmacol. Ther. 61: 15-23.  Matzke GR, Frye RF, Alexander ACM, Reynolds R, Dixon R, Johnston J, and Rault RM (1996) The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.  J. Clin. Pharmacol. 36: 144-151. ",,,1974,339.43,4,2,52.9,2,cationic,2.5,2
Naloxone,465-65-6,Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,1.7,23,0.54,1.2,1.1,"Ngai SH, Berkowitz BA, Yang JC, Hempstead J, and Spector S (1976) Pharmacokinetics of naloxone in rats and man: basis for its potency and short duration of action.  Anesthesiology 44: 398-401.  Asali LA and Brown KF (1984) Naloxone protein binding in adult and fetal plasma. Eur. J. Clin. Pharmacol. 27: 459-463.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1971,327.37,5,2,70,2,neutral,1.1,0.89
Naltrexone,16590-41-3,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]56[C@@H](Oc1c25)C(=O)CC[C@@]36O,7.6,57,0.79,2.2,1.9,"Wall ME, Brine DR, and Perez-Reyes M (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration.  Drug Metab. Dispos.  9: 369-375.  Ludden TM, Malspeis L, Baggot JD, Sokoloski TD, Frank SG, and Reuning RH (1976) Tritiated naltrexone binding in plasma from several species and tissue distribution in mice.  J. Pharm. Sci. 65: 712-716",Calculated from C vs t data provided in the report.,,1967,341.4,5,2,70,2,neutral,1.3,1
Naphtidrofuryl oxalate,31329-57-4,CCN(CC)CCOC(=O)C(Cc1cccc2c1cccc2)CC3CCCO3,0.98,10.8,0.2,1.5,1.35,"RYUICHIRO NISHIGAKI, KOSHIRO UMEMURA, KIYOSHI OKUI, TOSHIHIRO HAYASHI, TERUO YAMAMOTO, and YUJI SAKURAI. The Pharmacokinetical Analysis of the Fate of Naphtidrofuryl Oxalate (LS121) in Human Subjects. I. Single Intravenous Infusion and Multiple Intravenous Infusion. YAKUGAKU ZASSHI, 106(10)906-915(1986).//ppb: David R Goldsmith, Keri Wellington. Naphtidofuryl. Drugs and Aging, 2005, 22, 967-977.","Data also available in tabular form (Cp vs. time). Structure refers to free base. LS121 as oxalate, LS84 as free base. N=16 (across two doses), 65 kg average reported. VDss from V1 and k12 and k21. 120 and 200 mg 2 hr infusion. Table V. MRT from clearance and VDss and t1/2 from 0.693beta.//Review article citing ppb taken from another review article.",,1964,383.52,4,0,38.8,11,cationic,4.9,3.6
Naproxen,22204-53-1,C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)O,0.09,0.07,0.002,19.78,16.63,"M.V. Calvo, J.V. Lanao, A. Dominguez-Gil. Bioavailability of rectally administered naproxen. In. J. Pharm. 1987, 38, 117-122.//ppb: R. A. UPTON, R. L. WILLIAMS, J. KELLY  R. M. JONES Naproxen pharmacokinetics in the elderly. Br. J. Clin. Pharmacol. 1984, 18, 207-217.","Data digitized from plot 250 mg dose, N=8 and 63.3 kg average weight reported. Vdarea 7.14 L. Reported AUCinf = 842 ug.hr.mL-1, calculated 813 842 ug.hr.mL-1. PDR reports > 99% bound to plasma proteins.  ppb data from Upton et al. taken from young subjects. Determined at peak plasma at day 9 and not sttistically different than trough. Larger (2-fold) fu in elderly subjects at both peak and trough plasma level on day 9.",,1963,230.26,3,1,46.5,3,anionic,2.9,0.023
Napsagatran,154397-77-0,NC(=N)N1CCC[C@@H](CNC(=O)C[C@H](NS(=O)(=O)c2ccc3ccccc3c2)C(=O)N(CC(=O)O)C4CC4)C1,0.36,6.4,0.55,0.94,1.9,"Hauptmann J. (2002) Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs A review of small-molecule thrombin inhibitors.  Eur J Clin Pharmacol  57: 751-758. ppb:Marilyn E. Morrisa,, Xinning Yanga, Yash A. Gandhia, Suraj G. Bhansalia, and Lisa J. Benincosa. Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR. BIOPHARMACEUTICS & DRUG DISPOSITION Biopharm. Drug Dispos. 2012, 33: 1–14.",Ro 46-​6240,,1993,558.65,12,5,186,12,zwitterionic,0.68,-1.6
Naratriptan,121679-13-8,CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,2.4,6.6,0.7,6.1,6.6,Amerge Product Label. PDR accessed July 31 2014. http://www.pdr3d.com/detail.php?c=113877#section-12,,,1989,335.46,5,2,65.2,5,cationic,2.5,0.43
Nateglinide,105816-04-4,CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(=O)O,0.15,1.8,0.029,1.4,1.5,"Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, Mcleod JF, and Mangold JB (2001) Pharmacokinetics and metabolism of nateglinide in humans.  Drug Metab. Dispos. 29: 415-421.  Choudhury S, Hirschberg Y, Filipek R, Lasseter K, and McLeod JF (2000) Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.  J. Clin. Pharmacol. 40: 634-640.",,,1986,317.42,4,2,66.4,6,anionic,3.8,0.67
NBI-1,1190929-42-0,C[C@H](c1c2ccccc2sc1CCN(C)C)c1ccccn1,1.83,5.31,,6.8,9.1,"Ajay Madan, Zhihong O’Brien, Jianyun Wen, Chris O’Brien, Robert H. Farber, Graham Beaton, Paul Crowe, Berend Oosterhuis, R. Colin Garner, Graham Lappin,  Haig P. Bozigian.  A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2009, 67, 288–298","microdosing, 100 ug. N=4, median values reported. 70kg average weight assumed. However, diphenhydramine reported values differed significantly from data in non microdosing study. See above.",,2009,310.46,2,0,16.1,5,cationic,3.8,1.9
NBI-2,1190929-44-2,CN(C)CCC1Cc2cc(ccc2C=1Cc1cccnn1)F,1.11,2.33,,7.9,9,"Ajay Madan, Zhihong O’Brien, Jianyun Wen, Chris O’Brien, Robert H. Farber, Graham Beaton, Paul Crowe, Berend Oosterhuis, R. Colin Garner, Graham Lappin,  Haig P. Bozigian.  A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2009, 67, 288–298","microdosing, 100 ug. N=4, median values reported. 70kg average weight assumed. However, diphenhydramine reported values differed significantly from data in non microdosing study. See above.",,2009,297.37,3,0,29,5,cationic,2.9,1.3
NBI-3,1190929-46-4,C[C@H](C1=C(CCN(C)C)Cc2ccccc12)c1cnccn1,1.86,3.4,,10,11,"Ajay Madan, Zhihong O’Brien, Jianyun Wen, Chris O’Brien, Robert H. Farber, Graham Beaton, Paul Crowe, Berend Oosterhuis, R. Colin Garner, Graham Lappin,  Haig P. Bozigian.  A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2009, 67, 288–298","microdosing, 100 ug. N=4, median values reported. 70kg average weight assumed. However, diphenhydramine reported values differed significantly from data in non microdosing study. See above.",,2009,293.41,3,0,29,5,cationic,2.9,1.4
NBI-4,1190929-48-6,C[C@@H](c1cccnc1F)c1c2ccccc2sc1CCN(C)C,5.73,10.4,,10,15,"Ajay Madan, Zhihong O’Brien, Jianyun Wen, Chris O’Brien, Robert H. Farber, Graham Beaton, Paul Crowe, Berend Oosterhuis, R. Colin Garner, Graham Lappin,  Haig P. Bozigian.  A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2009, 67, 288–298","microdosing, 100 ug. N=4, median values reported. 70kg average weight assumed. However, diphenhydramine reported values differed significantly from data in non microdosing study. See above.",,2009,328.45,2,0,16.1,5,cationic,3.9,2
Nebivolol,118457-14-0,O[C@@H](CNC[C@H](O)[C@H]1CCc2cc(F)ccc2O1)[C@@H]3CCc4cc(F)ccc4O3,11,14,0.02,13,10,"Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers. Br. J. Clin. Pharmacol. 43: 563-570. ppb: The PDR states: The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations. Accessed January 7 2015. http://www.pdr3d.com/detail.php?c=53808#section-12",,,1987,405.44,5,3,70.9,6,cationic,3.9,3.3
Nedaplatin,95734-82-0,O1[Pt](OC(=O)C1)(N),0.67,4.05,0.84,2.75,2.1,"Niioka T,  Uno T,  Yasui-Furukori N,  Takahata T, Shimizu M, Sugawara K, Tateishi T. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma. Cancer Chemother Pharmacol (2007)  ppb: Yasutsuna Sasaki,  Tomohide Tamura, Kenji Eguchi  Tetsu Shinkai, Yasuhiro Fujiwara, Masaaki Fukuda, Yuichiro Ohe, Masami Bungo, Naoya Horichi, Shigeki Niimi, Koichi Minato , Kazuhiko Nakagawa and Nagahiro Saijo. Pharmacokinetics of (glycolato-0,0')-diammine platinum(II),a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol (1989)23:243-246.","57.2 kg average weight, N=19, VDss calculated from reported Vc and k12/k21. MRT from VDss and clearance.","Administered as infusion at 20 mg/m2,  in 1 hr. 1 hr after administration paclitaxel (30 mg/m2) was administered. 30' prior to initial infusion dexamethasone (iv, 20 mg), diphenhydramine, (50 mg po) and ranitidine (50 mg iv) were administered to all patients to manage hypersensitivity. ",1984,285.14,4,1,61.5,0,n/a,n/a,n/a
Nedocromil,69049-73-6,c12c(c3c(c(cc(o3)C(O)=O)=O)cc1c(cc(n2CC)C(O)=O)=O)CCC,0.43,10.2,0.11,0.7,0.9,"M. G. NEALE, K. BROWN, R. A. FOULDS, S. LAL1, D. A. MORRIS & D. THOMAS. The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease. Br. J. Clin. Pharmacol.  (1987), 24, 493-501//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf. Accessed June 15 2017.",420 ug total dose administered as 0.2 ug.kg-1.min-1 in 30 minutes. 70 kg average weight N=6 healthy. MRT from VDss and clearance.,80% excreted unchanged also reported in the FDA approval package. Very small amount excreted in urine after po or inhalation.,1978,371.34,8,2,127.1,5,anionic,2.8,-3.1
Nefazodone,83366-66-9,CCC1=NN(CCCN2CCN(CC2)c3cccc(Cl)c3)C(=O)N1CCOc4ccccc4,0.51,7.5,0.01,1.1,1.2,"Barbhaiya RH, Dandekar KA, and Greene DS (1996) Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.  Drug Metab. Dispos. 24:  91-5.  PPB data from http://www.drugs.com/ppa/nefazodone_hydrochloride.html",,,1982,470.01,7,0,51.6,10,neutral,4.4,4.3
Nefopam,13669-70-0,CN1CCOC(c2ccccc2)c3ccccc3C1,5.6,12,,8.1,5,"Chawla J, Le Guern ME, Alquier C, Kalhorn TF, and Levy RH (2005)  Effect of route of administration on the pharmacokinetic behavior of enantiomers of nefopam and desmethylnefopam.  Ther. Drug Monit. 25: 203-210.  ",VDss calculated from digitized C vs t data for (+) enantiomer.,,1968,253.34,2,0,12.5,1,cationic,2.9,2.4
Nelarabine,121032-29-9,COc1nc(N)nc2c1ncn2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O,4.9,81,0.8,1,0.5,PDR Arranon Product Label. Accessed July 31 2014. http://www.pdr3d.com/detail.php?c=103264#section-13,,,1968,297.27,10,4,148.8,3,neutral,-1.9,-1.9
Nemonoxacin,378746-64-6,C(C(=C(N1C2CC2)C(=C2N(C[C@](C[C@]3([H])C)(N)[H])C3)OC)C=C2)(C(=C1)C(O)=O)=O,1.9,3.8,0.84,8.4,13.5,"Cao Guo-Ying; Zhang Jing; Zhang Ying-Yuan; Guo Bei-Ning; Yu Ji-Cheng; Wu Xiao-Jie; Chen Yuan-Cheng; Shi Yao-Guo; Wu Ju-Fang . Safety, Tolerability, and Pharmacokinetics of Intravenous Nemonoxacin in Healthy Chinese Volunteers. Antimicrobial agents and chemotherapy. 2014 ; 58, 6116-6121; . ppb: Luke Lin, Li-Wen Chang, Cheng-Yuan Tsai, Ching-Hung Hsu, David T. Chung, William S. Aronstein, Funmi Ajayi, Barbara Kuzmak, and Robert A. LyonDose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Nemonoxacin (TG-873870), aNovel Potent Broad-Spectrum Nonfluorinated Quinolone, in Healthy Volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,  2010, 54, 405–410","TG-873870. Average of N=35 across 250, 500 and 750 mg dose. Data from table 4. Infusion 45', 90 and 135', respectively. 59 kg average body weight reported.",,2001,371.43,7,2,96.1,4,zwitterionic,2.5,0.077
Nemorubicin,108852-90-0,c1(cccc2c1C(c1c(O)c3c(c(c1C2=O)O)C[C@](C(CO)=O)(O)C[C@@H]3O[C@H]1C[C@@H]([C@@H]([C@@H](O1)C)O)[N@]1CCO[C@@H](C1)OC)=O)OC,49,15.32,,53.3,49.2,"M Bakker, JP Droz, AR Hanauske, J Verweij, AT van Oosterom, HJM Groen, MA Pacciarini, L Domenigoni, F van Weissenbruch, E Pianezzola, EGE de Vries. Broad phase 11 and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. British Journal of Cancer 1998 77, 139-146.","FCE23762.  PNU-152243A, MMRDX. 1.5 mg/m2, N=11, 1.73 m2/70 kg factor used. Data from Table 5.",,1986,643.64,14,5,201.7,7,neutral,0.75,0.59
Neostigmine,59-99-4,CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C,0.74,9.2,,1.3,1.3,"Morris RB, Cronnelly R, Miller RD, Stanski DR, and Fahey MR (1981) Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man.  Anesthesiol. 54: 399-402.",,,1932,223.29,4,0,29.5,3,neutral,-3.1,-3.1
Nesiritide,124584-08-3,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CC(C=CC=C1)=C1)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=CNC2)N=2)C(=O)O)C(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC2)N2C(=O)[C@@H](N)CO)C(C)C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC1=O)=O)CO)=O)CO)=O)CO)=O)CO)=O,0.19,9.2,,0.3,0.3,PDRprescribing information. Accessed July 31 2014. http://www.pdr3d.com/detail.php?c=114674#section-12,"In patients with heart failure (HF), NATRECOR® administered intravenously by infusion or bolus exhibits biphasic disposition from the plasma. The mean terminal elimination half-life (t1/2) of nesiritide is approximately 18 minutes and was associated with approximately 2/3 of the area-under-the-curve (AUC). The mean initial elimination phase was estimated to be approximately 2 minutes. In these patients, the mean volume of distribution of the central compartment (Vc) of nesiritide was estimated to be 0.073 L/kg, the mean steady-state volume of distribution (Vss) was 0.19 L/kg, and the mean clearance (CL) was approximately 9.2 mL/min/kg. MRT from Vss and Cl.",,1989,3464.04,92,56,1512.7,91,cationic,-9,-9
Netilmicin,56391-56-1,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(=CC[C@H]2N)CN)[C@H](O)[C@H]1O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O,0.073,0.55,1,2.2,3.2,"Welling PG, Baumueller A, Lau CC, and Madsen PO  (1977) Netilmicin Pharmacokinetics After Single Intravenous Doses to Elderly Male Patients.  Antimic. Agents Chemother. 12: 328-334.  Contrepois A, Brion N, Garaud JJ, Faurisson F, Delatour F, Levy JC, Deybach JC, and Carbon C (1985) Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans.  Antimic. Agents Chemother. 27: 520-524.",Used data from group 1 (mean age 54 yr) and analyzed C vs t data provided in the reference by Welling et al.,,1975,475.58,12,8,199.7,8,cationic,-3.8,-7.5
Netupitant,290297-26-6,Cc1ccccc1c2cc(ncc2N(C)C(=O)C(C)(C)c3cc(cc(c3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C,5.54,2.83,0.003,32.57,34.28,FDA Clinical Pharmacology and Biopharmaceutics review: accessed March 8 2017.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205718Orig1s000ClinPharmR.pdf,"Ro 67-3189. Data digitized from plots 0-24 and 0-72 hr. N=6, 25 mg dose (50, 75 and 100 mg doses available but not tolerated) as a 30' infusion. 70 kg average weight assumed. PKSolver used for calculation. Not completely linear across doses.",,2000,578.59,5,0,39.7,5,cationic,6.7,5.3
Nevirapine,129618-40-2,Cc1ccnc2N(C3CC3)c4ncccc4C(=O)Nc12,1.3,0.3,0.32,81,53,"Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M, and  Robinson P (1999) Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.  Biopharm. Drug Dispos. 20: 285-291.  Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R,  Reynolds HE, Garazzino S, Sinicco A,  Khoo SH, Back DJ, and Di Perri G (2004) The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests.  AIDS Res. Human Retroviruses  20: 716-722.",,,1990,266.3,5,1,58.1,1,neutral,1.3,1.1
Nicainoprol,76252-06-7,C1CCN(C(c2cccnc2)=O)c2c1cccc2OC[C@@H](CNC(C)C)O,0.67,3.6,,3.1,12.4,"Takashi Ishizaki, Yukio Horai, Kiyoshi Kubota, Akemi Minegishi., Hirotoshi Echizen, and Kan Chiba, Ph.D.Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. Clin. Pharmacol. Ther. 1987, 42, 525-534","N=8, 100 mg in 60' infusion. Clrenal 0.56 mL/min/kg. Erroneous MRT reported in Table 1 and corrected using AUC and clerance cross-checking.",,1981,369.46,6,2,74.7,7,cationic,1.4,-0.35
Nicardipine,55985-32-5,COC(=O)C1=C(C)NC(=C(C1c2cccc(c2)N(=O)=O)C(=O)OCCN(C)Cc3ccccc3)C,1,11,0.01,1.5,4.1,"Guerret M, Cheymol G, Hubert M, Julien-Larose C, and Lavene D (1989) Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope.  Eur. J.Clin. Pharmacol. 37: 381-385.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",,,1974,479.52,9,1,113.7,11,neutral,3.9,3.7
Nicorandil,65141-46-0,c1(C(NCCO[N+](=O)[O-])=O)cccnc1,1.4,8.9,0.76,2.7,3.6,"Frydman AM, Chapelle P, Diekmann H, Bruno R, Thebault JJ, Bouthier J, Caplain H, Ungethuem W, Gaillard C, Le Liboux A, Renard A, Gaillot J. Pharmacokinetics of Nicorandil. Am. J. Cardiol. 1989, 63, 25J-33J","Data digitized from plot reported. N=14, 75 kg median weight 5 mg dose. Clearance, MRT and t1/2 incorrectly reported in original table.",,1977,211.17,7,1,94.4,5,neutral,0.53,0.53
Nicotine,54-11-5,CN1CCC[C@H]1c2cccnc2,2.6,18,0.95,2.4,2,"Benowitz NL, Jacob P, Jones RT, and Rosenberg J (1982) Interindividual variability in the metabolism and cardiovascular effects of nicotine in man.  J. Pharmacol. Exp. Ther. 221: 368-372. ",,,1946,162.23,2,0,16.1,1,cationic,1.1,-0.46
Nifedipine,21829-25-4,COC(=O)C1=C(C)NC(=C(C1c2ccccc2N(=O)=O)C(=O)OC)C,0.79,7.3,0.044,1.8,1.9,"Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, and George CF (1995) Factors affecting the absolute bioavailability of nifedipine.  Br. J. Clin. Pharmacol. 40: 51-58.  Robertson DRC, Waller DG, Renwick AG, and George CF (1988) Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.  Br. J. Clin. Pharmacol. 25: 297-305.  Kleinbloesem CH, van Harten J, Wilson JPH, Danhof M, van Brummelen P, and Breimer DD (1986) Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin. Pharmacol. Ther. 40: 21-28.  Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, and Breimer DD (1984) Nifedipine: kinetics and dynamics in healthy subjects.  Clin. Pharmacol. Ther. 35: 742-749.    Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.  ",,,1974,346.33,8,1,110.4,6,neutral,2.4,2.4
Nifekalant,130636-43-0,n1(c(=O)n(c(=O)cc1NCC[N@@](CCCc1ccc(cc1)[N+](=O)[O-])CCO)C)C,1.96,20.89,0.09,1.56,1.52,"ZHANG Heng, WANG Ben-jie, GUO Rui-chen. Pharmacokinetics of Nifekalant Hydrochloride in Chinese Healthy Volunteers. Chin Pharm J，2009, 44, 136-140.//ppb: Haruaki Nakaya and Hiroko Uemura, Electropharmacology of Nifekalant, a New Class III Antiarrhythmic Drug. Cardiovascular Drug Reviews, 1998, 16, 133-144.","PK calculated from tabulated data in the paper. Average of 0.3 and 0.4 mg/kg doses as HCl, N=8 each. Corrected for HCl salt weight. 65.2 kg average weight. ppb taken as the midpoint of values reported from reference 19 in Nakaya et al. The actual ref. (Kato et al 1997) could not be found.",,1980,405.45,10,2,122.6,11,cationic,1.2,0.5
Nimodipine,66085-59-4,COCCOC(=O)C1=C(C)NC(=C(C1c2cccc(c2)N(=O)=O)C(=O)OC(C)C)C,1.1,15,0.016,1.2,1.3,"Muck W, Breuel HP, and Kuhlmann J (1996) The influence of age on the pharmacokinetics of nimodipine.  Int. J. Clin. Pharmacol. Ther. 34: 293-298.  Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.    Hynymen M, Siltanen T, Sahlman A, Pohjasvaara T, Muck W, and Kaste M (1995) Continuous infusion of nimodipine during coronary artery surgery: hemodynamics and pharmacokinetic study.  Br. J. Anaesth.  74: 526-533.",,,1949,418.44,9,1,119.7,10,neutral,3.2,3.2
Nintedanib,656247-17-5,CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5,15,19.9,0.02,12.6,9.5,"OFEV. PDR. Accessed January 20 2015. http://www.pdr3d.com/detail.php?c=135426. Same clearance, MRT and VDss, t1/2 data also reported in: Claudia Dallinger, Dirk Trommeshauser,  Kristell Marzin  Andre Liesener, Rolf Kaiser, and Peter Stopfer. Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. Published ahead of print, April 20 2016. J. Clin. Pharmacol. 2016. DOI: 10.1002/jcph.752","70 kg average weight assumed. MRT from Clearance and VDss. Nintedanib follows bi-phasic disposition kinetics. After intravenous infusion, a high volume of distribution which was larger than total body volume (Vss: 1050 L) was observed.
The in vitro protein binding of nintedanib in human plasma was high, with a bound fraction of 97.8%. Serum albumin is considered to be the major binding protein. Nintedanib is preferentially distributed in plasma with a blood to plasma ratio of 0.87.
Elimination: The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%). Total plasma clearance after intravenous infusion was high (CL: 1390 mL/min; gCV 28.8%). Urinary excretion of unchanged drug within 48 hours was about 0.05% of the dose after oral and about 1.4% of the dose after intravenous administration; the renal clearance was 20 mL/min.",,2001,539.62,9,2,94.2,8,cationic,3.8,3.4
Nisoldipine,63675-72-9,COC(=O)C1=C(C)NC(=C(C1c2ccccc2N(=O)=O)C(=O)OCC(C)C)C,5.5,15,0.003,6.5,11,"van Harten J, van Brummelen P, Lodewijks MTM, Danhof M, Breimer DD (1988) Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.  Clin. Pharmacol. Ther. 43: 332-341.  van Harten J, van Brummelen P, Wilson JHP, Lodewijks MTM, and Breimer DD (1988) Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 34: 387-394.  ",,,1977,388.41,8,1,110.4,8,neutral,3.7,3.7
Nitrazepam,146-22-5,O=C1CN=C(c2ccccc2)c3cc(ccc3N1)N(=O)=O,1.7,0.86,0.13,33,26,"Jochemsen R, VanBeusekom BR, Spoelstra P, Janssens AR, and Breimer DD (1983) Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam.  Br. J. Clin. Pharmacol. 15: 295-302.  Jochemsen R, Hogendoorn JJH, Dingemanse J, Hermans J, Boeijinga JK, and Breimer DD (1982) Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans.  J. Pharmacokinet. Biopharm. 10: 231-245.",VDss calculated using C vs t data obtained by digitization of the plot provided in the references.,,1960,281.27,6,1,87.3,2,neutral,2.1,2.1
Nitrendipine,39562-70-4,CCOC(=O)C1=C(C)NC(=C(C1c2cccc(c2)N(=O)=O)C(=O)OC)C,6.1,25,0.02,4.1,8.2,"Mikus G, Fischer C, Heuer B, Langen C, and Eichelbaum M (1987) Application of stable isotope methodology to study the pharmacokinetics, bioavailability, and metabolism of nitrendipine after i.v. and p.o. administration.  Br. J. Clin. Pharmacol. 24: 561-569.  Soons PA, DeBoer AG, Van Brummelen P, and Breimer DD (1989) Oral absorption ptrofile of nitrendipine in healthy subjects: a kinetic and dynamic study.  Br. J. Clin. Pharmacol. 27: 179-189.  Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.  ",,,1972,360.36,8,1,110.4,7,neutral,3,3
Nitrofurantoin,67-20-9,O=C1CN(\N=C\c2oc(cc2)N(=O)=O)C(=O)N1,0.57,9.7,0.17,0.98,0.97,"Hoener BA and Patterson SE (1981) Nitrofurantoin disposition.  Clin. Pharmacol. Ther. 29: 808-816.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.  Mannisto PT and Lamminsivu U (1982) Nitrofurantoin is highly bound to plasma protein. J. Antimic. Chemother. 9: 327-328.",,,1952,238.16,9,1,121,3,anionic,-0.64,-0.98
Nitroglycerin,55-63-0,C(CO[N+](=O)[O-])(CO[N+](=O)[O-])O[N+](=O)[O-],,194.3,0.4,,4.5,"Nitroglycerin - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021359/S-000. Accessed through Pharmapendium.","70 kg assumed. Vd reported as 3 L/kg, but without label. Likely to be VDz. T1/2 ranged from 1.5 to 7.5 minutes. Median point taken.",,1946,227.09,12,0,157.1,8,neutral,1.7,1.7
Nizatidine,76963-41-2,CN\C(=C/N(=O)=O)\NCCSCc1csc(CN(C)C)n1,1,9.8,0.65,1.7,1.5,"Aronoff GR, Bergstrom RF, Bopp RJ, Sloan RS, and Callaghan JT, (1988) Nizatidine disposition in subjects with normal and imparired renal function.  Clin. Pharmacol. Ther. 43: 688-695.  Knadler MP, Bergestrom RF, Callaghan JT, and Rubin A (1986) Nizatidine, an H2-blocker.  Its metabolism and disposition in man.  Drug Metab. Dispos. 14: 175-82",VDss calculated using C vs t data obtained by digitization of the plot provided in the reference.,,1982,331.46,7,2,86,10,neutral,-0.17,-0.24
NK 611,105760-98-3,COc1cc(cc(OC)c1O)C2C3C(COC3=O)C(OC4OC5COC(C)OC5C(O)C4N(C)C)c6cc7OCOc7cc26,0.3,0.4,0.013,17,14,"Mross K, Huettmann A, Herbst K, Hanauske AR, Schilling T, Manegold C, Burk K, and Hossfeld DK (1996) Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611: A study by the AIO groups PHASE-I and APOH. Cancer Chemother. Pharmacol. 38: 217-224. Rassmann I., Thodtmann R, Mross M, Huttmann A, Berdel WE, Manegold C, Fiebig HH, Kaeser-Frohlich A, Burk K, and Hanauske AR (1999) Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion.  Invest. New Drugs 16: 319-324.",CAS number used refers to the HCl salt. CAS number of parent 105655-99-0,,1986,615.63,13,2,143.8,6,neutral,0.23,0.21
Nocloprost,79360-43-3,C(\[C@@H]1[C@@H]([C@@H](Cl)C[C@@H]1O)C\C=C\CCCC(O)=O)=C\[C@@H](C(CCCC)(C)C)O,0.16,13.2,,0.2,0.8,"U. Tiiuber, M. Brudny-Kltippei , U. J akobs , C. Madetzki , and M. Mahler. Pharmacokinetics of nocloprost in human volunteers and its relation to dose. Eur J Clin Pharmacol (1993) 44:497-500",5 ug iv dose. N=10,,1981,400.98,4,3,77.8,12,anionic,5.1,2.6
Nomifensine,24526-64-5,CN1CC(c2ccccc2)c3cccc(N)c3C1,6,22,0.4,4.5,6.5,"Lindberg RLP, Syvalahti EKG, and Pihlajamaki KK (1986) Disposition of nomifensine after acute and prolonged dosing.  Clin. Pharmacol. Ther. 39: 384-388.  Heptner W, Hornke I, Cavagna F, Fehlhaber HW, Rupp W, and Neubauer HP (1978) Metabolism of nomifensine in man and animal species.  Arz. Forsch. 28: 58-64",VDss calculated from data obtained by digitization of a plot in the reference. ,,1969,238.33,2,1,29.3,1,cationic,2.3,0.87
Norfloxacine,70458-96-7,c12c(c(=O)c(cn1CC)C(=O)O)cc(c(c2)N1CCNCC1)F,1.88,6.96,0.13,4.5,4.45,"Chen, Xijing; Liu, xiaoquan; Huang, Shengkai; Wang, Fengchen. Pharmacokinetics of norfloxacin by constant rate infusion. Zhongguo Linchuang Yaolixue Zazhi 1992, 8, 82-86//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019384s066lbl.pdf. Accessed May 30 2017","N=8, 63.4 kg average weight, 1 hr infusion, 400 mg dose. MRT from clearance and VDss. VDss from Vc and k12, k21 and clearance from dose/AUC reported.",56% excreted unchanged in urine.,1979,319.33,6,2,74.6,3,zwitterionic,1.7,-0.72
Nortilidine,38677-94-0,CCOC(=O)[C@@]1(CCC=C[C@H]1NC)c2ccccc2,2.5,9.9,,4.2,4.4,"Hajda JP, Jahnchen E, Oie S, and Trenk D (2002) Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine.  J. Clin. Pharmacol. 42: 1257-1261.",VDss calculated from data obtained by digitization of a plot in the reference. ,,1971,259.34,3,1,38.3,5,cationic,3,1.9
Nortriptyline,72-69-5,CNCCC=C1c2ccccc2CCc3ccccc13,22,10,0.12,37,30,"Overo KF, Gram LF, and Hansen V (1977) Interaction of perphenazine with the kinetics of nortriptyline.  Acta Pharmacol. Toxicol. 40: 97-105.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.","VDss values were calculated for three of the subjects in the paper by Overo, et al, by digitizing the C vs t plots presented in the reference, and analyzing the resulting C vs t data.",,1962,263.38,1,1,12,3,cationic,4.1,1.9
Noscapine,128-62-1,CN1CCc2cc3c(c(c2[C@@H]1[C@@H]4c5ccc(c(c5C(=O)O4)OC)OC)OC)OCO3,2.3,16.88,,2.28,2.13,"B. Dahlström, T. Mellstrand , C.-G.  Löfdahl and M. Johansson. Pharmakokinetic Properties of Noscapine. Eur. J. Clin. Pharmacol. 1982, 22, 535-539.","(-)-Narcotine. N=5, 70 kg average weight reported, 66 mg dose. Data digitized from plot reported. AUCinf 18% higher than reported with AUC0-t calculated almost identical to reported. Data treated as bolus as no sampling during infusion was taken. Structure entered as lactone.",,1891,413.42,8,0,75.7,4,neutral,2.5,2.4
Octreotide,83150-76-9,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)CC2=CC=CC=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC2=CNC3=C2C=CC=C3)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,0.19,2.38,0.35,1.3,1.7,"Octreotide Acetate - FDA Approval Package
Label 019667/S-061. Accessed through Pharmapendium.",70 kg assumed. Data in healthy volunteers. MRT from VDss and clearance.,,1981,1019.24,20,13,332.2,17,cationic,-0.38,-3.4
Odanacatib,603139-19-1,CC(C)(C[C@@H](C(=O)NC1(CC1)C#N)N[C@@H](c2ccc(cc2)c3ccc(cc3)S(=O)(=O)C)C(F)(F)F)F,1.63,0.19,,147.3,108," Zajic, Stefan; Rossenu, Stefaan; Hreniuk, David; Kesisoglou, Filippos; McCrea, Jacqueline; Liu, Fang; Sun, Li; Witter, Rose; Gauthier, Don; Helmy, Roy; Joss, Darrick; Ni, Tong; Stoltz, Randall; Stone, Julie; Stoch, S. Aubrey. The absolute bioavailability and effect of food on the pharmacokinetics of odanacatib: a stable-​label i.v.​/oral study in healthy postmenopausal women. drug Metab. Disp. 2016, 44, 1450-1458.","MK 0822. L-1037536. 1 mg dose iv, N=21-24, depending on parameter. All postmenopausal women. 70 kg average weight assumed. MRT from VDss and clearance. Essentially identical parameters obtained for unlabeled and labeled odanacatib after dose of 13C labeled odnacatib. Data from Table4.",,2003,525.56,6,2,99.1,9,neutral,3.7,3.7
Ofloxacin,82419-36-1,CC1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(=O)O,1.6,2.5,0.75,11,8.9,"Gascon AR, Campo, E, Hernandez RM, Calvo B, Errasti J, and Pedraz JL (1998) Pharmacokinetics and tissue distribution of intravenous ofloxacin for antibiotic prophylaxis in biliary surgery.  Clin. Drug Invest. 15: 491-496.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750.",,,1982,361.37,7,1,73.3,2,zwitterionic,1.9,-0.4
OGT719,185843-61-2,O[C@H]1[C@@H](O[C@@H]([C@@H]([C@@H]1O)O)CO)n1c(=O)[nH]c(=O)c(c1)F,0.33,1.38,,3.95,4.21,"Sharma, Ricky A.; Eatock, Martin M.; Twelves, Christopher J.; Brown, Gill; McLelland, Heather R.; Clayton, Kathryn T.; O'Byrne, Kenneth J.; Moyses, Chris; Carmichael, James; Steward, William P.  Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. Cancer Chemother. Pharmacol. 2001, 48, 197-201.","OGT719 Data digitized from plot reported by  Sharma et al. 250 mg/m2. N=16, 1.73 m2/70kg conversion factor.  85% reported excreted unchenged in urine.",,1996,292.22,9,5,145,2,neutral,-3.1,-6.6
Olcegepant,204697-65-4,NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N2CCC(CC2)N3Cc4ccccc4NC3=O)C(=O)N5CCN(CC5)c6ccncc6,0.31,2.6,,1.9,2.5,"Iovino M, Feifel U, Yong CL, Wolters JM, and Wallenstein G (2004) Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers.    Cephalalgia 24: 645-56.",,,1998,869.65,14,5,176.5,12,cationic,4.1,2.2
Oleandomycin,3922-90-5,[H]O[C@H]1[C@H](C)O[C@@H](C[C@@H]1OC)O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@@H]([C@@H](C)C([C@]2(C[C@H](C)[C@@H]([C@H]1C)O[C@@H]1[C@@H]([C@@H](C[C@H](C)O1)N(C)C)O[H])CO2)=O)O[H],0.77,9.1,0.4,1.41,1.05,"Duthu G S. Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin. J Pharm Sci, 1985, 74(9), 943-946. ","Data in 70.0 Kg weight subjects (see Ref. 7). MRT calculated from CL and VDss.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",,1955,687.86,13,3,166,9,cationic,2,0.7
Oliceridine,1401028-24-7,COc1ccsc1CNCC[C@]2(CCOC3(C2)CCCC3)c4ccccn4,0.78,6.89,,1.9,1.8,"David G. Soergel, Ruth Ann Subach,   Brian Sadler,  John Connell,  Alan S. Marion,  Conrad L. Cowan,  Jonathan D. Violin,  Michael W. Lark. First Clinical Experience With TRV130:
Pharmacokinetics and Pharmacodynamics in Healthy Volunteers.J. of Clin.Pharmacol. 2014, 54, 351-357.","TRV130 N=6, 79.7 kg average weight, 7 mg infusion over 1 hr. Data digitized and claculations performed via PKSolver. AUC0-inf reported as 206 ng.h.mL and calculated as 213 ng.h.mL, or 3% different. Good apparent dose linearity. Lower doses available but only AUC at 7 or 0.25 mg doses were reported in text.",,2012,386.55,4,1,43.4,7,cationic,3.1,2.5
Olmesartan,144689-24-7,c1(nc(c(n1Cc1ccc(cc1)c1c(cccc1)c1nnn[nH]1)C(=O)O)C(C)(C)O)CCC,,0.29,,,10.8,"Lee R. Schwocho and Harvey N. Masonson. Pharmacokinetics of CS-866, a New Angiotensin II Receptor Blocker, in Healthy Subjects. Journal of Clinical Pharmacology, 2001;41:515-527","Angiosartan, CS-866 as medoxomil prodrug. RNH-6270. VD reported as VDz. Weighted average of studies C and D where RNH-6270 was administered as such. Data from Table V. This compound is a metabolite of CS-866 (prodrug) but dosed as RNH-6270. clearance 1.3 L/h. Average weight 76 kg. VDz 20.82 L. N=58 across doses",,1992,446.5,9,3,129.8,7,anionic,4.5,-0.93
Olodaterol,868049-49-4,O=C(N1)COC2=C1C=C(O)C=C2[C@@H](O)CNC(C)(CC3=CC=C(OC)C=C3)C,15.85,12.45,0.4,22.21,22.1,203108Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) FDA report. Accessed March 5 2016. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203108Orig1s000ClinPharmR.pdf,"From text.  A group of five healthy male subjects received 20 μg [14C]olodaterol (0.096 MBq) as intravenous infusion over 3 hours. .....After intravenous infusion, Cmax of olodaterol was observed at theend of the infusion. Thereafter, plasma concentrations declined multi-exponentially with a terminal half-life of 22.1 h. The volume of distribution at steady state (Vss) was 1110 L, and total clearance was 872 mL/min.  70 kg weight assumed. ",SMILES FROM STRUCTURE DRAWN IN CHEMDRAW. 50% recovered between urine and feces as metabolites (prevalent glucuronidation). 42% excreted as such in urine and feces. About 20% excreted unchanged in urine and 20% in feces.,2005,386.44,7,4,100,7,cationic,2.1,0.98
Olprinone,106730-54-5,c1(c(cc(c(=O)[nH]1)C#N)c1ccc2n(c1)ccn2)C,0.64,11,,0.97,1.13,"QIN Yong-ping，MIAO Jia，MEI Ya-jun, WANG Ying，NAN Feng，ZHU Xiao-hong, XIANG Jin，SHU Shi-qing，YU Qin，LI Mei，LIANG Mao-zhi. Pharmacokinetic study of olprinone hydrochloride injection in healthy volunteers. Chinese Journal of New Drugs 2015, 24(12), 1397-1403. ","Abstract in English. Article in Chinese. Seemingly 62% excreted unchanged in urine. VDss from clearance and MRTinf reported. Very tight data with N=9 across three doses (averaged) at 5, 10 and 20 ug/kg injected in 5 minutes.",,1986,250.26,5,1,74,2,neutral,0.59,-2.9
Olsalazine,15722-48-2,OC(=O)c1cc(ccc1O)N=Nc2ccc(O)c(c2)C(=O)O,0.07,1.2,0.01,0.97,0.9,Ryde EM and Ahnfelt NO (1988) The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food.  Eur. J. Clin. Pharmacol. 34: 481-488. ppb: The PDR states:  Olsalazine-S is more than 99% bound to plasma proteins. Its long half-life is mainly due to slow dissociation from the protein binding site. Less than 1% of both olsalazine and olsalazine-S appears undissociated in plasma. Accessed January 6 2015. http://pdr3d.com/detail.php?c=10084#section-4,,,1938,302.24,8,4,139.8,4,anionic,3.2,-3.6
Omadacycline,389139-89-3,CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(CNCC(C)(C)C)c(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)N(C)C,2.7,2.34,,19.24,15,"Haiying Sun, Lillian Ting, Surendra Machineni, Jens Praestgaard, Andreas Kuemmell, Daniel S. Stein, Gangadhar Sunkara, Steven J. Kovacs, Stephen Villano, S. Ken Tanaka. Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects. Antimicrob. Agents Chemother. 2016, 60, 7431-7435.","PTK 0796. Amadacycline.  N=21, 75.8 kg average weight, 100 mg dose as 30' infusion. Data digitized and calculation performed via PKSolver. AUCinf.  reported as 10 ug.h.mL-1; AUCinf calculated as 9.4 ug.h.mL-1. 6% difference.",,2002,556.65,11,6,176.7,6,zwitterionic,1.4,-2.1
Ombitasvir,1258226-87-7,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC,2.32,1.68,0.001,23.07,28.49,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207931Orig1s000ClinPharmR.pdf. Accessed December 19 2016,"ABT-267. N=8, 74.43 kg average weight, regimen B, with 25 ug dose of 14C-ABT-267 (plot in pg/mL vs. time). VDss 173 L, clearance 7.5 L/h. Plot shaped as ""hockey stick"".  Coadministered with  paritaprevir and ritonavir (both po) as well as ombitasvir po.",,2010,894.11,15,4,178.7,15,neutral,7.8,7.8
Ombrabulin,181816-48-8,O=C([C@@H](N)CO)NC1=C(OC)C=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=C1,0.44,22.6,,0.32,0.26,"H. Murakami,T. Kurata, Y. Onozawa, J. Watanabe, A. Ono,T. Takahashi, N. Yamamoto, Y. Fujisaka, H. Kiyota, H. Hayashi,K. Tanaka, K. Nakagawa, S. Kuroda. An open‑label, dose‑escalation, safety, and pharmacokinetics
phase I study of ombrabulin, a vascular disrupting agent, administered as a 30‑min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 73:623–630",AVE8062. Weighted average of data reported in ref. 30' infusion. 70 kg average weight assumed. Dose range 15.5 to 50 mg/m2.,,1996,402.44,8,3,112.3,9,neutral,1,0.91
Omeprazole,73590-58-6,COc1ccc2[nH]c(nc2c1)S(=O)Cc3ncc(C)c(OC)c3C,0.24,8.4,0.05,0.48,0.58,"Regardh CG, Andersson T, Lagerstrom PO, Lundborg P, and Skanberg I (1990) The pharmacokinetics of omeprazole in humans-a study of single intravenous and oral doses.  Ther. Drug Monit. 12: 163-172.  Regardh CG, Gabrielsson M, Hoffman KJ, Lofberg I, and Skanberg I (1985) Pharmacokinetics and metabolism of omeprazole in animals and man--an overview.  Scand. J Gastroent.108(Suppl): 79-94.",CL and t1/2 values were reported as medians.,,1979,345.42,6,1,77.1,5,neutral,2.2,2.2
Ondansetron,99614-02-5,Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C,1.8,5.8,0.27,5.2,3.4,"Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, and Powell JR (1992) Age and gender effects on ondansetron pharmacokinetics:  evaluation of healthy aged volunteers.  Clin. Pharmacol. Ther. 51: 51-55..  Zofran Product Label.",,,1985,293.36,4,0,39.8,2,cationic,2.1,1
ONO-4232,494222-30-9,O[C@H](/C=C/[C@@H]1N(CCSCCCC(O)=O)C(CC1)=O)CC2=CC=C(F)C=C2,0.48,15.79,,0.51,0.38,"Caroline L.Ward; Virginia Jamieson; Toshiya Nabata; John Sharpe; Koji Dozono; Fumitaka Suto;  Hashimoto; Ihor Gussak. First Clinical Experience with ONO-4232: A Randomized, Double-Blind,Placebo-Controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure. Clin. Ther. 2016, 38, 1109-1121.",Structure guessed from patent but not confirmed. Drawn in chemdraw and structure exported as smiles.,,2003,395.49,5,2,77.8,11,anionic,2.2,-0.44
OR-1896,220246-81-1,[H]N(C(C)=O)c1ccc(cc1)C1[C@H](C)CC(N([H])N=1)=O,2.38,0.45,0.4,88,70,"Puttonen, J. Eur. J. Pharm. Sci. 2007, 32, 271-277. 200 ug dose, HPLC analysis on OR-1896 after 14C OR-1896 dose. N=5, average weight 74 kg, VDss = 176 L, Cl reported as 2.0 L/h. ppb from Antila et al. Eur. J. Pharm. Sci. 2004, 23, 213-222.",A metabolite of levosimedan,,1991,245.28,5,2,70.6,2,neutral,0.71,0.71
Org 28611,1224731-00-3,COc3cccc(c13)c(C(=O)N(CC2C)CCN2C)cn1CC4CCCCC4,1,3,,5.7,4.2,"Zuurman, L.; Passier, P. C. C. M.; de Kam, M. L.; Kleijn, H. J.; Cohen, A. F.; van Gerven, J. M. A.  Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers  Journal of Psychopharmacology (London, United Kingdom) 2009, 23  (6)  633-644.",data digitized and averaged across all infusion (25 min) doses (03-10 ug/kg). Average body weight 77 kg.,,2009,383.53,5,0,37.7,4,cationic,3.4,2.3
Oritavancin,171099-57-3,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O[C@H]6C[C@](C)(N)[C@@H](O)[C@H](C)O6)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(=O)N)NC1=O)c8ccc(O)c(c8)c9c(O)cc(O)cc9[C@H](NC7=O)C(=O)O)c3O[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O[C@H]%11C[C@](C)(NCc%12ccc(cc%12)c%13ccc(Cl)cc%13)[C@@H](O)[C@H](C)O%11)c(Cl)c2,0.3,0.07,0.13,67.2,96.2,"Gerald J. Fetterly, Christine M. Ong, Sujata M. Bhavnani,Jeffrey S. Loutit, Steven B. Porter, Lisa G. Morello, Paul G. Ambrose, and David P. Nicolau. Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose. Antimicr. Agents Chemother. 2005, 49, 148-152.","Data digitized from plot (800 mg single dose) reported. N=8, 70 kg average weight assumed, AUC0-t calculated  essentially identical to reported value (2,284 ug.hr.mL-1 vs. 2,267 ug.hr.mL-1 , respectively). 90 minutes infusion.",,1995,1793.1,36,20,561,19,cationic,4.3,-0.82
Ornidazole,16773-42-5,"n1(c(cnc1C)[N+](=O)[O-])C[C@@H](CCl)O
",1.16,1.08,0.88,18.1,12,"Tolerability,Safety and Pharmacokinetics of ( S) -Ornidazole in Ascending Dose Study in Healthy Chinese Volunteers. ZHAO Ya-nan，WU Pei，SUN Hua，YANG Jing-jing,GUO Yi-yun，LIU Xiao-quan. Chin. Pharm. J. 2011, 46, 454-457. ppb: Schwartz DE, Jeunet F. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy, 1979, 22, 19-29.","S-enantiomer. 3 doses N=10 each, 500, 1000 and 1500 mg total dose. likely 1 hr infusion. Reported clearance likely to be in L/h. Cheched via cross-calculations of dose/auc and t1/2.",,1966,219.63,6,1,81.2,4,neutral,0.23,0.22
Ortataxel,186348-23-2,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@]5(C2(C)C)[C@H]([C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)OC(=O)O5)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C,13.83,8.12,,28.39,30.1,"N. Ramnath, J. Hamm, G. Schwartz S. Holdenc,S.G. Eckhardt, M.R. Vredenburg,  R.J. Bernacki C. Lathiad, P. Kanter, P.J. CreavenA Phase I and Pharmacokinetic Study
of BAY59: A Novel Taxane. Oncology 2004;67:123–129","BAY 59-8862. SB-T 101131
 N=25 weight averaged across doses from 30 to 100 mg/m2. 70 kg average weight assumed. MRT froim VDss and clearance.",,1997,871.92,18,3,245.8,15,neutral,3.6,3.6
Oseltamivir acid,187227-45-8,CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(=O)C)C(=O)O,0.37,4.8,0.97,1.3,1.8,"He G, Massarella J, and Ward P (1999) Clinical pharmacokinetics of the progrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37: 471-484.",,,1996,284.35,6,3,101.6,6,zwitterionic,0.57,-1.7
Otamixaban,193153-04-7,[H]/N=C(/c1cccc(c1)C[C@H]([C@@H](C)NC(=O)c2ccc(cc2)c3cc[n+](cc3)[O-])C(=O)OC)\N,0.89,7.38,,2.02,3,"Anne Paccaly, PharmD, Annke Frick, PhD, Shashank Rohatagi, PhD, Jingli Liu, PhD, Umesh Shukla, PhD, Ronald Rosenburg, MD, Markus Hinder, MD, and Bradford K. Jensen, PhD. Pharmacokinetics of Otamixaban, a Direct Factor
Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure. J Clin Pharmacol 2006;46:37-44.",From reference. Vdss values ranged from 35 (16) to 90 (25) L in the 6-hour infusion study and from 136 (81) to 202 (43) L in the 24-hour infusion study. Vdss values tended to decrease as the infusion rate increased. Median value of 62.5 L The mean (CV%) total plasma Cl ranged from 20 (21) to 42 (17) L/h in the 6-hour infusion study and from 29 (32) to 36 (25) L/h in the 24-hour infusion study and tended to decrease as the infusion rate increased. Median taken as 31 L/h. All data taken from 6-hour infusion across 0.04 to 1.1 mg/kg. Linear PK. 70 kg body weight assumed. N=6 for each dose. MRT from VDss and clearance. t1/2 highly dependent on sampling times post end of infusion. Tken as 3 hours from 6 hr infusion to 12 hrs total sampling.,,1997,446.5,8,3,132.2,9,cationic,0.89,-0.91
Oxacillin,66-79-5,Cc1onc(c2ccccc2)c1C(=O)N[C@H]3[C@H]4SC(C)(C)[C@@H](N4C3=O)C(=O)O,0.19,6.3,0.07,0.5,0.7,"Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 42-48.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  ",,1961,401.44,8,2,113,4,anionic,2.1,-1.2
Oxaliplatin,61825-94-3,C1CC[C@H]2[C@H](C1)N[Pt+2]3(N2)[O-]C(=O)C(=O)[O-]3,0.5,0.1,0.13,82.8,58.92,"Jing Liu, Eric Kraut, Jonathan Bender, Rebecca Brooks, Stanley Balcerzak, Michael Grever, Harriet Stanley, Steven D’Ambrosio Ruth Gibson-D’Ambrosio, Kenneth K. Chan. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.//ppb: Pendyala, L.; Creaven, P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Research. 1993, 53, 5970-5976.","Eloxatin. NSC 266046. Total plasma Pt data from Table 1. Plasma ultrafiltrate (PUF) data available. N=10, 2-hr iv infusion of a 60 mg/m2 dose. 70-kg average weight assumed. Reported as 85-88% bound by Pendyala and Creaven. ",,1976,395.28,6,2,80.8,0,n/a,n/a,n/a
Oxazepam,604-75-1,OC1N=C(c2ccccc2)c3cc(Cl)ccc3NC1=O,0.59,1.1,0.04,8.9,6.7,"Sonne J, Loft S, Dossing M, Vollmer-Larsen A, Olesen KL, Victor M, Andreasen F, and Andreasen PB (1988) Bioavailability and pharmacokinetics of oxazepam.  Eur. J. Clin. Pharmacol. 35: 385-389.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12: 612-619.  Desmond PV, Roberts RK,, Wood AJJ, Dunn GD, Wilkinson GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175.",,,1962,286.71,4,2,61.7,1,neutral,2.3,2.3
Oxiracetam,62613-82-5,NC(=O)CN1CC(O)CC1=O,0.55,1.8,,4.9,7.5,"Perucca E, Albrici A, Gatti G, Spalluto R, Visconti M, and Crema A (1984) Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet.  3: 267-274.",,,1977,158.16,5,2,83.6,2,neutral,-2.5,-2.5
Oxprenolol,6452-71-7,c1(c(cccc1)OC[C@@H](CNC(C)C)O)OCC=C,0.72,7.7,0.19,1.56,1.09,"I. D. BRADBROOK, V. A. JOHN, P. J. MORRISON, H. J. ROGERS and R. G. SPECITOR. Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release. Br. J. Clin. Pharmac. (1985), 19, 163S-169S.  ppb: J W Rigby  A K Scott G M Hawksworth  J C Petrie. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. Br. J. Clin. Pharmacol. 1985, 20, 327-331. ppb: Also, fu of 15% reported by Henry JA, Mitchell, SN. Effect of pH on human plasma protein binding of a series of β-adrenoceptor antagonists. British Journal of Clinical Pharmacology  1981 11(1):119-120P","20 mg dose iv, 78.6 kg average weight N=8. MRT from VDss and clearance.",,1965,265.35,4,2,50.7,9,cationic,2,0.24
Oxybutynin,5633-20-5,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2,0.85,5.1,0.0034,2.7,7.2,"Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, and Herchuelz A (1988) The pharmacokinetics of oxybutynin in man.  Eur. J. Clin. Pharmacol. 35: 515-520.  Mizushima H, Takanaka K, Abe K, Fukazawa I, and Ishizuka H (2007) Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica 37: 59-73.",Parameters calculated from C vs t data obtained by digitization of the plot provided in the reference.  Used data from 1 mg dose.,,1964,357.49,4,1,49.8,10,cationic,4.3,3.9
Oxycodone,76-42-6,COc1ccc2C[C@H]3N(C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,2.5,6.1,0.55,6.8,5.5,"Leow KP, Smith MT, Watt JA, Williams BE, and Cramond T (1992) Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration.  Ther. Drug Monit. 14: 479-484.  Leow KP, Wright AWE, Cramond T, and Smith MT (1993) Determination of the serum protein binding of oxycodone and morphine using ultrafiltration.  Ther. Drug Monit. 15: 440-447. ",,,1914,315.36,5,1,59,1,cationic,0.72,0.17
Oxymatrine,16837-52-8,C1C[C@@H]2[C@H]3CCC[N@+]4([C@H]3[C@@H](CCC4)CN2C(=O)C1)[O-],0.61,7.66,,1.33,1.69,"Xiao-luan Wu, Tai-jun Hang, Jian-ping Shen, Yin-di Zhang. Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2006, 41, 918–924.","calculated from digitized plot. 600 mg total dose, N=10, 65 kg average weight. 0.5 h infusion.",,1958,264.36,4,0,43.4,0,neutral,0.87,0.87
Oxytetracycline,79-57-2,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)C(=O)c4c(O)cccc4[C@@]3(C)O,1.7,2,0.9,12,10,"Kunin CM, Darnbush AC, and Finland M (1959) Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest.  38  1950-1963.",calculated from digitized plots ,,1948,460.43,11,7,201.8,2,zwitterionic,-1.9,-4.3
Paclitaxel,33069-62-4,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(=O)C)[C@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7)C(=C1C5(C)C)C,3,6.4,0.12,7.8,11,Sonnichsen DS and Relling MV (1994) Clinical pharmacokinetics of paclitaxel.  Clin. Pharmacokinet. 27: 256-269.,"Averaged values listed in Table 1 of Sonnichsen and Relling.  For t1/2 values, used longest value reported in each reference.",,1980,853.91,15,4,221.3,14,neutral,2.9,2.9
Paeoniflorin,23180-57-6,O1[C@@H](O[C@@]23[C@@]4([C@@H]([C@@]5(C[C@@]2(C)O[C@@H]4O5)O)C3)COC(=O)c2ccccc2)[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O,0.22,2.05,0.77,1.83,1.49,"Xiaobing Li  Fuguo Shi, Pan Gua, Lingye Liua, Hua Heb,, Li Dinga. A sensitive LC–MS/MS method for simultaneous determination of amygdalin and paeoniflorin in human plasma and its application.  Journal of Pharmaceutical and Biomedical Analysis 92 (2014) 160–164// ppb: Sun, Bing-ting; Dai, Guo-liang; Zang, Yu-xin; Zhao, Wen-zhu; He, Shu-fen; Zong, Yang; Ju, Wen-zheng; Tan, Heng-shan. Determination of human plasma protein binding rates of three main components in Baixiangdan capsules.Zhongguo Shiyan Fangjixue Zazhi 2016, 22, 68-72.","N=2, 70 kg assumed. 4 hours infusion. Digitized from plot. Huoxue-Tongluo lyophilized powders for injection (6 g, containing 25.3 mg of amygdalin and 35.8 mg of paeoniflorin) were supplied by Jiangsu Kanion Pharmaceutical Co., Ltd. (Lianyun-gang, China). ppb averaged form measurements at three concentrations but very close.",,1963,480.46,11,5,164.4,7,neutral,-1.2,-1.2
Paliperidone,144598-75-4,Cc1c(c(=O)n2c(n1)C(CCC2)O)CCN3CCC(CC3)c4c5ccc(cc5on4)F,,1.18,0.24,,24.6,"Title of Study: Disposition of Paliperidone Enantiomers After Treatment With Different Formulations of the Racemate and the Separate Enantiomers and the Determination of the Absolute Bioavailability of IR and ER OROS Paliperidone.  
Available on ClinicalTrials.gov. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=569&filename=CR004216_CSR.pdf. Accessed October 28 2016.","Data for racemate: 83.2 mL/min, iv 30 minutes infusion, 1 mg dose. 70 kg assumed. No VD reported, t1/2 24.6 hr. fu 0.24 for racemate. Very similar PK data for (+) or (-) enantiomer. No VDss data could be found.",,1990,426.48,7,1,84.7,4,cationic,1.5,0.94
Palonosetron,135729-61-2,O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]4CN5CCC4CC5,6.3,2.6,0.38,40,39,"Stoltz R, Cyong JC, Shah A, and Parisi S (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects.  J. Clin. Pharmacol. 44: 520-531.   Siddiqui M, Asif A, and Scott LJ.(2004) Palonosetron.    Drugs 64: 1125-1132.",VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1991,296.41,3,0,23.5,1,cationic,2.9,1.9
Pamidronic acid (Pamidronate),40391-99-9,C(P(O)(O)=O)(P(O)(O)=O)(CCN)O,1.8,2.5,0.7,12,32,"Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, and Seaman JJ (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.  J. Clin. Pharmacol. 37: 285-290. ppb: P.T. DALEY-YATES, J.C. CAL, A. COCKSHOTT, M. PONGCHAIDECHA and K. GILCHRIST. PLASMA PROTEIN BINDING OF APD: ROLE OF CALCIUM AND TRANSFERRIN. Chem.-Biol. Interactions, 1992, 81, 79-89.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1973,235.07,8,6,161.3,4,anionic,-3.5,-8.8
Pancopride,121650-80-4,c1c(c(cc(c1Cl)N)OCC2CC2)C(=O)NC3CN4CCC3CC4,3.9,5.2,,12.3,13.5,"P. Dewland, A. Perez Campos, and A. Martinez-Tobed, Single Dose Pharmacokinetics and Tolerance of Pancopride in Healthy Volunteers. Arzneim.-Forsch.lDrug Res.  (1995), 45 (I), 177-183.","LAS30451. Data digitized from plot in reference.
N = 12, average weight 71.8 kg.
20 mg administered in 15'.
Reported AUC 811 h*ug/L 
t1/2 15.82 h
VD(z) = 612 L",,1989,349.86,5,2,67.6,5,cationic,2.5,0.83
Pancuronium,15500-66-0,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(=O)C)[N+]5(C)CCCCC5)[C@@]2(C)C[C@@H]1[N+]6(C)CCCCC6,0.2,1.5,0.09,2.2,1.9,"Caldwell JE, Castagnoli KP, Canfell PC, Fahey MR, Lynam DP, Fisher DM, and Miller RD (1988) Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action.  Br. J. Anaesth. 61:  693-697.  Wood M, Stone WJ, and Wood AJJ (1983)  Plasma binding of pancuronium:  effects of age, sex, and disease.  Anesth. Analg.  62: 29-32",,,1966,572.86,6,0,52.6,6,neutral,-0.36,-0.36
Panipenem,87726-17-8,C[C@@H](O)[C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)S[C@H]3CCN(C3)C(=N)C,0.19,2.6,,1.2,0.96,Saito A (1991) Pharmacokinetics of panipenem/betamipron.  Chemotherapy 39(Suppl. 3)4: 227-235.,VDss calculated from C vs t data provided in the reference.,,1983,339.41,7,3,104.9,5,zwitterionic,0.18,-2.1
Panobinostat,404950-80-7,Cc1c(c2ccccc2[nH]1)CCNCc3ccc(cc3)/C=C/C(=O)NO,,10.2,0.1,,13.1,"Sunil Sharma,Joachim Beck, Monica Mita,Sofia Paul, Margaret M. Woo, Margaret Squier, Brian Gadbaw, H. Miles Prince. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.Invest New Drugs (2013) 31:974–985//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf. Accessed June 12 2017.",VDz reported. Average 801 L. 70 kg weight assumed. Data from average of several doses. Clearance 43 L/h. No cohort size reported. Novartis compound. LBH589.,,2002,349.43,5,4,77.1,7,cationic,2.6,0.73
Pantoprazole,102625-70-7,COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,0.17,2.2,0.02,1.3,1.9,"Pue MA, Laroche J, Meineke I, and deMey C (1993) Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects.  Eur. J. Clin. Pharmacol. 44: 575-578.  Huber R; Hartmann M; Bliesath H; Luhmann R; Steinijans V W; Zech K  Pharmacokinetics of pantoprazole in man.    International journal of clinical pharmacology and therapeutics  (1996),  34(1 Suppl),  S7-16",,,1986,383.37,7,1,86.3,7,neutral,1.6,1.6
Papaverine,58-74-2,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,1,11,0.073,1.4,1.8,"Garrett ER, Roseboom H, Green JR, and Schuermann W (1978) Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms.  Int. J. Clin. Pharmacol. Biopharm.  16: 193-208.  Berg G, Jonsson KA, Hammar M, and Norlander B (1988) Variable bioavailability of papaverine.  Pharmacol. Toxicol. 62: 308-310.","Parameters calculated from C vs t data obtained by digitization of the plots reported in Garrett, et al and averaged for two dose levels.  VDss was obtained by digitization of the plot in Berg, et al..  All data were averaged together weighted for the number of subjects in each study.",,1878,339.39,5,0,49.8,6,neutral,3.5,3.5
Paricalcitol,131918-61-1,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(=C\C=C3C[C@@H](O)C[C@H](O)C3)\CCC[C@]12C,0.41,0.89,0.0016,7.7,5.3,"Carr RA, Andre AK, Chen P, Grabowski BA, Chang MS, Locke CS, Williams LA, and Chojkier M (2006) The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (ZemplarR).  Nephron  103: c100-c105.",Free fraction calculated by comparing free and total AUC values reported in the reference.,,1990,416.64,3,3,60.7,4,neutral,6.4,6.4
Paritaprevir,1216941-48-8,Cc1cnc(cn1)C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)Oc5c6ccccc6c7ccccc7n5)C(=O)NS(=O)(=O)C8CC8,1.37,5.74,0.022,3.96,8.71,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207931Orig1s000ClinPharmR.pdf. Accessed December 19 2016,"ABT-450.  Veruprevir. N=8, 75.23 kg average weight, regimen A, with 100 ug dose of 14C-ABT-450 (plot in pg/mL vs. time). VDss 103 L, clearance 25.9 L/h. Plot shaped as ""hockey stick"". Coadministered with ombitasvir and ritonavir (both po) as well as paritaprevir po.",,2010,765.88,14,3,189.6,7,anionic,5.3,2.3
Paroxetine,61869-08-7,Fc1ccc(cc1)[C@@H]2CCNC[C@H]2COc3ccc4OCOc4c3,18,18,0.06,17,13,"Lund J, Thayssen P, Mengel H, Pedersen OI, Kristensen CB, and Gram LF (1982) Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man.  Acta Pharmacol. Toxicol. 51: 351-357.  Paxil Product Label.",VDss was calculated from micro rate constants reported in the reference.,,1978,329.37,4,1,39.7,4,cationic,3.8,1.5
Patupilone,152044-54-7,[C@H]12C[C@H](OC(=O)C[C@@H](C(C(=O)[C@H]([C@H]([C@H](CCC[C@]1(O2)C)C)O)C)(C)C)O)C(=C\c1nc(sc1)C)\C,14.4,2.17,0.22,110.6,92.3,"Forster M et al. A phase Ib and pharmacokinetic trial of Patupilone combined with Carboplatin in patients with advanced cancer. Clin. Cancer Res. 2007, 13(14) ,4178-4184. ppb: slight variation between 10 and 100 ng/mL in ED. From abstract in English. Tan, Qiong; Hong, Jin-chuan; Xu, Zhi-ru; Xiao, Feng; Zhao, Sha-sha; Qin, Yan. Determination of the plasma protein binding rate of epothilone b by lc-​ms. Shijie Linchuang Yaowu (2012), 33(10), 599-603.","Low dose. Data from Table 3 using 1.73 m2/70 kg conversion: N=11, 70 kg average weight assumed, 4.40 mg/m2 dose (= 0.11 mg/kg). MRT calculated from VDss and CL. (other names: EPO906, Epothilone B)",,1993,507.68,7,2,109.3,2,neutral,3.8,3.8
Pazopanib,4731-52-6,Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C,0.16,0.06,0.01,44.4,,Pazopanib Hydrochloride - EMA Approval Package. Accessed through Pharmapendium.,"70 kg assumed and MRT from VDss and clearance. The mean half-life after a single dose of 800 mg was
30.9 ±4 hours (VEG10003). This value is from an oral dose.",,2002,437.52,9,2,119,5,neutral,4,4
Pazufloxacin,127045-41-4,C1(CC1)(c1c(cc2c(=O)c(cn3[C@H](COc1c23)C)C(O)=O)F)N,0.68,4.87,0.79,2.32,2.1,"Pharmacokinetics of pazufloxacin single dose intravenous in healthy volunteers Qiao Hao-yi， Zhang Hui-lin， Cui Yi-ming，Sun Pei-hong,Zhao Xia, Zhou Yin，Liu Yu-wang and Zhao Dong-fan. Chin. J. Antibiot. 2006, 31, 220-223. Chinese journal zhong guo kang sheng su za zhi//ppb: S. Iwakura, H. Tanimura, K. Murakami. Basic study of regulating factors on the metabolism and biliary transfer of fluoroquinolones. Jap. J. Chemother. 1996, 44, 804-817.","Data taken from table 3 and PK calculated via Phoenix at 300 mg and 500 mg dose. N=10 70 kg average weight assumed.
",,1989,318.3,6,2,94.6,2,zwitterionic,1.6,-0.87
Pefloxacin,70458-92-3,CCN1C=C(C(=O)O)C(=O)c2cc(F)c(cc12)N3CCN(C)CC3,1.5,2,0.75,13,11,"Frydman AM, Le Roux Y, Lefebvre MA, Djebbar F, Fourtillan JB, and Gaillot J (1986) Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400mg bid) in young healthy volunteers.  J. Antimic. Chemother.  17(Suppl B): 65-79.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet.41: 741-750.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1979,333.36,6,1,64.1,3,zwitterionic,2.3,0.041
Peldesine,133432-71-0,c12c(Cc3cccnc3)c[nH]c1c([nH]c(n2)N)=O,1.2,6.2,0.86,3.2,3,"Viegas TX, Omura GA, Stoltz RR, Kisicki J.Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2000 Apr;40(4):410-20.","BCX-34. data digitized from figure 3. N=9, 18 mg/m2 (1.9 m2 average BSA, 77 kg average weight) in 30' infusion.
reported AUC= 1104 hr*ng/mL
reported clearance = 33.3 L/h
reported t1/2 = 2.1 h",Calculated from the ratio of Ae (29 mg) and dose (18 mg/m2*1.9m2 = 34.2 mg),1991,241.25,6,3,100.5,2,neutral,-0.38,-0.38
Pelrinone,94386-65-9,[H]N(Cc1cccnc1)C1=C(C#N)C(N=C(C)N1[H])=O,0.39,5.8,0.05,1.1,0.95,"Scatina, J. A.; Hicks, D. R.; Kraml, M.; Cayen, M. N. Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man Eur. J. Drug Metab. Pharmacokin. 1990, 15, 37-48."," N=4, 67 Kg average weight, 0.149 mg/Kg iv dose",,1985,241.25,6,2,90.2,4,neutral,-0.75,-0.8
Pemetrexed,137281-23-3,c12c(c[nH]c1nc(N)[nH]c2=O)CCc1ccc(C(N[C@H](CCC(=O)O)C(=O)O)=O)cc1,0.15,1.3,0.19,1.92,1.85,"Initial Phase I Evaluation of the Novel Thymidylate Synthase Inhibitor, LY231514, Using the Modified Continual Reassessment Method for Dose Escalation D.A. Rinaldi, H.A. Burris, F.A. Dorr, J.R. Woodworth, J.G. Kuhn, J.R. Eckardt, G. Rodriguez, S.W. Corso, S.M. Fields, C. Langley, G. Clark, D. Faries, P. Lu, and D.D. Von . ppb: the PDR states: In vitro studies indicate that pemetrexed is approximately 81% bound to plasma proteins. Binding is not affected by degree of renal impairment. Accessed december 31 2014. http://www.pdr3d.com/detail.php?c=104982#section-13","LY231514, Weighted average of N=24. across 10-40 mg/m2 doses.",,1963,427.41,11,6,191.3,9,anionic,-0.03,-5.6
Penciclovir,39809-25-1,NC1=NC(=O)c2ncn(CCC(CO)CO)c2N1,1.1,8.4,0.84,2.4,2.1,"Fowles SF, Pierce DM, Prince WT, and Staniforth D (1992) The tolerance to and pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects.  Eur. J. Clin. Pharmacol. 43: 513-516.  Filer CW, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE, Prince WT, and Ramji JV (1994) Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects.  Xenobiotica 24: 357-368.",Parameters calculated from digitized plots and averaged over all dose levels.,,1972,253.26,8,4,125.8,5,neutral,-1.6,-1.6
Penclomedine,108030-77-9,c1(c(c(c(Cl)c(n1)OC)OC)Cl)C(Cl)(Cl)Cl,9.1,29.9,,5.1,3.8,"Phase I and Pharmacologic Study of Penclomedine,
a Novel Alkylating Agent, in Patients With Solid Tumors Seamus O'Reilly, Louise B. Grochow, Ross C. Donehower, Tian-Ling Chen, Katherine Bowling, Neil R. Hartman,Robert F. Struck, and Eric K. Rowinsky. Journal of Clinical Oncology, 1997, Vol 15 1974-1984.","70 kg assumed. Average from Table 6. Data from day 1 taken. Day 5 very similar. N=6, 5 mg/kg 5 minutes infusion. 75.3 kg average weight. 45  to 550 mg/m2/day doses. ",,1987,325.4,3,0,31.3,2,neutral,4.4,4.4
Penehyclidine,87827-02-9,c1(ccccc1)[C@@](O)(C1CCCC1)CO[C@@H]1CN2CCC1CC2,2.12,1.99,,17.84,15.73,"Libo Zhao, Yannan Zang, Yuwen Sun, Zhongn Wei, Shan Jing, Qian Wang,Youzhong An, Yi Fang, Wanyu Feng. Development and validation of an improved HPLC-MS/MS method forcomparative pharmacokinetics of penehyclidine hydrochloridefollowing a single intravenous or intramuscular injection.  J. Chrom. B, 2015, 1004, 37–45.",3-(2 -Phenyl-2 -cyclopentyl-2 -hydroxyl-ethoxy) quinuclidine. Penequinine. N=18 crossover patients with a 0.5 mg dose.  i.m./i.v and i.v/i.m. in two groups of 9. Average reported weight 62.1 kg. VDss from MRTinf and clearance.,,1983,315.45,3,1,32.7,5,cationic,3.1,1.4
"Penicillamine, D-",52-67-5,CC(C)([C@H](C(=O)O)N)S,1.26,10.65,0.12,1.97,3.04,"WALTER R. KUKOVETZ, ECKHARD BEUBLER, FRANZ KREUZIG, ALFRED J. MORITZ,GONTHER NIRNBERGER, and LISBETH WERNER-BREITENECKER. Bioavailability and Pharmacokinetics of D-Penicillamine. J. Rheum. 1983, 10, 90-94.//ppb: M. A. ABOUNASSIF and T. M. JEFFERIES. The determination of D-penicillamine and its disulphide in plasma by reversed-phase ion-pair high-performance liquid chromatography. J. Pharm. Biomed. Anal. 1983, 1, 65-72.","N=6, 60.8 kg average weight, 250 mg bolus dose. 
Digitized from a very clear plot. The AUC corresponds to a calculation with a concentration of 0 at time 0 (run here for comparison) and NOT extrapolated  to t=0 from measured concentrations.The correct calculation was retained via PK solver. Also the clearance reported  uses units of AUC not clearance.//ppb: reported as 8-16% free. Median taken.",,1943,149.21,3,2,63.3,1,zwitterionic,-0.16,-1.8
Penicillin G,61-33-6,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O,0.24,6.9,0.4,0.58,0.7,"Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 9, 42-48.  Malerczyk VV, Ruegenberg W, Seiler KU, and Simon C (1979) Untersuchungen zur konkurrenz verscheidener antibiotika um ihre bindungsstellen an serumeiweissen. Arzneim. Forsch. 29: 169-171.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  ",,1946,334.39,6,2,86.7,4,anionic,2,-1.3
Pentamidine,100-33-4,NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(=N)N)cc1,53,74,0.09,12,25,"Conte JE, Duncan S, McKenna E, and Zurlinden E (1999) Effect of gender and race on the pharmacokinetics of pentamidine in HIV-infected patients.  Clin, Drug Invest. 17: 293-299.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191. ppb: Sihyung Yang,Tanja Wenzler,Patrik N. Miller, Huali Wu,David W. Boykin, Reto Brun Michael Zhuo Wang Pharmacokinetic Comparison To Determine the Mechanisms Underlying the Differential Efficacies of Cationic Diamidines against First- and Second-Stage Human African Trypanosomiasis. Antimicrobial Agents and Chemotherapy 2014, 58, 4064-4074",,,1939,340.42,6,4,118.2,10,cationic,2.5,-1.2
Pentazocine,359-83-1,CC1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C(C)C,3.4,23,0.39,2.5,2.5,"Ritschel WA, Bykadi G, Hoffmann KA, Norman EJ, Lucker PJ, and Rindt W (1982) Disposition and clinical side effectsof pentazocine when administered day and night.  Arz. Forsch. 32: 64-68.  Ritschel WA, Hoffmann KA, Willig JL, Frederick KA, and Wetzelberger N (1986) The effect of age on the pharmacokinetics of pentazocine.  Meth. Find. Expt. Clin. Pharmacol. 8: 497-503.  Ehrnebo M, Agurell S, Boreus LO, Gordon E, and Lonroth U (1974) Pentazocine binding to blood cells and plasma proteins.  Clin. Pharmacol. Ther. 16: 424-429.",,,1962,285.42,2,1,23.5,2,cationic,4.4,2.8
Pentobarbital,76-74-4,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,0.91,0.47,0.39,32,22,"Ehrenbo M (1974) Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration.  J. Pharm. Sci. 63: 1114-1118.  Bayliff CD, Schwartz ML, and Hardy BG (1985) Pharmacokinetics of high-dose pentobarbital in severe head trauma.    Clin. Pharmacol. Ther. 38: 457-461.  Ehrnebo M and Odar-Cederlof I (1975) Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients.  Eur. J. Clin. Pharmacol. 8: 445-453.",VDss calculated using micro rate constants reported in the reference by Ehrenbo.,,1926,226.27,5,2,75.3,4,neutral,2,1.9
Pentostatin,53910-25-1,n1(c2c(nc1)[C@@H](CNC=N2)O)[C@@H]1O[C@H]([C@@H](C1)O)CO,0.59,1.63,0.96,6,5.3,"Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Lathia, Chetan; Fleming, Gini F.; Meyer, Mark; Ratain, Mark J.; Whitfield, Lloyd.Cancer Chemother. Pharmacol. 2002,50 (2) 121-126. ppb: The PDR states: The plasma protein binding of pentostatin is low, approximately 4%. Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=21514#section-4","2'-Deoxycoformycin, NSC 218321. Average of N=6, dose range 4 mg/m2. Only patients with Clcr > 60 used. 70 kg average weight assumed.
",,1974,268.27,8,4,112.1,2,neutral,-2.7,-2.7
Pentoxifylline,6493-05-6,CN1C(=O)N(CCCCC(=O)C)C(=O)c2c1ncn2C,1.8,39,0.51,0.77,1.2,"Beermann B, Ings R, Mansby J, Chamberlain J, and McDonald A (1985) Kinetics of intravenous and oral pentoxifylline in healthy subjects.  Clin. Pharmacol. Ther. 37: 25-28.  Rames A, Poirier JM, LeCoz F, Midavaine M, Lecocq B, Grange JD, Poupon R, Cheymol G, and Jaillon P (1990) Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients.  Clin. Pharmacol. Ther. 47: 354-359.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",Calculated VDss from C vs t data obtained by digitization of plots included in the references. ,,1959,278.31,7,0,75.5,5,neutral,0.65,0.65
Perampanel,380917-97-5,c1ccc(cc1)n2cc(cc(c2=O)c3ccccc3C#N)c4ccccn4,1.36,0.1,0.05,229.4,183,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202834Orig1s000ClinPharmR.pdf. 
Accessed May 18 2017.","E2007. FYCOMPA. Data digitized (perampanel) from plot reported. N=5, 80 kg average, 10 ug of 14C dose in 15 minutes after 45 minutes from 80 mg dose po. Absolute BA 116%. Bl/pl ratio 0.57. AUC0-inf reported as 21600 pg.hr.mL-1. 3% difference with calculated (",,2001,349.38,4,0,58.7,4,neutral,3.1,3.1
Perflutren,76-19-7,C(C(F)(F)F)(C(F)(F)F)(F)F,1.6,590.71,,0.05,0.02,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-064_Definity_biopharmr.pdf.
 Accessed May 18 2017.","Definity.PFC 218. Data in blood. It may be assumed that bl/pl is =1. N=8, healthy volunteers. 70 kg average weight assumed.",,1930,188.02,0,0,0,0,neutral,2.5,2.5
Perindoprilat,95153-31-4,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O)C(=O)O,0.76,1.7,0.16,7.6,29,"Devissaguet JP, Ammoury N, Devissaguet M, and Perret L (1990) Pharmacokinetics of perindopril and its metabolites in healthy volunteers.  Fundam. Clin. Pharmacol. 4: 175-189.  Parker E, Aarons L, Rowland M, and Resplandy G (2005) The pharmacokinetics of perindoprilat in normal volunteers and patients: Influence of age and disease state.  Eur. J. Pharm. Sci. 26: 104-113.",VDss calculated from data obtained by digitization of a plot in the reference. ,,1984,340.41,7,3,106.9,7,anionic,0.92,-3.2
Perphenazine,58-39-9,OCCN1CCN(CCCN2c3ccccc3Sc4ccc(Cl)cc24)CC1,18,27,0.07,11,9.4,"Eggert Hansen C, Rosted CT, Elley J, Bolvig Hansen L, Kragh-Sorensen P, Larsen NE, Naestoft J, and Hvidberg  (1976) Clinical pharmacokinetics studies of perphenazine.  Br. J. Clin. Pharmacol. 3: 915-923.  Verbeek RK, Cardinal JA, Hill AG, and Midha KK (1983) Binding of phenothiazine neuroleptics to plasma proteins.  Biochem. Pharmacol. 32: 2565-2570.",VDss was determined from C vs t data obtained by digitization of the plots presented in the reference.,,1956,403.97,4,1,29.9,6,cationic,4.3,3.5
Pevonedistat,905579-51-3,c1ccc2c(c1)CC[C@@H]2Nc3c4ccn(c4ncn3)[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N,3.02,8.1,,6.21,5.62,"John Sarantopoulos, Geoffrey I Shapiro, Roger B Cohen, Jeffrey W Clark, John S Kauh,
Glen J Weiss,  James M Cleary, Devalingam Mahalingam, Michael D Pickard, Helene
Faessel, Allison J Berger, Kristine Burke, George Mulligan, Bruce J Dezube, R Donald
Harvey. Phase I Study of the Investigational NEDD8-activating Enzyme Inhibitor
Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2016, 22:847-857.","Pevonedistat. Data digitized from Figure 2A (50 mg/m2, Cycle 1, Day 1, 1hr inf.). N=6, 173.m2/kg conversion used. Reported AUC(0-24hr) 2180 ng.hr/mL; calculated AUC(0-24) ng.hr/mL.",,2006,443.52,9,3,132.4,6,neutral,2.5,2.5
PF-05212384 ,1197160-78-3,CN(C)C1CCN(CC1)C(=O)c2ccc(cc2)NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6,2.39,2.25,,17.65,35.8,"Geoffrey I. Shapiro, Katherine M. Bell-McGuinn, Julian R. Molina, Johanna Bendell, James Spicer, Eunice L. Kwak, Susan S. Pandya, Robert Millham, Gary Borzillo, Kristen J. Pierce, Lixin Han, Brett E. Houk, Jorge D. Gallo, Maria Alsina, Irene Braña, and Josep Tabernero. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced
Cancer. Clin Cancer Res. 2015, 21, 1888-1895. ","Getadolisib. Data from supplement 3. N=39, 154 mg dose, 70 kg average weight assumed. MRT from clearance and VDss.",,2009,615.73,13,2,128.3,7,cationic,3.3,2.3
PF-4776548,1515856-61-7,ON(CC1)C(C2=C1C(C=C3)=C(C=N2)N3CC4=C(OC)C=C(F)C=C4)=O,5.7,24,0.08,3.95,3.8,"Anthony Harrison, Iain Gardner, Tanya Hay, Maurice Dickins, Kevin Beaumont, Alex Phipps, Lynn Purkins, Gill Allan, Rachelle Christian, Jonathan Duckworth, Ian Gurrell, Sarah Kempshall, Mark Savage, Mark Seymour, Marie Simpson, Louise Taylor, and Paul Turnpenny. Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms. Xenobiotica, 2012; 42(1): 57–74.",VD reported checked and lower than Vdbeta from clearance and t1/2. taken as VDss. MRT from VDss and clearance.  SMILES drawn and copied from ChemDrawBio Ultra v. 12.0.2.1076,,2012,341.34,6,1,67.6,3,anionic,1.8,1
Phenacetin,62-44-2,CCOc1ccc(NC(=O)C)cc1,1.4,21,0.47,1.1,0.92,"Raaflaub J and Dubach UC (1975) On the pharmacokinetics of phenacetin in man.  Eur. J. Clin. Pharmacol.  8: 261-265.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",VDss data calculated from C vs t data reported in the paper.  Values are for whole blood.,,1941,179.22,3,1,38.3,3,neutral,1.7,1.7
Phenazepam,51753-57-2,c12C(=NCC(=O)Nc1ccc(c2)Br)c1c(cccc1)Cl,0.089,0.05,,28.31,14.88,"Maksutova E L; Sariev A K; Zherdev V P; Voronina T A; Zheleznova E V. The pharmacokinetic characteristics of fenazepam in epileptics. Eksperimental'naia i klinicheskaia farmakologiia. 1994, 57, 16-18.","VDss from clearance and MRT. N=5, 70 kg average weight assumed, 2 mg dose.",In house translation from Russian.,1974,349.61,3,1,41.5,1,neutral,3.8,3.8
Phencyclidine,77-10-1,C1CCN(CC1)C2(CCCCC2)c3ccccc3,6.9,5.1,0.35,23,16,"Cook CE, Brine DR, Jeffcoat AR, Hill JM, Wall ME, Perez-Reyes M, and Di Guiseppi SR (1982) Phencyclidine disposition after intravenous and oral doses. Clin. Pharmacol. Ther. 31: 625-634.",VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.,,1959,243.39,1,0,3.2,2,cationic,5.3,3.7
Phenethicillin,147-55-7,CC(Oc1ccccc1)C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O,0.3,4.2,0.25,1.2,0.91,"Overbosch D, Mattie H, and van Furth R (1985) Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin.  Br. J. Clin. Pharmacol.  19: 657-668.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated from reported rate micro-constants,,1954,364.42,7,2,95.9,5,anionic,2.2,-1.1
Phenobarbital,50-06-6,CCC1(C(=O)NC(=O)NC1=O)c2ccccc2,0.54,0.063,0.49,140,99,"Wilensky AJ, Friel PN, Levy RH, Confort CP, and Kaluzny SP (1982) Kinetics of phenobarbital in normal subjects an epileptic patients.  Eur. J. Clin. Pharmacol. 23: 87-92.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",,,1946,232.24,5,2,75.3,2,neutral,1.3,1.1
Phenoperidine,562-26-5,CCOC(=O)C1(CCN(CC1)CCC(c2ccccc2)O)c3ccccc3,5.7,22,,4.32,3.22,"M. FISCHLER, J. C. LEVRON, H. TRANG, J. F. VAXELAIRE, B. FLAISLER AND G. VOURC'H. PHARMACOKINETICS OF PHENOPERIDINE IN ANAESTHETIZED PATIENTS UNDERGOING GENERAL SURGERY. Br. J. Anaesth. (1985), 57, 872-876","N=5, anesthetized patients. Average weight 66.4 kg. 2M/3F, 2 mg iv injection. MRT from clearance and VDss.",,1958,367.48,4,1,49.8,8,cationic,4.1,3.6
Phenoxodiol,81267-65-4,C1C(=Cc2c(O1)cc(cc2)O)c1ccc(cc1)O,1.55,59.1,,0.44,0.67,"Jan B Howes, Paul L de Souza, Leanne West, Li Jiu Huang, Laurence G Howes. Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. BMC Clinical Pharmacology 2011, 11:1-8; doi: 10.1186/1472-6904-11-1","NV06. Data for the free form ONLY. Average clearance, VDss and t1/2 reported for N=6 subjects administered 5 mg/kg as iv bolus. 70 kg assumed. MRT from VDss and clearance.",,1981,240.25,3,2,49.7,1,neutral,1.9,1.8
Phenoxymethylpenicillin,87-08-1,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,0.41,6.8,0.45,1,0.84,"Overbosch D, Mattie H, and van Furth R (1985) Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin.  Br. J. Clin. Pharmacol.  19: 657-668.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",VDss calculated from reported rate micro-constants,,1948,350.39,7,2,95.9,5,anionic,1.9,-1.4
Phenprocoumon,435-97-2,c1([C@@H](c2ccccc2)CC)c(c2c(cccc2)oc1=O)O,0.2,0.02,0.57,182,126,"Haustein KO, Hüller G. Pharmacokinetics of phenprocoumon. International journal of clinical pharmacology and therapeutics, 1994, 32, 192-7","Data digitized from plot reported. 40% extrapolation to AUC inf. Not clear whether reported AUC is to infinity. Reported AUC 121 ug.h.mL-1. Calculated AUC(inf)  116.5ug.h.mL-1. N=18, 9 mg dose (iv bolus), 71.6 Kg average weight. ppb reported by these authors from another citation. Held H, van Busse G, MeissnerJ 1980 Beobachtungen bei Phenprocoumon(Marcumar) Vergiftung. Dtsch Med Wochenschr 105: 860-863. NOT CHECKED.",,1953,280.32,3,1,50.7,3,anionic,4,1.2
Phentolamine,50-60-2,N(c1cc(ccc1)O)(c1ccc(C)cc1)CC=1NCCN1,,42,,,2.5,"Phentolamine Mesylate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review. Accessed through Pharmapendium.",VD (likely to be VDz) reported as 442 L. 70 kg assumed as average weight. AUClast 1.76 ng.hr.mL-1 with AUCinf as 2.76 ng.hr.mL-1.,,1948,281.35,4,2,47.9,4,cationic,2.9,2.5
Phenytoin,57-41-0,c1ccc(cc1)C2(C(=O)NC(=O)N2)c3ccccc3,0.43,0.37,0.13,17.6,16.8,"Roland Gugler, Carl V. Manion, Daniel L. Azarnoff. Phenytoin: pharmacokinetics and bioavailability. Clin. Pharmacol. Ther. 1976, 19, 145-132//fu (concentration dependent, caverage 2.3 ug.mL). Ulf W Wiegand, Kenneth L. Hintze, John T. Slattery, Gerhard Levy. Protein binding of several drugs in serum and plasma of healthy subjects. Clin. Pharmacol. Ther. 1980, 27, 297-300.","N=6, 300 mg dose. VDss calculated from C vs. t data given in paper.",,1946,252.27,4,2,58.2,2,neutral,1.7,1.6
Phylloquinone,84-80-0,c12c(C(C(C)=C(C1=O)C\C=C(\CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)C)=O)cccc2,0.32,1.6,,3.3,7.3,"VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation Marinova, Milka; Luetjohann, Dieter; Breuer, Olof; Koelsch, Heike; Westhofen, Philipp; Watzka, Matthias; Mengel, Martin; Stoffel-Wagner, Birgit; Hartmann, Gunther; Coch, Christoph; et al European Journal of Clinical Pharmacology (2013), 69(3), 467-475.",Data averaged across three genotypes having no significant differences. N=30 overall. 70 kg weight assumed. MRT from Vss and clearance.,"Phytonadione, Vitamin K1.",1944,450.7,2,0,34.1,14,neutral,9,9
Physostigmine,57-47-6,c12[C@@]3([C@@H](N(C)c1ccc(c2)OC(NC)=O)[N@@](C)CC3)C,3.9,72,0.64,0.9,1,"Walter, K.; Mueller, M.; Barkworth, M. F.; Nieciecki, A. V.; Stanislaus, F. Pharmacokinetics of physostigmine in man following a single application of a transdermal system. British Journal of Clinical Pharmacology (1995), 39(1), 59-63// ppb: Unni, Latha K.; Somani, Satu M. Binding of physostigmine to rat and human plasma and crystalline serum albumins.",Dose 495 ug 6h infusion. N=6. BW=76 kg. Data from Table 1. MRT reported not corrected with half-time of infusion. PK from NCA of digitized profile shown on Figure 1. Reported t1/2 = 0.5h and CL = 75 mL/min/kg (5.7 L/min)// ppb: 29 to 43% bound over 50-fold increase of concentration.,,1906,275.35,5,1,44.8,2,cationic,1.6,0.79
Picumast,39577-19-0,o1c(=O)c(c(c2ccc(cc12)OCCCN1CCN(CC1)Cc1ccc(cc1)Cl)C)C,1.3,1.3,0.05,16.5,19.2,"Neugebauer G, Wittenbrink-Dix AM, Woelke-Seidl E, Kaufmann B, Ponton T, Dahmen W, Mosberg H, Nieder N, Besenfelder E. Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. Arzneimittelforschung. 1989 Oct;39(10A):1336-9.","N=11, 72 kg average weight, 10 mg iv dose. Median values reported: clearance 95 mL/min,  VDss 97 L,  MRT and t1/2 19.2 and 16.5, respectively.",Reported as almost exclusively celared by hepatic metabolism but no quantitative data in Neugebauer et al.,1972,440.96,5,0,46.2,7,cationic,4.7,3.9
Pidotimod,121808-62-6,C1[C@H](N(CS1)C([C@@H]1CCC(N1)=O)=O)C(O)=O,0.31,1.16,0.96,4.5,3.8," Pharmacokinetics and oral bioavailability of pidotimod in humans 
By Mailland, F.; Coppi, G.; Silingardi, S. 
From Arzneimittel-Forschung (1994), 44(12a), 1465-1469.","N=12, 200 mg dose iv, 73.2 kg average weight. VDss calculated from clearance and MRT. Data reported and analyzed via WInNonLin. Very similar values observed and values form the paper were kept. ppb ex-vivo dialysis from 1 hour samples.",,1991,244.27,6,2,86.7,2,anionic,-1.2,-4.6
Pimasertib,1236699-92-5,Ic1cc(F)c(Nc2c(C(=O)NC[C@H](O)CO)ccnc2)cc1,1.8,8.71,,3.55,4.59,"Oliver von Richter, Giorgio Massimini, Holger Scheible, Istvan Udvarosand Andreas Johne. Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. Br. J. Clin. Pharmacol. 2016, 82, 1498-1508.","AS-703026. N=6, average weight of 81.3 kg. ug i.v.  dose tracer 1 h after 60 mg po dose. Data digiztize. and verified by comparing the ""extravascular "" profile  shown in Figure 3 (showing C0 =0). Then parameters from normalized plot, treated as iv bolus were used. Good agreement (15% difference) when C0 treated as 0. PK parameters calculated via PKSolver.",,2010,431.2,6,4,94.5,6,neutral,2,2
Pimobendan,74150-27-9,COc1ccc(cc1)c2nc3cc(ccc3[nH]2)C4=NNC(=O)CC4C,2,14,0.024,2.2,1.8,"Chu KM, Shieh SM, and Hu OYP (1995) Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.  Eur. J. Clin. Pharmacol. 47: 537-542. ",Data from enantiomers averaged.,,1980,334.37,6,2,79.4,3,neutral,3.1,3.1
Pinacidil,60560-33-0,C(=N\c1ccncc1)(\N[C@@H](C(C)(C)C)C)NC#N,1.1,5.68,0.6,3.2,2.5,"A. McBURNEY, P. R. FARROW, S. AINSWORTH, J. W. WARD. Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers. Br. J. clin. Pharmac. (1985), 19, 91-94.//ppb: Ward, J. W.; McBurney, A.; Farrow, P. R.; Sharp, P. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator. Eur. J. Clin. Pharmacol. 1984,  26, 603-608.","Results from digitization from plot reported by cited ref. N=14, 0.2 mg/kg. No comparative data (except ratios of AUC between parent and metabolite) but accepted on the basis of Laher et al reported clearance. Laher, MS, Hickey, MP.  Pharmacokinetics and Bioavailability of Pinacidil Capsules in Human Volunteers. J Int Med Res (1985) 13, 159-162. N=12, 0.2 mg/kg 15' iv infusion. 70 kg average weight assumed. Clearance of 7.56 mL.min-1.kg-1. calculated from dose and AUC reported. Only Vdarea reported as 1.4 L/kg. ppb measured across the range 40-400 ng/mL. Not concentration dependent.",,1976,245.32,5,2,73.1,5,neutral,1.4,1.4
Pindolol,13523-86-9,CC(C)NCC(O)COc1cccc2[nH]ccc12,1.2,7.7,0.58,2.6,2.2,"Lavene D, Weiss YA, Safar ME, Loria Y, Agorus H, Georges D, and Milliez PL (1977) Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.  J. Clin. Pharmacol. 17: 501-508.  Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists. Br. J. Clin. pharmacol. 11: 119P-120P. ",VDss calcualted from reported micro rate constants.,,1966,248.32,4,3,57.3,6,cationic,1.8,0.05
Pinocembrin,480-39-7,c1ccc([C@H]2Oc3cc(O)cc(c3C(C2)=O)O)cc1,0.8,27,,0.47,0.7,"Determination of pinocembrin in human plasma by solid-phase extraction and LC/MS/MS: application to pharmacokinetic studies Bei Yan, Guoying Cao, Taohua Sun, Xi Zhao, Xin Hu, Jiling Yan, Yueying Peng, Aixin Shi, Yang Li, Wei Xue, Min Lia, Kexin Li*and Yingfa Liu*. Biomedical Chromatography, April 2014. (wileyonlinelibrary.com) DOI 10.1002/bmc.3186.","Digitized from plot reported. 30 minutes infusion, 20 mg, N=8, 70 kg average weight assumed.data in very good agreement with reported values in table.",,1928,256.25,4,2,66.8,1,neutral,2.5,2.3
Pipecuronium,68399-58-6,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(=O)C)N5CC[N+](C)(C)CC5)[C@@]2(C)C[C@@H]1N6CC[N+](C)(C)CC6,0.35,3,0.98,1.9,1.9,"D'Honneur G, Khalil M, Dominique C, Haberer JP, Kleef UW, and Duvaldestin P (1993) Pharmacokinetics and pharmacodynamics of pipercuronium in patients with cirrhosis.  Anesth. Analg. 77: 1203-1206.  Szeleczky G, Ronai-Lukacs S, and Vereczkey L (1984) Protein-binding of pipecuronium bromide (Arduan) in human plasma.  Stud. Org. Chem.  18: 251-254.",,,1980,602.89,8,0,59.1,6,neutral,-2.1,-2.1
Pipemidic acid,51940-44-4,c12c(c(c(C(O)=O)cn1CC)=O)cnc(n2)N1CCNCC1,0.88,2.84,0.7,5.15,3.69,"R. CADORNIGA, S. NEGRO, I. MOLINA, J. A. GUTIERREZ. Estudio farmacocinetico del acido pipemidico trihidrato despues de su administracion en perfusion. An. Real Acad. Farm. 1987,53: 585-595//ppb: Shimizu M, Nakamura S, Takase Y, Kurobe N. Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother. 1975, 7,441-446.","N=5, 67 kg average weight, 300 mg dose 20' infusion.",,1974,303.32,8,2,100.3,3,zwitterionic,0.63,-1.9
Piperacillin,61477-96-1,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O)c4ccccc4)C(=O)C1=O,0.27,4,0.5,1.1,0.96,"De Schepper PJ, Tjandramaga TB, Mullie A, Verbesselt R, van Hecken A, Verberckmoes R, and Verbist L (1982) Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure.  J. Antimic. Chemother. 9(Suppl B) 49-57. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, and Verbist L (1978) Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.  Antimic. Agents Chemother. 14: 829-837.   Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.",,,1977,517.55,12,3,156.4,6,anionic,0.84,-2.5
Piperphentonamine,712260-52-1,Oc1ccc(cc1)/C=C/C(=O)CCN(C)CCc2ccc3OCOc3c2,2.13,713,,0.05,0.1," Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteersFull Text By Shi, Aixin; Hu, Xin; Li, Kexin; Li, Jian; Han, Liping; Wan, Huayin; Li, Rubing 
Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2012), 908, 87-93",Data digitized from figure 3 (plot)  N=9 (assumed from study design 27 subject for 3 doses). 0.6 mg/kg dose digitized (0.2 and 0.4 mg/kg available). 10 minutes bolus treated as infusion due to time of sampling (40 min total). 5 minutes time point not reported in plot but assumed to be 93.2 ng/mL as reported Cmax (see table).  Reported AUC0-t 767.4 ng/mL min. t1/2 reported as 5.6 minutes. Clearance reported as 1 L.kg-1.min-1 which is quite different from calculated. Error found to be quite high for all parameters.,,1991,353.41,5,1,59,8,cationic,3.4,2.4
Pirarubicin,72496-41-4,N[C@@H]1[C@@H]([C@@H](O[C@H](O[C@@H]2c3c(O)c4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C[C@@](C2)(O)C(CO)=O)C1)C)O[C@@H]1CCCCO1,43.2,57.7,,12.5,11.1,"Dominique Marchiset-Leca,  Francois-Ren, Leca Anne Galeani, Alex Noble, Jacques Catalin Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics Cancer Chemother Pharmacol (1995) 36:239 243, 1995","Essentially a prodrug of doxorubicin. 80 courses of therapy over 27 patients. 1.73 m2/70 kg used as conversion factor. 25 to 50 mg/m2 in an average of 10 min infusion (5-15 min). Also, Nagasawa et al, J. Pharmacobio-Dynam., 1991, 14, 422-430. Data in 10 pediatric patients in agreement with cited paper.",Based on ratio of metabolites and parent in plasma. No excretion data available.,1978,627.64,13,5,204.3,7,zwitterionic,1.7,1.3
Pirenzepine,28797-61-7,N1(c2c(NC(c3c1cccc3)=O)cccn2)C(CN1CCN(C)CC1)=O,1.71,2.77,,10.3,11.1,"Krakamp B, Tanswell P, Vogel H, Bosler G (1989). Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction. Eur. J. Clin. Pharmacol. 36, 75-78.","N=13, normal volunteers (M/F), 65 kg average weight. Data generated after 9th dose at 8 am on day 5 (previous doses at 8 am and 8 pm for 4 days).",,1970,351.4,7,1,68.8,2,cationic,1.3,0.93
Piretanide,55837-27-9,NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc3ccccc3)C(=O)O,0.17,3.1,0.058,0.91,1.3,"Trenk D, Wagner F, Jaehnchen E, Spahn H, and Mutschler E (1987) Pharmacokinetics and bioavailability of piretanide in healthy volunteers following intramuscular administration. Arz.Forsch. 37: 1382-1385.  Elliott HL, Ansari AF, Campbell BC, and Lawrence JR (1982) Protein binding of piretanide in normal and uremic serum.  Eur. J. Clin. Pharmacol. 21: 311-313. ",,,1975,362.4,7,2,109.9,5,anionic,2.8,0.078
Piritramide,302-41-0,NC(=O)C1(CCN(CCC(C#N)(c2ccccc2)c3ccccc3)CC1)N4CCCCC4,4.7,7.8,0.061,10,8,"Keitzmann D, Briede I, Bouillon T, Gundert-Remy U, and Kettler D (1996) Pharmacokinetics of piritramide after and intravenous bolus in surgical patients.  Acta Anaesthesiol. Scand.  40: 898-903.",,,1961,430.59,5,1,73.4,8,cationic,3.9,3.2
Pirmenol,68252-19-7,C[C@@H]1CCC[C@H](C)N1CCCC(O)(c2ccccc2)c3ccccn3,1.4,1.8,0.13,13,8.4,"Hammill SC, Shand DG, Routledge PA. Hindman MC, Baker JT, and Pritchett ELC (1982) Pirmenol, a new antiarrhythmic agent:  initial study of efficacy, safety and pharmacokinetics.  Circulation 65: 369-375,  ",VDss calculated from reported rate microcnstants.,,1978,338.49,3,1,36.4,6,cationic,4.2,2.1
Piroximone,84490-12-0,c1(c([nH]c([nH]1)=O)CC)C(c1ccncc1)=O,0.65,9.03,,1.2,1.32,"J. P. FAUVEL, N. BERNARD, M. LAVILLE, N. POZET, J. SASSARD, P. Y. ZECH. Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency. Br J clin Pharmac 1995; 39: 187-189.","0.5 mg administered over 10'. 70 kg average weight assumed, 7 healthy subjects.",,1982,217.22,5,2,78.6,3,neutral,0.041,0.041
Pitavastatin,147511-69-1,c12ccccc1c(c(c(n2)C1CC1)\C=C\[C@H](C[C@H](CC(=O)O)O)O)c1ccc(cc1)F,0.9,5.85,0.005,2.7,4.6,Pitavastatin Calcium - FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 022363/S-000 Part 01. Accessed via Pharmapendium.,"Followed as acid. VDss from MRT and clearance. Vd reported as 148.1 L. N=18, 2 mg dose, 70 kg weight assumed.",,1997,421.46,5,3,90.6,8,anionic,3.9,0.54
Pixantrone,144510-96-3,c1nccc2C(c3c(C(c12)=O)c(ccc3NCCN)NCCN)=O,10.1,17.7,,8.9,13.4,"A Phase I and Pharmacokinetic Study of the Novel Aza-Anthracenedione Compound BBR 2778 in Patients with Advanced Solid Malignancies. Sandrine Faivre, Eric Raymond,1 Valerie Boige, Michel Gatineau, Xavier Buthaut, Olivier Rixe, Alberto Bernareggi, Gabriella Camboni, and Jean-Pierre Armand. Clin Cancer Res 2001;7:43-50","BBR2278. Weighted average of doses: 25 mg/m2 (N=6), 37.5 mg/m2 (N=1),  75 mg/m2 (N=1), 112.5 mg/m2 (N=3), 150 mg/m2 (N=2)",,1992,325.37,7,4,123.1,6,cationic,-0.21,-2.4
PK11195,85532-75-8,c1(nc(cc2ccccc12)C(=O)N([C@@H](CC)C)C)c1c(cccc1)Cl,1.7,5.9,,5.4,3.7,"A. FERRY, P. JAILLON, B. LECOCQ, V. LECOCQ and C. JOZEFCZAK. PHARMACOKINETICS AND EFFECTS ON EXERCISE HEART RATE
OF PK 11195 (52028 RP), AN ANTAGONIST OF PERIPHERAL BENZODIAZEPINE RECEPTORS, IN HEALTHY VOLUNTEERS. Fundam. Clin. Pharmacol., 3 (1989) 383-392","10 mg dose, N=10, 71 kg average weight.",,1983,352.86,3,0,33.2,4,neutral,5.4,5.4
Plazomicin,1154757-24-0,O([C@@H]([C@H](NC([C@H](CCN)O)=O)C1)[C@@H](O)[C@@H]([C@H]1N)O[C@@]1([C@H](N)CC=C(O1)CNCCO)[H])[C@]([C@H](O)[C@@H](NC)[C@@]1(C)O)(OC1)[H],0.22,1.14,0.84,3.2,3.4,"Robert T. Cass, Carter D. Brooks,Nancy A. Havrilla, Kenneth J. Tack, Marie T. Borin, Don Young, and Jon B. Bruss. Pharmacokinetics and Safety of Single and Multiple Doses of ACHN-490 Injection Administered Intravenously in Healthy Subjects. Antimicr. Agents Chemother. 2011, 55, 5874-5880.",ACHN-490. renal clearance 0.97 mL/min/kg. Doses from 1 mg/kg to 15 mg/kg across single dose or multiple dose on day 1 weighted average. 51 determinations (doses and subjects). Very low variation.,,2009,592.68,16,11,269.3,13,cationic,-6.3,-9
Plinabulin,714272-27-2,c1(=C\c2c([nH]cn2)C(C)(C)C)\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,3,7.4,,6.7,6.3,"Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas. Monica M. Mita, Matthew A. Spear, Lorrin K. Yee, Alain C. Mita, Elisabeth I. Heath,Kyriakos P. Papadopoulos, Kristine C. Federico, Steven D. Reich, Ofelia Romero,Lisa Malburg, MaryJo Pilat, G. Kenneth Lloyd, Saskia T.C. Neuteboom, Gillian Cropp,
Edward Ashton, and Patricia M. LoRusso. Clin Cancer Res 2010;16:5892-5899",NPI-2358. Data extracted from paper. 208 L (VD) and 31 L/h as mean values in text. MRT VD/Cl. 70 kg average weight assumed. Several cohorts of patients. Abstract reported in J. Clin. Oncol. 26: 2008(May 20 suppl. Abstract 3525). In abstract VDss 214 L; 37.3 L/h. Doses in full paper from 2 to 30 mg/m2. Linearity observed.,,2004,336.39,6,3,94.4,2,anionic,2.4,-2.8
Plitidepsin,137219-37-5,CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(=O)C)[C@@H](C)OC(=O)[C@H](Cc3ccc(OC)cc3)N(C)C(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@@H](OC(=O)C[C@@H]1O)C(C)C,6.95,8.05,,14.48,16.65,"Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 3105-12.","Dosed iv from 0.266 mg.mg-2.wk-1 to 3.6 mg.m-2.wk-1, and weight-averaged. DATA IN PLASMA ONLY. 70 kg average weight assumed.",,1991,1110.34,22,4,284.7,15,neutral,3.3,3.3
PNU-145156E,154788-16-6,Cn1cc(NC(=O)Nc2cc(C(=O)Nc3cc(C(=O)Nc4ccc5cc(cc(c5c4)S(=O)(=O)O)S(=O)(=O)O)n(C)c3)n(C)c2)cc1C(=O)Nc6cc(C(=O)Nc7ccc8cc(cc(c8c7)S(=O)(=O)O)S(=O)(=O)O)n(C)c6,0.27,0.0047,,960,730,"Groen HJM, deVries EGE, Wynendaele W, van der Graaf WTA, Fokkema W, Lechuga MJ, Poggesi T, Dirix LY, and van Oosterom AT (2001) PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.  Clin. Canc. Res.  7: 3928-3933.",VDss calculated from digitized plot of 200 mg/m2 dose.,,1994,1121.12,27,10,394.7,14,neutral,-2,-9
Ponesimod,854107-55-4,CCC/N=C\1/N(C(=O)/C(=C/c2ccc(c(c2)Cl)OC[C@@H](CO)O)/S1)c3ccccc3C,2.28,0.9,,42.6,32.9,"Margaux Boehler, Pierre-Eric Juif, Matthias Hoch, Jasper Dingemanse. Absolute Bioavailability of Ponesimod, a Selective S1P1 Receptor Modulator, in Healthy Male Subjects. Eur J Drug Metab Pharmacokinet. Published ahead of print. Online: February 16 2016. doi:10.1007/s13318-016-0325-6","5 mg iv dose via 3h infusion, N=14, 70 kg average weight assumed. All healthy male volunteers.  Absolute BA (10 mg po dose) 83.8 %.",,2005,460.97,6,2,82.4,8,cationic,4.4,4
Posaconazole,171228-49-2,c1c(n2c(n([C@@H](CC)[C@@H](O)C)nc2)=O)ccc(N2CCN(c3ccc(OC[C@@H]4C[C@](OC4)(Cn4cncn4)c4c(cc(cc4)F)F)cc3)CC2)c1,3.8,4.3,0.013,14.5,10.6,"Johan Maertens, Oliver A. Cornely, Andrew J. Ullmann, Werner J. Heinz, Gopal Krishna, Hernando Patino, Maria Caceres, Nicholas Kartsonis, Hetty Waskin, Michael N. Robertson. Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease. Antimicrobial Agents and Chemotherapy, 2014, 58, 3610-3617. ppb: Anders Lignell,Elisabeth Löwdin, Otto Cars, Erja Chryssanthou, and Jan Sjölin. Posaconazole in Human Serum: a Greater Pharmacodynamic Effect than Predicted by the Non-Protein-Bound Serum Concentration. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55, 3099–3104. ","Data digitized from plot reported. 200 mg cohort 1, N=20, 77.1 kg reported bw. AUC extrapolated ~ 46% but 24 hours profile (Day 14 at 24 hours bid) shows a similar terminal phase.",,1995,700.78,12,1,115.7,12,neutral,4.6,4.6
PR-104,851627-62-8,N(CCO[S](C)(=O)=O)(CC[Br])C(=C(C(NCCO[P](=O)(O)O)=O)C=C1N(=O)=O)C(N(=O)=O)=C1,0.86,44.8,,0.32,0.1,"A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients Mark J McKeage, Yongchuan Gu, William R Wilson, Andrew Hill, Karen Amies, Teresa J Melink and Michael B Jameson. BMC Cancer 2011, 11:432.",Phosphate pre-prodrug. Weighted average across 135-900  mg/m2 doses. N= 25 total patients. 1hr intravenous infusion of day 1 of cycle 1. MRT calculated from VDss and clearance averages.,,2005,579.27,16,3,234.1,14,anionic,0.27,-4.6
Practolol,6673-35-4,c1(ccc(NC(C)=O)cc1)OC[C@@H](CNC(C)C)O,,2.28,0.93,,12.2,"Tjandramaga TB, Altered Pharmacokinetics of beta-Adrenoreceptor Blocking Drugs in Patients with Renal Insuffency. Archives Internationales de Pharmacodynamie et de Therapie 1980, Suppl., Pages 38-53. ppb: reported by Henry JA, Mitchell, SN. Effect of pH on human plasma protein binding of a series of β-adrenoceptor antagonists. British Journal of Clinical Pharmacology  1981 11(1):119-120P",CL and T1/2 from Table III (N=7 dose 160 mg). BW assumed to be 70 kg. Fig. 3 to be digitized to confirm reported values,Renal > 90% (renal clearance and other properties are available for other beta-adrenergic),1966,266.34,5,3,70.6,7,cationic,0.95,-0.84
Pralatrexate (R),1320211-70-8,C#CC[C@H](Cc1cnc2c(n1)c(nc(n2)N)N)c3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,0.53,2.7,0.33,3.2,15,"Shakun M. Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghui Tang, W. David McGuinn, Jr.,S. Leigh Verbois, Anshu Marathe, Gene M. Williams, Julie Bullock, Christoffer Tornoe, Sue Ching Lin,Terrance Ocheltree, Milinda Vialpando, Alice Kacuba, Robert Justice, and Richard Pazdur.Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary Clin Cancer Res 2010, 16, 4921-4927",t1/2 as median of range (12 - 18 h) for both diastereoisomers (value for each diastereoisomer not reported) MRT calculated from VDss and CL ,,2011,477.47,12,5,207.3,11,anionic,0.35,-6
Pralatrexate (S),1320211-69-5,C#CC[C@@H](Cc1cnc2c(n1)c(nc(n2)N)N)c3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,1.5,6,0.33,4.2,15,"Shakun M. Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghui Tang, W. David McGuinn, Jr.,S. Leigh Verbois, Anshu Marathe, Gene M. Williams, Julie Bullock, Christoffer Tornoe, Sue Ching Lin,Terrance Ocheltree, Milinda Vialpando, Alice Kacuba, Robert Justice, and Richard Pazdur.Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary Clin Cancer Res 2010, 16, 4921-4927",t1/2 as median of range (12 - 18 h) for both diastereoisomers (value for each diastereoisomer not reported) MRT calculated from VDss and CL. ,,2011,477.47,12,5,207.3,11,anionic,0.35,-6
Pralidoxime,51-15-0,c1([n+](cccc1)C)\C=N\O,0.8,9,1,1.5,1.4,"Toxogonin and Pralidoxime: Kinetic Comparison after Intravenous Administration to Man FREDERICK R. SIDELL’, WILLIAM A. GROFF, and ANDRIS KAMINSKIS. J. Pharm. Sci. 1972, 61, 1765-1769. ppb: The PDR states: Pralidoxime chloride is not bound to plasma protein. Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=33217#section-3","Average of pralidoxime methansulfonate and chloride. N=6 total (3+3), all 5 mg/kg dose. Average weight 80 kg.",,1955,137.16,3,1,36.5,1,neutral,-3.2,-3.4
Pramipexole,104632-26-0,c12c(C[C@H](CC2)NCCC)sc(n1)N,7,7.2,0.85,16.1,12.4,Pramipexole Dihydrochloride - FDA Approval Package Pharmacology Review 020667/S-000 Part 07. Accessed through Pharmapendium. Ppb: The PDR states: It is about 15% bound to plasma proteins. Pramipexole distributes into red blood cells as indicated by an erythrocyte-to-plasma ratio of approximately 2. http://www.pdr3d.com/detail.php?c=123930#section-19. Accessed January 2 2015.,VDss from MRT and clearance. 70 kg assumed. 0.1 mg iv dose. N=6.,82% of dose excreted in urine after iv administration,1986,211.33,3,2,50.9,3,cationic,1.6,-0.51
Pramlintide,151126-32-8,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O,0.41,15.3,0.4,0.5,0.6,"Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro-amylin, Human) after intravenous bolus and infusion doses in patients with insuline-dependent diabetes. W. A. Colburn, Gottlieb, AB, Koda J., Koltermann, OG. J. Clin. Pharmacol. 1996, 36, 13-24. ppb: The PDR states: SYMLIN does not extensively bind to red blood cells or albumin (approximately 40% of the drug is unbound in plasma). Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=133005#section-14","AC-137, Triproamylin, Symlin.  N=24, avg weight 76.5 kg. Dose range 30-300 ug iv bolus and 30-300 ug 2 hr infusion 
Data from two-compartment constants in Table II (ug/mL corrected units have been used)",,1993,3951.41,104,56,1690.6,122,cationic,-9,-9
Pravastatin ,81093-37-0,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H]12,0.46,14,0.5,0.59,0.78,"Singhvi SM, Pan HY, Morrison RA, and Willard DA (1990) Dispositon of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.  Br. J. Clin. Pharmacol. 29: 239-243.  Quion JA and Jones PH (1994) Clinical pharmacokinetics of pravastatin.  Clin. Pharmacokinet. 27: 94-103.",,,1981,424.53,7,4,124.3,11,anionic,2.3,-0.54
Prazosin,19216-56-9,COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)c4occc4,0.73,4.7,0.06,2.6,2,"Meredith PA, Elliott HL, Kelman AW, and Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoreceptor agonists in normotensive volunteers.  J. Cardiovasc. Pharmacol. 7: 532-537.  Vanholder R, Van Landschoot N, De Smet R, Schoots A, and Ringoir S (1988) Drug protein binding in chronic renal failure: evaluation of nine drugs.  Kidney Int. 33: 996-1004.",,,1969,383.4,9,1,107.2,4,neutral,1.5,1.5
Prednisolone,50-24-8,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,0.86,2.9,0.25,4.8,3.4,"Rose JQ, Yurchak AM, Meikle AW, and Jusko WJ (1981) Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.  J. Pharmacokinet. Biopharm. 9: 1-14.",Note: prednisolone demonstrates complex dose-dependent PK (Frey BM and Fey FJ (1990) Clinical pharmacokinetics of prednisone and prednisolone.  Clin. Pharmacokinet. 19: 126-146.,,1953,360.44,5,3,94.8,2,neutral,1.7,1.6
Prednisone,53-03-2,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,0.57,2.5,0.27,3.8,2.9,"Georgitis JW, Flesher KA, and Szefler SJ (1982) Bioavailability assessment of a liquid prednisone preparation.  J. Allerg. Clin. Immunol. 70: 243-247.  Ferry JJ and Wagner JG (1987) The nonlinear pharmacokinetics of prednisone and prednisolone. II. Plasma protein binding of prednisone and prednsolone in rabbit and human plasma.  Biopharm. Drug Dispos. 8: 261-272.",Calculated parameters from C vs t data provided in the reference.,,1948,358.43,5,2,91.7,2,neutral,1.4,1.4
Prenalterol,57526-81-5,c1(ccc(O)cc1)OC[C@H](CNC(C)C)O,4.28,22.1,,3.23,2.85,"Clarke, A. F.; Jack, D. B.; Kendall, M. J.; Smith, S. R.  The pharmacokinetics of oral and intravenous prenalterol in young, healthy volunteers.    Biopharmaceutics & Drug Disposition  (1986),  7(1),  47-52.  ",5 mg dose. Data digitized. 71.3 kg reported average weight. N=10. ratio AUC digit/rep = 1.13,,1975,225.28,4,3,61.7,6,cationic,1.2,-0.55
Prexasertib,1234015-52-1,COc1cccc(OCCCN)c1c2cc(Nc3cnc(cn3)C#N)n[nH]2,22.75,34,,11.15,12.54,"David Hong, Jeffrey Infante, Filip Janku, Suzanne Jones, Ly M. Nguyen, Howard Burris, Aung Naing, Todd M. Bauer, Sarina Piha-Paul, Faye M. Johnson, Razelle Kurzrock, Lisa Golden, Scott Hynes, Ji Lin, Aimee Bence Lin, and Johanna Bendell. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol 2016, 34, 1764-1771.","LY2606368. Weighted average of schedule 1, cycle 1 day 1 (N=3 40 mg/m2) and schedule 2, cycle 1 day 1 (N=4 105 mg/m2). Other doses did not report a full PK profile sampling from plot. 70 kg average weight assumed. MRT from VDss and clearance.",,2010,365.39,9,3,134.8,9,cationic,1.7,-0.99
Prifinium bromide,10236-81-4,C(=C1\[C@@H]([N+](CC)(CC)CC1)C)(\c1ccccc1)c1ccccc1,1.87,12.5,,2.5,2.13,"Noguchi, H.; Tokuma, Y.; Tamura, Y. Pharmacokinetics of prifinium bromide in healthy volunteers. International Journal of Clinical Pharmacology, Therapy and Toxicology (1983), 21(5), 213-217.","CAS number and structure referring to cation NOT salt. Dose 7.5 mg, N=6, 2-min injection. CLrenal (mL/min/kg) = 5.8. Matrix = serum",,1965,306.46,1,0,0,4,neutral,2.3,2.3
Prilocaine,721-50-6,CCCNC(C)C(=O)Nc1ccccc1C,3.7,29,0.72,2.2,1.8,"van der Meer AD, Blum AGL, Stienstra R, van Kleef JW, Vletter AA, and Olieman W (1999) Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity.  Aneasthesiol. 90: 988-992.",Data for individual stereoisomers were averaged.,,1946,220.31,3,2,41.1,5,cationic,2,1.2
Primaquine,90-34-6,COc1cc(NC(C)CCCN)c2ncccc2c1,4,5.8,,11,7.1,"Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme MLE, and Breckenrodge AM (1985) Pharmacokinetics of primaquine in man.  I.  Studies of the absolute bioavailability and effects of dose size.  Br. J. Clin. Pharmacol.  19: 745-750.",VDss calculated from digitized C vs t plot.,,1946,259.35,4,2,60.2,6,cationic,2.7,-0.07
Probenecid,57-66-9,CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(=O)O,0.13,0.25,0.13,8.7,5.9,"Kartzinel R, Ebert MH, and Chase TN (1976) Intravenous probenecid loading.  Effect on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid.  Neurology 26: 992-996.  Emanuelsson BM, Beermann B, and Paalzow LK (1987) Non-linear elimination and protein binding of probenecid.  Eur. J. Clin. Pharmacol. 32: 395-401.",Parameters were determined using C vs t data obtained by digitization of the plot provided in the reference.  Protein binding is saturable; the value at half maximum is reported.,,1950,285.36,5,1,74.7,7,anionic,3.3,-0.017
Procainamide,51-06-9,CCN(CC)CCNC(=O)c1ccc(N)cc1,2.2,10,0.84,3.7,3.1,"Christoff PB, Conti DR, Naylor C, and Jusko WJ (1983) Procainamide disposition in obesity.  Drug Intell. Clin. Pharm. 17: 516-522.  Reidenberg MM, Drayer DE, Levy M, and Warner H (1975) Polymorphic acetylation of procainamide in man.  Clin. Pharmacol. Ther. 17: 722-730",,,1950,235.33,4,2,58.4,6,cationic,1.2,-0.39
Prochlorperazine,58-38-8,CN1CCN(CCCN2c3ccccc3Sc4ccc(Cl)cc24)CC1,22,16,,23,9,Taylor WB and Bateman DN (1987) Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers.  Br. J. Clin. Pharmacol. 23: 137-142. ,VDss was determined using C vs t data obtained by digitization of the plot provided in the reference.,,1957,373.94,3,0,9.7,4,cationic,5,3.7
Procyclidine,77-37-2,OC(CCN1CCCC1)(C2CCCCC2)c3ccccc3,0.74,0.86,,14,12,"Whiteman PD, Fowle ASE, Hamilton MJ, Peck AW, Bye A, dean K, and Webster A (1985) Pharmacokinetics and pharmacodynamics of procyclidine in man.  Eur. J. Clin. Pharmacol. 28: 73-78.",VDss calculated from digitized C vs t plot.,,1951,287.44,2,1,23.5,5,cationic,4.2,2.2
Promazine,58-40-2,CN(C)CCCN1c2ccccc2Sc3ccccc13,8.1,14,0.11,9.6,7.9,"Koytchev R, Alken RG, Kirkov V, Neshev G, Vagaday M, and Kunter U (1994) Absolute bioverfugbarkeit von chlorpromazin, promazin, und promethazin.  Arz. Forsch. 44: 121-125.  Hu OYP and Curry SH (1989) Stability, human blood distribution and rat tissue localization of promazine and desmonomethylpromazine.  Biopharm. Drug Dispos. 10: 537-548.",,,1947,284.42,2,0,6.5,4,cationic,4.4,2.8
Promethazine,60-87-7,CC(CN1c2ccccc2Sc3ccccc13)N(C)C,14,14,0.09,17,14,"Koytchev R, Alken RG, Kirkov V, Neshev G, Vagaday M, and Kunter U (1994) Absolute bioverfugbarkeit von chlorpromazin, promazin, und promethazin.  Arz. Forsch. 44: 121-125.  Quinn J and Calvert R (1976) The disposition of promethazine in man.  J. Pharm. Pharmacol. 28(Suppl.)  59P.  Hu OYP and Curry SH (1989) Stability, human blood distribution and rat tissue localization of promazine and desmonomethylpromazine.  Biopharm. Drug Dispos. 10: 537-548.  Taylor G, Houston JB, Shaffer J, and Mawer G (1983) Pharmacokinetics of promethazine and its sulfoxide metabolite after intravenous and oral administration to man.  Br. J. Clin. Pharmacol. 15: 287-293.",,,1946,284.42,2,0,6.5,3,cationic,4.2,2.4
Propafenone,54063-53-5,CCCNCC(O)COc1ccccc1C(=O)CCc2ccccc2,2.2,16,0.038,2.2,2.1,"Arboix M, Puigdemont A, Moya A, and Cinca J (1985) Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia.  Meth. Find. Exptl. Clin. Pharmacol. 7: 436-438.  Hollmann M, Brode E, Hotz D, Kaumeier S, and Kerhahn OH (1983) Investigations on the pharmacokinetics of propafenone in man.  Arzn. Forsch. 33: 763-770.  Chan GLY, Axelson JE, Price JDE, McErlane KM, and Kerr CR (1989) In vitro protein binding of propafenone in normal and uremic human sera.  Eur. J. Clin. Pharmacol. 36: 495-499.  Tonn GR, Kerr CR, and Axelson JE (1992) In vitro protein binding of propafenone and 5-hydroxypropafenone in serum, in solutions of isolated serum proteins, and to red blood cells. J. Pharm. Sci. 81: 1098-1103.","VDss calculated from analysis of the C vs t data provided in the reference by Arboix, et al and Hollmann et al..",,1961,341.44,4,2,58.6,11,cationic,3.3,1.5
Propionyl-L-carnitine,20064-19-1,CCC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,0.3,2.33,,2.15,1.28,"S. Pace, A. Longo,S. Toon, P. Rolan, A. M. Evans. Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. Br J Clin Pharmacol, 2000 50, 441-448.",Data digitized from plot. 1 g dose. 70 kg assumed as average weight. Very linear AUC. N=4,,1968,217.26,5,0,66.4,7,anionic,-3.7,-3.1
Propiverine,60569-19-9,c1(ccccc1)C(C(=O)OC1CCN(CC1)C)(OCCC)c1ccccc1,2.73,2.94,0.1,15.4,15.2,"May, Karen; Giessmann, Thomas; Wegner, Danilo; Oertel, Reinhard; Modess, Christiane; Oswald, Stefan; Braeter, Manfred; Siegmund, Werner (2008) Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination. European Journal of Clinical Pharmacology Volume 64 Issue 11 Pages 1085-1092.//ppb: Meisel, P.; Langner, Steffi; Siegmund W . In-​vitro binding of propiverine hydrochloride and some of its metabolites to serum albumin in man. J. Pharm. Pharmacol., 1997, 49, 270-272.","N=10 subjects, 15 mg iv dose, 70-kg average weight assumed.",,1976,367.48,4,0,38.8,8,cationic,4.7,3.1
Propofol,2078-54-8,CC(C)c1cccc(C(C)C)c1O,4.7,36,0.016,2.2,3.2,"Ibrahim A, Park S, Feldman J, Karim A, and Kharasch ED (2002) Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol.  Anesthesiology 96: 88-95.  Servin F, Desmonts JM, Haberer JP, Cockshott ID, Plummer GF, and Farinotti R (1988) Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology 69: 887-891.  Shafer A, Doze VA, Shafer SL, and White PF (1988) Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia.  Anesthesiology 69: 348-356.  Costela JL, Jimenez R, Calvo R, Suarez E, and Carlos R (1996) Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis.  Acta Anaesth. Scand. 40: 741-745.",,,1979,178.27,1,1,20.2,2,neutral,4.2,4.2
Propoxyphene,469-62-5,CCC(=O)O[C@@](Cc1ccccc1)([C@H](C)CN(C)C)c2ccccc2,12,15,0.24,13,18,"Gram LF, Schmidt K, Christensen FN, and Schou J (1984) D-Propoxyphene kinetics in man: significance of a deep third compartment.  Eur. J. Clin. Pharmacol. 26: 749-752.  Giacomini KM, Gibson TP, and Levy G (1978) Plasma protein binding of d-propoxyphene in normal subjects and anephric patients.  J. Clin. Pharmacol. 18: 106-109.",VDss calculated from exponential three-compartment coefficients reported in the reference.,,1955,339.47,3,0,29.5,9,cationic,4.1,3.3
Propranolol,525-66-6,CC(C)NCC(O)COc1cccc2ccccc12,3.1,12,0.13,4.3,3.4,"Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.  Br. J. Clin. Pharmacol. 11: 119P-120P.  Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers.  Br. J. Clin. Pharmacol. 43: 563-570. ",,,1964,259.34,3,2,41.5,6,cationic,2.7,0.93
Propylthiouracil,51-52-5,CCCC1=CC(=O)NC(=S)N1,0.34,3.1,0.18,1.8,1.3,"Kampmann J and Skovsted L (1974) Pharmacokinetics of propylthiouracil.  Acta Pharmacol. Toxicol. 35: 361-369.   Giles HG, Roberts EA, Orrego H, and Sellers EM (1981) Disposition of intravenous propylthiouracil. J. Clin. Pharmacol. 21: 466-471.",VDss calculated from reported rate microconstants.,,1946,170.23,3,2,41.1,2,neutral,1.2,1.2
Proquazone,22760-18-5,c12c(n(c(=O)nc1c1ccccc1)C(C)C)cc(C)cc2,0.52,9.45,0.02,0.92,1.27,"PETER H. HINDERLING and ANDRÉ ROOS. Pharmacokinetics of the Antirheumatic Proquazone in Healthy Humans. J. Pharm. Sci. 1984, 73, 332-340. //ppb:  Roos, Andre; Hinderling, Peter H. Protein binding and erythrocyte partitioning of the antirheumatic proquazone.  J. Pharm. Sci. 1981, 70, 252-257.","N=5, 75.2 kg average weight, data averaged across two doses (75 and 122 mg) reported in table I. MRT from VDss and clearance. Dosed in 40% human sterile albumine solution.",,1969,278.35,3,0,34.9,2,neutral,3.8,3.8
Proxyphyllin,603-00-9,CC(Cn1cnc2c1c(=O)n(c(=O)n2C)C)O,0.59,1.17,,8.39,7.8,"M. Kalla, O. Richter, D. Reinhardt. Pharmacokinetics and pharmacodynamics of proxyphylline in asthmatic children. Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde. 1985, 133, 520-526.","Oxypropyltheophylline. N=5, 2 children (9 and 11) and three young adults. 8.3 mg/kg dose. Data calculated from average of alpha (4.93 h-1), beta (0.113 h-1) macroconstants and intercepts (A= 18.36 mg/L and B = 11.56 mg/L) reported for each of the subjects. No AUC or clearance reported for iv leg with a VD for po leg of 0.6 L/kg (likely to be completely bioavailable). Data accepted on the basis of available two compartment macroconstant available. 8.3 mg/kg dose. VDss from clearance and MRT.",,1954,238.24,7,1,82.1,2,neutral,-0.044,-0.044
Prucalopride,179474-81-8,COCCCN1CCC(CC1)NC(=O)c2cc(c(c3c2OCC3)N)Cl,8.73,4.55,0.7,32.16,22.5,"Vera J. Van de Velde, Jannie Ausma, Lieve Vandeplassche. I.V. Kinetics and Absolute Oral Bioavailability of Prucalopride. Gastroenterol. 2010,  138, (5), Supplement 1, Page S-230. doi: http://dx.doi.org/10.1016/S0016-5085(10)61047-5","Abstract only. Non compartmental analysis after a 2 mg dose. 5M/8F. 70 kg average weight assumed. MRT from clearance and VDss reported.//See also:  Jan Tac, Maura Corsetti. Expert Opin. Drug Metab. Toxicol. (2012) 8(10), 1327-1335. Reported (ref. 21) as being excreted 60-70% intact in urine.//// fu value extracted from tac and Corsetti review. Cited as ref. 20 in that review.",,1996,367.87,6,2,76.8,6,cationic,2.5,1.3
Pseudohypericin,55954-61-5,Cc1cc(O)c2C(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6C(=O)c7c(O)cc(CO)c8c1c2c(c34)c(c56)c78,0.56,0.62,,15,20,"Kerb R, Brockmuller J, Staffeldt B, Ploch M, and Roots I (1996) Single dose and steady-state pharmacokinetics of hypericin and pseudohypericin.  Antimic. Agents Chemother.  40: 2087-2093.",,,1953,520.44,9,7,175.7,1,anionic,4,0.59
"Pyrazine, 2-diazohydroxide",103829-56-7,N(Nc1nccnc1)=O,0.31,15.13,,0.29,0.38,"Supko J, Balcerzak S P, Kraut E H. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Cancer Res. 1993, 53, 4843-4849.","Data averaged across 5 doses and 16 subjects. VDss, clearance and MRT as well as t1/2 reported. 1.73 m2/70 kg conversion factor used.",,1986,124.1,5,1,67.2,2,neutral,0.22,0.22
Pyridostigmine,155-97-5,CN(C)C(=O)Oc1ccc[n+](C)c1,1.1,9.6,1,1.8,1.5,"Aquilonius SM, Eckernaes SA, Hartvig P, Lindstroem B, and Osterman PO (1980) Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur. J. Clin. Pharmacol. 18: 423-428.  Kornfeld P, Samuels AJ, Wolf RL, and Osserman KE (1970) Metabolism of pyridostigmine-14C in myasthenia gravis.  Evidence for multiple metabolites.  Neurology 20: 634-641.",VDss calculated from C vs t data obtained by digitization of plots in the reference.,,1956,181.21,4,0,33.4,2,neutral,-3.7,-3.7
Pyrimethamine,58-14-0,CCc1nc(N)nc(N)c1c2ccc(Cl)cc2,0.43,0.052,0.095,140,140,"Almond DS, Szwandt ISF, Edwards G, Lee MG, and Winstanley PA (2000) Disposition of intravenous pyrimethamine in healthy volunteers.  Antimic. Agents Chemother.  44: 1691-1693.  Cavallito JC, Nichol CA, Brenckman WD, Deangelis RL, Stickney DR, Simmons WS, and Sigel CW (1978) Lipid-soluble inhibitors of dihydrofolate reductase.  I.  Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man.  Drug Metab. Dispos. 6: 329-337.  Rudy AC and Poynor WJ (1990) Binding of pyrimethamine to human plasma proteins and erythrocytes.  Pharm. Res. 7: 1055-1060.",Note: Incorrect calculations in the original paper.,,1951,248.71,4,2,77.8,2,neutral,2.9,2.7
Quercetin,117-39-5,OC1=C(Oc2cc(O)cc(O)c2C1=O)c3ccc(O)c(O)c3,0.12,11,0.009,0.2,0.6,"Ferry DR, Smith A, Malkhandi J, Fyfe DW,DeTakats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. 2: 659-668.  Boulton DW, Walle UK, and Walle T (1998) Extensive binding of the bioflavonoid quercetin to human plasma proteins. J. Pharm. Pharmacol. 50: 243-249.  ",,,1948,302.24,7,5,127.4,1,anionic,2.1,-0.38
Quinacrine,83-89-6,CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc3ccc(OC)cc13,45,5.1,0.13,150,120,"Shannon JA, Earle DP, Brodie BB, Taggart JV, and Berliner RW (1944) The pharmacological basis for the rational use of atabrine in the treatment of malaria.  J. Pharmacol. Exp. Ther. 81: 307-330.",Mepacrine. Pharmacokinetic parameters were calculated from C vs t provided in the reference. ,,1934,399.96,4,1,37.4,9,cationic,6.3,2.8
Quinaprilat,82768-85-2,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2Cc3ccccc3C[C@H]2C(=O)O,0.13,0.93,0.32,2.3,2.3,"Breslin E, Posvar E, Neub M, Trenk D, and Jahnchen E (1996) A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.  J. Clin. Pharmacol. 36: 414-421.  Accuretic Product Label.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1982,410.46,7,3,106.9,8,anionic,1.8,-2.4
Quinidine,56-54-2,COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1,2.9,4,0.26,12,6.6,"Ueda CT, Williamson BJ, and Dzindzio BS (1976) Disposition kinetics of dihydroquinidine following quinidine administration.  Res. Comm. Chem. Path. Pharmacol. 14: 215-225.  Fremstad D, Nilson OG, Stirsein L, Amlie J, and Jacobson S (1979) Pharmacokinetics of quinidine related to protein binding in man.  Eur. J. Clin. Pharmacol. 15: 187-192.  Woo E and Greenblatt DJ (1979) Pharmacokinetic and clinical implications of quinidine protein binding.  J. Pharm. Sci. 68: 465-469.",,,1890,324.42,4,1,45.6,4,cationic,2.9,2.1
Quinine,130-95-0,COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1,1.8,1.9,0.3,16,11,"White NJ, Clinical pharmacokinetics of antimaliria drugs.  Clin. Pharmacokinet.  10: 187-215.  White NJ, Chanthavanich P, Krishna S, Bunch C, and Silamut K (1983) Quinine disposition kinetics.  Br. J. Clin. Pharmacol.  16: 399-403.",VDss calculated from reported rat micro-constants.,,1918,324.42,4,1,45.6,4,cationic,2.9,2.1
Quinupristin,120138-50-3,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]3CC(=O)[C@H](CS[C@@H]4CN5CCC4CC5)CN3C(=O)C(Cc6ccc(cc6)N(C)C)N(C)C(=O)[C@@H]7CCCN7C1=O)c8ccccc8,0.67,16,0.34,0.7,0.87,"Chevalier P, Rey J, Pasquier O, Rouzier-Panis R, Harding N, and Montay G (2001) Multiple-dose pharmacokinetics and safety of two regimens of quinupristine/dalfopristin (Synercid) in healthy volunteers.  J. Clin. Pharmacol. 41: 404-414.  Bergeron M and Montay G (1997) The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.  J. Antimic. Chemother. 39(Supp. A): 129-138.  Bearden DT (2004) Clinical pharmacokinetics of quinupristin/dalfopristin.  Clin. Pharmacokinet. 43: 239-252.",~16% excreated in urine and feces unchanged,,1987,1022.22,19,4,231.2,10,zwitterionic,3,0.59
R 82913,126347-69-1,c1c(cc2[nH]c(n3C[C@@H]([N@@](Cc1c23)C\C=C(\C)C)C)=S)Cl,21.98,10.41,,35.17,25.96,"De Wit S; Hermans P; Sommereijns B; O'Doherty E; Westenborghs R; van de Velde V; Cauwenbergh G F; Clumeck N. Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-​finding study of oral administration compared with intravenous infusion. Antimicr. Agents Chemother. 1992, 36, 2661-2663.","9-Cl-TIBO. TIBO-R 82913. N=5, Day 29 infusion, 1 hr, 100 mg dose. Data digitized from plot. 70 kg average weight assumed. Only AUC0-24 after Day 29 and Day 0 was reported and the AUC 24 after digitization was about ~86% and thus considered acceptable. However, all data were calculated using the calculated AUCinf (2286 ng.hr.mL-1) obtainded from digitization. SOme accumulation observed (Day 0 to Day 29) but limited to 40%.  ",,1990,321.87,3,1,24,2,neutral,5,1.7
Rabeprazole,117976-89-3,COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,0.22,4,0.037,0.92,1,"Setoyama T, Laurent A, Humphries T, and Hasegawa J (2005) Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects.  Int. J. Clin. Pharmacol. Ther. 43:  37-42.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1988,359.44,6,1,77.1,8,neutral,2.1,2.1
Raclopride,84225-95-6,c1(c(c(cc(c1O)Cl)Cl)OC)C(=O)NC[C@H]1N(CCC1)CC,1.1,1.2,0.06,15.3,14,"MOVIN-OSSWALD G. ; NORDSTRÖM A.-L. ; HAMMARLUND-UDENAES M. ; WAHLEN A. ; FARDE L. Pharmacokinetics of raclopride formulations : influence of prolactin and tolerability in healthy male volunteers. Clin. Pharmacokin. 1992, 22, 152-161.",MRT from VDss and clearance. 78 kg average weight reported. 3.6 mg of raclopride tartrate (2.8 mg of free base) admisntered over 10'. N=15.,reported in ref. as extensively metabolized. Very low renal excretion of unchanged drug.,1982,347.24,5,2,61.8,5,zwitterionic,2.9,2.1
Raloxifene,84449-90-1,c1(c(c2ccc(O)cc2)sc2c1ccc(c2)O)C(c1ccc(OCCN2CCCCC2)cc1)=O,7.5,10.8,0.05,11.6,12.1,"Raloxifene Hydrochloride - FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020815/S-000. Accessed through Pharmapendium. Ppb: the PDR states: Raloxifene and the monoglucuronide conjugates are highly (95%) bound to plasma proteins. Raloxifene binds to both albumin and α1-acid glycoprotein, but not to sex-steroid binding globulin. http://www.pdr3d.com/detail.php?c=127942#section-14. Accessed January 5 2015.","Evista. N=6, 1 mg infusion iv.",Interconverted with glucuronide and subject to enterohepatic recycling.,1982,473.58,5,2,70,7,cationic,6.4,4.3
Raltitrexed,112887-68-0,c1c(sc(N(Cc2cc3c(cc2)[nH]c(nc3=O)C)C)c1)C(=O)N[C@@H](CCC(O)=O)C(=O)O,6.57,0.9,0.05,123,140,"I Judson, T Maughan, P Beale, J Primrose, P Hoskin, J Hanwell, C Berry, M Walker and F Sutcliffe. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694) British Journal of Cancer (1 998) 78(9). 1188-1193. ppb: Stephen J. Clarke, Philip J. Beale and Laurent P. Rivory. Clinical and Preclinical Pharmacokinetics of Raltitrexed. Clin Pharmacokinet 2000 , 39 (5): 429-443. From the ref. the authors cite own original work and state: Using ultrafiltration, binding was shown to be approximately 95% over a range of plasma concentrations. Therefore the review article data was accepted. ","Tomudex, ZD1694. Dose 3.0 mg/m^2 i.v. 15-min infusion (N=8, with normal renal function) Avg weight = 75 kg. Extremely long gamma phase. 3 compartment study.",,1987,458.49,10,4,152.7,9,anionic,1.6,-3.4
Ramelteon,196597-26-9,c1c2OCCc2c2[C@H](CCNC(CC)=O)CCc2c1,1.05,13.1,0.2,1.3,1.9,Ramelteon - FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 021782/S-000. Accessed through Pharmapendium.,MRT from VDss and clearance. 70 kg assumed. ,"From PDR. Accessed March 8 2013. http://www.pdr3d.com/detail.php?c=4560#section-3. Following oral administration of radiolabeled ramelteon, 84% of total radioactivity was excreted in urine and approximately 4% in feces, resulting in a mean recovery of 88%. Less than 0.1% of the dose was excreted in urine and feces as the parent compound. Elimination was essentially complete by 96 hours post-dose.",1997,259.34,3,1,38.3,4,neutral,2.7,2.7
Ranitidine,66357-35-5,CN\C(=C/N(=O)=O)\NCCSCc1oc(CN(C)C)cc1,1.2,9.6,0.95,2.1,2.1,"Chau NP, Zech PY, Pozet N, and Hadj-Aissa A (1982) Ranitidine kinetics in normal subjects.  Clin. Pharmacol. Ther. 31: 770-774.  Van Hecken AM, Tjandramaga TB, Mullie A, Verbesselt R, and De Schepper PJ (1982) Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.  Br. J. Clin. Pharmacol. 14: 195-200.  Smith IL, Ziemniak JA, Bernhard H, Eshelman FN, Martin LE, and Schentag JJ (1984) Ranitidine disposition and systemic availability in hepatic cirrhosis.  Clin. Pharmacol. Ther. 35: 487-494.",VDss calculated from micro rate constants reported in the reference.,,1978,314.4,7,2,86.6,10,cationic,0.33,-0.71
Ranolazine,95635-55-5,c1(c(cccc1)OC)OC[C@@H](CN1CCN(CC(Nc2c(cccc2C)C)=O)CC1)O,1.2,9.5,0.38,2.1,1.8,"Ranolazine - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021526/S-000 Part 05. Accessed through Pharmapendium.","2,000 ng/mL as target treatment (infusion) dose. MRT from VDss and clearance. 70 kg assumed. Lower clearance and higher VDss at higher doses, such as 4,00, 10,000 and 15,000 ng/mL target treatment. ","Ranolazine - FDA Approval Package
Label 021526/S-022.  Ranolazine is metabolized mainly by CYP3A and, to a lesser extent, by CYP2D6. Following a
single oral dose of ranolazine solution, approximately 75% of the dose is excreted in urine and
25% in feces. Ranolazine is metabolized rapidly and extensively in the liver and intestine; less
than 5% is excreted unchanged in urine and feces. The pharmacologic activity of the metabolites
has not been well characterized. After dosing to steady state with 500 mg to 1500 mg twice
daily, the four most abundant metabolites in plasma have AUC values ranging from about 5 to
33% that of ranolazine, and display apparent half-lives ranging from 6 to 22 hours.",1984,427.54,7,2,74.3,9,neutral,2.3,2.2
Reboxetine,71620-89-8,CCOc1ccccc1O[C@@H]([C@H]2CNCCO2)c3ccccc3,0.65,0.82,0.019,13,10,"Fleishaker JC, Mucci M, Pellizzoni C, and Poggesi I (1999) Absolute bioavailability of reboxetine enantiomers and effect of gender of pharmacokinetics.  Biopharm. Drug Dispos.  20: 53-57.  Hendershot PE, Fleishaker JC, Lin KM, Nuccio ID, and Poland RE (2001) Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents.  Psychopharmacology 155: 148-53.",Administered as a racemate; averaged data for the two enantiomers.,,1979,313.39,4,1,39.7,6,cationic,2.7,1.5
Recainam,74738-24-2,CC(C)NCCCNC(=O)Nc1c(C)cccc1C,1.4,4.5,0.86,5.2,5,"Anderson JL, Reddy P, Myerburg RJ, Waxman HL, and deVane PJ (1993) Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia.  Am. J. Cardiol. 71: 686-694.  Scatina JA, Kimmel HB, Weinstein V, Troy SM, Sisenwine SF, and Cayen MN (1990) Species differences in the pharmacokinetics of recainam, a new antiarrythmic drug.  Biopharm. Drug Dispos. 11: 445-461.",,,1980,263.38,4,3,53.2,6,cationic,2.3,0.31
Regadenoson,313348-27-5,OC[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O1)n1cnc2c(N)nc(nc12)n1ncc(c1)C(=O)NC,0.94,7.3,0.7,2.1,2,"Gordi T, Blackburn B, Lieu H. Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal Function. J Clin Pharmacol 2007, 47, 825-833","Dose 400 ug i.v. bolus, N=6, avg BW 79.5 kg. Creatinine clearance > 80 mL/min group ",,2000,390.35,13,5,186.5,4,neutral,-2.5,-2.5
Remifentanil,132875-61-7,CCC(=O)N(c1ccccc1)C2(CCN(CCC(=O)OC)CC2)C(=O)OC,0.4,37,0.3,0.18,0.8,"Egan TD, Lemmens HJM, Fiset P, Hermann DJ, Muir KT, Stanski DR, and Shafer SL (1993) The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers.  Anesthesiology  79: 881-892.  Ultiva Product Label.",Terminal half-life was calculated from a population pharmacokinetic analysis in which clearance and volume of distribution were identical to parameters determined from a standard pharmacokinetic study.,,1959,376.45,7,0,76.1,9,neutral,2.3,2.1
Remikiren,126222-34-2,[H]N(C([C@@H](Cc1ccccc1)CS(C(C)(C)C)(=O)=O)=O)[C@@H](Cc1cn([H])cn1)C(N([H])[C@@H](CC1CCCCC1)[C@H](C(C1CC1)O[H])O[H])=O,0.77,11.6,0.055812888,1.1,5.2,"Kleinbloesem CH, Weber C, Fahrner E, Dellenbach M, Welker H, Schroter V, Belz GG (1993) Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin. Pharmacol. Ther. 53, 585-592.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191","n=6, 40 mg dose used",,1989,630.84,10,5,161.5,17,neutral,2,2
Remimazolam,308242-62-8,Brc3cc2\C(=N/[C@H](c1ncc(n1c2cc3)C)CCC(=O)OC)c4ncccc4,0.44,15.02,,0.5,0.75,"Laurie J. Antonik, MD, D. Ronald Goldwater, MD, Gavin J. Kilpatrick, PhD, Gary S. Tilbrook, PhD, and Keith M. Borkett, BSc. A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics. Anesth. Analg. 2012, 115, 274-283.","CNS 7056. softdrug. Data reported as the overall mean of 54 subjects (N=6 each, 9 cohorts from 0.01 to 0.3 mg/kg). 78 kg median overall weight. ",,2000,439.31,6,0,69.4,5,cationic,2.1,2
Remoxipride,80125-14-0,CCN1CCC[C@H]1CNC(=O)c2c(OC)ccc(Br)c2OC,0.65,1.7,0.16,6.4,5.5,"Widman M, Nilsson LB, Bryske B, and Lundstroem J (1993) Disposition of remoxipride in different species: species differences in metabolism.  Arz. Forsch. 43: 287-297.  von Bahr C, Movin G, Yisak WA, Jostell KG, and Widman M (199) Clinical pharmacokinetics of remoxipride.  Acta Psych Scand. 358(Suppl) 41-44.",Note probable typo in the article by von Bahr et al stating that CL is 119 liter/min--interpreted as 119 mL/min,,1981,371.27,5,1,50.8,6,cationic,2.5,0.86
Repaglinide,135062-02-1,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3)ccc1C(=O)O,0.35,7.8,0.015,0.75,0.87,"Hatorp V, Oliver S, and Su CAPF (1998) Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.  Int. J. Clin. Pharmacol. Ther.  36: 636-641.  Plum A, Muller LK, and Jansen JA (2000) The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma.  Meth. Find. Exp. Clin. Pharmacol. 22: 139-143.",AG-EE 388 ZW,,1991,452.59,6,2,78.9,10,anionic,5.8,2.4
Repinotan,144980-29-0,O=C1N(CCCCNC[C@H]2CCc3ccccc3O2)S(=O)(=O)c4ccccc14,0.21,2.2,,1.6,1.2,"Heining R,  Sundaresan P, Shah A and Boettcher M (2005) Effect of Gender and Age on the Pharmacokinetics of Repinotan.  Clin. Drug. Invest. 25: 125-134.  ",,,1992,400.49,6,1,75.7,7,cationic,3.9,3.5
RGB-286638,784210-88-4,N(C(=O)NN1CCOCC1)c1c2C(=O)c3c([nH]nc3c3ccc(cc3)CN3CCN(CC3)CCOC)c2ccc1,5.9,11.5,,8.5,9.9,"Diane A.J. van der Biessen, Herman Burger, Peter de Bruijn, Cor H.J. Lamers, Nicole Naus, Hannes Loferer, Erik A.C. Wiemer, Ron H.J. Mathijssen, Maja J.A. de Jonge.  Phase I study of RGB-286638, a novel, multi-targeted cyclin-dependent kinase inhibitor in patients with solid tumors. Clin Cancer Res 2014 20(18); 4776–83","Data  digitized from plot for 1 representative subject at 80mg dose.  Linear PK from 20 mg/d to 160 mg/d on day 1. Well within range in Table 4 and accepted. 70 kg average weight assumed.  SMILES and CAS number corresponding to free base. Dihydrochloride salt CAS # 784210-87-3. Reported data at 80 mg/d clearance 12.3 mL/min/kg,  and t1/2 9.1 hr. ",,2004,545.63,11,3,115.1,8,cationic,0.95,0.41
Ribavirin,36791-04-5,NC(=O)c1ncn(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,14,5.2,1,45,45,"Paroni R, DelPuppo M, Borghi C, Sirtoni CR, and Galli Kienle M (1989) Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers.  Int. J. Clin. Pharmacol. Ther. Toxicol. 27: 302-307.  Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, and McNamara P (1999) Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.  Antimic. Agents Chemother. 43: 2451-2456.  Morse GD, Shelton MJ, and O'Donnell AM (1993) Comparative pharmacokinetics of antiviral nucleoside analogues.  Clin. Pharmacokinet. 24: 101-123.",,,1962,244.2,9,4,143.7,3,neutral,-2.8,-2.8
Ribostamycin,25546-65-0,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[C@H](N)[C@@H](O)[C@@H]1O,0.25,1.5,,2.8,2.5,"Yamasaku F, Suzuki Y, and Umemura K (1980) Pharmacokinetics of ribostamycin in healthy volunteers and patients with impaired renal function.  Jap. J. Antibiot. 33: 1318-1331.",VDss calculated from micro rate constants reported in the reference.,,1969,454.47,14,10,262.4,6,cationic,-7.3,-8.7
Ridogrel,110140-89-1,[H]OC(CCCCON=C(c1cccc(c1)C(F)(F)F)c1cccnc1)=O,0.43,1.05,0.033,6.8,7.54,"De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780.  ",70 kg average weight assumed.  MRT calculated from CL and VDss. 100 mg iv dose,,1987,366.33,5,1,71.8,9,anionic,3.5,0.95
Rifabutin,72559-06-9,CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4C(=O)C(=C5NC6(CCN(CC(C)C)CC6)N=C5c4c3C2=O)NC(=O)\C(=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)C)[C@@H]1C)\C,9.3,2.4,0.29,65,37,"Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, Merigan TC, and Blaschke TF (1989) Pharmacokinetics of rifabutin.  Antimic. Agents Chemoter. 33: 1237-1241.",,,1973,847,15,5,205.5,5,zwitterionic,6.3,3.7
Rifampin,13292-46-1,CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\C(=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)C)[C@@H]1C)\C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O,0.97,3.5,0.2,4.6,3.8,"Houin G, Beucler A, Richelet S, Brioude R, Lafaix C, and Tillement JP (1983) Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculosis patients after different rates of infusion.  Ther. Drug Monit. 5: 67-72.","One compartment model described, so VD was assumed as VDss.",,1965,822.94,16,6,220.1,5,anionic,4.6,1.7
Rigosertib,592542-59-1,COc1ccc(cc1NCC(=O)O)CS(=O)(=O)/C=C/c2c(cc(cc2OC)OC)OC,0.11,1.51,,1.2,0.95,"Wen Wee Ma, Wells A. Messersmith, Grace K. Dy, Colin D. Weekes, Amy Whitworth, Chen Ren, Manoj Maniar, Francois Wilhelm, S. Gail Eckhardt, Alex A. Adjei, and Antonio Jimeno Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer. Clin Cancer Res 2012; 18: 2048-2055",data reported in table. Average of Day 1 and Day 14. 70 kg average weight assumed. 1.73 m2/70 kg. N=46 overall but PK N but not clear. MRT from VDss and clearance.,,2003,451.49,9,2,120.4,11,anionic,3.2,0.36
Rilmenidine,54187-04-1,C1CC1C(C2CC2)NC3=NCCO3,4.5,7.1,0.9,10.6,8.3,"PATRICK  GENISSEL,   NORBERT  BROMET, JEAN  BERNARD  FOURTILLAN,  ALAIN  MIGNOT, HENRI  ALBIN.  Pharmacokinetics of rilmenidine in healthy subjects. Am. J. Cardiol. 1988, 61, D47-D53.",Assumed 65 kg b.w. (not given in paper but studied even number of men and women). Calculated VDss from C vs t graph in paper.  (VD provided in paper was not described.)//ppb:  The binding of rilmenidine on the human free fatty-acid serum albumin fraction (equilibriumdialysis) is approximately 7.5% and on the a1 glycoprotein acid approximately 3.5% (data not shown). Approximated to 90% free.,65% excreted unchanged in urine.,1981,180.25,3,1,33.6,4,cationic,0.91,-2.2
Riluzole,1744-22-5,s1c(nc2c1cc(cc2)OC(F)(F)F)N,3.5,11.3,0.04,5.2,,"Riluzole - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 020599. Accessed through Pharmapendium.","N=15, 50mg dose iv, 70 kg assumed, MRT from VDss and clearance. t/12 not found.",91.5% of oral dose recovered in urine with only 2% as ntact riluzole.,1963,234.2,3,1,48.1,1,neutral,3.1,3.1
Rimiducid,195514-63-7,CC[C@@H](c1cc(c(c(c1)OC)OC)OC)C(=O)N2CCCC[C@H]2C(=O)O[C@H](CCc3ccc(c(c3)OC)OC)c4cccc(c4)OCC(=O)NCCNC(=O)COc5cccc(c5)[C@@H](CCc6ccc(c(c6)OC)OC)OC(=O)[C@@H]7CCCCN7C(=O)[C@@H](CC)c8cc(c(c(c8)OC)OC)OC,0.82,6.61,,2.08,7.18,"John D. Iuliucci, Stuart D. Oliver,  Steve Morley,  Chris Ward Janet Ward, David Dalgarno, Tim Clackson,  and Harvey J. Berger. Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers. Journal of Clinical Pharmacology 2001, 41, 870-879","AP1903. Plasma data Table II. Blood parameters also available. Blood/plasma 1.75. N= 4 per dose group. Doses 0.05  0.1, 0.5 and  1 mg,/kg, 2 hr infusion. Averaged across 4 doses. t 1/2 varied from 3.92 to 12 hours (the latter at 1 mg/kg). All other parameters quite reproducicle dose-to-dose.",,1997,1411.63,24,2,262.2,39,neutral,9,9
Riociguat,625115-55-1,CN(c1c(nc(nc1N)c2c3cccnc3n(n2)Cc4ccccc4F)N)C(=O)OC,0.44,0.74,,10.03,9.1,"Corina Becker, Reiner Frey, Christiane Hesse, Sigrun Unger, Michael Reber, Wolfgang Mück. Absorption of riociguat (BAY 63-2521): bioavailability, food effects,
and dose proportionality. Pulm Circ. 2016 Mar; 6(Suppl 1): S27–S34","N=15 (non-smokers), 1 mg dose (60 minute iv infusion), 70 kg average weight assumed. MRT from VDss and clearance.",,2003,422.42,10,2,138.1,5,neutral,2.3,2.3
Risedronic acid (Risedronate),105462-24-6,OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O,6.3,1.5,0.76,70,200,"Mitchell DY, Barr WH, Eusebio RA, Stevens KAP, Duke FP, Russell DA, Nesbitt JD, Powell JH, and Thompson GA (2001) Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.  Pharm. Res. 18: 166-170.  See als:  Actonel Product Label. PDR. Accessed July 29 2014. http://www.pdr3d.com/detail.php?c=26372#section-13",,,1986,283.11,8,5,148.2,4,anionic,-2.2,-7
Risperidone,106266-06-2,CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1,1.1,5.4,0.1,3.4,3.2,"Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z, Visscher HW, and Jonkman JHG (1993)  Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.  Clin. Pharmacol. Ther.  54: 257-268.  Mannens G, Meuldermans W, Snoeck E, and Heykants J (1994) Plasma protein binding of risperidone and its distribution in blood.    Psychopharmacology 114: 566-572.",CYP2D6 EM data only.,,1986,410.48,6,0,62.2,4,cationic,3.1,2.6
Ritanserin,87051-43-2,CC1=C(CCN2CCC(CC2)=C(c2ccc(cc2)F)c2ccc(cc2)F)C(N2C=CSC2=N1)=O,1.41,0.51,0.008,46.1,40,"De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780. ",70 kg average weight assumed.  MRT calculated from CL and VDss. 5 mg iv dose,,1984,477.57,4,0,35.9,5,cationic,5.7,4.9
Ritipenem ,84845-58-9,C1(=O)N2[C@@H]([C@H]1[C@H](O)C)SC(COC(N)=O)=C2C(=O)[O-].[Na+],0.24,7.55,0.72,0.54,0.54,". Weighted data for diverse doses and number of patients (N=61) from Table XII (BW 65-80 kg) in Lovering, A. M.; White, L. O.; Lewis, D. A.; MacGowan, A. P.; Routh, K. R.; Pickin, D. M.; Reeves, D. S.  Pharmacokinetics of FCE 22101 in man following different modes of administration.    Journal of Antimicrobial Chemotherapy  (1989),  23(Suppl. C),  179-95; and from Table 2 in Jannuzzo, M. G.; Mandelli, M.; Strolin Benedetti, M.; Moro, E.; Carnovali, M.; Vaiani, R.; Sassella, D.  Pharmacokinetics and tolerance of a new penem antibiotic, FCF 22101, in healthy volunteers after a single intravenous dose.    European Journal of Clinical Pharmacology  (1989),  36(6),  633-635.    fu in Efthymiopoulos, C.; Battaglia, R.; Strolin Benedetti, M.  Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic.    Journal of Antimicrobial Chemotherapy  (1991),  27(4),  517-26.",FCE-22101. In Jannuzzo et al the renal CL = 1.94 mL/min/kg was also reported. CAS number reported refers to sodium salt. Parent compound CAS 84845-57-8.,,1982,310.26,8,2,133,5,anionic,-2.1,-5.6
Ritodrine,26652-09-5,C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c2ccc(O)cc2,4.4,31,0.64,2.4,2.6,"Caritis SN, Venkataramanan R, Darby MJ, Chiao JP, and Krew M (1990) Pharmacokinetics of ritodrine administered intravenously: recommendations for changes in the current regimen.  Am. J. Obstet. Gynecol. 162: 429-437.  Gross AS and Brown KF (1985) Plasma protein binding of ritodrine at parturition and in nonpregnant women.  Eur. J. Clin. Pharmacol. 28: 479-481.",Data from pregnant women.,,1971,287.35,4,4,72.7,6,cationic,1.9,0.37
Rivaroxaban,366789-02-8,C1OCCN(c2ccc(cc2)N2C(O[C@H](C2)CNC(c2sc(cc2)Cl)=O)=O)C1=O,0.7,2.4,0.06,4.9,7,PDR. Prescribing in formation for rivaroxaban. Accessed July 29 2014. http://www.pdr3d.com/detail.php?c=126082#section-14,70 kg assumed. MRT from Clearance and VDss.,,2003,435.88,8,1,88.2,5,neutral,2.6,2.6
Rivastigmine,123441-03-2,CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,1.3,12,0.6,1.9,1.4,"Polinsky RJ (1998) Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.  Clin. Ther. 20: 634-647. Hossain M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F, and Cutler NR (2002) Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.  Clin. Pharmacokinet.  41: 225-234.","VDss calculated from data digitized from Hossain, et al.,",,1988,250.34,4,0,32.8,5,cationic,2.8,1.9
Rizatriptan,144034-80-0,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,1.9,16,0.86,2,2.2,"Vyas KP, Halpin RA, Geer LA, Ellis JD, Liu L, Cheng H, Chavez-Eng C, Matuszewski BK, Varga SL, Guiblin AR, and Rogers JD (2000) Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.  Drug Metab. Dispos. 28: 89-95.  Lee Y, Conroy JA, Stepanavage ME, Mendel CM, Somers G, McLoughlin DA, Olah TV, De Smet M, Keymeulen B, and Rogers JD (1999) Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers.  Br. J. Clin. Pharmacol.  47: 373-378.  Lee Y, Ermlich SJ, Sterrett AT, Goldberg MR, Blum RA, Brucker MJ, McLoughlin DA, Olah TV, Zhao J, and Rogers JD (1998) Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females.  Biopharm Drug Dispos. 19: 577-581.  Cheng H, Polvino WJ, Sciberras D, Yogendran L, Cerchio KA, Christie K, Olah TV, McLaughlin D, James I, and Rogers JD (1996) Pharmacokinetics and food interaction of MK-462 in healthy males.  Biopharm. Drug Dispos. 17: 17-24.  Hargreaves RJ, Longmore J, Beer M, Shepheard S, Cumberbatch M, Williamson D, Stanton J, Razzaque Z, Sohal B, Street L, Seabrook G, and Hill R (2000) The pharmacology and mechanisms of action of rizatriptan.  Monogr. Clin. Neurosci. 17: 141-161.",,,1992,269.34,5,1,49.7,5,cationic,1.6,0.41
Ro 02-70608,1160849-72-8,O=C(C(C(Cl)=CC=C1)=C1C)N[C@H](C(O)=O)CC2=CC=C(NC(C(C(Cl)=CN=C3)=C3Cl)=O)C=C2,0.3,3.7,0.1,1.3,3.3,"Youssef Hijazi, , Horst Welker, Albert E. Dorr, Jian-Ping Tang,  Roger Blain Louis M. Renzetti, Richat Abbas. Pharmacokinetics, Safety, and Tolerability of R411, a Dual  4 alpha- 4 beta Integrin Antagonist After Oral Administration at Single andMultiple Once-Daily Ascending Doses in Healthy Volunteers. Youssef Hijazi et al. J Clin Pharmacol 2004;44:1368-1378. ","Active metabolite of R411 administered as such. Data digitized from plot reported. 100 mg over 1 hr infusion, 82.6 kg average weight, N=11. Reported AUC0-∞ 5821 h•μg/L CLt, 19.37 L/h (= 3.91 mL/min/kg) t1/2, 3.5 h ppb reported as > 90%",Only 26% excreted renally. Assigned as metabolic with percentage unknown. Hijazi et al.,2004,506.77,7,3,108.4,7,anionic,4.6,1.5
Ro25-6833,161672-76-0,[H]N([H])c1nc(cs1)C(C(N([H])[C@@H]1C(N2C(=C(CS[C@H]12)C=C1CCN(CC(F)(F)F)C1=O)C(=O)O[H])=O)=O)=NO[H],0.11,0.38,0.043,4.8,3.8,"Weidekamm E, Schweizer J, McClelland G, Joubert P, Heizmann P (1995) Pharmacokinetics of the new cephalosporin Ro25-6833 in humans. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 122.; Richter WF, Heizmann P, Meyer J, Starke V, Lave T (1998) Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. J. Pharm. Sci. 87, 496-500. ",500 mg infusion,,1994,546.5,12,4,178.5,9,anionic,0.36,-2.6
Rocuronium,143558-00-3,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCOCC5)[N+]6(CC=C)CCCC6,0.21,3.7,0.54,0.95,1.6,"Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, and Fitzpatrick KT (1993) Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaethesia in patients with and without renal failure.  Br. J. Anaesth. 71: 222-226.  Roy JJ and Varin F (2004) Physicochemical Br. J. Anaesth. (2000) 85 (5): 717-723. properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",Org 9426,,1989,529.77,6,1,59,6,cationic,0.19,-0.28
Rofecoxib,162011-90-7,c1ccc(cc1)C=1C(=O)OCC1c1ccc(cc1)S(=O)(=O)C,1.3,2,0.13,10.8,7.5,"Rofecoxib - FDA Approval Package
Label 021042/S-000. Accessed Through Pharmapendium.","70 kg assumed. MRT from Clearance and VDss. Ppb from Rofecoxib - FDA Approval Package
Label 021042/S-000.","Rofecoxib - FDA Approval Package
Label 021042/S-000. 72. % recovered from urine with          < 1% as unchanged drug. ORAL DOSE?.",1995,314.36,4,0,60.4,3,neutral,-0.29,-0.29
Roflumilast,162401-32-3,C(=O)(c1ccc(c(c1)OCC1CC1)OC(F)F)Nc1c(cncc1Cl)Cl,1.92,2.2,0.01,14.5,15.1,"High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast T.D. Bethke and G. Lahu. Int. J.of Clin. Pharmacol. and Therapeutics, 2011,  49, 51-57."," Calculated from digitized plot. Median weight 75kg. Reported AUC(-inf)= 14.1 ug*h/L.Calculated AUC 15.1 ng*h/mL. 150 ug dose, N=12.",,1995,403.21,5,1,60.4,7,neutral,3.5,3.5
Rolapitant,552292-08-7,C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@]3(CCC(=O)N3)CN2)c4ccccc4,,0.38,0.002,,148.5,"X Wang, ZY Zhang, D Powers, J Wang, S Lu and V Kansra. Rolapitant Absolute Bioavailability and PET Imaging Studies in Healthy Adult Volunteers. Clin. Phramacol. Ther. 2017. Accessed May 12 2017. doi:10.1002/cpt.637.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206500s000lbl.pdf. Accessed May 12 2017.",SCH 619734. Varubi. 100 ug iv dose of 14C rolapitant together with 180 mg of drug po. N=4. No plot or data relevant for MRT or VDss.,,2003,500.48,4,2,50.4,5,cationic,5.1,3.8
Rolipram,61413-54-5,c1(c(ccc(c1)[C@@H]1CNC(C1)=O)OC)OC1CCCC1,0.67,6.3,0.11,1.77,7,"Pharmacokinetics of ( + )-rolipram and ( - )-rolipram in healthy volunteers W. Krause, G. Ktthne, and N. Sauerbrey. Eur J Clin Pharmacol (1990) 38:71-75.  ppb:  S. G. SUMMERFIELD, A. J. LUCAS, R. A. PORTER, P. JEFFREY, R. N. GUNN, K. R. READ, A. J. STEVENS, A. C. METCALF, M. C. OSUNA, P. J. KILFORD, J. PASSCHIER,  A. D. RUFFOToward an improved prediction of human in vivo brain penetration. Xenobiotica,  2008; 38(12): 1518–1535. Average of (+) and (-) rolipram. Very similar values. ",Average of (+) and (-) enantiomer administered separately. AUCs almost identical. 0.1 mg dose. N=6 in each cohort. 71 kg average weight. MRT = VDss/Cl. MTT (?) reported as 2.1 hours (average.as ,,1976,275.34,4,1,47.6,4,neutral,2.1,2.1
Rolitetracycline,751-97-3,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)NCN4CCCC4)C(=O)c5c(O)cccc5[C@@]3(C)O,0.54,0.97,0.5,9.3,8.8,Dimmling T and Vanderbeke O (1975) Pharmakokinetik oral und intravenos verabreichbarer tetracyclinpraparate.  Med. Klin. 70: 279-285.  Rinati MV and Fleischmann L (1973) Legame con sieroproteine di alcune tetracicline e loro derivati idrosolubili. Cl. Terap. 71: 57-61.,Calculations made from reported C vs t data.  Plasma concentrations were determined using bioassay.,,1957,527.57,11,6,170.9,4,cationic,0.097,-4.1
Rolofylline,136199-02-5,C12CC3C(C1)(CC(C3)C2)c1nc2n(c(=O)n(c(=O)c2[nH]1)CCC)CCC,4.3,5,,14.1,18.1,"Mark Stroh, PhD,Victor Dishy, MD,Waldemar Radziszewski, MD, PhDEunhee Hwang, PhD, Nicole Lazarus-Shipitofsky, PharmD, Howard Dittrich, MD, Amy O. Johnson-Levonas, PhD, Ryan Lutz, MS,
John A. Wagner, MD, PhD, and Eseng Lai, MD, PhD. The Effects of Multiple Doses of Rolofylline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Subjects.American Journal of Therapeutics 17, 53–60 (2010)","KW 3902. Data digitized from plot reported by Stroh et al. Data corrected for residual concentration at the start of day 4 (39 nM) with kel assumed to be the same. All points digitized were corrected by subtracting 
the corresponding C(t) = C(0)*exp(-kel*t) at that point. 22% extrapolation.Initial AUC (uncorrected)  within 9% of reported AUC0-t.",,1991,356.46,6,1,72.7,5,neutral,3.2,3.2
Romidepsin,128517-07-7,C\C=C\1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,1.2,7.4,0.07,2.6,11,"Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, and Bates SE (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.Clin. Cancer Res. 8: 718-728. ppb: The PDR states: Romidepsin is highly protein bound in plasma (92% to 94%) over the concentration range of 50 ng/mL to 1000 ng/mL with α1-acid-glycoprotein (AAG) being the principal binding protein. Median of 93% taken. Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=134699#section-13",,,1990,540.7,10,4,142.7,2,neutral,-0.14,-0.14
Ropinirole,91374-21-9,N1C(Cc2c1cccc2CCN(CCC)CCC)=O,7.7,30,0.6,4.3,6,"Ropinirole Hydrochloride - FDA Approval Package
Pharmacology Review 020658/S-000 Part 01. Accessed through Pharmapendium.","VDss reported but not sure whether from po or iv data. ""absorption"" reported as 100%","   Ropinirole Hydrochloride - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 020658/S-000. Oral data. 88% of radioactivity excreted in urine with less than 10% as unchanged drug.",1984,260.37,3,1,32.3,7,cationic,2.9,1.1
Ropivacaine,84057-95-4,CCCN1CCCC[C@H]1C(=O)Nc2c(C)cccc2C,0.75,5.5,0.06,2.3,2.2,"Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, and Widman M (1996) Metabolism and excretion of ropivacaine in humans.  Drug Metab. Dispos. 24: 962-968.  Jokinen MJ, Olkkola KT, Ahonen J, and Neuvonen PJ (2003) Effect of ciprofloxacin on the pharmacokinetics of ropivacaine.  Eur. J. Clin. Pharmacol. 58: 653-657.  Jokinen MJ, Olkkola KT, Ahonen J, and Neuvonen PJ (2001) Effect of rifampin and tobacco smoling on the pharmacokinetics of ropivacaine.  Clin. Pharmacol. Ther. 70: 344-350.  Emanuelsson BM, Norsten-Hoog C, Sandberg R, and Sjovall J (1997) Ropivicaine and its 2H3-labelled analogue--bioanalysis and disposition in healthy volunteers.  Eur. J. Pharm. Sci. 5: 171-177.   Jokinen MJ, Neuvonen PJ, Lindgren L, Hoeckerstedt K, Sjoevall J, Breuer O, Askemark Y, Ahonen J, and Olkkola KT (2007) Pharmacokinetics of Ropivacaine in Patients with Chronic End-stage Liver Disease.  Anesthesiology 106: 43-55.  Naropin Product Label.",,,1983,274.4,3,1,32.3,4,cationic,3.5,2.9
Roquinimex,84088-42-6,CN(C(=O)C1=C(O)c2ccccc2N(C)C1=O)c3ccccc3,0.21,0.082,,43,31,"Strandgarden K, Hoglund P, Nordle O, Polacek J, Wannman H, and Gunnarsson PO.(1999) Dissolution rate-limited absorption and complete bioavailability of roquinimex in man.  Biopharm. Drug Dispos. 20: 347-354. Biopharm Drug Dispos. 2000 Mar;21(2):53-67.
Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers.
Strandgården K, Höglund P, Grönquist L, Svensson L, Gunnarsson PO.",,,1982,308.33,5,1,60.9,2,anionic,2.4,-0.95
Rosaramicin,35834-26-5,C1=CC([C@@H](C[C@@H]([C@@H]([C@@H](C)[C@@H](CC(O[C@@H]([C@@H](C)[C@@H]2O[C@@]12C)CC)=O)O)O[C@@H]1O[C@@H](C[C@@H]([C@@H]1O)N(C)C)C)CC=O)C)=O,2.83,13.3,,3.54,3.34,"Pharmacokinetics and Metabolism of Rosaramicin in Humans. CHIN-CHUNG LIN, MENGER CHUNG, RICHARD GURAL, DAVID SCHUESSLER, HONG-KI KIM, ELAINE
RADWANSKI, ALICEANN MARCO, CHARLES DiGIORE, AND SAMSON SYMCHOWICZ. Antimicr. Agents Chemother. 1984, 26, 522-526.",Data digitized from plot reported by Lin et al . N=12 74.4 kg average weight estimated from dose/AUC vs. clearance in mL.min-1.kg-1 reported. 500 mg dose administered as 1-hr infusion. Reported clearance 13.4 mL.min-1.kg-1 and 3.78 L/kg as Vdarea. Calculated VDz 3.86 L/kg. AUC calculated 8.38 hr*ug/mL vs. reported as 8.35 hr*ug/mL.,,1971,581.74,10,2,135.1,6,cationic,2.5,1.2
Rosiglitazone,122320-73-4,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,0.2,0.65,0.002,5.1,3.9,"Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, and Cowley H (2000) Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.  Drug Metab. Dispos. 28: 772-780.  Miller AK, DiCicco RA, and Freed MI (2002) The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.  Clin. Ther. 24: 1062-1071.  Avandia Product Label",,,1989,357.43,6,1,71.5,7,anionic,3.2,0.25
Rosuvastatin,287714-41-4,CC(C)c1nc(nc(c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(=O)(=O)C,1.7,11,0.12,2.6,2,"Martin PD, Warwick MJ, Dane AL,  Brindley C, and Short T (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.  Clin. Ther. 25: 2553-2563.  Crestor Product Label.",,,2000,481.54,9,3,140.9,10,anionic,2,-1.3
Rotigotine,99755-59-6,c12c(CC[C@@H](C1)[N@@](CCc1cccs1)CCC)c(ccc2)O,5.7,37,0.08,2.6,4,"Cawello W, Braun M, Boekens H. (A)DME of the dopamine agonist rotigotine in man- Administration by intravenous infusion or transdermal delivery. DMD Fast Forward article published July 16 2009. ppb:The PDR states: The binding of rotigotine to human plasma proteins is approximately 92 % in vitro and 89.5 % in vivo. 92% taken as the vast majority of data were from in vitro determinations. Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=121976#section-13.","Data digitized from plot reported. N=6, 1.2 mg dose, 12 hour infusion, 83.6 kg average weight. Reported AUC 6.13 = ng*h/mL, calculated 6.43 ng*h/mL, reported t1/2 = 2.5 hours. In Avalon as PKF209-495-NX-1",,1985,315.47,2,1,23.5,6,cationic,5,3.4
RSD921,114419-77-1,CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)Cc3cccc4c3ccs4,1.1,3,,5.9,5.5,"Wellington Ribeiro, Demian R. Ifa, Gaetano Corso, John Salmon, Leonardo A. Moraes, Marcos N. Eberlin,  Gilberto de Nucci. Determination of RSD921 in human plasma by high-performance liquid chromatography–tandem mass spectrometry using tri-deuterated RSD921 as internal standard: application to a phase I clinical trial. J. Mass Spectrom. 2001; 36: 1133–1139","PD-123497. Digitized from plot reported but no comparative data offered.  NCA: AUCall (ng*h/mL) = 21.5, AUCinf (ng*h/mL) = 22.3",,1988,356.52,3,0,23.5,4,cationic,4.4,3.2
Rucaparib,283173-50-2,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,3.28,4.31,,12.71,16.6,"ABSTRACT. D. D. Wang, K. A. Kern, M. Carpentieri, S. Zhang, B. Hee, M. R. Middleton, J. F. Spicer, L. R. Molife, R. Plummer. Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients. J. Clin. Oncol. 2011;29(15 supplement):e13615","AG-14447. PF-01367338 with CAS#  459868-92-9 reported as rucaparib phosphate. N=6, 12-18 mg dose iv, 70 kg average weight assumed. MRT from clearance and VDss. Absolute F = 34%",,2000,323.36,4,3,56.9,3,cationic,2,0.21
S 12363,123286-01-1,C1[N@@]2CC=C[C@@]3([C@@H]([C@@]([C@@H]4N(C)c5cc(OC)c(cc5[C@@]4(C1)[C@@H]23)[C@@]1(c2c(CC[N@@]3C[C@@](C[C@@H](C1)C3)(O)CC)c1ccccc1[nH]2)C(OC)=O)(O)C(=O)N[C@@H](C(C)C)P(OCC)(=O)OCC)O)CC.S(=O)(=O)(O)O,4.67,3.5,0.1,22.24,34.3,"Ings, R. M. J.; Lelievres, E.; Ardiet, C.; Clavel, M.; Leyvraz, S.; Minaidis, D.; Lokiec, F.; Turpin, F.; Solere, P.; Lucas, C.. Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs:  data from phase I tolerance studies on a new vinca alkaloid derivative. Xenobiot. 1992, 22, 871-880.// ppb: Urien, Saik; Bastian, Gerard; Lucas, Catherine; Bizzari, Jean Pierre; Tillement, Jean Paul. Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique. Invest. New Drugs. 1992, 10, 263-268.","N=23, 70 kg weight assumed. Doses from 0.12 to 0.84 mg/m2. MRT from Vss and clearance. Reported as 85-95% bound. Median value taken.",,1989,1044.2,19,7,261,14,cationic,4.3,3.9
S-0139,162059-95-2,C(OC(/C=C/C(=C1NC(/C=C/C(O)=O)=O)C=C(C=C1)O)=O)[C@@](C([C@@]([C@]1(C(O)=O)CC2)(CC2(C)C)[H])=CC2)([C@@](C)([C@]2([C@](C)([C@@]2(C(C)(C)C(C3)=O)[H])C3)[H])CC2)CC1,1.45,7.6,,3.18,,"Prolonged pharmacodynamic effects of S-0139, an intravenously administered endothelin A (ETA) antagonist, in the human forearm blood flow model  Lunnon, Martin W.; Wallace, Sharon M. L.; Palmer, Joanne E.; Francis-Lang, Andrew; Laurijssens, Bart E.; Mistry, Prafull; Albala, Bruce; Nagafuji, Toshiaki; Wilkinson, Ian B.; Maltby, Kay  British Journal of Clinical Pharmacology (2010), 69(3), 252-261.",Average of 3 doses and 19 subjects total. Data from 3 hours infusion.  VDss from reported Css and dose. No t1/2 reported. MRT = VDss/CL,,1994,729.9,10,4,167.3,9,anionic,6.8,1.7
Sabeluzole,104383-17-7,[H]O[C@H](CN1CCC(CC1)N(C)c1nc2ccccc2s1)COc1ccc(cc1)F,5.5,4.05,0.014,22.6,18.9,"De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780.  ",MRT calculated from CL and VDss. 10 mg iv dose.  ,,1986,415.52,5,1,48.8,8,cationic,4.7,4.2
Safinamide,133865-89-1,C[C@@H](C(=O)N)NCc1ccc(cc1)OCc2cccc(c2)F,2.19,1.17,,31.16,21.67,"Annick Seithel‐Keuth, Andreas Johne, Achim Freisleben, Katrin Kupas,
Michael Lissy, and Sonja Krösser. Absolute Bioavailability and Effect of Food
on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects. Clin.Pharmacol. Drug. dev. 2013, 2, 79-89.","N=14, 7M/7F, 50 mg iv dose as a 30 minutes infusion. Average weight assumed to be 70 kg. Data digitized from plot reported and PK parameters calculated via PKSolver. AUCinf reported 11022 . Calculated AUC0-inf 10168 ng.h.mL-1. AUC0-t highly truncated.",,1990,302.34,4,2,64.3,7,cationic,1.7,1.1
Salvianolic acid B,121521-90-2,c1cc(c(cc1C[C@H](C(=O)O)OC(=O)/C=C/c2ccc(c3c2[C@@H]([C@H](O3)c4ccc(c(c4)O)O)C(=O)OC(Cc5ccc(c(c5)O)O)C(=O)O)O)O)O,0.14,7.17,0.08,0.42,0.29,"Xiuxue Li , Chen Cheng , Fengqing Wang , Yühong Huang , Weiwei Jia , Olajide E. Olaleye ,
Meijuan Li , Yanfen Li , Chuan Li. Pharmacokinetics of catechols in human subjects intravenously receiving XueBiJing injection, an emerging antiseptic herbal medicine. Drug Metab. Pharmacokin. 2015. http://dx.doi.org/10.1016/j.dmpk.2015.10.005//ppb: Yuan, Hai-jian; An, Yi-qiang; Chen, Yi-gang . Determination of protein binding rates of salvianolic acid B and danshensu with different plasmas. Zhongguo Shiyan Fangjixue Zazhi. 2014, 20, 136-139.",3 different dosage regimens to 6 M and 6 F each. (three different infusions). Actual doses not reported. Standardized solution? Data averaged across all patients (N=36). Reported to be eliminated by bile after methylation in rat.,,1981,718.61,16,9,278,14,anionic,3.7,-3.1
Sameridine,143257-97-0,c1(C2(C(=O)N(C)CC)CCN(CC2)CCCCCC)ccccc1,,24,,,3.6,"Åsa Österlund, MD, Eva Arlander, MScPharm, Lars I. Eriksson, MD, PhD, Sten G. E. Lindahl, MD, PhD, FRCA. The Effects on Resting Ventilation of Intravenous Infusions of Morphine or Sameridine, a Novel Molecule with Both Local Anesthetic and Opioid Properties. Anesth Analg 1999, 88:160 –165.",N=12. Clearance and t 1/2 reported in text. 0.73 mg/kg dose. 70 kg average weight assumed. Ref. 6 cited in the paper (abstract) with clearance of 1.4 L/min (20 mL/min/kg),,1986,330.51,3,0,23.5,8,cationic,4.1,2.5
Saquinavir,127779-20-8,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)N)NC(=O)c4ccc5ccccc5n4,3.6,13,0.028,4.6,13,"Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, and Krahenbuhl S (1998) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.  Br. J. Clin. Pharmacol. 45: 355-359.  Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, and Back DJ (2001) Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.  Drug Metab. Dispos.  29: 299-303.",,,1990,670.84,11,5,166.7,12,neutral,3.6,3.3
SAR 125844,1116743-46-4,O=C(NC1=NC2=CC=C(C=C2S1)SC3=NN=C4C=CC(C5=CC=C(C=C5)F)=NN43)NCCN6CCOCC6,4.1,8.34,,8.19,19.44,"Eric Angevin, Gianluca Spitaleri, Jordi Rodon, Katia Dotti, Nicolas Isambert, Stefania Salvagni, Victor Moreno, Sylvie Assadourian, Corinne Gomez, Marzia Harnois ,Antoine Hollebecque, Analia Azaro, Alice Hervieu, Karim Rihawi, Filippo De Marinis. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. Eur. J. Cancer 2017, 87, 131-139.",Slow infusion. Weighted average of dose levels from 50 mg/m2 to 740 mg/m2. 70 kg average weight assumed. N=57. MRT from VDss and clearance. Dose proportional across range.,,2009,550.63,10,2,109.6,7,neutral,3.6,3.4
SarCNU,81965-43-7,CN(CC(=O)N)C(=O)N(CCCl)N=O,0.76,9,,1.4,1,"Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH, Batist G, Patenaudr F, Bangash N, Panarello L, Alaoui-Jamali M, and Sausville E (2003) SarCNU, a nitosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.  J. Clin. Oncol. 21: 232-240.",VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.,,1982,222.63,7,1,96.1,5,neutral,-0.4,-0.4
Sardomozide,149400-88-4,c12c(C(=N)N)cccc1\C(=N\NC(=N)N)CC2,20,3.2,,104.1,65.4,"A Phase I and Pharmacokinetic Study of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, Administered on a Dailytimes-five every-three-week Schedule in Patients with Advanced Solid Malignancies. Lillian L. Siu, Eric K. Rowinsky, Lisa A. Hammond, Geoffrey R. Weiss,Manuel Hidalgo, Gary M. Clark, Judy Moczygemba, Les Choi, Ron Linnartz, Nicholas C. Barbet, Ivo T. Sklenar, Renaud Capdeville, Gregory Gan, Carl W. Porter, Daniel D. Von Hoff, and S. Gail Eckhardt. Clin. Cancer Res. 2002, 8, 2157–2166. ",SAM486A or CGP48664.  Weighted average across several doses (3.6 to 202.8 mg/m2/day) and 18 patients. Total VDss calculated 811 L/m2 for 18 patients. Clearance 7.75 L/h/m2. 1.73m2/70 factor used.  T1/2 on 19 patients. MRT = VDss/Cl. Highly variable PK. ,,1993,230.27,6,5,124.1,3,cationic,-0.14,-5
Satavaptan,185913-78-4,C1C[C@H](CC[C@@]21c1cc(OCC)ccc1N(S(=O)(c1c(cc(C(NC(C)(C)C)=O)cc1)OC)=O)C2=O)OCCN1CCOCC1,7,12.3,0.1,9.4,10.4,"Satavaptan - EMA Approval Package
Withdrawal Report EMEA/CHMP/316130/2008. Accessed through Pharmapendium.","Data taken at lowest 91 mg) dose. Very tight at 5 and 10 mg doses as well. Somewhat higher (both VDss and clearance but well within two-fold) at higher doses (25, 50 and 100 mg). 70 kg assumed and MRT from VDss and clearance. ",Seemingly biliary but not clear from EMA package.,1997,643.79,11,1,123.7,10,neutral,3.5,3.2
Saxagliptin,361442-04-8,N1([C@H](CC2[C@H]1C2)C#N)C(=O)[C@@H](C12CC3CC(C1)(O)CC(C3)C2)N,1.8,7.1,1,4.1,7.5,"Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin Boulton, David W.; Kasichayanula, Sreeneeranj; Keung, Chi Fung; Arnold, Mark E.; Christopher, Lisa J.; Xu, Xiaohui; LaCreta, Frank  British Journal of Clinical Pharmacology (2013), 75(3), 763-768. ",40 ug labelled iv dose given at Tmax of a po pharmacological dose (5mg). N=8 and 70 kg average weight assumed.MRT from Cl and Vss. Negligible protein binding. Fu assumend to be 1 from PDR data. PDR. Accessed June 12 2013. http://www.pdr3d.com/detail.php?c=56625#section-13. ,PDR. Accessed June 12 2013. http://www.pdr3d.com/detail.php?c=56625#section-13. Data in PDR suggestive of some renal clearance with active secretion component but no definitive quantitative data available. ,2004,315.41,5,2,90.4,3,neutral,0.086,0.077
Sch34343,95415-91-1,C[C@@H](O)[C@@H]1[C@H]2SC(=C(N2C1=O)C(=O)O)SCCOC(=O)N,0.3,7.5,0.35,0.67,0.8,"Lin CC, Lim J, Radwanski E, Kim, HK, Marco A, Lapiguera A, DiGiore C, and Symchowicz S (1987) Pharmacokinetics and metabolism of an intravenously administered penem (Sch 34343) in humans.  Antimic. Agents Chemother.  31: 84-87.  Eliopoulos GM, Reiszner E, and Moellering RC (1985) In vitro activity of Sch 34343 against enterococci and other Gram-positive bacteria.  Antimic. Agents Chemother. 27: 28-32.",VDss calculated from digitized C vs t plot.,,1984,334.37,8,3,130.2,7,anionic,-1.6,-4.6
Scopolamine,51-34-3,CN1[C@@H]2C[C@H](C[C@H]1[C@@H]3O[C@H]23)OC(=O)[C@H](CO)c4ccccc4,3.1,16,,3.2,4.5,"Putcha L, Cintron NM, Tsui J, Vanderploeg JM and Kramer WG (1989) Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.  Pharm. Res. 6: 481-485.  AHFS drug information 2005. McEvoy GK, ed. Scopolamine. Bethesda, MD: American Society of Health-System Pharmacists; 2005:1254-7.",VDss calculated from digitized C vs t plot.,,1891,303.35,5,1,62.3,5,cationic,1.1,0.66
Scutellarin,27740-01-8,c1cc(ccc1c2cc(=O)c3c(o2)cc(c(c3O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O,0.88,46.58,0.1,0.31,1.18,"Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325.//ppb: Huang, Yong; Chen, Hui; Zheng, Lin; He, Feng; Zhang, Zhirong; Wang, Yonglin . Determination of plasma protein binding rates of protocatechuic acid, isoorientin and scutellarin in Compound Hongcao freeze-​dried powder for injection by ultrafiltration combined with UPLC-​ESI-​MS​/MS. Zhongguo Yaoxue Zazhi (Beijing, China). 2011, 46, 1200-1204.","Data digitized from plot reported.  All from average males/females. 6 vials EH product tested for content via HPLC. 37.2 mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.",,1889,462.36,12,7,207.6,4,anionic,0.29,-4.5
Secretin (human),108153-74-8,C[C@H]([C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc2cnc[nH]2)N)O,0.16,6.73,,0.4,2.41,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-136_SecreFlo_BioPharmr.pdf. Accessed on May 17 2017,"Secretin human. Synthetic human peptide. MW= 3039.436. N=12, 0.4 ug/kg iv in human. 77.2 kg average weight. . Cross-over study with porcine peptide. Data digitized from plot reported in biopharmaceutics review. No AUC reported but clearance reported as 580.9 mL/min or 7.52 mL.min-1.kg-1 when normalized by body weight. 12% difference. t1/2 calculated by PK solver using only the last three points. May be overestimated.",,1986,3039.41,84,51,1401.2,109,cationic,-9,-9
Secretin (porcine),1393-25-5,C([C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(NCC(N[C@@H](C(N[C@@H](C(C)C)C(O)=O)=O)CC(C)C)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)C)=O)CO)=O)CC(O)=O)=O)CCCNC(N)=N)=O)CC(C)C)=O)CCCNC(N)=N)=O)CO)=O)CC(C)C)=O)CCC(O)=O)=O)CO)=O)[C@@H](C)O)=O)NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](Cc1[nH]ccn1)N)=O)CO)=O)CC(O)=O)=O)=O)[C@@H](C)O)=O)c1ccccc1,0.03,5.95,,0.08,0.13,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-136_SecreFlo_BioPharmr.pdf. Accessed on May 17 2017,"Secreflo. Secretin (porcine), 15-L-glutamic acid-16-glycine-. ChiRoClin. MW= 3056.42. Synthetic but identical to porcine peptide. Cross-over study with human peptide N=12, 0.4 ug/kg iv in human. 77.2 kg average weight. Data digitized from plot reported in biopharmaceutics review. No AUC reported. Clearance reported as 487 mL/min. Converted in units of mL.min-1.kg-1 yields 6.31 mL.min-1.kg-1. 6% difference",,1907,3056.39,85,52,1415.7,109,zwitterionic,-9,-9
Selegiline,2323-36-6,CC(Cc1ccccc1)N(C)CC#C,1.9,20,0.13,1.6,1.3,"Heinonen, EH, Anttila, MI, Lammintausta, RAS.(1994) Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 56: 742-749.   De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S (2004)  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet.  43: 157-185.  Emsam Product Label.  Zelapar Product Label.",,,1963,187.28,1,0,3.2,5,cationic,2.8,2.3
Sematilide,101526-83-4,CCN(CC)CCNC(=O)c1ccc(NS(=O)(=O)C)cc1,0.82,3.7,0.96,3.7,3.8,"Shi J, Ripley E, Gehr TWB, Sica DA, Dandekar KA, and Hinderling PH (1996) Pharmacokinetics of sematilide in renal failure.  J. Clin. Pharmacol. 36: 131-143.  Hinderling PH, Dilea C, Koziol T, and Millington G (1993) Comparative kinetics of sematilide in four species.  Drug Metab. Dispos. 21: 662-669.",,,1985,313.42,6,2,78.5,8,zwitterionic,1.1,-1.6
Semaxanib,194413-58-6,N1C(\C(c2ccccc12)=C/c1[nH]c(cc1C)C)=O,0.98,14,0.008,1.17,0.83," Sukbuntherng, Juthamas; Cropp, Gillian; Hannah, Alison; Wagner, Gregory S.; Shawver, Laura K.; Antonian, Lida. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.  Journal of Pharmacy and Pharmacology (2001), 53(12), 1629-1636","TSU16. Data in rat, dog and monkey available in the same reference. N=69, 0.1-5 mg/kg iv, cancer patients with advanced malignancies and on a variety of concomitant medications. Human data originally reported by Cropp et al at conference proceedings. Deemed accurate.","Semoxind, SU5416. Mixture of diastereomers reported as semaxinib with CAS# 204005-46-9",1998,238.28,3,2,44.9,1,neutral,2.2,2.2
Seraspenide,120081-14-3,CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O,,18.7,,,0.08,"ERIC EZAN, PATRICE CARDE, JOEL LE KERNEAU, THIERRY ARDOUIN, FRANCOIS THOMAS, FRANCOISE ISNARD, EVELYNE DESCHAMPS DE PAILLETTE, AND JEAN-MARC GROGNET. PHARMACOKINETICS IN HEALTHY VOLUNTEERS AND PATIENTS OF NAc-SDKP (SERASPENIDE), A NEGATIVE REGULATOR OF HEMATOPOIESIS. Drug Metab. Disp. 1994, 22, 843-848.","Goralatide, Ac-SDKP. N=6, 69.7 kg average weight, 62.5 ug/kg/12 hr (128 nmol). Digitization yielded a much higher AUC (155 nM.hr) than reported (112 nM.hr) and  clearance and t 1/2 were taken from reported data.",Alternate smiles: C(N1CCC[C@H]1C(=O)O)(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)C,1988,487.5,14,7,228.5,14,anionic,-3.3,-8.6
Sermorelin,86168-78-7,"C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](Cc1ccc(O)cc1)N)=O)C)=O)CC(O)=O)=O)C)=O)[C@@H](CC)C)=O)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](Cc1ccc(O)cc1)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(NCC(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](CCCNC(N)=N)C(N)=O)=O)CO)=O)CCSC)=O)[C@@H](CC)C)=O)CC(O)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CCCCN)=O)CCCNC(N)=N)=O)C)=O)CO)=O)CC(C)C)=O)CCC(N)=O)=O)=O)CC(C)C)=O)C(C)C)=O)CCCCN)=O)CCCNC(N)=N)=O)=O)CO)=O)CC(N)=O)=O)[C@@H](C)O)=O)c1ccccc1
",0.34,39.3,,0.14,0.19,Sermorelin Acetate - FDA Approval Package Administrative documents 020443. Accessed through Pharmapendium. ,"Data digitized and VDss calculations performed via Phoenix. Average of 3 doses (0.25, 0.5 and 1 mg). N=12.",no metabolism studies performed in humans.,1982,3357.88,86,52,1446.9,118,cationic,-9,-9
Silatecan,220913-32-6,[Si](C(C)(C)C)(C)(C)C(=C1C(C(N(C1)C(=O)C1=C2[C@](CC)(O)C(OC1)=O)=C2)=N1)C(C1=CC1)=CC=1O,0.47,6,,1.3,1.4,"A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies  Susanne M. Arnold, John J. Rinehart, Eleftheria Tsakalozou, John R. Eckardt, Scott Z. Fields, Brent J. Shelton, Philip A. DeSimone, Bryan K. Kee, Jeffrey A. Moscow, and Markos Leggas Clin Cancer Res January 15, 2010 16:673-680",DB-67 or AR-67. Data for total of lactone and acid form but lactone accounting for 88% of total drug on average. Doses from 1.2 to 12.4 mg/m2. Weighted average across doses for a toital of 26 patients. Day 1 data only. 1 hour infusion.,,1999,478.61,7,2,100,2,neutral,4.9,4.8
Sildenafil,139755-83-2,c1(c2nc3c(c(=O)[nH]2)n(nc3CCC)C)c(ccc(c1)S(=O)(=O)N1CCN(CC1)C)OCC,1.36,9,0.04,2.5,2.2,"Sildenafil 2009-Dec-21  PDF(322k)
Assessment Report EMEA/H/C/638/X/0019",EMEA review through PP. weighted average of N=12 (50 mg) and 3 (25mg). 70 kg average weight assumed.,PDR. Accessed February 14 2013.  http://www.pdr3d.com/detail.php?c=75609#section-3,1992,474.58,10,1,113.4,7,cationic,1.6,1.1
Silodosin,160970-54-7,C(O)CCN1c2c(cc(C[C@H](NCCOc3c(cccc3)OCC(F)(F)F)C)cc2CC1)C(=O)N,,2.8,0.05,,3.6,"Silodosin - EMA Approval Package
Assessment Report EMEA/H/C/001209. Accessed through Pharmapendium.",2 mg dose administered as iv infusion 0.8 L/kg reported as VD after iv dose but likely to be VDz.,No conclusive data in EMA package,1994,495.53,7,3,97.1,13,cationic,3,2.3
Sinitrodil,143248-63-9,C(CON(=O)=O)N1COc2ccccc2C1=O,0.68,29.59,,0.38,0.38,"Monzani MV, Coltro G, Sala A, Sardina M., Pharmacokinetics of ITF 296 (Sinitrodil) a novel organic nitrate, in healthy volunteers. Eur J Pharm Sci, 1999, 7, 179-184. ","Data from 10 mg dose 30-min iv infusion, N=11, 78.08 kg average weight",,1992,238.2,7,0,84.6,4,neutral,1.8,1.8
Sipatrigine,130800-90-7,c1(c2c(nc(N3CCN(C)CC3)nc2)N)c(c(cc(c1)Cl)Cl)Cl,15.31,20.9,,12.26,10.98,"A. J. MERCER, R. J. LAMB, HUSSEIN, S. HOBBIGER, J. POSNER. The Tolerability, Pharmacokinetics and Pharmacodynamics of Increasing Intravenous Doses of 619C89, a Novel Compound for the Acute Treatment of Stroke, in Healthy Volunteers. Ann N. Y. Acad. Sci., 1995, 754, 324-326."," 619C89. Data digitized from reported plot. 1 mg/kg only but linear PK. N=8, 70 kg average weight assumed. Reported AUCinf = 885 ng.hr.mL-1. Calculated 798 ng.hr.mL-1 (11% difference). Clearance reported 1.2 L.hr-1.kg-1. Calculated 1.25 L.hr-1.kg-1.","in STROKE PATIENTS: Z. HUSSEIN, I. J. FRASER, K. R. LEES, K. W. MUIR, M. W. LUNNON, S. F. HOBBIGER, J. POSNER. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. Br J Clin Pharmacol 1996; 41: 505–511//619C89. 5 dose groups (loading and maintenance infusion). Data were weight averaged accoding to number of patients. N=23 overall (N=22 for t1/2). Reported mean body weight 74 kg.",1990,372.68,5,1,58.3,2,cationic,4.4,3.6
Sisomicin,32385-11-8,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(=CC[C@H]3N)CN)[C@@H]2O)OC[C@]1(C)O,0.19,1,0.15,3.2,2.4,"Chung M, Schrogie JJ, and Symchowicz S (1981) Pharmacokinetic study of sisomicin in humans.  J. Pharmacokinet. Biopharm. 9: 535-551.  Lode H, Kemmerich B, and Koeppe P(1975)  Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin.  Antimic. Agents Chemother. 8: 396-401.  Pechere JC, Pechere MM, and Dugal R (1976) Clinical pharmacokinetics of sisomycin: two-compartment model analysis of serum data after I.V. and I.M. administration.  Eur. J. Clin. Pharmacol. 10: 251-256.  Ramirez-Ronda CH, Holmes RK, and Sanford JP (1975)  Effects of divalent cations on binding of aminoglycoside antibiotics to human serum proteins and to bacteria.  Antimic. Agents Chemother  7: 239-45. ",Siseptin. Rickamicin. Sch 13475,,1960,447.53,12,8,213.7,6,cationic,-4.5,-8.4
Sitafloxacin,127254-12-0,N[C@@H]1CN(CC12CC2)c3c(F)cc4C(=O)C(=CN([C@@H]5C[C@@H]5F)c4c3Cl)C(=O)O,1.5,3.7,0.51,6.7,6.6,"O'Grady J, Briggs A, Atarashi S, Kobayashi H, Smith RL, Ward J, Ward C, and Milatovic D (2001) Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucsian subjects.  Xenobiotica 31: 811-822.  Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Xenobiotica. 2001 Nov;31(11):811-22.
Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects.
O'Grady J, Briggs A, Atarashi S, Kobayashi H, Smith RL, Ward J, Ward C, Milatovic D.and Tanaka M (1995) Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.  Antimic. Agents Chemother. 39: 170-174.",VDss calculated from CL and MRT reported in the reference.,,1989,409.81,6,2,86.9,3,zwitterionic,2.5,0.26
Sitagliptin,486460-32-6,N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc3cc(F)c(F)cc3F,2.8,6,0.62,7.8,12,Januvia Product Label. PDR accessed on July 29 2014. http://www.pdr3d.com/detail.php?c=53747#section-13,"Intravenous clearance was calculated from oral dose, oral exposure, and absolute bioavailability reported in the product label for a 100 mg dose.",,2003,407.31,6,1,77,4,cationic,0.46,-0.4
"Sitosterol, β-",83-46-5,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,0.3,0.02,,250,372.4,"Duchateau, Guus; Cochrane, Brett; Windebank, Sam; Herudzinska, Justyna; Sanghera, Davindera; Burian, Angela; Mueller, Markus; Zeitlinger, Markus; Lappin, Graham. Absolute oral bioavailability and metabolic turnover of β-​sitosterol in healthy subjects. Drug Metab. Disp. 2012, 40, 2026-2030.","Nimbosterol. Betaprost. Angelicin. N=6, male volunteers. 2.9 to 4.2 ug doses. 70 kg assumed as average weight. MRT from clearance and VDss.",,1908,414.71,1,1,20.2,6,neutral,9,9
SK-896,131418-27-4,O=C(N(CCC1)[C@@H]1C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(N[C@]([C@H](O)C)([H])C(N[C@H](C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CCO)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC2=CC=C(O)C=C2)=O)=O)CC3=CC=CC=C3)=O)=O)[C@H](C(C)C)NC([C@@H](N)CC4=CC=CC=C4)=O,0.07,8.08,0.03,0.14,0.08,"Yoshiyuki Furuta, Yukiharu Nakayama, Mitsuyoshi Nakashima, Yoshio Suzuki. Pharmacokinetic and
Pharmacodynamic Studies of SK-896, a New Human Motilin Analogue, in Healthy Male Volunteers. Clin Pharmacokinet 2003; 42 (6): 575-584
",Table I. SK-896 pharmacokinetic parameters during and after single intravenous infusion of the indicated doses over 20 minutes in healthy male volunteers. The values are geometric means (geometric SD) [range] for n = 6 ppb cited from ref. 21 in the reported reference. All data are average of different doses in the 10-80 ug infusion.,,1990,2782.11,72,41,1215.5,98,cationic,-9,-9
SNS-032,345627-80-7,N1CCC(CC1)C(=O)Nc1sc(cn1)SCc1oc(cn1)C(C)(C)C,5.14,13,,7.13,9.3,"Phase I and Pharmacologic Study of SNS-032, a Potentand Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma Wei-Gang Tong, Rong Chen, William Plunkett, David Siegel, Rajni Sinha, R. Donald Harvey, Ashraf Z. Badros, Leslie Popplewell, Steven Coutre, Judith A. Fox, Kristi Mahadocon, Tianling Chen, Peggy Kegley, Ute Hoch, and William G. Wierda. J Clin Oncol 201. 28:3015-3022.",BMS 387032. Weighted average across 32 patients. Dose range 15 to 100 mg/m2. ,,2001,380.53,6,2,80.3,5,cationic,2,0.64
Soblidotin,149606-27-9,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)NCCc2ccccc2)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C,0.42,1.6,,4.6,5.67,"Nobuyuki Yamamoto,Masahiro Andoh,Masaaki Kawahara,Masahiro Fukuoka, Hisanobu Niitani. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci 2009; 100: 316–321. // J. Horti · E. Juhasz · Z. Monostori · K. Maeda · S. Eckhardt · I. Bodrogi.  Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2008) 62:173–180","TZT-1027. VDss from clearance and MRT in both cases. Some trend toward lower clearance at higher doses in both reports. However, fairly contained. Very similar number of patient in each cohort across many doses in both studies. NOT WEIGHT AVERAGED.",,1993,701.98,11,2,120.5,20,neutral,3.9,3.8
Sobrerol,42370-41-2,CC1=CC[C@H](C[C@@H]1O)C(C)(C)O,0.43,2.7,,3.1,1.9,"Schiavi M., Ventura P., Giachetti, C., Poletti, P., Canali, S., Zanolo, G.  Systemic availability of two oral formulations of trans-sobrerol in healthy volunteers. Third European Congress of Biopharmaceutics and Pharmacokinetics : proceedings : Freiburg, April 21-24, 1987, p.228-233",trans-sobrerol.,,1938,170.25,2,2,40.5,0,neutral,1.3,1.3
Solifenacin,242478-37-1,O=C(O[C@H]1CN2CCC1CC2)N3CCc4ccccc4[C@@H]3c5ccccc5,8.2,2.1,0.02,65,52,"Kuipers ME, Krauwinkel WJJ, Mulder H, and Visser N (2004) Solifenacin demonstrates high absolute bioavailability in healthy men.  Drugs R D 5: 73-81.  Krauwinkel WJJ, Smulders RA, Mulder H, Swart PJ, and Taekema-Roelvink MEJ (2005) Effect of age on the pharmacokinetics of solifenacin in men and women.  Int. J. Clin. Pharmacol. Ther. 43: 227-238. ppb from second ref.",YM-905,,2000,362.46,4,0,32.8,3,cationic,4.4,3.3
Sotalol,3930-20-9,CC(C)NCC(O)c1ccc(NS(=O)(=O)C)cc1,1.3,2,0.62,11,6.3,"Poirier JM, Jaillon P, Lecocq B, Lecocq V, Ferry A, and Cheymol G (1990) The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers.  Eur. J. Clin. Pharmacol. 38: 579-582.  Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, and Slugg PH (1997) A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J. Clin. Pharmacol. 37: 799-809.   Schnelle K, Klein G, and Schinz A (1979) Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man. J. Clin. Pharmacol. 19: 516-522.  Fiset C, Philippon F, Gilbert M, and Turgeon J (1993) Stereoselective disposition of (+/-)-sotalol at steady-state conditions.  Br. J. Clin. Pharmacol. 36: 75-77.",,,1964,272.36,5,3,78.4,6,cationic,0.43,-1.4
Sparfloxacin,110871-86-8,C[C@@H]1CN(C[C@H](C)N1)c2c(F)c(N)c3C(=O)C(=CN(C4CC4)c3c2F)C(=O)O,3.9,2.7,0.55,24,20,"Zagam Product Label. Montay. G. Journal of Antimicrobial Chemotherapy (1996), 37, Suppl. A, 27-39 Pharmacokinetics of sparfloxacin in healthy volunteers and patients",,,1987,392.4,7,3,98.9,3,zwitterionic,2.7,-0.36
Sparfosic acid,51321-79-0,[H]N(C(CP(=O)(O[H])O[H])=O)[C@@H](CC(=O)O[H])C(=O)O[H],0.33,1.22,,4.51,4.78,"Erlichman C, Strong J M, Chabner B A, Application of a Simple Competitive Protein-binding Assay Technique to the Pharmacokinetics of N-(Phosphonacetyl)-L-aspartate in Humans Cancer Research 1980, 40, 1902-1906. N=7.  Data from iv infusion (T=15 min) of 600-2000 mg/sq m/day doses. CL assumed average BW 70 Kg. MRT calculated from VDss and CL. t1/2 beta.",VDss SD = 0.18,,1973,255.12,9,5,161.2,10,anionic,-2.8,-9
Spectinomycin,1695-77-8,CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O,0.13,0.99,,2.2,1.8,"Wagner, JG, Novak, E, Leslie, LG, Metzler, CM (1968) Absorption, distribution and elimination of spectinomycin dihydrochloride in man.  Int. Zeit. Klin. Pharmakol. Ther. Toxikol. 1: 261-285. ",VDss calculated from C vs t data obtained by digitization of plots in the reference.,,1961,332.35,9,5,129.5,2,cationic,-2.9,-5.3
Spiramycin,8025-81-8,O1[C@H](CC[C@@H](N(C)C)[C@@H]1C)O[C@@H]1[C@@H](C[C@@H]([C@@H]([C@@H](OC)[C@@H](CC(O[C@H](C)CC=CC=C1)=O)O)O[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)N(C)C)O[C@@H]1O[C@H]([C@@H]([C@@](C1)(O)C)O)C)C)CC=O)C,5.4,12.8,0.26,7,5.2,"A. M. Frydmana,Y. Le Rouxa, J. F. Desnottesa,  P. Kaplan, F. Djebbar, A. Cournof, J. Ducbier and J. Gaillofl Pharmacokinetics of spiramycin in man.Journal of Antimicrobial Chemotherapy (1988) 22, Suppl. B, 93-103. ppb: Hashimoto, T. FUNDAMENTAL STUDIES ON PHARMACOKINETICS OF ANTIBIOTICS. PART 1. BINDING OF ANTIBIOTICS TO PLASMA PROTEINS. Chemotherapy (Tokyo). 1973, 21, 38-44","0.5 g dose, 69 kg average weight, N=12, data from Table II study A. MRT from VDss and clearance. 17·1% and 6% binding to albumin and a1-acid glycoprotein respectively",,1954,843.05,16,4,195.4,11,cationic,2,0.92
Spirapril,83647-97-6,c1ccccc1CC[C@H](N[C@@H](C(N1[C@@H](CC2(C1)SCCS2)C(=O)O)=O)C)C(=O)OCC,0.43,11.9,,0.61,8.6,"    Spirapril Hydrochloride - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 020240 Part 01. Accessed through Pharmapendium.","Data digitized and calculations performed via Phoenix. Data digitized from Figure 7.1 in FDA report (NDA: 20-240):
Reported ""readable"" data (table 7.1): N=5, 70kg body weight assumed AUCinf = 92 ng*h/mL, CL = 0.96 L/min (13.7 mL/min/70kg)",Transformed into diacid spiraprilat in analogy with other ACE inhibitors.,1982,466.61,7,2,95.9,10,anionic,2.7,-0.81
Spisulosine,196497-48-0,N[C@@H](C)[C@H](O)CCCCCCCCCCCCCCC,30.7,57.6,,8.89,29.7,"Massard, C.; Salazar, R.; Armand, J. P.; Majem, M.; Deutsch, E.; Garcia, M.; Oaknin, A.; Fernandez-Garcia, E. M.; Soto, A.; Soria, J. C. Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. Investigational New Drugs 2012, 30, 2318-2326.","ES-285. N=54 across doses from 4 to 256 mg/m2. Weight-averaged for number of patients at each dose. 3-hr infusion q3wk. Large range for VDss somewhat less for clearance. Clearance within a factor of 2 from largest to smallest value across dose, but VDss > 1o-fold between largest (3786 L) and smallest (334 L) values. Even larger spread for t1/2 ranging from 51 to 0.6 hours. MRT calculated as VDss/Cl. ",,1997,285.51,2,2,46.3,15,cationic,6.6,4.3
Squalamine,148717-90-2,CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(=O)(=O)O,0.23,1.2,,3.2,9.5,"Hao D, Hammond LA, Eckhardt SG, Patnaik A, Takimoto CH, Schwartz GH, Goetz AD, Tolcher AW, McCreery HA, Mamun K, Williams JI, Holroyd KJ, and Rowinsky EK (2003) A phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.  Clin. Canc. Res. 9: 2465-2471.",VDss calculated from C vs t data obtained by digitization of the representative plot provided in the report.,,1993,627.96,8,5,133.9,16,cationic,3.8,0.76
SR 271425,155990-20-8,N(CCN(CC)CC)C(C(=C(C1CNC=O)S2)C(=O)C(C2=CC=C2OC)=C2)=CC=1,1.01,3.1,,5.4,6.19,"Lockhart AC, Calvo E, Tolcher AW, Rowinsky EK, Shackleton G, Morrison JG Rafi R, VerMeulen W, Rothenberg ML (2009) A Phase I dose-escalation study of SR 271425, an intravenously dosed thioxantone analog, administered weekly in patients with refractory solid tumors. Am J Clin Oncol 2009;32: 9–14","N=16 across 5 dose groups (64-675 mg/m2).  Weight averaged by number of patients. 70 kg average weight assumed. VDss 70.9 L, Cl 13.02 L/h, ",,1994,413.53,6,2,70.7,9,cationic,3.7,2.4
SR 4554,167648-73-9,"c1cn(c(n1)[N+](=O)[O-])CC(=O)NCC(C(F)(F)F)O
",0.69,3,,3.86,3.45,"Beatrice M. Seddon, Geoffrey S. Payne, Laura Simmons, Ruth Ruddle, Rachel Grimshaw, Siew Tan, Alison Turner, Florence Raynaud, Gavin Halbert, Martin O. Leach, Ian Judson, Paul Workman. A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy. Clinical Cancer Research, 2003, Vol. 9, 5101–5112.",Average values reported across several doses. N=8 70 kg average weight assumed. 400 to 1600 mg/m2. MRT from clearance and VDss.,,1995,282.18,8,2,110.3,5,neutral,-0.68,-0.68
Stavudine,3056-17-5,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,0.67,8.2,1,1.4,1.4,"Dudley MN, Graham KK, Kaul S, Geletko S, Dunkle L, Browne M, and Mayer K (1992) Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.  J. Infec. Dis. 166: 480-485.  Horton CM, Dudley MN, Kaul S, Mayer KH, Squires K, Dunkle L, and Anderson R (1995) Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex.  Antimic. Agents Chemother. 39: 2309-2315.  Zerit XR Product Label.",,,1964,224.21,6,2,78.9,2,neutral,-0.71,-0.71
Streptomycin,57-92-1,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O,0.34,0.78,0.65,7.3,4.3,"Zhu M, Burman WJ, Jaresko GS, Berning SE, Jeliffe RW, and Peloquin CA (2001) Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis.  Pharmacother. 21: 1037-1045.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.",,Seemingly biliary but not clear from EMA package.,1964,581.57,19,14,331.4,11,cationic,-7.8,-9
Stresscopin,351999-19-4,"N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C(C(C)C))C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C(C)C))C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C(C)C))C(=O)N[C@@H](C(C(C)C))C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C(C)C))C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](C(C(C)C))C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N
",2.5,14.2,,2.9,4,"Gheorghiade, Mihai; Greene, Stephen J.; Ponikowski, Piotr; Maggioni, Aldo P.; Korewicki, Jerzy; Macarie, Cezar; Metra, Marco; Grzybowski, Jacek; Bubenek-Turconi, Serban-Ion; Radziszewski, Waldemar; Olson, Allan; Bueno, Orlando F.; Ghosh, Atalanta; Deckelbaum, Lawrence I.; Li, Lilian Y.; Patel, Ayan R.; Koester, Andreas; Konstam, Marvin A. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. European Journal of Heart Failure 2013, 15 (6),679-689",Urocortin III. MRT from VDss and clearance. Data reported as range. Median taken.,,2001,4367.15,109,59,1783.7,148,cationic,-9,-9
Sufentanil,56030-54-7,CCC(=O)N(c1ccccc1)C2(COC)CCN(CCc3cccs3)CC2,9.4,15,0.075,10,14,"Hudson RJ, Bergstrom RG, Thomson IR, Sabourin MA, Rosenbloom M, and Strunin L (1989) Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery.  Anesthesiol. 70: 426-431.  Scholz J, Bause H, Schulz M, Klotz U, Krishna DR, Pohl S, Schulte am Esch J (1994) Pharmacokinetics and effects on intracranial pressure of sulfentanil in head trauma patients.  Br. J. Clin. Pharmacol. 38: 369-372.  Meuldermans WEG, Hurkmans RMA, and Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.  Arch. Int. Pharmacodyn. Ther. 257: 4-19.",,,1976,386.55,4,0,32.8,8,cationic,3.9,2.9
Sugammadex,343306-71-8,C(SCCC(=O)O)[C@@H]1[C@H]2O[C@H]3O[C@H](CSCCC(=O)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CSCCC(=O)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CSCCC(=O)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@@H]([C@@H](O[C@H]4O[C@@H]([C@@H](O[C@H]5O[C@@H]([C@@H](O[C@H]6OC([C@@H](O[C@@H](O1)[C@@H]([C@H]2O)O)[C@H](O)[C@H]6O)CSCCC(=O)O)[C@H](O)[C@H]5O)CSCCC(=O)O)[C@H](O)[C@H]4O)CSCCC(=O)O)[C@@H]([C@H]3O)O)CSCCC(=O)O,0.18,1.28,,2.41,2.53,"Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Pierre Peetersa, Paul Passiera, Jean Smeets, Alex Zwiers, Marcel de Zwart,
Saskia van de Wetering-Krebbers, Marlou van Iersel, Sjoerd van Marle, and Diels van den Dobbelsteen. Biopharm. Drug Dispos. 2011, 32: 159–167.","N=6, mean weight 75.8 kg, 4 mg/kg dose, single bolus. MRT calculated from VDss and Cl.",,2001,2002.15,48,24,769.8,40,anionic,-9,-9
Sulbactam,68373-14-8,CC1(C)C(N2C(CC2=O)S1(=O)=O)C(=O)O,0.32,5.1,0.62,1,1.1,"Foulds G, Stankewich JP, Marshall DC, O'Brien MM, Hayes SL, Weidler DJ, and McMahon FG (1983) Pharmacokinetics of sulbactam in human.  Antimic. Agents Chemother. 23: 692-699.  Rho JP, Castle S, Smith K, Bawdon RE, and Norman DC (1992) Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam.  J. Antimic. Chemother. 29: 701-709.  Foulds G, Miller RD, Knirsch AK, and Thrupp LD (1985) Sulbactam kinetics and excretion into breast milk in postpartum women.  Clin. Pharmacol. Ther. 38: 692-696.  Blum RA, Kohli RK, Harrison NJ, and Schentag JJ (1989) Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.  Antimic. Agents Chemother.  (1989),  33: 1470-1476.  de la Pena A and Derendorf H (1999) Pharmacokinetic properties of beta-lactamase inhibitors.  Int. J. Clin. Pharmacol. Ther. 37: 63-75.",,,1978,233.24,6,1,91.8,1,anionic,-0.25,-3.7
Sulbenicillin,41744-40-5,CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](c3ccccc3)S(=O)(=O)O)C(=O)N2[C@H]1C(=O)O,0.15,1.6,0.5,1.6,1.2,"Hansen I, Jacobsen E, and Wels J (1975) Pharmacokinetics of sulbenicillin, a new broad-spectrum semisynthetic penicillin.  Clin. Pharmacol. Ther.  17: 339-347.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98. Antimicrobial agents and chemotherapy (1998) P 325-331",CL and VDss calculated from digitized plot.  Serum concentrations were detemined using bioassay.,,1971,414.45,9,3,141.1,5,anionic,0.59,-4.7
Sulfadiazine,68-35-9,Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2,0.29,0.55,0.44,8.8,7,"Mannisto PT, Mantyla R, Mattila J, Nykanen S, and Lamminsivu (1982) Coparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous administration.  J. Antimic. Chemother. 9: 461-470.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration. J. Pharm. Biomed. Anal. 1: 293-299. Winter and Unadkat DMD (2005) 33(7) 969-967",VDss deteremined from Cvs t data obtained by digitization of plots in the reference.  ,,1900,250.28,6,2,98,3,anionic,0.11,-0.75
Sulfamethoxazole,723-46-6,Cc1onc(NS(=O)(=O)c2ccc(N)cc2)c1,0.3,0.36,0.23,14,9.8,"Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, and Nightingale CH (1984) Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.  Antimic. Agents Chemother. 26: 811-814.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration. J. Pharm. Biomed. Anal. 1: 293-299.",,,1957,253.28,6,2,98.5,3,anionic,1.1,-0.56
Sulfasalazine,599-79-1,c1(S(Nc2ccccn2)(=O)=O)ccc(\N=N\c2cc(c(O)cc2)C(O)=O)cc1,0.11,0.26,0.004,6.8,7.6,"Sulfasalazine - FDA Approval Package
Label 007073/S-124. See also Sulfasalazine - FDA Approval Package
Bioequivalence Review 007073.  Accessed through PharmaPendium. Ppb: Kochansky, Christopher J.; McMasters, Daniel R.; Lu, Ping; Koeplinger, Kenneth A.; Kerr, Haley H.; Shou, Magang; Korzekwa, Kenneth R. Impact of pH on Plasma Protein Binding in Equilibrium Dialysis. Mol. Pharm. 2008, 5, 438-448",70 kg assumed.  MRT from VDss and clearance.,renal clearance estimated as 37% of total. Anecdotally assigned to metabolic. See FDA package.,1944,398.39,9,3,141.3,6,anionic,3.6,0.17
Sulfinpyrazone,57-96-5,O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4,0.12,0.34,0.017,5.9,6.2,"Lecaillion JB, Souppart C, Schoeller JP, Humbert G, and Massias P (1979) Sulfinpyrazone kinetics after intravenous and oral administration.  Clin. Pharmacol. Ther. 26: 611-617.  Schlicht F, Staiger C, de Vries J, Gundert-Remy U, Hildebrandt R, Harenberg J, Wang NS, and Weber E (1985) Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.  Eur. J. Clin. Pharmacol. 28: 97-103.",VDss calculated from rate microconstants reported in the reference.,,1954,404.48,5,0,57.7,6,anionic,2.2,-1.2
Sulfisoxazole,127-69-5,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,0.17,0.3,0.079,9.4,7.4,"Kaplan SA, Weinfeld RE, Abruzzo CW, and Lewis M (1972) Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man.  J. Pharm. Sci. 61; 773-778.  Oie S, Gambertoglio JG, and Fleckenstein L (1982) Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing.  J. Pharmacokinet. Biopharm. 10: 157-72.  Du Souich P, Calvo R, and Erill S (1990) Effects of cefotaxime on the serum protein binding of sulfisoxazole.  Biopharm. Drug Dispos. 11: 371-379.","Pharmacokinetic parameters were calculated from C vs t data provided in the reference by Kaplan, et al..",,1946,267.3,6,2,98.5,3,anionic,0.79,-1.6
Sulmazole,73384-60-8,[H]n1c2cccnc2nc1c1ccc(cc1OC)S(C)=O,0.62,10,0.41,1,0.8," Roth, W.; Zimmer, A.; Busch, U.  Human pharmacokinetics of AR-​L 115 BS. Arzneim-Forsch. 1981, 31, 239-236. ","ARL115 BS. Data digitized from plots reported. Data normalized to 50 mg dose as reported in Table 2. Average AUC after normalization (0.7*78= 54.6 mg, 54.6/50 =1.09) Average AUC reported, (after normalization factor and average in Table 2) = 1241 ng.hr.mL-1 No other data reported except approximate t1/2 = 50 (in text). Calculated AUC data within 7% of reported. fu = 0.41. N=12, 78 kg median weight taken. 0.7 mg/kg mg dose and 1' bolus. ",,1981,287.34,5,1,67.9,3,neutral,1.3,1.3
Sulpiride,15676-16-1,c1(c(ccc(c1)S(=O)(=O)N)OC)C(NC[C@@H]1[N@@](CCC1)CC)=O,0.94,1.9,1,8.01,6.5," Bres, Janine; Bressolle, Francoise. Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations  Journal of Pharmaceutical Sciences (1991), 80(12), 1119-24. ",Dogmatil. Reported as not bound to plasma protein and essentially all cleared renally. Blood/plasma ratio ~ 1.,,1967,341.43,7,2,101.7,6,cationic,0.7,-0.75
Sumatriptan,103628-46-2,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,1.7,19,0.83,1.5,1.7,"Cosson VF, Fuseau E, Efthymiopoulos C, and Bye A (1997) Mixed effect modeling of sumatriptan pharmacokinetics during drug development.  I Interspecies allometric scaling.  J. Pharmacokinet. Biopharm. 25: 149-167.  Scott AK (1994) Sumatriptan clinical pharmacokinetics. Clin. Pharmacokinet. 27: 337-344.",,,1986,295.4,5,2,65.2,6,cationic,1.5,0.3
Suprofen,40828-46-4,CC(C(=O)O)c1ccc(cc1)C(=O)c2cccs2,0.04,0.76,0.006,0.88,2.1,"Zulliger HW and Fassolt A (1985) Pharmacokinetics and bioavailability of suprofen injection solution after intravenous application versus capsules on six healthy male volunteers. Arzneim.Forsch. 35: 976-980.  Chaikin P, Chasin M, Kennedy B, and Silverman BK (1983) Suprofen concentrations in human breast milk.  J. Clin. Pharmacol. 23: 385-390.  ",All parameters were calculated from C vs t data provided in the reference.,,1957,260.31,3,1,54.4,4,anionic,2.7,-0.31
Suramin,145-63-1,Cc1ccc(cc1NC(=O)c2cccc(NC(=O)Nc3cccc(c3)C(=O)Nc4cc(ccc4C)C(=O)Nc5ccc(c6cc(cc(c56)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)c2)C(=O)Nc7ccc(c8cc(cc(c78)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,0.54,0.0057,0.003,1400,1200,"Collins, JM, Klecker, RW, Yarchoan, R, Lane, HC, Fauci, AS, Redfield, RR, Broder, S, Myers, CE (1986) Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 26: 22-26.",,,1941,1297.28,29,12,483.8,16,neutral,-4.2,-9
Susalimod,149556-49-0,[H]N(c1c(C)cccn1)S(c1ccc(C#Cc2ccc(c(c2)C(=O)O[H])O[H])cc1)(=O)=O,0.1,0.07,0.0019,23.8,16,"Pahlman I, Edholm M, Kankaanranta S, Odell M-L (1998) Pharmacokinetics of susalimod, a highly biliary excreted sulphasalazine analogue, in various species. Nonpredictable human clearance by allometric scaling. Pharm. Pharmacol. Commun. 4, 493-498.","100 mg dose, n=3, fu measured at 25uM ED",,1993,408.43,7,3,116.6,8,anionic,4.1,0.52
Suvorexant,1030377-33-3,Cc1ccc(c(c1)C(=O)N2CCN(CC[C@H]2C)c3nc4cc(ccc4o3)Cl)n5nccn5,0.69,0.84,0.05,13.76,10.37,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204569Orig1s000ClinPharmR.pdf. Accessed December 16 2016,"70 kg average weight, N=8 for each dose: 5, 10, 20 and 30 mg iv.VDss from iv data 48.3 L as average across doses. Similarly clearance reported as 58.55 as average across all doses. 30 mg dose was less than proportional (higher clearance) but within a factor of two and it was included. MRT from VDss and clearance.",,2008,450.92,8,0,80.6,3,neutral,5.9,5.9
Tacrine,321-64-2,Nc1c2CCCCc2nc3ccccc13,11,56,0.25,3.3,3.3,"Lou G, Montgomery PR, and Sitar DS (1996) Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.  J. Psych. Neurosci.  21: 334-339.  Makela PM, Truman CA, Ford JM, and Roberts CJC (1994) Characteristics of plasma protein binding of tacrine hydrochloride: a new drug for Alzheimer's disease. Eur. J. Clin. Pharmacol. 47:  151-155.",,,1945,198.26,2,1,38.9,0,cationic,3.3,0.83
Tacrolimus,104987-11-3,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)\[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@H]([C@H](C[C@@H](C)C\C(=C/[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)\C)OC)[C@H](C[C@H]4C)OC,1.2,0.7,0.01,27,26,"Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, and Christians U (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.  Clin. Pharmacol. Ther. 69: 24-31.  Iwasaki K, Miyazaki Y, Teramura Y, Kawamura A, Tozuka Z, Hata T, and Undre N (1996) Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid.  Res. Comm. Molec. Path. Pharmacol. 94: 251-257.",,,1986,804.02,13,3,178.4,7,neutral,4,4
Talinolol,57460-41-0,CC(C)(C)NCC(O)COc1ccc(NC(=O)NC2CCCCC2)cc1,3.3,4.9,0.39,11,11,"Trausch B, Oertel R, Richter K, and Gramatte T (1995) Disposition and bioavailability of the beta1-adrenoreceptor antagonist talinolol in man.  Biopharm. Drug Dispos. 16: 403-414.  Trausch B, Oertel R, Richter K, and Gramatte T (1995) Die proteinbindung von talinolol.  Pharmazie   50: 72.",,,1972,363.49,6,4,82.6,7,cationic,3.3,1.4
Tamsulosin,106133-20-4,CCOc1ccccc1OCCN[C@H](C)Cc2ccc(OC)c(c2)S(=O)(=O)N,0.21,0.62,0.01,5.6,6.8,"van Hoogdalem E, Soeishi Y, Matsushima H, and Higuchi S (1997) Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling.  J. Pharm. Sci.  86: 1156-1161.  Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, and Tsunoo M (1998) Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans.  Drug Metab. Dispos. 26: 240-245.",,,1986,408.51,7,2,99.9,11,cationic,2.5,1.6
Tanespimycin,75747-14-7,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(=C\C=C/[C@H](OC)[C@@H](OC(=O)N)\C(=C\[C@H](C)[C@H]1O)\C)\C)C2=O,2,10.18,,3.27,3,"Paul G. Richardson, Asher A. ChananKhan,Sagar Lonial, Amrita Y. Krishnan, Michael P. Carroll, Melissa Alsina, Maher Albitar, David Berman,8 Marianne Messina and Kenneth C. Anderson. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br. J. Haematol, 2011, 153, 729–740.  doi:10.1111/j.1365-2141.2011.08664.x","CP 127374. 17-AAgents Average of two administrations at 340 mg/m2, to 18 patients each, with either a cremophor or a nanosuspension formulation. 173 m2/70 kg conversion factor. MRT from clearance and VDss.",AUC of 17-AG metabolite reported.,1980,585.69,11,4,166.3,7,neutral,2.9,2.9
Tanshinol,23028-17-3,OC(C(O)CC1=CC(O)=C(O)C=C1)=O,0.38,17.75,,0.53,0.37,"Xiuxue Li , Chen Cheng , Fengqing Wang , Yühong Huang , Weiwei Jia , Olajide E. Olaleye ,
Meijuan Li , Yanfen Li , Chuan Li. Pharmacokinetics of catechols in human subjects intravenously receiving XueBiJing injection, an emerging antiseptic herbal medicine. Drug Metab. Pharmacokin. 2015. http://dx.doi.org/10.1016/j.dmpk.2015.10.005",3 different dosage regimens to 6 M and 6 F each. (three different infusions). Actual doses not reported. Standardized solution? Data averaged across all patients (N=36). 70% eliminated in urine.,Structure drawn in ChemDraw and exported as SMILES,1952,198.17,5,4,98,3,anionic,0.19,-3
Tapentadol,175591-23-8,c1cc(cc(c1)[C@@H]([C@@H](C)CN(C)C)CC)O,4.64,21.33,,3.62,2.39,"Göhler K ,  Brett M ,  Smit JW ,  Rengelshausen J ,  Terlinden R. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int. J. Clin. Pharmacol. Ther. 2013, 51,338-348.","N=24,  34 mg iv dose as a 15 minutes infusion. Average weight assumed to be 70 kg. Data digitized from plot reported and PK parameters calculated via PKSolver. AUC0-inf reported essentially identical to AUCinf calculated: 379 ng.h.mL. reported t 1/2 =  4.09 h. ",,1996,221.34,2,1,23.5,5,cationic,3.6,1.8
Tariquidar,206873-63-4,n1cc(cc2ccccc12)C(=O)Nc1c(cc(c(c1)OC)OC)C(=O)Nc1ccc(cc1)CC[N@@]1Cc2cc(c(cc2CC1)OC)OC,6.4,2.8,,38,29,"Bauer, M.; Zeitlinger, M.; Todorut, D.; Boehmdorfer, M.; Mueller, M.; Langer, O.; Jaeger, W. . Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects Pharmacology (2013), 91(1-2), 12-19.","N=15 , across 4, 6 and 8 mg/kg doses via iv infusion, from 1.5 to 2.6 hours.. Average of each cohort of 5 with reported BW of 85, 88 and 74 kg, respectively. 5.84, 6.15 and 7.12 l/kg respectively. Same calculation performed for clearance (1.85, 2.44 and 4.07 mL/min/kg, respectively). MRT from VDss and clearance.",From Bauer et al. comments on negligible metabolism but possible enterohepatic recirculation.,1998,646.73,10,2,111.2,11,cationic,5.5,4.5
TAS-106,180300-43-0,[C@H]1(n2c(=O)nc(cc2)N)O[C@@H]([C@]([C@H]1O)(O)C#C)CO,1.1,1.6,,11.7,10.9,"A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of TAS-106 Once per Week for Three Consecutive Weeks Every 28 Days in Patients with Solid Tumors. BENJAMIN FRIDAY, YVONNE LASSERE, CHRISTINA A. MEYERS,.AKIRA MITA, JAMES L. ABBRUZZESE and MELANIE B. THOMAS. Anticancer Res. 2012, 32,1689-1695.",3'-c-Ethynylcytidine. Ecyd. Weighted average of 15 subjects. Doses of 0.33 to 2.64 mg/m2 across 15 subjects in total. Data reported corrected for weight. ,,1996,267.24,8,4,130.8,3,neutral,-3.2,-3.2
Tasidotin,192658-64-3,Cl.O=C(N1[C@@H](CCC1)C(=O)NC(C)(C)C)[C@H]1N(CCC1)C(=O)[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C)C)C(C)C,0.33,9.6,,0.58,0.57,"Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Cunningham, Casey; Appleman, Leonard J.; Kirvan-Visovatti, Miora; Ryan, David P.; Regan, Eileen; Vukelja, Svetislava; Bonate, Peter L.; Ruvuna, Francis; Fram, Robert J.; Jekunen, Antti; et al Clinical Cancer Research (2005), 11(21), 7825-7833","Doses from 3.9 mg/m2 up to 45.7 mg/m2, N-31 patients (total). 1.73m2/70 kg factor assumed. Weighted average of median values for each cohort. 30' infusion.",,1997,643.3,11,2,122.4,11,neutral,3.5,3.4
Tasimelteon,609799-22-6,CCC(=O)NC[C@@H]1C[C@H]1c2cccc3c2CCO3,0.33,9.04,,0.62,0.75,"Rosarelis Torres,  Marlene A. Dressman,  William G. Kramer, 
and Paolo Baroldi. Absolute Bioavailability of Tasimelteon. Am. J.  Ther. 2015, 22, 355–360.","Data digitized from plot reported. Clearance within 14% of reported. N=14 (7M/7F), 2 mg, 30' infusion, average weight 63.6 kg",,1998,245.32,3,1,38.3,4,neutral,2.1,2.1
Tazarotene,118292-40-3,c12c(cc(C#Cc3ccc(C(OCC)=O)cn3)cc1)C(CCS2)(C)C,3.55,37.2,,1.56,6.22,"Tazarotene - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 020600/S-000 Part 01","15 ug/kg, 20' infusion. N=8",,1988,351.46,3,0,39.2,5,neutral,5.3,5.3
Tazobactam,89786-04-9,S1([C@@]([C@@H](N2C(=O)C[C@@H]12)C(O)=O)(Cn1ccnn1)C)(=O)=O,0.26,4.81,0.7,0.89,0.97,"Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses Miller, Benjamin; Hershberger, Ellie; Benziger, David; Trinh, My My; Friedland, Ian 
Antimicrobial Agents and Chemotherapy (2012), 56(6), 3086-3091. ppb. The PDR states: Both piperacillin and tazobactam are approximately 30% bound to plasma proteins.  Accessed January 15 2015. http://www.pdr3d.com/detail.php?c=137294#section-13.","BRN 4787943, Cl 298741. Average of 500 and 750 mg doses, administered alone to healthy volunteers, N=5 per dose, day 1 only. No accumulation noted at day 10.  71.4 kg average weight. MRT calculated from Cl and VDss. Renal clearance calculated as 66% across the two doses.",,1984,300.29,9,1,122.5,3,anionic,-1.7,-5.2
Tebufelone,112018-00-5,[H]C#CCCCC(c1cc(c(c(c1)C(C)(C)C)O[H])C(C)(C)C)=O,12,8.9,,22.3,50.7,"Cruze CA, Kelm GR, Meredith MP (1995) Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharm. Res. 12, 895-901.","Data digitized from Dedrick-like plot reported. AUC reported 579 ng.h.mL-1; clearance reported 9.87 mL.min-1.kg-1.  These data refer to the corrected t and C data for human. 25 mg dose and 72.9 average weight.
",,1987,300.44,2,1,37.3,6,neutral,5.4,5.4
Tedizolid,856866-72-3,Cn1nc(nn1)c2ccc(cn2)c3ccc(cc3F)N4C[C@@H](OC4=O)CO,0.91,1.19,0.11,12.64,10.16,"S. Flanagan, S. L. Minassian, D. Morris, R. Ponnuraj,T. C. Marbury, H. W. Alcorn, E. Fang, P. Prokocimer. Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic
Impairment. Antimicrobial Agents and Chemotherapy, 2014, 58, 6471-6476.
","Data digitized from plot reprorted, N=8, healthy volunteers, 70 kg average weight assumed, 0.82 correction factor for dose from administered phosphate prodrug (rapidly cleaved) to tedizolid. AUCinf essentially identical to reported value. ppb data from Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012;56(5):2627–2634.",,2005,370.34,9,1,106.3,4,neutral,2,2
Tegafur,17902-23-7,c1c(c(=O)[nH]c(=O)n1C2CCCO2)F,0.62,0.95,,10.75,8.69,"Markku I. Anttila, Eero A. Sotaniemi, Matti I. Kairaluoma, Risto E. Mokka, and Hannu T. Sundquist. Pharmacokinetics of Ftorafur After Intravenous
and Oral Administration. Cancer Chemother Pharmacol (1983) 10:150-153.","Ftorafur. Fluorofur. Citofur. 5-Fluoro-1-(tetrahydrofuran-2-yl)uracil. Data digitized from figure 1. 2 g dose, iv bolus, N=7, average weight 55.7 kg. AUC0-inf 617 mg.h.L-1. Calculated AUC0-inf 624 ug.h.mL-1. 1% difference.",,1967,200.17,5,1,64.1,1,neutral,0.078,-3.4
Tegaserod,145158-71-0,CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12,5.3,18,0.02,4.9,11,"Appel-Dingemanse S, Lemarechal MO, Kumle A, Hubert M, and Legangneux E (1999) Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.  Br. J. Clin. Pharmacol.  47: 483-491.  Appel-Dingemanse S (2002) Clinical pharmacokinetics of tegaserod, a serotonin 5-HT4 receptor partial agonist with promotile activity.  Clin. Pharmacokinet. 41: 1021-1042.",,,1992,301.39,6,4,85.3,9,cationic,4.3,0.86
Teicoplanin A2-1,91032-34-7,C(C(=O)N[C@H]1[C@H](Oc2c3cc4[C@H](C(N[C@@H]5c6cc(c7c([C@@H](NC([C@H]([C@@H](c8cc(c(O3)cc8)Cl)O[C@H]3[C@@H]([C@H]([C@H](O)[C@H](O3)CO)O)NC(C)=O)NC5=O)=O)C(=O)O)cc(O)cc7O[C@H]3O[C@@H]([C@@H](O)[C@@H]([C@@H]3O)O)CO)c(cc6)O)=O)NC([C@@H]3c5cc(Oc6cc(ccc6O)[C@@H](C(N[C@@H](C(N3)=O)Cc3cc(c(Oc2c4)cc3)Cl)=O)N)cc(c5)O)=O)O[C@@H]([C@H](O)[C@@H]1O)CO)C\C=C/CCCCC,0.92,0.32,0.14,45.6,48.1,"Bernareggi A, Borgonovi M, Del Favero A, Rosina R, and Gavanaghi L (1991)  Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet. 256-260.",Dosed as mixture of all components but PK reported separately for each compound.N=5. MRT from VDss and clearance.,,1983,1877.64,42,24,662.4,19,anionic,0.47,-2.2
Teicoplanin A2-2,91032-26-7,C(C)(CCCCCCC(=O)N[C@H]1[C@H](Oc2c3cc4[C@H](C(N[C@@H]5c6cc(c7c([C@@H](NC([C@H]([C@@H](c8cc(c(O3)cc8)Cl)O[C@H]3[C@@H]([C@H]([C@H](O)[C@H](O3)CO)O)NC(C)=O)NC5=O)=O)C(=O)O)cc(O)cc7O[C@H]3O[C@@H]([C@@H](O)[C@@H]([C@@H]3O)O)CO)c(cc6)O)=O)NC([C@@H]3c5cc(Oc6cc(ccc6O)[C@@H](C(N[C@@H](C(N3)=O)Cc3cc(c(Oc2c4)cc3)Cl)=O)N)cc(c5)O)=O)O[C@@H]([C@H](O)[C@@H]1O)CO)C,0.83,0.25,0.09,56.1,54.2,"Bernareggi A, Borgonovi M, Del Favero A, Rosina R, and Gavanaghi L (1991)  Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet. 256-260.",Dosed as mixture of all components but PK reported separately for each compound.N=5. MRT from VDss and clearance.,,1983,1879.66,42,24,662.4,19,anionic,0.88,-1.8
Teicoplanin A2-3,91032-36-9,C(CC)CCCCCCC(=O)N[C@H]1[C@H](Oc2c3cc4[C@H](C(N[C@@H]5c6cc(c7c([C@@H](NC([C@H]([C@@H](c8cc(c(O3)cc8)Cl)O[C@H]3[C@@H]([C@H]([C@H](O)[C@H](O3)CO)O)NC(C)=O)NC5=O)=O)C(=O)O)cc(O)cc7O[C@H]3O[C@@H]([C@@H](O)[C@@H]([C@@H]3O)O)CO)c(cc6)O)=O)NC([C@@H]3c5cc(Oc6cc(ccc6O)[C@@H](C(N[C@@H](C(N3)=O)Cc3cc(c(Oc2c4)cc3)Cl)=O)N)cc(c5)O)=O)O[C@@H]([C@H](O)[C@@H]1O)CO,0.57,0.18,0.06,51.7,49.3,"Bernareggi A, Borgonovi M, Del Favero A, Rosina R, and Gavanaghi L (1991)  Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet. 256-260.",Dosed as mixture of all components but PK reported separately for each compound.N=5. MRT from VDss and clearance.,,1983,1879.66,42,24,662.4,20,anionic,1,-1.7
Teicoplanin A2-4,91032-37-0,C([C@@H](CC)C)CCCCCC(=O)N[C@H]1[C@H](Oc2c3cc4[C@H](C(N[C@@H]5c6cc(c7c([C@@H](NC([C@H]([C@@H](c8cc(c(O3)cc8)Cl)O[C@H]3[C@@H]([C@H]([C@H](O)[C@H](O3)CO)O)NC(C)=O)NC5=O)=O)C(=O)O)cc(O)cc7O[C@H]3O[C@@H]([C@@H](O)[C@@H]([C@@H]3O)O)CO)c(cc6)O)=O)NC([C@@H]3c5cc(Oc6cc(ccc6O)[C@@H](C(N[C@@H](C(N3)=O)Cc3cc(c(Oc2c4)cc3)Cl)=O)N)cc(c5)O)=O)O[C@@H]([C@H](O)[C@@H]1O)CO,0.57,0.15,0.044,64.8,58.1,"Bernareggi A, Borgonovi M, Del Favero A, Rosina R, and Gavanaghi L (1991)  Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet. 256-260.",Dosed as mixture of all components but PK reported separately for each compound.N=5. MRT from VDss and clearance.,,1983,1893.68,42,24,662.4,20,anionic,1.4,-1.3
Teicoplanin A2-5,91032-38-1,C(C(C)C)CCCCCCC(=O)N[C@H]1[C@H](Oc2c3cc4[C@H](C(N[C@@H]5c6cc(c7c([C@@H](NC([C@H]([C@@H](c8cc(c(O3)cc8)Cl)O[C@H]3[C@@H]([C@H]([C@H](O)[C@H](O3)CO)O)NC(C)=O)NC5=O)=O)C(=O)O)cc(O)cc7O[C@H]3O[C@@H]([C@@H](O)[C@@H]([C@@H]3O)O)CO)c(cc6)O)=O)NC([C@@H]3c5cc(Oc6cc(ccc6O)[C@@H](C(N[C@@H](C(N3)=O)Cc3cc(c(Oc2c4)cc3)Cl)=O)N)cc(c5)O)=O)O[C@@H]([C@H](O)[C@@H]1O)CO,0.42,0.09,0.033,78.2,66.8,"Bernareggi A, Borgonovi M, Del Favero A, Rosina R, and Gavanaghi L (1991)  Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet. 256-260.",Dosed as mixture of all components but PK reported separately for each compound.N=5. MRT from VDss and clearance.,,1983,1893.68,42,24,662.4,20,anionic,1.4,-1.3
Telavancin,372151-71-8,CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc3c4Oc5ccc(cc5Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@H]6C(=O)N[C@H]7C(=O)N[C@@H]([C@H](O)c8ccc(Oc3cc6c4)c(Cl)c8)C(=O)N[C@H](C(=O)O)c9cc(O)c(CNCP(=O)(O)O)c(O)c9c%10cc7ccc%10O)O[C@@H](C)[C@H]1O,0.11,0.2,0.07,9.2,6.7,"Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, and Nicolau DP (2006) Tissue penetration of telavancin after intravenous administration in healthy subjects.  Antimicr. Agents Chemother. 50: 788-790.  Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, and Barriere S (2005) Pharmacokinetics, serum inhibitory and bacteriocidal activity, and safety of telavancin in healthy subjects.  Anitmic. Agents Chemother. 49: 195-201.",,,2001,1755.63,38,23,598.1,30,anionic,2,0.08
Telcagepant,781649-09-0,O=c1n(c2c([nH]1)nccc2)C1CCN(CC1)C(=O)N[C@H]1C(=O)N(CC(F)(F)F)C[C@@H](CC1)c1c(F)c(F)ccc1,0.86,5.8,,2.5,8.2,"The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects. Tae H. Han, Rebecca L. Blanchard,  John Palcza,  Ashley Martucci, Cynthia M. Miller-Stein,  Maria Gutierrez, Deborah Panebianco, Ronda K. Rippley,  Christopher Lines,  and M. Gail Murphy. Arch Drug Info 2010,3:55–62","MK-0974. 70 kg average weight assumed. Weighted average across all 7 doses from 5 mg to  250 mg (N=10 for each one).  t1/2 calculated only from 4 doses from 50 to 250 
MRT calculated from VD and CL
Microdose?",,2004,566.52,9,2,103.3,4,neutral,3.5,-0.022
Telithromycin,191114-48-4,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCn4cnc(c4)c5cccnc5)C(=O)O[C@]13C)OC,3,14,0.41,3.6,12,"Perret C, Lenfant B, Weinling E, Wessels DH, Scholtz HE, Montay G, and Sultan E (2002) Pharmacokinetics and Absolute Oral Bioavailability of an 800-mg Oral Dose of Telithromycin in Healthy Young and Elderly Volunteers.  Chemotherapy 48: 217-223.  Yamazaki H, Lamy S, Ducelier C, Bonnat C, and Lenfant B (2003) Study of binding of telithromycin to human serum proteins. Nippon Kagaku Ryoho Gakkai Zasshi  51: 206-209. ",,,1995,812,15,1,171.8,11,cationic,3.7,2.4
Telmisartan,144701-48-4,CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)c4ccccc4C(=O)O)c5nc6ccccc6n5C,5.3,8.4,0.004,11,20,"Stangier J, Schmid J, Turck D, Switek H, Verhagen A, Peeters PAM, van Marle SP, Tamminga WJ, Sollie FAE, and Jonkman JHG (2000) Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers.  J. Clin. Pharmacol. 40: 1312-1322.",,,1992,514.62,6,1,72.9,7,anionic,7.7,4.7
Temocillin,66148-78-5,N12[C@H](C(S[C@@H]2[C@](C1=O)(OC)NC(=O)[C@@H](c1cscc1)C(=O)O)(C)C)C(=O)O,0.11,0.34,0.21,5.2,4.1,"M.R. Lockley, R.M. Brown and R. Wise. Pharmacokinetics and Tissue Penetration of Temocillin. Drugs 1985, 29 (Suppl. 5): 106-108//ppb: Overbosch, D.; Van Gulpen, C.; Mattie, H. Renal clearance of temocillin in volunteers. Drugs, 1985, 29, 128-134.","BRL 17421. N=6, 1 g dose and 69.2 kg as average weight reported. Data digitized from plot. AUCinf calculated within 2% of reported if AUCinf (not specified)  or within 10% if AUClast.//ppb concentration dependent. Midpoint taken between 0.17 and 0.26.",,1978,414.45,9,3,133.2,6,anionic,0.81,-5.7
Temoporfin,122341-38-2,c1(c2[nH]c(c(c3nc(c(c4cc(ccc4)O)c4[nH]c(c(c5nc1CC5)c1cc(ccc1)O)cc4)C=C3)c1cc(ccc1)O)cc2)c1cc(ccc1)O,,0.06,0.14,,91.5,"Temoporfin - EMA Approval Package
Scientific Discussion. Accessedd through Pharmapendium.","average of two studies at 0.15 mg/kg in healthy volunteers. VD reported as 0.39 and 0.46 L/kg, without definition and likely to be VDz.",Metabolic pthway not identified. EMA Package,1989,690.83,8,8,136.6,4,neutral,5.1,5
Temozolomide,85622-93-1,CN1N=Nc2c(ncn2C1=O)C(=O)N,0.5,3.6,,2.3,1.5,"Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, and Lejeune F (1998)  Pharmacokinetics of temozolomide in association with fitemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.  Canc. Chemother. Pharmacol.  42: 433-440. ",VDss calculated from digitized C vs t plot provided in the report. ,,1983,194.15,8,1,105.9,1,neutral,-1.1,-1.1
Temsirolimus,162635-04-3,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,3,7.7,,10,18,"Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, and Armand JP (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.  J. Clin. Oncol. 12: 2336-2347.",CCI-779. Additional information indicating strong DDI with CYP3A4. Suggestive of metabolic pathway. However no definitive quantitative data could be found.,,1994,1030.29,17,4,242,11,neutral,5.6,5.6
Tenidap,120210-48-2,c1cc(sc1)/C(=C/2\c3cc(ccc3N(C2=O)C(=O)N)Cl)/O,0.11,0.058,0.01,31.6,22.7,"Gardner, M. J.; Wilner, K. D.; Hansen, R. A.; Fouda, H. G.; McMahon, G. F.
Single- and multiple-dose pharmacokinetics of tenidap sodium in healthy subjects.
British Journal of Clinical Pharmacology (1995), 39(Suppl. 1), 11S-15S.//ppb: Madhok, Rajan. Tenidap. Lancet, 1995, 346, 481-485.","CAS# and struture entered for the enolic tautomer. Keto tautomer CAS# 100599-27-7. Data iv from table 2 only for deuterated compound (Day 1), N=12; BW=74.4 kg, Dose = 20 mg 1h infusion. MRT from VDss and clearance.",,1988,320.75,5,2,83.6,1,anionic,2.1,0.95
Tenifatecan,850728-18-6,CCc1c2cc(ccc2nc-3c1Cn4c3cc5c(c4=O)COC(=O)[C@@]5(CC)O)OC(=O)CCC(=O)Oc6c(c(c7c(c6C)CC[C@@](O7)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)C,0.15,0.81,,3.34,3.77,"Marier, Jean-Francois; Pheng, Leng; Trinh, My My; Burris, Howard A., III; Jones, Suzanne; Anderson, Kirsten; Warner, Serina; Porubek, David. Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors. J. Pharm. Sci. 2011, 100, 4536-4545.","SN2310. Weighted average of 24 patients across 4 doses. 15, 20, 25, 30 mg/m2. 1.73 m2/70 kg factor used.",,2005,905.17,11,1,143.2,21,neutral,9,9
Teniposide,29767-20-2,COc1cc(cc(OC)c1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)c6cccs6)c7cc8OCOc8cc27,0.41,0.19,0.0044,37,16,"Holthuis JJM, de Vries LGE, Postmus PE, van Oort WWJ, Verleun H, Hulshoff A, Sleijfer DT, and Mulder NH (1987) Pharmacokinetics of high-dose teniposide. Canc. Treatm. Rep. 71: 599-603.  Petros WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, and Evans WE (1992) Variability in teniposide plasma protein binding is correlated with serum albumin concentrations.  Pharmacother. 12: 273-277.",,,1953,656.65,13,3,160.8,6,neutral,0.15,0.15
Tenofovir,147127-20-6,C[C@H](Cn1cnc2c(N)ncnc12)OCP(=O)(O)O,0.83,3.1,0.93,3.8,5.8,"Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellman NS, Safrin S, and Kahn JO (1998) Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.  Antimic. Agents Chemother. 42: 2380-2384.  Fung HB, Stone EA, and Piacenti FJ (2002) Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.  Clin. Ther. 24: 1515-1548",Averaged data from two dose levels.,,1993,287.21,9,3,136.4,5,anionic,-1.3,-6.4
Tenoxicam,59804-37-4,CN1C(=C(O)c2sccc2S1(=O)=O)C(=O)Nc3ccccn3,0.19,0.03,0.0085,92,67,"Heintz RC, Guentert TW, Enrico JF, Dubach UC, Brandt R, and Jeunet FS (1984) Pharmacokinetics of tenoxicam in healthy human volunteers. Eur. J. Rheum. Inflam. 7: 33-44.  Nilsen OG, Aasarod K, Wideroe TE, and Guentert TW (2001) Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.  Pharmacol. Toxicol. 89: 265-272.","VDss calculated from reported micro rate constants in Heintz, et al..",,1975,337.37,7,2,99.6,2,anionic,2.5,-0.92
Terazosin,63590-64-7,COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4,0.98,1.1,0.08,15,9,Patterson SE (1985) Terazosin kinetics after oral and intravenous doses.  Clin. Pharmacol. Ther. 38: 423-427.  Sonders RC (1986) Pharmacokinetics of terazosin.  Am. J. Med. 80: 20-24.,VDss calculated from reported micro rate constants.,,1977,387.43,9,1,103,4,neutral,2,1.9
Terbutaline,23031-25-6,CC(C)(C)NCC(O)c1cc(O)cc(O)c1,1.5,3.4,0.75,7.4,15,"Borgstrom L, Nyberg L, Jonsson S, Lindberg C, and Paulson J (1989) Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.  Br. J. Clin. Pharmacol. 27: 49-56.  Nyberg L (1984) Pharmacokinetic parameters of terbutaline in healthy man.  An overview.  Eur. J. Resp. Dis. 65(Suppl 134) 149-160.  Leferink JG, van den Berg W, Wagemaker-Engels I, Kreukniet J, and Maes RAA (1982) Pharmacokinetics of terbutaline, a beta2-sympathomimetic, in healthy volunteers and asthmatic patients.  Arz. Forsch. 32: 159-164.",Cited terminal phase t1/2.  Data are for the racemate.,,1969,225.28,4,4,72.7,3,cationic,0.93,-0.41
Teriflunomide,163451-81-8,c1c(ccc(c1)C(F)(F)F)NC(=O)/C(=C(/C)O)C#N,0.16,0.007,0.01,367,350,PDR prescribing information for teriflunomide (Aubagio). Accessed July 29 2014.http://www.pdr3d.com/detail.php?c=78104#section-13,"Leflunomide metabolite (A 771726, CAS 108605-62-5) ppb > 99%. Assumed 70 kg as average weight.MRT from VDss and clearance. t1/2 not reported. Probably extremely long.","Teriflunomide - FDA Approval Package
Label 202992/S-000. Some indication of biliary excretion but no accurate mass balance or certain figures. Also marketed as parent, leflunomide.",1991,270.21,4,2,73.1,3,anionic,3.9,2.4
Teriparatide,52232-67-4,c12c(C[C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](Cc3c[nH]cn3)NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](Cc3c[nH]cn3)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](CO)N)=O)C(C)C)=O)CO)=O)CCC(O)=O)=O)[C@@H](CC)C)=O)CCC(N)=O)=O)CC(C)C)=O)CCSC)=O)=O)CC(N)=O)=O)CC(C)C)=O)=O)CCCCN)=O)=O)CC(C)C)=O)CC(N)=O)=O)CO)=O)CCSC)=O)CCC(O)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CCC(O)=O)=O)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](Cc3c[nH]cn3)C(N[C@@H](C(N[C@@H](Cc3ccccc3)C(O)=O)=O)CC(N)=O)=O)=O)C(C)C)=O)CC(O)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CCCCN)=O)CCCCN)=O)CCCNC(N)=N)=O)CC(C)C)=O)c[nH]c1cccc2,0.17,21.4,,0.13,0.14,"Teriparatide (Rdna Origin) - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021318/S-000. Accessed through Pharmapendium.","Data digitized and calculations performed via Phoenix. Calculated AUC 195 pg.h/mL, reported 205 pg.h/mL  ppb not determined Structure and smiles refer to cation. ",,1974,4117.72,106,60,1752.6,146,cationic,-9,-9
Terlipressin,14636-12-5,c1ccc(cc1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N2)Cc3ccc(cc3)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,0.24,8.2,,0.5,0.9,"Nilsson, G.; Lindblom, P.; Ohlin, M.; Berling, R.; Vernersson, E.. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs under Experimental and Clinical Research, 1990, 16, 307-314.","Data available in tabular form. Linear PK and 10 ug/kg dose taken since administered to the larger cohort (N=14, some point N=12). 77 kg average weight. Clearance 9 mL/min/kg. No AUC reported.",,1966,1227.37,31,16,512.8,25,cationic,-7.1,-9
Terodiline,15793-40-5,CC(CC(c1ccccc1)c2ccccc2)NC(C)(C)C,5.1,1.1,0.08,81,56,"Hallen B, Gabrielsson J, Palmer L, and Ekstrom B (1993) Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers.  Pharmacol. Toxicol.  73: 153-158.  Hallen B, Gabrielsson J, Nyambati S, Johansson A, Larsson E, and Guilbaud O (1995) Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites.    Pharmacol. Toxicol.  76: 171-177.",,,1963,281.44,1,1,12,5,cationic,5,2.1
Tesaglitazar,251565-85-2,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(=O)(=O)C)cc2)cc1)C(=O)O,0.13,0.039,0.0011,56,45,"Ericsson H, Hamren B, Bergstrand S, Elebring M, Fryklund L, Heijer M, and Ohman KP (2004) Pharmacokinetics and metabolism of tesaglitazar, a novel dual acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.  Drug Metab. Dispos.  32: 923-929.",,,1999,408.47,7,1,99.1,11,anionic,2.7,-0.53
Testosterone,58-22-0,[C@@H]12[C@@H]([C@@]3(C(=CC(=O)CC3)CC2)C)CC[C@]2([C@H]1CC[C@@H]2O)C,0.35,24.5,0.057,0.25,0.17,"Täuber U, Schröder K, Düsterberg B, Matthes H.  Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur J Drug Metab Pharmacokinet. 1986, 11,145-149.//ppb: Forest MG, Rivarola MA, Migeon CJ. Percentage binding of testosterone, androstenedione and dehydroisoandrosterone in human plasma. Steroids, 1968, 12, 323-343.","1.5 ug/kg, N=5 (all females). VDss calculated from the mean C vs t data provided in a plot in the paper.//for ppb: averaged the men and women; excluded the pregnant women (very different value).  Used the equilibrium dialysis data only.",,1946,288.42,2,1,37.3,0,neutral,3.3,3.3
Tetracycline,60-54-8,CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)C(=O)c4c(O)cccc4[C@@]3(C)O,1.2,1.5,0.78,12,9.4,"Kunin CM, Darnbush AC, and Finland M (1959) Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest.  38:  1950-1963.",calculated from digitized plots ,,1947,444.43,10,6,181.6,2,anionic,-0.87,-3.4
"Tetrahydrocannabinol, D9-",1972-08-3,CCCCCc1cc(O)c2[C@@H]3C=C(C)CC[C@H]3C(C)(C)Oc2c1,8.9,3.2,0.05,46,33,"Wall ME, Sadler BM, Brine D, Taylor H, and Perez-Reyes M (1983)  Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.  Clin. Pharmacol. Ther. 34: 352-363.  Busto U, Bendayan R, and Sellers EM (1989) Clinical pharmacokinetics of non-opiate abused drugs.  Clin. Pharmacokinet. 16: 1-26.",Dronabinol. Δ9-THC. VDss was calculated using C vs t data  provided in the reference.,,1940,314.46,2,1,29.5,4,neutral,7,7
"Tetrahydrocannabinol,11-Nor-9-carboxy-D9-",56354-06-4,CCCCCc1cc(c2c(c1)OC([C@H]3[C@H]2C=C(CC3)C(=O)O)(C)C)O,1.28,1.2,,18.1,17.6,"A Glaz-Sandberg, L Dietz, H Nguyen, H Oberwittler, Rolf Aderjan and Gerd Mikus. Pharmacokinetics of 11-nor-9-Carboxy-D9- Tetrahydrocannabinol (CTHC) After Intravenous Administration of CTHC in Healthy Human Subjects. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, VOLUME 82, 63-69.","N=10, 5 mg iv dose.",,1975,344.44,4,2,66.8,5,anionic,5.9,3.5
Tezosentan,180384-57-0,COc1ccccc1Oc2c(NS(=O)(=O)c3ccc(cn3)C(C)C)nc(nc2OCCO)c4ccnc(c4)c5nnn[nH]5,0.28,8.1,0.0085,0.58,3.8,"Dingemanse J, Clozel M, and Giersbergen PLM (2002) Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.  Br. J. Clin. Pharmacol. 53: 355-362.  Treiber A, Van Giersbergen PLM, and Dingemanse J (2003) In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans.  Xenobiotica 33: 399-414.",,,1996,605.63,15,3,200.1,12,anionic,3.5,-1.6
TH-302,918633-87-1,C(OP(=O)(NCCBr)NCCBr)c1n(C)c(nc1)N(=O)=O,0.64,14.8,,0.72,1,"A First-in-Man Phase 1 Study of TH-302, A Hypoxia-Activated Cytotoxic Prodrug (HAP). Glen J Weiss, Jeffrey R Infante, Mitesh Borad, Virginia K Langmuir, Stewart Kroll, Donald Jung, Raoul Tibes, E Gabriela Chiorean, Suzanne F Jones, Howard A Burris. Poster presented at the EORTC-NCI-AACR symposium - Berlin, November 16-19th 2010.",Evophosphamide. Data reported on poster available at http://www.thresholdpharm.com/pdf/weiss_eortc_annual_10-08.pdf. Accessed September 15 2011. TH-302 has a large Vdss (26 L/m2) and high clearance (36 L/h/m2).  MRT calculated via VDss and Cl..  t1/2 reported as 0.5-1 hour range.,,2007,449.04,9,2,114,10,neutral,0.35,0.35
Thalidomide,50-35-1,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,0.95,3.4,0.4,4.3,4.7,"Eriksson T, Bjorkman S, Roth B, and Hoglund P (2000) Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.  J. Pharm. Pharmacol. 52: 807-817.  Eriksson T, Bjorkman S, and Hoglund P (2001) Clinical pharmacology of thalidomide.  Eur. J. Clin. Pharmacol. 57: 365-376.  ","Values represent the average for bioth stereoisomers, which interconvert.",,1956,258.23,6,1,83.5,1,neutral,0.87,0.58
Theophylline,58-55-9,CN1C(=O)N(C)c2[nH]cnc2C1=O,0.51,0.86,0.61,9.9,7.2,"Kraan J, Borgstrom L, Koeter GH, Laseur M, Jonkman JHG, and deNoord OE (1988) Creation of four consecutive intantaneous steady-state plasma concentration plateaus of theophylline and enprofylline by repeated infusions with expoonentially decreasing delivery rates. Eur. J. Clin. Pharmacol. 35: 657-661.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res.  20: 1015-1021.  Lombardi TP, Bertino JS, Goldberg A, Middleton E, and Slaughter RL (1987) The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance.    J. Clin. Pharmacol. 27: 523-529.",,,1946,180.16,6,1,69.3,0,neutral,-0.22,-0.22
Thiamphenicol glycinate,2393-92-2,C(CN)(=O)OC[C@H]([C@@H](c1ccc(cc1)S(=O)(=O)C)O)NC(=O)C(Cl)Cl,0.13,9.6,0.27,0.23,0.28,"Yang, Bing; Li, Ning; Lu, Yang; Qiu, Zhixia; Zhao, Di; Song, Pengfei; Chen, Xijing. Pharmacokinetics of thiamphenicol glycinate and its active metabolite by single and multiple intravenous infusions in healthy Chinese volunteers. Xenobiotica, 2014, 44, 819-826. ppb: Hashimoto, T. FUNDAMENTAL STUDIES ON PHARMACOKINETICS OF ANTIBIOTICS. PART 1. BINDING OF ANTIBIOTICS TO PLASMA PROTEINS. Chemotherapy (Tokyo). 1973, 21, 38-44","VDss from MRT and clearance. N=24, across 500, 1000, 1500 mg. 30' infusion. Body weight average 58 kg.",,1963,413.27,8,3,135.8,9,cationic,-1.4,-1.8
Thioguanine,154-42-7,n1c2c(nc[nH]2)c([nH]c1N)=S,2.89,15.4,,3.13,24.35," Kitchen, Brenda J.; Balis, Frank M.; Poplack, David G.; O'brien, Michelle; Craig, Catherine E.; Adamson, Peter C.  A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. Clinical Cancer Research, 1997, 3, 713-717.","2-amino-6-mercaptopurine. 6-mercaptoguanine. Data digitized from plot 20 mg/m2/h, 24 hr infusion. N=13. 70 kg average weight assumed. 1.73 m2/70 kg conversion factor used. Reported clearance 608 mL/min/m2 corresponding to 15.02 mL/min/kg.",,1948,167.19,5,3,83.4,0,anionic,-1.2,-4.7
Thionylan (Methapyrilene),91-80-5,CN(C)CCN(Cc1cccs1)c2ccccn2,3.3,28,,2,1.6,"Calandre EP, Alferez N, Hassanein K, and Azarnoff DL (1981) Methapyrilene kinetics and dynamics.  Clin. Pharmacol. Ther. 29: 527-532. ",VDss calculated from C vs t data obtained by digitization of the plot included in the reference.,,1946,261.39,3,0,19.4,6,cationic,2.7,1.6
Thiopental,76-75-5,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,1.2,8.2,0.14,2.4,2,"Cordato DJ, Gross AS, Herkes GK, and Mather LE (1997) Pharmacokinetics of thiopentone enantiomers following intravenous injection or prolonged infusion of rac-thiopentone.  Br. J. Clin. Pharmacol. 43: 355-362.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",Data from individual stereoisomers were combined.  Half-life was estimated from the C vs t plot provided in the reference.,,1935,242.34,4,2,58.2,4,anionic,2.8,2.5
Thiotepa,52-24-4,S=P(N1CC1)(N2CC2)N3CC3,1.6,6.7,0.9,4,2.7,"Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA, and Bitran JD (1988) Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.  J. Clin. Oncol. 6: 1192-1196.  Hagen B and Nilsen OG (1987) The binding of thio-TEPA in human serum and to isolated serum protein fractions.  Cancer Chemother. Pharmacol. 20: 319-323.",,,1952,189.22,3,0,9,3,neutral,0.53,0.53
Tiagabine,115103-54-3,Cc1ccsc1C(=CCCN2CCC[C@H](C2)C(=O)O)c3sccc3C,1.1,1.6,0.04,12,10,"Jansen JA, Oliver S, Dirach J, and Mengel HB (1995)  Absolute bioavailability of tiagabine. Epilepsia  36(Suppl. 3): s159",,,1987,375.55,3,1,40.5,6,zwitterionic,5.3,2.4
Tianeptine,66981-73-5,c1(cc2c(cc1)[C@@H](c1c(cccc1)N(S2(=O)=O)C)NCCCCCCC(O)=O)Cl,0.3,2.8,0.05,1.9,1.4,"C Salvadori, C Ward, R Defrance, R Hopkins. The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans -
influence of alcohol co-administration. Fundam CIin Pharmacol(1990) 4, 1 15 - 125. ppb: R. ZINI, D. MORIN, C. SALVADORI J. P. TILLEMENT Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure. Br. J. clin. Pharmac. (1990), 29, 9-18","BRN1232295. CAS # in Scifinder as 72797-41-2 but both will lead to the same compound. N=12 (6M/6F) 12.5 mg of sodium salt (11.87 mg of free acid), 12' infusion and 78 kg reported as average weight. Reported AUC = 922 ng.hr/mL, clearance = 230 mL/min; t1/2 = 1.7 hr and VDz 0.47 L/kg",,1978,436.95,6,2,86.7,8,anionic,4.4,1.6
Tiapride,51012-32-9,c1(c(ccc(c1)S(C)(=O)=O)OC)C(NCCN(CC)CC)=O,1.1,4.7,,3.8,3.2,"Rey E, d'Athis P, Richard MO, de Lauture D, Olive G  Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms. International Journal of Clinical Pharmacology, Therapy, and Toxicology [1982, 20(2):62-67]","Values calculated from hybrid constants and intercepts reported. N=8 (4M, 4F) 57.2 kg average body weight. 200 mg dose.",Almost exclusively excreted unchanged renally.,1962,328.43,6,1,75.7,8,cationic,0.7,-0.86
Tiaprofenic acid,33005-95-7,O=C(c1ccccc1)c1sc(cc1)[C@@H](C(=O)O)C,0.08,0.62,0.015,2.3,2.1,"Human Pharmacokinetics of Tiaprofenic Acid. Pottier J. Cousty-Berlin D., Busigny M. Rheumatol. 1982, 7, 70-77.// ppb reported as > 98.5 %. Fakhreddin Jamali, ALAIN, ANTHONY S . RUSSELL,C ARMEN  LEHMANN, AND BRIAN W . BERRY. Pharmacokinetics of taiprofenic acid in healthy and arthritic subjects. J. Phar.Sci.. 1985, 74, 953-956","Digitized from plot reported. N=5 female subjects, 400 mg dose, iv bolus. 60 kg average weight assumed.",,1971,260.31,3,1,54.4,4,anionic,2.7,-0.53
Tiazofurin,60084-10-8,NC(=O)c1csc(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,1.1,2.4,0.47,7.6,5.9,"Jayaram HN, Lapis E, Tricot G, Kneebone P, Paulik E, Zhen W, Engeler GP, Hoffmann R, and Weber G (1992) Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion.  Int. J. Canc. 51: 182-188.  Roberts JD, Stewart JA, McCormish JJ, Krakoff IR, Culham CA, Hartshorn JN, Newman RA, Haugh LD, and Young JA (1987) Phase 1 trail of tiazofurin administered by iv bolus daily for 5 days, with pharmacokinetic evaluation.  Canc. Treatm. Rep. 71: 141-149.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",,,1976,260.27,7,4,125.9,3,neutral,-1.8,-1.8
Ticagrelor,274693-27-5,Sc1nc(N[C@@H]2C[C@H]2c3ccc(F)c(F)c3)c4nnn([C@@H]5C[C@H](OCCO)[C@@H](O)[C@H]5O)c4n1,1.25,3.38,0.002,6.16,6.8,"R. Teng, J. Maya. Absolute bioavailability and regional absorption
of ticagrelor in healthy volunteers. J. Drug Assess. 2014, 3, 43-50.//ppb: Sillen, Henrik; Cook, Melanie; Davis, Patty. Determination of unbound ticagrelor and its active metabolite (AR-​C124910XX) in human plasma by equilibrium dialysis and LC-​MS​/MS. J. Chrom. B: Analytical Technologies in the Biomedical and Life Sciences 2011, 879, 2315-2322","N=12, 70 kg average weight assumed, 15 mg dose as iv bolus. MRT from VDss and clearance",,2000,480.49,10,4,138.4,7,anionic,0.93,-1.2
Ticarcillin,34787-01-4,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O,0.16,1.8,0.55,1.5,1,"Watanabe K, Koyama M, Iijima F, Nakazawa H, and Nakahira K (1986) Phase I studies on BRL 28500 (clavulanic acid-ticarcillin).  Chemotherapy 34: 247.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.  Libke RD, Clarke JT, Ralph ED, Luthy RP, and Kirby WMM (1975) Ticarcillin vs carbenicillin: clinical pharmacokinetics.  Clin. Pharmacol. Ther.  17: 441-446.",Combined data from Watanabe and Libke papers,,1972,384.43,8,3,124,5,anionic,0.88,-5.7
Tigecycline,220620-09-7,CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)N(C)C,12,3.8,0.2,53,48,"Muralidharan G, Micalizzi M, Speth J, Raible D, and Trpy S (2005) Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.  Antimic. Agents Chemother.  49: 220-229.  Doan TL, Fung HB, Mehta D, and Riska PF (2006) Tigecycline: a glycylcycline antimicrobial agent.  Clin. Ther. 28: 1079-1106.",,,1999,585.65,13,7,205.8,6,cationic,-0.11,-2.9
Tilidine,51931-66-9,CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)c2ccccc2,4,16,0.21,4.2,5,"Vollmer KO, Thomann P, and Hengy H (1989) Pharmacokinetics of tilidine and metabolites in man.  Arz. Forsch. 39: 1283-1288.  Janicke UA and Gundert-Remy U (1985) Stereoselective protein binding of (+/-)-cis and (+/-) trans tilidine.  Arch. Pharmacol. 329: R101.",,,1968,273.37,3,0,29.5,5,cationic,4.1,3.4
Tiludronate,89987-06-4,c1cc(ccc1Cl)SC(P(O)(O)=O)P(O)(O)=O,0.23,0.4,0.1,9.5,7.7,"Sansom LN, Necciari J and Thiercelin JF (1995) Human pharmacokinetics of tiludronate. Bone
17:479S-483S.","Data digitized from plot reported. Average of 10, 20 and 30 mg 30' minutes infusion. Terminal phase extended and prone to error. AUCinf/AUClast 1.22. Prossibly overestimation of clearance due to tight binding and slow release form bone tissue. 70 kg average weight assumed. ",,1984,318.61,6,4,115.1,4,anionic,0.35,-4.4
Timolol,26839-75-8,CC(C)(C)NC[C@H](O)COc1nsnc1N2CCOCC2,1.5,8.5,0.9,3,2.2,"Vermeij P, el Sherbini-Schepers M, and van Zweiten PA (1978) The disposition of timolol in man.  J. Pharm. Pharmacol. 30: 53-55.  Meier J (1982) Pharmacokinetic comparison of pindolol with other beta adrenoceptor blocking agents.  Am. Heart J. 104: 364-373.",Parameters were calculated from C vs t data obtained by digitization of plots in the reference.,,1969,316.42,7,2,79.7,6,cationic,1.4,-0.34
Tinidazole,19387-91-8,CCS(=O)(=O)CCn1c(C)ncc1N(=O)=O,0.59,0.6,0.8,16,13,"Vinge E, Andersson KE, Ando G, and Lunell E (1983) Biological availability and pharmacokinetics of tinidazole after single and repeated doses.  Scand. J. Infect. Dis.  15: 391-397.  Sawyer PR, Brogden RN, Pinder RM, Speight TM, and Avery GS (1976) Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy.  Drugs 11: 423-440.",VDss calculated from digitized C vs t plot.,,1968,247.27,7,0,97.8,5,neutral,-0.48,-0.48
Tiopronin,1953-02-2,C[C@@H](C(NCC(O)=O)=O)S,1.39,1.48,0.45,15.7,55,"M. S. Carlsson , T. Denneberg  , B.-M. Emanuelsson , B. Kagedal , and S. Lindgren. Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. Eur J Clin Pharmacol (1990) 38:499-503. fu from clearance total and unbound reported. M. S. Carlsson , T. Denneberg  , B.-M. Emanuelsson , B. Kagedal , and S. Lindgren. Pharmacokinetics of oral tiopronin Eur J Clin Pharmacol (1993) 45:79-84. Data initially and erroneously entered from this work being a follow-up p.o. of 1990 work. Corrected on January 6 2015.","2-MPG. N=10, 71 kg average weight. 250 mg iv dose.",Almost exclusively excreted unchanged renally. As reported by Carlsson et al.,1963,163.19,4,2,66.4,3,anionic,-0.23,-3.6
Tiotropium,186691-13-4,O(C(=O)C(c1sccc1)(O)c1cccs1)C1C[C@@H]2[C@H]3O[C@H]3[C@H](C1)[N+]2(C)C,32,12.6,0.28,42.3,,"Tiotropium Bromide Monohydrate - FDA Approval Package
Label 021395/S-014. See also, Tiotropium Bromide Monohydrate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021395/S-000 Part 01. Accessed through Pharmapendium.",Structure and smiles refer to cation. 70 kg average weight assumed. MRT from VDss and clearance. T1/2 estimated between 5-6 days (~ 132 hours),"Tiotropium Bromide Monohydrate - FDA Approval Package
Label 021395/S-014. Accessed through Pharmapendium. 74% excreted unchanged.",1997,392.51,5,1,59.1,5,neutral,-2.3,-2.3
Tipifarnib,192185-72-1,Cn1cncc1[C@@](c2ccc(cc2)Cl)(c3ccc4c(c3)c(cc(=O)n4C)c5cccc(c5)Cl)N,0.93,5.03,0.006,3.07,2.52,"Zhang, Steven; Zannikos, Peter; Awada, Ahmad; Piccart-Gebhart, Martine; Dirix, Luc Y.; Fumoleau, Pierre; Verhaeghe, Tom; Francois, Marc; De Porre, Peter. Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer. J.Clin. Pharmacol. 2006, 46(10), 1116-1127.","Zarnestra. Data digitized from plot reported in Fig. 1. Calculations performed with PKSOlver. N=24, 100 mg dose, 2 hr infusion, 70 kg assumed as average weight, range 48-92 kg and reported median 58 kg.Reported AUC(0-10) 4487 ng.h.mL-1; calculated, 4390 ng.h.mL-1. 2% difference.",,1997,489.4,5,1,65.8,4,neutral,4.1,4.1
Tirapazamine,27314-97-2,Nc1n[n+]([O-])c2ccccc2[n+]1[O-],0.56,8.9,0.81,1,0.78,"Senan S, Rampling R, Graham MA, Wilson P, Robin H, Eckardt N, Lawson N, McDonald A, von Roemeling R, Workman P, and Kaye SB (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.  Clin. Cancer Res. 3: 31-38.  Robin H, Senan S, Workman P, and Graham MA (1995) development and validation of a sensitive solid-phase extraction and high performance liquid chromatoigraphy assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose selection.  Canc. Chemother. Pharmacol. 36: 266-270.",,,1957,178.15,6,1,92.8,0,neutral,-1.7,-1.7
Tirilazad,110101-66-1,C1(C=C[C@@]2(C3=CC[C@@]4([C@H]([C@@H](C[C@@H]4[C@@H]3CCC2=C1)C)C(CN1CCN(CC1)c1nc(nc(c1)N1CCCC1)N1CCCC1)=O)C)C)=O,9.8,7,0.006,23.2,49.3,"JOSEPH C. FLEISHAKER, PAUL G. PEARSON, LARRY C. WIENKERS, LAURA K. PEARSON and GARY A. PETERS. Biotransformation of Tirilazad in Human: 2. Effect of
Ketoconazole on Tirilazad Clearance and Oral Bioavailability. JPET 277:991-998, 1996.","2 mg/kg dose 10' infusion.N=12 (6M, 6F). Ppb > 99.4%",,1987,624.86,8,0,72.9,6,cationic,8.1,6.1
Tirofiban,142373-60-2,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,0.34,3,0.36,1.8,1.6,"Barrett JS, Murphy G, Peerlinck K, De Lepeliere I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, and Arnout J (1994) Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycprotein-IIb/IIIa receptor antagonist, in healthy men.  Cin. Pharmacol. Ther. 56: 377-388.  Kondo K and Umemura K (2002) Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: Comparison with the monoclonal antibody abciximab. Clin. Pharmacokinet. 41: 187-195.",CAS reported is the number of HCl salt. Parent CAS # 144494-65-5. data for 0.15 ug/kg/min infusion digitized and claculation performed via Phoenix.,,1992,440.6,7,3,104.7,14,zwitterionic,4.4,1.6
Tizanidine,51322-75-9,Clc1ccc2nsnc2c1NC3=NCCN3,2.4,11,0.7,3.6,2.4,"Zanaflex Product Label.  Granfors MT, Backman JT, Laitila J, and Neuvonen PJ (2004) Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro.  Br. J. Clin. Pharmacol. 57: 349-353.","Clearance value cited in Granfors, et al.",,1973,253.71,5,2,62.2,2,cationic,1.4,-0.26
TLK286,158382-37-7,c1ccc(cc1)[C@H](C(=O)O)NC(=O)[C@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)NC(=O)CC[C@@H](C(=O)O)N,0.46,28.5,,0.27,0.28,"Lee S. Rosen, Joseph Brown, Bernadette Laxa, Leny Boulos, Laura Reiswig, William D. Henner,
Robert T. Lum, Steve R. Schow, Christopher A. Maack, James G. Keck, Julie C. Mascavage, Jacqueline A. Dombroski, Reinaldo F. Gomez, and Gail L. Brown. Phase I Study of TLK286 (Glutathione S-Transferase P1-1 Activated Glutathione Analogue) in Advanced Refractory Solid Malignancies. Clinical Cancer Research, 2003, 9, 1628-1638.","Canfosfamide. (TLK286 is the R-isomer) DATA in BLOOD. No b/p ratio reported. N=6 for each two doses averaged (180 and 720 mg/m2, in the middle of range) very reproducible and largest two cohorts. 64 kg average weight of two cohorts derived from clearance in mL/min and mL/min/kg reported. MRT from VDss and clearance. Range 60 to 1280 mg/m2. Clearance from largest dose (N=5) ~3-fold smaller than smallest dose. Possible saturation observed at 960 mg/m2 as well. Authors report dose dependent clearance at the highest doses.",,1994,787.47,15,5,225.7,25,anionic,-1,-5.9
Toborinone,143343-83-3,c1c(OC[C@@H](CNCc2cc(c(OC)cc2)OC)O)cc2c(c1)[nH]c(cc2)=O,1.6,8.9,,3.2,3.3,"Akihiro Ohnishi, Takaaki Toyoki, Toshiyuki Ohno, Yoshiko Takeshige, Tsuyoshi Fujita, PharmD, Kazuhisa Kodama, Masayoshi Mishima, Atsushi Hirayama, Mami Kitani, Gohhachiro Miyamoto, Masatoshi Odomi, and Teruji Tanaka Pharmacokinetics and Pharmacodynamics of Intravenous OPC-18790 in Humans: A Novel Nonglycosidic Inotropic Agent. J Clin Pharrnacol 1994, 34, 176-183.","OPC-18790 Average of all data from Table 1 (rapid iv dose range 0.05-0.4 mg/kg, N=16) and Table 2 (1h infusion dose range 0.5-15 ug/kg/min N=20). PK values are not greatly affected by the inclusion of the lowest doses (shorter profiles). N=36 Avg body Weight 63.0 kg. With the exclusion of the lowest doses from either bolus or infusion MRT and t1/2 would yield 3.6 and 3.7 hr values respectively. VDss would equal to 1.7 L/kg and clearance would be calculated as 7.6 mL/min/kg.",,1990,384.43,7,3,92.8,9,cationic,1.5,-0.85
Tobramycin,32986-56-4,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,0.23,1.6,1,2.4,2,"Bourget P, Fernandez H, Delouis C, abd Taburet AM (1991) Pharmacokinetics of tobramycin in pregnant women, safety and efficacy of a once-daily dose regimen.  J. Clin. Pharm. Ther.  16: 167-176.  Champoux N, Du Souich P, Ravaoarinoro M, Phaneuf D, Latour J, and Cusson JR (1996) Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers.  Br. J. Clin. Pharmacol. 42: 325-331.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.",Data from Champeaux et al was digitized to calculate parameters.  ,,1971,467.51,14,10,268.2,6,cationic,-7,-8.5
Tocainide,41708-72-9,CC(N)C(=O)Nc1c(C)cccc1C,1.8,2.2,0.87,14,12,"Lalka D, Meyer MB, Duce BR, and Elvin AT (1976) Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.  Clin. Pharmacol. Ther. 19: 757-766.  Thomson AH, Murdoch G, Pottage A, Kelman AW, Whiting B, and Hillis WS (1986) The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.  Br. J. Clin. Pharmacol. 21: 149-154,  Sedman AJ, Bloedow DC, and Gal J (1982) Serum binding of tocainide and its enantiomers in human subjects.  Res. Comm. Chem Path. Pharmacol. 38: 165-168.",Combined data from individual enantiomers.,,1973,192.26,3,2,55.1,2,cationic,0.65,0.27
Tofacitinib,477600-75-2,[C@@H]1([C@H](CN(CC1)C(=O)CC#N)N(c1ncnc2[nH]ccc12)C)C,1.24,5.88,0.6,3.5,,"PDR. Accessed February 12 2013. http://www.pdr3d.com/detail.php?c=82134#section-13. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol. 8(4), 319–331 (2012). Cristiano AF Zerbini* and Andrea Barranjard Vannucci Lomonte",Clearance mechanisms for tofacitinib are approximately 70% hepatic metabolism and 30% renal excretion of the parent drug. No clearance or t1/2 reported in PDR. MRT from VDss and clearance.,PDR. Accessed February 12 2013.  http://www.pdr3d.com/detail.php?c=82134#section-13,2002,312.37,7,1,88.9,4,neutral,1.5,1.5
Tofogliflozin,903565-83-3,CCc1ccc(cc1)Cc2ccc3c(c2)[C@]4([C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC3,0.63,2.07,0.46,5.1,4.7,"Dietmar Schwab, Agnes Portron, Zoe Backholer, Berthold Lausecker, Kosuke Kawashima.  A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans. Clin Pharmacokinet 2013, 52, 463–473.","Microdose, 100 ug total, N=6, 80.4 kg average reported weight.",,2006,386.44,6,4,99.4,4,neutral,1.6,1.6
Tolamolol,38103-61-6,Cc1ccccc1OCC(O)CNCCOc2ccc(cc2)C(=O)N,4,14,0.089,4.8,2.5,"Faulkner JK, Stopher DA, Walden R, Singleton W, and Taylor SH (1975) Pharmacokinetic and pharmacological studies with tolamolol in man.  Br. J. Clin. Pharmacol. 2: 423-428.",VDss calculated from reported micro rate constants.,,1970,344.4,6,3,93.8,10,cationic,1.5,0.63
Tolbutamide,64-77-7,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,0.12,0.21,0.05,9.5,7,"Zilly W, Breimer DD, and Richter E (1975) Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.  Eur. J. Clin. Pharmacol. 9: 219-227.  Ayanoglu G, Uihlein M, and Grigoleit HG (1986) A new aspect of serum protein binding of tolbutamide.  Int. J. Clin. Pharmacol. Ther. Toxicol. 24: 65-68.",Concentration-dependent protein binding reported; free fraction value is cited that was collected at relevant circulating concentrations.,,1959,270.35,5,2,75.3,5,anionic,2.3,0.17
Tolcapone,134308-13-7,Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)N(=O)=O,0.12,1.9,0.0012,1.1,1.1,"Jorga KM, Kroodsma JM, Fotteler B, Heizmann P, Meyer J, Rasch MC, and van Hattum J (1998) Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites.  Clin. Pharmacol. Ther. 63: 646-654. ",,,1990,273.24,6,2,103.3,3,anionic,3,0.84
Tolfenamic acid,13710-19-5,c1ccc(c(c1Nc1ccccc1C(=O)O)C)Cl,0.16,2.37,0.003,1.13,2.15,"P. J. Pentikäinen,  P. J. Neuvonen,  and C. Backman.  Human Pharmacokinetics of Tolfenamic Acid, a New Anti-Inflammatory Agent. Eur. J. Clin. Pharmacol. 1981, 19, 359-365.","N=6, 65.5 kg average weight, 100 mg dose as 0.5 hr infusion. MRT from VDss and clearance. ",,1962,261.7,3,2,49.3,3,anionic,4.8,2
Toloxatone,29218-27-7,Cc1cccc(c1)N2CC(CO)OC2=O,1.5,11,0.49,2.3,1.6,"Strolin Benedetti M, Rovei V, Dencker SJ, Nagy A, and Johansson R (1982) Pharmacokinetics of toloxatone in man following intravenous and oral administrations.  Arz. Forsch. 32: 276-280.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1970,207.23,4,1,49.8,2,neutral,1.9,1.9
Tolterodine,124937-51-5,CC(C)N(CC[C@H](c1ccccc1)c2cc(C)ccc2O)C(C)C,1.5,8.4,0.037,3,2.4,"Brynne N, Stahl MMS, Hallen B, Edlund PO, Palmer L, Hoglund P, and Gabrielsson J (1997) Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.  Int. J. Clin. Pharmacol. Ther. 35: 287-295.  Brynne N, Dalen P, Alvan G, Bertilsson L, and Gabrielsson J (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine.  Clin. Pharmacol. Ther. 63: 529-539.  Pahlman I and Gozzi P (1999) Serum protein binding of tolterodine and its major metabolites in humans and several animal species.  Biopharm. Drug Dispos. 20: 91-99.",Data from CYP2D6 EM subjects included.,,1989,325.49,2,1,23.5,7,cationic,5.4,3.6
Tolvaptan,150683-30-0,c1cc(c(cc1)C)C(=O)Nc1ccc(C(=O)N2CCC[C@@H](c3c2ccc(c3)Cl)O)c(c1)C,0.5,2.4,0.01,3.5,2.9,"   Tolvaptan - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 022275/S-000 Part 02 ","Data digitized and calculations performed via Phoenix. Reported data (Table 9.2.3.2-1):
AUCinf = 106 ng*h/mL
t1/2 = 3.3 h
CL = 2.34 mL/min/kg",,1992,448.94,5,2,69.6,3,neutral,5.2,5.2
Tomopenem,222400-20-6,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(=C(N2C1=O)C(=O)O)S[C@H]3C[C@H](N(C)C3)C(=O)N4CC[C@@H](C4)NC(=O)CNC(=N)N,0.23,1.9,0.91,2,1.7,"Shibayama T, Matsushita Y, Hirota T, Ikeda T, and Kuwahara S (2006) Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.  Antimicr. Agents Chemother. 50: 4186-4188.  Shibayama T, Matsushita Y, Kawai K, Hirota T, Ikeda T, and Kuwahara S (2007) Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals   Antimic. Agents Chemother. 51: 257-263.  ",,,1999,537.63,13,6,192.4,9,zwitterionic,-2.3,-4.7
Tonapofylline,340021-17-2,C12(CCC(CC1)(CC2)c1[nH]c2c(n(c(n(c2n1)CCC)=O)CCC)=O)CCC(=O)O,0.76,1.08,0.1,11.7,16,"Clinical Pharmacokinetics of Tonapofylline:Evaluation of Dose Proportionality, Oral Bioavailability, and Gender and Food Effects in Healthy Human Subjects Zhaoyang Li, Christopher TenHoor, Thomas Marbury, Suzanne Swan, Barry Ticho, Mark Rogge,  and Ivan Nestorov, J Clin Pharmacol 2011 51, 1004-1014. ppb from same paper.","BG 9928. N=6, 1 mg/kg 30' infusion. N=4, 76.5 average weight.",,2001,416.51,8,2,110,8,anionic,3.2,0.73
Topiramate,97240-79-4,[C@]12([C@H]([C@H]3[C@@H](CO2)OC(O3)(C)C)OC(O1)(C)C)COS(=O)(=O)N,0.8,0.27,0.72,48.7,34.8,"Intravenous topiramate: Comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers Anne M. Clark, Robert L. Kriel, Ilo E. Leppik,  Susan E. Marino, Usha Mishra,Richard C. Brundage, and James C. Cloyd. Epilepsia, 2013, 54, (6), 1099–1105. ppb: The PDR states: Topiramate is 15% to 41% bound to human plasma proteins over the blood concentration range of 0.5 to 250 mcg/mL. The fraction bound decreased as blood concentration increased. Median value of 28% taken. Accessed January 6 2015. http://pdr3d.com/detail.php?c=13144#section-3","Data digitized from plots reported in reference cited. N=10, 78.2 kg average weight, 100 mg dose, 15' infusion.
Reported AUC0-a (h*lg/ml) 72.6   
Reported CL (L/h) 1.33 (= 0.28 mL/min/kg)
",,1985,339.36,9,1,115.5,3,neutral,0.47,0.44
Topixantrone,156090-18-5,CN(C)CCNc1ccc2c3c(nn2CCNCCO)c4cnccc4C(=O)c13,57,27,,39,45,"Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni MG, Barbieri P, Verdi E, Vincenzi B, and Bernareggi A (2004) Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthropyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase 1 study group trial of the Central European Society of Anticancer Drug Research (CESAR).  Anti-Cancer Drugs 15: 15-22.",BBR 3576,,1994,394.47,8,3,95.3,9,cationic,0.69,-1.4
Topotecan,123948-87-8,CC[C@@]1(O)C(=O)OCC2=C1C=C3N(Cc4cc5c(CN(C)C)c(O)ccc5nc34)C2=O,1.8,13,0.65,2.3,2.3,"Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, and Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.  Br. J. Canc. 73: 1268-1271.  van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, de Boer-Dennert M, Maes RAA, and Beijnen JH (1995) Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.  Canc. Chemother. Pharmacol. 35: 237-245.  Masubuchi N, May RD, and Atsumi R (2004) A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the In vitro Colony-Forming Unit Granulocyte/Macrophage Assay.  Clin. Cancer Res. 10: 6722-6731.",,,1957,421.45,8,2,103.2,3,cationic,1.3,-1.5
Torsemide,56211-40-6,CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc2cccc(C)c2,0.21,0.53,0.01,6.6,5.1,"Spahn H, Knauf H, and Mutschler E (1990) Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.  Eur. J. Clin. Pharmacol. 39: 345-348.  Knauf H and Mutschler E (1998) Clinical pharmacokinetics and pharmacodynamics of torasemide.  Clin. Pharmacokinet. 34: 1-24.",VDss calculated from reported MRT.,,1975,348.42,7,3,100.2,5,anionic,2.9,0.095
Toxogonin,114-90-9,[n+]1(ccc(\C=N\O)cc1)COC[n+]1ccc(\C=N\O)cc1.[ClH-].[ClH-],0.17,1.9,,1.5,1.2,"Toxogonin and Pralidoxime: Kinetic Comparison after Intravenous Administration to Man FREDERICK R. SIDELL’, WILLIAM A. GROFF, and ANDRIS KAMINSKIS. J. Pharm. Sci. 1972, 61, 1765-1769.","Obidoxime. CAS number refers to chloride salt. Parent CAS # 7683-36-5. N=5, 0.5 and 1.0 mg/kg, average weight 69 kg. MRT from VDss and clearance.",,1963,361.22,7,2,82.2,6,neutral,-9,-9
Tozasertib,639089-54-6,c1(cc(nc(n1)Sc1ccc(cc1)NC(=O)C1CC1)N1CCN(CC1)C)Nc1n[nH]c(c1)C,5.1,18.4,,4.5,8.4,"Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Anne M. Traynor Maureen Hewitt Glenn Liu  Keith T. Flaherty Jason Clark Steven J. Freedman Boyd B. Scott Ann Marie Leighton  Patricia A. Watson Baiteng Zhao Peter J. O’Dwyer George Wilding. Cancer Chemother Pharmacol 2011 67:305–314.",MK-457 or MK-0457. Data from Table 5 in Cancer Chemother Pharmacol (2011) 67:305–314. Dose range 8 to 96 mg/m2/h 24 h infusion. Body weight 70 kg assumed Weighted PK values (total N = 25) :,,2003,464.59,9,3,102.1,7,cationic,4.5,3.5
Trabectedin,114899-77-3,COc1cc2c(CCN[C@]23CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](Cc7cc(C)c(OC)c(O)c67)[C@H](O)N5[C@@H](COC3=O)c8c9OCOc9c(C)c(OC(=O)C)c48)cc1O,25,12,0.06,35,44,"Lau L, Supko JG, Blaney S, Harshon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, and Baruchel S (2005) A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors.  A children's oncology group study.  Clin. Canc. Res.  11: 672-677. ppb: Jan Handrick Beumer, L. Lopez-Lazaro, Jan H.M. Schellens, Jos H. Beijnen, Olaf van Tellingen. Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™,ET-743). Current Clinical Pharmacology, 2009, 4, 38-42",Note: Pharmacokinetic data were determined in children.,,1987,761.84,14,4,168.7,4,cationic,1.8,1.2
Tramadol,27203-92-5,COc1cccc(c1)[C@@]2(O)CCCC[C@@H]2CN(C)C,2.8,6.5,0.8,7.2,5.8,"Lintz W, Barth H, Osterloh G, and Schmidt-Boethelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd communication. Suppositories.  Arz. Forsch. 48: 889-899.  Grond S and Sablotzki A (2004) Clinical pharmacology of tramadol.  Clin. Pharmacokinet. 43: 879-923.","Parameters calculated from data reported in a table in Lintz, et al.",,1973,263.38,3,1,32.7,4,cationic,2.6,0.99
Trametinib,871700-17-3,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,13.94,0.8,0.03,304,229,"Cathrine Leonowens, Carolyn Pendry, John Bauman, Graeme C. Young, May Ho, Frank Henriquez,  Lei Fang,  Royce A. Morrison,Keith Orford, Daniele Ouellet. Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Br J Clin Pharmacol 2014, 78:3, 524–532. ppb: the PDR states: Trametinib is 97.4% bound to human plasma proteins. Accessed January 5 2015. http://www.pdr3d.com/detail.php?c=128014#section-13.","N=4, 70 kg average weight assumed. MRT from VDss and clearance.",5 ug (microdose),2005,615.39,9,2,102.1,5,neutral,4.6,4.6
Trandolapril,87679-37-6,C1CC[C@@H]2C[C@H](N([C@@H]2C1)C([C@H](C)N[C@@H](CCc1ccccc1)C(OCC)=O)=O)C(=O)O,0.25,12.5,0.17,0.34,0.26,"Trandolapril - FDA Approval Package
Approval Package 020528/S-001 Part 03", 70 kg average weight assumed. MRT from VDss and clearance.,Ester cleavage transformed into trandolaprilat.,1983,430.54,7,2,95.9,10,anionic,3.2,-0.16
Tranexamic acid,1197-18-8,NC[C@@H]1CC[C@H](CC1)C(=O)O,0.38,2.4,0.97,2.6,2.3,"Puigdellivol E, Carral ME, Moreno J, Pla-Delfina JM, and Jane F (1985) Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man.  Int. J. Clin. Pharmacol. Ther. Toxicol.  23: 298-301. ppb: the PDR states: The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen. Tranexamic acid does not bind to serum albumin. Accessed January 5 2015. http://www.pdr3d.com/detail.php?c=129323#section-3",PK parameters were calculated from reported C vs t data.  Data table in the report has incorrect units.,,1955,157.21,3,2,63.3,2,zwitterionic,0.34,-1.9
Traxoprodil,134234-12-1,C[C@@H]([C@@H](O)c1ccc(O)cc1)N2CCC(O)(CC2)c3ccccc3,4.4,27,0.63,2.6,3.7,"Taylor TJ, Diringer K, Russell T, Venkatakrishnan K, Wilner K, Crownover PH, Benincosa LJ, and Gibbs MA (2006) Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolizers.  Clin. Pharmacokin. 45: 989-1001.  ",Data from CYP2D6 extensive metabolizers.,,1990,327.42,4,3,63.9,4,cationic,2.1,1
Trazodone,19794-93-5,Clc1cccc(c1)N2CCN(CCCN3N=C4C=CC=CN4C3=O)CC2,0.52,1.4,0.08,6.2,7.3,Nilsen OG and Dale O (1992) Single dose pharmacokinetics of trazodone in healthy subjects.  Pharmacol. Toxicol. 71: 150-153. ppb: The PDR states: Trazodone is 89% to 95% protein bound in vitro at concentrations attained with therapeutic doses in humans. Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=82125#section-14,VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1968,371.86,6,0,42.4,5,neutral,4.5,4.3
Treosulfan,299-75-2,S(=O)(=O)(OC[C@@H]([C@H](COS(=O)(=O)C)O)O)C,0.59,4.9,,2,1.83,"Franciszek Główka, Anna Kasprzyk , Michał Romanski , Tomasz Wróbel , Jacek Wachowiak ,
Dawid Szpecht, Krzysztof Kałwak, Anna Wiela-Hojenska, Paulina Dziatkiewicz, Artur Tezyk ,
Czesław Zaba. Pharmacokinetics of treosulfan and its active monoepoxide in pediatric
patients after intravenous infusion of high-dose treosulfan prior to HSCT. European Journal of Pharmaceutical Sciences, 2015. 68, 87–93",PEDIATRIC PATIENTS. N=16 with ages ranging from 5 months to 18 years. Mean values across doses. MRT from VDss and clearance.,,1962,278.3,8,2,127.2,7,neutral,-3,-3
Treprostinil,81846-19-7,[H]OC(COc1cccc2C[C@H]3[C@H](CC[C@@H](CCCCC)O[H])[C@H](C[C@H]3Cc12)O[H])=O,0.23,10.7,0.09,0.36,0.82,"Absolute Bioavailability and Pharmacokinetics of Treprostinil Sodium Administered by Acute Subcutaneous Infusion. Michael Wade ,F. Jo Baker, Robert Roscigno, Wayne DellaMaestra, Thomas L. Hunt and Allen A. Lai J. Clin. Pharmacol. 2004, 44, 83-88.  ppb: The PDR states: In vitro treprostinil is 91% bound to human plasma proteins over the 330-10,000 mcg/L concentration range. Accessed January 6 2015. http://pdr3d.com/detail.php?c=128637#section-13.","Remodulin, Uniprost. Data digitized and calculations performed via WinNonLin. N=15, 150' infusion, 15 ng/kg/min, data very in very good agreement to reported PK parameters.",,1981,390.51,5,3,87,13,anionic,4.6,1.4
Triamcinolone Acetonide,76-25-5,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,1.4,9.4,0.2,2.5,2.4,"Argenti D, Shah B, Heald D (1999) A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration.  J. Clin. Pharmacol. 39: 695-702.  Mager DE and Jusko WJ (2002) Quantitative structure pharmacokinetic/pharmacodynamic relationships of corticosteroids in man.  J. Pharm. Sci. 91: 2441-2451.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1958,434.5,6,2,93.1,2,neutral,2.3,2.3
Triamterene,396-01-0,Nc1nc(N)c2nc(c(N)nc2n1)c3ccccc3,13,63,0.42,3.4,4.3,"Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, and Volger KD (1983) Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.  Eur. J. Clin. Pharmacol. 25: 237-241.  Hasegawa J, Lin ET, Williams RL, Sorgel F, and Benet LZ  (1982) Pharmacokinetics of triamterene and its metabolite in man.  J. Pharmacokinet. Biopharm. 10: 507-523.",,,1954,253.26,7,3,129.6,1,neutral,1.1,1.1
Triapine,143621-35-6,c1ccc(c(\C=N\NC(N)=S)n1)N,0.41,2.65,,2.6,1.9,"Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion. Scott Wadler, Della Makower, Caroline Clairmont, Paula Lambert, Karen Fehn, and Mario Sznol. J. Cin. Onc. 2004, 22, 1553-1563","3-aminopyridine-2-carboxaldehyde thiosemicarbazone  (3-AP, PAN811). Weighted average of several cohorts receiving doses from 20 to 160 mg/m2. Clearance reported in mL/min but it is likely to be L/min.MRT calculated from VDss and clearance.",,1992,195.24,5,3,89.3,3,neutral,0.048,0.041
Triazolam,28911-01-5,Cc1nnc2CN=C(c3ccccc3Cl)c4cc(Cl)ccc4n12,0.58,3,0.1,3.2,2.7,"Vanderveen RP, Jirak JL, Peters GR, Cox SR, and Bombardt PA (1991) Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin. Pharm. 10: 539-543.  Kroboth PD, Smith RB, Sorkin MI, Silver MR, Rault R, Garry M, and Juhl RP (1984) Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration.  Clin. Pharmacol. Ther. 36: 379-383.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1970,343.21,4,0,43.1,1,neutral,2.6,2.6
Trimazosin,35795-16-5,COc1cc2c(N)nc(nc2c(OC)c1OC)N3CCN(CC3)C(=O)OCC(C)(C)O,0.18,0.96,,3.1,3.1,"Meredith PA, Elliott HL, Kelman AW, and Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoreceptor agonists in normotensive volunteers.  J. Cardiovasc. Pharmacol. 7: 532-537.",,,1971,435.47,11,2,132.5,6,neutral,1.7,1.6
Trimethoprim,738-70-5,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,1.5,2.1,0.5,12,9.6,"Mannisto PT, Mantyla R, Mattila J, Nykanen S, and Lamminsivu U (1982) Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion.  J. Antimic. Chemother.  9: 461-470.   Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, and Nightingale CH (1984) Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.  Antimic. Agents Chemother. 26: 811-814.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration.  J. Pharm. Biomed. Anal. 1:  293-299.",VDss calculated from C vs t data obtained by digitization of the plot showing the 200 mg dose.,,1959,290.32,7,2,105.5,5,neutral,1.1,0.94
Trimetrexate,52128-35-5,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,0.77,0.77,0.05,17,17,"Neutrexin (trimetexate glucuronate) Product Label. PDR, accessed July 28 2014. http://www.pdr3d.com/detail.php?c=1000",,,1975,369.42,8,3,117.5,6,neutral,2.4,2.3
Trimipramine,739-71-9,CC(CN(C)C)CN1c2ccccc2CCc3ccccc13,16,16,0.051,17,23,"Abernethy DR, Greenblatt DJ, and Shader RI (1984) Trimipramine kinetics and absolute bioavailability:  use of gas-liquid chromatography with nitrogen-phosphorus detection.  Clin. Pharmacol. Ther. 35: 348-353.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1952,294.43,2,0,6.5,4,cationic,4.6,3.1
Triptorelin,57773-63-4,CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H](Cc4c[nH]c5ccccc45)NC(=O)[C@H](Cc6c[nH]cn6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N8CCC[C@H]8C(=O)NCC(=O)N,0.4,2.67,,2.48,2.81," Muller, F. O.; Terblanche, J.; Schall, R.; Van Zyl Smit, R.; Tucker, T.; Marais, K.; Groenewoud, G.; Porchet, H. C.; Weiner, M.; Hawarden, D. Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br. J. Clin. Pharmacol. 1997, 44, 335-341.","CL 118532. 0.5 mg, N=6, in normal renal function subjects. 78.7 kg.",,1975,1311.45,31,18,487.9,34,cationic,-1.5,-5.5
Tropatepine,27574-24-9,CN1C2CCC1CC(=C3c4ccccc4CSc5c3cccc5)C2,11.85,4.98,,39.5,29.8,"Bun, H.; Monjanel-Mouterde, S.; Audebert, C.; Du Laurier, M. Vincent; Durand, A.; Cano, J. P. Pharmacokinetics of tropatepine in healthy volunteers. Clinical Drug Investigation, 1997, 14, 53-60.",Data digiztized from plot. 20 mg and N=8. 71.6 kg average weight. Reported AUC 1135 ug.h/L. Clearance 19 L/h. AUCinf 931 ug.h/L (extrapolation 16% due to high t1/2). Clearance calculated as 21.4 L/h (13% difference from reported).,,1970,333.49,1,0,3.2,0,cationic,5.5,3.9
Tropisetron,89565-68-4,CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c3c[nH]c4ccccc34,9.7,26,,6.3,5.6,"Kees F, Farber L, Bucher M, Mair G, Morike K, and Grobecker H (2001) Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.    Br. J. Clin. Pharmacol. 52: 705-707.",,,1983,284.35,4,1,45.3,3,cationic,3.4,1.8
Trospectomycin,88669-04-9,CCCC[C@@H]1CC(=O)[C@]2(O)O[C@@H]3[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]3O[C@@H]2O1,0.7,1.7,0.65,6.9,11,"Nichols DJ, Bye A, and Novak E (1991) . Pharmacokinetics of trospectomycin sulphate in healthy subjects after single intravenous and intramuscular doses.British journal of clinical pharmacology  32(2), 255-7   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",Averaged data from all dose levels.,,1983,374.43,9,5,129.5,5,cationic,-1.4,-3.8
Trospium,47608-32-2,c1ccc(cc1)C(c2ccccc2)(C(=O)O[C@@H]3C[C@@H]4CCC(C3)[N+]45CCCC5)O,5.1,13.9,0.33,6.1,5,Trospium Chloride - FDA Approval Package. Clinical Pharmacology and Biopharmaceutics Review 021595/S-000 Part 03. Accessed via Pharmapendium. Ppb: the PDR states: Protein binding ranged from 50 to 85% when concentration levels of trospium chloride (0.5 to 50 ng/mL) were incubated with human serum in vitro.  Accessed January 6 2015. http://pdr3d.com/detail.php?c=104533#section-13. Median value of 67% taken.,Structure and smiles refer to cation. 70 kg assumed. MRT reported. Ppb reported as range between 50 and 85%.,"72% of dose elininated in urine, of which 80% is unchanged. ~ 60% total unchanged. Trospium Chloride - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021595/S-000 Part 03. Accessed via Pharmapendium.",1997,392.51,4,1,46.5,5,neutral,0.83,0.83
Trovafloxacin,147059-72-1,N[C@@H]1[C@H]2CN(C[C@@H]12)c3nc4N(C=C(C(=O)O)C(=O)c4cc3F)c5ccc(F)cc5F,1.3,1.4,0.24,15,11,"Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ, and Friedman HL (1997) Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrovafloxacin.  J. Antimic. Chemother. 39(Suppl B): 75-80.  Teng R, Liston TE, Harris SC (1996) Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.  J. Antimic. Chemother.  37: 955-963.",Dosed as alatrovafloxacin prodrug which is very rapidly converted to trovafloxacin.,,1992,416.35,7,2,99.8,3,zwitterionic,2.6,0.28
Troxacitabine,145918-75-8,NC1=NC(=O)N(C=C1)[C@@H]2CO[C@H](CO)O2,1,2.4,,6.9,82,"Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, and Kantarjian HM. (2001) Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.  J. Clin. Oncol. 19: 762-771.",,,1992,213.19,7,2,97.4,2,neutral,-1.9,-1.9
Tubocurarine,57-94-3,COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4,0.45,3.4,0.58,2.2,2,"Razman IM, Shanks CA, and Triggs EJ (1978) Studies of d-tubocurarine pharmacokinetics in humans and dogs.  Anaesth. Intens. Care 6: 30-35.  Ghoneim MM, Kramer SE, Bannow R, Pandya H, and Routh JI (1973) Binding of d-tubocurarine to plasma proteins in normal man and in patients with hepatic or renal disease.  Anesthesiol.  39: 410-415.",CAS number reported refers to chloride salt. Parent cation CAS number 57-95-4. Pharmacokinetic parameters determined from reported two-compartment model parameters.,,1935,609.73,8,2,80.6,2,cationic,4.7,3.9
TZP 101,842131-33-3,[H]N1CCCc2ccccc2O[C@H](C)CN([H])[C@@H](C2CC2)C(N(C)[C@H](C)C(N([H])[C@H](Cc2ccc(cc2)F)C1=O)=O)=O,0.1,0.1,0.01,15.2,11.8,"Kenneth C. Lasseter, Laura Shaughnessy,  David Cummings, John C. Pezzullo,  William Wargin, Rene Gagnon, Jesus Oliva, and Gordana Kosutic. Ghrelin Agonist (TZP-101): Safety, Pharmacokinetics and Pharmacodynamic Evaluation in Healthy Volunteers: A Phase I, First-in-Human Study. J. Clin. Pharmacol. 2008; 48; 193-202//  ppb: Wargin, William; Thomas, Helmut; Clohs, Lilian; St-Louis, Carl; Ejskjaer, Niels; Gutierrez, Maria; Shaughnessy, Laura; Kosutic, Gordana. Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-​101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-​blind studies and a binding profile study. Clin. Drug Invest., 2009, 29, 409-418.","Ulimorelin. Data digitized and calculations performed via WinNonLin.  N=6 each group, 20 and 600 ug/kg examined (N=12 overall) and averaged, linear PK and very good agreement with reported values.  PPB > 99% as reported by Wargin et al. Clin. Drug Invest. 2009, 29(6),409-418.In rat dog and monkey reported as 85, 85 and 83% respectively.",,2005,538.65,8,3,99.8,3,cationic,4.3,3.7
"UK-240,455",178908-09-3,CS(=O)(=O)N(CCO)c1c(Cl)c(Cl)cc2NC(=O)C(=O)Nc12,0.8,6,0.13,2.2,1.4,"Webster R, Cole S, Gedge J, Roffey S, Walker D, and Wild W (2003) Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs, and man.  Xenobiotica 33: 541-560.",,,1996,368.19,8,3,115.8,4,neutral,-0.31,-0.43
Umeclidinium,869185-19-3,c1ccc(cc1)COCC[N+]23CCC(CC2)(CC3)C(c4ccccc4)(c5ccccc5)O,1.23,35.95,0.11,0.57,19,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002809/WC500167431.pdf. Accessed July 29 2016,70 kg assumed. MRT from VDss and clearance. T1/2 reported after inhalation was reported to be 19 hours. Possible very low residual concentration as clearance is very high. To be verified.,,2011,428.59,3,1,29.5,8,neutral,1.6,1.6
Urapidil,34661-75-1,COc1ccccc1N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2,0.75,3.1,,4,3.5,"Zech K, Steinijans VW, and Radtke HW (1986) Pharmacokinetics of urapidil in normal subjects. In Amery (Ed) Treatment of Hypertension with Urapidil: Preclinical and Clinical Update. 29-38, ICSS 101, RSM Services Ltd, London.",VDss calculated using C vs t data obtained from a digitized plot.,,1971,387.48,8,1,68.4,7,cationic,1.8,1.1
Ursolic acid,77-52-1,C1[C@@]2([C@@H]3[C@@](CC[C@H]2C(C)([C@H](C1)O)C)([C@@]1(C(=CC3)[C@H]2[C@@](CC1)(CC[C@H]([C@@H]2C)C)C(O)=O)C)C)C,0.54,3.87,,2.34,4.8,"Quantitation of ursolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its pharmacokinetic study. Yuanyuan Xia, Guangli Wei, Duanyun Si, Changxiao Liu. Journal of Chromatography B, 2011, 879, 219–224","Data digitized from fig. 3 in Xia et al Journal of Chromatography B, 879 (2011) 219–224. Dose 98 mg/m2 converted to 170 mg (1.73 m^2 to 70 kg).Body weight reported as 75 kg PK parameter reported in Table 3. Calculations performed via Gastroplus. Calculated AUC  =  9.753  µg-h/mL; reported AUC = 9918  ng-h/mL.",,1910,456.7,3,2,57.5,1,anionic,6.9,4.8
Vaborbactam,1360457-46-0,B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)Cc2cccs2)O,0.29,2.94,0.67,1.64,1.34,"David C. Griffith, Jeffery S. Loutit, Elizabeth E. Morgan, Stephanie Durso, Michael N. Dudley. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2016, 60:6326–6332.",Data extracted from table 2.Weighted average across dose (n=60 total). 79.4 kg average weight. 250-2000 mg doses administred as 3 hour infusion. Urinary recovery  87.4%. MRT from VDss and clearance.,,2012,297.14,6,3,95.9,5,anionic,0.36,-2.1
Valbenazine,1025504-45-3,CC(C)C[C@@H]1CN2CCc3cc(c(cc3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC,1.31,1.71,0.01,12.78,18,"Label from FDA site. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf. 
Accessed May 16 2017",Ingrezza. NBI 98854. Prodrug. Absolute BA (49%) reported in label and VDss and clearance taken to be from iv studies. MRT from VDss and clearance. 70 kg average weight assumed. T1/2 range 15 to 22 hours. 18 h taken. Ppb > 99% from label.,,2008,418.57,6,1,74,8,cationic,3.4,2.5
Valdecoxib,181695-72-7,o1nc(c(c1C)c1ccc(cc1)S(=O)(=O)N)c1ccccc1,0.75,1.4,0.02,9.4,7.4,"Valdecoxib - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021341/S-000 Part 02",72.5 median weight reported. 10 mg administered as 30' infusion. N=24. ,"Valdecoxib - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021341/S-000 Part 02",1996,314.36,5,1,86.5,3,neutral,2.5,2.5
Valproic Acid,99-66-1,CCCC(CCC)C(=O)O,0.14,0.16,0.08,15,12,"Bryson SM, Verma N, Scott PJW, and Rubin PC (1983) Pharmacokinetics of valproic acid in young and elderly subjects.  Br. J. Clin. Pharmacol. 16: 104-105.  Hussein Z, Patterson KJ, Lamm JE, Cavanaugh JH, and Granneman GR (1993) Effect of infusion duration on valproate pharmacokinetics.  Biopharm. Drug Dispos. 14: 389-399.  Gugler R and Meuller G (1978) Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.  Br. J. Clin. Pharmacol. 5: 441-446.",,,1963,144.21,2,1,37.3,5,anionic,2.6,0.25
Valsartan,137862-53-4,CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3nnn[nH]3)[C@@H](C(C)C)C(=O)O,0.22,0.49,0.04,7.5,9.5,"Flesch G, Muller P, and Lloyd P (1997) Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin receptor antagonist, in man.  Eur. J. Clin. Pharmacol. 52: 115-120.  Colussi DM, Parisot C, Rossolino ML, Brunner LA, and Lefevre GY (1997) Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist.  J. Clin. Pharmacol. 37: 214-221.",,,1991,435.52,8,2,112.1,10,anionic,5,-0.22
Valspodar,121584-18-7,C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C,1.8,2.6,0.022,12,10,"Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, and Figg WD (1997) Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.  J. Clin. Pharmacol. 37: 123-128.  Simon N, Dailly E, Combes O,  Malaurie E,  Lemaire M, Tillement JP, and Urien S (1998) Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br. J. Clin. Pharmacol. 45: 173-175.",,,1988,1214.62,23,4,275.6,15,neutral,6.8,6.8
Vancomycin,1404-90-6,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]6NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(=O)N)NC1=O)c7ccc(O)c(c7)c8c(O)cc(O)cc8[C@H](NC6=O)C(=O)O)c3O[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O[C@H]%10C[C@](C)(N)[C@H](O)[C@H](C)O%10)c(Cl)c2,0.54,1.3,0.7,6.9,6.5,"Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, and Riff LJ (1988) Vancomycin pharmacokinetics in patients with various degrees of renal function.  Antimic. Agents Chemother. 32: 848-852.  Matzke GR, McGory RW, Halstenson CE, and Keane WF (1984) Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimic. Agents Chemother. 25: 433-437.  Cutler NR, Narang PK, Lesko LJ, Ninos M, and Power M (1984) Vancomycin disposition: the importance of age.  Clin. Pharmacol. Ther. 36: 803-810.  Nakashima M, Katagiri K, Oguma T (1992) Phase 1 studies for vancomycin hydrochloride for injection.  Chemotherapy 40: 210-224.",,,1955,1449.25,33,19,530.5,13,cationic,0.29,-2.6
Vardenafil,224785-90-4,CCCc1nc(C)c2C(=O)NC(=Nn12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC)CC4,3,13,0.05,3.8,4.5,Levitra Product Label,,,1999,488.6,10,1,109.1,8,cationic,1.2,0.56
Vecuronium Bromide,50700-72-6,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(=O)C)[N+]5(C)CCCCC5)[C@@]2(C)C[C@@H]1N6CCCCC6,0.3,4.5,0.25,1.1,1.4,"Arden JR, Lynam DP, Castagnoli KP, Canfell PC, Cannon JC, and Miller RD (1988) Vercuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis.  Anesthesiology  68: 771-776.  Cameron M, Donati F, and Varin F (1995) In vitro plasma protein binding of neuromuscular blocking agents in different subpopulations of patients.  Anesth. Analg 81: 1019-1025.  Bencini AF, Scaf AH, Sohn YJ, Meistelman C, Lienhart A, Kersten UW, Schwarz S, and Agoston S (1986) Disposition and urinary excretion of vecuronium bromide in anethetised patients with normal renal function or renal failure.  Anesth. Analg. 65: 245-251. ",,,1973,557.83,6,0,55.8,6,cationic,3.1,1.6
Velcalcetide,1262780-97-1,C[C@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C,1.98,1.67,,19.9,19.05,"Kevin J. Martin, Gregory Bell, Karen Pickthorn, Saling Huang, Andrew Vick, Peter Hodsman4 and Munro Peacock. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant (2014) 29: 385–392","AMG416, Etelcalcetide. N=24 across 4 doses (0.5, 2, 5 and 10 mg). 70 kg assumed and MRT from VDss and clearance.",,2011,1048.25,31,22,557.7,40,cationic,-8.1,-9
Venlafaxine,93413-69-5,COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2,4.4,14,0.73,5.2,5,"Patat A, Troy S, Burke J, Trocherie S, Danjou P, LeCoz F, Allain H, and Gandon JM (1998) Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects.  J. Clin. Pharmacol. 38: 256-267.  Effexor Product Label.",,,1984,277.4,3,1,32.7,5,cationic,3.4,1.4
Verapamil,52-53-9,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC,3.7,18,0.093,3.4,2.8,"Abernethy DR, Wainer IW, Longstreth JA, and Andrawis NS (1993) Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration.  J. Pharmacol. Exp. Ther. 266: 904-911.  Zachariah PK, Moyer TP, Theobald HM, Frantz RP, Kurtz SB, McCarthy JT, and Smith RL (1991) The pharmacokinetics of racemic verapamil in patients with impaired renal function.  J. Clin. Pharmacol. 31: 45-53.  Eichelbaum M, Mikus G, and Vogelgesang B (1984) Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after ntravenous administration.  Br. J. Clin. Pharmacol. 17: 453-458.  Eichelbaum M, Somogyi A, von Unruh GE, and Dengler HJ (1981) Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isoyope-labelled verapamil.  Eur. J. Clin. Pharmacol. 19: 133-137.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",Values for indivudual enantiomers were averaged.,,1946,454.6,6,0,64,14,cationic,4.5,2.9
Verlukast,120443-16-5,CN(C)C(=O)CCS[C@H](SCCC(=O)O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1,0.11,0.68,0.0004,2.7,2.3,"Depre M, Margolskee DJ, Hseih JYK, Van Hecken A, Buntinx A, De Lepeleire I, Rogers JD, and De Schepper PJ (1992) Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.  Eur. J. Clin. Pharmacol. 43: 427-430.  Cheng H, Schwartz JI, Lin C, Amin RD, Seibold JR, Lasseter KC, Ebel DL, Tocco DJ, and Rogers JD (1994) The bioavailability and nonlinear pharmacokinetics of MK-679 in humans. Biopharm. Drug Dispos. 15: 409-418.","Parameters were determined using C vs t data obtained by digitization of the plots in the reference by Depre, et al. L-660,711 represents the compound without defined stereochemistry (except for double bond) and with CAS # 115104-28-4  ",,1987,515.09,5,1,70.5,11,anionic,5.1,1.6
Vernakalant,794466-70-9,c1(c(cc(cc1)CCO[C@H]1[C@@H](CCCC1)N1C[C@@H](CC1)O)OC)OC,1.8,8.29,,3,3.13,"Disposition and Mass Balance of [14C]Vernakalant After Single Intravenous and Oral Doses in Healthy Volunteers. Z. L. Mao, A. Alak, J. J. Wheeler and J. Keirns. Drug Metabolism Letters, 2011, 5, 114-125.","Weighted average of EM (n=5) and PM (N=2) subjects. 240 mg dose, 10' infusion treated as boluse, since no infusion profile was reported and digitization performed on plots.",,2004,349.46,5,1,51.2,7,cationic,2.9,1.6
Verteporfin-Mac,133513-12-9,C=1(CCC(OC)=O)c2cc3c(c(c(cc4nc(cc5C=6[C@@]([C@@H](C(=CC6)C(OC)=O)C(=O)OC)(c([nH]5)cc(n2)C1C)C)C(C)=C4C=C)[nH]3)C)CCC(O)=O,0.63,1.6,,6.6,5.6,"Verteporfin - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021119/S-000 Part 02",MAc regioisomer. Data averaged across 4 doses (8-14 mg/m2) N=32 (Caucasian and Japanese). MRT from VDss and clearance.,,1991,730.89,12,5,168.1,12,cationic,3.4,-0.66
Verteporfin-Mad,142878-05-5,OC(=O)CCC(=C(C)C1C2)C(N=1)=CC(=C(CCC(OC)=O)C(C)=C1C=C(N3)C(=C(C=3C=C3C([C@@](C=2N3)(C)[C@H](C(=O)OC)C(=C2)C(=O)OC)=C2)C)C=C)N1,0.51,1.73,,4.9,6.06,"Verteporfin - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021119/S-000 Part 03",MAd regioisomer Data averaged across 4 doses (8-14 mg/m2) N=32 (Caucasian and Japanese). MRT from VDss and clearance.,,1992,718.79,12,3,168.7,12,zwitterionic,2.3,-3.5
Vestipitant,334476-46-9,Cc1cc(ccc1[C@H]2CNCCN2C(=O)N(C)[C@H](C)c3cc(cc(c3)C(F)(F)F)C(F)(F)F)F,3.8,5.09,,12.8,10.03,"Richard A. Brigandi, Steven F. Russ, Chantal Petit, Brendan Johnson, Scott Croy,
Peter Hodsman, Fran Muller. Intravenous Pharmacokinetics, Local Tolerability, and Hemolysis of an SBE7‐β‐Cyclodextrin Formulation of the Neurokinin‐1 Receptor
Antagonist Vestipitant. Clinical Pharmacology in Drug Development 2015, 4(2) 130–136","Average across 41 subjects, doses from 12 to 48 mg, very short infusion time and variable solution volume. 70 dose assumed, MRT from clearance and VDss. Formulated in Captisol.™",,2001,491.44,4,1,35.6,3,cationic,4.7,4.3
Vilanterol,503068-34-6,c1cc(c(c(c1)Cl)COCCOCCCCCCNC[C@@H](c2ccc(c(c2)CO)O)O)Cl,2.38,25.7,0.06,1.53,2.4,"Anoro Ellipta, Product label. PDR, accessed October 13 2014. http://www.pdr3d.com/detail.php?c=130062#section-13. For clearance see also, The Pharmacokinetics of Fluticasone Furoate and Vilanterol Following Single Inhaled Administration in Combination and Intravenous Administration of Individual Components in Healthy Subjects.  Ann Allen, Ludovic Apoux, Jo Bal, Joseph Bianco, Alison Moore,  Ramiya Ravindranath,  Lee Tombs, Rodger D Kempsford. J Bioequiv Availab, 2013, 5:165-173.",VDss reported as 165 (PDR168 L) L. 70 kg assumed. Clearance reported as 108 L/hr. 70 kg assumed. ppb reported in PDR. MRT from clearance and VDss.,,2003,486.43,6,4,91.2,16,cationic,3.9,2
Vilazodone,163521-12-8,"C1CN(CCN1CCCCc1c[nH]c2c1cc(cc2)C#N)c1cc2c(cc1)oc(c2)C(=O)N	",4.85,3.76,0.03,21.47,15.66,"Vilazodone, FDA package, accessed November 30 2016, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf","EMD 68843. N=12, 7M/5F, 70 kg average weight assumed. 5 mg infusion over 4 hours, with actual dose estimated as 4.686 mg (and used as such). Absolute BA Study: PGX-08-P1-08. Data digitized and PK calculated via PK solver. Reported AUC0-ing as 320 ng.h.mL-1. Calculated 296 ng.h.mL-1 (8% difference). BA 77%",,1995,441.52,7,2,102.6,8,cationic,4,3
Vildagliptin,274901-16-5,[H]N(CC(N1CCC[C@@H]1C#N)=O)C12C[C@@H]3C[C@H](C1)CC(C3)(C2)O[H],1.03,9.9,0.885123618,1.74,1.67,"Yan-Ling He, Brian M. Sadler, Ron Sabo, Sebastien Balez, Yibin Wang, Joelle Campestrini, Aziz Laurent, Monica Ligueros-Saylan and Dan Howard. The Absolute Oral Bioavailabilityand Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers Clin. Pharmacokin. 2007, 46, 787-802. ","30-minute intravenous infusion in 11 volunteers, 25 mg dose. VDss reported as 70.5 L, and 68.1 kg average weight. Cl reported as 40.6 L/h, and MRT calculated from VD and Cl. (LAF237).  fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",,2000,303.4,5,2,76.4,5,cationic,0.17,-1.5
Viloxazine,46817-91-8,CCOc1ccccc1OCC2CNCCO2,0.73,2.1,,5.8,4.1,"Pisani F, Fazio A, Spina E, Artesi C, Pisani B, Russo M, Trio R, and Perucca E (1986) Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.  Psychopharmacol.  90: 295-298.",VDss calculated from data obtained by digitization of the C vs t plot in the report.,,1972,237.29,4,1,39.7,5,cationic,1.3,0.23
Vinblastine,865-21-4,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](OC(=O)C)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC)C1,28,3.1,0.14,150,67,"Lu K, Yap HY, and Loo TL (1983) Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.  Canc. Res. 43: 1405-1408.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm.Res. 20: 1015-1021.",Highly variable; used the median value.,,1959,810.97,13,3,154.1,10,neutral,3.9,3.6
Vincristine,57-22-7,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C=O)[C@H]7[C@](O)([C@H](OC(=O)C)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC)C1,2.4,2,0.4,20,23,"Sethi VS, Jackson DV, White DR, Richards F, Stuart JJ, Muss HB, Cooper MR, and Spurr CL (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients.  Cancer Res. 41: 3551-3555.  Abdel-Rahman M, Wosch F, Harder S, and Woodcock BG (1992) Interaction between verapamil and vincristine binding to plasma proteins. Int. J. Clin. Pharmacol. Ther. Toxicol. 30:536",,,1946,824.96,14,3,171.2,10,neutral,2.9,2.7
Vindesine,53643-48-4,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](O)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)N)C1,5,2.2,,38,35,"Ohnuma T, Norton L, Andrejczuk A, and Holland JF (1995) Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans. Cancer Res. 45: 464-469.  ",VDss calculated using micro rate constants provided in the reference.,,1974,753.93,12,5,164.8,7,cationic,2.3,1.5
Vinorelbine,71486-22-1,CCC1=C[C@@H]2CN(C1)Cc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](OC(=O)C)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC,23,20,0.87,18,26,"Sorio R, Robieux I, Galligioni E, Freschi, A, Colussi AM, Crivellari D, Saracchini S, and Monfardini S (1997) Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer.  Eur. J. Cancer  33: 301-303.   Gebbia V and Puozzo C (2005) Oral versus intravenous vinorelbine: clinical safety profile.  Exp. Op. Drug Safety 4: 915-928. ",,,1979,778.93,12,2,133.9,10,neutral,4.1,3.9
Vinpocetine,42971-09-5,[C@@H]12c3n4c5c(c3CCN2CCC[C@]1(C=C4C(=O)OCC)CC)cccc5,2.08,6.1,0.02,5.68,4.83,"Pharmacokinetics of vinpocetine in humans. Verczkey L., Czira, G., Tamas J, Szentirmay Zs., Botar, Z., Szporny, L. Arzneim-Forsch. 1979, 29, 957-960. ppb: Storm, G.; Oosterhuis, B.; Sollie, F. A. E.; Visscher, H. W.; Sommer, W.; Beitinger, H.; Jonkman, J. H. G. Lack of pharmacokinetic interaction between vinpocetine and oxazepam. British Journal of Clinical Pharmacology (1994), 38(2), 143-146","N=6, 78kg average weight, 10 mg dose.",,1973,350.45,4,0,34.5,4,neutral,4.2,4.1
Viqualine,72714-74-0,c12c(ccc(c2)OC)nccc1CCC[C@@H]1[C@@H](CNCC1)C=C,24.4,26,,15.6,12.1,"J. B. Fourtillan, S. Bouquet, J. Girault, M. A. Lefebvre, C. Maulet, Ph. Courtois. Pharmacokinetics and bioavailability of viqualine a new antidepressant. European Journal of Drug Metabolism and Pharmacokinetics. 1985, 10(1) , 3-10","Mean BW = 64.8 kg (N=5), 25 mg infusion dose. ",,1979,310.43,3,1,34.1,6,cationic,4.3,2
Vismodegib,879085-55-9,n1ccccc1c1c(ccc(c1)NC(=O)c1c(cc(cc1)S(=O)(=O)C)Cl)Cl,0.23,0.01,0.01,341,245,"Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I Pharmacokinetic (PK) study in healthy female subjects. 46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010, Abst e13009  
Graham, R.A.; Morrison, G.E.; Chang, I.; et al. Following the IV bolus dose GDC-0449 plasma concentrations decreased markedly over the first 30 minutes; this short distribution phase was followed by a slower elimination phase through the remainder of the study, with an average terminal t of 10.2 ± 2.06 d. Clearance was 47.2 ± 14.1 mL/hr; volume of distribution (Vss) was 16.1 ± 2.34 L; mean bioavailability was 34.7 ± 5.76%. ","ppb > 99%. (PDR) Assumed 70 kg as average weight. 12 days hal-life after single dose. No clearance reported in PDR. MRT from Cl and VDss. Microdose, 10 ug.",,2006,421.3,5,1,76.1,4,neutral,3.9,3.9
Volasertib,755038-65-4,C(=O)(c1cc(c(cc1)Nc1nc2c(cn1)N(C(=O)[C@H](N2C(C)C)CC)C)OC)N[C@H]1CC[C@@H](CC1)N1CCN(CC1)CC1CC1,80.5,11.6,,116,113,"A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Patrick Schoffski , Ahmad Awada , Herlinde Dumez , Thierry Gil ,Sylvie Bartholomeus , Pascal Wolter, Martine Taton, Holger Fritsch , Patricia Glomb , Gerd Munzert. EUROPEAN JOURNAL OF CANCER 4 8 ( 2 0 1 2 ) 1 7 9 –1 8 6",Assumed 70 kg. Weighted average across doses. MRT from VDss and clearance. N=45 (total) 12-450 mg doses.,,2004,618.81,11,2,106.2,10,cationic,5.1,4.2
Vorapaxar,618385-01-6,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c4ccc(cn4)c5cccc(F)c5,3.74,0.34,0.01,183,149,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000ClinPharmR.pdf. Accessed May 23 2017. ,"Plot digitized from Figure 2 reported. Raw data normalized per mg dose. 73 ug of 14C labelled vorapaxar administered iv 60 minues after 2.5 po dose was administered. N=6, 70 kg average weight assumed. AUC 0-inf reported as 43.2 ng.h.mL-1. 18% difference from calculated. Time points corrected from data in text and concentrations back-calculated from normalized concentration (per mg dose) reported in plot. Ppb > 99%.",,2003,492.58,6,1,77.5,6,neutral,5.1,5.1
Voriconazole,137234-62-9,C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F,2.2,8.3,0.42,4.4,5.6,"Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, and Nichols D (2003) The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.  Br. J. Clin. Pharmacol. 56(Suppl. 1):  2-9.   Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, Smith DA, Walker DK, and Wood N (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.  Drug Metab. Dispos. 31: 731-741.",,,1991,349.31,6,1,76.7,5,neutral,1.5,1.5
Vorinostat,149647-78-9,ONC(=O)CCCCCCC(=O)Nc1ccccc1,0.5,28,0.29,0.3,0.76,"Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.  Clin. Cancer Res.  9: 3578-3588.  Zolinza Product Label.",VDss calculated from digitized C vs t plot.,,1993,264.32,5,3,78.4,8,neutral,1.6,1.6
Vortioxetine,508233-74-7,CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1,35.3,5.8,0.02,101,72,"Johan Areberg, Birgitte Søgaard and Astrid-Maria Højer. The Clinical Pharmacokinetics of Lu AA21004 and its Major Metabolite in Healthy Young Volunteers Basic & Clinical Pharmacology & Toxicology, 2012, 111, 198–205. ppb: the PDR states: The plasma protein binding of vortioxetine in humans is 98%, independent of plasma concentrations. Accessed January 5 2015. http://www.pdr3d.com/detail.php?c=131238#section-15"," Lu AA21004. Brintellix. Trintellix. AUCinf reported as 376 hr*ng/mL, clearance 26 L/h (5.8 mL/min/kg).  75 kg median weight reported, 10 mg dose over 6 hours infusion. N=22.",,2003,298.45,2,1,15.3,3,cationic,4.8,3.1
Vosaroxin,175414-77-4,CN[C@H]1CN(C[C@@H]1OC)c2ccc3c(=O)c(cn(c3n2)c4nccs4)C(=O)O,1.46,0.79,,30.6,25.5,"C.M. Nijenhuis, L. Lucas, H. Rosing, A.D.R. Huitema, M. Mergui-Roelvink, G. C. Jamieson., J.A. Fox, D.R. Mould, J.H.M. Schellens, J.H. Beijnen. Metabolismand disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II. Invest. New Drugs. DOI 10.1007/s10637-017-0428-1.","AG 7352. Voreloxin. SNS 595. N=6, 1.92 m2/73.6 kg as reported by authors using median weight and BSA. This is the factor that was used in the calculations. Dose 60 mg/m2.",,1995,401.44,9,2,109.6,5,zwitterionic,1.1,-0.23
Warfarin,81-81-2,CC(=O)CC(C1=C(O)c2ccccc2OC1=O)c3ccccc3,0.13,0.055,0.015,39,29,"Bjornsson TD, Meffin PJ, Swezey S, and Blaschke TF (1979) Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.  J. Pharmacol. Exp. Ther. 210: 316-321.",,,1944,308.33,4,1,63.6,4,anionic,2.6,0.2
WCK771,154357-42-3,C[C@H]1CCc2c3n1cc(c(=O)c3cc(c2N4CCC(CC4)O)F)C(=O)O,0.25,0.54,,7.87,6.04,"R.D. Yeole , V.L. Kulkarni, S.B. Latad, R.P. Chavan, Y. Chugh, M.V. Patel, H.F. Khorakiwala. Simple liquid chromatography–tandem mass spectrometry method for determination of novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771 in human serum. J Chromatog. B, 2007, 846 , 306–312.","Levonadifloxacin. S-(-)-nadifloxacin. Data digitized from plot reported. N=6, 600 mg iv infusion. 70 kg average weight assumed. Dosed as arginine salt tetrahydrate. CAS # 306748-89-0. Assumed the dose of parent was NOT corrected for equivalence to 600 mg of salt. No mention of the correction was made and the drug was described as the tetrahydrate salt. (MW tetrahydrate salt = 606.64; free base = 360.38. A dose of 356.43 mg was then used.",,1993,360.38,6,2,82.8,2,anionic,3,1.6
Xamoterol,81801-12-9,OC(CNCCNC(=O)N1CCOCC1)COc2ccc(O)cc2,0.64,3,0.97,3.6,7.7,"Bastain W, Boyce MJ, Stafford LE, Morton PB, Clarke DA, and Marlow HF (1988) Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. Eur. J. Clin. Pharmacol. 34: 469-473.  ",,,1982,339.39,8,4,103.3,8,cationic,-0.65,-1.1
XG-102,1198367-70-2,C[C@@H]([C@H](C(=O)N[C@H]([C@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N3CCC[C@@H]3C(=O)N4CCC[C@@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc5ccccc5)NC(=O)[C@H]6CCCN6C(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](C(C)C)NC(=O)[C@H]7CCCN7C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC(=O)O)N)O,0.22,3.62,,1,0.57,"Catherine Deloche, Luis Lopez-Lazaro, Sebastien Mouz, Julien Perino, Claire Abadie, Jean-Marc Combette. XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study. Pharma Res Per, 2 (1), 2014, e00020, doi: 10.1002/prp2.20","D-JNK-1. 31 aminoacids, all D forms. 10 ug/mL chosen from Table 7. From the text: The dose normalized pharmacokinetic parameter values shown in Table 7 suggest that Cmax, AUC0–last, and exploratorily AUC0–∞ increase more than in proportion with XG-102 dose in the evaluated dose range.",,2004,3823.43,106,64,1789.1,135,cationic,-9,-9
XK469R,157435-10-4,CC(C(=O)O)Oc1ccc(cc1)Oc2cnc3ccc(cc3n2)Cl,0.19,0.05,0.0036,63,48.2,"Wendy Stock,  Samir D. Undevia, Carol Bivins, Farhad Ravandi, Olatoyosi Odenike, Stefan Faderl, Elizabeth Rich, Gautam Borthakur, Lucy Godley, Srdan Verstovsek , Andrew Artz , William Wierda, Richard A. Larson, Yanming Zhang,  Jorge Cortes, Mark J. Ratain, Francis J. Giles. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. // ppb: Alousi AM1, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase II beta inhibitor. Invest. New Drugs, 2007, 25, 147-154.",Weight averaged across 4 doses (1400 to 2750 mg) average weight assumed to be 70 kg. MRT from clearance and VDss. Both CAS number and smiles refer to free acid,,1994,344.75,6,1,81.5,5,anionic,4,0.79
XR5000,89459-25-6,CN(C)CCNC(=O)c1cccc2c1nc3ccccc3c2,3.41,16.31,0.03,3.49,2.08,"D.J. Propper, J. de Bono, A. Saleem, S. Ellard, E. Flanagan, J. Paul, T.S. Ganesan, D.C. Talbot, E.O. Aboagye, P. Price, A.L. Harris, C. Twelves.  Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000. J Clin Oncol 2003, 21:203-210//ppb: Evans S M; Robertson I G; Paxton J W. Plasma protein binding of the experimental antitumour agent acridine-​4-​carboxamide in man, dog, rat and rabbit.  J. Pharm. Pharmacol., 1994, 46, 63-67.","NSC 601316. DACA. Mean values taken from text across several doses. MRT from VDss and clarance. N=23 and 70 kg average weight assumed.  1.73m2/70 kg taken as conversion factor. Note: in the text the authors refer to VDss but in the pharmacokinetics analysis section they use the equation Vd = (Dose/ ke AUC). However, VD was taken as VDss.",,1984,293.36,4,1,45.2,4,cationic,2.8,1.5
Xylose_D,58-86-6,O[C@@H]1[C@H]([C@H](OC[C@H]1O)O)O,0.23,2.38,,1.9,1.2,"Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failureCraig R M; Murphy P; Gibson T P; Quintanilla A; Chao G C; Cochrane C; Patterson A; Atkinson A J Jr  The Journal of laboratory and clinical medicine (1983), 101(3), 496-506","Average weight of normal subject 75.3 kg, 10 g dose iv. N=12. VDss calculated by digitization of one patient plot, but data very tight across normal subjects and reported as VD (unspecified). Authors report VD values of 0.11, 0.12, and 0.23 L/kg for Vc, Vp, and “Vd” respectively.  What “Vd” refers to in the paper is not described in the calculations.  VDss and MRT was calculated from digitization of plot in Figure (which is for one subject).","Xylose_D reported originally to have a clearance of 7.7 mL/min/kg but due to erroneously taking intercompartmental clearance, 578 mL/min. Actual Cl(total) 179.7 mL/min",1890,150.13,5,4,90.1,0,neutral,-2.5,-2.5
Y 20811,107433-19-2,Cc1ccc(cc1C(c2c(cc(cc2C)C(=O)O)C)O)n3ccnc3,0.37,2.91,,2.17,2.37,"Mitsutaka Kanamaru,  Mitsuyoshi Nakashima. Phase I Study of Y-20811, a New Long- Acting Thromboxane Synthetase Inhibitor by Intravenous Administration. J ClIn Pharmacol 1989;29: 563-567 ","N=6 for each dose. 5, 10 and 25 mg doses. Data averaged across doses. 62.7 kg average weight. MRT from VDss and clearance.",SMILES and CAS # referring to free acid but dosed as sodium salt.,1986,336.38,5,2,75.3,4,anionic,3.6,1.2
YM 060,132036-88-5,Cn1cc(c2c1cccc2)C(=O)[C@@H]3CCc4c(nc[nH]4)C3,2.65,7.03,,6.28,4.94,"SEKINO HISAYUKI NAKAMICHI NOBORU, MIURA YUYA, TAKESHIGE TETSUO. Phase I Study of YM 060: Tolerance and Pharmacokinetics of YM 060 Following Repeat Intravenous administration in Healthy Male Volunteers. Yakuri to Chiryo (Jpn. Pharmacol. Ther.) 1994, 22, 3877-3888.","Ramosetron. Dosed as ramosetron HCl. CAS # 132907-72-3. 0.8 mg, N=6, healthy male volunteers. 61.6 kg as average weight.Average and single subject data reported in tabular form, for Day 1. PK parameters calculated via PKSolver.Reported AUC0-12h 24.93 ng.h.mL-1. Tested with the same time range: calculated AUC0-12 was 24.92 ng.h.mL-1 ",,1990,279.34,4,1,50.7,2,cationic,2.4,0.85
YM155,781661-94-7,c1(n(c2c(C(=O)c3ccccc3C2=O)[n+]1Cc1cnccn1)CCOC)C,23.7,11.3,,34.5,24.8,"Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. Anthony W. Tolcher, Alain Mita, Lionel D. Lewis, Christopher R. Garrett, Elizabeth Till, Adil I. Daud, Amita Patnaik, Kyri Papadopoulos, Chris Takimoto, Pamela Bartels, Anne Keating, and Scott Antonia. J. Cin. Onc. 2008, 26, 5198-5203.",Sepantronium bromide. 3.6 (N=7) and 4.8 mg/m2 (N=25). Weighted average from data reported on Table 4. T1/2 questionable. 168 hr infusion. Quaternary ammonium salt. Bromide counter-ion omitted from smiles.,,2001,363.39,7,0,78,5,neutral,-1.2,-1.2
Yohimbine,146-48-5,c12[C@H]3[N@@](C[C@@H]4CC[C@@H]([C@@H]([C@@H]4C3)C(OC)=O)O)CCc1c1ccccc1[nH]2,0.48,14.6,0.2,0.5,1.5,"Pascal Le Corre, Gilles Dollo, Francois Chevanne, Roger Le Verge. Biopharmaceutics and metabolism of yohimbine in humans. European Journal of Pharmaceutical Sciences 9 (1999) 79–84","N=11, 5 mg dose. MRT from VDss and clarance. Ppb cited from anoter ref. in text.",Metabolism postulated as primary pathway for elimination. Clr negligible.,1908,354.44,5,2,65.6,2,neutral,2.4,2.1
Zalcitabine,7481-89-2,NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2,0.54,5.6,0.96,1.6,1.2,"Klecker RW, Collins JM, Yarchoan RC, Thomas R, McAtee N, Broder S, and Myers CE (1988) Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.  J. Clin. Pharmacol. 28: 837-842. ppb: The PDR states: The drug was <4% bound to plasma proteins, indicating that drug interactions involving binding-site displacement are unlikely. Accessed January 6 2015. http://pdr3d.com/detail.php?c=867#section-5",,,1967,211.22,6,2,88.1,2,neutral,-0.96,-0.96
Zaleplon,151319-34-5,CCN(C(=O)C)c1cccc(c1)c2ccnc3c(cnn23)C#N,1.3,16,0.4,1.4,1.1,"Rosen AS, Fournie P, Darwish M, Danjou P, and Troy SM (1999) Zaleplon pharmacokinetics and absolute bioavailability.  Biopharm. Drug Dispos. 20: 171-175.   Sonata Product Label.",,,1986,305.33,6,0,74.3,4,neutral,1.8,1.8
Zalypsis,308359-57-1,FC(F)(F)c1cccc(c1)/C=C/C(=O)NC[C@H]2c7c(C[C@@H]5N2[C@@H](O)[C@@H]4Cc3cc(C)c(OC)c(O)c3[C@H]5N4C)c(OC(C)=O)c(C)c6OCOc67,12.6,12,,17.5,22.2,"First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. Yap, T. A.; Cortes-Funes, H.; Shaw, H.; Rodriguez, R.; Olmos, D.; Lal, R.; Fong, P. C.; Tan, D. S.; Harris, D.; Capdevila, J.; et al British Journal of Cancer (2012), 106(8), 1379-1385.","two schedules of infusion 1 and 3 hour. N=27 and N=18 respectively. Across multiple doses and 70 kg average weight assumed.  1h schedule calculated values (weighted average) : VDss = 14 L/kg; clearance = 12.3 mL/min/kg, t 1/2 = 22.9 h; MRT (VDss/Cl) = 19 hr//3h schedule calculated values (wighted average) : VDss = 11.2 L/kg; clearance = 11.8 mL/min/kg, t 1/2 = 21.6 h; MRT (VDss/Cl) = 15.9 hr. Very similar values and overall average taken.",,2000,709.71,11,3,130,7,cationic,4.7,3
Zanamivir,139110-80-8,CC(=O)N[C@@H]1[C@@H](NC(=N)N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(=O)O,0.23,1.6,0.86,2.4,1.7,"Cass LMR, Efthymiopoulos C, and Bye A (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.  Clin. Pharmacokinet. 36(Suppl. 1): 1-11.  Daniel MJ, Barnett JM, and Pearson BA (1999) The low potential for drug interactions with zanamivir.  Clin. Pharmacokinet. 36(Suppl. 1): 41-50.",,,1991,332.31,11,8,198.2,7,zwitterionic,-3.8,-6.1
Zatebradine,85175-67-3,CN(CCCN1CCc2cc(c(cc2CC1=O)OC)OC)CCc3ccc(c(c3)OC)OC,1.6,8.4,,3.2,2.8,"Roth, W.; Bauer, E.; Heinzel, G.; Cornelissen, P. J. G.; Van Tol, R. G. L.; Jonkman, J. H. G.; Zuiderwijk, P. B. M.  Zatebradine: pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects. J. Pharm. Sci. 1993, 82, 99-106.","7.5 mg dose, N=6, 75.2 kg average weight.",,1982,456.57,7,0,60.5,11,cationic,3,1.6
ZD-9331,153537-73-6,n1c(=O)c2cc(CN(c3ccc(C(=O)N[C@@H](CCc4nnn[nH]4)C(=O)O)c(c3)F)CC#C)c(C)cc2[nH]c1C,0.53,0.29,0.01,30.38,78.5,"Maja JA de Jonge, B Glimelius, Jaap Verweij, C van Groening en, J Bonneterre, EGE de Vries, S Culine, J Young ,7 Rob Smith,  J Droz. E¡ects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. Anti-Cancer Drugs 2002, 13,  645–653",Plevitrexed. NSC 696259. Data from subject with normal renal function. N=10. 70 kg average weight assumed. MRT from clearance and VDss.,,1993,532.53,12,4,169.8,11,zwitterionic,2.4,-2.6
Ziconotide,107452-89-1,S1SC[C@@H]2NC([C@@H](CCCCN)NC([C@@H](NC(CNC([C@@H](NC(CNC([C@@H](NC([C@@H](CSSC[C@@H]3NC([C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC2=O)CO)=O)CCCNC(=N)N)=O)CC(C)C)=O)CCSC)=O)Cc2ccc(cc2)O)CC(O)=O)CSSC[C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](C1)NC([C@@H](NC(CNC(=O)[C@@H]([C@@H](C)O)NC3=O)=O)CO)=O)=O)CCCNC(=N)N)=O)CO)=O)=O)CCCCN)=O)C(=O)N)=O)N)=O)CCCCN)=O)=O)CCCCN)=O)=O)C)=O)=O,0.43,4.05,0.5,1.8,1.3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-060_Prialt_Biopharmr.PDF. Accessed December 18 2016.,70 kg average weight assumed. Ppb reported as 50%. MRT from clearance and VDss.,,1987,2639.13,68,42,1133.8,40,cationic,-9,-9
Zidovudine,30516-87-1,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,1.8,25,0.8,1.2,1.3,"Aweeka FT, Mak M, Al-Uzri A, Peter K, Dett C, Franco J, Affrime M, Guerciolini R, Cutler DL, et al.(1995)  Oral and intravenous zidovudine pharmacokinetics: The effect of granulocyte-macrophage colony stimulating factor.  J. Clin. Pharmacol. 35: 856-864.  Blum MR, Liao SHT, Good SS, and deMiranda P (1988) Pharmacokinetics and bioavailability of zidovudine in human.  Am. J. Med. 85(Suppl 2A): 189-194.  Morse GD, Shelton MJ, and O'Donnell AM (1993) Comparative pharmacokinetics of antiviral nucleoside analogues.  Clin. Pharmacokinet. 24: 101-123.  ",,,1951,267.24,9,2,127.6,3,neutral,-0.32,-0.32
Zimelidine,56775-88-3,C(\c1ccc(Br)cc1)(c1cccnc1)=C\CN(C)C,6.8,13.8,0.086,8.22,6.26,"Love B L; Moore R G; Thomas J; Chaturvedi S. Pharmacokinetics of zimelidine in humans-​-​plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine. European journal of clinical pharmacology. 1981, 20, 135-139.//ppb: Calil H M; Jostell K G; Cowdry R W; Potter W Z   (1982) Zimelidine and norzimelidine protein binding measured by equilibrium dialysis and cerebrospinal fluid   Clin. Pharmacol Ther. 31: 522-527","Zimelidine. BRN 0479680. Data digitized from plot reported. Subject BL1. 70 kg average weight. 20 mg dose as a 20' infusion.  Reported AUCinf 341 ug.h/L, calculated AUCinf 345  ng.h/mL. Fairly large extrapolation (23%)",,1974,317.22,2,0,16.1,4,cationic,3.6,2.3
Ziprasidone,146939-27-7,Clc1cc2NC(=O)Cc2cc1CCN3CCN(CC3)c4nsc5ccccc45,1,5.1,0.0012,3.3,3.1,"Miceli JJ, Wilner KD, Swan SK, and Tensfeldt TG (2005) Pharmacokinetics, safety, and tolerability of intramuscular Ziprasidone in healthy volunteers. J.Clin. Pharmacol.  45:  620-630.   Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, and Turncliff RZ (2000)  The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.  Br. J. Clin. Pharmacol. 49(Suppl 1): 27s-33s. ",,,1993,412.94,5,1,48.5,4,neutral,3.8,3.5
Ziracin,109545-84-8,[H]Oc1cc(C)c(C(=O)O[C@H]2CO[C@]3(C4[C@H]2OCO4)O[C@@H]2CO[C@@H]([C@@H]([C@H]2O3)O[H])O[C@@H]2[C@H]([C@@H]([C@H]([C@H](COC)O2)O[C@H]2[C@@H]([C@H]([C@H]([C@@H](C)O2)OC)O[C@@H]2[C@@H]([C@]3(C)[C@H]([C@@H](C)O2)O[C@]2(C[C@H]([C@@H]([C@@H](C)O2)O[C@@H]2C[C@@H]([C@H]([C@H](C)O2)OC(c2c(C)c(c(c(c2OC)[Cl])O[H])[Cl])=O)O[C@H]2C[C@](C)([C@H]([C@@H](C)O2)OC)[N+]([O-])=O)O[H])O3)O[H])O[H])O[H])OC)c(c1)O[H],0.39,0.61,0.04,10.7,16.6,"Kozawa O. et al. Antimicr. Agents Chemother. 2001, 45, 917-921. Pharmacokinetics of a new parenteral oligosaccharide antibiotic, SCH27899 (ziracin) in healthy subjects. Ppb: G. L. DRUSANO, S. L. PRESTON, C. HARDALO, R. HARE, C. BANFIELD,
D. ANDES, O. VESGA, W. A. CRAIG. Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint. Antimicrob. Agents Chemother.  2001, 45 (1)13-22 ","23 subjects across 1,3,6 and 9 mg/kg Japanese healthy volunteers. Weight-averaged data (1 mg/kg dose N=5) . MRT from clearance and VDss and t1/2 gamma taken. 3-compartment analysis. Also called SCH 27899 or evernimicin or everninomicin.",,1964,1631.41,39,8,479.1,31,anionic,1.6,-0.36
Zoledronic Acid,118072-93-8,OC(Cn1ccnc1)(P(=O)(O)O)P(=O)(O)O,0.6,2.2,0.78,4.5,11,"Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Ravera C, Schran H, Seaman J, and Waldmeier F (2003) The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.  J. Clin. Pharmacol. 43: 154-162.  Reclast Product Label.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1988,272.09,9,5,153.1,4,anionic,-3.2,-9
Zolmitriptan,139264-17-8,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,1.8,6.7,0.75,4.6,3.6,"Seaber EJ, Peck RW, Smith DA, Allanson J, Hefting NR, Van Lier JJm Sollie FAE, Wemer J, and Jonkman JHG (1998) The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br. J. Clin. Pharmacol. 46: 433-439.   Dixon R and Warrander A  (1997) The clinical pharmacokinetics of zolmitriptan.  Cephalalgia 17(Suppl 18): 15-20.",,,1991,287.36,5,2,57.4,5,cationic,1.5,0.24
Zolpidem,82626-48-0,CN(C)C(=O)Cc1c(nc2ccc(C)cn12)c3ccc(C)cc3,0.54,4.3,0.08,2.1,1.7,"Thenot JP, Hermann P, Durand A, Burke JT, Allen J, Garrigou D, Vajta S, Albin H, Thebault JJ, Olive G, and Warrington SJ (1988) Pharmacokinetics and metabolism of zolpidem in various animal species and humans.  In Imidazopyridines in Sleep Disorders (ed Sauvanet JP, Langer SZ, and Morselli PL).  Raven Press, New York, pp 139-153.",,,1950,307.39,4,0,37.6,3,neutral,3,3
Zonampanel,210245-80-0,OC(=O)CN1C(=O)C(=O)Nc2cc(c(cc12)n3ccnc3)N(=O)=O,0.19,5.3,,0.6,0.78,"Minematsu T, Sohida KY, Hashimoto T, Imai H, Usui T, and Kamimura H (2005) Identification of metabolites of [14C]zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers.  Xenobiotica  35: 359-371.",,,1998,331.24,11,2,150.4,4,anionic,-0.45,-3.8
Zoniporide,241800-98-6,C(=O)(NC(=N)N)c1c(n(nc1)c1c2c(ccc1)nccc2)C1CC1,1.7,21,0.34,1.3,2,"Cross-Species Comparison of the Metabolism and Excretion of Zoniporide: Contribution of Aldehyde Oxidase to Interspecies Differences. Deepak Dalvie, Chenghong Zhang, Weichao Chen, Teresa Smolarek, R. Scott Obach, and Cho-Ming Loi. DRUG METABOLISM AND DISPOSITION, 2010,38:641–654.// ppb: Zientek M, Jiang Y, Youdim, K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.  Drug Metab. Dispos. 38: 1322-1327.","MRT from clearance and VDss. 80 mg, 1 h infusion.",,1999,320.35,7,3,109.7,4,neutral,1,1
Zopiclone,43200-80-2,CN1CCN(CC1)C(=O)OC2N(C(=O)c3nccnc23)c4ccc(Cl)cn4,1.3,3.3,0.2,6.6,5.2,"Gaillot J, Heusse D, Hougton GW, Marc Aurele J, Dreyfus JF (1983) Pharmacokinetics and metabolism of zopiclone.  Pharmacology 27(suppl. 2): 76-91.  Fernandez C, Gimenez F, Thuillier A, and Farinotti R (1999) Stereoselective binding of zopiclone to human plasma proteins.  Chirality 11: 129-132.",,,1973,388.81,9,0,91.8,3,cationic,0.77,0.045
Zoptarelin doxorubicin,139570-93-7,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)COC(=O)CCCC(=O)NCCCC[C@@H](NC(=O)[C@H](Cc6ccc(O)cc6)NC(=O)[C@H](CO)NC(=O)[C@H](Cc7c[nH]c8ccccc78)NC(=O)[C@H](Cc9cnc[nH]9)NC(=O)[C@@H]%10CCC(=O)N%10)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N%11CCC[C@H]%11C(=O)NCC(=O)N,,22,,,2.02,"Günter Emons, Manfred Kaufmann, Grigor Gorchev, Valentina Tsekova, Carsten Gründker, Andreas R. Günthert, Lars C. Hanker, Maya Velikova, Herbert Sindermann, Jürgen Engel, Andrew V. Schally. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol. Oncol. 2010, 119, 457–461.","AEZS-108. Weighted average based on cycles on two doses (160 and 267 mg/m2, 14 and 9 cycles respectively, N=6 for each dose group) administered as infusion. Average weight of the two dosing group = 73 kg. Conversion factor 173 m2/70 kg. No plot or VDss reported.",,1994,1893.01,45,23,713.4,48,cationic,-1.8,-6.3
Zotarolimus,221877-54-9,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@@H]1n5cnnn5,1.3,0.67,0.26,33,35,"Palaparthy R, Pradhan R, Chan J, Wang Q, Ji Q, Achari R, Chira T, Schwartz LB, O'Dea R (2005) Pharmacokinetics and safety of ABT-578, a sirolimus (rapamycin) analogue, after single intravenous bolus injection in healthy male volunteers.  Clin. Drug. Invest. 25: 491-498.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022334s6lbl.pdf.Accessed May 28 2017.",,,1999,966.21,17,2,218.8,7,neutral,5.4,5.4
